CF Nutrition

Nutrition and Health
Series Editor: Adrianne Bendich
Elizabeth H. Yen
Amanda Radmer Leonard Editors
Nutrition in
Cystic Fibrosis
A Guide for Clinicians

Adrianne Bendich, Ph.D., FASN, FACN, Series Editor
More information about this series at http://www.springer.com/series/7659
Elizabeth H. Yen Amanda Radmer Leonard

Editors
Nutrition in Cystic Fibrosis

A Guide for Clinicians
Editors
Elizabeth H. Yen, M.D.
Department of Pediatrics
Division of Gastroenterology
Hepatology and Nutrition
University of California
San Francisco, CA, USA
Amanda Radmer Leonard, M.P.H., R.D., L.D., C.D.E.

The Johns Hopkins Childrens Center
Department of Pediatrics
Division of Gastroenterology and Nutrition
Baltimore, MD, USA
Benioff Childrens Hospital


ISBN 978-3-319-16386-4
ISBN 978-3-319-16387-1
DOI 10.1007/978-3-319-16387-1
(eBook)
Library of Congress Control Number: 2015952012

Springer Cham Heidelberg New York Dordrecht London
Springer International Publishing Switzerland 2015
This work is subject to copyright. All rights are reserved by the Publisher, whether the whole or part of the material is concerned,
specifically the rights of translation, reprinting, reuse of illustrations, recitation, broadcasting, reproduction on microfilms or in
any other physical way, and transmission or information storage and retrieval, electronic adaptation, computer software, or by
similar or dissimilar methodology now known or hereafter developed.
The use of general descriptive names, registered names, trademarks, service marks, etc. in this publication does not imply, even
in the absence of a specific statement, that such names are exempt from the relevant protective laws and regulations and
therefore free for general use.
The publisher, the authors and the editors are safe to assume that the advice and information in this book are believed to be true
and accurate at the date of publication. Neither the publisher nor the authors or the editors give a warranty, express or implied,
with respect to the material contained herein or for any errors or omissions that may have been made.
Printed on acid-free paper
Humana Press is a brand of Springer
Springer International Publishing AG Switzerland is part of Springer Science+Business Media (www.springer.com)
We dedicate this book to all patients and families of patients with cystic fibrosis.
Their dedication to their care and to the advancement of medicine and science
in the field is exemplary and humbling.
Preface
Over the past half-century, advances in the treatment of cystic fibrosis have resulted in remarkable
improvements in patients quality of life and longevity. Nutritional therapies were key early
interventions, and remain central to the well-being and survival of patients with cystic fibrosis. The
nature of the disease causes significant alterations in a patients ability to process and assimilate
nutrients. Furthermore, many factors contribute to higher metabolic demands throughout a patients
life. In combination, maldigestion, malabsorption, and increased metabolic demands pose a high
hurdle for the patient to overcome in order to maintain optimal nutritional status. Yet much data exist
demonstrating the importance of good nutrition on outcomes in cystic fibrosis.
The book provides an introduction to cystic fibrosis and nutritional assessments. It also serves as a
comprehensive guide to the nutritional monitoring and management of patients with cystic fibrosis,
including special populations within cystic fibrosis that require additional considerations.
The book consists of 18 chapters, written by experts in their fields, and includes the most up to date
scientific information. The first chapter lays the groundwork for the importance of nutritional status on
outcomes. Macronucrient requirements, including how to assess for their absorption and assimilation,
are the topic of the second chapter, while the third chapter goes into careful detail about specific fatty
acids taking into consideration the altered fatty acid metabolism in cystic fibrosis. The important role of
vitamin D in bone health and extra-skeletal co-morbidities, along with management recommendations,
are presented, followed by the remainder of the micronutrient considerations in cystic fibrosis.
Cystic fibrosis patients are now living well into their adulthood. Separate chapters on infant,
pediatric, and adult nutrition provide guidance for the care of cystic fibrosis patients over the lifespan,
followed by a chapter dedicated to nutritional interventions. Complications of cystic fibrosis which
impact nutrition are each given their own chapters, each explaining the impact of the complication on
nutritional requirements, nutrition assimilation, and methods to overcome these. Nutritional
requirements during pregnancy are amplified in cystic fibrosis, and this book dedicates an entire
chapter to this special population, there is also a separate chapter on the treatment of patients with SEP
in, a condition often neglected due to its milder impact on nutrition, but nonetheless meriting increased
nutritional attention over healthy populations. The final chapters of the book address behavioral
interventions for improved nutrition, and quality improvement approaches to implement in the clinic
aimed at improving the nutritional status at the clinic population level.
Nutrition in Cystic Fibrosis: A Guide for Clinicians is designed as a resource for physicians,
nurses, dietitians and other medical providers who deliver care for patients with cystic fibrosis.
Students of medicine, nursing, nutrition, as well as professors will find value in this book.
Baltimore, MD, USA
Elizabeth H. Yen
Amanda Radmer Leonard
vii
Series Editor Page
The great success of the Nutrition and Health Series is the result of the consistent overriding mission
of providing health professionals with texts that are essential because each includes: (1) a synthesis of
the state of the science, (2) timely, in-depth reviews by the leading researchers and clinicians in their
respective fields, (3) extensive, up-to-date fully annotated reference lists, (4) a detailed index, (5)
relevant tables and figures, (6) identification of paradigm shifts and the consequences, (7) virtually no
overlap of information between chapters, but targeted, inter-chapter referrals, (8) suggestions of areas
for future research and (9) balanced, data-driven answers to patient as well as health professionals
questions which are based upon the totality of evidence rather than the findings of any single study.
The series volumes are not the outcome of a symposium. Rather, each editor has the potential to
examine a chosen area with a broad perspective, both in subject matter and in the choice of chapter
authors. The international perspective, especially with regard to public health initiatives, is emphasized
where appropriate. The editors, whose trainings are both research and practice oriented, have the
opportunity to develop a primary objective for their book; define the scope and focus, and then invite
the leading authorities from around the world to be part of their initiative. The authors are encouraged
to provide an overview of the field, discuss their own research, and relate the research findings to
potential human health consequences. Because each book is developed de novo, the chapters are
coordinated so that the resulting volume imparts greater knowledge than the sum of the information
contained in the individual chapters.
Nutrition in Cystic Fibrosis: A Guide for Clinicians, edited by Elizabeth H. Yen, M.D. and
Amanda R. Leonard, M.P.H., R.D., C.D.E. is a welcome addition to the Nutrition and Health Series.
The editors are experts in the care of cystic fibrosis (CF) patients and have significant expertise in the
development of nutritional strategies to aid in the growth and development of children diagnosed with
CF. They have invited the leaders in the field to develop the 18 relevant, practice-oriented chapters in
this unique and clinically valuable volume. Dr. Yen is currently the Associate Director of Clinical
Research in the Liver Disease Therapeutic Area at Gilead Sciences. Prior to this position, she served
as Assistant Clinical Professor in Pediatric Gastroenterology at the University of California in San
Francisco. Amanda R Leonard is an Advanced Nutrition Practitioner at Johns Hopkins Childrens
Center in Baltimore, MD, where she assesses patients with cystic fibrosis and educates staff, medical
students, and the pediatric population on the topic of cystic fibrosis. She also serves as Facilitator in
the CF Nutrition Mentoring Program for the Cystic Fibrosis Foundation in Bethesda, MD, where in
2008 she assisted in implementing a full-scale, national nutrition mentoring program.
Nutrition in Cystic Fibrosis: A Guide for Clinicians fulfills an unmet need for pediatric and adult
pulmonologists and gastroenterologists, residents and fellows, internists, pediatricians, nurses,
dietitians, and general practitioners who treat patients with cystic fibrosis by providing data-driven
ix
Series Editor Page
advice concerning the implementation of nutritional interventions to CF patients from infancy to

adulthood. The book provides an introduction to cystic fibrosis and nutritional assessments. It serves
as a comprehensive guide to the nutritional monitoring and management of patients with cystic
fibrosis including special populations with both cystic fibrosis and other medical issues that require
additional nutritional considerations. The chapters are written by experts in their fields and include the
most up-to-date scientific and clinical information. Nutritional therapies have been key to successful
care and remain central to the well-being and survival of patients with cystic fibrosis. The nature of
the disease causes significant alterations in a patients ability to process and assimilate nutrients.
Electrolyte balance is a critical issue for the CF patient. Furthermore, many factors contribute to
higher caloric needs throughout the patients life. The volume provides chapters that can answer
critical questions for health professionals as well as knowledgeable family members, educators and
others involved in the lives of CF patients.
Chapter 1, written by the volumes co-editor, provides a comprehensive overview of cystic fibrosis
from an historical perspective and reminds us that CF, although relatively rare, is the most common
life-shortening inherited disease in the United States, affecting approximately 30,000 children and
adults. In 1989, the gene mutation responsible for causing this recessive disorder was found to be on
the gene encoding the cystic fibrosis transmembrane regulator (CFTR), which serves as an ion
channel. The defect results in impaired fluid movement through the channel resulting in a dehydrated
and thickened mucus layer and decreased function in the tissues and organs where the gene is active.
At present, there is neonatal screening for CF and major advances have been made in the treatment of
the adverse nutritional and other effects of this disease. Key effects of the disease include increased
energy expenditure, small for age, loss of pancreatic enzyme production resulting in incomplete
absorption of fats, and pulmonary dysfunction resulting in the inability to breathe in deeply, greater
risk of infections and significantly lowered forced expiratory lung volume. Chapter 2 reviews the
studies to determine the energy requirements for CF patients and also to provide guidance to healthcare
providers concerning the sources of the calories (useful tables are included). This chapter also presents
an historical analysis of the development of recommendations for both macro and micronutrients in
addition to antioxidants. The importance of pancreatic enzyme replacement therapy (PERT) and its
development are discussed. Increased caloric intake compared to age and sex-matched children is
required for CF patients especially during the growth years. High fat diets that include essential fatty
acids and high protein diets containing certain amino acids including taurine, essential amino acids,
and fiber-rich complex carbohydrates are recommended. The next chapter, Chapter 3, follows logically
and contains an extensive review of the importance of fats in the diet of CF patients. The reader is
guided through the terminology used to describe dietary fats, their metabolism and the physiological
effects of different fats and fatty acids. There is a detailed description of fatty acid metabolism and the
importance of providing sufficient essential fatty acids especially linoleic acid in the CF patients diet.
Chapter 4 examines the critical role of vitamin D in the bone development of CF patients. The
chapter integrates clinical practice with the underlying science. CF-related bone disease, including
osteoporosis, osteopenia, and/or fractures, is the second most prevalent co-morbidity in patients with
CF. Adequate intake and absorption of the fat-soluble vitamin D is also important in reducing the risk
of lung impairment, inflammation, diabetes, and depression that are often seen in CF. Likewise, in
addition to vitamin D, other factors such as vitamin K, calcium, and physical activity are major
nutrition-related contributors to bone health in CF. The author notes the importance of bone heath for
the CF patients and emphasizes the importance of optimizing bone mineral density, as bone disease
contributes to increased fracture risk, impaired lung function, and exclusion for lung transplant
candidacy. Chapter 5 continues the discussion of the essential micronutrient requirements for CF
patients. The chapter includes a review of the many reasons for low vitamin (both fat soluble and
water soluble vitamins) and mineral levels in CF patients including maldigestion and malabsorption,
inadequate dietary intake, inadequate adherence to therapy, incorrect use of supplements and PERT,
Series Editor Page
xi
drugnutrient interactions, and/or medical challenges, such as bowel resection or liver disease. Sodium
chloride is central both to the diagnosis and to the care of persons who have CF. Of importance is the
additional requirements for women of childbearing potential with CF who are also taking oral
contraceptives that are known to increase the need for folate and certain other vitamins. There are
excellent tables included in the chapter that outline the nutritional content of vitamin supplements that
are formulated to meet the needs of the CF patient and meet the recommendations of the International
CF Foundation. Also included is a comprehensive review of each of the critical micronutrients and
over 150 relevant references.
The next three chapters examine the effects of CF in the infant, in the child from age 2 to 20, and
in adults. Chapter 6 describes the critical needs of the infant diagnosed with CF during the first few
weeks of life and through 2 years of age. As indicated above, there is an increased requirement for
calories and fats in CF infants compared to age-matched infants who do not have CF. This requirement
is difficult to reach as pancreatic insufficiency is seen in up to 60 % of infants with CF diagnosed
through newborn screening and increases to over 90 % of children diagnosed within the first year of
life. The chapter describes the studies of dosing with PERT and its importance in helping to maintain
infant growth. The importance of the trained CF Registered Dietitian is stressed as is the need for
frequent weight assessments during infancy. This practice-oriented chapter provides detailed
discussions of the CF Foundation Consensus Guidelines recommendations for the care of the CF
infant. Chapter 7 contains a detailed description of the clinic nutrition evaluation for individuals with
CF who are 220 years of age. Children with CF can have several complications that can adversely
affect their attainment of sufficient nutrients for growth. Some of these conditions that are addressed
in the chapter include maldigestion with resultant malabsorption secondary to pancreatic insufficiency;
intestinal resection due to meconium ileus, poorly controlled CF-related diabetes, and impaired bile
flow in cases of severe CF-related liver disease as well recurrent pulmonary infections and increased
oxidative stress, fevers, and increased metabolic rates. The 11 detailed tables included in the chapter
provide valuable guidelines for the assessment of the nutritional status of the CF patient during these
years of growth and sexual maturation. Chapter 8 reviews the continued need to monitor the nutritional
status of adults with CF to reduce the risk of malnutrition. There are discussions concerning diet,
clinical assessment, pancreatic enzyme status, vitamin and mineral supplementation, gradual loss of
lung function, reduced bone health, and diabetes that results from deterioration of the pancreas and
gastroesophageal reflux. CF patients are living longer (average over 40 years) than ever before and are
experiencing new non-respiratory illness such as diabetes, osteoporosis, overweight and obesity, and
reproductive concerns. The chapter examines these relatively new issues for adult CF patients and
refers to current CF Foundation and other national assessment guidelines.
The ninth chapter concentrates on the nutritional care of CF patients who experience weight loss
or growth faltering. The nutrition interventions reviewed include increasing energy intake from solid
food, oral supplements, and/or enteral feeding; use of appetite stimulants and parenteral nutrition are
also reviewed. Behavioral strategies to increase calories without increasing food/beverage volume
(boosting) that are considered to be central to optimizing energy intake in children are reviewed in
detail. The use of supplemental tube feedings and the clinical studies that examined the effects on lung
function are objectively evaluated. The mechanisms of action and the efficacy of several appetite
stimulant drugs as well as the uses of parenteral nutrition are discussed.
Four chapters examine the effects of the major co-morbidities often seen in CF patients. Chapter 10
reviews the importance of both the exocrine and endocrine functions of the pancreas and concentrates
on the development of pancreatic insufficiency, links to the genetic defect causing CF, and consequences
of pancreatic insufficiency, historic development of PERT and the modern screening methods for
pancreatic insufficiency that are currently available. We learn that the cystic fibrosis transmembrane
regulator (CFTR) protein is expressed in the exocrine ducts of the pancreas, where it allows water and
ions to enter the ducts. When there is a genetic defect in the receptor in the pancreas, duct fluid is
xii
Series Editor Page
reduced resulting in a concentration of proteins and eventual obstruction leading to pancreatic

damage and fibrosis. Depending on the genetic defect, these injuries can begin in utero, and at birth
the pancreas can be severely damaged. Pancreatic insufficiency (PI) is defined as greater than 85 %
loss of pancreatic enzyme function, and therefore CF patients can have a greater than 50 % loss of
function and still not be considered pancreatic insufficient, but would benefit from PERT. The
assessment tests for pancreatic function are reviewed and compared for efficacy and the chapter
contains over 100 relevant references.
In addition to the pancreas, the liver is a second organ that is adversely affected by CF. Chapter 11
reviews the disorders that occur in the liver as a result of CF nutritional deficiencies and discusses the
management of cholestasis and cirrhosis, the two liver diseases in CF that directly affect nutritional
status. Neonatal cholestasis results in significant decrease in bile formation with further reduction in
fat absorption beyond that seen with decreased pancreatic enzyme formation. Fat soluble vitamin
deficiencies, especially vitamin E deficiency, may also occur. Liver cirrhosis is discussed in detail and
secondary effects are enumerated as are the nutritional consequences that may be seen in the CF
patient with cirrhosis. Nutritional recommendations are included for these diseases. There is also a
discussion of the nutritional role of hepatic steatosis. Both the pancreas and the liver communicate
with the gastrointestinal (GI) system that is the site of nutrient absorption, formation of hormones that
control eating behavior and movement of dietary components through the GI tract.
Chapter 12 examines the effects of the mutation of the CFTR in the GI tract and its adverse effects
on the movement of chloride and bicarbonate across the epithelial cell membrane, altered luminal
physiology with dehydrated mucus, altered pH, immune deficiency, nutrient malabsorption, and
small bowel bacterial overgrowth. As a consequence of these pathological changes, diseases of the
esophagus, stomach, small intestine, and colon are not uncommon in patients with CF. The chapter
includes a detailed discussion of the importance of the new CFTR potentiator drug, ivacaftor and its
benefit to improvements in GI functions for the CF patient. Also, there are reviews of the effects of
CF on the small and large intestine. The fourth chapter that deals with comorbid conditions reviews
the development of diabetes in the CF patient. Chapter 13 describes the development and consequences
of Cystic Fibrosis Related Diabetes Mellitus (CFRD). CFRD is a unique form of diabetes that has
both a different cause and natural history than seen with either type 1 or type 2 diabetes mellitus.
CFRD requires a different approach to nutritional therapy. Patients with CFRD require insulin, yet
must continue to consume high fat, high calorie diets that can be difficult as they must also be aware
of their carbohydrate intakes. Lung function is directly linked to control of CFRD. The chapter
includes practice-oriented details concerning insulin use, nutritional recommendations with and
without acute illnesses, insulin therapy with enteral and total parenteral nutrition, pregnancy issues,
and other relevant topics.
Chapter 14 provides a unique perspective on the critical importance of the nutritional status of the
CF patient prior to and following lung transplant surgery. We learn that for CF patients, respiratory
failure is the main cause of mortality. Lung transplantation can provide a survival advantage and
improved quality of life. Optimizing nutritional status prior to transplantation can improve posttransplant outcomes; however, this is challenging. CF patients have been shown to have improvements
in nutritional status after lung transplantation, however, they face multiple unique nutritional
challenges that are reviewed in this chapter. Indications and contraindications for transplant and other
valuable practice-related guidelines are tabulated. Chapter 15 also examines the effects of CF during
the unique time of pregnancy. The chapter discusses the CF-related nutrition issues during prepregnancy, pregnancy, post-pregnancy, and breast-feeding. Specific areas discussed in the chapter
include vitamin/mineral supplementation, GI issues affecting intake and absorption, weight gain,
diabetes, and other medications. Women with CF who become pregnant are at a higher risk of
gestational diabetes and screening starting at 810 weeks gestation is recommended. Women with CF
who have diabetes prior to conception should be closely monitored to optimize blood sugar control.
Series Editor Page
xiii
The chapter includes detailed information concerning individual vitamin requirements as well as
strategies for improving the intake of the added caloric needs during pregnancy.
Although the vast majority of CF patients suffer from pancreatic insufficiency that usually
develops at birth through adolescence, there are CF patients who are pancreatic enzyme sufficient
(PS) and Chapter 16 examines the needs of this population. Generally, PS is associated with
milder CFTR phenotypes and better nutritional status. However, persons with CF PS often have
gastrointestinal and/or nutritional problems including overweight and obesity. PS patients should
be tested for exocrine PI annually and especially if there is evidence of pancreatic dysfunction
such as diarrhea due to malabsorption, steatorrhea, abdominal pain, or weight loss. CF PS patients
are at increased risk of acute pancreatitis compared to pancreatic enzyme insufficient CF patients
and careful monitoring is required.
The second to last chapter of this highly informative volume includes an in-depth discussion of the
role of behavioral therapy in helping clinicians respond to CF children and their parents as they
attempt to reach the difficult nutritional goals associated with CF. Chapter 17 reviews the studies that
have demonstrated the effectiveness of combined behavioral nutrition interventions in helping parents
of children with CF manage disruptive child behaviors and promote increased energy intake and
weight. Key behavioral components reviewed include monitoring energy intake, setting calorie goals
and providing timely feedback, and educating and coaching parents in the use of child behavioral
management strategies to promote improved behavior at mealtimes and acceptance of new foods.
Inclusion of anticipatory guidance about feeding challenges and early empirically informed assessment
and intervention are needed to reduce the risks of growth deficits. The authors provide examples of
behavioral programs that have been shown to have efficacy with young CF children. One example is
a program called Be-In-CHARGE where parents are taught several child behavioral management
strategies and how to apply them at meals. Examples include how to effectively use parent attention
to encourage increased energy intake and behavioral cooperation, setting specific action-oriented
goals for each meal as a way to gradually increase calories over time, and tracking calories to monitor
intake patterns and providing feedback toward progress with goals. Chapter 18 reviews the role of
quality improvement (QI) in CF treatment strategies. The chapter reviews the value of initiating a set
of quality standards for care that include patient registries, benchmarking projects, patient and family
involvement and care team education in improvement methods. The chapter author, who is also the
volumes co-editor, suggests that implementing nutrition quality improvement projects using a
standardized approach can also potentially improve nutrition outcomes. An aspect of QI that has been
of great help globally is the development of patient registries. In the USA, the CF Foundation began
its registry in 1966 and tracks not only survival, but also more than 300 unique variables and can be
used to identify variability and measure outcomes. Registries have been used to extract nutritionrelated data and have improved patient life expectancies by increasing fat intake, as one example. The
chapter includes detailed discussions of a number of successful QI programs that have resulted in
improved nutritional status in CF patients.
The above description of the volumes 18 chapters attests to the depth of information provided by
the 27 well-recognized and respected chapter authors. Each chapter includes complete definitions of
terms with the abbreviations fully defined for the reader and consistent use of terms between chapters.
The volume includes over 60 detailed tables and informative figures, an extensive, detailed index and
more than 1350 up-to-date references that provide the reader with excellent sources of worthwhile
information. Thus, the volume provides a broad base of knowledge concerning the physiology and
pathology associated with CF and nutritionally relevant interventions that can enhance the potential
for the patients more healthful life.
In conclusion, Nutrition in Cystic Fibrosis: A Guide for Clinicians, edited by Elizabeth H. Yen,
M.D. and Amanda R. Leonard, M.P.H., R.D., C.D.E., provides health professionals in many areas of
research and practice with the most up-to-date, well-referenced volume on the importance of
xiv
Series Editor Page
maintaining the nutritional status of the CF patient from the day of diagnosis through the remainder
of their lifetime. The volume chapters carefully document the critical value of medical nutrition
evaluation by a specialized CF dietitian/nutritionist as part of the overall CF team; review the treatment
support and management of CF patients who often have additional chronic diseases, such as diabetes
and organ failures including the lung and/or liver. Each of the conditions is covered in depth in
individual chapters. Unique chapters examine the nutritional requirements for the CF patient who
undergoes lung transplant, or pregnancy, or has sufficient pancreatic enzyme capacity but is at
increased risk of other nutrition-related complications. This volume will serve the reader as the
benchmark in this complex area of interrelationships between diet, nutritional and enzyme supplements
and the specific treatments required to optimize the GI tract, liver and pancreatic functions to help
assure the nutritional status of the CF patient. Moreover, these physiological and pathological
interactions are clearly delineated so that medical students, nurses, dietitians as well as practitioners
can better understand the complexities of these interactions. Unique chapters that examine the
importance of behavioral modification and the use of quality standards to improve patient adherence
to nutritional therapies are included. These provide the health professionals involved in the treatment
of CF patients with the enhanced capability of understanding the potential to improve CF patient
outcomes. The editors are applauded for their efforts to develop the most authoritative resource in the
field to date and this excellent text is a very welcome addition to the Nutrition and Health Series.
Morristown, NJ, USA
Adrianne Bendich, Ph.D., F.A.C.N., F.A.S.N.
About Series Editor
Dr. Adrianne Bendich, Ph.D., F.A.S.N., F.A.C.N. has served as the Nutrition and Health Series
Editor for 20 years and has provided leadership and guidance to more than 200 editors who have
developed the 70+ well-respected and highly recommended volumes in the Series.
In addition to Nutrition in Cystic Fibrosis: A Guide for Clinicians, edited by Elizabeth H. Yen, M.D.
and Amanda R. Leonard, M.P.H., R.D., C.D.E., major new editions published in 20122016 include:
1. Preventive Nutrition: The Comprehensive Guide For Health Professionals, Fifth Edition, edited
by Adrianne Bendich, Ph.D. and Richard J. Deckelbaum, M.D., 2016
2. Glutamine in Clinical Nutrition, edited by Rajkumar Rajendram, Victor R. Preedy, and Vinood
B. Patel, 2015
3. Nutrition and Bone Health, Second Edition, edited by Michael F. Holick and Jeri W. Nieves, 2015
4. Branched Chain Amino Acids in Clinical Nutrition, Volume 2, edited by Rajkumar Rajendram,
Victor R. Preedy, and Vinood B. Patel, 2015
5. Branched Chain Amino Acids in Clinical Nutrition, Volume 1, edited by Rajkumar Rajendram,
Victor R. Preedy, and Vinood B. Patel, 2015
6. Fructose, High Fructose Corn Syrup, Sucrose and Health, edited by James M. Rippe, 2014
7. Handbook of Clinical Nutrition and Aging, Third Edition, edited by Connie Watkins Bales,
Julie L. Locher, and Edward Saltzman, 2014
8. Nutrition and Pediatric Pulmonary Disease, edited by Dr. Youngran Chung and Dr. Robert
Dumont, 2014
9. Integrative Weight Management, edited by Dr. Gerald E. Mullin, Dr. Lawrence J. Cheskin, and
Dr. Laura E. Matarese, 2014
xv
xvi
About Series Editor
10. Nutrition in Kidney Disease, Second Edition, edited by Dr. Laura D. Byham-Gray, Dr. Jerrilynn
D. Burrowes, and Dr. Glenn M. Chertow, 2014
11. Handbook of Food Fortification and Health, Volume I, edited by Dr. Victor R. Preedy,
Dr. Rajaventhan Srirajaskanthan, and Dr. Vinood B. Patel, 2013
12. Handbook of Food Fortification and Health, Volume II, edited by Dr. Victor R. Preedy,
Dr. Rajaventhan Srirajaskanthan, and Dr. Vinood B. Patel, 2013
13. Diet Quality: An Evidence-Based Approach, Volume I, edited by Dr. Victor R. Preedy,
Dr. Lan-Ahn Hunter, and Dr. Vinood B. Patel, 2013
14. Diet Quality: An Evidence-Based Approach, Volume II, edited by Dr. Victor R. Preedy,
Dr. Lan-Ahn Hunter, and Dr. Vinood B. Patel, 2013
15. The Handbook of Clinical Nutrition and Stroke, edited by Mandy L. Corrigan, M.P.H., R.D.,
Arlene A. Escuro, M.S., R.D., and Donald F. Kirby, M.D., F.A.C.P., F.A.C.N., F.A.C.G., 2013
16. Nutrition in Infancy, Volume I, edited by Dr. Ronald Ross Watson, Dr. George Grimble, Dr. Victor
Preedy, and Dr. Sherma Zibadi, 2013
17. Nutrition in Infancy, Volume II, edited by Dr. Ronald Ross Watson, Dr. George Grimble,
Dr. Victor Preedy, and Dr. Sherma Zibadi, 2013
18. Carotenoids and Human Health, edited by Dr. Sherry A. Tanumihardjo, 2013
19. Bioactive Dietary Factors and Plant Extracts in Dermatology, edited by Dr. Ronald Ross Watson
and Dr. Sherma Zibadi, 2013
20. Omega 6/3 Fatty Acids, edited by Dr. Fabien De Meester, Dr. Ronald Ross Watson, and
Dr. Sherma Zibadi, 2013
21. Nutrition in Pediatric Pulmonary Disease, edited by Dr. Robert Dumont and Dr. Youngran
Chung, 2013
22. Magnesium and Health, edited by Dr. Ronald Ross Watson and Dr. Victor R. Preedy, 2012.
23. Alcohol, Nutrition and Health Consequences, edited by Dr. Ronald Ross Watson, Dr. Victor
R. Preedy, and Dr. Sherma Zibadi, 2012
24. Nutritional Health, Strategies for Disease Prevention, Third Edition, edited by Norman J. Temple,
Ted Wilson, and David R. Jacobs, Jr., 2012
25. Chocolate in Health and Nutrition, edited by Dr. Ronald Ross Watson, Dr. Victor R. Preedy, and
Dr. Sherma Zibadi, 2012
26. Iron Physiology and Pathophysiology in Humans, edited by Dr. Gregory J. Anderson, and
Dr. Gordon D. McLaren, 2012
Earlier books included Vitamin D, Second Edition edited by Dr. Michael Holick; Dietary Components
and Immune Function edited by Dr. Ronald Ross Watson, Dr. Sherma Zibadi, and Dr. Victor R. Preedy;
Bioactive Compounds and Cancer edited by Dr. John A. Milner and Dr. Donato F. Romagnolo; Modern
Dietary Fat Intakes in Disease Promotion edited by Dr. Fabien De Meester, Dr. Sherma Zibadi, and
Dr. Ronald Ross Watson; Iron Deficiency and Overload edited by Dr. Shlomo Yehuda and Dr. David
Mostofsky; Nutrition Guide for Physicians edited by Dr. Edward Wilson, Dr. George A. Bray,
Dr. Norman Temple, and Dr. Mary Struble; Nutrition and Metabolism edited by Dr. Christos Mantzoros
and Fluid and Electrolytes in Pediatrics edited by Leonard Feld and Dr. Frederick Kaskel. Recent
volumes include: Handbook of DrugNutrient Interactions edited by Dr. Joseph Boullata and
Dr. Vincent Armenti; Probiotics in Pediatric Medicine edited by Dr. Sonia Michail and Dr. Philip
Sherman; Handbook of Nutrition and Pregnancy edited by Dr. Carol Lammi-Keefe, Dr. Sarah
Couch, and Dr. Elliot Philipson; Nutrition and Rheumatic Disease edited by Dr. Laura Coleman;
Nutrition and Kidney Disease edited by Dr. Laura Byham-Grey, Dr. Jerrilynn Burrowes, and Dr. Glenn
Chertow; Nutrition and Health in Developing Countries edited by Dr. Richard Semba and Dr. Martin
Bloem; Calcium in Human Health edited by Dr. Robert Heaney and Dr. Connie Weaver and Nutrition
and Bone Health edited by Dr. Michael Holick and Dr. Bess Dawson-Hughes.
About Series Editor
xvii
Dr. Bendich is President of Consultants in Consumer Healthcare LLC, and is the editor of ten
books including Preventive Nutrition: The Comprehensive Guide for Health Professionals, Fifth
Edition co-edited with Dr. Richard Deckelbaum (www.springer.com/series/7659). Dr. Bendich serves
on the Editorial Boards of the Journal of Nutrition in Gerontology and Geriatrics, and Antioxidants,
and has served as Associate Editor for Nutrition the International Journal; served on the Editorial
Board of the Journal of Womens Health and Gender-based Medicine, and served on the Board of
Directors of the American College of Nutrition.
Dr. Bendich was Director of Medical Affairs at GlaxoSmithKline (GSK) Consumer Healthcare
and provided medical leadership for many well-known brands including TUMS and Os-Cal.
Dr. Bendich had primary responsibility for GSKs support for the Womens Health Initiative (WHI)
intervention study. Prior to joining GSK, Dr. Bendich was at Roche Vitamins Inc. and was involved
with the groundbreaking clinical studies showing that folic acid-containing multivitamins significantly
reduced major classes of birth defects. Dr. Bendich has co-authored over 100 major clinical research
studies in the area of preventive nutrition. She is recognized as a leading authority on antioxidants,
nutrition and immunity and pregnancy outcomes, vitamin safety and the cost-effectiveness of vitamin/
mineral supplementation.
Dr. Bendich received the Roche Research Award, is a Tribute to Women and Industry Awardee, and
was a recipient of the Burroughs Wellcome Visiting Professorship in Basic Medical Sciences.
Dr. Bendich was given the Council for Responsible Nutrition (CRN) Apple Award in recognition of
her many contributions to the scientific understanding of dietary supplements. In 2012, she was
recognized for her contributions to the field of clinical nutrition by the American Society for Nutrition
and was elected a Fellow of ASN. Dr Bendich is Adjunct Professor at Rutgers University. She is listed
in Whos Who in American Women.
About Volume Editors
Amanda Radmer Leonard, M.P.H., R.D./L.D., C.D.E. is an Advanced Nutrition Practitioner at The
Johns Hopkins Childrens Center in Baltimore, M.D., where she assesses patients with cystic fibrosis
and educates staff, medical students, and the pediatric population on the topic of cystic fibrosis. She
has been at Hopkins since 1997. Prior to this, she worked as a pediatric dietitian at Tulane Hospital
for Children in New Orleans, L.A. Ms. Leonard also serves as Facilitator in the CF Nutrition Mentoring
Program for the Cystic Fibrosis Foundation in Bethesda, M.D., where in 2008 she assisted in
implementing a full-scale, national nutrition mentoring program. She earned her bachelors degree in
dietetics and nutritional science from the University of Delaware in Newark and went on to get her
masters of public health in nutrition from the Tulane School of Public Health and Tropical Medicine
in New Orleans, L.A. She is actively involved in several professional societies including the American
Dietetic Association, the ADA Pediatric Nutrition Practice group, and the Cystic Fibrosis Foundation
Conference Planning Committee. Ms. Leonard has published several articles in peer-reviewed
journals including the Journal of Pediatrics, the Journal of Cystic Fibrosis, and the Journal of
Pediatric Psychology. She has given more than two dozen national and international presentations on
the topic of nutrition, namely nutrition for pediatrics, diabetes, and for patients with cystic fibrosis, at
conferences such as the North American Cystic Fibrosis Conference, the Brazilian Cystic Fibrosis
Congress and the American Dietetic Association Food and Nutrition Expo.
xix
xx
About Volume Editors
Elizabeth H. Yen, M.D. is a Board Certified Pediatric Gastroenterologist who specializes in the
gastrointestinal and nutritional care of children with cystic fibrosis and University of California, San
Francisco, Benioff Childrens Hospital. Prior to joining UCSF, Dr. Yen worked at Boston
Childrens Hospital. She completed her training in Pediatric Gastroenterology at Boston Childrens
Hospital and Harvard Medical School. Prior to that, Dr. Yen completed her residency training
in Pediatrics at the University of Washington. She received her medical degree from Weill Cornell
Medical College. Her research has focused on nutrition in cystic fibrosis. Dr. Yen has authored several
articles in peer reviewed journals including Journal of Pediatrics, the Journal of Pediatric
Gastroenterology and Nutrition, Journal of Cell Biology, and Molecular Biology of the Cell. She
has received grant funding from the National Institutes of Health and the Cystic Fibrosis Foundation.
Contents
Preface ..........................................................................................................................................
v
Series Editor Page ....................................................................................................................... vii
About the Author ........................................................................................................................ xiii
About Volume Editor .................................................................................................................. xvii
1
What Is Cystic Fibrosis? The Relationship Between Nutrition

and Outcomes in Cystic Fibrosis .......................................................................................
Danielle Usatin and Elizabeth H. Yen
Macronutrient Requirements ............................................................................................

Jaclyn Brownlee
11
Dietary Fat and Fat Metabolism in CF .............................................................................

Asim Maqbool and Birgitta Strandvik
35
Vitamin D and Bone Health ...............................................................................................

Jessica A. Alvarez and Vin Tangpricha
49
Vitamins and Minerals .......................................................................................................

Suzanne H. Michel and Donna H. Mueller
67
Nutrition in Infancy ............................................................................................................

Evans Machogu and Tami Miller
87
Nutritional Assessment: Age 220 Years ..........................................................................

Karen Maguiness and Molly Bozic
101
Nutrition Assessment: Adults and Obesity .......................................................................

Judith A. Fulton and Alexandra W.M. Wilson
117
Nutrition Intervention ........................................................................................................

Ala K. Shaikhkhalil, Suzanne H. Michel, Maria R. Mascarenhas,
and Virginia A. Stallings
129
10
Pancreatic Insufficiency......................................................................................................
Elissa Downs and Sarah Jane Schwarzenberg
149
xxi
xxii
Contents
11
Nutrition and Cystic Fibrosis Related Liver Disease .......................................................

Kristin J. Brown, Cathy Lingard, and Michael R. Narkewicz
12
Gastrointestinal Complications of Cystic Fibrosis and Their Impact

on Nutrition .........................................................................................................................
Daniel Gelfond
165
179
13
Nutritional Management of Cystic Fibrosis Related Diabetes Mellitus.........................

Katie Larson Ode and Carol Brunzell
191
14
Nutrition Pre and Post Lung Transplant ..........................................................................

Teresa Schindler
207
15
Pregnancy, Nutrition, and Cystic Fibrosis ........................................................................

Michelle Brotherwood
219
16
Nutrition for Pancreatic Sufficient Individuals with Cystic Fibrosis .............................

John F. Pohl and Catherine M. McDonald
231
17
Behavioral Interventions and Anticipatory Guidance ....................................................

Jamie L. Ryan, Stephanie S. Filigno, and Lori J. Stark
239
18
Nutrition and Quality Improvement in Cystic Fibrosis ..................................................

255
Index .............................................................................................................................................
265
Contributors
Jessica A. Alvarez, Ph.D., R.D. Division of Endocrinology, Metabolism, and Lipids Emory
University School of Medicine, Atlanta, GA, USA
Molly Bozic, M.D. Pediatric Gastroenterology, Riley Hospital for Children, Indianapolis, IN, USA
Michelle Brotherwood, R.D., C.D.E. Pulmonary, Childrens Hospital Los Angeles, Los Angeles,
CA, USA
Kristin J. Brown, M.S., R.D., C.N.S.C. Childrens Hospital Colorado, Aurora, CO, USA
Jaclyn Brownlee, R.D., C.N.S.C. Department of Nutrition and Food Service, UCSF Benioff
Childrens Hospital, San Francisco, San Francisco, CA, USA
Carol Brunzell, R.D., L.D., C.D.E. Diabetes Care Centers, University of Minnesota Health,
Fairview, Minneapolis, MN, USA
Elissa Downs, M.D., M.P.H. Department of Pediatric Gastroenterology, Hepatology, and Nutrition,
University of Minnesota Medical Center, Minneapolis, MN, USA
Stephanie S. Filigno, Ph.D. Division of Behavioral Medicine and Clinical Psychology, Cincinnati
Childrens Hospital Medical Center, Cincinnati, OH, USA
Judith A. Fulton, M.P.H., R.D., L.D.N. Clinical Nutrition, Childrens Hospital Colorado, University
of Colorado, Cystic Fibrosis Center, Aurora, CO, USA
Daniel Gelfond, M.D. WNY Pediatric Gastroenterology, Batavia, NY, USA
University of Rochester Medical Center, Rochester, NY, USA
Amanda Radmer Leonard, M.P.H., R.D., C.D.E. The Johns Hopkins Childrens Center,
Department of Pediatrics, Division of Gastroenterology and Nutrition, Baltimore, MD, USA
Cathy Lingard, R.D. Childrens Hospital Colorado, Aurora, CO, USA
Evans Machogu, M.B.Ch.B., M.S. Section of Pediatric Pulmonology, Allergy, and Sleep Medicine,
Indiana University Health, Indianapolis, IN, USA
Karen Maguiness, M.S., R.D., C.S.P. Pediatric Pulmonology, Riley Hospital for Children,
Indianapolis, IN, USA
xxiii
xxiv
Contributors
Asim Maqbool, M.D. Gastroenterology, Hepatology and Nutrition, The Childrens Hospital of
Philadelphia, University of Pennsylvania Perelman School of Medicine, Philadelphia, PA, USA
Maria R. Mascarenhas, M.B.B.S. Division of Gastroenterology, Hepatology and Nutrition,
Childrens Hospital of Philadelphia, Philadelphia, PA, USA
Perelman School of Medicine University of Pennsylvania, Philadelphia, PA, USA
Catherine M. McDonald, Ph.D., R.D.N. Division of Pediatric Gastroenterology, Department of
Pediatrics, Primary Childrens Hospital, University of Utah, Salt Lake City, UT, USA
Suzanne H. Michel, M.P.H., R.D., L.D.N. Pulmonary Medicine, Medical University of South
Carolina, Folly Beach, SC, USA
Tami Miller, R.D., C.S.P., C.D. Cystic Fibrosis Program, Childrens Hospital of Wisconsin,
Milwaukee, WI, USA
Donna H. Mueller, Ph.D., R.D. F.A.D.A., L.D.N., F.C.P.P. Department of Nutrition Sciences,
Drexel University, Philadelphia, Pennsylvania, USA
Michael R. Narkewicz, M.D. Childrens Hospital Colorado, Aurora, CO, USA
Section of Pediatric Gastroenterology, Hepatology and Nutrition, Department of Pediatrics, University
of Colorado School of Medicine, Aurora, CO, USA
Katie Larson Ode, M.D., M.S. University of Iowa Childrens Hospital, Iowa City, IA, USA
John F. Pohl, M.D. Division of Pediatric Gastroenterology, Department of Pediatrics, Primary
Childrens Hospital, University of Utah, Salt Lake City, UT, USA
Jamie L. Ryan, Ph.D. Division of Behavioral Medicine and Clinical Psychology, Cincinnati
Childrens Hospital Medical Center, Center for Adherence and Self-Management, Cincinnati,
OH, USA
Teresa Schindler, M.S., R.D.N. Pediatric Pulmonology, Rainbow Babies and Childrens Hospital
Case Medical Center, Cleveland, OH, USA
Sarah Jane Schwarzenberg, M.D. Department of Pediatric Gastroenterology, Hepatology, and
Nutrition, University of Minnesota Medical Center, Minneapolis, MN, USA
Ala K. Shaikhkhalil, M.D. Division of Gastroenterology, Hepatology and Nutrition, The Ohio State
University College of Medicine, Nationwide Childrens Hospital, Columbus, OH, USA
Virginia A. Stallings, M.D. Division of Gastroenterology, Hepatology and Nutrition, Childrens
Hospital of Philadelphia, Philadelphia, PA, USA
Lori J. Stark, Ph.D., A.B.P.P. Division of Behavioral Medicine and Clinical Psychology, Cincinnati
Childrens Hospital Medical Center, Cincinnati, OH, USA
Birgitta Strandvik, M.D., Ph.D. Department of Pediatrics and Department of Bioscience and
Nutrition, Karolinska Institutet, Huddinge, Stockholm, Sweden
Vin Tangpricha, M.D., Ph.D. Division of Endocrinology, Metabolism, and Lipids Emory University
School of Medicine, Atlanta, GA, USA
Contributors
xxv
Danielle Usatin, M.D. Department of Pediatrics, Division of Gastroenterology, Hepatology and

Nutrition, UCSF Benioff Childrens Hospital, San Francisco, San Francisco, CA, USA
Alexandra W.M. Wilson, M.S., R.D.N., C.D.E. Food Service and Clinical Nutrition, National
Jewish Health, Adult Cystic Fibrosis Program, Colorado Cystic Fibrosis Center, Denver, CO, USA
Elizabeth H. Yen, M.D. Department of Pediatrics, Division of Gastroenterology, Hepatology and
Nutrition, University of California, San Francisco, CA, USA
Benioff Childrens Hospital, San Francisco, CA, USA
Chapter 1
What Is Cystic Fibrosis? The Relationship Between

Nutrition and Outcomes in Cystic Fibrosis
Danielle Usatin and Elizabeth H. Yen
Key Points
Cystic brosis is the most common life-shortening, inherited disease in the USA
It is known to be an autosomal recessive disorder, caused by mutations in an ion channel, affecting
organs throughout the body
Appropriate nutrition remains inexorably linked with optimized outcomes
Optimal nutrition and growth throughout life remain the focus of the cystic brosis community
Keywords Cystic brosis Nutrition Outcomes Growth Malnutrition Pulmonary function
Pancreatic insufciency PERT
Introduction
Cystic brosis (CF) is the most common life-shortening inherited disease in the USA, affecting
approximately 30,000 children and adults. This autosomal recessive disorder is caused by mutations
in the gene encoding the cystic brosis transmembrane regulator (CFTR) [1]. CFTR is an ion channel
that is present in multiple organs throughout the body. Mutations in this gene are divided into ve
major categories. Class I, II, and III mutations generally result in more severe pulmonary disease and
pancreatic insufciency; CF patients with these mutations generally have symptomatic disease in
infancy or childhood. Class IV and V mutations typically result in milder disease, which is often
diagnosed later in life [2]. Neonatal screening catches most patients in the USA with diagnosis
conrmed by sweat or genetic testing. Diagnosis in the neonatal period leads to opportunities to
optimize nutrition earlier in life.
D. Usatin, M.D. (*)
Department of Pediatrics, Division of Gastroenterology, Hepatology and Nutrition, UCSF Benioff Childrens
Hospital, San Francisco, Mail Code 0136, 550 16th Street, 5th Floor, San Francisco, CA 94143, USA
e-mail: [email protected]
E.H. Yen, M.D.
Department of Pediatrics, Division of Gastroenterology,
Hepatology and Nutrition, University of California, San Francisco, CA, USA
Benioff Childrens Hospital, San Francisco, CA, USA
e-mail: [email protected]; [email protected]
E.H. Yen, A.R. Leonard (eds.), Nutrition in Cystic Fibrosis: A Guide for Clinicians, Nutrition and Health,
DOI 10.1007/978-3-319-16387-1_1, Springer International Publishing Switzerland 2015
D. Usatin and E.H. Yen
History of Cystic Fibrosis

Historically, infants with cystic brosis were identied by their salty sweat and failure to thrive. German
literature dating back to the eighteenth century cautioned: [w]oe to the child who tastes salty from a
kiss on the brow, for he is cursed and soon must die. [3] The clinical spectrum of cystic brosis was not
claried until the early twentieth century. At that time, children with cystic brosis were often mistakenly
classied as having celiac disease because of their poor growth, distended abdomen, and diarrhea
(Fig. 1.1). In the 1930s, several case series reported children who carried the diagnosis of celiac disease
with unusual presentations. They were born with meconium plugging and died early in life. Autopsy
found them to have changes in their lung, pancreas, and liver. Dr. Dorothy Andersen rst described this
constellation calling it cystic brosis of the pancreas in 1938, differentiating these patients from those
with failure to thrive and steatorrhea due to celiac disease. She linked brotic changes in the pancreas
with bronchiectasis in the lungs [4]. Dr. Andersens paper combined 20 of her cases with those reported
by other physicians and previous publications. This seminal paper led to the recognition of cystic
brosis as a disease of exocrine pancreatic insufciency and recurrent pulmonary infections.
Fig. 1.1 A child with cystic brosis at 1 year 7 months (a); lungs at 1 year 2 months (b), lungs (c) and patient (d) at 2
years 5 months (c). Reprinted from The Journal of Pediatrics, Volume 34 (6), May CD and Lowe CU, Fibrosis of the
pancreas in infants and children: An illustrated review of certain clinical features with special emphasis on the pulmonary
and cardiac aspects. p. 674, Copyright 1949, with permission from Elsevier
What Is Cystic Fibrosis? The Relationship Between Nutrition and Outcomes in Cystic Fibrosis
When Andersen and others described cystic brosis in the 1930s, malnutrition was the main cause
of death. Until the mid-twentieth century, many cystic brosis patients died in childhood from a
combination of malnutrition and lung disease. Children with cystic brosis were noted to be smaller
in weight and stature than their healthy siblings [5].
Thanks to improvements in nutritional and pulmonary management, life expectancy has increased
in this population from death in childhood to a mean survival into the fourth decade of life [6]. Despite
changing therapies, malnutrition and growth retardation remain common in this patient population.
In 2001, 25% of children in the Cystic Fibrosis Foundation Registry had a weight less than the 10th
percentile for age according to the CDC growth curves. This has improved only slightly over the last
decade, to 15% in 2011 [6].
Affects of Cystic Fibrosis on Nutrition

Cystic brosis affects all organ systems, causing a systemic impact on growth and nutrition. Patients
suffer from increased energy expenditure, decreased caloric intake, as well as nutrient losses from
malabsorption. Pulmonary exacerbations, with cough, tachypnea, infection, and post-tussive emesis
lead to both increased energy expenditures and decreased appetite. Resting energy requirements in
patients with cystic brosis are higher than their non-diseased siblings [5]. Chronic inammation
likely also results in decreased growth, although the mechanism remains poorly understood. Pancreatic
insufciency and alterations in bile salts lead to poor absorption of nutrients. Cystic brosis patients
thus struggle to maintain adequate nutritional intake to support growth and development.
Treatment with Pancreatic Enzymes

At least 85% of patients with cystic brosis are born with pancreatic insufciency. More than 25% of
those remaining develop pancreatic insufciency within 3 years of age [79]. Pancreatic dysfunction
and destruction begins in the womb. It is caused by thickened secretions obstructing intrapancreatic
ducts. Over time the pancreas undergoes autolysis and replacement of the body of the pancreas with
fat [2]. When only 10% of pancreas functionality is left patients develop the symptoms of pancreatic
insufciency [9]. Pancreatic Enzyme Replacement Therapy (PERT) has long been the method of
treatment for maldigestion due to pancreatic insufciency. Porcine pancreatic enzymes were available
prior to the publishing of the Federal Food, Drug and Cosmetic Act of 1938, so they were not required
to undergo review by the FDA for safety and efcacy prior to marketing [10]. Early formulations of
pancreatic enzyme were obtained by freeze-drying hog pancreas and then extracting and purifying the
enzymes. They were recommended in children who had oily stools suggestive of fat malabsorption,
but they were not well tolerated, largely due to bad taste. Many pediatricians and families felt that the
enzymes adversely affected childrens appetites. Thus, they were not widely used as therapy for the
rst 20 years.
In 1955, Harris et al. reported improvement of fat absorption from 46 to 71% of daily intake with
use of pancreatin [11]. Subsequently PERT became a more standard part of therapy. In that same year,
the National Cystic Fibrosis Research Foundation (later called the Cystic Fibrosis Foundation) was
formed in New York. Optimizing PERT in cystic brosis became an active area of interest and
research, largely thanks to the foundations efforts.
In the 1970s, the formation of cystic brosis specialty centers in many major cities led to more
consistent and aggressive treatment of malabsorption and other conditions associated with CF. As
children survived through adolescence, their nutritional state and growth deteriorated progressively.
Despite the known effect of pancreatic enzymes in improving fat absorption, specialized diets high in
protein and low in fat like the Allan diet [12, 13] were initially popularized and somewhat successful
[14]. This was mainly due to the inconsistency and intolerability of pancreatic enzymes.
Early preparations of pancreatic enzymes were also not as effective as modern ones due to the fact
that they were inactivated in the acidic environment of the stomach [10]. The co-administration of
acid suppression medication with pancreatin helped alleviate this problem [15]. The Hospital for Sick
Children in Toronto was one of the rst centers to show improved outcomes with high fat diets and
large doses of pancreatic enzymes [16]. In the 1980s, acid resistant formulations became available
that were more effective and widely adopted [10]. Cystic brosis centers started to use dietitians as
part of their integrated care approach, as evidence accumulated that early, aggressive PERT and
nutritional support improved survival.
For example, a 1988 comparison of outcomes in Boston and Toronto demonstrated better survival
rates in Toronto. The most signicant difference between these two centers was the improved
nutritional outcomes among those in Toronto. This was thought to be due to their aggressive
supplementation of pancreatic enzymes and increased dietary fat and vitamin supplements [17]. This
nding led to the development of more specic PERT guidelines, which were published as part of the
rst Cystic Fibrosis Foundation Nutritional Consensus Report in 1992 [18].
Associations with Malnutrition in Cystic Fibrosis

Poor nutritional status has long been associated with worse clinical outcomes in cystic brosis
patients. As early as the 1970s, it was clear that vigorous attention to care with aggressive pulmonary
interventions and appropriate nutrition led to longer survival [16, 19, 20]. In 1992, Kerem et al. noted
that poor nutrition predicted earlier mortality [21]. Several studies followed demonstrating that
nutritional rehabilitation with supplemental feedings improved lung function in patients whose Forced
Expiratory Volume in 1 second (FEV1) started at less than 40% predicted [22, 23]. Among cystic
brosis patients with advanced lung disease, better nutritional status is associated with higher exercise
tolerance [24].
Earlier diagnosis of cystic brosis allows for early, intensive nutritional support. This has been a
major contributor to improvements in long-term survival and decreased morbidity [21, 2531].
Multiple subsequent studies have demonstrated that early nutritional interventions and improved
anthropomorphic measures have a positive impact on lung function in childhood [29, 30, 3234].
In 2001 a randomized clinical trial compared CF diagnosis by universal neonatal screening to
traditional, symptom-driven diagnostic workup. This trial reported that earlier diagnosis with neonatal
screening prevented malnutrition and promoted long-term growth in the patients with CF [35].
Additional studies have repeatedly demonstrated that neonatal screening leads to fewer pulmonary
exacerbations, fewer hospital days, and better growth parameters in childhood [36, 37]. Researchers
hypothesize that early malnutrition affects lung growth and development. Rao et al. found in a cross
sectional study that on high resolution computed tomography lung volume was very closely correlated
with body length in healthy infants and toddlers [38]. Animal models also suggest that poor nutrition
early in life may result in poor lung development and disease progression [39].
The links between adequate nutrition and pulmonary outcomes provided a foundation for the
second Consensus Report on Nutrition commissioned by the Cystic Fibrosis Foundation in 2002. The
purpose of this report was to help cystic brosis care centers identify undernourished patients and
give guidance on interventions. This report recommended the Moore method of calculating percent
Ideal Body Weight (%IBW), as well as weight-for-length percentile and BMI percentile based on the
CDC 2000 growth curves. This allowed stratication of patient nutritional status as acceptable, at
risk, or in nutritional failure. Height was classied by genetic potential using mid parental heights.
Patients classied as having acceptable growth parameters had weight-for-length or BMI greater than
the 25 percentile for age, and IBW 90% [40]. If patients fell into the nutritional failure category,
the guidelines recommended targeted interventions to promote growth by boosting their weight.
Subsequent to the 2002 nutritional consensus guidelines, several publications supported even more
aggressive nutritional goals. Peterson et al. prospectively collected data on over 300 children followed
at the Minnesota Cystic Fibrosis Center. They demonstrated that each 1 kg of weight was associated
with 55 mL higher average FEV1. During their follow-up period, children with steady weight gain had
greater increases in FEV1 than those whose weight gain was not steady [30]. Also publishing in 2003,
Konstan et al. reported on the Epidemiology Study of Cystic Fibrosis (ESCF). They followed 931
patients cared for at 139 different centers in the USA and Canada from age 3 to at least age 6. They
noted that weight-for-age and height-for-age were strong predictors of FEV1 at age 6 years. Weightfor-age maintained above the 10th percentile from age 3 to 6 was associated with better lung function
when compared to patients who fell below the 10th percentile at age 6 after previously being above it
age 3 [29].
The implementation of %IBW as a standard for determining optimal growth parameters, as
recommended in the 2002 guidelines, proved difcult and cumbersome for many centers. They found
poor reproducibility of this measure between patients and in any given patient poor reducibility
between examiners [41]. Furthermore, patients nutritional status might be classied differently
depending on the anthropomorphic index used [42]. Zhang and Lai compared %IBW and BMI as
predictors of undernourishment and lung function in 2004. They found good agreement between the
two indices in children <10 years of age with average stature. But, in older children and in children
with height-for-age outside of 2575th percentile they found that these two measures diverged
signicantly. Even more striking, however, was their nding that in all ranges of stature, BMI
percentile more sensitively predicted improvements in lung function [43].
In 2008, the Cystic Fibrosis Foundation Subcommittee on Growth and Nutrition updated their
recommendations again based on interim evidence. BMI and BMI percentile replaced %IBW for
dening nutritional status. Additionally, they published a series of graphs demonstrating, in varying
age categories, an association between higher BMI percentile and FEV1 percent-predicted for age
(Fig. 1.2). Furthermore, evidence suggested that among cystic brosis patients, reaching 50th
percentile weight-for-length at age 2 years correlated signicantly with higher percent-predicted
FEV1 at age 6 through 15. Higher BMI also seemed to correlate with pulmonary function in adults
[44] (Fig. 1.3). BMI goals were set conservatively at 50th BMI percentile for all children, 22 kg/m2
for adult females, and 23 kg/m2 for adult males. The committee also recommended interventions
to help children reach 50th percentile weight-for-length by 2 years of age.
More recently, Lai et al. demonstrated that children who recovered their birth weight z-score by
age 2 years had overall better lung function at 6 years of age [45]. Additionally, a link between
pulmonary disease severity and delayed growth velocities has been demonstrated [46]. Yen et al.
demonstrated that at age 4 years, weight-for-age strongly predicted height and growth velocity.
Moreover, weight-for-age percentile at age 4 predicted lung function as measured by percent-predicted
FEV1 at age 18. Weight and height-for-age percentiles at age 4 years correlated with survival, fewer
pulmonary exacerbations, and fewer days in the hospital at age 18 years [47] (Fig. 1.4). Given that
lung volume expands with height [48], these ndings suggest that greater weight at age 4 may lead to
larger lung volumes and enhanced pulmonary reserve.
Despite the strength of the literature to support the association between anthropomorphic
parameters and pulmonary outcomes in cystic brosis there remain several areas in need of further
research. Many have demonstrated that systematic implementation of PERT and enteral supplements
improve weight gain [22, 23]. Clinical trials to evaluate if nutritional interventions that increase
weight percentiles result in a slower rate of pulmonary functional decline are needed. Specically,
children between the 10th and 50th percentiles should be targeted to nd the optimal zone for
aggressive nutritional intervention. Thus far, cystic brosis care providers have set the goal of normal
Fig. 1.2 Association of BMI percentile and percent-predicted FEV1 for children with cystic brosis and pancreatic
insufciency by age and sex group, from the 2005 Cystic Fibrosis Patient Registry. Reprinted from Journal of the
American Dietetic Association, VA Stallings, LJ Stark, KA Robinson, AP Feranchak, H Quinton, Evidence-Based
Practice Recommendations for Nutrition-Related Management of Children and Adults with Cystic Fibrosis and
Pancreatic Insufciency: Results of a Systematic Review. Pages 835, Copyright 2008, with permission from Elsevier
Fig. 1.3 Association of BMI and percent-predicted FEV1 in adults aged 21 to 40 years with cystic brosis and
pancreatic insufciency, from the 1994 to 2003 Cystic Fibrosis Patient Registry. Reprinted from Journal of the American
Dietetic Association, VA Stallings, LJ Stark, KA Robinson, AP Feranchak, H Quinton, Evidence-Based Practice
Recommendations for Nutrition-Related Management of Children and Adults with Cystic Fibrosis and Pancreatic
Insufciency: Results of a Systematic Review. Pages 836, Copyright 2008, with permission from Elsevier
Fig. 1.4 KaplanMeier survival curves of patients with CF born between 1989 and 1992, stratied by A, weight and
B, height categories at age 4 years. Reprinted from The Journal of Pediatrics, EH Yen, H Quinton, D Borowitz. Better
Nutritional Status in Early Childhood Is Associated with Improved Clinical Outcomes and Survival in Patients with
Cystic Fibrosis. Page 533, Copyright 2013, with permission from Elsevier
anthropomorphic measures. Perhaps further consideration needs to be taken to individual inherited

variance in patient size.
Prospective clinical trials to evaluate if nutritional interventions that increase weight percentiles
result in a slower rate of lung function decline are needed. Signicant resources and stress on the part
of patients and their families go into meeting nutritional goals. It is important that a direct causal link
between efforts to achieve these goals and better outcomes is made. A cluster randomization model
would be an ideal method to evaluate this question and could target children with BMI ranges between
the 25th and 50th percentiles with aggressive nutritional interventions versus standard of care, which
already calls for increased interactions with a CF dietitian for dietary counseling. An aggressive
nutritional intervention could be a combination of increased visit frequency, frequent contact with
patients in between visits either via telephone calls or digital media, maximizing PERT, consultation
with relevant subspecialties (e.g., Gastroenterology and Endocrinology) and introduction of high
calorie nutritional supplements.
Francis and Welch identied the disease causing mutation in 1989 [1]. This breakthrough discovery
marked a turning point in cystic brosis research and the search for a cure for the disease. At the
forefront of current therapies are treatments that improve the function of the defective CFTR protein.
These therapies have already shown that they can halt the progression of CF end-organ damage, and
sometimes even reverse pulmonary damage. Despite the hope that these therapies hold for the health
and longevity of patients with cystic brosis, patients will continue to require careful monitoring of
their health, with special attention to their lung function and nutritional status.
References
1. Riordan JR, Rommens JM, Kerem B, Alon N, Rozmahel R, Grzelczak Z, et al. Identication of the cystic brosis
gene: cloning and characterization of complementary DNA. Science. 1989;245(4922):106673.
2. O'Sullivan BP, Freedman SD. Cystic brosis. Lancet. 2009;373(9678):1891904.
3. Busch R. On the history of cystic brosis. Acta Univ Carol Med. 1990;36(14):135.
4. Andersen DH. Cystic brosis of the pancreas and its relation to celiac disease: a clinical and pathologic study. Am
J Dis Child. 1938;56(2):34499.
5. Anthony H, Bines J, Phelan P, Paxton S. Relation between dietary intake and nutritional status in cystic brosis.
Arch Dis Child. 1998;78(5):4437.
6. Cystic Fibrosis Foundation. Patient Registry 2011: Annual Report. Bethesda, MD: Cystic Fibrosis Foundation 2011.
7. Waters DL, Dorney SF, Gaskin KJ, Gruca MA, O'Halloran M, Wilcken B. Pancreatic function in infants identied
as having cystic brosis in a neonatal screening program. N Engl J Med. 1990;322(5):3038.
8. Bronstein MN, Sokol RJ, Abman SH, Chateld BA, Hammond KB, Hambidge KM, et al. Pancreatic insufciency,
growth, and nutrition in infants identied by newborn screening as having cystic brosis. J Pediatr. 1992;120
(4 Pt 1):53340.
9. Couper RT, Corey M, Moore DJ, Fisher LJ, Forstner GG, Durie PR. Decline of exocrine pancreatic function in
cystic brosis patients with pancreatic sufciency. Pediatr Res. 1992;32(2):17982.
10. Somaraju UR, Solis-Moya A. Pancreatic enzyme replacement therapy for people with cystic brosis. Cochrane
Database Syst Rev. 2014;10, CD008227.
11. Harris R, Norman AP, Payne WW. The effect of pancreatin therapy on fat absorption and nitrogen retention in
children with brocystic disease of the pancreas. Arch Dis Child. 1955;30(153):4247.
12. Allan JD, Milner J, Moss D. Therapeutic use of an articial diet. Lancet. 1970;1(7650):7856.
13. Allan JD, Mason A, Moss AD. Nutritional supplementation in treatment of cystic brosis of the pancreas. Am J Dis
Child. 1973;126(1):226.
14. Berry HK, Kellogg FW, Hunt MM, Ingberg RL, Richter L, Gutjahr C. Dietary supplement and nutrition in children
with cystic brosis. Am J Dis Child. 1975;129(2):16571.
15. Graham DY. Pancreatic enzyme replacement: the effect of antacids or cimetidine. Dig Dis Sci. 1982;27(6):48590.
16. Crozier DN. Cystic brosis: a not-so-fatal disease. Pediatr Clin North Am. 1974;21(4):93550.
17. Corey M, McLaughlin FJ, Williams M, Levison H. A comparison of survival, growth, and pulmonary function in
patients with cystic brosis in Boston and Toronto. J Clin Epidemiol. 1988;41(6):58391.
18. Ramsey BW, Farrell PM, Pencharz P. Nutritional assessment and management in cystic brosis: a consensus report.
The Consensus Committee. Am J Clin Nutr. 1992;55(1):10816.
19. Chase HP, Long MA, Lavin MH. Cystic brosis and malnutrition. J Pediatr. 1979;95(3):33747.
20. Phelan PD, Allan JL, Landau LI, Barnes GL. Improved survival of patients with cystic brosis. Med J Aust.
1979;1(7):2613.
21. Kerem E, Reisman J, Corey M, Canny GJ, Levison H. Prediction of mortality in patients with cystic brosis. N Engl
J Med. 1992;326(18):118791.
22. Efrati O, Mei-Zahav M, Rivlin J, Kerem E, Blau H, Barak A, et al. Long term nutritional rehabilitation by
gastrostomy in Israeli patients with cystic brosis: clinical outcome in advanced pulmonary disease. J Pediatr
Gastroenterol Nutr. 2006;42(2):2228.
23. Walker SA, Gozal D. Pulmonary function correlates in the prediction of long-term weight gain in cystic brosis
patients with gastrostomy tube feedings. J Pediatr Gastroenterol Nutr. 1998;27(1):536.
24. Marcotte JE, Canny GJ, Grisdale R, Desmond K, Corey M, Zinman R, et al. Effects of nutritional status on exercise
performance in advanced cystic brosis. Chest. 1986;90(3):3759.
25. Augarten A, Akons H, Aviram M, Bentur L, Blau H, Picard E, et al. Prediction of mortality and timing of referral
for lung transplantation in cystic brosis patients. Pediatr Transplant. 2001;5(5):33942.
26. Beker LT, Russek-Cohen E, Fink RJ. Stature as a prognostic factor in cystic brosis survival. J Am Diet Assoc.
2001;101(4):43842.
27. Dalzell AM, Shepherd RW, Dean B, Cleghorn GJ, Holt TL, Francis PJ. Nutritional rehabilitation in cystic brosis:
a 5 year follow-up study. J Pediatr Gastroenterol Nutr. 1992;15(2):1415.
28. George L, Norman AP. Life tables for cystic brosis. Arch Dis Child. 1971;46(246):13943.
29. Konstan MW, Butler SM, Wohl ME, Stoddard M, Matousek R, Wagener JS, et al. Growth and nutritional indexes
in early life predict pulmonary function in cystic brosis. J Pediatr. 2003;142(6):62430.
30. Peterson ML, Jacobs Jr DR, Milla CE. Longitudinal changes in growth parameters are correlated with changes in
pulmonary function in children with cystic brosis. Pediatrics. 2003;112(3 Pt 1):58892.
31. Liou TG, Adler FR, Fitzsimmons SC, Cahill BC, Hibbs JR, Marshall BC. Predictive 5-year survivorship model of
cystic brosis. Am J Epidemiol. 2001;153(4):34552.
32. Zemel BS, Jawad AF, FitzSimmons S, Stallings VA. Longitudinal relationship among growth, nutritional status,
and pulmonary function in children with cystic brosis: analysis of the Cystic Fibrosis Foundation National CF
Patient Registry. J Pediatr. 2000;137(3):37480.
33. Steinkamp G, Wiedemann B. Relationship between nutritional status and lung function in cystic brosis: cross sectional
and longitudinal analyses from the German CF quality assurance (CFQA) project. Thorax. 2002;57(7):596601.
34. McPhail GL, Acton JD, Fenchel MC, Amin RS, Seid M. Improvements in lung function outcomes in children with
cystic brosis are associated with better nutrition, fewer chronic pseudomonas aeruginosa infections, and dornase
alfa use. J Pediatr. 2008;153(6):7527.
35. Farrell PM, Kosorok MR, Rock MJ, Laxova A, Zeng L, Lai HC, et al. Early diagnosis of cystic brosis through
neonatal screening prevents severe malnutrition and improves long-term growth. Wisconsin Cystic Fibrosis
Neonatal Screening Study Group. Pediatrics. 2001;107(1):113.
36. Siret D, Bretaudeau G, Branger B, Dabadie A, Dagorne M, David V, et al. Comparing the clinical evolution of cystic
brosis screened neonatally to that of cystic brosis diagnosed from clinical symptoms: a 10-year retrospective
study in a French region (Brittany). Pediatr Pulmonol. 2003;35(5):3429.
37. Sims EJ, Clark A, McCormick J, Mehta G, Connett G, Mehta A, et al. Cystic brosis diagnosed after 2 months of
age leads to worse outcomes and requires more therapy. Pediatrics. 2007;119(1):1928.
38. Rao L, Tiller C, Coates C, Kimmel R, Applegate KE, Granroth-Cook J, et al. Lung growth in infants and toddlers
assessed by multi-slice computed tomography. Acad Radiol. 2010;17(9):112835.
39. Gaultier C. Malnutrition and lung growth. Pediatr Pulmonol. 1991;10(4):27886.
40. Borowitz D, Baker RD, Stallings V. Consensus report on nutrition for pediatric patients with cystic brosis.
J Pediatr Gastroenterol Nutr. 2002;35(3):24659.
41. Poustie VJ, Watling RM, Ashby D, Smyth RL. Reliability of percentage ideal weight for height. Arch Dis Child.
2000;83(2):1834.
42. Lai HC, Kosorok MR, Sondel SA, Chen ST, FitzSimmons SC, Green CG, et al. Growth status in children with
cystic brosis based on the National Cystic Fibrosis Patient Registry data: evaluation of various criteria used to
identify malnutrition. J Pediatr. 1998;132(3 Pt 1):47885.
43. Zhang Z, Lai HJ. Comparison of the use of body mass index percentiles and percentage of ideal body weight to
screen for malnutrition in children with cystic brosis. Am J Clin Nutr. 2004;80(4):98291.
44. Stallings VA, Stark LJ, Robinson KA, Feranchak AP, Quinton H, Clinical Practice Guidelines on Growth and
Nutrition Subcommittee, et al. Evidence-based practice recommendations for nutrition-related management of
children and adults with cystic brosis and pancreatic insufciency: results of a systematic review. J Am Diet
Assoc. 2008;108(5):8329.
45. Lai HJ, Shoff SM, Farrell PM, Wisconsin Cystic Fibrosis Neonatal Screening Group. Recovery of birth weight z
score within 2 years of diagnosis is positively associated with pulmonary status at 6 years of age in children with
cystic brosis. Pediatrics. 2009;123(2):71422.
46. Assael BM, Casazza G, Iansa P, Volpi S, Milani S. Growth and long-term lung function in cystic brosis: a
longitudinal study of patients diagnosed by neonatal screening. Pediatr Pulmonol. 2009;44(3):20915.
47. Yen EH, Quinton H, Borowitz D. Better nutritional status in early childhood is associated with improved clinical
outcomes and survival in patients with cystic brosis. J Pediatr. 2013;162(3):530535. e1.
48. Wang X, Dockery DW, Wypij D, Fay ME, Ferris Jr BG. Pulmonary function between 6 and 18 years of age. Pediatr
Pulmonol. 1993;15(2):7588.
Chapter 2
Macronutrient Requirements
Jaclyn Brownlee
Key Points
Many individuals with cystic brosis will likely require higher nutrient intakes in order to overcome
losses in the stool and to achieve expected growth or weight gain/maintenance. However needs are
very individualized and will depend on many factors including severity of illness.
Calorie needs will be best determined by each individuals current intake as well as their clinical
and nutritional status.
Patients, especially those with high energy needs, may benet from a diet higher in fat (approximately
35% of total calories).
Protein is an important nutrient to prevent catabolism; recommended intakes are 1.52 times
greater than the recommended daily allowance or ~15% of total calories.
There are no specic recommendations for carbohydrate provision and intake is generally adequate
in people with CF.
With adequate enzyme intake, no clear benet of medium chain fats or hydrolyzed proteins has
been found compared to long chain fats except for in patients with additional digestive and/or
allergic issues.
Due to concern about the ongoing oxidative stress it has been suggested that patients with CF may
benet from a diet rich in antioxidants to help optimize the benets of a high fat diet.
There is no clear consensus on the appropriate amount of ber to provide to individuals with
CF. As ber-rich foods, in particular fruits, vegetables, legumes, and whole grains, provide the
additional benet of being rich in vitamins, minerals, and antioxidants it may be wise to recommend
that patients incorporate these foods into their diets. However, it should be noted that high ber
intake may cause more problems, including calorie displacement and possible abdominal pain
exacerbations.
Personalized diet assessment and recommendations are best for patients with cystic brosis.
When giving patients recommendations on recommended macronutrient intake, patients may be
able to work better with the number of grams/day (as opposed to percent of diet) as this information
is readily available on food labels or calorie tracker programs.
J. Brownlee, R.D., C.N.S.C. (*)

Department of Nutrition and Food Services, UCSF Benioff Childrens Hospital San Francisco,
1855 4th Street, San Francisco, CA 94143, USA
11
J. Brownlee
12
Keywords Calories Energy expenditure Estimated energy requirement Fat Antioxidants

Protein Protein hydrolysate Catabolism Carbohydrate Fiber
Abbreviations
BMI
CF
CFRD
DIOS
EER
EFAD
g
kcal
LCT
MCT
MUFA
PA
PERT
PI
PS
PUFA
RDA
REE
RQ
SFA
TEE
Body mass index

Cystic brosis
Cystic brosis-related diabetes
Distal intestinal obstruction syndrome
Estimated energy needs
Essential fatty acid deciency
Gram
Kilocalorie
Long chain triglycerides
Medium chain triglycerides
Monounsaturated fatty acid
Physical activity
Pancreatic enzyme replacement therapy
Pancreatic insufcient
Pancreatic sufcient
Polyunsaturated fatty acid
Recommended daily allowance
Resting energy expenditure
Respiratory quotient
Saturated fatty acid
Total energy expenditure
Introduction
When discussing cystic brosis and nutrition an important topic is the question of are all calories
created equal? This chapter will review the available literature regarding kilocalorie and macronutrient
recommendations for people with cystic brosis (CF). The history behind and changes leading up to
current nutrition standards will also be addressed. There are several recommendations about energy
and nutrient requirements in CF that have been so frequently espoused that they virtually seem to be
common knowledge and solid fact- when in actuality rm guidelines are difcult to nd. This chapter
will explore the sometimes controversial and contradictory nutrition recommendations with the goal
of providing realistic calorie and macronutrient intake goals for individuals with CF based on the
current state of the literature.
Calories
Given the well-dened need for people with CF to receive adequate nutrition for proper growth and
to promote improved prognosis [17], the goal of determining just how many calories are needed has
been a prominent point of many studies conducted in the CF population. Energy needs are thought to
2 Macronutrient Requirements
13
be affected by gastrointestinal symptoms [810] as well as pulmonary symptoms [11] in addition to

the usual factors considered in the general population: gender, age, weight, height, and physical
activity levels [12].
An often cited recommendation is to provide 120150% of the recommended daily allowance
(RDA) for energy to allow for the goal of normal growth for age [1316] by compensating for
malabsorption and increased calorie needs secondary to pulmonary dysfunction and any required
catch up growth [13, 16]. This recommendation has historically been validated by studies which
reported that individuals with CF have an increased resting energy expenditure (REE) compared to
healthy controls [1732] or to estimated values based on predictive equations [3338]. However,
controversy surrounds these ndings. While many studies support increased REE and a few have
observed increased total energy expenditure (TEE) [39, 40], most studies did not observe an increase
in TEE when it was measured as a study outcome [30, 4144]. A handful of studies even suggest that
REE is not actually elevated in CF patients [4345].
Energy Expenditure in Cystic Fibrosis

A multitude of studies on the measurement of energy expenditure in CF patients have resulted in
conicting ndings.
Several studies have found increased REE values in CF patients based on the comparison of
indirect calorimetry measurements with predictive equations and/or control subjects. This difference
has appeared to be more pronounced in CF patients with more severe respiratory disease [1719,
33, 34]. Even when the measurements were corrected for ideal weight-for-height or lean body
mass, the REE measurements remained elevated in the CF subjects [17, 18]. When compared to
malnourished individuals with anorexia nervosa, CF subjects had a much higher REE. The REE of
the anorexic subjects was less than predicted, suggesting that the increased REE in CF was not due
to malnutrition [17]. Yet other studies failed to nd a relationship between REE and severity of lung
disease [2022, 35].
Pancreatic status may contribute to differences in REE, with pancreatic insufciency associated
with an elevated REE compared to pancreatic sufciency [23, 3335]. In fact, the pancreatic sufcient
(PS) patients tended to have normal REE [33, 34]. One study observed that REE was increased in PI
subjects even when compared to PS individuals with similar pulmonary function test results leading
to the possible conclusion that pancreatic status contributes more to REE than respiratory status [34].
The inuence of gender on REE has also been investigated. The majority of these studies have
found that while CF subjects in both genders have higher REE than expected, the REE of CF females
tends to be more elevated above expected values [23, 35] or more likely to increase over time [20]
compared to the REE of CF males. The REE in CF females is increased compared to healthy females
even when controlling for fat free mass and pubertal stage [19, 24]. In studies on the effect of puberty,
REE decreased post-menarche in all subjects compared to pre-menarche but remained higher in
subjects with CF [19, 24].
The effect of an acute pulmonary exacerbation on the REE of CF patients has been another area of
study. While some studies have found REE measurements decrease between the early part and the end
of an exacerbation, others have found no change [36, 37, 46]. REE increases during the initial days of
a hospital stay may possibly be due to increased energy consumption and/or increased physical
therapy and mucous clearance [37]. A trend for the patients with the highest REE at the beginning of
an exacerbation to have the largest decrease by the end of the exacerbation has been observed [36, 37].
TEE has been observed to remain similar to baseline, or even lower, during the exacerbation despite
increases in measured REE [46]. It is possible that the trend for a lower TEE during illness is due to
decreased physical activity [46].
14
J. Brownlee
Studies on the energy cost of activity in CF have yielded various results. Several studies have found
that CF patients required less or the same amount of additional energy on top of their REE in order to
complete the same activities as controls [25, 26, 45]. A nding that TEE was not elevated above
controls despite an increased REE in CF subjects led to the conclusion that CF patients are able to
compensate for their increased REE [25]. Conversely, other investigations have indeed observed an
elevated energy cost of activity in CF patients compared to controls [21]. Differences in the length of
the measured activities and use of fat free mass to assess REE may have contributed to the contradictory
ndings [21].
Several researchers have suggested that the increased energy expenditure in CF patients is due to a
genetically linked metabolic abnormality [18, 2730, 47, 48]. This conclusion was reached due to
noting that the increased REE or TEE was not fully explained by pulmonary function [2729] or
differences in weight [18, 39] and/or by nding differences in the energy expenditure in individuals
of various CF genotypes [2729, 48]. Mitochondrial dysfunction has been cited as a cause of increased
energy expenditure [48]. However, not all studies have found evidence to support such a genetic link
[20, 21], and others have suggested that at most the genetic contribution to increased energy
expenditure is minimal [33]. This issue has been further explored by studying the energy expenditure
of infants and young children with CF, as these patients should be without signicant lung disease.
Thus elevations in their energy expenditure may reect an intrinsic energy-consuming defect. Two
studies found an elevated REE in CF infants versus controls per kilogram weight and per kilogram fat
free mass or total body potassium [30, 31]. Other investigators have found elevated TEE in infants
older than 6 months and in toddlers [39, 40], but a lack of assessment of the effect of fat free mass on
the measured energy expenditure may have contributed to this nding [39, 41]. Studies of infants
under six months of age have not found a difference in TEE between CF subjects and controls [40, 42,
43], supporting the argument that disease progression, rather than an intrinsic genetic defect, is the
primary cause of elevated energy needs.
Translating Energy Expenditure into Energy Needs

The vast majority of the available studies conclude that REE is generally increased in individuals with
CF, from approximately 105 to 130% of expected. There is a wide variety of ages and levels of disease
severity within the studied CF subjects. The methods utilized to determine the expected REE also
varied between the studies. Some utilized predictive equations that have questionable accuracy in
healthy groups [31] and others referred to the RDA values, which have changed over the years. Due
to these factors, it is difcult to fully compare all of the studies and draw concrete conclusions for
estimating energy needs in CF. Within the studies that do conclude that REE is elevated, there is still
debate as to whether or not certain disease characteristics, such as pulmonary function, pancreatic
status, nutritional status, and specic alleles contribute to energy expenditure. There is also not a clear
nding as to whether the energy cost of activity is different in the CF population compared to the
healthy population. The general consensus is that TEE is not elevated in CF compared to healthy
controls. However, it is not known how CF patients may compensate for their likely high basal
metabolic rate in order to yield normal TEE. It is agreed that the normalization of TEE in CF by a
spontaneous decrease in physical activity should be prevented by ensuring adequate nutrition intake
[25]; however it is not certain that decreased activity in CF is truly the case [25, 28].
Another factor to consider is how much of their consumed intake CF patients are able to utilize.
Having similar total energy expenditure to the healthy population does not necessarily indicate that an
individual with CF can consume the same amount as a healthy person and reap the same nutritional
benet. CF patients on established pancreatic enzyme replacement therapy (PERT) with controlled
15
gastrointestinal symptoms have been found to have higher stool energy and stool fat losses than the
healthy population [9, 49, 50]. This suggests that CF patients may still experience some degree of
malabsorption despite receiving standard treatment for PI.
One group of investigators measured the TEE of CF children aged 68 years old with mild-tomoderate lung disease. Measured fecal energy loss and standardized energy required for growth were
added to the TEE to better estimate the total energy requirement for each subject [51]. The results were
compared to multiple predictive equations to determine which was most accurate for predicting energy
needs in children with CF. The estimated energy requirement (EER) equation with an active physical
activity level factor (1.26 in boys and 1.31 in girls) [12] was the most consistent with the study results at
both group and individual levels. Further, it was observed that the 1989 RDA, the 1989 RDA multiplied
by 1.2, and equations developed for estimating energy needs in CF all overestimated needs, with the
RDA multiplied by 1.2 resulting in the largest overestimation. However, these results are not necessarily
applicable to CF populations of different ages or with more progressed lung disease [51].
What Happens in Real Life?

Actual intake in CF patients has been measured many times over the years. Diet records maintained
by CF individuals have been compared to control subjects and to national standards to determine if
the patients actually consume the minimum goal of 120% of the recommended calorie intake for the
population. Growth and nutritional status have been assessed in comparison to dietary intake. Overall,
the studies from recent decades have found that individuals with CF eat considerably more than their
age-matched control counterparts, but as a group they do not achieve 120% of recommended intake
[5257]. Of note, the recommended intake varied based on the country in and the time at which each
study took place. Despite eating more than the control subjects, the CF subject tended to have less
optimal growth and lower weight, height, weight-for-height, and/or body mass index (BMI) z-scores
than expected and/or compared to controls [5255].
When reported, approximately 1139% of CF subjects attained the 120% recommended intake
marker [52, 56, 57]. A few studies noted that in patient groups with better compliance to calorie goals
and enzyme therapies, weight, growth, and pulmonary status were actually worse [52, 53]. This may
indicate that compliance improves in sicker patients [52] and may also reect higher calorie needs in
sicker patients [53].
The relationship between energy intake and growth status is variable among the studies. A positive
correlation between intake and growth parameters was found in some study groups [53, 54] but this
correlation was not always present for each age group [53]. Some studies found that nutritional status
was suboptimal in CF patients despite their consumption of 100120% of the population
recommendations for age, and 718% more total calories than the control subjects [54, 55].
Alternatively, other studies observed that CF patients were able to attain growth similar to control
subjects while consuming less than 120% of the RDA, though calorie intakes were approximately
1015% higher than those of the controls [56, 57]. Some of these patients were less than the tenth
percentile for weight-for-height, which is of nutritional concern, particularly in CF [57].
It is not surprising to observe that in many studies comparing actual recorded intake CF patients do
seem to consume and require more calories than control subjects for, at best, similar growth. It does
remain important to remember that studies requiring the subjects to record diet intake may be subject
to inaccurate record keeping and/or changes from baseline intake. CF patients may have consumed or
been reported to consume more than usual, as that is the recommendation they often hear during clinic
visits [55, 57].
J. Brownlee
16
Calorie Recommendations
Overall, the recommendationto provide 120150% of the RDA for calories to all CF patients is not
fully validated. The majority of data discussed above supports that as a group, CF patients require
more calories than the normal population. On an individual level, this may not be the case. Healthy
patients may be capable of growing and maintaining their weight with intakes similar to normal,
healthy peer groups, and/or the RDA alone [43, 55, 5760]. However, underweight or particularly sick
individuals may require at least 120150% of the RDA [5255, 58, 60]. Recent CF Foundation
guidelines promote intakes of 110200% of the requirements established for the general population
[6]. Table 2.1 presents the 2005 EER equations, which replaced the RDA for calories.
Given the wide range of clinical statuses of the CF population as well as lifestyle factors, it seems
impractical to assume that there is a one-size-ts-all method for determining energy needs. The best
practice to adopt in estimating energy needs in individuals with CF is to assess the patients current
intake and nutritional status and to then make recommendations for adjusting caloric intake as
indicated for patients who are not meeting or are exceeding goals for growth or weight maintenance
[5]. Adjusting intake in increments of 10% at a time is considered to be an attainable goal for
Table 2.1 2005 estimated energy requirement equations [12]

Age
Estimated energy requirement equation (kcal/day)
03 months
46 months
712 months
1336 months
Boys 38 years
(89 weight 100) + 175 kcal

(89 weight 100) + 56 kcal
88.5 (61.9 age [year]) + PA (26.7 weight
[kg] + 903 height [m]) + 20 kcal
88.5 (61.9 age [year]) + PA (26.7 weight
662 (9.53 age [year]) + PA (15.9 weight
[kg] + 539.6 height [m])
Boys 918 years

Men >19 years
Girls 38 years
Girls 918 years
Women >19 years
Pregnancy
Lactation
135.3 (30.8 age [year]) + PA (10 weight

135.3 (30.8 age [year]) + PA (10 weight
354 (6.91 age [year]) + PA (9.36 weight
[kg] + 726 height [m])
Age appropriate + additional energy expended

during pregnancy + energy deposition
1st Trimester: EERnonpregnant + 0 + 0
2nd Trimester: EERnonpregnant + 160 kcal + 180 kcal
3rd Trimester: EERnonpregnant + 272 kcal + 180 kcal
Age appropriate EER + milk energy output weight loss
1st 6 months: EERnonpregnant + 500 170
2nd 6 months: EERnonpregnant + 400 0
Physical activity (PA) factors

(equivalents of miles walked)
Sedentary = no miles walked
Low active = 1.53 miles walked
Active = 510 miles walked
Very active = 1222 miles walked
Sedentary = 1
Low active = 1.13
Active = 1.26
Very active = 1.42
Sedentary = 1
Low active = 1.11
Active = 1.25
Very active = 1.48
Sedentary = 1
Low active = 1.16
Active = 1.31
Very active = 1.56
Sedentary = 1
Low active = 1.12
Active = 1.27
Very active = 1.45
17
individuals [8, 59]. Early education of families and patients on the risk of malnutrition and the
potential reasons for inadequate intake soon after a patients diagnosis is important to promote optimal
growth and nutritional status [5].
Macronutrients
The recommendations for the macronutrient composition of diets of individuals with CF have shifted
over the years. Given the importance of ensuring adequate caloric intake in patients who may suffer
from poor appetite and unpleasant gastrointestinal symptoms [10, 15, 61], getting calories in however
possible and focusing on easily digested food, such as simple sugars, were at one point more standard
recommendations than ensuring a balanced diet [1]. The remainder of this chapter will explore the
different macronutrients and will provide recommendations for diet composition.
Fat
Fat is a macronutrient of critical importance in CF. In the general population, fat is considered an
efcient source of energy as it provides 9 cal/g. Dietary fat consists mostly of triglycerides with
sterols and phospholipids making up the small remainder [62]. The majority of fat is not soluble in
water; the digestion of fat requires emulsication by bile salts so that pancreatic and intestinal lipases
are able to hydrolyze triglycerides and fatty acid esters to allow for absorption [62]. Digestion of fat
in patients with CF is complicated by decreased availability of lipase and bile salts due to obstruction
of pancreatic and gall bladder ducts with mucous [63]. This has historically affected the opinion
regarding the use of fat in cystic brosis.
Historical Recommendations for Fat Intake in Cystic Fibrosis

Due to the difculty digesting and thus utilizing fat, it was common practice in the 1960s and 1970s
to recommend low fat diets [1, 6466]. At that time, PERT was suboptimal and individuals with CF
demonstrated only minimal improvement of fat absorption when using it [64]. It was thought that a
low fat diet would help limit steatorrhea and thus improve digestion and absorption of other nutrients
[64, 67, 68]. Unfortunately, this was not the case as the low fat diet was not adequate in providing the
calories needed for growth and health in CF children. In fact, it was found that patients were generally
only receiving 8090% of the RDA for calories and were experiencing growth failure [64, 65].
An alternative recommendation in the 1960s and 1970s was to provide a diet high in medium chain
triglycerides (MCT) [64]. This recommendation was based on a study that found that fat excretion by
infants with CF drinking an MCT-based formula was normal [64]. However, it was later discovered
that the method used for quantifying fat in stool was not appropriate for MCT and thus stool loss of
MCT had been underestimated [64]. This recommendation also resulted in growth failure for the CF
patients receiving MCT-based formulas [64].
The Shift to a High Fat Diet in Cystic Fibrosis

Despite the prevalence of the low fat diet recommendation throughout the 1960s and 1970s, the
concept was questioned as early as the 1950s [67]. Dr. Crozier, of the Toronto Cystic Fibrosis Clinic,
18
J. Brownlee
started to make the case for a higher fat diet in the early 1970s [1, 66]. Given the improved caloric
density of fat compared to carbohydrate and protein, he suspected that increasing fat consumption
with the simultaneous increase of PERT in patients would result in improved intake and absorption
[66]. These patients consequently demonstrated improved growth despite ongoing fat malabsorption,
leading to the conclusion that net energy absorption was indeed improved [66]. When Toronto clinic
patients were compared to CF patients in Boston for the years 19721982, it was found that the
patients from Toronto had much improved growth and survival compared to the Boston patients [1].
The only signicant difference between the two centers was that the Toronto center encouraged a high
energy, high fat diet with increased PERT and the Boston center encouraged a high energy, fat
restricted diet [1].
Subsequent studies conrmed that calorie intake, absorption, and growth could be improved on a
high calorie, high fat diet [64, 65, 67, 69]. Investigators were able to demonstrate that increased fat
intake did not result in increased fat excretion [67]. PI was shown to be well controlled even in CF
subjects who consumed diets with greater than 35% of calories from fat [70].
Defining a High Fat Diet

Initial recommendations for a high fat diet were to aim for a fat consumption of 3545% of total
calories [64, 66, 71, 72]. Recent CF nutrition consensus guidelines still promote 3540% of dietary
calories to come from fat [5]. For perspective, the acceptable macronutrient distribution range for the
general healthy population is 2035% of total energy intake from fat [62] with a normal intake
considered to be approximately 30% of calories from fat [73].
It has been noted that the percentage of calories from fat may not correlate well with total calorie
intake and overall nutritional status [70, 74]. Several investigators did not nd an association between
percent of calories provided by fat and the percentage of the recommended energy index consumed
[74] or the percentage of ideal body weight [70]. Grams of fat consumed per day did positively
correlate with total daily energy intake and percent ideal body weight, thus it was concluded that it
would be more benecial to set an actual daily fat gram goal for patients to achieve [70, 74]. There are
several benets to this practice, as counting grams of fat would be simpler for patients than determining
percentage of dietary intake from fat and could assist with accurate dosing of PERT [70, 74].
MCT Versus LCT

As briey mentioned above, MCT were previously recommended over long chain triglycerides
(LCT) [64]. Despite the aws of the initial study promoting the use of MCT-based formulas, MCT
absorption was better than that of LCT in patients taking an older version of PERT [64]. The use of
MCT in CF remains controversial. The benets of MCT include that they are soluble in water and
are absorbed directly into the intestinal enterocytes without requiring bile salts or lipase. Steatorrhea
and abdominal pain were reported as being decreased in the setting of supplementation with MCT;
however these patients did not gain weight during the 6-month trial [75]. MCT are also noted to
cause increased diet-induced thermogenesis [76, 77], to have decreased deposition into adipose
stores [76, 78], and to cause increased energy expenditure [76, 78] compared to LCT. These factors
suggest that MCT would not be as benecial of a calorie source as LCT for individuals with CF,
unless the patient has additional complications that further limit absorption, such as short bowel
syndrome or cholestasis [76].
19
Potential Benefits of a High Fat Diet in Cystic Fibrosis

A high fat diet for individuals with CF could yield other advantages in addition to caloric density. A
diet high in fat could help prevent essential fatty acid deciency (EFAD) and also may provide a more
optimal fuel mix to help decrease carbon dioxide production.
Patients with CF have historically been noted to have EFAD [76, 7984], thought to be due to the
low fat diet and poor absorption of fatty acids [76, 80]. Other factors may also contribute to EFAD in
CF, including defects in the metabolism of fatty acids and excessive use of fatty acids as an energy
source and for production of eicosanoids [80]. Effects of a high fat diet on EFAD in CF appear to be
mixed; several studies have noted that EFAD continues to exist in CF patients consuming high fat
diets [80, 81] and that serum fatty acid levels do not correlate with the individuals level of fat
absorption [84]. Yet, other studies have observed that serum fatty acid levels can be similar to controls
in CF patients on a high fat diet with PERT [85] or can improve with consumption of high fat,
particularly high linoleic acid, oral supplements [86]. While a high fat diet in CF may not completely
prevent EFAD, recommendations for supplementation of specic fatty acids do not yet exist [81, 83].
Patients may benet from increasing dietary linoleic acid and alpha-linolenic acid [81]. For further
discussion and recommendations regarding the different types of dietary fat please refer to Chapter 6.
Enteral formulas high in carbohydrate can lead to an increased production of carbon dioxide,
which may exacerbate the pulmonary status of patients with advanced lung disease [87, 88]. In studies
comparing the use of different formulas in CF patients, the formulas which were higher in fat and
lower in carbohydrate resulted in lower carbon dioxide production, lower respiratory quotient (RQ),
and lower minute ventilation compared to higher carbohydrate, lower fat formulas [88, 89]. Of note,
due to the increased minute ventilation on the higher carbohydrate formulas, the patients studied were
able to breathe off the additional carbon dioxide to avoid increased carbon dioxide retention and
hypoxia [89]. Another study veried that provision of a higher fat formula resulted in a decreased RQ
compared to a higher carbohydrate formula but alternatively found that production of carbon dioxide
was similar between the two formulas [90]. Overall, it remains possible that CF patients with severe
lung disease who require enteral supplementation may benet from the use of high fat formulas,
especially at high levels of supplementation [8790].
Concerns About a High Fat Diet in Cystic Fibrosis

Despite the known and potential benets of a high fat diet, some concerns remain. In an era of
increasing lifespan in CF, the co-morbidities of an aging population must be considered. A diet high
in fat, particularly saturated fat, can have negative effects on cardiovascular health [91, 92]. CF
patients have historically been noted to have minimal signs of atherosclerosis, very likely due to the
low fat diet and poor fat absorption typical in CF patients in the past [91]. More recent studies have
reported that CF patients on high fat diets have low to normal serum cholesterol levels compared to
controls [85, 9396]; although it was noted that adult patients with PS had high normal serum
cholesterol levels [93, 96]. Alternatively, higher serum triglyceride levels in patients with CF compared
to the standard population with several incidences of hypertriglyceridemia have been observed [94,
95]. The etiology and consequences of the elevated triglycerides are not fully known. A positive
correlation between serum triglyceride level and BMI was found [96]. Otherwise, there were overall
minimal signicant correlations between elevated triglycerides in CF and other risk factors for
cardiovascular disease, including glucose intolerance and blood pressure. Chronic inammation,
excessive carbohydrate intake or absorption and chronic high fat diets have been proposed mechanisms
of elevated triglyceride levels [9496]. Furthering the concern regarding the tolerance of a high fat diet,
CF patients have recently been observed to have premature arterial damage compared to controls [97].
J. Brownlee
20
Table 2.2 High fat, high calorie foods and ideas for how to incorporate into diet [101, 102]
Food (serving size)
Butter (1 tbsp)
Olive oil (1 tbsp)
Canola oil (1 tbsp)
Flaxseed oil (1 tbsp)
Coconut oil (1 tbsp)
Avocado ( cup
cubed)
Type of fat
SFA
MUFA
MUFA,
PUFAa
PUFAa
SFA, MCT
MUFA
G fat/
serving
11.5
13.5
14
kcal/serving
102
119
124
13.6
13.6
11
120
117
120
Serving suggestions
Use to cook vegetables, grains, meats
Serve on warm bread/grains (melts in)
Add to shakes
Add extra to served foods (vegetables,
grains)
Cheese, most
varieties (1 oz)
SFA
610
85115
Heavy whipping
cream (1 oz)
SFA
11
103
Sour cream (1 tbsp)
SFA
2.4
23
Ice cream (1/2 cup)
SFA
7.3
137
Yogurt, whole milk,

plain (6 oz)
SFA
5.5
104
Nuts (1 oz)
1320
163204
Peanut butter
(1 tbsp)
MUFA,
PUFA
MUFA,
PUFA
8.2
96
Egg (1 large)
SFA
5.3
72
Bacon (1 slice)
SFA
4
54
Salami (1 slice)
SFA
3.2
41
Abbreviations: g gram, kcal kilocalorie, SFA saturated fatty acid,

polyunsaturated fatty acid, MCT medium chain triglycerides
a
Food considered to be a major source of omega-3 fatty acids
Make guacamole for chips, crackers,

vegetables
Add to sandwiches, tacos, burritos, soups,
salads
Mix into smoothies and/or shakes
Serve with crackers, fruit
Add extra to pasta, casseroles, pizza
Add to eggs, soups, vegetables, salads
Use melted cheese as a dip for chips,
vegetables, crackers, fruit
Mix with whole milk to drink
Use in recipes that call for milk
Use to make hot cereals
Use to make dips for chips, vegetables
Make a sweet dip for fruit
Add to soups, potatoes, casseroles
Ice cream sundaes
Milkshakes
Soda oats
Mix with granola
Use in smoothies
Make a dip for fruit (add sugar/honey)
Add to hot cereal, salads, baked goods
Trail mix
Serve on warm bread/grains
Add to milkshakes, smoothies
Serve with apples, bananas and celery
Peanut butter crackers, pretzels
Add extra yolk to French toast, baked
goods, quiches, scrambled eggs
Add hard boiled eggs to salads, sandwiches
Add to ground meat
Use as the binder for breaded meats
Add to salads, sandwiches
Add to sandwiches
Serve with cheese and crackers
MUFA monounsaturated fatty acid, PUFA
This may lead to complications in cardiovascular health, especially as the population ages [97].
Notably, myocardial infarction has been reported in CF patients [98, 99]. Due to this potential for
cardiovascular disease, encouraging increased intake of monounsaturated and polyunsaturated fatty
acids rather than saturated fatty acids may be wise [92, 100]. Table 2.2 presents common food sources
of unsaturated and saturated fatty acids.
21
Table 2.3 Examples of antioxidant-rich foods [102, 104]
Food (serving size)

Kale (1/2 cup cooked)
Spinach (1/2 cup cooked)
Broccoli (1/2 cup cooked)
Carrots (1/2 cup cooked)
Brussels sprouts (1/2 cup cooked)
Red bell pepper (1/2 cup chopped raw)
Sweet potatoes (1/2 cup mashed)
Mango (1/2 cup chopped raw)
Orange (1/2 cup sections raw)
Strawberries (1/2 cup halves raw)
Blueberries (1/2 cup raw)
Pomegranates (1/2 cup seeds raw)
Millet (1/2 cup cooked)
Oats (1/2 cup cooked)
Pinto beans (1/2 cup cooked)
Soybeans (1/2 cup cooked)
Brazil nuts (1/2 cup whole)
Walnuts (1/2 cup halves)
Sunower seeds (1/2 cup with hulls, edible
portion)
Wild salmon (3 oz cooked)
Calories/
serving
18
21
27
27
28
23
125
50
42
24
42
72
104
83
104
127
438
387
134
Grams protein/
serving
1.24
2.67
1.86
0.59
1.99
0.74
2.25
0.68
0.85
0.51
0.55
1.45
3.05
2.97
6.39
11.12
9.52
15.04
4.78
Grams fat/
serving
0.26
0.23
0.32
0.14
0.39
0.22
0.23
0.31
0.11
0.23
0.24
1.02
0.87
1.78
0.82
5.76
44.62
37.08
11.84
Grams
carbohydrate/
serving
3.66
3.38
5.6
6.41
5.54
4.49
29
12.36
10.58
11.63
10.72
16.27
20.59
14.04
18.48
9.94
7.81
5.99
4.6
155
21.62
6.91
Another concern is that a diet high in fat may be a source of increased oxidative stress in CF
patients [103]. An investigation monitoring CF patients as they improved following a pulmonary
exacerbation observed that as their intake of fatty foods increased so did their serum plasma fatty
acids [103]. The increase in plasma fatty acids correlated with an increase in oxidative stress, which
was further complicated by a lack of observed improvement in antioxidant circulation [103]. Due to
concern about the ongoing oxidative stress it has been suggested that patients with CF may benet
from a diet rich in antioxidants to help optimize the benets of a high fat diet [103]. Please refer to
Table 2.3 for a review of foods high in antioxidants.
Dietary Fat Goal for Patients with Cystic Fibrosis

Individuals with CF benet from a higher fat diet in order to more easily meet their energy needs
[1, 5, 6467, 69, 72, 73]. Consensus committees have suggested that 3540% of calories from fat is a
reasonable high fat diet goal [5]. An appropriate tactic for practitioners to use would be to determine
the grams of fat necessary to achieve 3540% of their patients individualized calorie goal. This fat
gram number could easily be provided to patients along with instructions for counting fat grams as
needed. If a patient in need of additional calories is consuming signicantly less fat at the time of
assessment, the practitioner could start by increasing fat intake by 10%, similar to the method
discussed for increasing calories. A fat gram goal could still be provided to the patient and/or the
patients family. Education on incorporating high fat foods into the diet ad libitum is another method
that has shown success [69]. For high fat, high calorie foods and suggestions on how to incorporate
into the diet please refer to Table 2.2.
22
J. Brownlee
Protein
Proteins are organic compounds made up of amino acids, nitrogen containing molecules [105]. Amino
acids are necessary for building and replacing the majority of structures within the body including
bones, muscles, blood, and skin [105]. They also can act as hormones, enzymes, transporters, and
antibodies, work to regulate uid balance and acidbase balance and can be utilized to provide energy
and glucose if needed [105]. Protein is not as efcient of an energy source as fat; each gram of protein
provides four calories. However, adequate intake of protein is critical to ensure the maintenance of
bodily structures and functions and to provide the essential amino acids that the human body is unable
to produce on its own [105]. In order to be absorbed in the intestine, proteins must be denatured by
stomach acid and then broken down into di- and tri-peptides and free amino acids [105]. In the general
population, protein intake should provide between 10 and 35% of total calorie needs, based on the
recommendations for fat and carbohydrate provision [105]. Average dietary intake of protein is
1015% of total kcal [106]. In developed countries, people are easily able to attain this goal [105].
Similar to fat, people with CF were historically noted to have difculty with the digestion and
absorption of protein with loss of nitrogen in stools [107]. Fecal loss of up to 50% of consumed
protein has been recorded [61]. The recommendations for protein intake have thus also shifted over
the years with improvements in PERT.
Historical Recommendations for Protein Intake in Cystic Fibrosis

As early as 1943 patients with CF were noted to have excessive loss of protein in their stool while
consuming a regular diet [107]. Improvement in fecal loss of nitrogen was observed in patients placed
on casein hydrolysate, despite increases in the total protein load provided to the patients [107]. Despite
several early success stories use of protein hydrolysate formulas was not further considered for several
decades. The concept of a low fat, high calorie diet was promoted as discussed earlier, with an
emphasis on high protein intake to make up for stool protein losses [107].
Intact Versus Hydrolyzed Protein Sources

In the 1970s, a mixture of beef serum protein hydrolysate, MCT, and modied starch was found to
improve growth, energy, and digestive symptoms in children with CF who consumed enough to meet
greater than 80% of their total energy needs [107]. Previous attempts in using formulas with only
MCT or hydrolyzed protein resulted in improved digestive symptoms but not in improved growth
[107]. In trials of amino acid based supplements weight and markers of protein absorption seemed to
be improved but patients did not experience any reduction in the signs and symptoms of malabsorption
[108], possibly due to ongoing fat malabsorption. Further it was noted that it was difcult to continue
the trial due to the high expense of the amino acid mixture [108]. In a cross-over study of nitrogen
balance in CF patients on a variety of different protein sources with or without PERT, it was found that
patients had similar absorption of intact protein with enzyme supplementation as they did on
hydrolyzed protein without enzyme supplementation [109]. However, individual patients overall had
higher nitrogen balance while on the hydrolyzed protein supplement due to decreased urinary nitrogen
loss [109]. Thus throughout the 1970s and 1980s hydrolyzed protein was overall considered superior
to intact protein [76].
In the late 1980s and early 1990s intact protein made a comeback. One study observed that despite
intermittent issues with gastrointestinal tolerance in some patients, formulas with intact protein led to
better protein deposition compared to partially hydrolyzed formulas [110]. This was attributed to the
better quality protein and higher calorie content of the intact formula and resulted in the conclusion
23
that there was no benet of the broken down formula [110]. Additional studies found that there was
no difference in the growth and growth rate of infants [111] and the weight patterns of children and
young adults [112] on formulas with intact protein with enzyme replacement versus partially
hydrolyzed formulas with [111] or without [112] enzyme replacement. Additional benets include
that the intact formulas are more affordable and more palatable [111, 112].
For the majority of patients with CF who require oral or enteral formula supplementation, provision
of an intact formula with PERT seems to be adequate to promote growth and nutritional status [110
112]. It is important to note that a patient with an allergic or digestive issue in addition to PI, such as
cows milk protein allergy, cholestatic liver disease, or short bowel syndrome, would benet from a
protein hydrolysate formula [76]. PERT is still necessary when using broken down formulas [76].
Protein Metabolism in Cystic Fibrosis

Protein turnover and balance is an issue of signicance in CF. Illness and inammatory disease states
are associated with high levels of skeletal muscle breakdown and increased synthesis of acute phase
proteins [113]. Even though proteins are being synthesized, protein catabolism and loss of skeletal
muscle are the main characteristics of the inammatory response [113]. Given the importance of
maintaining and improving the nutritional status of patients with CF [17], preventing or reversing
catabolism would be a valuable outcome. There is some controversy regarding protein turnover in
CF. Many studies agree that at baseline, patients with CF have higher levels of catabolism than healthy
controls [114116]. However it is thought that this may be due to malnutrition rather than an intrinsic
element of CF [61]. Conversely, other investigations have not found evidence of increased protein
turnover in CF compared to controls [117, 118] and conclude that observed variations in protein
metabolism in CF reect expected changes with malnutrition and infection [117]. Patients with CF do
seem to be able to achieve anabolism with adequate nutrition intake of energy and protein [115, 119,
120]. Overall, it is agreed that it is imperative to promote adequate calorie and protein intake to avoid
protein catabolism in CF patients [118].
Specific Amino Acids in Cystic Fibrosis

Taurine
Taurine has been suggested to be an especially important amino acid for individuals with CF by
improving fat absorption [76]. Taurine and glycine are the amino acids used in the conjugation of bile
salts; taurine-bound bile salts provide increased fat solubility, which could be of benet in the PI
population [76]. Due to fat malabsorption, patients with CF have been found to lose more taurine in
their stools than control patients [121]. There is some evidence that supplementation with taurine
normalizes bile-acid taurine levels [76, 121]. In some individuals with particularly severe fat
malabsorption, 30 mg taurine per kilogram body weight per day has helped to decrease loss of fat in
stools [122, 123]. More research is needed to assess for impact on nutritional status [123].
It has also been suggested that taurine may also help protect against muscular protein breakdown
[119]. This theory was not substantiated by a crossover trial, as no differences in protein metabolism
on and off taurine supplementation were found [119].
Leucine and Arginine

In certain situations, the amino acids leucine and arginine have helped to promote anabolism [124].
Given concern for possible excessive catabolism in CF patients [114116] the effects of leucine
24
J. Brownlee
enriched supplements on protein synthesis in CF have been studied; however no added benet of
leucine were observed [118]. Arginine and/or citrulline, the precursor of peripheral arginine, may yet
prove to be benecial in stimulating muscle anabolism in CF, however studies are needed to further
explore this possible effect [118, 124].
Cysteine and Glutathione

Glutathione is an antioxidant comprised of three amino acids: cysteine, glutamate, and glycine, of
which cysteine is a rate-limiting precursor [125]. As previously discussed, antioxidants and their
possible benecial effect on lung health is of interest in the CF population. A negative association
between lymphocyte glutathione levels and lung function has been found, suggesting that there is
increased utilization of glutathione in stressed lungs [125]. There is evidence that supplementation
with cysteine rich foods, such as whey protein or N-acetylcysteine supplements, can help increase
levels of glutathione [126, 127] and improve markers of inammation [126]. However, changes in
lung function have not been observed during the short study time frames (13 months) [126, 127]. It
is possible that supplementation with cysteine to improve glutathione status may help stabilize lung
function in the long term and may have preventative effects, especially if utilized earlier in life [126,
127]. Longer term studies in CF patients of a variety of ages are needed to better determine true
effects and recommended intakes of cysteine.
Concerns About a High Protein Diet in Cystic Fibrosis

In the general population a diet exceptionally high in protein can put an individual at risk for azotemia,
metabolic acidosis, and neurodevelopmental problems [113]. These effects have been observed in
patients consuming 46 g protein per kilogram body weight [113]. Individuals with renal disease or
liver disease are particularly at risk for the toxic effects of protein due to limitations metabolizing and
excreting protein. There has been a report of an individual with cystic brosis-related liver disease
becoming encephalopathic after consumption of 4.5 g protein per kilogram during a 6-h block of time
[106]. This individual recovered, but the incident serves as a good reminder to be aware of total
protein intake and to encourage appropriate distribution of food over the course of the day [106].
Another concern is the source of the amino acids. Protein should ideally come in the form of whole
foods or regulated supplements. Patients and their providers should be wary of over-the-counter protein
and amino acid supplements [105]. These supplements are often not regulated and may not be pure.
They may contain an inappropriate distribution of amino acids putting individuals at risk for both
deciencies and toxicities of specic amino acids as well as unanticipated effects on metabolism [128].
Some amino acids in inappropriate quantities have been shown to affect hormonal or neurological
function or may disrupt electrolyte balance [128]. Intake of protein supplements may also lead to
excessive protein intake faster than intake of whole food or balanced oral supplements [105].
Dietary Protein Goal for Patients with Cystic Fibrosis

Protein requirements for individuals with CF have been expressed in different ways; however there is
overall agreement that the CF diet should be high in protein. An increase of 1.52 times above the
RDA for age has been recommended [129]. Please refer to Table 2.4 for a review of the 2005 RDA for
protein. A protein intake of 15% of total calories has also been suggested [72], with others suggesting
intake up to 20% of total calories [58, 65]. Some investigators have had success improving whole
body protein synthesis with very high protein doses up to 5 g protein per kilogram body weight for
25
Table 2.4 2005 recommended daily allowance for protein [12, 105]
Age (years)
Grams protein/day
00.5
9.1
0.51
13.5
13
13
48
19
913 male
34
1418 male
52
19 male
56
913 female
46
1418 female
46
19 female
46
Pregnancy
1st trimester
71
2nd trimester
71
3rd trimester
71
Lactation
1st 6 months
71
2nd 6 months
71
a
Based on reference body weights (~50 percentile for age)
Grams protein/kilogram
weighta per day
~2.2
1.5
1.1
0.95
0.95
0.85
0.8
0.95
0.85
0.8
1.1
1.1
1.1
1.1
1.1
children aged 7 to 12 years old [117]; this represents 500% of the RDA for age. As just discussed, a
consistent protein intake this high may have dangerous side effects.
Given the wide variety of clinical presentations and calorie needs of individuals with CF,
determining protein needs based on energy needs would be helpful to promote a well-balanced diet.
Approximately 1215% of calories from protein would be consistent with the literature and
recommendations to increase protein intake relative to energy intake [61, 72]. This value should be
compared to the RDA times 1.52 to help assess appropriateness of the protein load and to avoid
excessive protein intake [105]. As with fat, if recommending a protein goal to a patient, it may be best
to provide the goal in total grams protein per day. It is worth noting that overall patients seem to easily
achieve, at the very least, adequate intake of protein when consuming a high calorie diet [61, 119,
129131]. For examples of protein rich foods please refer to Table 2.5.
Carbohydrate
The term carbohydrate encompasses simple carbohydrates, mono- and disaccharides, requirements.
Otherwise known as sugars, and complex carbohydrates or polysaccharides, which are starches and
bers [132]. Digestible carbohydrates provide approximately 4 cal/g [132]. Fibers are not digestible
and as such provide minimal calories [132]. The bacteria in the colon can convert some ber to short
chain fatty acids (SFCA) which are important fuel for colonocytes; this conversion allows ber to
contribute up to 1.52.5 cal/g [132]. The general population is recommended to get 4565% of total
energy from carbohydrates [132].
The digestion of carbohydrates begins in the mouth with salivary amylase and is completed with
pancreatic amylases and brush border enzymes [132]. Unlike fat and protein, individuals with CF
have been observed to have minimal loss of carbohydrates in their stool [133]. Carbohydrate loss has
been observed to be less than 1% of consumed carbohydrate in patients on standard PERT compared
to loss of approximately 40% of consumed fat and 20% of consumed protein [133].
J. Brownlee
26
Table 2.5 Examples of high protein foods [102]
Food (serving size)
Beef (3 oz short loin)
Pork chop (3 oz)
Chicken (3 oz breast)
Chicken (1 thigh)
Fish (tilapia llet)
Egg (1 large)
Milk, whole (1 cup)
Cheese, most varieties (1 oz)
Yogurt, plain whole milk (6 oz)
Tofu (1/2 cup)
Tempeh (3.5 oz)
Nuts (1 oz)
Peanut butter (2 tbsp)
Quinoa (1/2 cup cooked)
Pumpkin seeds (1 oz)
Beans (1/2 cup)
Grams protein/serving
23
22
28
23
23
6
7.7
67
5.9
10
18.2
37
7
4.1
5.3
58
Calories/serving
188
178
122
183
111
72
149
85115
104
88
196
160200
191
111
126
~110
Historical Recommendations for Carbohydrate Intake in Cystic Fibrosis

Due to seemingly adequate carbohydrate absorption in CF, it was most commonly recommended for
patients to achieve their high calorie needs by increasing their intake of carbohydrates [10, 66, 133].
Carbohydrates were used to replace fat in children on the historical standard low fat diet to promote
improved absorption and decreased gastrointestinal side effects [10, 66]. Unfortunately, as previously
discussed, patients were not able to achieve high calorie intakes on the high carbohydrate diet and
growth and health suffered [1, 10, 66].
Potential Benefits of Carbohydrates in Cystic Fibrosis

Aside from being easily digested and absorbed, carbohydrates, specically ber, may also support
colonic bacteria and result in SCFA. Several studies have observed minimal or normal loss of SCFA
in the stools of CF patients, which may help to support the energy needs of colonocytes and provide
additional energy to the individual [133, 134]. There is a possible downside to this mechanism as
excessive production and absorption of SCFA in a person with CF may increase the systemic acid load
and exacerbate the acidbase balance in someone with severe lung disease [133]. However, not all
studies found reason to be concerned about excessive SFCA absorption [134].
Concerns About High Carbohydrate Intake in Cystic Fibrosis

As previously discussed, a high intake of carbohydrate has been associated with an increased
production of carbon dioxide which could lead to an exacerbation of respiratory status, especially in
particularly sick individuals [8890, 135]. Some studies have found that enteral formulas with a high
percentage of energy from carbohydrate increased carbon dioxide production and the RQ more than
high fat formulas [88, 89], however not all corroborate this [90, 135]. All of the studies agree that
patients can compensate for the increased carbohydrate load without aggravating their pulmonary
27
status. There is still concern that at higher levels of intake or in certain situations the high carbohydrate
formulas might be more detrimental than observed [8890, 135].
With the increasing occurrence of cystic brosis-related diabetes (CFRD) in the aging CF
population, glucose tolerance does become a concern [135]. Formulas high in carbohydrate were
found to signicantly increase serum glucose concentrations and thus exacerbate hyperglycemia in
patients with CFRD [135]. The main goal in managing CFRD is promotion of glycemic control. This is
usually accomplished with insulin and pairing carbohydrate intake with protein and/or fat to allow an
unrestricted diet [136]. For patients who require enteral nutrition support, it may be of some benet to
choose a formula that is higher in fat, instead of a high carbohydrate formula, to promote improved
glucose control [135]. For more information about the management of CFRD please refer to Chapter
10.
Fiber and Cystic Fibrosis

In the general population a high ber diet, 2035 g of ber per day for adults, is recommended for
bowel health as well as for possible cardiovascular health and cancer prevention effects [132]. In
children, the typical recommendation for determining daily grams of ber is to add ve to the current
years of life [137]. Due to the focus on a high calorie diet, a high ber diet has not historically been
promoted in patients with CF [138]. There have been conicting reports about the benet of ber in
the diets of CF patients. One study observed very low ber intake in English CF children and noted
that the patients with a higher, but still low overall, ber intake had less abdominal pain than those
with even lower ber intakes [138]. Thus, there is some thought that a higher ber diet may help
improve appetite and intake [60]. Alternatively, a higher occurrence of distal intestinal obstruction
syndrome (DIOS) was found in Belgian CF patients with ber intakes that were adequate to meet or
exceed the recommended amount of ber for the healthy population [137]. Low dietary ber intake
was not related to gastrointestinal symptoms [137]. These conicting ndings may reect dietary
differences in the country of origin, as overall ber intake was much lower in the English study [137,
138]. It is also possible that the Belgian children with DIOS increased their ber intake secondary to
experiencing constipation [137].
Another study also found that incidence of constipation in patients with CF was not related to ber
or uid intake, with all patients on average consuming less than 60% of the recommended amount of
ber [139].
There is no clear consensus on the appropriate amount of ber to provide to individuals with CF. It
appears that moderate ber intake may be helpful in limiting abdominal pain in some patients but high
ber intake may cause more problems, including calorie displacement and possible abdominal pain
exacerbations. As ber rich foods, in particular fruits, vegetables, legumes, and whole grains provide
the additional benet of being rich in vitamins, minerals, and antioxidants it may be wise to recommend
that patients incorporate these foods into their diet. Patients may not benet as much from foods with
added ber or from ber supplements. As with the general population, individuals with CF should
increase their intake of ber slowly [132] and with close supervision by providers [138], if they
increase at all. Please refer to Table 2.6 for examples of high ber foods.
Dietary Carbohydrate Goal for Patients with Cystic Fibrosis

The contemporary recommendation is to provide a diet with a normal amount of carbohydrates [140].
Due to the recommendations for a higher fat and high protein diet, carbohydrate intake may make up a
smaller proportion of the CF diet compared to the general population. Based on the recommendations
of approximately 35% of calories from fat and 15% from protein, 50% remains to come from
J. Brownlee
28
Table 2.6 Examples of high ber foods by food group [102, 132]
Food (serving size)
Grains
Barley (1/2 cup cooked)
Oats (1/2 cup cooked)
Brown rice
Rye bread (1 slice)
Whole wheat bread (1 slice)
Bran cereal (1/2 cup)
Vegetables
Broccoli (1/2 cup cooked)
Zucchini (1/2 cup cooked)
Asparagus (1/2 cup cooked)
Cabbage (1/2 cup cooked)
Brussels Sprouts (1/2 cup cooked)
Corn (1/2 cup cooked)
Spinach (1/2 cup cooked)
Kale (1/2 cup cooked)
Carrots (1/2 cup raw)
Fruit
Apple with skin (1 small-medium)
Pear with skin (1 small-medium)
Peach with skin (1 small-medium)
Orange (1 small-medium)
Banana (1 small-medium)
Kiwi (1/2 cup raw)
Strawberries (1/2 cup raw)
Legumes
Peanuts (1 oz)
Beans, most varieties (1/2 cup cooked)
Grams ber/
serving
Calories/
serving
3
2
1.8
1.8
2.6
9
97
83
108
83
87
65
Good source of vitamins and minerals

Can easily add calories with butter,
oils, nut butters, cheese, whole milk
2.6
0.9
1.8
1.4
2
1.7
2.2
1.3
1.8
27
14
20
17
28
25
21
18
72
Good sources of vitamins and minerals

Rich in antioxidants
Can provide additional calories with
butter, oils, bacon, cheese, sour cream,
ranch or other salad dressings, and
hummus
3.6
4.6
2
3.4
2.6
2.7
2.9
77
84
51
65
90
55
27
Good source of vitamins A and C

Rich in antioxidants
Add extra calories and protein with
cheese, nut butters, nutella and yogurt
dips
2.4
58
166
~110
Good source of protein, vitamins and

minerals
Other benets
carbohydrate; this is on the lower end of the range suggested for the healthy population (4565%)
[132]. It is still important that patients receive, at minimum, the RDA for carbohydrate, which is based
on the brains glucose needs. The RDA is 6095 g during the rst year of life and is 130 g after that,
other than during periods of pregnancy and lactation when it is 175 and 210 g, respectively [132]. This
minimum goal should be easily achieved with a high calorie diet. Patients likely do not need to receive
a specic carbohydrate goal, though counseling on ber may help some.
Conclusion
This chapter opened with a question, and in conclusion, not all calories are equal in CF. While those
with CF may likely have higher energy needs than is considered typical, a balanced diet with
wholesome foods is still important. High fat foods will help achieve high calorie needs but encouraging
intake of mono and polyunsaturated fatty acids may help prevent cardiovascular complications in a
population experiencing increasing longevity. Foods that are high in protein will help limit catabolism.
Carbohydrates, once the foundation of the CF diet are no longer emphasized as patients likely consume
29
enough carbohydrate foods. Some adjustments to carbohydrate intake may be helpful as certain
patients might benet from additional ber. Additionally, pairing carbohydrates with fat and/or
protein will help promote calorie intake and glucose control.
The diet recommendations for someone with CF will be as individual and varied as their disease.
Personalized assessment and recommendations are best for this population, however the
recommendations provided in this chapter can serve as a guide.
References
patients with cystic brosis in Boston and Toronto. J Clin Epidemiol. 1988;41 Suppl 6:58391.
2. Kraemer R, Ruderberg A, Hadorn B, Rossi E. Relative underweight in cystic brosis and its prognostic value. Acta
Paediatr Scand. 1978;67:337.
3. Stern RD, Boat TF, Doershuk CF, Tucker AF, Primiano Jr FP, Matthews LW. Course of cystic brosis in 95
patients. J Pediatr. 1976;89:40611.
4. Parsons HG, Beaudry P, Dumas A, Pencharz PB. Energy needs and growth in children with cystic brosis.
J Pediatr Gastroenterol Nutr. 1983;2 Suppl 1:449.
J Pediatr Gastroenterol Nutr. 2002;35:24659. doi:10.1097/01.MPG.0000025580.85615.14.
6. Stallings VA, Stark LJ, Robinson KA, Feranchak AP, Quinton H. Evidence-based practice recommendations for
nutrition-related management of children and adults with cystic brosis and pancreatic insufciency: results of a
systematic review. J Am Diet Assoc. 2008;108 Suppl 5:8329. doi:10.1016/j.jada.2008.02.020.
outcomes and survival in patients with cystic brosis. J Pediatr. 2013;162 Suppl 3:5305. doi:10.1016/j.
jpeds.2012.08.040.
8. Ramsey BW, Farrell PM, Pencharz P. Consensus Committee. Nutritional assessment and management in cystic
brosis: a consensus report. Am J Clin Nutr. 1992;55:10816.
9. Murphy JL, Wootton SA, Bond SA, Jackson AA. Energy content of stools in normal healthy controls and patients
with cystic brosis. Arch Dis Child. 1991;61:495500.
10. Chase HP, Long MA, Lavin MH. Cystic brosis and nutrition. J Pediatr. 1979;3 Suppl 3:33747.
11. Schoni MH, Casaulta-Aebischer C. Nutrition and lung function in cystic brosis patients: review. Clin Nutr.
2000;19 Suppl 2:7985. doi:10.1054/clnu.1999.0080.
12. Institute of Medicine. Energy. In: Dietary reference intakes for energy carbohydrate, ber, fat, fatty acids,
cholesterol, protein and amino acids. Washington: National Academy Press; 2002. p. 104264.
13. Dodge JA. Nutritional requirements in cystic brosis: a review. J Pediatr Gastroenterol Nutr. 1988;7 Suppl
1:S811.
14. Dodge JA, Turck D. Cystic brosis: nutritional consequences and management. Best Pract Res Clin Gastroenterol.
2006;20 Suppl 3:53146. doi:10.1016/j.bpg.2005.11.006.
15. Pencharz PB, Durie PR. Pathogenesis of malnutrition in cystic brosis, and its treatment. Clin Nutr. 2000;19 Suppl
6:38794. doi:10.1054/clnu.1999.0079.
16. Amin R, Ratjen F. Cystic Fibrosis: a review of pulmonary and nutritional therapies. Adv Pediatr. 2008;55:99121.
doi:10.1016/j.yapd.2008.07.015.
17. Vaisman N, Pencharz PB, Corey M, Canny GJ, Hahn E. Energy expenditure of patients with cystic brosis.
J Pediatr. 1987;111 Suppl 4:496500.
18. Buchdahl RM, Cox M, Fulleylove C, Marchant JL, Tomkins AM, Brueton MJ, Warner JO. Increased resting
energy expenditure in cystic brosis. J Appl Physiol. 1988;64:18106.
19. Stallings VA, Tomezsko JL, Schall JI, Mascarenhas MR, Stettler N, Scanlin TF, Zemel BS. Adolescent development
and energy expenditure in females with cystic brosis. Clin Nutr. 2005;24:73745. doi:10.1016/j.clnu.2005.02.005.
20. Zemel BS, Kawchaw DA, Cnaan A, Zhao H, Scanlin TF, Stallings VA. Prospective evaluation of resting energy
expenditure, nutritional status, pulmonary function and genotype in children with cystic brosis. Pediatr Res.
1996;40:57885.
21. Richards ML, Davies PSW, Bell SC. Energy cost of physical activity in cystic brosis. Eur J Clin Nutr.
2001;55:6907.
22. Shepherd RW, Greer RM, McNaughton SA, Wotton M, Cleghorn GJ. Energy expenditure and the body cell mass
in cystic brosis. Nutrition. 2001;17 Suppl 1:225.
30
J. Brownlee
23. Allen JR, McCauley JC, Selby AM, Waters DL, Gruca MA, Baur LA, Asperen PV, Gaskin KJ. Differences in
resting energy expenditure between male and female children with cystic brosis. J Pediatr. 2003;142:159.
doi:10.1067/mpd.2003.38.
24. Barclay A, Allen JR, Blyler E, Yap J, Gruca MA, Asperen PV, Cooper P, Gaskin KJ. Resting energy expenditure
in females with cystic brosis: is it affected by puberty? Eur J Clin Nutr. 2007;61:120712. doi:10.1038/sj.
ejcn.1602637.
25. Spicher V, Roulet M, Schutz Y. Assessment of total energy expenditure in free-living patients with cystic brosis.
J Pediatr. 1991;118 Suppl 6:86572.
26. Gunrow JE, Azcue MP, Berall G, Pencharz PB. Energy expenditure in cystic brosis during activities of daily
living. J Pediatr. 1993;122 Suppl 2:2436.
27. ORawe A, McIntosh I, Dodge JA, Brock DJ, Redmond AO, Ward R, Macpherson AJ. Increased energy
expenditure in cystic brosis is associated with specic mutations. Clin Sci. 1992;82 Suppl 1:716.
28. Tomezsko JL, Stallings VA, Kawchak DA, Goin JE, Diamond G, Scanlin TF. Energy expenditure and genotype of
children with cystic brosis. Pediatr Res. 1994;35 Suppl 4:45160.
29. Thomson MA, Wilmott RW, Wainwright C, Masters B, Francis PJ, Shepherd RW. Resting energy expenditure,
pulmonary inammation, and genotype in the early course of cystic brosis. J Pediatr. 1996;129 Suppl
3:36773.
30. Girardet JP, Tounian P, Sardet A, Veinberg F, Grimfeld A, Tournier G, Fontaine JL. Resting energy expenditure in
infants with cystic brosis. J Pediatr Gastroenterol Nutr. 1994;18 Suppl 2:2149.
31. Thomson MA, Bucolo S, Quirk P, Shepherd RW. Measured versus predicted energy expenditure in infants: a need
for reappraisal. J Pediatr. 1995;126 Suppl 1:217.
32. Bell SC, Saunders MJ, Elborn JS, Shale DJ. Resting energy expenditure and oxygen cost of breathing in patients
with cystic brosis. Thorax. 1996;51:12631.
33. Fried MD, Durie PR, Tsui LC, Corey M, Levison H, Pencharz PB. The cystic brosis gene and resting energy
expenditure. J Pediatr. 1991;119 Suppl 6:9136.
34. Moudiou T, Galli-Tsinopoulou A, Vamvakoudis E, Nousia-Arvanitakis S. Resting energy expenditure in cystic
brosis as an indicator of disease severity. J Cyst Fibros. 2007;6:1316. doi:10.1016/j.jcf.2006.06.001.
35. Magofn A, Allen JR, McCauley J, Gruca MA, Peat J, Asperen PV, Gaskin K. Longitudinal analysis of resting
energy expenditure in patients with cystic brosis. J Pediatr. 2008;152:7038. doi:10.1016/j.jpeds.2007.10.021.
36. Steinkamp G, Drommer A, von der Hardt H. Resting energy expenditure before and after treatment for
Pseudomonas aeroginosa in patients with cystic brosis. Am J Clin Nutr. 1993;57:6859.
37. Stallings VA, Fung EB, Hoey PM, Scanlin TF. Acute pulmonary exacerbation is not associated with increased
energy expenditure in children with cystic brosis. J Pediatr. 1998;132 Suppl 3:4939.
38. Groleau V, Schall JI, Dougherty KA, Latham NE, Maqbool A, Mascarenhas MR, Stallings VA. Effect of dietary
intervention on growth and energy expenditure in children with cystic brosis. J Cyst Fibros. 2014. doi:10.1016/j.
jcf.2014.01.009.
39. Shepherd RW, Vasques-Velasquez L, Prentice A, Holt TL, Coward WA, Lucas A. Increased energy expenditure in
young children with cystic brosis. Lancet. 1988;2:13003.
40. Davies PSW, Erskine JM, Hambridge KM, Accurso FJ. Longitudinal investigation of energy expenditure in infants
with cystic brosis. Eur J Clin Nutr. 2002;56:9406.
41. Pencharz PB, Berall G, Vaisman N, Corey M, Canny G. Energy expenditure in children with cystic brosis.
Lancet. 1988;2:5134.
42. Bronstein MN, Davies PS, Hambidge KM, Accurso FJ. Normal energy expenditure in the infant with
presymptomatic cystic brosis. J Pediatr. 1995;126 Suppl 1:2833.
43. Bines JE, Truby HD, Armstrong DA, Phelan PD, Grimwood K. Energy metabolism in infants with cystic brosis.
J Pediatr. 2002;140 Suppl 5:52733. doi:10.1067/mpd.2002.123284.
44. Marin VB, Velandia S, Hunter B, Gattas V, Fielbaum O, Herrera O, Diaz E. Energy expenditure, nutrition status
and body composition in children with cystic brosis. Nutrition. 2004;20 Suppl 2:1816. doi:10.1016/j.
nutr.2003.10.010.
45. Johnson MR, Ferkol TW, Shepherd RW. Energy cost of activity and exercise in children and adolescents with
cystic brosis. J Cyst Fibros. 2006;5:538. doi:10.1016/j.jcf.2005.10.001.
46. McCloskey M, Redmond AOB, McCabe C, Pyper S, Westerterp KR, Elborn SJ. Energy balance in cystic brosis
when stable and during a respiratory exacerbation. Clin Nutr. 2004;23:140512. doi:10.1016/j.clnu.2004.06.010.
47. Shapiro BL. Mitochondrial dysfunction, energy expenditure and cystic brosis. Lancet. 1988;2:289.
48. ORawe A, Dodge JA, Redmond AOB, McIntosh I, Brock DJH. Gene/energy interaction in cystic brosis. Lancet.
1990;2:5523.
49. Kuhn RD, Gelrud A, Munck A, Caras S. CREON (pancrelipase delayed release capsules) for the treatment of
exocrine pancreatic insufciency. Adv Ther. 2010;27 Suppl 12:895916. doi:10.1007/s12325-010-0085-7.
50. Walkowiak J, Nousia-Arvanitakis S, Henker J, Stern M, Sinaasappel M, Dodge JA. Indirect pancreatic function
tests in children. J Pediatr Gastroenterol Nutr. 2005;40 Suppl 2:10714.
31
51. Trabulsi J, Ittenbach RF, Schall JI, Olsen IE, Yudkoff M, Daikhin Y, Zemel BS, Stallings VA. Evaluation of
formulas for calculating total energy requirements of preadolescent children with cystic brosis. Am J Clin Nutr.
2007;85:14451.
52. Schall JI, Bentley T, Stallings VA. Meal patterns, dietary fat intake and pancreatic enzyme use in preadolescent
children with cystic brosis. J Pediatr Gastroenterol Nutr. 2006;43 Suppl 5:6519.
53. White H, Wolfe SP, Foy J, Morton A, Conway SP, Brownlee KB. Nutritional intake and status in children with
cystic brosis: does age matter? J Pediatr Gastroenterol Nutr. 2007;44 Suppl 1:11623.
54. Kawchak DA, Zhao H, Scanlin TF, Tomezsko JL, Cnaan A, Stallings VA. Longitudinal, prospective analysis of
dietary intake in children with cystic brosis. J Pediatr. 1996;129 Suppl 1:11929.
55. Woestenenk JW, Castelijns SJAM, van der Ent CK, Houwen RHJ. Dietary intake in children and adolescents with
cystic brosis. Clin Nutr. 2014;33:52832. doi:10.1016/j.clnu.2013.07.011.
56. Tomezsko JL, Stallings VA, Scanlin TF. Dietary intake of healthy children with cystic brosis compared with
normal control children. J Pediatr. 1992;90:54753.
57. Powers SW, Patton SR, Byars KC, Mitchell MJ, Jelalian E, Mulvihill MM, Hovell MF, Stark LJ. Caloric intake
and eating behavior in infants and toddlers with cystic brosis. J Pediatr. 2002. doi:10.1542/peds.109.5.e75.
58. Macdonald A, Holden C, Harris G. Nutritional strategies in cystic brosis: current issues. J R Soc Med. 1991;84
Suppl 18:2835.
59. Pencharz PB, Berall G, Corey M, Durie P, Vaisman N. Energy intake in cystic brosis. Nutr Rev. 1989;47:312.
60. Sinaasappel M, Stern M, Littlewood J, Wolfe S, Steinkamp G, Heijerman HGM, Robberecht E, Doring G. Nutrition
in patients with cystic brosis: a European consensus. J Cyst Fibros. 2002;1:5175.
61. Turck D, Michaud L. Cystic brosis: nutritional consequences and management. Baillieres Clin Gastroenterol.
1998;12 Suppl 4:80522.
62. Hise ME, Brown JC. Lipids. In: Gottschlich MM, DeLegge MH, Mattox T, Mueller C, Worthington P, editors. The
A.S.P.E.N. nutrition support core curriculum: a case based approach the adult patient. USA: American Society
for Parenteral and Enteral Nutrition; 2007. p. 4870.
63. Green MR, Buchanan E, Weaver LT. Nutritional management of the infant with cystic brosis. Arch Dis Child.
1995;72:4526.
64. Gaskin KJ. Nutritional care in children with cystic brosis: are our patients becoming better? Eur J Clin Nutr.
2013;67:55864. doi: 10.1038/ejcn.2013.20.
65. Luder E, Kattan M, Thornton JC, Koehler KM, Bonforte RJ. Efcacy of a nonrestricted fat diet in patients with
cystic brosis. Am J Dis Child. 1989;143:45864.
66. Pencharz PB. Energy intakes and low-fat diets in children with cystic brosis. J Pediatr Gastroenterol Nutr.
1983;2:4002.
67. Daniels L, Davidson GP, Martin JA. Comparison of the macronutrient intake of healthy controls and children with
cystic brosis on low fat or nonrestricted fat diets. J Pediatr Gastroenterol Nutr. 1987;6 Suppl 3:3816.
68. Marlotta RB, Floch MH. Dietary therapy of steatorrhea. Gastroenterol Clin North Am. 1989;18:485512.
69. Walkowiak J, Przyslawski J. Five-year prospective analysis of dietary intake and clinical status in malnourished
cystic brosis patients. J Hum Nutr Diet. 2003;16:22531.
70. Anthony H, Bines J, Phelan P, Paxton S. Relation between dietary intake and nutritional status in cystic brosis.
Arch Dis Child. 1998;78:4437.
71. Landon C, Kerner JA, Castillo R, Adams L, Whalen R, Lewiston NJ. Oral correction of essential fatty acid
deciency in cystic brosis. J Parenter Enteral Nutr. 1981;5:5014. doi:10.1177/0148607181005006501.
72. Macdonald A. Nutritional management of cystic brosis. Arch Dis Child. 1996;74:817.
73. Robinson P. Nutritional status and requirements in cystic brosis. Clin Nutr. 2001;20 Suppl 1:816. doi:10.1054/
clnu.2001.0408.
74. Collins CE, OLoughlin EV, Henry RL. Fat gram target to achieve high energy intake in cystic brosis. J Paediatr
Child Health. 1997;31:1427.
75. Widhalm K, Gotz M. Long-term use of medium chain triglycerides in cystic brosis (authors translation). Wien
Klin Wochenschr. 1976;88 Suppl 17:55761.
76. Koletzko S, Reinhardt D. Nutritional challenges of infants with cystic brosis. Early Hum Dev. 2001;65:S5361.
77. Kasai M, Nosaka N, Maki H, Suzuki Y, Takeuchi H, Aoyama T, Ohra A, Harada Y, Okazaki M, Kondo
K. Comparison of diet-induced thermogenesis of foods containing medium- versus long-chain triacylglycerols. J
Nutr Sci Vitaminol. 2002;48:53640.
78. Clegg ME. Medium-chain triglycerides are advantageous in promoting weight loss although not benecial to
exercise performance. Int J Food Sci Nutr. 2010;61 Suppl 7:65379. doi:10.3109/09637481003702114.
79. Maqbool A, Schall JI, Garcia-Espana JF, Zemel BS, Strandvik B, Stallings VA. Serum linoleic acid status as a
clinical indicator of essential fatty acid status in children with cystic brosis. J Pediatr Gastroenterol Nutr.
2008;47:63544.
80. Roulet M, Frascarolo P, Rappaz I, Pilet M. Essential fatty acid deciency in well nourished young cystic brosis
patients. Eur J Pediatr. 1997;156:9526.
32
J. Brownlee
81. Maqbool A, Schall JI, Gallagher PR, Zemel BS, Strandvik B, Stallings VA. Relation between dietary fat intake
type and serum fatty acid status in children with cystic brosis. J Pediatr Gastroenterol Nutr. 2012;5:60511.
doi:10.1097/MPG.0b013e3182618f33.
82. Al-Turkmani RM, Freedman SD, Laposata M. Fatty acid alterations and n-3 fatty acid supplementation in cystic
brosis. Prostaglandins Leukot Essent Fatty Acids. 2007;77:30918. doi:10.1016/j.plefa.2007.10.009.
83. Coste TC, Armand M, Lebacq J, Lebecque P, Wallemacq P, Leal T. An overview of monitoring and supplementation
of omega 3 fatty acids in cystic brosis. Clin Biochem. 2007;40:51120. doi:10.1016/j.clinbiochem.2007.01.002.
84. Thompson GN. Relationships between essential fatty acid levels, pulmonary function and fat absorption in preadolescent cystic brosis children with good clinical scores. Eur J Pediatr. 1989;148:3279.
85. Burdge GC, Goodale AJ, Hill CM, Halford PH, Lambert EJ, Postle AD, Rolles CJ. Plasma lipid concentrations in
children with cystic brosis: the value of a high fat diet and pancreatic supplementation. Br J Nutr.
1994;71:95964.
86. Rettammel AL, Marcus MS, Farrell PM, Sondel SA, Koscik RE, Mischler EH. Oral supplementation with a highfat, high-energy product improves nutritional status and alters serum lipids in patients with cystic brosis. J Am
Diet Assoc. 1995;95 Suppl 4:4549.
87. Heymseld SB, Casper K, Funfar J. Physiologic response and clinical implications of nutrition support. Am J
Cardiol. 1987;60:75G81.
88. Kane RE, Hobbs P. Energy and respiratory metabolism in cystic brosis: the inuence of carbohydrate content of
nutritional supplements. J Pediatr Gastroenterol Nutr. 1991;12 Suppl 2:21723.
89. Kane RE, Hobbs PH, Black PG. Comparison on low, medium, and high carbohydrate formulas for nighttime
enteral feedings in cystic brosis patients. J Parenter Enteral Nutr. 1990;14 Suppl 1:4752.
doi:10.1177/014860719001400147.
90. Gottrand F, Hankard R, Michaud L, Ategbo S, Dabadie A, Druon D, Turck D. Effect of glucose to fat ratio on
energy substrate disposal in children with cystic brosis fed enterally. Clin Nutr. 1999;18 Suppl 5:297300.
91. Moss TJ, Austin GE, Moss AJ. Preatherosclerotic aortic lesions in cystic brosis. J Pediatr. 1979;1:327.
92. Smith C, Winn A, Seddon P, Ranganathan S. A fat log of good: balance and trends in fat intake in children with
cystic brosis. J Cyst Fibros. 2012;11:1547. doi:10.1016/j.jcf.2011.10.007.
93. Slesinski MJ, Gloninger MF, Costantino JP, Orenstein DM. Lipid levels in adults with cystic brosis. J Am Diet
Assoc. 1994;94 Suppl 4:4028. doi:10.1016/0002-8223(94).
94. Figueroa V, Milla C, Parks EJ, Schwarzenberg SJ, Moran A. Abnormal lipid concentrations in cystic brosis. Am
J Clin Nutr. 2002;75:100511.
95. Georgiopoulou VV, Denker A, Bishop KL, Brown JM, Hirsh B, Wolfenden L, Sperling L. Metabolic abnormalities
in adults with cystic brosis. Respirology. 2010;15:8239. doi:10.1111/j.1440-1843.2010.01771.x.
96. Rhodes B, Nash EF, Tullis E, Pencharz PB, Brotherwood M, Dupuis A, Stephenson A. Prevalence of dyslipidemia
in adults with cystic brosis. J Cyst Fibros. 2010;9:248. doi:10.1016/j.jcf.2009.09.002.
97. Hull JH, Garrod R, Ho TB, Knight RK, Cockcroft JR, Shale DJ, Bolton CE. Increased augmentation index in
patients with cystic brosis. Eur Respir J. 2009;34 Suppl 6:13228.
98. ONady GM, Farinet CL. An adult cystic brosis patient presenting with persistent dyspnea: case report. BMC
Pulm Med. 2006;6:912. doi:10.1186/1471-2466-6-9.
99. Aratari MT, Venuta F, De Giacoma T, Rendina EA, Anile M, Diso D, Francioni F, Quattrucci S, Rolla M, Pugliese
F, Liparulo V, Di Stasio M, Ricella C, Tsagkaropoulos S, Ferretti G, Coloni CF. Lung transplantation for cystic
brosis: ten years of experience. Transplant Proc. 2008;40:20012. doi:10.1016/j.transproceed.2008.05.029.
100. De Aragao Dantas Alves C, Seabra Lima D. Cystic brosis-related dyslipidemia. J Bras Pneumol. 2008;34 Suppl
10:82939.
101. Whitney E, Rolfes SR. The lipids: triglycerides, phospholipids and sterols. In: Understanding nutrition. 10th ed.
USA: Thomson Wadsworth; 2005. p. 14079.
102. USDA National Nutrient Database for Standard Reference. USDA National Agricultural Library. Beltsville MD.
2011. http://ndb.nal.usda.gov. Accessed 30 Sept 2014, 3 Oct 2014, 4 Oct 2014.
103. Wood LG, Fitzgerald DA, Gibson PG, Cooper DM, Garg ML. Increased plasma fatty acid concentration after
respiratory exacerbations are associated with elevated oxidative stress in cystic brosis patients. Am J Clin Nutr.
2002;75:66875.
104. Whitney E, Rolfes SR. Antioxidant nutrients in disease prevention. In: Understanding nutrition. 10th ed. USA:
Thomson Wadsworth; 2005. p. 38993.
105. Whitney E, Rolfes SR. Protein: amino Acids. In: Understanding nutrition. 10th ed. USA: Thomson Wadsworth;
2005. p. 180206.
106. Pandit C, Graham C, Selvadurai H, Gaskin K, Cooper P, van Asperan P. Festival food coma in cystic brosis.
Pediatr Pulmonol. 2013;48:7257. doi:10.1002/ppul.22702.
107. Berry HK, Kellogg FW, Hunt MM, Ingberg RL, Richter L, Guthar C. Dietary supplement and nutrition in children
with cystic brosis. Am J Dis Child. 1975;129:16571.
33
108. Darby C, Seakins JWT. Trial of amino acid supplements in cystic brosis of the pancreas. Arch Dis Child. 1971;46
Suppl 250:8667.
109. Clegg KM. Nitrogen balance trials in cystic brosis patients. Nutr Metab. 1977;21 Suppl 1:779.
110. Pelekanos JT, Holt TL, Ward LC, Cleghorn GJ, Shepherd RW. Protein turnover in malnourished patients with
cystic brosis: effects of elemental and nonelemental nutritional supplements. J Pediatr Gastroenterol Nutr.
1990;10 Suppl 3:33943.
111. Ellis L, Kalnins D, Corey M, Brennan J, Pencharz P, Durie P. Do infants with cystic brosis need a protein
hydrolysate formula? A prospective, randomized comparative study. J Pediatr. 1998;132 Suppl 2:2706.
112. Erskine JM, Lingard CD, Sontag MK, Accurso FJ. Enteral nutrition for patients with cystic brosis: comparison
of a semi-elemental and nonelemental formula. J Pediatr. 1998;132 Suppl 2:2659.
113. Mehta NM, Compher C, ASPEN Board of Directors. A.S.P.E.N. clinical guidelines: nutrition support or the
critically ill child. J Parenter Enteral Nutr. 2009;33:26077. doi:10.1177/0148607109333114.
114. Holt TL, Ward LC, Francis PJ, Isles A, Cooksley WGE, Shepherd RW. Whole body protein turnover in
malnourished cystic brosis patients and its relationship to pulmonary disease. Am J Clin Nutr. 1985;41:10616.
115. Shepherd RW, Holt TL, Thomas BJ, Kay L, Ilsles A, Francis MD, Ward LC. Nutritional rehabilitation in cystic
brosis: controlled studies of effects on nutritional growth retardation, body protein turnover and course of
pulmonary disease. J Pediatr. 1986;109 Suppl 5:78894.
116. Hardin DS, Ellis KJ, Dyson M, Rice J, McConnell R, Seilheimer DK. Growth hormone decreases protein
catabolism in children with cystic brosis. J Clin Endocrinol Metab. 2001;86 Suppl 9:44248.
117. Thompson GN, Tomas FM. Protein metabolism in cystic brosis: responses to malnutrition and taurine
supplementation. Am J Clin Nutr. 1987;46:60613.
118. Vaisman N, Clarke R, Rossi M, Goldberg E, Zello GA, Pencharz PB. Protein turnover and resting energy
expenditure in patients with under nutrition and chronic lung disease. Am J Clin Nutr. 1992;55:639.
119. Geukers VGM, Oudshoorn JH, Taminiau JAJM, van der Ent CK, Schilte P, Ruiter AFC, Ackermans MT, Endert
E, Jonkers-Schuitema CF, Heymans HAS, Sauerwein HP. Short-term protein intake and stimulation of protein
synthesis in stunted children with cystic brosis. Am J Clin Nutr. 2005;81:60510.
120. Engelen MPKJ, Com G, Wolfe RR, Deutz NEP. Dietary essential amino acids are highly anabolic in pediatric
patients with cystic brosis. J Cyst Fibros. 2013;12:44553. doi:10.1016/j.jcf.2012.12.011.
121. Thompson GN. Excessive fecal taurine loss predisposes to taurine deciency in cystic brosis. J Pediatr
Gastroenterol Nutr. 1988;7:2149.
122. Belli DC, Levy E, Darling P, Leroy C, Lepage G, Giguere R, Roy CC. Taurine improves the absorption of a fat
meal in patients with cystic brosis. Pediatrics. 1987;80:51723.
123. Smith LJ, Lacaille F, Lepage G, Ronco N, Lamarre A, Roy CC. Taurine decreases fecal fatty acid and sterol
excretion in cystic brosis. Am J Dis Child. 1991;145:14014.
124. Jonker R, Engelen MPKJ, Deutz NEP. Role of specic dietary amino acids in clinical conditions. Br J Nutr.
2012;108:S13948. doi:10.1017/S0007114512002358.
125. Lands LC, Grey V, Smountas AA, Kramer VG, McKenna D. Lymphocyte glutathione levels in children with cystic
brosis. Chest. 1999;116 Suppl 1:2015.
126. Tirouvanziam R, Conrad CK, Bottiglieri T, Herzenberg LA, Moss RB, Herzenberg LA. High-dose oral
N-acetylcysteine, a glutathione prodrug, modulates inammation in cystic brosis. Proc Natl Acad Sci U S A.
2006;103 Suppl 12:462833.
127. Grey V, Mohammed SR, Smountas AA, Bahlool R, Lands LC. Improved glutathione status in young adult patients
with cystic brosis supplemented with whey protein. J Cyst Fibros. 2003;2:1958. doi:10.1016/
S1569-1993(03)00097-3.
128. Garlick PJ. Assessment of the safety of glutamin and other amino acids. J Nutr. 2001;131:2556S61.
129. Leonard A, Schindler T. Cystic brosis nutrition 101: getting started 6th edition. 2014. https://portcf2dev.cff.org/
RegistryLaunch/Documents/CFNutrition101version20140722.pdf. Accessed 20 Sept 2014.
130. Hanning RM, Blimkie CJR, Bar-Or O, Lands LC, Moss LA, Wilson WM. Relationships among nutritional status
and skeletal and respiratory muscle function in cystic brosis: does early dietary supplementation make a
difference? Am J Clin Nutr. 1993;57:5807.
131. Michel SH, Maqbool A, Hanna MD, Mascarenhas M. Nutrition management of pediatric patients who have cystic
brosis. Pediatr Clin North Am. 2009;56:112341. doi:10.1016/j.pcl.2009.06.008.
132. Whitney E, Rolfes SR. The carbohydrates: sugars, starches, and bers. In: Understanding nutrition. 10th ed. USA:
Thomson Wadsworth; 2005. p. 102131.
133. Hoffman RD, Isenberg N, Powell GK. Carbohydrate malabsorption in minimal in school-age cystic brosis
children. Dig Dis Sci. 1987;32 Suppl 10:10714.
134. Vaisman N, Tabachnik E, Sklan D. Short-chain fatty acid absorption in patients with cystic brosis. J Pediatr
Gastroenterol Nutr. 1992;15 Suppl 2:1469.
34
J. Brownlee
135. Milla C, Doherty L, Raatz S, Schwarzenberg SJ, Regelmann W, Moran A. Glycemic response to dietary
supplements in cystic brosis is dependent on the carbohydrate content of the formula. J Parenter Enteral Nutr.
1996;20:1826. doi:10.1177/0148607196020003182.
136. Wilson DC, Kalnin C, Stewart C, Hamilton N, Hanna AK, Durie PR, Tullis E, Pencharz PB. Challenges in the
dietary treatment of cystic brosis related diabetes mellitus. Clin Nutr. 2000;19 Suppl 2:8793.
137. Proesmans M, De Boeck K. Evaluation of dietary ber intake in Belgian children with cystic brosis: is there a
link with gastrointestinal complaints. J Pediatr Gastroenterol Nutr. 2002;35:6104.
138. Gavin J, Ellis J, Dewar AL, Rolles CJ, Connett GJ. Dietary bre and the occurrence of gut symptoms in cystic
brosis. Arch Dis Child. 1997;76:357.
139. Van der Doef HPJ, Kokke FTM, Beek FJA, Woestenenk JW, Froeling SP, Houwen RHJ. Constipation in pediatric
cystic brosis patients: an underestimated medical condition. J Cyst Fibros. 2010;9:5963. doi:10.1016/j.
jcf.2009.11.003.
140. Anton DT, Moraru D, Cirdei E, Bozomitu L. Malnutrition and complex nutritional therapy in cystic brosis. Rev
Med Chir Soc Med Nat Iasi. 2006;110 Suppl 4:8016.
Chapter 3
Dietary Fat and Fat Metabolism in CF

Asim Maqbool and Birgitta Strandvik
Key Points
Patients with cystic brosis are at risk for essential fatty acid deciency and for fatty acid
abnormalities, which may be multifactorial in etiology.
While the debate over whether to restrict fat or to promote fat in the diet has been decided in favor
of the latter, there still remains controversy about what fats to recommend.
Linoleic acid deciency is well documented, as well as its association with growth impairment and
clinical outcomes in patients with CF.
Improving linoleic acid status is a goal, as status is associated with many important clinical
outcomes of interest, including growth, anthropometric measures, and lung function (FEV1).
There is concern that providing linoleic acid in the diet may drive inammation, as demonstrated
by in vitro and animal models, mostly.
In contrast, clinical pediatric studies have shown that LA and energy supplementation have been
associated with improved growth and other clinical outcomes of interest.
Energy intake remains an important factor and variable in this discussion and fat remains an
important source of energy intake.
Docosahexaenoic acid (DHA) is also frequently low in patients with CF, and supplementation with
DHA is thought to be safe, improves DHA levels, but has improved clinical status in only one
human study.
Rather than focus on normalization of fatty acid status as a function of what is observed in the
general population, the goal of energy and fat quality in patients with CF shown be directed
towards interventions that help improve growth, improve or preserve FEV1, and other clinical
outcomes of interest.
An approach to modify dietary fat based on the medical literature helps forge a direction and a path
forward. Additional prospective studies are required to more precisely determine specic dietary
fat needs by age and life stage in patients with CF.
A. Maqbool, M.D. (*)

Gastroenterology, Hepatology and Nutrition, The Childrens Hospital of Philadelphia, University of Pennsylvania
Perelman School of Medicine, 34 and Civic Center Boulevard, Room 8C09H, Philadelphia, PA 19104, USA
B. Strandvik, M.D., Ph.D.
Department of Biosciences and Nutrition, Karolinska Institutet,
NOVUM, Halsovagen 7-9, 14183 Huddinge, Stockholm, Sweden
35
36
A. Maqbool and B. Strandvik
Keywords Essential fatty acid deciency Linoleic acid Docosahexaenoic acid DHA Metabolism
Inammation Eicosanoid Dietary and outcome goals
Introduction
Individuals with cystic brosis (CF) and in particular those with pancreatic insufciency (PI) are
prone to fatty acid abnormalities, especially essential fatty acid (EFA) deciency, which may be
multifactorial in origin. While the debate of whether or not to restrict fat in the diet has been settled
with respect to clinical outcomes favoring fat supplementation, the amount and quality of fat in the
diet required for improving health outcomes by life stage groups has yet to be dened. Furthermore,
while there have been advancements in our understanding of the importance of specic types of fats
in the diet, there is discordance between the clinical data and basic science data regarding the essential
fats. Moving beyond these existing controversies, consensus may be forming about a paradigm shift
in how we think about these dietary fats and fatty acidsless maybe to normalize themthan to
modify their status towards one associated with improving clinical outcomes.
Dietary Fat Requirements

Dietary fat intake is required to provide EFAs and fat soluble vitamins. Dietary fat is also important
to provide energy substrate to meet needs for normal growth, development, and energy expenditure.
We require approximately 12% of our dietary intake to be from EFAs to meet our needs [1, 2], but
actual daily intake is about 10% in the form of linoleic acid [2]. The current Acceptable Macronutrient
Distribution Range for fat intake as a function of energy intake is between 30 and 40% for children
one to three years of age and 2035% for children greater than four years of age and for adults [1]. Fat
constitutes 50% of the energy intake from breast milk [3].
A Primer on Fatty Acid Metabolism

Fat Tissue Compartments and Reporting Modalities
Fatty acid status is determined in different tissue compartments, including cholesterol esters,
triglycerides, erythrocyte and total phospholipids in plasma and cell membranes. Fatty acid status
can be presented as a relative measure, weight/weight (mol%), or in absolute units [umol/L] [4].
Fat obtained from the diet is predominantly as triglycerides. However, when discussing fat tissue
compartments from a metabolic perspective, the phospholipid compartment is perhaps the most
relevant, as it represents the environment of cell metabolism. When total lipids in plasma (or
serum) are presented, all the classes of fat compartments are included. It is noteworthy that the
most labile of these tissue compartments with respect to fatty acid composition in circulation is
that of triglycerides. Triglyceride fatty acid proles undergo dramatic shifts in the post-prandial
period.
37
3 Dietary Fat and Fat Metabolism in CF
Essential Fatty Acids and Their Metabolism

Humans are unable to synthesize fatty acids with a double bond proximal to the 6 position, and
therefore are dependent on dietary fat sources to meet their EFA requirements, i.e. the fatty acids of
the 6 and 3 series. Linoleic acid (LA; 18:26) is the essential 6 polyunsaturated fatty acid (PUFA),
and it has important structural and functional roles, and is an important constituent of the lipid bilayer
membrane. Alpha linolenic acid (ALA; 18:33) is the essential 3 PUFA. These EFAs are
enzymatically sequentially desaturated and elongated to long-chain polyunsaturated fatty acids
(LCPUFA), which have important structural and functional roles in human health and disease states
(Fig. 3.1). ALA is desaturated and elongated to eicosapentaenoic acid (EPA; 20:53) and
docosahexaenoic acid (DHA; 22:63), whereas LA is desaturated and elongated to di-homo-gammalinolenic acid (DHGLA; 20:3 6) and arachidonic acid (ARA; 20:46).These LCPUFA exert negative
feedback on the desaturases. EFA deciency, conversely, is associated with increased elongation of
precursor fatty acids to their respective longer chain counterparts, to effect or maintain membrane
uidity and preserve function. The metabolic pathways for these fatty acids are parallel and interrelated, and there is substrate competition between these fatty acid series for the desaturases and
elongases. The rate limiting step is at the level of the delta 6 desaturase, which is the rst enzyme in
this cascade. Certain dietary factors may inhibit or facilitate the respective enzymes in these
transformations. Humans can synthesize fatty acids of the 9 and 7 series, which are desaturated and
Series of major fay acids and their

lipid mediators
18:2 6(LA)
18:3 3(ALA)
Elongases
Desaturases
20:4 n-6 (ARA)
18:1 9(OA)
Elongases
Desaturases
20:5 n-3 (EPA)
20:3 n-9(ETA)
22:6 n-3 (DHA)

Prostaglandin E2
LTC4/LTB4
Tromboxanes
HETEs
E-Resolvins
Lipoxins
D-Resolvins
Protecns
Maresins
Fig. 3.1 The major fatty acids and their most important lipid mediators. Linoleic acid (LA) and alpha-linolenic acid
(ALA) are the essential fatty acids, and humans are dependant on dietary intake provide these and meet our needs. LA
and ALA are transformed by desaturation (see text) to highly unsaturated fatty acids and by elongases to longer fatty
acids (more carbons). The most important long-chain fatty acids are arachidonic acid (ARA), eicosapentaenoic acid
(EPA) and docosahexaenoic acid (DHA). ARA is mainly transformed to pro-inammatory mediators (indicated by
filled arrow) and EPA and DHA mainly to anti-inammatory mediators (indicated by open arrows). The transformation
steps compete about the same enzymes. In the setting of essential fatty acid deciency, oleic acid (OA), which can be
synthesized in the body, is transformed to eicosatrienoic acid (Mead acid). For further explanations, see text
38
elongated to compensate for longer chain 6 and 3 LCPUFA in the setting of decreased LA or ALA
availability. Transformation of the 9 series of fatty acids results in increased concentrations of Mead
Acid (eicosatrienoic acid, 20:39). Biochemically, EFA deciency is primarily characterized by
decreased levels of LA as well as by an increased triene: tetraene (20:39/20:46; T: T) ratio (Fig. 3.1).
The T:T ratio was initially described by Holman et al. in the 1960s as abnormal if >0.04, and was later
revised in the 1990s to abnormal if greater than >0.02 by the same investigators, reecting changes in
dietary intake in the general population, in which EFA deciency is rare [5, 6]. Renement in analytical
techniques led to a revision of the cutoffs to one decimal place (0.4 or 0.2) [7]. The clinical
consequences of EFA deciency include impaired growth, seborrhea, platelet dysfunction, and poor
wound healing [8, 9].
Membrane function follows membrane structure, and PUFA confer uidity to the membrane. The
LCPUFA have several important structural and functional roles. ARA has been suggested as important
for growth and development. DHA is the most important structural component of the retina and of the
central nervous system. Both ARA and DHA are actively transported across the placenta (most
actively in the third trimester). They are also enriched in early breast milk and are frequently
supplemented in infant formulae [10, 11]. ARA is the precursor to eicosanoids (prostaglandins,
thromboxanes and leukotrienes) which are pro-inammatory; however, ARA is also the precursor for
lipoxin A, which has anti-inammatory function. DHGLA and EPA are precursors to different
prostaglandins, thromboxanes, and leukotrienes, which have other functions. The most important
products of EPA and DHA are the anti-inammatory lipid mediators named resolvins, protectins, and
maresins (Fig. 3.1). These mediators function to resolve acute inammation, and are necessary to
prevent a chronic inammatory state [12]. The balance of 6 and 3 fatty acids in the diet is thought
to have changed at a population level over time, in transitioning from traditional and historical diets
to the modern Western diet [13], and is postulated to be associated with the increase in the incidence
and prevalence of several non-communicable diseases characterized by inammatory states. The ratio
of ARA to DHA serves as a surrogate marker for inammation, and may differ by tissue type based
on respective disease processes. For example, in patients with CF, this ratio is abnormal in serum [14]
and in nasal epithelium [15].
Fatty Acid Abnormalities and Cystic Fibrosis: Concepts and Controversies

Fat malabsorption and steatorrhea are common in individuals with CF and PI. Steatorrhea has
historically posed a challenge for quality of life for subjects with CF, more pronounced prior to the
recent development of more efcient pancreatic enzyme replacement therapy (PERT). Restricting fat
in the diet for individuals with CF versus not restricting fat has been associated with comparatively
worse clinical outcomes [16]. Currently, fat intake is encouraged and recommended for individuals
with CF, and in infants, the CF Foundation has suggested that ~3540% of calories in the diet be from
fat [17]. EFA deciency has been described in subjects with CF and PI for more than 50 years [18], and
is present in neonates with CF [19, 20] and in apparently well-nourished children with CF [14, 21].
There is evidence that the etiology of EFA deciency in subjects with CF is multifactorial, and in
addition to pancreatic insufciency and fat malabsorption [22, 23], may relate to increased oxidative
stress [24], increased membrane turnover [25], abnormal release of ARA from the cell membrane [26],
increased expression and activity of desaturases as a primary event [27], to defects that may relate to
genotype [14, 28], and to increased energy expenditure and imbalance, as reviewed elsewhere [29].
LA deciency was the rst fatty acid abnormality described in patients with CF in 1962 [18]. DHA
deciency was subsequently described a decade later [30]. LA and DHA are the most frequently
described FA abnormalities in CF. ARA levels are not reported consequently to be abnormal in
39
patients with CF; according to some reports, ARA levels may be increased, the same/similar to, or less
than those observed in control subjects [14, 31].
EFA and PUFA abnormalities in CF may be multifactorial. PUFA abnormalities may relate to fat
malabsorption [23], which conversely may be related to EFA deciency and fatty acid abnormalities
inuencing the intestinal phospholipids [32], which may explain in part malabsorption that persists
despite PERT [22]. Bile acid deciency does not seem to contribute signicantly to PUFA
malabsorption in CF [33, 34]. Abnormal release of ARA from the lipid membrane bilayer has been
previously described, mediated by phospholipase A2, and may contribute to LA deciency, as LA may
be elongated to compensate for low membrane ARA levels [26, 28]. DHA deciency may also relate
to dietary intake, (since 3 consumption is relatively much less relative to LA consumption [13, 35]
or to an increased turnover of phosphatidylcholine in the membranes) [25, 29]. Less than 0.5% of
ALA is converted to DHA in healthy subjects [36]. In CF models, the conversion of ALA to DHA
may be impaired, further contributing to DHA deciency [37].
While there is agreement that individuals with CF are prone to EFA deciency, the approach to
management remains controversial. Given the potential health consequences of EFA deciency in
patients with CF and PI, and the similarities in symptoms between animal models with EFA deciency
and patients with CF [3840], several investigators have studied approaches to correct EFA deciency;
these warrant some discussion.
Nutritional Interventions
There are many short-term studies with supplementation in order to improve LA status, and, more
recently, with 3 fatty acids to improve DHA status. Supplementation studies with high energy foods
or supplements rich in LA have yielded similar results as giving LA enterally [4144] or parentally
[45, 46] (see relevant reviews[29, 47]). These studies highlight the observation that adequate energy
intake is required (but not always sufcient in itself) to preserve EFA to act as a membrane constituent
and precursor to long chain counterparts, respectively, and to prevent these fats from being oxidized
for energy. Energy intake has been described as an important factor in infants as much as
supplementation with LA, and has been the source of a confounding variable in subsequent studies
examining the relationship between type of dietary fat intake and serum FA status in children and
adults with CF [48, 49]. Subsequent clinical pediatric studies in subjects with CF which controlled for
energy as a confounding variable did nd an association between type of dietary fat intake and serum
fatty acid status [31, 50, 51]. Long-term LA supplementation studies have been demonstrated to
inuence the pathophysiology of the disease [46, 52, 53]. LA supplementation in the diet improves
serum LA status. More importantly, dietary LA intake has been shown to be associated with
improvements in growth in children with CF [31, 41, 42, 50, 54]. Following these landmark fatty acid
supplementation studies demonstrating improvements in the pathophysiology of disease in CF in
Sweden [46, 52, 53], the Swedish model of CF care has subsequently included both parenteral and
oral supplementation to all patients as part of clinical standard of care practices [55]. These
interventions are thought to have contributed to the improved clinical status and outcomes of CF
patients with respect to pulmonary status, bone status, and anthropometry into adulthood [5558].
As started above, LA status and LA intake have been associated with important clinical outcomes
with CF. Improving LA status is clearly a goal and is not controversial. However, the manner in
which we approach improving LA status has generated some debate. Specically, there is concern
that LA supplementation to improve LA status may increase transformation to ARA and to proinammatory eicosanoids [59, 60]. However, high LA has an inhibitory effect on ARA in human
cells [61], and similar results have been demonstrated in human subjects with CF[62]; in these
40
studies, dietary intake of ARA only (not LA) was associated with high serum levels of ARA [63],
as shown in healthy individuals [64].
DHA supplementation studies in subjects with CF have had multiple aims: to improve DHA status,
to increase the anti-inammatory DHA lipid mediators, and to inuence the elongases and desaturases
by exerting competitive inhibition of the elongation of LA to ARA. DHA also may have antibacterial
properties towards Burkholderia cenocepacia, which may be desirable in individuals with CF [65].
Mouse model studies in CF have suggested that LA supplementation increases ARA, and DHA
supplementation (in some studies) improves LA status and does not contribute to increased ARA
production, but, via pathway interactions, may decrease ileal inammation, and may reverse some of
the CF related morphological pancreatic changes observed [60, 6669]. The case for supplementation
of DHA has been made on the basis of these studies and other studies reviewed elsewhere [47, 70].
DHA supplementation is thought to be safe, and oral supplementation of DHA may increase DHA
concentrations in erythrocyte membranes [71], in serum phospholipids [72] and in plasma [73].
Enteral supplementation of 3 fatty acids has also been demonstrated to increase EPA levels in
neutrophils [74]. DHA supplementation in adult subjects was associated with improving DHA in
plasma, erythrocyte, and duodenal tissue [75]. Intravenous supplementation of sh oil (which is rich
in 3 fatty acids) likewise increased DHA and EPA levels. DHA supplementation has been associated
with decreasing the AA:DHA ratio [73], and in decreasing the ratio of pro-inammatory to antiinammatory leukotrienes as well [74]. Perhaps the strongest case for EPA and DHA supplementation
for patients with CF comes from an eight-month EPA and DHA supplementation trial in pediatric
subjects with CF, which demonstrated increased levels of DHA and EPA in erythrocyte membranes,
and decreased levels of ARA. The same study showed increases in LA alongside decreases in
inammatory markers, and is the only study that demonstrated an improvement in FEV1 [76]. Other
DHA supplementation studies in human subjects with CF varied from 6 weeks to 1 year in duration,
and while improvements in DHA status were noted, did not demonstrate an effect on clinical outcomes
of interest, including FEV1 [7173]. Interestingly, weekly intravenous 3 supplementation over a
12-week period improved DHA status, but did not improve oxidation markers, and was actually
associated deleterious effects of decreased glutathione levels and weight loss [77]. Contrary to most
studies in patients with CF [71, 72, 74], some animal studies have shown benet of DHA
supplementation without a decrease or increase of ARA [66, 67, 78]. The primary benecial effects
of DHA on pancreas and ileum in a small study [69] have to date not been replicated in subsequently
performed longer term studies [79]. However, liver histopathological/pathophysiological abnormalities
appear to have been prevented in a longer term supplementation study [79]. Patients with CF related
liver disease have been shown to have lower serum concentration of DHA than patients without that
specic complication [80]. A Cochrane report, while stating that there may be some benets to the use
of 3 fatty acids, did not currently support DHA or 3 FA supplementation in CF [81].
How then to account for the discordance between DHA supplementation versus LA
supplementation studies? Some of these observed differences may relate to the animal models
versus human studies, since murine CFTR has only 70% homology to human CFTR. There are
also different study populations across these studies, specically, pediatric versus adult studies;
growth is an important variable in the former, for which the intake requirements for LA may be
greater as compared to needs for fully grown or adult subjects, in which deterioration of lung
status might be most prominent. The type of supplement used may also affect study results. The
duration of these respective supplementation studies may also be a factor; the duration of
supplementation may need to be several months or longer prior to observing not only changes in
concentrations of these respective fatty acids, but also changes in inammatory markers and
eventually outcomes of clinical interest [52].
41
Fatty Acid Status in CF: Normalization or Modification?

EFA deciency is rare in the general population. The revision of the denition what constitutes a
normal T:T ratio was based on trends in the general population and likely reected changes in
dietary fat intake patterns. The ratio of 6:3 fatty acids has risen following the industrial revolution,
and across populations globally, following departure from traditional diets to the modern Western
diet. Parallel to these shifts, the incidence and prevalence of non-communicable diseases and
inammatory diseases has also increased [2, 13, 82]. These observations as well as EFA deciency
lead to the question: what should our goals be for fatty acid supplementation in CF?
Normalization is a natural goal, but is not always readily achievable [20, 83]. Christophe et al.
[84] have proposed targeted modication of FA status associated with clinical outcomes, as opposed
to correction of status as a function of levels seen in the general population. This line of reasoning
would suggest that we have to examine the various fatty acid status markers routinely used and
clinically available in relation to outcomes as a starting point. We then need to review not only how
EFA status is dened currently, but also which of the markers are more clinically relevant. EFA status
is dened by LA status, ALA status, or by an abnormal T:T ratio. Maqbool et al. [54] studied these
markers of EFA status in relationship to clinically relevant outcomes (growth and pulmonary function)
in pre-adolescent children with CF and PI, and reported that LA status predicted these outcomes of
interest; LA cut points between 18 and 26 mol% were evaluated in this study, with a threshold effect
noted in LA > 21 mol%. Of note, neither the 0.2 nor 0.4 T:T cut points were associated with clinically
relevant outcomes. It is important to recognize that the T:T ratio may be inuenced by other PUFAs
in addition to LA [85]. Furthermore, EFA status as reported by LA or T:T reported similar biochemical
information [54]. Shoff et al. also reported better growth status for infants and young children with CF
to be associated with LA status [50]. These studies suggest that LA status may be more clinically
relevant biomarker than the T:T ratio.
Therefore, our thinking regarding EFA status is undergoing a paradigm shift, from dening status
as function of the healthy population to that associated with pulmonary and growth outcomes.
Modication of the diet to provide sufcient energy, LA as well as ALA and longer chain 3 PUFAS
may be a reasonable approach. Olveira et al. [86] recently demonstrated that supplementation of a
combination of EPA, DHA, LA, and gamma-linolenic acid in 17 adult subjects with CF for 1 year
resulted in increased DHA, total 3 PUFA, and LA levels, decreased the AA:DHA ratio, and decreased
serum TNF-alpha, IgG, and IgM levels. Additionally, supplementation was associated with
improvements in spirometry, and decreased number of days of respiratory exacerbations and antibiotic
use. These results were similar to those reported from Sweden [55]. Fat free mass and handgrip
dynamometry also improved, and were reportedly satisfactory in the Swedish population giving
regular supplementation [87, 88]. This dietary fat modication study by Olveira and colleagues [86]
and the more than 30 years of practical experience in Sweden reinforces the need for both LA and
DHA, and suggests a path forward.
Other nutritional considerations for correcting the fatty acid abnormalities observed in
individuals with CF relate to membrane phospholipids and their metabolic interfaces. Choline is the
major component of phosphatidylcholine as the major phospholipid in the outer layer of the bilayer
membrane, and is also at risk for deciency in subjects with CF [89, 90]. Choline is required for
methyl metabolism, cholinergic neurotransmission, transmembrane signaling, lipid cholesterol
transport, and metabolism [91]. Choline supplementation studies have demonstrated improvement in
choline status in CF [92]. Supplementation with LYM-X-SORBTM, a novel organized lipid matrix
containing choline and fatty acids, was shown to improve fatty acid and fat soluble vitamin status in
pediatric subjects with CF [93]. Choline phospholipid metabolism intersects with 1-methyl
metabolism, and supplementation with vitamin 5-tetrahydrofolate (a co-factor for these pathways)
may improve choline status in subjects with CF as well [94]. There may be increased choline and
42
membrane turnover in patients with CF [25], which may also explain the low DHA [29] and account
for some of the phospholipid and fatty acid abnormalities observed in CF.
Abnormalities in ceramide metabolism have also been reported in CF, but the reports are divergent,
which might refer to differences in species of ceramides [9597]. Fenretinide blocks IL1- formation
and inuences ceramide transformation, normalizing the fatty acid prole in an animal model of CF
[95]. The implications of ceramide supplementation for patients with CF-particularly in limiting ARA
production are intriguing, if these animal study results can be replicated in human subjects with CF.
There are indications that oxidative stress may contribute to EFA deciency [24, 98, 99]. Fatty
acids contain a number of double bonds, and are prone to oxidative damage. The high levels of
markers of oxidative products frequently reported support this hypothesis; however, some studies also
support these ndings to be more indicative of the inammatory and infectious status of these study
subjects [100]. The relation between glutathione and CFTR in particular might suggest a link to
defective oxidation defense. Of note, while intravenous 3 fatty acid supplementation improved DHA
status in patients with CF, it was also associated with a decrease in glutathione [101]; DHA has six
double bonds, and may be more prone to oxidative stress. The role of lung transplantation in correcting
FA abnormalities in CF may have to do with decreasing inammation by restoring CFTR function to
that specic tissue [102]. However, although the absolute fatty acid levels normalize, the pathological
relation between the fatty acid concentrations persisted [102]. Lastly, basic science and animal models
suggest that CFTR dysfunction may lead the PUFA abnormalities observed in CF [29, 103, 104],
which might indicate that future treatment regulating CFTR expression might also compensate for the
fatty acid abnormality by modulating the binding to the bilayer of the membranes [105] and/or could
relate to additional or different mechanisms [29]. This association between CFTR and the lipid
abnormalities described may also explain in part the relationship to genotype [14], and the difculty
in normalizing or improving LA concentrations by supplementation [44, 84].
Dietary Requirements: What We Know, and What We Dont Know

It is clear that individuals with CF have better outcomes by not restricting fat in their diets. Energy
intake with energy dense nutrients such as fat is an important factor in thinking about fatty acids.
Providing sufcient fat in the diet to reduce utilization of essential fats as a source of energy is an
important goal, as essential fats are needed to contribute to cell membrane structure and function. The
2002 CF nutrition consensus statement may have suggested fat intake to comprise 3540% of total
caloric intake [17]. The work of Shoff et al. has suggested that greater than 120% of the estimated
energy requirement may be indicated for young children with CF [50]. The relationship between LA
energy intake and growth has also shown that regular supplementation with LA-rich supplements was
associated with normal growth in pediatric subjects with CF, and did not require energy intake in
excess of that recommended for normal individuals [106]. Energy intake requirements for preadolescent children with CF has been determined to be in active physical activity range of the
estimated energy requirement (EER) of the Dietary Reference Intakes using doubly labelled water
experiments [107, 108].
Until recently the type of dietary fat intake to improve serum FA status has not been dened. The
data by Shoff et al. suggested that both energy intake and LA intake predict LA status [50]. Walkowiak
et al. [31] and subsequently Maqbool et al. [54] showed that type of dietary fat intake does in fact
predict serum fatty acid status. Similar to recommendations for the general population, limiting
saturated fats, eliminating trans fats, and increasing monounsaturated fatty acids and PUFA are
desirable. The high 6 PUFA intake currently observed in the general population may be benecial
for patients with CF- but is questionable for the general population itself [109]. This area of dietary
recommendation divergence can be navigated with some careful consideration. As an example of
43
making sensible food choices, tuna has many health benets, including provision of important 3
PUFA. Balancing health benets and risks, light canned tuna in water may be the better product for
the general population, as it is a good source of 3 LCPUFA, has a desirable low 6:3 ratio, and is
relatively lower in mercury content than albacore tuna; the canned tuna in oil (which is actually
packaged in vegetable oil and is rich in LA) could be a better choice for individuals with CF [110].
LA intake and interventions associated with improving LA status are associated with improved
clinical and growth outcomes. DHA intake and improved DHA status is associated with decrease in
inammatory markers. The clinical data supports LA supplementation, and the DHA data supports
DHA supplementation. The data published by Olveira et al. demonstrated that a DHA, EPA, LA, and
gamma linolenic acid supplementation improved FA status, markers of inammation, and also
important clinical outcomes, and provides insights for future studies to help forge a path forward [86].
Fat and energy intake requirements may change by life stage group, physical activity, and other factors
which need to be determined by means of prospective studies. Early identication of CF and early
nutritional interventions are required, as these may improve survival and clinical outcomes [19, 111].
Conclusion
Cystic brosis is a condition frequently associated with steatorrhea, and with fatty acid abnormalities.
Adequate energy intake to meet needs is key to improve clinical outcomes. Fat intake is important in
patients with CF. There are indications that fat intake for people with CF should be similar to those
recommended for the general population, in choosing less saturated fat and more MUFA and
PUFA. Intake of LA in excess of that recommended for the general population may be of benet for
patients with CF. Fat intake goals should be oriented towards improving growth in pediatric patients
in particular, as well as clinical outcomes in patients with CF of all ages. Further studies are required
to determine amount and type of fat intake required by life stage group, and what blend of dietary fats
and dietary fat supplements are required to reach these goals. Interventions that improve CFTR
function may improve fatty acid status as well as clinical outcomes of interest in CF.
References
1. Institute of Medicine. Dietary reference intakes for energy, carbohydrate, ber, fat, fatty acids, cholesterol, protein
and amino acids. Washington: National Academy Press; 2002.
2. Lands B. Historical perspectives on the impact of n-3 and n-6 nutrients on health. Prog Lipid Res.
2014;55:1729.
3. Innis SM. Human milk and formula fatty acids. J Pediatr. 1992;120(4 Pt 2):S5661.
4. Lagerstedt SA, Hinrichs DR, Batt SM, Magera MJ, Rinaldo P, McConnell JP. Quantitative determination of
plasma c8-c26 total fatty acids for the biochemical diagnosis of nutritional and metabolic disorders. Mol Genet
Metab. 2001;73(1):3845.
5. Holman RT. The ratio of trienoic: tetraenoic acids in tissue lipids as a measure of essential fatty acid requirement.
J Nutr. 1960;70:40510.
6. Holman RT, Johnson SB, Ogburn PL. Deciency of essential fatty acids and membrane uidity during pregnancy
and lactation. Proc Natl Acad Sci U S A. 1991;88(11):48359.
7. Siguel EN, Chee KM, Gong JX, Schaefer EJ. Criteria for essential fatty acid deciency in plasma as assessed by
capillary column gasliquid chromatography. Clin Chem. 1987;33(10):186973.
8. Hansen RC, Lemen R, Revsin B. Cystic-brosis manifesting with acrodermatitis enteropathica-like eruption
association with essential fatty-acid and zinc deciencies. Arch Dermatol. 1983;119(1):515.
9. Hansen AE, Haggard ME, Boelsche AN, Adam DJ, Wiese HF. Essential fatty acids in infant nutrition. III. Clinical
manifestations of linoleic acid deciency. J Nutr. 1958;66(4):56576.
44
10. Hanebutt FL, Demmelmair H, Schiessl B, Larque E, Koletzko B. Long-chain polyunsaturated fatty acid
(LC-PUFA) transfer across the placenta. Clin Nutr. 2008;27(5):68593.
11. Koletzko B, Lien E, Agostoni C, Bohles H, Campoy C, Cetin I, et al. The roles of long-chain polyunsaturated fatty
acids in pregnancy, lactation and infancy: review of current knowledge and consensus recommendations. J Perinat
Med. 2008;36(1):514.
12. Levy BD, Serhan CN. Resolution of acute inammation in the lung. Annu Rev Physiol. 2014;76:46792.
13. Simopoulos AP. Importance of the ratio of omega-6/omega-3 essential fatty acids: evolutionary aspects. World
Rev Nutr Diet. 2003;92:122.
14. Strandvik B, Gronowitz E, Enlund F, Martinsson T, Wahlstrom J. Essential fatty acid deciency in relation to
genotype in patients with cystic brosis. J Pediatr. 2001;139(5):6505.
15. Freedman SD, Blanco PG, Zaman MM, Shea JC, Ollero M, Hopper IK, et al. Association of cystic brosis with
abnormalities in fatty acid metabolism. N Engl J Med. 2004;350(6):5609.
18. Kuo PT, Huang NN, Bassett R. The fatty acid composition of the serum chylomicrons and adipose tissue of
children with cystic brosis of the pancreas. J Pediatr. 1962;60:394403.
19. Marcus MS, Sondel SA, Farrell PM, Laxova A, Carey PM, Langhough R, et al. Nutritional status of infants with
cystic brosis associated with early diagnosis and intervention. Am J Clin Nutr. 1991;54(3):57885.
20. Lai HC, Kosorok MR, Laxova A, Davis LA, FitzSimmon SC, Farrell PM. Nutritional status of patients with cystic
brosis with meconium ileus: a comparison with patients without meconium ileus and diagnosed early through
neonatal screening. Pediatrics. 2000;105(1 Pt 1):5361.
21. Roulet M, Frascarolo P, Rappaz I, Pilet M. Essential fatty acid deciency in well nourished young cystic brosis
patients. Eur J Pediatr. 1997;156(12):9526.
22. Kalivianakis M, Minich DM, Bijleveld CM, van Aalderen WM, Stellaard F, Laseur M, et al. Fat malabsorption in
cystic brosis patients receiving enzyme replacement therapy is due to impaired intestinal uptake of long-chain
fatty acids. Am J Clin Nutr. 1999;69(1):12734.
23. Kalivianakis M, Verkade HJ. The mechanisms of fat malabsorption in cystic brosis patients. Nutrition.
1999;15(2):1679.
24. Wood LG, Fitzgerald DA, Lee AK, Garg ML. Improved antioxidant and fatty acid status of patients with cystic
brosis after antioxidant supplementation is linked to improved lung function. Am J Clin Nutr. 2003;77(1):
1509.
25. Ulane MM, Butler JD, Peri A, Miele L, Ulane RE, Hubbard VS. Cystic brosis and phosphatidylcholine
biosynthesis. Clin Chim Acta. 1994;230(2):10916.
26. Carlstedt-Duke J, Bronnegard M, Strandvik B. Pathological regulation of arachidonic acid release in cystic
brosis: the putative basic defect. Proc Natl Acad Sci U S A. 1986;83(23):92026.
27. Seegmiller AC. Abnormal unsaturated fatty acid metabolism in cystic brosis: biochemical mechanisms and
clinical implications. Int J Mol Sci. 2014;15(9):1608399.
28. Bhura-Bandali FN, Suh M, Man SFP, Clandinin MT. The Delta F508 mutation in the cystic brosis transmembrane
conductance regulator alters control of essential fatty acid utilization in epithelial cells. J Nutr.
2000;130(12):28705.
29. Strandvik B. Fatty acid metabolism in cystic brosis. Prostaglandins Leukot Essent Fatty Acids. 2010;
83(3):1219.
30. Underwood BA, Denning CR, Navab M. Polyunsaturated fatty acids and tocopherol levels in patients with cystic
brosis. Ann N Y Acad Sci. 1972;203:23747.
31. Walkowiak J, Lisowska A, Blaszczynski M, Przyslawski J, Walczak M. Polyunsaturated fatty acids in cystic
brosis are related to nutrition and clinical expression of the disease. J Pediatr Gastroenterol Nutr. 2007;45(4):
4889. author reply 9.
32. Korotkova M, Strandvik B. Essential fatty acid deciency affects the fatty acid composition of the rat small
intestinal and colonic mucosa differently. Biochim Biophys Acta. 2000;1487(23):31925.
33. Strandvik B, Einarsson K, Lindblad A, Angelin B. Bile acid kinetics and biliary lipid composition in cystic
brosis. J Hepatol. 1996;25(1):438.
34. Werner A, Minich DM, Havinga R, Bloks V, Van Goor H, Kuipers F, et al. Fat malabsorption in essential fatty
acid-decient mice is not due to impaired bile formation. Am J Physiol Gastrointest Liver Physiol.
2002;283(4):G9008.
35. Simopoulos AP. Overview of evolutionary aspects of omega 3 fatty acids in the diet. World Rev Nutr Diet.
1998;83:111.
36. Vermunt SH, Mensink RP, Simonis MM, Hornstra G. Effects of dietary alpha-linolenic acid on the conversion and
oxidation of 13C-alpha-linolenic acid. Lipids. 2000;35(2):13742.
45
37. Njoroge SW, Seegmiller AC, Katrangi W, Laposata M. Increased Delta5- and Delta6-desaturase, cyclooxygenase-2,
and lipoxygenase-5 expression and activity are associated with fatty acid and eicosanoid changes in cystic brosis.
Biochim Biophys Acta. 2011;1811(78):43140.
38. Aaes-Jorgensen E, Leppik EE, Hayes HW, Holman RT. Essential fatty acid deciency. II. In adult rats. J Nutr.
1958;66(2):24559.
39. Hjelte L, Larsson M, Alvestrand A, Malmborg AS, Strandvik B. Renal function in rats with essential fatty acid
deciency. Clin Sci (Lond). 1990;79(4):299305.
40. Hjelte L, Ahren B, Andren-Sandberg A, Bottcher G, Strandvik B. Pancreatic function in the essential fatty acid
decient rat. Metabolism. 1990;39(8):8715.
41. Steinkamp G, Demmelmair H, Ruhl-Bagheri I, von der Hardt H, Koletzko B. Energy supplements rich in linoleic
acid improve body weight and essential fatty acid status of cystic brosis patients. J Pediatr Gastroenterol Nutr.
2000;31(4):41823.
42. Rettammel AL, Marcus MS, Farrell PM, Sondel SA, Koscik RE, Mischler EH. Oral supplementation with a highfat, high-energy product improves nutritional-status and alters serum-lipids in patients with cystic-brosis. J Am
Diet Assoc. 1995;95(4):4549.
43. Parsons HG, Oloughlin EV, Forbes D, Cooper D, Gall DG. Supplemental calories improve essential fatty-acid
deciency in cystic-brosis patients. Pediatr Res. 1988;24(3):3536.
44. Lloyd-Still JD, Johnson SB, Holman RT. Essential fatty acid status in cystic brosis and the effects of safower
oil supplementation. Am J Clin Nutr. 1981;34(1):17.
45. Chase HP, Cotton EK, Elliott RB. Intravenous linoleic acid supplementation in children with cystic brosis.
Pediatrics. 1979;64(2):20713.
46. Kusoffsky E, Strandvik B, Troell S. Prospective study of fatty acid supplementation over 3 years in patients with
cystic brosis. J Pediatr Gastroenterol Nutr. 1983;2(3):4348.
47. Coste TC, Armand M, Lebacq J, Lebecque P, Wallemacq P, Leal T. An overview of monitoring and supplementation
of omega 3 fatty acids in cystic brosis. Clin Biochem. 2007;40(8):51120.
48. Colombo C, Bennato V, Costantini D, Valmarana L, Dacco V, Zazzeron L, et al. Dietary and circulating
polyunsaturated fatty acids in cystic brosis: are they related to clinical outcomes? J Pediatr Gastroenterol Nutr.
2006;43(5):6605.
49. Olveira G, Dorado A, Olveira C, Padilla A, Rojo-Martinez G, Garcia-Escobar E, et al. Serum phospholipid fatty
acid prole and dietary intake in an adult Mediterranean population with cystic brosis. Br J Nutr.
2006;96(2):3439.
50. Shoff SM, Ahn HY, Davis L, Lai H. Temporal associations among energy intake, plasma linoleic acid, and growth
improvement in response to treatment initiation after diagnosis of cystic brosis. Pediatrics. 2006;117(2):
391400.
51. Maqbool A, Schall JI, Gallagher PR, Zemel BS, Strandvik B, Stallings VA. Relation between dietary fat intake
type and serum fatty acid status in children with cystic brosis. J Pediatr Gastroenterol Nutr. 2012;55(5):60511.
52. Strandvik B, Berg U, Kallner A, Kusoffsky E. Effect on renal function of essential fatty acid supplementation in
cystic brosis. J Pediatr. 1989;115(2):24250.
53. Strandvik B, Hultcrantz R. Liver function and morphology during long-term fatty acid supplementation in cystic
brosis. Liver. 1994;14(1):326.
2008;47(5):63544.
55. Strandvik B. Care of patients with cystic brosis: treatment, screening, and clinical outcome. Annales Nestle
Birgitta. 2006;2006(64):13140.
56. Sahlberg M, Eriksson BO, Sixt R, Strandvik B. Cardiopulmonary data in response to 6 months of training in
physically active adult patients with classic cystic brosis. Respiration. 2008;76(4):41320.
57. Gronowitz E, Garemo M, Lindblad A, Mellstrom D, Strandvik B. Decreased bone mineral density in normalgrowing patients with cystic brosis. Acta Paediatr. 2003;92(6):68893.
58. Gronowitz E, Mellstrom D, Strandvik B. Normal annual increase of bone mineral density during two years in
patients with cystic brosis. Pediatrics. 2004;114(2):43542.
59. Zaman MM, Martin CR, Andersson C, Bhutta AQ, Cluette-Brown JE, Laposata M, et al. Linoleic acid
supplementation results in increased arachidonic acid and eicosanoid production in CF airway cells and in cftr
/ transgenic mice. Am J Physiol Lung Cell Mol Physiol. 2010;299(5):L599606.
60. Katrangi W, Lawrenz J, Seegmiller AC, Laposata M. Interactions of linoleic and alpha-linolenic acids in the
development of fatty acid alterations in cystic brosis. Lipids. 2013;48(4):33342.
61. Spector AA, Kaduce TL, Hoak JC, Fry GL. Utilization of arachidonic and linoleic acids by cultured human
endothelial cells. J Clin Invest. 1981;68(4):100311.
62. Strandvik B, Holmberg B. Plasma phospholipid arachidonic acid is inversely correlated to the linoleic acid
concentration also in patients with cystic brosis. J Cyst Fibros. 2011;10 Suppl 1:S73.
46
63. Keen C, Olin AC, Eriksson S, Ekman A, Lindblad A, Basu S, et al. Supplementation with fatty acids inuences
the airway nitric oxide and inammatory markers in patients with cystic brosis. J Pediatr Gastroenterol Nutr.
2010;50(5):53744.
64. Strandvik B, Chen Y, Dangardt F, Eriksson S, Friberg P, Garemo M, et al. From the Swedish to the Mediterranean
diet and the omega-6/omega-3 balance. World Rev Nutr Diet. 2011;102:7380.
65. Mil-Homens D, Bernardes N, Fialho AM. The antibacterial properties of docosahexaenoic omega-3 fatty acid
against the cystic brosis multiresistant pathogen Burkholderia cenocepacia. FEMS Microbiol Lett. 2012;
328(1):619.
66. Al-Turkmani MR, Andersson C, Alturkmani R, Katrangi W, Cluette-Brown JE, Freedman SD, et al. A mechanism
accounting for the low cellular level of linoleic acid in cystic brosis and its reversal by DHA. J Lipid Res.
2008;49(9):194654.
67. Mimoun M, Coste TC, Lebacq J, Lebecque P, Wallemacq P, Leal T, et al. Increased tissue arachidonic acid and
reduced linoleic acid in a mouse model of cystic brosis are reversed by supplemental glycerophospholipids
enriched in docosahexaenoic acid. J Nutr. 2009;139(12):235864.
68. Njoroge SW, Laposata M, Boyd KL, Seegmiller AC. Polyunsaturated fatty acid supplementation reverses cystic
brosis-related fatty acid abnormalities in CFTR / mice by suppressing fatty acid desaturases. J Nutr Biochem.
2015;26(1):3643.
69. Freedman SD, Katz MH, Parker EM, Laposata M, Urman MY, Alvarez JG. A membrane lipid imbalance plays a
role in the phenotypic expression of cystic brosis in cftr / mice. Proc Natl Acad Sci. 1999;96(24):
139954000.
70. Cawood AL, Carroll MP, Wootton SA, Calder PC. Is there a case for n-3 fatty acid supplementation in cystic
brosis? Curr Opin Clin Nutr Metab Care. 2005;8(2):1539.
71. Lloyd-Still JD, Powers CA, Hoffman DR, Boyd-Trull K, Lester LA, Benisek DC, et al. Bioavailability and safety
of a high dose of docosahexaenoic acid triacylglycerol of algal origin in cystic brosis patients: a randomized,
controlled study. Nutrition. 2006;22(1):3646.
72. Van Biervliet S, Devos M, Delhaye T, Van Biervliet JP, Robberecht E, Christophe A. Oral DHA supplementation
in DeltaF508 homozygous cystic brosis patients. Prostaglandins Leukot Essent Fatty Acids. 2008;78(2):
10915.
73. Alicandro G, Faelli N, Gagliardini R, Santini B, Magazzu G, Bif A, et al. A randomized placebo-controlled study
on high-dose oral algal docosahexaenoic acid supplementation in children with cystic brosis. Prostaglandins
Leukot Essent Fatty Acids. 2013;88(2):1639.
74. Panchaud A, Sauty A, Kernen Y, Decosterd LA, Buclin T, Boulat O, et al. Biological effects of a dietary omega-3
polyunsaturated fatty acids supplementation in cystic brosis patients: a randomized, crossover placebo-controlled
trial. Clin Nutr. 2006;25(3):41827.
75. Jumpsen JA, Brown NE, Thomson AB, Paul Man SF, Goh YK, Ma D, et al. Fatty acids in blood and intestine
following docosahexaenoic acid supplementation in adults with cystic brosis. J Cyst Fibros. 2006;5(2):7784.
76. De Vizia B, Raia V, Spano C, Pavlidis C, Coruzzo A, Allesio M. Effect of an 8-month treatment with omega-3 fatty
acids (eicosapentaenoic and docosahexaenoic) in patients with cystic brosis. J Parenter Enteral Nutr.
2003;27(1):527.
77. Durieu I, Vericel E, Guichardant D, Roth H, Steghens JP, Drai J, et al. Fatty acids platelets and oxidative markers
following intravenous n-3 fatty acids administration in cystic brosis: an open pilot observational study. J Cyst
Fibros. 2007;6(5):3206.
78. Njoroge SW, Laposata M, Katrangi W, Seegmiller AC. DHA and EPA reverse cystic brosis-related FA
abnormalities by suppressing FA desaturase expression and activity. J Lipid Res. 2012;53(2):25765.
79. Beharry S, Ackerley C, Corey M, Kent G, Heng YM, Christensen H, et al. Long-term docosahexaenoic acid
therapy in a congenic murine model of cystic brosis. Am J Physiol Gastrointest Liver Physiol. 2007;292(3):
G83948.
80. Van Biervliet S, Van Biervliet JP, Robberecht E, Christophe A. Fatty acid composition of serum phospholipids in
cystic brosis (CF) patients with or without CF related liver disease. Clin Chem Lab Med. 2010;48(12):17515.
81. Oliver C, Watson H. Omega-3 fatty acids for cystic brosis. Cochrane Database Syst Rev. 2013;11, CD002201.
82. Shoda R, Matsueda K, Yamato S, Umeda N. Epidemiologic analysis of Crohn disease in Japan: increased dietary
intake of n-6 polyunsaturated fatty acids and animal protein relates to the increased incidence of Crohn disease in
Japan. Am J Clin Nutr. 1996;63(5):7415.
83. Aldamiz-Echevarria L, Prieto JA, Andrade F, Elorz J, Sojo A, Lage S, et al. Persistence of essential fatty acid
deciency in cystic brosis despite nutritional therapy. Pediatr Res. 2009;66(5):5859.
84. Christophe A, Robberecht E. Directed modication instead of normalization of fatty acid patterns in cystic brosis:
an emerging concept. Curr Opin Clin Nutr Metab Care. 2001;4(2):1113.
85. Sabel KG, Lundqvist-Persson C, Bona E, Petzold M, Strandvik B. Fatty acid patterns early after premature birth,
simultaneously analysed in mothers food, breast milk and serum phospholipids of mothers and infants. Lipids
Health Dis. 2009;8:20.
47
86. Olveira G, Olveira C, Acosta E, Espildora F, Garrido-Sanchez L, Garcia-Escobar E, et al. Fatty acid supplements
improve respiratory, inammatory and nutritional parameters in adults with cystic brosis. Arch Bronconeumol.
2010;46(2):707.
87. Gronowitz E, Lorentzon M, Ohlsson C, Mellstrom D, Strandvik B. Docosahexaenoic acid is associated with
endosteal circumference in long bones in young males with cystic brosis. Br J Nutr. 2008;99(1):1607.
88. Sahlberg ME, Svantesson U, Thomas EM, Strandvik B. Muscular strength and function in patients with cystic
brosis. Chest. 2005;127(5):158792.
89. Innis SM, Davidson AG, Chen A, Dyer R, Melnyk S, James SJ. Increased plasma homocysteine and
S-adenosylhomocysteine and decreased methionine is associated with altered phosphatidylcholine and
phosphatidylethanolamine in cystic brosis. J Pediatr. 2003;143(3):3516.
90. Innis SM, Davidson A, Chen A, Dyer RA. Malabsorption of phosphatidylcholine and lysophosphatidylcholine
occur concurrently with altered phospholipid and thiol metabolism in children with cystic brosis. Pediatr
Pulmonol. 2003;Suppl 25.
91. Zeisel SH. Choline: an essential nutrient for humans. Nutrition. 2000;16(78):66971.
92. Innis SM, Davidson A, James S, Hasman D, Melnyk S. Choline-related supplements improve abnormal methyl
metabolism and glutathione balance in children with cystic brosis. Pediatr Pulmonol. 2006;Suppl 29:383.
93. Lepage G, Yesair DW, Ronco N, Champagne J, Bureau N, Chemtob S, et al. Effect of an organized lipid matrix on
lipid absorption and clinical outcomes in patients with cystic brosis. J Pediatr. 2002;141(2):17885.
94. Scambi C, De Franceschi L, Guarini P, Poli F, Siciliano A, Pattini P, et al. Preliminary evidence for cell membrane
amelioration in children with cystic brosis by 5-MTHF and vitamin B12 supplementation: a single arm trial.
PLoS One. 2009;4(3), e4782.
95. Guilbault C, De Sanctis JB, Wojewodka G, Saeed Z, Lachance C, Skinner TAA, et al. Fenretinide corrects newly
found ceramide deciency in cystic brosis. Am J Respir Cell Mol Biol. 2008;38(1):4756.
96. Guilbault C, Wojewodka G, Saeed Z, Hajduch M, Matouk E, De Sanctis JB, et al. Cystic brosis fatty acid
imbalance is linked to ceramide deciency and corrected by fenretinide. Am J Respir Cell Mol Biol.
2009;41(1):1006.
97. Teichgraber V, Ulrich M, Endlich N, Riethmuller J, Wilker B, De Oliveira-Munding CC, et al. Ceramide
accumulation mediates inammation, cell death and infection susceptibility in cystic brosis. Nat Med. 2008;14(4):
38291.
98. Wood LG, Fitzgerald DA, Garg ML. Hypothesis: vitamin E complements polyunsaturated fatty acids in essential
fatty acid deciency in cystic brosis. J Am Coll Nutr. 2003;22(4):2537.
99. Brown RK, Kelly FJ. Role of free-radicals in the pathogenesis of cystic-brosis. Thorax. 1994;49(8):73842.
100. McKeon DJ, Cadwallader KA, Idris S, Cowburn AS, Pasteur MC, Barker H, et al. Cystic brosis neutrophils have
normal intrinsic reactive oxygen species generation. Eur Respir J. 2010;35(6):126472.
101. de Lima Marson FA, Bertuzzo CS, Secolin R, Ribeiro AF, Ribeiro JD. Genetic interaction of GSH metabolic
pathway genes in cystic brosis. BMC Med Genet. 2013;14:60.
102. Witters P, Dupont L, Vermeulen F, Proesmans M, Cassiman D, Wallemacq P, et al. Lung transplantation in cystic
brosis normalizes essential fatty acid proles. J Cyst Fibros. 2013;12(3):2228.
103. Andersson C, Al-Turkmani MR, Savaille JE, Alturkmani R, Katrangi W, Cluette-Brown JE, et al. Cell culture
models demonstrate that CFTR dysfunction leads to defective fatty acid composition and metabolism. J Lipid Res.
2008;49(8):1692700.
104. Strandvik B, Bronnegard M, Gilljam H, Carlstedt-Duke J. Relation between defective regulation of arachidonic
acid release and symptoms in cystic brosis. Scand J Gastroenterol Suppl. 1988;143:14.
105. Artigas P, Alaref SJ, Hobart EA, Diaz LF, Sakaguchi M, Straw S, et al. 2,3-butanedione monoxime affects cystic
brosis transmembrane conductance regulator channel function through phosphorylation-dependent and
phosphorylation-independent mechanisms: the role of bilayer material properties. Mol Pharmacol. 2006;70(6):
201526.
106. Kindstedt-Arfwidson K, Strandvik B. Food intake in patients with cystic brosis on an ordinary diet. Scand J
Gastroenterol Suppl. 1988;143:1602.
107. Trabulsi J, Schall JI, Ittenbach RF, Olsen IE, Yudkoff M, Daikhin Y, et al. Energy balance and the accuracy of
reported energy intake in preadolescent children with cystic brosis. Am J Clin Nutr. 2006;84(3):52330.
108. Trabulsi J, Ittenbach RF, Schall JI, Olsen IE, Yudkoff M, Daikhin Y, et al. Evaluation of formulas for calculating
total energy requirements of preadolescent children with cystic brosis. Am J Clin Nutr. 2007;85(1):14451.
109. Baum SJ, Kris-Etherton PM, Willett WC, Lichtenstein AH, Rudel LL, Maki KC, et al. Fatty acids in cardiovascular
health and disease: a comprehensive update. J Clin Lipidol. 2012;6(3):21634.
110. Maqbool A, Strandvik B, Stallings VA. The skinny on tuna fat: health implications. Public Health Nutr.
2011;14(11):204954.
outcomes and survival in patients with cystic brosis. J Pediatr. 2013;162(3):5305. 3.
Chapter 4
Vitamin D and Bone Health

Jessica A. Alvarez and Vin Tangpricha
Key Points
Both vitamin D insufciency and bone disease are widespread in cystic brosis.
Vitamin D deciency is linked to bone health and additional extra-skeletal outcomes in CF such as
lung impairment and inammation.
Bone mineral density screening should be performed regularly with dual energy X-ray
absorptiometry.
Nutritional prevention and management of CF-related bone disease includes optimization of
vitamin D, vitamin K, and calcium status and intake as well as other bone-related nutrients.
Physical activity and maintenance of lean body mass are important factors in bone health.
Guidelines exist for the prevention and management of both vitamin D deciency and bone disease
in CF.
Keywords Vitamin D Cholecalciferol 25-hydroxyvitamin D Bone Dual energy X-ray
absorptiometry Cystic brosis Nutrition
Abbreviations
1,25(OH)2D
25(OH)D
BMD
BMI
CF
CFTR
DEXA
HPLC
IGF-1
IL-6
1,25-dihydroxyvitamin D or calcitriol
25-hydroxyvitamin D
Bone mineral density
Body mass index
Cystic brosis
Cystic brosis transmembrane conductance regulator
Dual energy X-ray absorptiometry
High-performance liquid chromatography
Insulin-like growth factor
Interleukin-6
J.A. Alvarez, Ph.D., R.D. (*) V. Tangpricha, M.D., Ph.D.

Division of Endocrinology, Metabolism, and Lipids Emory University School of Medicine,
101 Woodruff Memorial Research Cr, WMRB 1313, Atlanta, GA 30322, USA
49
J.A. Alvarez and V. Tangpricha
50
LC-MS/MS
LL-37
PICP
PINP
PIVKA-II
PTH
RANKL
TNF-
ucOC
VDBP
VDR
VDRE
Liquid chromatography tandem mass spectroscopy

Cathelicidin
Carboxy-terminal propeptide of type I procollagen
Amino-terminal propeptide of type I procollagen
Prothrombin induced by vitamin K absence or antagonism
Parathyroid hormone
Receptor activator of nuclear factor kappa-B ligand
Tumor necrosis factor-
Undercarboxylated osteocalcin
Vitamin D binding protein
Vitamin D receptor
Vitamin D response element
Introduction
There has been a global increased awareness of the importance of vitamin D in health and disease.
Whereas the role of vitamin D in bone outcomes is well characterized, investigations within the past
several decades have shifted focus to understand the role of vitamin D in extra-skeletal health
outcomes. Both vitamin D insufciency and bone disease are common manifestations in individuals
with cystic brosis (CF). Although the two conditions are linked, vitamin D deciency/insufciency
has been connected to additional extra-skeletal CF health outcomes such as lung function and
inammation, and bone disease is inuenced by additional nutritional and endocrine factors. This
chapter provides background and nutritional guidance on the prevention and maintenance of optimal
vitamin D and bone health status in CF.
Vitamin D
A basic understanding of vitamin D nomenclature and physiology is essential for managing vitamin D
status in CF, other diseases, and health in general. Vitamin D as a nutrient is available in two forms,
vitamin D2 (ergocalciferol) or vitamin D3 (cholecalciferol) [1]. Ergocalciferol is derived from UVB
irradiation of the plant sterol, ergosterol, and is typically obtained through vitamin D-fortied foods
and supplements and irradiated mushrooms. Cholecalciferol can be produced endogenously upon
exposure to UVB radiation or can be acquired through fortied foods (such as dairy products, cereal,
and orange juice) and supplements, as well as a limited number of foods naturally containing
cholecalciferol (such as fatty sh). Common foods and CF supplements containing vitamin D are listed
in Table 4.1. Endogenous production involves the conversion of 7-dehydrocholesterol in the skin to
pre-vitamin D3 which undergoes a thermally induced isomerization to form the nutrient, cholecalciferol.
Factors inuencing endogenous production of vitamin D include sunscreen and clothing practices,
angle of the sun (latitude, time of year), skin pigmentation (melanin competition with
7-dehydrocholesterol for UVB radiation), and age-related decreases in 7-dehydrocholesterol. Vitamin
D (either as cholecalciferol or ergocalciferol) has a circulating half-life of approximately 24 h [2] and
is quickly converted by the enzyme, 25-hydroxylase, to 25-hydroxyvitamin D [25(OH)D] in the liver
or is distributed into adipose tissue. Blood 25(OH)D is the primary circulating vitamin D metabolite
and has a half-life of approximately 23 weeks. Both vitamin D and 25(OH)D are generally considered
to be relatively inactive forms. They are transported throughout circulation bound to vitamin D binding
protein (VDBP). A second hydroxylation step occurs, catalyzed by the enzyme 1-hydroxylase (also
known as CYP27B1), to convert 25(OH)D to 1,25-dihydroxyvitamin D [1,25(OH)2D or calcitriol], the
4 Vitamin D and Bone Health
51
Table 4.1 Potential sources of vitamin D in individuals with cystic brosis

Dietary sources
Salmon, fresh
Canned sh (sardines, tuna)
Shiitake mushrooms
Fortied milk or orange juice
Infant formula
Fortied yogurt
Fortied breakfast cereals
Supplemental sources
General multivitamin
Over-the-counter vitamin D
Prescription vitamin D
AquADEKs, CF fat-soluble vitamins
Libertas ABDEKs, CF fat-soluble vitamins
Vitamax, CF fat-soluble vitamins

MVW Complete Formulation, CF
fat-soluble vitamins
MVW Complete Formulation D3000,
CF fat-soluble vitamins
ChoiceFul, CF fat-soluble vitamins
Estimated amount of vitamin D
Type of vitamin D
Wild-caught: ~6001000 IU per 3.5 oz

Farmed: ~100250 IU per 3.5 oz
~236300 IU per 3.5 oz
Sun-dried: ~1600 IU per 3.5 oz
Fresh: ~100 IU per 3.5 oz
100 IU per 8 oz
100 IU per 8 oz
100 IU per 8 oz
~100200 IU per serving
Vitamin D3
4001000 IU per serving

40050,000 IU per serving
50,000 IU per serving
Liquid: 600 IU per mL
Chewable: 600 IU per chewable
Softgel: 1200 IU per softgel
3000 IU per softgel
Vitamin D3
Vitamin D3 or D2
Vitamin D3 or D2
Vitamin D3
Vitamin D3
Vitamin D2
Vitamin D3
Vitamin D3
Vitamin D3
Vitamin D3
Vitamin D3
Vitamin D3
Vitamin D3
Vitamin D3

Vitamin D3
Sources: (1) Holick MF. Vitamin D deciency. N Engl J Med. 2007;357:26681. (2) Michel, S. MVW Nutritionals
Vitamin Comparison Chart 2014, available at: http://mvwnutritionals.com/wp-content/uploads/2014/12/
VitaminTable-12_1_14.pdf
biologically active vitamin D metabolite with an estimated half-life of 46 h [3]. The production of
1,25(OH)2D primarily occurs in the kidneys for the regulation of calcium and phosphorus metabolism
in bone homeostasis, although numerous other tissues are recognized as being capable of producing
1,25(OH)2D via the 1-hydroxylase enzyme [48]. The biological action of 1,25(OH)2D is initiated by
its binding to a nuclear vitamin D receptor (VDR) and its heterodimerization with a retinoic X receptor
[1, 9]. This complex subsequently binds to a vitamin D response element (VDRE) in the promoter
region of target genes to modulate gene transcription. A non-genomic mechanism of action of
1,25(OH)2D has also been described in which 1,25(OH)2D binds to a membrane VDR and activates
second messenger systems, including calcium mobilization and signaling.
The clinical determinant of vitamin D status is measurement of circulating total 25(OH)D
concentrations, given its longer half-life and reection of both endogenous and exogenous vitamin
D production/intake. Several assays are available for measurement of circulating 25(OH)D levels,
including radioimmunoassays, enzyme-immunoassays, high-performance liquid chromatography
(HPLC), and liquid chromatography tandem mass spectroscopy (LC-MS/MS) [10]. An advantage
of HPLC and LC-MS/MS is the ability to distinguish 25(OH)D derived from ergocalciferol
(25(OH)D2) and cholecalciferol (25(OH)D3). Because analytic variability exists between assays,
practitioners should choose laboratories that participate in external vitamin D standardization testing
programs, such as the Vitamin D External Quality Assurance Survey, the Centers for Disease Control
52
Hormone Standardization program, or the National Institutes of Health Vitamin D Metabolites

Quality Assurance Program. Also, to avoid misinterpretation, care should be taken to use proper
nomenclature when ordering laboratory assays for assessing vitamin D status.
Vitamin D Pathophysiology in CF
Prevalence estimates of suboptimal vitamin D status in CF have varied widely, with reports of up to
90% prevalence [11, 12]. Numerous factors preclude inadequate vitamin D status in CF [13, 14].
Exocrine pancreas insufciency induces intestinal malabsorption of fat and fat-soluble vitamins,
including vitamin D. Vitamin D malabsorption may also occur independently of pancreatic function
in CF, as suggested in a vitamin D2 absorption study [15]. Overall dietary intake may be low secondary
to illness and reduced appetite. Sun exposure may be limited due to frequent illness and use of
antibiotic-induced photosensitivity [16]. Low body fat may reduce the storage capability of fat-soluble
vitamins. Adherence to prescribed supplements might also be considered [17]. Additional hypotheses
have been proposed based on indirect evidence: Circulating VDBP is reduced in CF [18, 19],
potentially reducing the transport and availability of vitamin D metabolites [12]. Enhanced 25(OH)D
degradation may be present secondary to elevated cytochrome P450 enzyme activity in CF [20].
Altered membrane phospholipid composition in CF [21] or cystic brosis transmembrane conductance
regulator (CFTR) in the epidermis [22] may potentially inuence photobiosynthesis of cholecalciferol
[12]. Elevated urinary excretion of low-molecular weight proteins in CF [23] may inuence excretion
of VDBP-bound 25(OH)D [12]. Finally, frequent corticosteroid use in CF may promote degradation
of vitamin D metabolites through enhanced 24-hydroxylase expression [24, 25]. Further research will
be needed to directly address causes of low vitamin D status in CF.
Role of Vitamin D in CF Health

The biologically active form of vitamin D, 1,25(OH)2D, plays a critical role in maintaining optimal
circulating calcium and phosphorus concentrations. For normal physiological function, blood calcium
concentrations require tight regulation within a narrow range. Decreases in blood calcium will stimulate
1,25(OH)2D production (via parathyroid hormone, PTH) which enables normalization of blood calcium
levels by (1) binding to nuclear VDR in the intestine and stimulating absorption of dietary calcium and
phosphorus, and (2) if dietary calcium is insufcient, promoting the formation and activation of bone
resorbing osteoclasts for release of calcium in conjunction with PTH [26, 27]. This latter action may
lead to loss of skeletal calcium and promote risk of osteoporosis. Another function of the vitamin D
system is to suppress hyperplasia of the parathyroid gland and secretion of PTH [27]. Vitamin D
deciency can therefore lead to secondary hyperparathyroidism, thus further promoting calcium
mobilization from bone. In individuals with CF, vitamin D deciency is associated lower bone mineral
density (BMD) [2833] and is a risk factor for CF-related bone disease (discussed below).
The vitamin D system is becoming increasingly recognized for its role in innate and adaptive
immunity [34]. Cells involved in immune function, such as macrophages, monocytes, and respiratory
epithelial cells contain the machinery needed to convert 25(OH)D to 1,25(OH)2D [3538]. When
activated, this pathway promotes the upregulation of the antimicrobial peptide cathelicidin (LL-37)
and other host defenses and reduces pro-inammatory cytokine production [38, 39]. Given the large
microbial and inammatory burden in individuals with CF, this immunomodulatory action of the
vitamin D system may be critical in management of the disease. Human studies in CF, although
relatively few in number, provide some evidence. Grossmann et al. [40] reported a decrease in the
53
pro-inammatory cytokines, tumor necrosis factor- (TNF-), and interleukin-6 (IL-6) (but no change
in LL-37) in a pilot randomized, placebo-controlled trial of a bolus oral dose of 250,000 IU
cholecalciferol in hospitalized adults with CF. Vitamin D allocation also improved one-year survival
in this pilot study [41]. Some cross-sectional studies in CF have also linked vitamin D status to
lung function [42, 43], inammation [44], rates of pulmonary exacerbation [43], hospitalization [45],
and history of Pseudomonas colonization [46].
Additional health outcomes in CF may be linked to vitamin D status. In a large CF cohort, vitamin
D deciency was associated with the presence of CF-related diabetes and elevated glycosylated
hemoglobin concentrations [47]. The vitamin D system has been suggested to inuence both insulin
resistance and insulin secretion, potentially through direct effects on insulin signaling or through its
anti-inammatory effects [48]. Vitamin D has also been hypothesized to inuence brain function [49].
Two small cross-sectional studies in patients with CF have indicated a relationship between vitamin
D status and depression [50, 51]. A 2014 Cochrane Review of vitamin D supplementation was unable
to establish a clear benet or harm in vitamin D supplementation for CF, given the limited number of
studies (3 full studies, 3 abstracts) and unclear risk of bias [52]. Further prospective studies will need
to conrm the role vitamin D plays in extra-skeletal CF health.
Vitamin D Management in CF
The North American Cystic Fibrosis Foundation (CFF) developed guidelines in 2012 specically for
the screening, diagnosis, and management of vitamin D deciency in CF [14] (see Table 4.2 for
summary). Vitamin D status should be assessed with total circulating 25(OH)D concentrations, and a
minimum target goal level is 30 ng/mL (75 nmol/L). Total 25(OH)D levels should be measured
annually, at the end of winter when 25(OH)D levels are at their lowest. Routine measurement of other
markers (i.e., PTH, calcitriol, alkaline phosphatase, osteocalcin) is not recommended for assessment
of vitamin D status. This latter guideline differs from the 2011 European Bone Mineralization
Guidelines for CF [53]; however, the CF Foundation considered the increased cost and lack of
evidence that other markers reect vitamin D status [14].
The CF Foundation developed an age-specic stepwise approach to improving vitamin D status
(described in Table 4.2) [14]. The use of cholecalciferol (vitamin D3), as opposed to ergocalciferol
(vitamin D2), is recommended. Cholecalciferol has been suggested to more effectively increase blood
25(OH)D concentrations compared to ergocalciferol [54]. Indeed, in a head-to-head study in CF
comparing cholecalciferol to ergocalciferol (50,000 IU vitamin D for 12 weeks), cholecalciferol
achieved a better total 25(OH)D response [55]. Both vitamin D3 and vitamin D2 are available by
prescription (or over the counter in smaller doses). Clinicians should be aware of the vitamin D
formulation prescribed and being taken as supplements by patients. Absorption of fat-soluble vitamins
may be improved when taken with food, and in CF, supplements should be taken with pancreatic
enzymes, if applicable [14]. The question of oil-based vs. powder-based vitamin D supplements
remains a topic of investigation in CF. The CF Foundation does not give specic recommendations for
the frequency of supplementation (i.e., daily, weekly, monthly); the dosing schedule may be
individualized and should be sufcient to maintain a minimum serum 25(OH)D level of 30 ng/
mL. The use of ultraviolet lamps to improve vitamin D status has been considered [55, 56]; however,
insufcient evidence is available to make recommendations and the potential for increased
photosensitivity and/or burns is a concern [14]. A specialist with expertise in vitamin D therapy
should be consulted in difcult-to-treat vitamin D deciency. Supplementation with hydroxylated
vitamin D compounds (oral 25(OH)D supplement) may be considered if vitamin D therapy does not
work, although there are insufcient studies available to afrm their safety or efcacy [14]. Likewise,
calcitriol or other vitamin D analogs (doxercalciferol or paricalcitol) may be considered in cases of
difcult-to-treat vitamin D deciency, but only in consultation with a vitamin D specialist.
54
Table 4.2 Summary of cystic brosis foundation guidelines for the screening, diagnosis, management, and treatment
of vitamin D deciency
Assessment of vitamin D status
Vitamin D status should be assessed with serum 25(OH)D at least annually at the end of winter.
The goal serum 25(OH)D concentrations should be at least 30 ng/mL (75 nmol/L).
Adherence to vitamin D prescriptions should be assessed in individuals with serum 25(OH)D < 30 ng/mL.
Treatment and management of vitamin D deficiency
Cholecalciferol (vitamin D3) should be used as a once-daily therapy or its weekly equivalent to achieve and
maintain goal serum 25(OH)D concentrations.
For infants <12 months of age, an initial dose of daily 400500 IU vitamin D3 is recommended with an increase
to 8001000 IU per day if serum 25(OH)D concentrations are between 20 and 30 ng/mL (50 and 75 nmol/L) or
to a maximum of 2000 IU per day if serum 25(OH)D levels are less than 20 ng/mL (50 nmol/L) or persist at a
range of 2030 ng/mL (5075 nmol/L).
Infants 12 months of age with a serum 25(OH)D concentration <10 ng/mL (<25 nmol/L) should be assessed for
rickets and urgently managed in consultation with a specialist.
For children between 1 and 10 years of age, an initial dose of daily 8001000 IU vitamin D3 is recommended
with an increase to 16003000 IU per day if serum 25(OH)D concentrations are between 20 and 30 ng/mL
(5075 nmol/L) or to a maximum of 4000 IU per day if serum 25(OH)D levels are less than 20 ng/mL
(50 nmol/L) or persist at a range of 2030 ng/mL (5075 nmol/L).
For all individuals greater than 10 years of age, an initial dose of daily 8002000 IU vitamin D3 is recommended
with an increase to 16006000 IU per day if serum 25(OH)D concentrations are between 20 and 30 ng/mL
(5075 nmol/L) or to a maximum of 10,000 IU per day if serum 25(OH)D levels are less than 20 ng/mL
(50 nmol/L) or persist at a range of 2030 ng/mL (5075 nmol/L).
For individuals unable to meet goal 25(OH)D concentrations after maximum recommended intake, and
conrmed adherence to prescribed therapy, vitamin D treatment should be managed in consultation with a
specialist.
Vitamin D deciency that is difcult to treat should be managed with calcitriol or other vitamin D analogs only
in consultation with a specialist.
Serum 25(OH)D concentrations should be re-checked 3 months after a change in vitamin D dosing.
Adapted from Tangpricha et al. J Clin Endocrinol Metab 2011;97:10821093.
Abbreviations: 25(OH)D; 25-hydroxyvitamin D
Vitamin D toxicity is rare and manifests as hypercalcemia (blood calcium concentration >10.5 mg/
dL). The CF Foundation recommends that blood 25(OH)D concentrations not exceed 100 ng/mL
(250 nmol/L) [14]. This is the level at which the risk for hypercalcemia increases [4]. Symptoms of
hypercalcemia are nonspecic and include fatigue, anorexia, polydipsia, polyuria, nausea, constipation,
diarrhea, vomiting, abdominal pain, muscle weakness or pain, memory loss, confusion, and/or
nephrocalcinosis [57]. A diagnosis of vitamin D intoxication is based on the presence of elevated
blood 25(OH)D concentrations with hypercalcemia or hypercalciuria and hyperphosphatemia.
Treatment for vitamin D toxicity includes removal of vitamin D source and intravenous hydration
with or without loop diuretics to increase calcium excretion. Thiazides promote calcium resorption
and, therefore, should be avoided. Persistent hypercalcemia may be treated with glucocorticoids.
Additional treatment options for vitamin D toxicity include intravenous hydration, calcitonin,
bisphosphonates, and as a last resort, hemodialysis [57].
Cystic Fibrosis-Related Bone Disease

CF-related bone disease, manifesting as osteoporosis, osteopenia, and/or fractures, is the second most
prevalent co-morbidity in patients with CF. In 2012, the CF Patient registry report indicated that
14.8% of all patients with CF had bone disease [58]. The prevalence among adults aged 35 and older
55
is greater than 36% [58]. This prevalence is expected to increase as the CF population ages. The
pathophysiology of CF-related bone disease remains a topic of scientic investigation, although it is
a multifactorial disease, as described below.
CF-related bone disease can contribute to existing lung impairment in this population. Specically,
manifestations of bone disease in CF that inuence lung function include rib and vertebral fractures,
kyphosis (curving of the spine), and chest wall deformities, which may result in reduced lung volumes
and ineffective cough and airway clearance [5964]. Severe bone disease may also be an exclusion
factor for lung transplant candidacy. Thus, management of bone disease is critical for optimizing
health in CF. Maintenance of adequate nutritional status plays an integral role in preventing and
treating CF-related bone disease. A summary of recommendations for prevention and nutritional
management of bone disease is provided in Table 4.3.
Pathophysiology of Bone Disease in CF
The pathophysiology of CF-related bone disease is a multifactorial process resulting in insufcient

bone accrual during puberty and accelerated bone loss during adulthood [64]. Direct nutritional factors,
discussed below, include general malnutrition, inadequate intake of nutrients important for bone health,
vitamin D and vitamin K malabsorption secondary to pancreatic insufciency, and physical inactivity.
Endocrine factors contributing to bone disease include delayed puberty, hypogonadism, and insulin
deciency. Puberty is a critical developmental period for bone mineral accrual, which is largely
inuenced by sex steroids and the growth hormone-insulin-like growth factor-1 (IGF-1) axis [65].
Individuals with CF are at risk for delayed puberty during childhood, potentially impeding normal
bone mineral accretion, and for hypogonadism as adults, potentially accelerating bone loss [66].
Circulating IGF-1 levels are known to be lower in CF compared to healthy controls [67] and are
positively associated with BMD and bone mineral content in CF [68, 69]. Insulin is an anabolic
hormone that stimulates osteoblast activity [70]. Thus CF-related diabetes, characterized by both
impaired insulin secretion and sensitivity, may contribute to bone disease [64]. Additional factors relate
to CF care and the disease progression, including glucocorticoid therapy and chronic inammation,
respectively. Glucocorticoids reduce intestinal calcium absorption, increase urinary calcium excretion,
and directly affect bone cells [62, 71]. Oral steroid use increases the risk of osteoporosis in CF [72].
Pro-inammatory cytokines promote bone-resorptive pathways [73] and circulating levels are inversely
associated with bone mass in CF [68]. The defective CFTR protein may also directly contribute to bone
pathophysiology. CFTR protein is expressed in human osteoclasts and osteoblasts [74] and has been
shown to regulate osteoprotegerin and prostaglandin E2, which are involved in inhibiting and inducing
osteoclast differentiation, respectively [75]. Together, these multiple factors result in a combination of
reduced osteoblast and increased osteoclast activity, leading to an imbalance between bone formation
and resorption, and ultimately, to CF-related bone disease [62, 76].
Assessment of Bone Health

BMD measured with dual energy X-ray absorptiometry (DEXA) is the gold standard method to assess
bone health [11, 53, 64]. DEXA is widely available, emits a minimal radiation dose, and has good
reproducibility [53]. Per CF Foundation guidelines, a DEXA scan is recommended for all individuals
with CF by 18 years of age, with repeat testing every 5 years if BMD is normal (Table 4.3) [64]. An
initial DEXA screen is also recommended for children greater than 8 years of age with the following
risk factors: ideal body weight <90%, FEV1 <50% predicted, long-term glucocorticoid treatment
56
Table 4.3 Summary of nutrition-related recommendations for bone health in cystic brosis
Assessment of bone healtha
Bone mineral density should be assessed with dual energy X-ray absorptiometry (DEXA).
DEXA screens should be performed in all adults 18 years.
DEXA screens should be performed in children if:
ideal body weight is <90%
FEV1 <50% predicted
glucocorticoid intake is 5 mg/day for 90 days/year
puberty is delayed
there is a history of fractures
Z-score should be used to assess BMD in children <18 years of age. Z- or T-score can be used in adults aged
1830 years. T-score should be used in adults 30 years of age.
Repeat DEXA scan every 5 years if BMD Z- or T-score is 1.0, every 24 years if BMD Z- or T-score is
between 1.0 and 2.0, and annually if BMD Z- or T-score is 2.0 or there is a history of fragility fracture or a
signicant reduction in BMD (>3% in the lumbar spine or >56% in the proximal femur).
Nutritional assessment and recommendations for bone healthb
Maintain an optimal BMI through adequate energy and macronutrient intake, with emphasis on lean body mass:
50th percentile on BMI growth chart for children and adolescents 20 yearsc
23 kg/m2 for men, 22 kg/m2 for women > 20 yearsc
Assess dietary intake (energy, protein, calcium, etc.) at least annually, and more frequently in cases of abnormal
growth or weight loss, by a registered dietitian.
Ensure daily calcium intake meets the age-specic Institute of Medicine Dietary Reference Intakes: 06 months,
200 mg; 712 months, 260 mg; 13 years, 700 mg; 48 years, 1000 mg; 918 years, 1300 mg; 1950 years,
1000 mg; >50 years, 1200 mg (females) and 1000 mg (males).d
Increase dietary sources of calcium when indicated with calcium supplements if necessary.
Minimize intake of substances that may inhibit calcium absorption and/or inhibit bone formation when
consumed in excess: phosphorus (found in colas), caffeine, aluminum-containing antacids, alcohol, or
supplementary retinol.
For optimal vitamin D status, achieve or maintain a blood 25-hydroxyvitamin D (25(OH)D) level 30 ng/
mL. Refer to the 2012 CF Foundation Guidelines for vitamin D recommendations.
Vitamin D status and calcium intake and vitamin D status should be corrected before prescribing
bisphosphonates or other medical treatments.
Vitamin K status should be assessed with circulating PIVKA-II, vitamin K1, and undercarboxylated osteocalcin
concentrations.
All pancreatic insufcient patients should take a vitamin K supplement.
Daily vitamin K intake should be at least 0.30.5 mg/day.
For vitamin K deciency, starting doses of vitamin K should be: 0.52.0 mg/day in infants <1 year of age,
110 mg/day in children and adults 1 year of age.
Encourage weight-bearing exercise for all (2030 min three times per week for children and adolescents; regular
weight bearing and resistance activities for adults).
a
From Aris RM, et al. Guide to bone health and disease in cystic brosis. J Clin Endocrinol Metab. 2005
Mar;90(3):188896
b
From Aris RM, et al. Guide to bone health and disease in cystic brosis. J Clin Endocrinol Metab. 2005 Mar;90(3):
188896 and Sermet-Gaudelus I, et al. European cystic brosis bone mineralisation guidelines. J Cyst Fibros. 2011
Jun;10 Suppl 2:S16-23
c
From Stallings VA et al. Evidence-based practice recommendations for nutrition-related management of children and
adults with cystic brosis and pancreatic insufciency: results of a systematic review. J Am Diet Assoc. 2008
May;108:8329
d
From Food and Nutrition Board, Institute of Medicine. Dietary Reference Intakes for Calcium and Vitamin D. National
Academy Press, Washington, D.C., 2010
(5 mg/day for 90 days/year), delayed puberty, or a history of fractures. The European CF Society
guidelines recommend that DXA screens should begin in all CF children at 8 years of age [53].
BMD should be expressed in terms of Z-scores or T-scores [53, 64]. A BMD Z-score is the
difference in standard deviations between an individuals BMD value and the mean BMD value of
57
an age- and gender-matched healthy reference group. Z-scores should be used to interpret BMD in
children <18 years of age. A BMD T-score is the difference in standard deviations between an
individuals BMD value and the mean BMD value of a sex-matched, healthy young adult (30 years
of age) reference population. T-score should be used in adults 30 years of age. Z- or T-score can be
used in adults aged 1830 years, as they are generally equivalent [64]. According to CF Foundation
Guidelines, DEXA scans should be repeated every 5 years if BMD Z- or T-score is 1.0, every 24
years if BMD Z- or T-score is between 1.0 and 2.0, and annually if BMD Z- or T-score is 2.0
or there is a history of fragility fracture or a signicant reduction in BMD (>3% in the lumbar spine
or >56% in the proximal femur).
Nutritional Management of Bone Health

Assessment of anthropometric changes (height, weight, BMI) in individuals with CF is a clinically
useful method of monitoring nutritional status and, subsequently, risk for bone disease. A goal of
clinical management of CF should be to achieve and maintain an optimal weight-for-height status. In
children and adolescents, growth should be assessed using appropriate percentile charts (weight-forlength, BMI-for-age) at every clinic and in-patient visit [53]. Infants should meet or exceed a weightfor-length in the 50th percentile by the age of 2 years [77]. Children and adolescents aged 220 years
should meet or exceed a BMI in the 50th percentile. In adults, BMI should be assessed at every clinic
and in-patient visit [53]. Women should maintain a BMI 22 kg/m2; men should maintain a BMI
23 kg/m2 at minimum [77] (Table 4.3). Dietary intake of energy, protein, and key micronutrients
involved in bone health should be assessed at least annually by a registered dietitian, and more
frequently in cases of weight loss or abnormal growth velocity [53].
Calcium
Bone, which is comprised of 39.9% calcium, is the storage reservoir of more than 99% of body
calcium [78]. Optimization of calcium intake is therefore critical for bone health. Schulze et al. [79
81] have conducted calcium balance studies in pancreatic sufcient girls with CF and indicated that
intestinal calcium absorption is normal, yet the rate of bone calcium deposition during pre- and late
puberty is lower than healthy controls. This is possibly related to the observed excess endogenous
fecal calcium losses in CF [80]. There is little data available from supplemental calcium studies in
CF. Hillman et al. [82] did not nd changes in serum calcium concentrations, calcium absorption, or
bone mineralization with 1 g calcium supplementation (cholecalciferol) for 6 months in children
with CF. Given the absence of CF-specic data, consensus statements from both the North American
and European CF Foundations recommend adherence to the Institute of Medicine Dietary Reference
Intakes for calcium [53, 64] (Table 4.3).
Several dietary factors inhibit calcium absorption and/or bioavailability and may be particularly
detrimental to bone in the absence of adequate dietary calcium intake. Excess phosphorus can form
complexes with calcium leading to interference with calcium absorption and increasing PTH secretion
and subsequent bone resorption [8385]. Cola sodas are a major source of excess phosphorus (in the
form of phosphoric acid) [85]. Epidemiological studies in relatively healthy populations have indicated
that cola consumption is associated with lower BMD [86] and fracture risk [87]. Caffeine increases
urinary calcium excretion and is associated with reduced BMD and increased fracture risk in
epidemiological studies [85, 88, 89], although these ndings are typically in the setting of inadequate
calcium intake [9093]. Aluminum-containing antacids increase fecal and urinary calcium excretion
58
[94, 95], and their use should be limited in CF. Sodium, which is typically supplemented in CF to
offset skin losses [96], also promotes renal calcium excretion [85, 97]. To offset any potential
interfering dietary factors, it is imperative that calcium intake is optimized in individuals with CF.
Vitamin K
Despite routine supplementation, the prevalence of suboptimal vitamin K status is high in CF
populations [17, 32, 98, 99]. In addition to fat-soluble vitamins malabsorption and inadequate intake
as a cause for low vitamin D status, long-term use of antibiotics may limit gut-derived vitamin K
production by normal intestinal ora [100]. Low vitamin K status is associated with an increased risk
for bone disease in the general population [101]. Vitamin K is an enzyme cofactor for -glutamyl
carboxylase, which is required for proper function of the bone protein, osteocalcin that is involved in
the regulation of bone mineralization, maturation, and remodeling.
Vitamin K status can be assessed with circulating levels of undercarboxylated prothrombin
(PIVKA-II, prothrombin induced by vitamin K absence or antagonism), undercarboxylated osteocalcin
(ucOC), vitamin K1 concentrations, and prothrombin time [53], although the latter two assays (vitamin
K1 and prothrombin time) should be interpreted with caution. Serum vitamin K1 may be inuenced by
recent dietary intake [102], and prothrombin time is an indicator of advanced vitamin K deciency
[100]. Because bone is more susceptible to vitamin K deciency than the liver, ucOC is a highly
sensitive indicator of vitamin K status [100], although the assay is not widely available and reference
values have not been established. The link between ucOC and bone mineral outcomes has only been
investigated in two published studies in CF, with one reporting a positive association [103] and the
other reporting no statistically signicant association [99]. Vitamin K1 supplementation should be
considered in individuals with low serum vitamin K1 levels (reference range = 0.292.64 nmol/L) or
increased serum PIVKA-II (reference range <2 nmol/L [102]), or prothrombin time (reference range
11.113.1 s) [53, 102, 104].
An optimal vitamin K intake range for bone health in CF has not yet been dened [64]. Randomized,
controlled vitamin K supplementation studies in CF have been limited, and none have included BMD
as an outcome [105]. In an open, non-randomized clinical trial, Nicolaidou et al. [106] reported
improved serum markers of bone formation [increased total osteocalcin, increased amino-terminal
propeptide of type I procollagen (PINP), increased carboxy-terminal propeptide of type I procollagen
(PICP), and decreased ucOC] and reduced serum PTH with 10 mg/week vitamin K supplementation
for 1 year in children and adolescents with CF, although BMD did not change. The CF Foundation
recommends a daily vitamin K intake of 0.30.5 mg/day [64, 96]. For vitamin K deciency, the
European bone guidelines recommend a starting vitamin K dose of 110 mg/day [53].
Additional Nutrients for Bone Health

Numerous other nutrients are involved in bone homeostasis, and optimal intake should be ensured.
Bone matrix contains additional nutrients such as protein, magnesium, and phosphorus [85]. Dietary
protein is the source of amino acids required for building the bone matrix [107]. Magnesium plays a
role in the crystallization of hydroxyapatite and directly affects osteoblasts and osteoclasts [108].
Although excess phosphorus is a more likely scenario, phosphorus deciency leads to reduced bone
mineralization [109]. Potassium enhances renal calcium retention [85] and has been shown to increase
serum osteocalcin and decrease urinary hydroxyproline [110]. Iron, copper, and vitamin C are
cofactors in the formation and maintenance of collagen, the protein providing the structural framework
of bone [85]. The antioxidant effects of vitamin E may protect against bone resorptive factors, although
59
potential detrimental effects of high-dose supplementation have also been proposed [111, 112].
Vitamins B12, B6, and folate may inuence bone by regulating homocysteine, which has been
suggested to impair collagen cross-linking, alter osteoclast and osteoblast activity, and decrease bone
blood ow [85, 113, 114]. Carotenoids may stimulate bone formation and inhibit resorption [115].
The relationships between these nutrients and bone health are supported by some epidemiological
studies and interventions in non-CF populations, although their relationships with bone health have
not been investigated in CF populations.
Additional dietary factors may inhibit bone formation or promote bone resorption. Heavy alcohol
intake increases risk for multiple nutrient deciencies, but also may have direct effects on osteocyte
apoptosis and other bone resorptive pathways [85, 116]. Higher retinol (vitamin A) intake and blood
levels are associated with fracture risk in some epidemiological studies [117119], possibly via
competition with vitamin D at the retinoic X receptor or by direct action on bone cells [120]. Serum
retinol levels should be monitored in CF, given the current vitamin A supplementation practices [121].
Physical Activity and Body Composition

Impaired lung function and repeated illness may reduce or limit physical activity in CF. Increased
physical activity and tness, however, is strongly associated with greater BMD both in CF and general
populations [72, 122124]. Increased mechanical load (strain) from exercise induces a
mechanotransduction pathway, whereby osteocytes detect the load and respond by signaling the bone
remodeling process in an effort to strengthen the area under strain [125, 126]. Physical activity,
particularly weight-bearing exercises such as jogging, jumping, and dancing, should therefore be
promoted in individuals with CF. The European CF Bone Mineralization Guidelines provide detailed
physical activity recommendations: in addition to usual activities, children and adolescents should
perform weight-bearing activities at least three times per week for 2030 min, and adults should
perform weight bearing and resistance exercises regularly [53].
A normal BMI with an emphasis on lean body mass (i.e., muscle) should be maintained [53]. Total
body weight is positively associated with BMD, likely through the effect of mechanical loading induced
by gravity [127]. Weight-loss studies in generally healthy subjects have shown that a 10% loss in body
weight is associated with a 12% loss in BMD [85, 128]. Independent of body weight, muscle
contractions induce the largest physiological strain on bones [129, 130], thus reinforcing the need to
maintain lean body mass. In CF, lean body mass depletion is associated with bone loss [131, 132].
Medical Treatment of Bone Disease

Medical treatment of CF-related bone disease should include management of CF-related diabetes
and sex steroid deciency or pubertal delay, if applicable, as well as correction of vitamin D
insufciency or suboptimal calcium intake [53, 64]. Per CF Foundation consensus guidelines,
bisphosphonate therapy should be considered as treatment for individuals with a T- or Z-score 2
or those with a T- or Z-score between 1 and 2 with fragility fractures, a BMD loss of >35% per
year, and/or awaiting organ transplantation [64]. Bisphosphonates effectively increase BMD in
adults with CF; although their effect on fracture reduction has not yet been conrmed CF and side
effects include severe bone pain and u-like symptoms [133]. Additional therapeutic options may
include teriparatide (a recombinant human PTH analog), growth hormone, IGF-1 therapy, or
denosumab [an inhibitor of receptor activator of nuclear factor kappa-B ligand (RANKL)], although
clinical trials in CF are needed [62, 69, 134].
60
Conclusion
The underlying pathophysiology of CF places individuals with the disease at risk for vitamin D
deciency and bone disease. Vitamin D deciency is a known risk factor for bone disease but it has
also been linked to impaired pulmonary function, inammation, and other extra-skeletal outcomes
in CF. In addition to vitamin D, nutritional prevention and management of bone disease includes
ensuring adequate calcium intake and absorption, maintaining proper vitamin K status and that of
other bone-related nutrients, and encouraging physical activity. Consensus guidelines for vitamin D
deciency and bone health in CF should be followed, although there is a general lack of randomized,
controlled trials available to specically address the role of nutrition in CF bone health and other
related outcomes. The registered dietitian is a vital member of the CF care team and is key in
optimizing nutrition status for the prevention and management of vitamin D deciency and bone
disease in CF.
References
1. Lips P. Vitamin D physiology. Prog Biophys Mol Biol. 2006;92:48.
2. Holick MF. The use and interpretation of assays for vitamin D and its metabolites. J Nutr. 1990;120 Suppl
11:14649.
3. Holick MF. Vitamin D status: measurement, interpretation, and clinical application. Ann Epidemiol. 2009;19:738.
4. Holick MF. Vitamin D deciency. N Engl J Med. 2007;357:26681.
5. Somjen D, Weisman Y, Kohen F, Gayer B, Limor R, Sharon O, et al. 25-hydroxyvitamin d3-1alpha-hydroxylase
is expressed in human vascular smooth muscle cells and is upregulated by parathyroid hormone and estrogenic
compounds. Circulation. 2005;111:166671.
6. Jablonski KL, Chonchol M, Pierce GL, Walker AE, Seals DR. 25-hydroxyvitamin D deciency is associated with
inammation-linked vascular endothelial dysfunction in middle-aged and older adults. Hypertension. 2011;57:
639.
7. Zehnder D, Bland R, Chana RS, Wheeler DC, Howie AJ, Williams MC, et al. Synthesis of 1,25-dihydroxyvitamin
D(3) by human endothelial cells is regulated by inammatory cytokines: a novel autocrine determinant of vascular
cell adhesion. J Am Soc Nephrol. 2002;13:6219.
8. Bland R, Markovic D, Hills CE, Hughes SV, Chan SL, Squires PE, et al. Expression of 25-hydroxyvitamin
d3-1alpha-hydroxylase in pancreatic islets. J Steroid Biochem Mol Biol. 2004;8990:1215.
9. Mizwicki MT, Norman AW. The vitamin D sterol-vitamin D receptor ensemble model offers unique insights into
both genomic and rapid-response signaling. Sci Signal. 2009;2:re4.
10. Granado Lorencio F, Blanco-Navarro I, Perez-Sacrsitan B. Critical evaluation of assays for vitamin D status. Curr
Opin Clin Nutr Metab Care. 2013;16:73440.
11. Siwamogsatham O, Alvarez JA, Tangpricha V. Diagnosis and treatment of endocrine comorbidities in patients
with cystic brosis. Curr Opin Endocrinol Diabetes Obes. 2014;21:4229.
12. Mailhot G. Vitamin D bioavailability in cystic brosis: a cause for concern? Nutr Rev. 2012;70:28093.
13. Hall WB, Sparks AA, Aris RM. Vitamin D deciency in cystic brosis. Int J Endocrinol. 2010;2010:218691.
14. Tangpricha V, Kelly A, Stephenson A, Maguiness K, Enders J, Robinson KA, et al. An update on the screening,
diagnosis, management, and treatment of vitamin D deciency in individuals with cystic brosis: evidence-based
recommendations from the cystic brosis foundation. J Clin Endocrinol Metab. 2012;97:108293.
15. Lark RK, Lester GE, Ontjes DA, Blackwood AD, Hollis BW, Hensler MM, et al. Diminished and erratic absorption
of ergocalciferol in adult cystic brosis patients. Am J Clin Nutr. 2001;73:6026.
16. Burdge DR, Nakielna EM, Rabin HR. Photosensitivity associated with ciprooxacin use in adult patients with
cystic brosis. Antimicrob Agents Chemother. 1995;39:793.
17. Siwamogsatham O, Dong W, Binongo JN, Chowdhury R, Alvarez JA, Feinman SJ, et al. Relationship between
fat-soluble vitamin supplementation and blood concentrations in adolescent and adult patients with cystic brosis.
Nutr Clin Pract. 2014;29:4917.
18. Coppenhaver D, Kueppers F, Schidlow D, Bee D, Isenburg JN, Barnett D, et al. Serum concentrations of vitamin
D-binding protein (group-specic component) in cystic brosis. Hum Genet. 1981;57:399403.
19. Speeckaert MM, Wehlou C, Vandewalle S, Taes YE, Robberecht E, Delanghe JR. Vitamin D binding protein, a
new nutritional marker in cystic brosis patients. Clin Chem Lab Med. 2008;46:36570.
61
20. Rey E, Trluyer JM, Pons G. Drug disposition in cystic brosis. Clin Pharmacokinet. 1998;35:31329.
21. Rogiers V, Crokaert R, Vis H-L. Altered phospholipid composition and changed fatty acid pattern of the various
phospholipid fractions of red cell membranes of cystic brosis children with pancreatic insufciency. Clin Chim
Acta. 1980;105:10515.
22. Sato F, Soos G, Link C, Sato K. Cystic brosis transport regulator and its mRNA are expressed in human epidermis.
J Invest Dermatol. 2002;119:122430.
23. Jouret F, Bernard A, Hermans C, Dom G, Terryn S, Leal T, et al. Cystic brosis is associated with a defect in apical
receptormediated endocytosis in mouse and human kidney. J Am Soc Nephrol. 2007;18:70718.
24. Kurahashi I, Matsunuma A, Kawane T, Abe M, Horiuchi N. Dexamethasone enhances vitamin d-24-hydroxylase
expression in osteoblastic (UMR-106) and renal (LLC-PK1) cells treated with 1,25-dihydroxyvitamin d3.
Endocrine. 2002;17:10918.
25. Herscovitch K, Dauletbaev N, Lands LC. Vitamin D as an anti-microbial and anti-inammatory therapy for cystic
brosis. Paediatr Respir Rev. 2014;15:15462.
26. Holick MF. Vitamin D and bone health. J Nutr. 1996;126:1159S64.
27. DeLuca HF. Overview of general physiologic features and functions of vitamin D. Am J Clin Nutr. 2004;80:
1689S96.
28. Donovan DS, Papadopoulos A, Staron RB, Addesso V, Schulman L, McGregor C, et al. Bone mass and vitamin D
deciency in adults with advanced cystic brosis lung disease. Am J Respir Crit Care Med. 1998;157:18929.
29. Sheikh S, Gemma S, Patel A. Factors associated with low bone mineral density in patients with cystic brosis.
J Bone Miner Metab. 2014;33(2):1805.
30. Robertson J, Macdonald K. Prevalence of bone loss in a population with cystic brosis. Br J Nurs. 2010;19:
6369.
31. Douros K, Loukou I, Nicolaidou P, Tzonou A, Doudounakis S. Bone mass density and associated factors in cystic
brosis patients of young age. J Paediatr Child Health. 2008;44:6815.
32. Grey V, Atkinson S, Drury D, Casey L, Ferland G, Gundberg C, et al. Prevalence of low bone mass and deciencies
of vitamins D and K in pediatric patients with cystic brosis from 3 Canadian centers. Pediatrics. 2008;122:
101420.
33. Cemlyn-Jones J, Gamboa F, Loureiro M, Fontes BM. Evaluation of bone mineral density in cystic brosis patients.
Rev Port Pneumol. 2008;14:62534.
34. Kamen DL, Tangpricha V. Vitamin D and molecular actions on the immune system: modulation of innate and
autoimmunity. J Mol Med (Berl). 2010;88:44150.
35. Adams JS, Rason B, Witzel S, Reyes RE, Shieh A, Chun R, et al. Regulation of the extrarenal cyp27b1hydroxylase. J Steroid Biochem Mol Biol. 2014;144, Part A:227.
36. Adams JS, Sharma OP, Gacad MA, Singer FR. Metabolism of 25-hydroxyvitamin d3 by cultured pulmonary
alveolar macrophages in sarcoidosis. J Clin Invest. 1983;72:185660.
37. Liu PT, Stenger S, Li H, Wenzel L, Tan BH, Krutzik SR, et al. Toll-like receptor triggering of a vitamin D-mediated
human antimicrobial response. Science. 2006;311:17703.
38. Hansdottir S, Monick MM, Hinde SL, Lovan N, Look DC, Hunninghake GW. Respiratory epithelial cells convert
inactive vitamin D to its active form: potential effects on host defense. J Immunol. 2008;181:70909.
39. Yim S, Dhawan P, Ragunath C, Christakos S, Diamond G. Induction of cathelicidin in normal and cf bronchial
epithelial cells by 1,25-dihydroxyvitamin D(3). J Cyst Fibros. 2007;6:40310.
40. Grossmann RE, Zughaier SM, Liu S, Lyles RH, Tangpricha V. Impact of vitamin D supplementation on markers
of inammation in adults with cystic brosis hospitalized for a pulmonary exacerbation. Eur J Clin Nutr.
2012;66:10724.
41. Grossmann RE, Zughaier SM, Kumari M, Seydafkan S, Lyles RH, Liu S, et al. Pilot study of vitamin D
supplementation in adults with cystic brosis pulmonary exacerbation: a randomized, controlled trial.
Dermatoendocrinol. 2012;4:1917.
42. Green D, Carson K, Leonard A, Davis JE, Rosenstein B, Zeitlin P, et al. Current treatment recommendations
for correcting vitamin D deciency in pediatric patients with cystic brosis are inadequate. J Pediatr. 2008;
153:5549.e2.
43. McCauley LA, Thomas W, Laguna TA, Regelmann WE, Moran A, Polgreen LE. Vitamin D deciency is associated
with pulmonary exacerbations in children with cystic brosis. Ann Am Thorac Soc. 2013;11:198204.
44. Pincikova T, Nilsson K, Moen IE, Karpati F, Fluge G, Hollsing A, et al. Inverse relation between vitamin D and
serum total immunoglobulin g in the Scandinavian cystic brosis nutritional study. Eur J Clin Nutr. 2011;65:
1029.
45. Marcondes NA, Raimundo FV, Vanacor R, Corte BP, Ascoli AM, de Azambuja AZ, et al. Hypovitaminosis D in
patients with cystic brosis: a cross-section study in south brazil. Clin Respir J. 2014;8:4559.
46. Simoneau T, Bazzaz O, Sawicki GS, Gordon C. Vitamin D status in children with cystic brosis. Associations with
inammation and bacterial colonization. Ann Am Thorac Soc. 2014;11:20510.
62
47. Pincikova T, Nilsson K, Moen IE, Fluge G, Hollsing A, Knudsen PK, et al. Vitamin D deciency as a risk factor
for cystic brosis-related diabetes in the Scandinavian cystic brosis nutritional study. Diabetologia. 2011;54:
300715.
48. Alvarez JA, Ashraf A. Role of vitamin D in insulin secretion and insulin sensitivity for glucose homeostasis. Int J
Endocrinol. 2010;2010:351385.
49. Eyles DW, Burne TH, McGrath JJ. Vitamin D, effects on brain development, adult brain function and the links
between low levels of vitamin D and neuropsychiatric disease. Front Neuroendocrinol. 2013;34:4764.
50. Kopp BT, Hayes Jr D, Ratkiewicz M, Baron N, Splaingard M. Light exposure and depression in hospitalized adult
patients with cystic brosis. J Affect Disord. 2013;150:5859.
51. Smith BA, Cogswell A, Garcia G. Vitamin D and depressive symptoms in children with cystic brosis.
Psychosomatics. 2014;55:7681.
52. Ferguson JH, Chang AB. Vitamin D supplementation for cystic brosis. Cochrane Database Syst Rev. 2014;5,
CD007298.
53. Sermet-Gaudelus I, Bianchi ML, Garabedian M, Aris RM, Morton A, Hardin DS, et al. European cystic brosis
bone mineralisation guidelines. J Cyst Fibros. 2011;10 Suppl 2:S1623.
54. Armas LA, Hollis BW, Heaney RP. Vitamin D2 is much less effective than vitamin D3 in humans. J Clin Endocrinol
Metab. 2004;89:538791.
55. Khazai NB, Judd SE, Jeng L, Wolfenden LL, Stecenko A, Ziegler TR, et al. Treatment and prevention of vitamin
D insufciency in cystic brosis patients: comparative efcacy of ergocalciferol, cholecalciferol, and UV light.
J Clin Endocrinol Metab. 2009;94:203743.
56. Gronowitz E, Larko O, Gilljam M, Hollsing A, Lindblad A, Mellstrom D, et al. Ultraviolet B radiation improves
serum levels of vitamin D in patients with cystic brosis. Acta Paediatr. 2005;94:54752.
57. Vogiatzi MG, Jacobson-Dickman E, DeBoer MD. Vitamin D supplementation and risk of toxicity in pediatrics: a
review of current literature. J Clin Endocrinol Metab. 2014;99:113241.
58. Cystic brosis foundation patient registry 2012 annual data report. Bethesda, MD: Cystic Fibrosis Foundation;
2013.
59. Putman MS, Milliren CE, Derrico N, Uluer A, Sicilian L, Lapey A, et al. Compromised bone microarchitecture
and estimated bone strength in young adults with cystic brosis. J Clin Endocrinol Metab. 2014;99:3399407.
60. Aris RM, Renner JB, Winders AD, Buell HE, Riggs DB, Lester GE, et al. Increased rate of fractures and severe
Kyphosis: sequelae of living into adulthood with cystic brosis. Ann Intern Med. 1998;128:18693.
61. Rossini M, Del Marco A, Dal Santo F, Gatti D, Braggion C, James G, et al. Prevalence and correlates of vertebral
fractures in adults with cystic brosis. Bone. 2004;35:7716.
62. Stalvey MS, Clines GA. Cystic brosis-related bone disease: insights into a growing problem. Curr Opin
Endocrinol Diabetes Obes. 2013;20:54752.
63. Latzin P, Griese M, Hermanns V, Kammer B. Sternal fracture with fatal outcome in cystic brosis. Thorax. 2005;
60:616.
64. Aris RM, Merkel PA, Bachrach LK, Borowitz DS, Boyle MP, Elkin SL, et al. Guide to bone health and disease in
cystic brosis. J Clin Endocrinol Metab. 2005;90:188896.
65. Saggese G, Baroncelli GI, Bertelloni S. Puberty and bone development. Best Pract Res Clin Endocrinol Metab.
2002;16:5364.
66. Curran DR, McArdle JR, Talwalkar JS. Diabetes mellitus and bone disease in cystic brosis. Semin Respir Crit
Care Med. 2009;30:51430.
67. Rogan MP, Reznikov LR, Pezzulo AA, Gansemer ND, Samuel M, Prather RS, et al. Pigs and humans with cystic
brosis have reduced insulin-like growth factor 1 (IGF1) levels at birth. Proc Natl Acad Sci U S A. 2010;107:
205715.
68. Gordon CM, Binello E, LeBoff MS, Wohl ME, Rosen CJ, Colin AA. Relationship between insulin-like growth
factor I, dehydroepiandrosterone sulfate and proresorptive cytokines and bone density in cystic brosis. Osteoporos
Int. 2006;17:78390.
69. Hardin DS, Ahn C, Prestidge C, Seilheimer DK, Ellis KJ. Growth hormone improves bone mineral content in
children with cystic brosis. J Pediatr Endocrinol Metab. 2005;18:58995.
70. Fulzele K, Clemens TL. Novel functions for insulin in bone. Bone. 2012;50:4526.
71. Henneicke H, Gasparini SJ, Brennan-Speranza TC, Zhou H, Seibel MJ. Glucocorticoids and bone: local effects
and systemic implications. Trends Endocrinol Metab. 2014;25:197211.
72. Neri AS, Lori I, Festini F, Masi L, Brandi ML, Galici V, et al. Bone mineral density in cystic brosis patients under
the age of 18 years. Minerva Pediatr. 2008;60:14754.
73. Weitzmann MN. The role of inammatory cytokines, the RANKL/OPG axis, and the immunoskeletal interface in
physiological bone turnover and osteoporosis. Scientica (Cairo). 2013;2013:125705.
74. Shead EF, Haworth CS, Condliffe AM, McKeon DJ, Scott MA, Compston JE. Cystic brosis transmembrane
conductance regulator (cftr) is expressed in human bone. Thorax. 2007;62:6501.
63
75. Le Heron L, Guillaume C, Velard F, Braux J, Touqui L, Moriceau S, et al. Cystic brosis transmembrane conductance
regulator (CFTR) regulates the production of osteoprotegerin (OPG) and prostaglandin (PG) e2 in human bone.
J Cyst Fibros. 2010;9:6972.
76. Ambroszkiewicz J, Sands D, Gajewska J, Chelchowska M, Laskowska-Klita T. Bone turnover markers,
osteoprotegerin and rankl cytokines in children with cystic brosis. Adv Med Sci. 2013;58:33843.
systematic review. J Am Diet Assoc. 2008;108:8329.
78. Weaver CM, Heaney RP. Calcium. In: Ross CA, Caballero B, Cousins RJ, Tucker KL, Ziegler TR, editors. Modern
nutrition in health and disease. 11th ed. Philadelphia: Lippincott Williams & Wilkins; 2014. p. 13349.
79. Schulze KJ, OBrien KO, Germain-Lee EL, Booth SL, Leonard A, Rosenstein BJ. Calcium kinetics are altered in
clinically stable girls with cystic brosis. J Clin Endocrinol Metab. 2004;89:338591.
80. Schulze KJ, OBrien KO, Germain-Lee EL, Baer DJ, Leonard AL, Rosenstein BJ. Endogenous fecal losses of
calcium compromise calcium balance in pancreatic-insufcient girls with cystic brosis. J Pediatr. 2003;143:
76571.
81. Schulze KJ, OBrien KO, Germain-Lee EL, Baer DJ, Leonard A, Rosenstein BJ. Efciency of calcium absorption
is not compromised in clinically stable prepubertal and pubertal girls with cystic brosis. Am J Clin Nutr.
2003;78:1106.
82. Hillman LS, Cassidy JT, Popescu MF, Hewett JE, Kyger J, Robertson JD. Percent true calcium absorption, mineral
metabolism, and bone mineralization in children with cystic brosis: effect of supplementation with vitamin D and
calcium. Pediatr Pulmonol. 2008;43:77280.
83. Kemi VE, Karkkainen MU, Lamberg-Allardt CJ. High phosphorus intakes acutely and negatively affect ca and
bone metabolism in a dose-dependent manner in healthy young females. Br J Nutr. 2006;96:54552.
84. Kemi VE, Karkkainen MU, Rita HJ, Laaksonen MM, Outila TA, Lamberg-Allardt CJ. Low calcium:phosphorus
ratio in habitual diets affects serum parathyroid hormone concentration and calcium metabolism in healthy women
with adequate calcium intake. Br J Nutr. 2010;103:5618.
85. Tucker KL, Rosen CJ. Prevention and management of osteoporosis. In: Ross CA, Caballero B, Cousins RJ, Tucker
KL, Ziegler TR, editors. Modern nutrition in health and disease. 11th ed. Philadelphia: Lippincott Williams &
Wilkins; 2014. p. 122744.
86. Tucker KL, Morita K, Qiao N, Hannan MT, Cupples LA, Kiel DP. Colas, but not other carbonated beverages, are
associated with low bone mineral density in older women: the Framingham osteoporosis study. Am J Clin Nutr.
2006;84:93642.
87. Wyshak G, Frisch RE. Carbonated beverages, dietary calcium, the dietary calcium/phosphorus ratio, and bone
fractures in girls and boys. J Adolesc Health. 1994;15:2105.
88. Kiel DP, Felson DT, Hannan MT, Anderson JJ, Wilson PW. Caffeine and the risk of hip fracture: the Framingham
study. Am J Epidemiol. 1990;132:67584.
89. Hallstrom H, Melhus H, Glynn A, Lind L, Syvanen AC, Michaelsson K. Coffee consumption and cyp1a2 genotype
in relation to bone mineral density of the proximal femur in elderly men and women: a cohort study. Nutr Metab.
2010;7:12.
90. Harris SS, Dawson-Hughes B. Caffeine and bone loss in healthy postmenopausal women. Am J Clin Nutr.
1994;60:5738.
91. Heaney RP. Effects of caffeine on bone and the calcium economy. Food Chem Toxicol. 2002;40:126370.
92. Barrett-Connor E, Chang JC, Edelstein SL. Coffee-associated osteoporosis offset by daily milk consumption. The
Rancho Bernardo study. JAMA. 1994;271:2803.
93. Hallstrom H, Wolk A, Glynn A, Michaelsson K. Coffee, tea and caffeine consumption in relation to osteoporotic
fracture risk in a cohort of Swedish women. Osteoporos Int. 2006;17:105564.
94. Spencer H, Kramer L. Antacid-induced calcium loss. Arch Intern Med. 1983;143:6579.
95. Spencer H, Kramer L, Norris C, Osis D. Effect of small doses of aluminum-containing antacids on calcium and
phosphorus metabolism. Am J Clin Nutr. 1982;36:3240.
J Pediatr Gastroenterol Nutr. 2002;35:24659.
97. Devine A, Criddle RA, Dick IM, Kerr DA, Prince RL. A longitudinal study of the effect of sodium and calcium
intakes on regional bone density in postmenopausal women. Am J Clin Nutr. 1995;62:7405.
98. Dougherty KA, Schall JI, Stallings VA. Suboptimal vitamin K status despite supplementation in children and
young adults with cystic brosis. Am J Clin Nutr. 2010;92:6607.
99. Conway SP, Wolfe SP, Brownlee KG, White H, Oldroyd B, Truscott JG, et al. Vitamin K status among children
with cystic brosis and its relationship to bone mineral density and bone turnover. Pediatrics. 2005;115:
132531.
100. Conway SP. Vitamin K in cystic brosis. J R Soc Med. 2004;97 Suppl 44:4851.
64
101. Pearson DA. Bone health and osteoporosis: the role of vitamin K and potential antagonism by anticoagulants.
102. Council NR. Dietary reference intakes for vitamin A, vitamin K, arsenic, boron, chromium, copper, iodine, iron,
manganese, molybdenum, nickel, silicon, vanadium, and zinc. Washington: The National Academies Press; 2001.
103. Fewtrell MS, Benden C, Williams JE, Chomtho S, Ginty F, Nigdikar SV, et al. Undercarboxylated osteocalcin and
bone mass in 812 year old children with cystic brosis. J Cyst Fibros. 2008;7:30712.
104. Kratz A, Ferraro M, Sluss PM, Lewandrowski KB. Case records of the Massachusetts general hospital. Weekly
clinicopathological exercises. Laboratory reference values. N Engl J Med. 2004;351:154863.
105. Jagannath VA, Fedorowicz Z, Thaker V, Chang AB. Vitamin K supplementation for cystic brosis. Cochrane
Database Syst Rev. 2013;4, CD008482.
106. Nicolaidou P, Stavrinadis I, Loukou I, Papadopoulou A, Georgouli H, Douros K, et al. The effect of vitamin K
supplementation on biochemical markers of bone formation in children and adolescents with cystic brosis. Eur J
Pediatr. 2006;165:5405.
107. Rizzoli R, Bianchi ML, Garabedian M, McKay HA, Moreno LA. Maximizing bone mineral mass gain during
growth for the prevention of fractures in the adolescents and the elderly. Bone. 2010;46:294305.
108. Castiglioni S, Cazzaniga A, Albisetti W, Maier JA. Magnesium and osteoporosis: current state of knowledge and
future research directions. Nutrients. 2013;5:302233.
109. Takeda E, Yamamoto H, Yamanaka-Okumura H, Taketani Y. Dietary phosphorus in bone health and quality of life.
Nutr Rev. 2012;70:31121.
110. Sebastian A, Harris ST, Ottaway JH, Todd KM, Morris Jr RC. Improved mineral balance and skeletal metabolism
in postmenopausal women treated with potassium bicarbonate. N Engl J Med. 1994;330:177681.
111. Guralp O. Effects of vitamin E on bone remodeling in perimenopausal women: mini review. Maturitas. 2014;
79:47680.
112. Chin KY, Ima-Nirwana S. The effects of alpha-tocopherol on bone: a double-edged sword? Nutrients.
2014;6:142441.
113. Vacek TP, Kalani A, Voor MJ, Tyagi SC, Tyagi N. The role of homocysteine in bone remodeling. Clin Chem Lab
Med. 2013;51:57990.
114. Herrmann M, Peter Schmidt J, Umanskaya N, Wagner A, Taban-Shomal O, Widmann T, et al. The role of
hyperhomocysteinemia as well as folate, vitamin B(6) and B(12) deciencies in osteoporosis: a systematic review.
Clin Chem Lab Med. 2007;45:162132.
115. Yamaguchi M. Role of carotenoid beta-cryptoxanthin in bone homeostasis. J Biomed Sci. 2012;19:36.
116. Maurel DB, Boisseau N, Benhamou CL, Jaffre C. Alcohol and bone: review of dose effects and mechanisms.
Osteoporos Int. 2012;23:116.
117. Melhus H, Michaelsson K, Kindmark A, Bergstrom R, Holmberg L, Mallmin H, et al. Excessive dietary intake of
vitamin A is associated with reduced bone mineral density and increased risk for hip fracture. Ann Intern Med.
1998;129:7708.
118. Michaelsson K, Lithell H, Vessby B, Melhus H. Serum retinol levels and the risk of fracture. N Engl J Med.
2003;348:28794.
119. Feskanich D, Singh V, Willett WC, Colditz GA. Vitamin A intake and hip fractures among postmenopausal
women. JAMA. 2002;287:4754.
120. Conaway HH, Henning P, Lerner UH. Vitamin A metabolism, action, and role in skeletal homeostasis. Endocr
Rev. 2013;34:76697.
121. Maqbool A, Graham-Maar RC, Schall JI, Zemel BS, Stallings VA. Vitamin A intake and elevated serum retinol
levels in children and young adults with cystic brosis. J Cyst Fibros. 2008;7:13741.
122. Gracia-Marco L, Moreno LA, Ortega FB, Leon F, Sioen I, Kafatos A, et al. Levels of physical activity that predict
optimal bone mass in adolescents: the Helena study. Am J Prev Med. 2011;40:599607.
123. Dodd JD, Barry SC, Barry RB, Cawood TJ, McKenna MJ, Gallagher CG. Bone mineral density in cystic brosis:
benet of exercise capacity. J Clin Densitom. 2008;11:53742.
124. Frangolias DD, Pare PD, Kendler DL, Davidson AG, Wong L, Raboud J, et al. Role of exercise and nutrition status
on bone mineral density in cystic brosis. J Cyst Fibros. 2003;2:16370.
125. Santos A, Bakker AD, Klein-Nulend J. The role of osteocytes in bone mechanotransduction. Osteoporos Int.
2009;20:102731.
126. Bonnet N, Ferrari SL. Exercise and the skeleton: how it works and what it really does. IBMS BoneKEy.
2010;7:23548.
127. Wardlaw GM. Putting body weight and osteoporosis into perspective. Am J Clin Nutr. 1996;63:433S6.
128. Shapses SA, Riedt CS. Bone, body weight, and weight reduction: what are the concerns? J Nutr. 2006;136:
14536.
129. Schoenau E, Neu MC, Manz F. Muscle mass during childhoodrelationship to skeletal development.
J Musculoskelet Neuronal Interact. 2004;4:1058.
65
130. Burr DB. Muscle strength, bone mass, and age-related bone loss. J Bone Miner Res. 1997;12:154751.
131. Ionescu AA, Evans WD, Pettit RJ, Nixon LS, Stone MD, Shale DJ. Hidden depletion of fat-free mass and bone
mineral density in adults with cystic brosis. Chest. 2003;124:22208.
132. Bianchi ML, Romano G, Saraifoger S, Costantini D, Limonta C, Colombo C. BMD and body composition in
children and young patients affected by cystic brosis. J Bone Miner Res. 2006;21:38896.
133. Conwell LS, Chang AB. Bisphosphonates for osteoporosis in people with cystic brosis. Cochrane Database Syst
Rev. 2014;3, CD002010.
134. Siwamogsatham O, Stephens K, Tangpricha V. Evaluation of teriparatide for treatment of osteoporosis in four
patients with cystic brosis: a case series. Case Reports in Endocrinology. 2014;2014:893589.
Chapter 5
Vitamins and Minerals

Suzanne H. Michel and Donna H. Mueller
Key Points
Persons who have CF are at risk for vitamins and minerals deciencies.
Persons who have CF use CF-specic multivitamin supplements with zinc
CF-specic multivitamin supplements contain higher levels of fat-soluble vitamins when compared
to over-the-counter products.
Published vitamin and mineral screening, annual assessment, and prescription recommendations
are available from international CF Foundations and Societies.
Research and anticipatory guidance for vitamins and minerals are necessary.
Keywords Vitamins Minerals Fat-soluble vitamins Retinol Alpha-tocopherol Vitamin K
Water-soluble vitamins Sodium chloride Calcium Iron Zinc Magnesium Copper
Introduction
The importance of vitamin and mineral supplementation for persons who have cystic brosis (CF) is
well established [17]. Prior to the widespread availability of newborn screening, symptoms of overt
vitamin or mineral deciencies often were initial signs indicative of the CF diagnosis [811]. Low
vitamin serum levels continue to be seen, but signs of overt deciency are infrequent and descriptions
often are published as case reports [1, 1215]. The introduction of CF-specic multivitamin
supplements coupled with improved pancreatic enzyme replacement therapy (PERT) has contributed
to the reduction in the incidence and prevalence of deciencies. Table 5.1 lists the nutrient content of
S.H. Michel, M.P.H., R.D., L.D.N. (*)

Pulmonary Medicine, Medical University of South Carolina,
PO Box 1674, Folly Beach, SC 29439-1674, USA
D.H. Mueller, Ph.D., R.D. F.A.D.A., L.D.N., F.C.P.P.
Department of Nutrition Sciences, Drexel University,
2132 Mt. Vernon Street, Philadelphia, Pennsylvania 19130-3134, USA
67
S.H. Michel and D.H. Mueller
68
Table 5.1 Nutrient content of CF-specic multivitamins with zinc and select over-the-counter products
Fat-soluble vitaminsa,b
MVW Complete
Formulation, drops, AQUADEKs,
Vitamax,
chewables, softgels, drops, chewdrops,
D3000 softgelsc
ables, softgels
chewables
Total vitamin A (IU) (retinold and beta carotene)
4627/0.5 ml
5751/1 ml
3170/1 ml as
75% as
87% as
100% retinol
beta-carotene
beta-carotene
palmitate
9254/1 ml
11,502/2 ml
6340/2 ml as
75% as
87% as
100% retinol
beta-carotene
beta-carotene
palmitate
16,000/1 chewable
18,167/2
5000/1
88% as
chewables
chewable
beta-carotene
92% as
50% as
beta-carotene
betacarotene
32,000/2 softgels
36,334/2 softgels NP
88% as
92% as
beta-carotene
beta-carotene
32,000/2 softgels
(D3000)
88% as
beta-carotene
Vitamin E (IU)
50/0.5 ml
100/1 ml
200/1 chewable
400/2 softgels
400/2 softgels
(D3000)
Vitamin D (IU)
750/0.5 ml
1500/1 ml
1500/1 chewable
3000/2 softgels
6000/2 softgels
(D3000)
Vitamin K (mcg)
500/0.5 ml
1000/1 ml
1000/1 chewable
1600/2 softgels
1600/2 softgels
(D3000)
ChoiceFul,
chewables,
softgels, label
data
NP
NP
13,000/1
chewable
88% as
betacarotene
28,000/2
softgels
88% as
betacarotene
NP
Libertas, ABDEK,
drops, chewables,
softgels
Poly-Vi-Sol
drops,
Centrum,
chewable, tablet
4627/1 ml
100% retinol
palmitate
9254/2 ml
100% retinol
palmitate
16,000/1 chewable
100% as
beta-carotene
750/ml
32,000/2 softgels
88% as
beta-carotene
7000/2 tablets
29% as
betacarotene
NP
NP
1500/2 ml
3500/1 chewable
29% as
betacarotene
NP
NP
50/1 mle
100/2 mle
100/2 chewablese
NP
NP
180/1 chewable
50/1 ml
100/2 ml
200/1 chewable
5/1 ml
10/2 ml
30/1 chewable
300/2 softgelse
NP
50/1 ml
100/2 ml
200/1
chewable
NP
NP
340/2 softgels
NP
400/2 softgels
NP
60/2 tablets
NP
600/1 ml
1200/2 ml
1200/2
chewables
2400/2 softgels
NP
400/1 ml
800/2 ml
400/1
chewable
NP
NP
NP
NP
800/1 chewable
500/1 ml
1000/2 ml
1000/1 chewable
400/1 ml
800/2 ml
400/1 chewable
2000/2 softgels
NP
2000/2 softgels
NP
800/2 tablets
NP
400/1 ml
800/2 ml
700/2 chewables
300/1 ml
600/2 ml
200/1
chewable
NP
NP
NP
NP
600/1 chewable
400/1 ml
800/2 ml
800/1 chewable
0
0
10/1 chewable
1400/2 softgels
NP
1600/2 softgels
NP
50/2 tablets
NP
1400/2 softgels
NP
(continued)
69
Table 5.1 (continued)

Water-soluble vitamins & zinca,b
MVW Complete
Formulation
Drops, Chewables,
Softgels, D3000
AQUADEKs,
Drops, Softgels
Softgels
Thiamin B1 (mg)
0.5/0.5 ml
0.6/1 ml
1/1 ml
1.2/2 ml
1.5/1 chewable
1.5/2 chewables
3/2 softgels or 2
3/2 softgels
softgels with
D3000
Riboflavin B2 (mg)
0.6/0.5 ml
0.6/1 ml
1.2/1 ml
1.2/2 ml
1.7/1 chewable
1.7/2 chewables
3.4/2 softgels or 2
3.4/2 softgels
softgels with
D3000
Niacin (mg)
6/0.5 ml
6/1 ml
12/1 ml
12/2 ml
10/1 chewable
10/2 chewables
40/2 softgels or 2
20/2 softgels
softgels with
D3000
Pyridoxine B6 (mg)
0.6/0.5 ml
0.6/1 ml
1.2/1 ml
1.2/2 ml
1.9/1 chewable
1.9/2 chewables
3.8/2 softgels or 2
3.8/2 softgels
softgels with
D3000
B12 (mcg)
4/0.5 ml
0
8/1 ml
0
6/1 chewable
12/2 chewables
12/2 softgels or 2
24/2 softgels
softgels with
D3000
Biotin (mcg)
15/0.5 ml
15/1 ml
30/1 ml
30/2 ml
100/1 chewable
100/2 chewables
200/2 softgels or 2
200/2 softgels
softgels with
D3000
Vitamax
Drops,
Chewables
ChoiceFul
Chewables,
Softgels
Label Data
Libertas
ABDEK
Drops,
Chewables,
Softgels
Poly-Vi-Sol
Drops
Centrum
Chewable,
Tablet
0.5/1 ml
1/2 ml
1.5/1 chewable
NP
NP
NP
1.2/1 chewable
2/2 softgels
0.5/1 ml
1/2 ml
1.5/1 chewable
3/2 softgels
0.5/1 ml
1/2 ml
1.5/1 chewable
3/2 tablets
0.6/1 ml
1.2/2 ml
1.7/1 chewable
NP
NP
NP
1.4/1 chewable
3/2 softgels
0.6/1 ml
1.2/2 ml
1.7/1 chewable
3.4/2 softgels
0.6/1 ml
1.2/2 ml
1.7/1 chewable
3.4/2 tablets
6/1 ml
12/2 ml
20/1 chewable
NP
NP
NP
8/1 chewable
36/2 softgels
6/1 ml
12/2 ml
10/1 chewable
40/2 softgels
8/1 ml
16/2 ml
20/1 chewable
40/2 tablets
0.6/1 ml
1.2/2 ml
2/1 chewable
NP
NP
NP
1.5/1 chewable
3.8/2 softgels
0.6 1 ml
1.2/2 ml
1.9/1 chewable
3.8/2 softgels
0.4/1 ml
0.8/2 ml
2/1 chewable
4/2 tablets
4/1 ml
8/2 ml
6/1 chewable
NP
NP
NP
6/1 chewable
10/2 softgels
4/1 ml
8/2 ml
6/1 chewable
12/2 softgels
2/1 ml
4/2 ml
6/1 chewable
12/2 tablets
15/1 ml
30/2 ml
300/1 chewable
NP
NP
NP
80/1 chewable
160/2 softgels
15/1 ml
30/2 ml
100/1 chewable
200/2 softgels
0
0
45/1 chewable
60/2 tablets
(continued)
70
Water-soluble vitamins & zinca,b
MVW Complete
Formulation
Drops, Chewables,
Softgels, D3000
AQUADEKs,
Drops, Softgels
Softgels
Folic acid (mcg)
0
0
200/1 chewable
400/softgels or 2
softgels with
D3000
Ascorbic acid C (mg)
45/0.5 ml
90/1 ml
100/1 chewable
200/2 softgels or 2
softgels with
D3000
Pantothenic acid (mg)
3/0.5 ml
6/1 ml
12/1 chewable
24/2 softgels or 2
softgels with
D3000
Zinc (mg)
5/0.5 ml
10/1 ml
15/1 chewable
20/2 softgels or 2
softgels with
D3000
a
Vitamax
Drops,
Chewables
ChoiceFul
Chewables,
Softgels
Label Data
Libertas
ABDEK
Drops,
Chewables,
Softgels
Poly-Vi-Sol
Drops
Centrum
Chewable,
Tablet
0
0
200/2 chewables
200/2 softgels
0
0
200/1 chewable
NP
NP
NP
180/1 chewable
360/2 softgels
0
0
200/1 chewable
400/2 softgels
0
0
400/1 chewable
800/2 tablets
45/1 ml
90/2 ml
70/2 chewables
150/2 softgels
45/1 ml
90/2 ml
60/1 chewable
NP
NP
NP
60/1 chewable
60/2 softgels
45/1 ml
90/2 ml
100/1 chewable
200/2 softgels
35/1 ml
70/2 ml
60/1 chewable
120/2 tablets
3/1 ml
6/2 ml
12/2 chewables
24/2 softgels
3/1 ml
6/2 ml
10/1 chewable
NP
NP
NP
10/1 chewable
16/2 softgels
3/1 ml
6/2 ml
12/1 chewable
24/2 softgels
0
0
10/1 chewable
20/2 tablets
5/1 ml
10/2 ml
10/2 chewables
20/2 softgels
7.5/1 ml
15/2 ml
7.5/1 chewable
NP
NP
NP
15/chewable
30/2 softgels
5/1 ml
10/2 ml
15/1 chewable
30/2 softgels
0
0
15/1 chewable
22/2 tablets
The content of this table was conrmed as of October 2014

Created by Suzanne H. Michel, MPH, RD, LDN. Please be aware that companies have copied the look and format of
this table. Unless the table has Ms. Michels name on it, she cannot attest to its accuracy
c
Tangpricha V, Kelly A, Stephenson A, Maguiness K, Enders J, Robinson KA, Marshall BC, Borowitz D, for the Cystic
Fibrosis Foundation Vitamin D Evidence-Based Review Committee. An update on the screening, diagnosis,
management, and treatment of vitamin D deciency in individuals with cystic brosis: Evidence-based recommendations
from the Cystic Fibrosis Foundation. J Clin Endocrinol Metab. 2012;97(4):108293
d
All products contain retinyl palmitate with the exception of Vitamax Chewable which contains retinol acetate.
e
Also contains mixed tocopherols
f
AquADEKs is a registered trademark of Yasoo Health Inc., Vitamax is a registered trademark of Shear/Kershman
Labs. Inc., Poly-Vi-Sol is a registered trademark of Mead Johnson and Company, Centrum is a registered trademark
of Wyeth Consumer Care, MVW Complete Formulation is a registered trademark of MVW Nutritionals, LLC
g
NP no product
2014MVWNutritionals, Inc. All rights reserved 5/30/2014
b
71
currently available CF-specic multivitamins with zinc. The content of CF-specic vitamins has
evolved since their introduction over 20 years ago resulting in improvement of targeted micronutrient
serum levels [16].
Low serum vitamin and/or mineral levels may reect maldigestion and malabsorption of CF,
inadequate dietary intake, inadequate dosing, inadequate adherence to therapy, incorrect use of
supplements and PERT, drugnutrient interaction, or medical challenges, such as bowel resection or
liver disease [1719]. For optimal absorption fat-soluble vitamins should be taken with a fat-containing
food/drink and PERT. Women who have CF, have marginal serum vitamin and mineral levels, and use
oral contraceptives may require special attention to optimize micronutrient levels. These women may
need additional sources of vitamins B-6, folic acid, riboavin, ascorbic acid, retinol, and the minerals
iron, zinc, and copper [20].
Inadequate serum levels have been reported in pancreatic sufcient patients. Some researchers
believe the low levels may reect challenges at the cellular level, while others postulate that a decline
in fat-soluble vitamin serum levels actually may be a sign of developing pancreatic insufciency [14,
21, 22].
Deciencies of vitamins A, D, and E and the mineral zinc were identied in infants as young as six
weeks of age [23, 24]. Follow-up of the infants up to ten years of age found that despite the use of
PERT and vitamin supplementation some children continued to present with low levels of the vitamins,
with vitamin E being the most frequent [25]. Treatment with PERT along with zinc containing
CF-specic vitamins corrected zinc deciency in infants [26].
Several of the micronutrients in this chapter are antioxidants, namely beta-carotene, vitamins C
and E and the minerals selenium and zinc. The role of antioxidants and CF was reviewed with the
conclusion that additional research is necessary prior to recommending supplemental antioxidants
beyond what currently is recommended in nutrition consensus reports [27, 28]. Ofcial vitamin
recommendations may not reect currently available evidence. Table 5.2 provides a summary of
international CF Foundations vitamin and mineral recommendations [17].
This chapter reviews current knowledge of vitamin and mineral nutrition in CF. Readers are
referred to the chapters on pregnancy, lung transplant, and liver disease for vitamin and mineral
information specic to those topics. Vitamin D is covered in a separate chapter.
Vitamin A
Vitamin As role in eye health is well documented but it is also essential for cellular integrity, growth,
immune function, and bone and tooth development. Vitamin A deciency and vitamin A toxicity are
of concern in the care of persons who have CF [30]. Serum retinol is homeostatically maintained,
while hepatic stores increase indenitely with increased ingestion [31]. Excessive vitamin A serum
level is linked to liver and bone damage [32, 33]. Night blindness has been reported in persons who
have CF either prior to or following diagnosis [15, 34, 35]. Vitamin A plays a pivotal role in CF lung
health [36, 37]. Rivas-Crespo described better lung function in patients with CF with serum retinol
levels up to 110 g/dL [38]. Although other researchers have noted the relationship of optimal serum
vitamin A levels to lung function they have not reported a similar correlation with higher serum levels
[39, 40]. Reduced serum retinol levels have been reported in pancreatic sufcient patients [21].
Serum retinol level should be evaluated in the fasting state and is effected by medications, fat
malabsorption, liver disease, malnutrition, zinc deciency, chronic infection, and decreased retinol
binding protein [32]. The blood sample should be protected from bright light [41]. Vitamin A status
assessed via serum retinol will identify deciency, while serum retinyl esters as a function of total
serum retinol may be more appropriate when concerned about retinol toxicity [30]. Roddy described
using molar ratio of retinol to retinol binding protein when providing vitamin A to a decient patient
Consider for poor

growth or
refractory vitamin
A deciency.
6 month. zinc trial
Minimum: 1997
IOM recommendations
Zinc
Supplement if decient
Consider with poor

growth or severe
steatorrhea
Infants: PRI: 2346 mg/

kg daily
Breast-fed:supplement
with fever or
summer mo
As indicated
Supplement if dietary
intake is inadequate
PI
400010,000
PI and cholestasis 1 mg/

day to 10 mg/week
100400
European 2002 [3] All

ages
Consensus
NI
NI
Infants: 12 mmol/kg/
day if urine Na < 10
>2 year: additional
requirement in
warm climates
NI
NI
01 year: 1050 mg
110 years: 50100 mg
>10 years:
100200 mg
<1 year: 4000
<1 year: 400010,000
UK CF trust 2002 [7]

all ages
Evidence and
consensus
10000
NI
As indicated
especially
women
If indicated
NI
NI
10,000
200400 IU/
day
2.55 mg/week
USA-CFF 2004
[4] adult
Consensus
ND
As indicated
Supplement if dietary
intake is inadequate
or with terminal
ileum resection
Infants: 5001000 mg/
day
Children: 4000 mg
>12 year: 6000 mg
036 month: 150

500 > 4: 300500
012 month: 4080
13 year: 50150
47 year: 150300
>8 years: 150500
012 month: 15002000
13 year: 15002500
4-Adult: 2500-5000
Australasian 2006 [6]

all ages
Evidence
Consider for inadequate growth

despite PERT and sufcient
calories.
1 mg/kg/day, 6 month zinc trial.
NI
06 mo: 1/8 tsp/day (12.6 mEq)

>6 month: 1/4 t/day (25.2 mEq)
USA CFF newborn 2009 [5]

birth to 2 year
Evidence and consensus
Recommended daily
NI
intake or
1500 mg/day with low
bone density
Abbreviations: PI pancreatic insufcient, PRI population reference intake, tsp teaspoon, IOM institute of medicine, NI not included in recommendations
a
Adapted from Table 5.1, reference [31]
b
Start CF-specic multivitamins shortly after diagnosis
As indicated
Iron
Calcium
Infants: 1/8 tsp

(12.6 mEq)
Others: high salt diet
012 month: 4050

13 year: 80150
48 year: 100200
>8 year: 200400
012 month: 1500
13 year: 5000
48 year: 500010,000
>8 year: 10,000
NI
300500
USA-CFF 2002 [2]

pediatric
Consensus
Sodium Per
day
Water
Soluble
Vitamin A
IU/day
Vitamin K
mcg/day
Vitamin E
IU/day
Nutrient
Table 5.2 International vitamin and mineral recommendations for CF carea
72
73
Table 5.3 Retinol activity equivalent (RAE) content of CF-specic vitaminsa

MVWComplete
AquADEKs
Vitamax
formulation g RAE
g RAE
g RAE
Liquid
984/0.5 ml
911/1 ml
1744/1 ml
Chewable
2464/1
2470/2
1100/1b
Softgels
4928/2
4940/2
NA
See Table 5.1 for retinol and beta-carotene content of each product
Beta-carotene IU 0.10
Retinyl palmitate IU 0.55
Retinol acetate IU 0.34
a
Conversion factors from reference [43]
b
Retinol acetate all others retinyl palmitate
Choiceful
g RAE
NA
2002/1
4312/2
Libertas g RAE
2545/1 ml
1600/1
4928/2
[15]. In a patient with liver disease better serum retinol level was achieved in response to a higher
retinol product [15]. Patients refractory to vitamin A supplementation may require zinc supplements
[32]. Vitamin A is an acute phase reactant, therefore serum levels should not be checked during a
pulmonary exacerbation. CRP and IgG are used to identify inammation [42]. Providing vitamin A
supplementation based on individualized needs, which reect evaluation of serum levels, is integral to
avoid deciency and toxicity [42].
Development of CF-specic multivitamins has aided in the reduction of vitamin A deciency.
Vitamin A content of the early products was predominantly retinol, while later products contain a
combination of retinol and beta-carotene [16]. Table 5.3 provides the retinol activity equivalents
(RAE) of currently available CF-specic multivitamins using conversion factors found in reference
43. In a series of studies on similar CF patients and using similar methods, changes in vitamin A
intake from food and supplements and serum retinol levels were noted [16, 43, 44]. When compared
to the DRI and NHANES, retinol intake and serum levels were found to be greater than recommended,
yet lower than suggested by Rivas-Crespo [16, 38, 43, 44]. Serum retinol was lower, and the increase
in the number of subjects with low serum levels in the Bertolas study may reect the increase in betacarotene content of CF-specic vitamins [16].
Vitamin A deciency or excess are teratogenic and associated with adverse reproductive outcomes
[45]. Increased serum retinol levels have been reported in patients, CF and non-CF, post-lung
transplant [46]. The reader is referred to the chapters on pregnancy and on transplant for greater detail.
Vitamin E
Vitamin E is essential for normal development, cell membrane stability, and prevention of hemolysis.
It is an antioxidant. Overt symptoms of vitamin E deciency presenting as peripheral neuropathy or
cerebellar ataxia were seen prior to the use of enteric-coated enzymes and routine vitamin
supplementation [8, 4749]. Neurological symptoms of vitamin E deciency are seen less frequently
today but case reports can still be found [50, 51]. Low plasma vitamin E levels were reported in
patients taking multivitamins not formulated for person who have CF [52, 53]. In a study of 69
children who had CF, Huang found that following current standards of care resulted in normal to high
levels of vitamin E [54]. Little evidence is available describing the impact of polyunsaturated fatty
acids on serum tocopherol levels of persons who have CF [5557]. Liver disease, short bowel
syndrome, failure to thrive, and bacterial overgrowth may result in vitamin E deciency.
74
Evaluation of serum vitamin E in infants diagnosed through newborn screening revealed vitamin E
deciency that was corrected in the majority of infants with use of CF-specic multivitamins
containing vitamin E along with the use of PERT [39, 49]. During a ten-year follow-up in one study
11.8% of the subjects were found to be decient in vitamin E while in another study vitamin E
deciency was corrected in all infants [25, 39]. Correcting vitamin E deciency early in infancy is
critical to prevent detrimental effect of prolonged deciency on cognitive function [58].
Varying results have been reported describing the impact of vitamin E on lung function [22, 39,
59]. Limited reports describe hemorrhagic effects of excessive vitamin E (1000 IU or more daily)
supplementation on PIVKA [60]. Individuals decient in vitamin K may be at increased risk of
coagulation defects with excessive supplementation with vitamin E [61]. Vitamin E may demonstrate
a dual role in relationship to bone health, that is at appropriate doses benecial but at excessive doses
may be harmful [62].
Increased serum vitamin E levels have been reported in patients, CF and non-CF, post-lung
transplant [46]. Please see the transplant chapter for additional information. Vitamin E deciency has
been found in pancreatic sufcient persons who have CF [21].
The efcacy of various forms of vitamin E has been evaluated [6367]. One study described
vitamin E absorption with the use of d-alpha-tocopherol polyethylene glycol 1000 succinate (TPGS)
[67]. When taken with PERT, the fat-soluble form of vitamin E is equally well absorbed as the watersoluble form [63, 65]. In a series of studies with the same subjects, using similar methods little change
was seen in vitamin E status, with 13% of the subjects decient [16].
Since vitamin E is transported throughout the body with serum lipids, serum vitamin E levels are
dependent on serum lipid levels. Clinically, vitamin E serum levels may be assessed using either of
the two calculations based on serum levels: serum/plasma concentration as a ratio to total cholesterol
or as a ratio to total lipids (cholesterol, triglycerides, and phospholipids combined) [54, 68]. Although
total lipids commonly are not available, some researchers prefer to use it to assess vitamin E
(-tocopherol) status in patients who have CF, others believe that the vitamin E:cholesterol is
appropriate [54, 69]. A patient is considered vitamin E decient when: vitamin E:total lipids is less
than 0.8 mg/dL or vitamin E:cholesterol is less than 2.47 mg/g [54]. James suggested a vitamin
E:cholesterol ratio of less than 5.4 mg/g is decient in those who have CF [70]. Vitamin E evaluation
is performed fasting and the tube of blood should be protected from light [41].
Vitamin K
Vitamin K was rst identied in 1929 and its role in coagulation was quickly dened [71]. It wasnt
until the late seventies that the relationship of vitamin K to bone health was reported [72]. Individuals
who have CF are at risk for vitamin K deciency due to maldigestion and resultant malabsorption, bile
salt deciency, liver disease, bowel resection, bacterial overgrowth, chronic antibiotic use, diet low in
vitamin K, insufcient PERT, and/or lack of suitable vitamin K supplementation [73]. Excessive
vitamins A and E may antagonize vitamin K absorption or function [60, 74].
Vitamin K refers to similar fat-soluble compounds, with different chemical structures, sources, and
biologic actions including blood clotting and bone metabolism. Phytonadione (Vitamin K1) commonly
is found in plants, especially dark green leafy vegetables and is commercially manufactured for
supplemental use. The menaquinones (vitamin K2) are synthesized by obligate anaerobic bacteria in
the ileum and colon.
In the 1960s Shwachman and Di SantAgnese reported vitamin K deciency and resultant
bleeding was so frequently seen in CF that it could be an early sign of CF [75, 76]. Reports of severe
life-threatening bleeding were frequently reported in the literature [77, 78]. Case reports of diagnosis
based on severe bleeding or cerebral hemorrhage continue to be found in the literature [7981].
Sokal did not nd increased PIVKA in infants identied through newborn screening, perhaps
75
reecting prophylactic vitamin K provided by injection versus oral dose [23, 80]. Lack of normalization
of vitamin K by oral doses may reect malabsorption of the vitamin prior to diagnosis of CF [80].
Although overt symptoms of vitamin K deciency may no longer be seen following diagnosis,
using more sensitive markers of vitamin K nutrition, reports of deciency continue to be published
[82]. Elevated PIVKA and suboptimal bone health related to vitamin K deciency has been reported
in persons who have CF [8386]. Liver disease and frequent or chronic antibiotic use will inuence
vitamin K status [41].
Vitamin K nutritional status is difcult to determine clinically since there is no single index or
biomarker indicative of adequacy versus deciency [87]. Plasma concentrations of phylloquinone
reect intake during the previous 24 h. Customary laboratory tests such as for prothrombin/
international normalized ratio (PT/INR) reect blood clotting times, rather than actual vitamin K
status and is insensitive to mild deciency. Only 50% of the normal prothrombin concentration is
necessary for normal test results [84]. PIVKA or DCP (protein induced in vitamin K absence or desgamma-carboxy prothrombin) and undercarboxylated OC (osteocalcin) are more specic and sensitive
markers of vitamin K deciency when compared to prothrombin concentration [87]. PIVKA and
gamma-carboxy prothrombin are more widely available than they were some years ago.
Little evidence is available to guide vitamin K treatment in CF [83, 8892]. Recommended doses
of vitamin K from international CF societies range from 0.5 mg daily to 10 mg weekly, including one
recommendation of 10 mg daily, see Table 5.2 [24, 6, 7]. At one point the need for supplemental
vitamin K in healthy persons with CF was questioned [93]. Daily versus weekly supplementation may
be more effective [88, 94]. There are no reports of toxicity from intakes of excessive amounts of
vitamin K1 or K2 [95]. Based on currently available evidence vitamin K supplementation is necessary
for all persons who have CF.
Water-Soluble Vitamins
There are no specic intake recommendations for water-soluble vitamins in CF. This may reect the
assumption that persons who have CF and consume a balanced diet do not develop overt symptoms of
deciencies [11, 96]. Deciencies may be related to inappropriate diet, acute illness, liver or renal
disease, or medications. McCabe reported riboavin deciency in three patients who presented with
angular stomatitis. All of the children were ill and required supplementation [97]. Deciencies of vitamin
B12 and folic acid were reported in persons who have CF presenting with peripheral neuropathy [51].
Preliminary work with CF patients receiving 5-methyltetrahydrofolate (the active form of folic acid) and
vitamin B12 demonstrated improved inammatory response [98]. Plasma ascorbic acid decreases with
age, the explanation for this is unclear [99]. CF-specic vitamins contain a full complement of the watersoluble vitamins. Thus, in general, overt symptoms of deciencies are prevented. However, research
describing the more subtle role of the water-soluble vitamins and CF is needed.
Minerals: Sodium Chloride, Calcium, and Magnesium

Sodium Chloride
Sodium chloride is central to both the diagnosis and to the care of persons who have CF. Genotype may
inuence sodium chloride losses through the skin, although at this time there are no recommendations
to adjust dietary salt intake based on sweat test results [100102]. There are many reports of
hypoelectrolytemia in infants and older patients who are not supplemented with salt or insufcient salt
76
[101105]. Infants who have CF need supplemental salt as human milk and infant formulas do not
contain sufcient sodium chloride to meet needs. When salt was removed from commercially available
infant foods some infants with CF experienced electrolyte depletion [103]. Without added dietary salt,
persons who have CF are at risk of electrolyte abnormalities and compromised growth [106, 107].
Patients who, in addition to CF, have an ileostomy require additional salt [107].
Assessing sodium status is challenging and a patient may develop symptoms of sodium chloride
depletion (decreased appetite, nausea, vomiting, muscle cramps, fatigue, poor concentration, headaches,
poor growth) prior to the development of decreased plasma or urine sodium levels [105, 108]. Urine
sodium to creatinine may be a more informative measure of sodium nutrition for infants [108].
Persons who have CF may be at risk for electrolyte abnormalities during excessive sweating, which
may blunt the trigger to drink and cause voluntary dehydration [104, 106]. Extra care is needed to
consume optimal sodium chloride when exercising [104]. United States CFF salt recommendations
for infants are: 1/8 teaspoon of table salt for the stable, growing infant from birth to 6 months of age,
increased to 1/4 teaspoon at 6 months of age [5]. To avoid complications of over or under dosing,
parents need to demonstrate that they understand the recommendations. Older patients are encouraged
to eat a high salt diet while those active in warm environments should add 0.125 (1/8) teaspoon of salt
to every 12 oz of sports drink to avoid voluntary dehydration [109]. International sodium
recommendations for children, adolescents, and adults who have CF range from 1000 to 6000 mg
daily and reect usual versus extreme conditions. Extreme conditions include very high ambient
temperature, excessive exercise, or illness with fever, vomiting, and/or diarrhea [6, 7].
Calcium
Although there are numerous papers describing bone health in persons who have CF, limited studies
are available that specically assess calcium needs. Calcium nutrition in CF is compromised by
endogenous fecal and urinary losses; the specic mechanism is not clear and may be more complex
than saponication with intestinal fat [110, 111]. Persons with CF using high doses of supplemental
pancreatic enzymes are small for age, young, and use gastric acid inhibitors may have limited calcium
availability for bone mineralization [112].
Optimizing calcium intake at times of greatest bone calcium deposition is paramount [111, 113
115]. Both US and European CFF recommend a minimum calcium intake as described by the Food
and Nutrition Board [115, 116]. Optimal calcium intake may play a role in preventing kidney stones
[117]. If a review of the usual diet reveals inadequate intake, calcium supplementation may be
necessary. Calcium carbonate is best absorbed when taken with food. Calcium citrate and calcium
maleate do not require food for optimal absorption.
Magnesium
Magnesium plays an important role in bone health and cardiorespiratory function. Persons who have
CF may be at risk for magnesium deciency due to inadequate intake, malabsorption, and drug/
nutrient interaction [118]. Medications such as aminoglycosides and immunosuppressants used with
transplant patients may interfere with magnesium nutrition [73]. Monitoring serum levels is difcult
since only 1 % of the bodys magnesium is found in the blood, yet necessary for patients on specic
medications, or who have renal insufciency, low bone mineral density, or CF-related diabetes [74,
119]. Magnesium supplementation has been shown to improve respiratory muscle strength in children
and adolescents and to play an important role in the effectiveness of rhDNase therapy [120, 121].
77
Trace Minerals: Zinc, Iron, Selenium, Copper, Fluoride

Zinc
Zinc is involved in over 300 body functions including many related to pulmonary health, immunity,
and growth [123]. Its role in health for the person who has cystic brosis is critical, especially for the
lungs and pancreas [124]. Zinc absorption is inuenced by the zinc content of the diet and fat
malabsorption, thereby making persons who have CF at risk for zinc deciency [26, 125]. Prior to
initiation of PERT, infants who have CF are at risk for zinc deciency due to malabsorption and
endogenous losses [24, 126]. Case reports of acrodermatitis enteropathica-like rash due to zinc
deciency prior to diagnosis are described in the literature [127, 128]. In trials of zinc supplementation,
subjects decient in zinc demonstrated improved outcomes as seen by improved appetite, weight,
and lung function [124, 129132]. Plasma and serum zinc laboratory measures are not informative
for marginal zinc levels. Results are inuenced by inammation, food intake, and time of day that
the study sample is obtained [133]. Contamination from the skin at the time of phlebotomy or zinc
in collection materials may result in an inaccurate result [133]. Careful evaluation of dietary zinc
intake in addition to clinical assessment is important in making the diagnosis of zinc deciency.
Empiric zinc supplementation for 6 months is recommended for those with CF exhibiting growth
failure, vitamin A deciency, or night blindness refractory to vitamin A supplementation [2, 29].
Dose is based on the elemental content of the zinc compound. The various elemental zinc compounds
of supplements and their elemental zinc content are: zinc sulfate 23%, zinc gluconate 14%, zinc
acetate 30%, zinc oxide 80%.
Iron
Iron nutrition involves a complex system including: dietary intake, absorption, transport, storage,
and excretion. In CF, iron status also may be impacted by increased losses in sputum and the GI tract,
and the severity of suppurative lung disease [134, 135]. Iron may facilitate pseudomonas aeruginosa
growth and iron loss through the airway may contribute to iron deciency [134, 136]. The incidence
of iron deciency anemia ranges from 33% in children to 74% in adults who have CF and is associated
with poorer lung function and vitamin deciency [13, 137139]. The progression of iron status from
normal, through iron deciency, to iron deciency anemia usually is gradual and subtle. Assessing
iron status and treating iron deciency in persons who have CF is challenging [140142]. Interpreting
the laboratory results of each change can be formidable [138]. There are numerous laboratory
methods to identify anemia. The tests usually obtained for annual assessment (hemoglobin, mean
corpuscular volume, and hematocrit) can identify late stages of anemia. Ferritin, which can identify
early and diminished iron stores, is an acute phase reactant and is not informative during periods of
inammation [138]. Soluble transferrin receptor levels has been recommended in addition to iron,
transferrin, and ferritin levels, although in work by Uijterschout, hepcidin was more useful in
identifying early decient iron stores [74, 143]. Skikne has suggested the calculation of soluble
transferrin receptor to log ferritin ratio as an accurate method of identifying true iron deciency in
CF [144].
Concern about iron supplementation and increased lung disease in persons who have CF has made
treatment decisions challenging. Finding the optimal treatment route of delivery has yet to be identied
[145]. Treating a group of CF patients identied with iron deciency with low dose oral iron
supplementation for six weeks did not change markers of iron deciency, but did not cause worsening
78
of lung disease [141]. Intravenous iron supplementation is another possible route for treating iron
deciency but may result in complications including allergic phenomenon [142, 145].
As noted by Hoo et al. there may be a risk of respiratory deterioration if oral iron supplementation
is continued after the patient has become iron replete. Therefore careful identication of the truly iron
decient patient is necessary as is optimal repletion [140]. Preventing iron deciency through optimal
dietary intake may be the best option.
Selenium
Selenium is an antioxidant and vital for the proper functioning of the immune system and is a catalyst
for the production of active thyroid hormone. It is required for sperm motility in males and may
reduce the risk for miscarriage in females [147]. In CF there was a great deal of interest in selenium
in the 1970s reecting a veterinary pathologists claim that selenium supplementation could cure
CF. No evidence was found that conrmed his assertion [148]. One death was reported in a child with
CF who was given selenium supplements [149]. Mislabeling and manufacturing of selenium and of
vitamin supplements resulted in reports of selenium poisoning in the non-CF population [150]. Some
research specic to seleniums role in CF was published in the 1980s1990s. Those studies identied
low serum levels in persons who have CF [27, 151, 152]. Supplementation with PERT resulted in
increased plasma serum selenium and glutathione peroxidase activity [151]. The enzymes in PERT
are obtained from animal pancreas and reect selenium content of the animals diet. In studies to
improve antioxidant levels in persons who have CF, selenium supplementation alone was not effective
[153]. However, when combined with other antioxidants improved serum selenium levels and
improved FEV1% were noted [154]. Reviews of the role of antioxidants, including selenium, concluded
that selenium supplementation was not recommended [27, 28].
Copper
Copper plays a role in iron metabolism and antioxidant activity, yet little is known about copper
metabolism in persons who have CF. Assessing copper status in humans is challenging since
physiological stress raises serum copper laboratory values [155]. Few studies are available describing
copper nutrition and CF. Percival found altered copper status in children and adult males who have CF
and noted the results may reect poor copper absorption, inadequate dietary intake, chronic
inammation, or defect in ion transport [156, 157]. Copper combined with or without zinc
supplementation did not change serum copper levels suggesting moderate copper deciency in CF may
reect abnormal copper metabolism [155]. Reduced copper enzyme activity was noted in patients who
have CF, suggesting a functional deciency not easily corrected by increased copper intake [155, 157].
Fluoride
Fluoride is critical for preventing dental caries. Vitamin supplements designed for persons who have
CF do not contain uoride. Due to the wide variation in the uoride content of community drinking
water infants, toddlers, and children who have CF are best referred to their primary care provider for
individualized uoride supplementation recommendation [5, 158].
79
Conclusion
Optimal vitamin and mineral nutrition is essential for overall health of persons who have CF. A diet
varied in food intake contributes to overall nutrient intake. The use of vitamin and mineral supplements
reective of need identied through laboratory assessment avoids deciencies or toxicities. Assessment
of vitamin and mineral supplementation adherence along with PERT is crucial to care. Healthcare
providers are encouraged to use available resources to educate families and persons who have CF
about the importance of vitamin and mineral nutrition. Future research is necessary to inform
healthcare providers regarding optimal form and dose of vitamins and minerals in CF.
References
1. Ramsey BW, Farrell PM, Pencharz P, The Consensus Committee. Nutritional assessment and management in cystic
3. Sinaasappel M, Stern M, Littlewood J, Wolfe S, Steinkamp G, Harry GM, Heijerman HGM, Robberecht E, Dring
G. Nutrition in patients with cystic brosis: a European consensus. J Cyst Fibros. 2002;1:5175.
4. Yankaskas JR, Marshall BC, Suan B, Simon RH, Rodman D. Cystic brosis adult care: consensus conference
report. Chest. 2004;125:1S39.
5. Borowitz D, Robinson KA, Rosenfeld M, Davis SD, Sabadosa KA, Spear SL, Michel SH, Parad RB, White TB,
Farrell PM, Marshall BC, Accurso FJ. Cystic brosis foundation evidence-based guidelines for management of
infants with cystic brosis. J Pediatr. 2009;155:S7393.
6. Australasian clinical practice guidelines for nutrition in cystic brosis. daa.asn.au/wp-content/uploads/2012/09/
Guidelines_CF-Final.pdf. Accessed July 2014.
7. Nutritional management of cystic brosis. www.cysticbrosis.org.uk/media/82052/nutritional-management-ofcystic-brosis-apr02.pdf. Accessed July 2014.
8. Farrell PM, Bieri JG, Fratononi JF, Wood RE, di SantAgnese PA. The occurrence and effects of human vitamin E
deciency-a study in patients with cystic brosis. J Clin Invest. 1977;60:23341.
9. Palin D, Underwood BA, Denning CF. The effect of oral zinc supplementation on plasma levels of vitamin A and
retinol-binding protein in cystic brosis. Am J Clin Nutr. 1979;32:12539.
10. Hubbard VS, Farrell PM, di SantAgnese PA. 25-Hydroxy cholecalciferol levels in patients with cystic brosis.
J Pediatr. 1979;94:846.
11. Solomons NW, Wagoneld JB, Rieger C, Jacob RA, Bolt M, Horst JV, Rothberg R, Sandstead H. Some biochemical
indices of nutrition in treated cystic brosis patients. Am J Clin Nutr. 1981;34:46274.
12. Leung M, Bayliff CD, Patersn NA, Leggatt P. Night blindness secondary to vitamin A deciency in a patient with
cystic brosis and short gut syndrome. Can J Hosp Pharm. 2006;59(2):745.
13. Obeid M, Price J, Sun L, Scantlebury MH, Overby P, Sidhu R, et al. Facial palsy and idiopathic intracranial
hypertension in twins with cystic brosis and hypovitaminosis A. Pediatr Neurol. 2011;44:1502.
14. Rana M, Wong-See D, Katz T, Gaskin K, Whitehead B, Jaffe A, Coakley J, Lochhead A. Fat-soluble vitamin
deciency in children and adolescents with cystic brosis. J Clin Pathol. 2014;14(7):14. doi:10.1136/jclinpath2013-201787.
15. Roddy MF, Greally P, Clancy G, Leen G, Feehan S, Elnazir B. Night blindness in a teenager with cystic brosis.
16. Bertolaso C, Groleau V, Schall JI, Maqbool A, Mascarenhas M, Latham NE, Dougherty KA, Stallings VA. Fatsoluble vitamins in cystic brosis and pancreatic insufciency: efcacy of a nutrition intervention. J Pediatr
17. Hollander FM, de Roos NM, Dopheide J, Hoekstra T, van Berkhout FT. Self-reported use of vitamins and other
nutritional supplements in adult patients with cystic brosis. Is daily practice in concordance with recommendations?
Int J Vitam Nutr Res. 2010;80(6):40815.
18. Palmery M, Saraceno A, Vaiarelli A, Carlomagno G. Oral contraceptives and changes in nutritional requirements.
Eur Rev Med Pharmacol Sci. 2013;17:180413.
19. Siwamogsatham O, Dong W, Binongo JN, Chowdhury R, Alvarez JA, Feinman SJ, Enders J, Tangpricha
V. Relationship between fat-soluble vitamin supplementation and blood concentrations in adolescent and adult
patients with cystic brosis. Nutr Clin Pract. 2014;29:4917.
80
20. Wilson SMC, Bivins BN, Russell KA, Bailey LB. Oral contraceptive use: impact on folate, vitamin B6 and vitamin
B12 status. Nutr Rev. 2011;69:57283.
21. Lancellotti L, DOrazio C, Mastella G, Mazzi G, Lippi U. Deciency of vitamins E and A in cystic brosis is
independent of pancreatic function and current enzyme and vitamin supplementation. Eur J Pediatr.
1996;155:2815.
22. Hakim F, Kerem E, Rivlin J, Bentur L, Stankiewicz H, Bdolach-Abram T, Wilschanski M. Vitamins A and E and
pulmonary exacerbations in patients with cystic brosis. J Pediatr Gastroenterol Nutr. 2007;45:34753.
23. Sokol RJ, Reardon MC, Accurso FJ, Stall C, Narkewicz M, Abman SH, Hammond KB. Fat-soluble-vitamin status
during the rst year of life in infants with cystic brosis identied by screening of newborns. Am J Clin Nutr.
1989;50:106471.
24. Krebs NF, Sontag M, Accurso FJ, Hambidge KM. Low plasma zinc concentrations in young infants with cystic
brosis. J Pediatr. 1998;133:7614.
25. Feranchak AP, Sontag MK, Wagerer JS, Hammond KB, Accurso FJ, Sokol RJ. Prospective, long-term study of fatsoluble vitamin status in children with cystic brosis identied by newborn screen. J Pediatr. 1999;135:60110.
26. Easley D, Krebs N, Jefferson M, Miller L, Erskine J, Accurso F, Hambidge KM. Effect of pancreatic enzymes on
zinc absorption in cystic brosis. J Pediatr Gastroenterol Nutr. 1998;26:1369.
27. Cantin AM, White TB, Cross CE, Forman HJ, Sokol RJ. Borowitz. Antioxidants in cystic brosis: conclusions from
the CF antioxidant workshop, Bethesda, Maryland, November 1112, 2003. Free Radic Biol Med. 2007;42:1531.
28. Shamseer L, Adams D, Brown N, Johnson JA, Vohra S. Antioxidant micronutrients for lung disease in cystic
brosis. Cochrane Database Syst Rev. 2010;12, CD007020.
29. Tinley CG, Withers NJ, Sheldon CD, Quinn AG, Jackson AA. Zinc therapy for night blindness in cystic brosis.
J Cyst Fibros. 2008;7:333335.
Vitamin A
30. James DR, Owen G, Campbell IA, Goodchild MC. Vitamin A absorption in cystic brosis: risk of hypervitaminosis
A. Gut. 1992;33:70710.
31. Maqbool A, Dougherty K, Rovner AJ, Michel S, Stallings VA. Nutrition. In: Allen JL, Panitch HB, Rubenstein RC,
editors. Nutrition. New York: Informa healthcare; 2010. p. 30827.
32. Institute of Medicine. Dietary reference intakes for vitamin A, vitamin K, arsenic, boron, chromium, copper, iodine,
iron, manganese, molybdenum, nickel, silicon, vanadium and zinc. Washington: National Academy Press, 2001.
p 82161.
33. Michalsson K, Lithell H, Vessby B, Melhus H. Serum retinol levels and the risk of fracture. N Engl J Med.
2003;348:28794.
34. Huet F, Semama DM, Maingueneau C, Charavel A, Nivelon JL. Vitamin A deciency and nocturnal vision in
teenagers with cystic brosis. Eur J Pediatr. 1997;156:94951.
35. Schupp C, Olano-Martin E, Gerth C, Morrissey BM, Cross CE, Werner JS. Lutein, zeazanthin, macular pigment,
and visual function in adult cystic brosis patients. Am J Clin Nutr. 2004;79:104552.
36. Greer RM, Buntain HM, Lewindon PJ, Wainwright CE, Potter JM, Wong JC, Francis PW, Batch JA, Bell
SC. Vitamin A levels in patients with CF are inuenced by the inammatory response. J Cyst Fibros.
2004;3:1439.
37. Aird FK, Greene SA, Ogston SA, Macdonald TM, Mukhopadhyay S. Vitamin A and lung function in CF. J Cyst
Fibros. 2006;5:12931.
38. Rivas-Crespo MR, Jimnez DG, Acua Quirs MD, Aguirre AS, Gonzlez SH, Martin JJD, Otero JMG, Almarza
AL, Bousoo-Garcia C. High serum retinol and lung function in young patient with cystic brosis. J Pediatr
39. Bines JE, Truby HD, Armstrong DS, Carzino R, Grimwoood K. Vitamin A and E deciency and lung disease in
infants with cystic brosis. J Paediatr Child Health. 2005;41:6638.
40. Bonifant CM, Shevill E, Chang AB. Vitamin A supplementation for cystic brosis. Cochrane Database Syst Rev.
2014;(5): CDoo6751.
41. Krauses food & the nutrition care process. 13th ed. In: Mahan LK, Escott-Stump S, Raymond JL, editors. Elsevier
Saunders, St Louis, Missouri, 2012. p 108994.
42. Brei C, Simon A, Krawinkel MB, Naehrlich L. Individualized vitamin A supplementation for patients with cystic
brosis. Clin Nutr. 2013;32:80510.
43. Graham-Maar RC, Schall JI, Stettler N, Zemel BS, Stallings VA. Elevated vitamin A intake and serum retinol in
preadolescent children with cystic brosis. Am J Clin Nutr. 2006;84:17482.
44. Maqbool A, Graham-Maar RC, Schall JI, Zemel BS, Stallings VA. Vitamin A intake and elevated serum retinol
levels in children and young adults with cystic brosis. J Cyst Fibros. 2008;7:13741.
81
45. World Health Organization. Vitamin A dosage during pregnancy and lactation: recommendations and report of a
consultation. 1998. Document NUT/98.4.
46. Ho T, Gupta S, Brotherwood M, Robert R, Cortes D, Verjee Z, Tullis E, Keshavjee S, Chaparro C, Stephenson
A. Increased vitamin A and E levels after lung transplant. Transplantation. 2011;92:6016.
Vitamin E
47. Farrell PM, Mischler EH, Gutcher G. Evaluation of vitamin E deciency in children with lung disease. Ann N Y
Acad Sci. 1982;393:96106.
48. Cynamon HA, Milov DE, Valenstein E, Wagner M. Effect of vitamin E deciency on neurologic function in patients
with cystic brosis. J Pediatr. 1988;113:63740.
49. Sokol RJ, Butler-Simon N, Heubi JE, Iannaccone ST, McClung HJ, Accurso F, Hammond K, Heyman M, Sinatra
F, Riely C, Perrault J, Levy J, Siverman A. Vitamin E deciency neuropathy in children with fat malabsorption.
Studies in cystic brosis and chronic cholestasis. Ann N Y Acad Sci. 1989;570:15669.
50. Sitrin MD, Lieberman F, Jensen WE, Noronha A, Milburn C, Addington W. Vitamin E deciency and neurologic
disease in adults with cystic brosis. Ann Intern Med. 1987;107:514.
51. Chakrabarty B, Kabra SK, Gulati S, Toteja GS, Lodha R, Kabra M, Pandey RM, Srivastava A. Peripheral neuropathy
in cystic brosis: a prevalence study. J Cyst Fibros. 2013;12:75460.
52. Kelleher J, Miller MG, Littlewood JM, McDonald AM, Losowsky MS. The clinical effect of correction of vitamin
E depletion in cystic brosis. Int J Vitam Nutr Res. 1987;57:2539.
53. Leonard DH, Roos-Wilson C, Smyth AR, Polnay J, Range SP, Knowx AJ. A study of a single high potency
multivitamin preparation in the management of cystic brosis. J Hum Nutr Diet. 1998;11:490500.
54. Huang SH, Schall JI, Zemel BS, Stallings VA. Vitamin E status in children with cystic brosis and pancreatic
insufciency. J Pediatr. 2006;148:5569.
55. Van Biervliet S, Vanbillemont G, Van Biervliet JP, Declercq D, Robberecht E, Christophe A. Relation between fatty
acid composition and clinical status or genotype in cystic brosis patients. Ann Nutr Metab. 2007;51:5419.
56. Van Biervliet BS, Devos M, Delhaye T, Van Biervliet JP, Robberecht E, Christophe A. Oral DHA supplementation
in delta F508 homozygous cystic brosis patients. Prostaglandins Leukot Essent Fatty Acids. 2008;78:10915.
57. Wood LG, Gitzgerald DA, Garg ML. Hypothesis: vitamin E complements polyunsaturated fatty acids in essential
fatty acid deciency in cystic brosis. J Am Coll Nutr. 2003;22:2537.
58. Kosick RL, Lai HC, Laxova A, Zaremba KM, Losorok MR, Douglas JA, Rock MJ, Splaingard ML, Farrell
PM. Preventing early, prolonged vitamin E deciency: an opportunity for better cognitive outcomes via early
diagnosis through neonatal screening. J Pediatr. 2005;147:S516.
59.Oudshoorn JH, Klijn PH, Hofman Z, Voorbji HA, van der Ent CK, Berger R, Houwen RH. Dietary supplementation
with multiple micronutrients: no benecial effects in pediatric cystic brosis patients. J Cyst Fibros. 2007;6:3540.
60. Booth SL, Golly I, Sacheck JM, Roubenoff R, Dallal GE, Hamada K, Blumberg JB. Effect of vitamin E
supplementation on vitamin K status in adults with normal coagulation status. Am J Clin Nutr. 2004;80(1):1438.
61. Institute of Medicine. Dietary reference intakes for vitamin C, vitamin E, selenium, and carotenoids. Washington:
National Academy Press; 2000.
62. Chin KY, Ima-Nirwana S. The effects of alpha-tocopherol on bone: a double-edged sword? Nutrients. 2014;6:
142441.
63. Nasir SZ, OLeary H, Hillermeier C. Correction of vitamin E deciency with fat-soluble versus water-miscible
preparations of vitamin E in patients with cystic brosis. J Pediatr. 1993;122:8102.
64. Winklhofer-Roob BM, vant Hof MA, Shmerling DH. Long-term oral vitamin E supplementation in cystic brosis
patients: RRR-alpha-tocopherol compared with all-rac-alpha-tocopheryl acetate preparations. Am J Clin Nutr.
1996;63(5):7228.
65. Soltani-Frisk S, Gronowitz E, Andersson H, Strandvik B. Water-miscible tocopherol is not superior to fat-soluble
preparation for vitamin E absorption in cystic brosis. Acta Paediatr. 2001;90(10):11125.
66. Back EI, Frindt C, Ocenaskova E, Nohr D, Stern M, Biesalski HK. Can changes in hydrophobicity increase the
bioavailability of alpha-tocopherol? Eur J Nutr. 2006;45:16.
67. Papas K, Kalbeisch J, Mohon R. Bioavailability of a novel, water-soluble vitamin E formulation in malabsorbing
patients. Dig Dis Sci. 2007;52:34752.
68. Sokol RJ, Heubi JE, Iannaccone ST, Bove KE, Balistreri WF. Vitamin E deciency with normal serum vitamin E
concentrations in children with chronic cholestasis. N Engl J Med. 1984;310:120912.
69. Sokol R. Selection bias and vitamin E status in cystic brosis. J Pediatr. 2007;150(5):e856.
70. James DR, Alfaham M, Goodchild MC. Increased susceptibility to peroxide-induced haemolysis with normal
vitamin E concentrations in cystic brosis. Clin Chim Acta. 1991;204:27990.
82
Vitamin K
71. Dam H. The antihaemorrhagic vitamin of the chick. Biochemistry. 1935;29:127385.
72. Nelsestuen GL, Zytkovica TH, Howard JB. The mode of action of vitamin K. Identication of gammacarboxyglutamic acid as a component of protrombin. J Biol Chem. 1974;249:634750.
brosis. Pediatr Clin N Am. 2009;56:112341.
74. Alexander G, Suttie J. The effects of vitamin E on vitamin K activity. FASEB J. 1999;13:A535.
75. Shwachman H. Therapy of cystic brosis of the pancreas. Pediatrics. 1960;25:15563.
76. Di SantAgnese P, Vidaurreta A. Cystic brosis of the pancreas. J Am Med Assoc. 1960;172:206572.
77. Torstenson OL, Humphrey GB, Edson JR, Warwick WJ. Cystic brosis presenting with severe hemorrhage due to
vitamin K malabsorption: a report of 3 cases. Pediatrics. 1970;45:85761.
78. Walters TR, Koch HF. Haemorrhagic diathesis and cystic brosis in infancy. Am J Dis Child. 1972;124:6412.
79. Hamid B, Khan A. Cerebral hemorrhage as the initial manifestation of cystic brosis. J Child Neurol. 2007;22:
1145.
80. Verghese T, Beverley D. Vitamin K decient bleeding in cystic brosis. Arch Dis Child. 2003;88:5535.
81. Ngo B, Van Pelt K, Labarque V, Van De Casseye W, Penders J. Late vitamin K deciency bleeding leading to a
diagnosis of cystic brosis: a case report. Acta Clin Belg. 2011;66(2):1423.
82. Rashid M, Durie P, Andrew M, Kalnins D, Shin J, Corey M, Tullis E, Pencharz PB. Prevalence of vitamin K
deciency in cystic brosis. Am J Clin Nutr. 1999;70:37882.
83. Beker LT, Ahrens RA, Fink RJ, OBrien ME, Davidson KW, Sokoll LJ, Sadowski JA. Effect of vitamin K1
supplementation on vitamin K status in cystic brosis patients. J Pediatr Gastroenterol Nutr. 1997;24:5127.
84. Conway SP, Wolfe SP, Brownlee KG, White H, Oldroyd B, Truscott JG, Harvey JM, Shearer MJ. Vitamin K status
among children with cystic brosis and its relationship to bone mineral density and bone turnover. Pediatrics.
2005;115:132531.
85. Nicolaidou P, Stavrinadis I, Loukou I, Papadopoulou A, Georgouli H, Douros K, Priftis KN, Gourgiotis D, Matsinos
YG, Doudounakis S. The effect of vitamin K supplementation on biochemical markers of bone formation in
children and adolescents with cystic brosis. Eur J Pediatr. 2006;165:5405.
86. Fewtrell MS, Benden C, Williams JE, Chomtho S, Ginty F, Nigdikar SV, Jaffe A. Undercarboxylated osteocalcin
and bone mass in 812 year old children with cystic brosis. J Cyst Fibros. 2008;7:30712.
87. Mosler K, von Kries R, Vermeer C, Saupe J, Schmitz T, Schoster A. Assessment of vitamin K deciency in CF-how
much sophistication is useful? J Cyst Fibros. 2003;2:916.
88. Wilson DC, Rashid M, Durie PR, Tsang A, Kalnins D, Andrew M, Corey M, Shin J, Tullis E, Pencharz PB. Treatment
of vitamin K deciency in cystic brosis: effectiveness of a daily fat-soluble vitamin combination. J Pediatr.
2001;138:8515.
89. van Hoorn JH, Hendriks JJ, Vermeer C, Forgot PP. Vitamin K supplementation in cystic brosis. Arch Dis Child.
2003;88:9745.
90. Drury D, Grey VL, Ferland G, Gunberg C, Lands LC. Efcacy of high dose phylloquinone in correcting vitamin K
deciency in cystic brosis. J Cyst Fibros. 2008;7:4579.
91. Dougherty KA, Schall JI, Stallings VA. Suboptimal vitamin K status despite supplementation in children and young
adults with cystic brosis. Am J Clin Nutr. 2010;92:6607.
92. Jagannath VA, Fedorowicz Z, Thaker V, Chang AB. Vitamin K supplementation for cystic brosis (Review).
Cochrane Database Syst Rev. 2013;(4). CD008482.
93. Durie PR. Vitamin K, and the management of patients with cystic brosis. Can Med Assoc J. 1994;151:9336.
94. Olsen RE. Vitamin K. In: Shils ME, Olson JA, Shike M, editors. Modern nutrition in health and disease. 8th ed.
Baltimore: Williams and Wilkins; 1994. p. 34358.
95. Food and Nutrition Board, Institute of Medicine. Dietary reference intakes for vitamin A, vitamin K, arsenic, boron,
chromium, copper, iodine, iron, manganese, molybdenum, nickel, silicon, vanadium and zinc. Washington: National
Academy Press, 2001. p. 16296.
Water-Soluble Vitamins
96. Carr SB, McBratney J. The role of vitamins in cystic brosis. J R Soc Med. 2000;93 Suppl 38:149.
97. McCabe H. Riboavin deciency in cystic brosis: three case reports. J Hum Nutr Diet. 2001;14:36570.
83
98.Scambi C, DeFranceschi L, Gurini P, Poli F, Siciliano A, Pattini P, et al. Preliminary evidence for cell membrane
amelioration in children with cystic brosis by 5-MTHF and vitamin B12 supplementation: a single arm trial. PLoS
One. 2009;4, e4782.
99. Back EL, Frindt C, Nohr D, Frank J, Ziebach R, Stern M, Ranke M, Biesalski HK. Antioxidant deciency in cystic
brosis: when is the right time to take action. Am J Clin Nutr. 2004;80:37484.
Sodium chloride
100. Leoni GB. A specic cystic brosis mutation (T3381) associated with phenotype of isolated hypotonic dehydration. J Pediatr. 1995;127:2813.
101. Fustik S, Pop-Jordanova N, Slaveska N, Koceva S, Efremov G. Metabolic alkalosis with hypoelectrolytemia in
infants with cystic brosis. Pediatr Int. 2002;44:28992.
102. Yalcin E. Clinical features and treatment approaches in cystic brosis with pseudo-Bartter syndrome. Ann Trop
Paediatr. 2005;25:11924.
103. Laughlin JJ, Brady MS, Eigen H. Changing feeding trends as a cause of electrolyte depletion in infants with cystic
brosis. Pediatrics. 1981;68:2037.
104. Bar-Or O, Blimkie CJR. Voluntary dehydration and heat intolerance in cystic brosis. Lancet. 1992;339:6969.
105. Scurati-Manzoni E, Fossali EF, Agostoni C, Riva E, Simonetti GD, Zanolari-Calderari M, Bianchetti MG, Lava
SA. Electrolyte abnormalities in cystic brosis: systematic review of the literature. Pediatr Nephrol.
2014;29:101523.
106. Orenstein DM, Henke KG, Costill DL, Doershuk CF, Lemon PJ, Stern RC. Exercise and heat stress in cystic
brosis patients. Pediatr Res. 1983;17:2679.
107. Bower TR, Pringle KC, Soper RT. Sodium decit causing decreased weight gain and metabolic acidosis in infants
with ileostomy. J Pediatr Surg. 1988;23:56772.
108. Coates AJ, Crofton PM, Marshall T. Evaluation of salt supplementation in CF infants. J Cyst Fibros.
2009;8:3825.
109. Kriemler S, Wilk B, Schurer W, Wilson WM, Bar-Or O. Preventing voluntary dehydration in children with cystic
brosis who exercise in the heat. Med Sci Sports Exerc. 1999;31:7749.
Calcium
110. Schulze KJ, OBrien KO, Germain-Lee EL, Baer DJ, Leonard AL, Rosenstein BJ. Efciency of calcium absorption is not compromised in clinically stable prepubertal and pubertal girls with cystic brosis. Am J Clin Nutr.
2003;78:1106.
111. Schulze KJ, OBrien KO, Germain-Lee EL, Booth SL, Leonard AL, Rosenstein BJ. Calcium kinetics are altered
in clinically stable girls with cystic brosis. J Clin Endocrinol Metab. 2004;89:338591.
112. Schulze KJ, OBrien KO, Germain-Lee EL, Baer DJ, Leonard AL, Rosenstein BJ. Endogenous fecal losses of
calcium compromise calcium balance in pancreatic-insufcient girls with cystic brosis. J Pediatr.
2003;143:76571.
113. Schulze KJ, Cutchins C, Rosenstein BJ, Germain-Lee EL, Obrien KO. Calcium acquisition rates do not support
age-appropriate gains I total body bone mineral content in prepuberty and late puberty in girls with cystic brosis.
Osteoporos Int. 2006;17:73140.
114. Hillman LS, Cassidy JT, Popescu MF, Hewett JE, Kyger J, Robertson JD. Percent true calcium absorption, mineral metabolism, and bone mineralization in children with cystic brosis: effect of supplementation with vitamin
D and calcium. Pediatr Pulmonol. 2008;43:77280.
115. Sermet-Gaudelus I, Bianchi ML, Garabdian M, Aris RM, Morton A, Hardin DS, Elkin SL, Compston JE,
Conway SP, Castanet M, Wolfe S, Saworth CS. European cystic brosis bone mineralization guidelines. J Cyst
Fibros. 2011;10 Suppl 10:1623.
116. Aris RM, Merkel PA, Bachrach LK, Borowitz DS, Boyle MP, Elkin SL, Guise TA, Hardin DS, Haworth CS,
Holick MF, Joseph PM, OBiren K, Tullis E, Watts NB, White TB. Consensus statement: guide to bone health and
disease in cystic brosis. J Clin Endocrinol Metab. 2005;90:188896.
117. Sorensen MD, Kahn AJ, Reiner AP, Tseng TY, Shikany JM, Wallace RB, Chi T, Wactawski-Wend J, Jackson RD,
OSullivan MJ, Sadetshy N, Stoller ML, WHI Working Group. Impact of nutritional factors on incident kidney
stone formation: a report from the WHI OS. J Urol. 2012;187:164549.
84
Magnesium
118. Hersh T, Siddiqui DA. Magnesium and the pancreas. Am J Clin Nutr. 1973;26:3626.
119. Saris NEL, Mervaala E, Karppanen H, Khawaja J, Lewenstam A. Magnesium: an update on physiological, clinical and analytical aspects. Clin Chim Acta. 2000;294:126.
120. Sanders NN, Franckx H, DeBoeck K, Haustraete J, DeSmedt SC, Demeester J. Role of magnesium in the failure
of rhDNase therapy in patients with cystic brosis. Thorax. 2006;61:9628.
121. Gontijo-Amaral C, Guimares EV, Camargos P. Oral magnesium supplementation in children with cystic brosis
improves clinical and functional variables: a double-blind, randomized, placebo-controlled crossover trial. Am J
Clin Nutr. 2012;96:506.
122. Atsmon J, Dolev E. Drug-induced hypomagnesaemia: scope and management. Drug Saf. 2005;28:76388.
Zinc
123. Prasad AS. Zinc deciency in women, infants, and children. J Am Coll Nutr. 1996;15:11320.
124. Damphousse V, Mailhot M, Berthiaume Y, Rabasa-Lhoret R, Mailhot G. Plasma zinc in adults with cystic brosis:
correlations with clinical outcomes. J Trace Elem Med Biol. 2014;28:604.
125. Krebs NF. Overview of zinc absorption and excretion in the human gastrointestinal tract. J Nutr. 2000;130 Suppl
5:13747.
126. Krebs NF, Westcott JE, Arnold TD, Kluger BM, Accurso FJ, Miller LV, Hambidge KM. Abnormalities in zinc
homeostasis in young infants with cystic brosis. Pediatr Res. 2000;48:25661.
127. Crone J, Huber WD, Eichler I, Granditsch G. Acrodermatitis enteropathica-like eruption as the presenting sign of
cystic brosis and review of the literature. Eur J Pediatr. 2002;161:4758.
128. Bernstein ML, McCusker MM, Grant-Kels JM. Cutaneous manifestations of cystic brosis. Pediatr Dermatol.
2008;25:1507.
129. Abdulhamid I, Beck FW, Millard S, Chen X, Prasad A. Effect of zinc supplementation on respiratory tract infections in children with cystic brosis. Pediatr Pulmonol. 2008;43:2817.
130. Van Biervliet S, Van Biervliet JP, Robberecht E. Serum zinc in patients with cystic brosis at diagnosis and after
one year of therapy. Biol Trace Elem Res. 2006;112:20511.
131. Van Biervliet S, VandeVelde S, Van Biervliet JP, Robberecht E. The effect of zinc supplements in cystic brosis
patients. Ann Nutr Metab. 2008;52:1526.
132. Ataee P, Naja M, Gharagozlou M, Aatounian M, Khodadad A, Farahmand F, Motamed F, Fallahi GH, Kalantari
N, Soheili H, Modarresi V, Sabbaghian M, Rezaei N. Effect of supplementary zinc on body mass index, pulmonary function and hospitalization in children with cystic brosis. Turk J Pediatr. 2014;56:12732.
133. Krebs NF. Update on zinc deciency and excess in clinical pediatric practice. Ann Nutr Metab. 2013;62 Suppl
1:1929.
Iron
134. Reid DW, Withers NJ, Francis L, Wilson JW, Kotsimbos TC. Iron deciency in CF: relationship to lung disease
severity and chronic pseudomonas aeruginosa infection. Chest. 2002;121:4854.
135. Reid DW, Lam QT, Schneider H, Walter EH. Airway iron and iron-regulatory cytokines in CF. Eur Respir
J. 2004;24:28691.
136. Uljterschout L, Nuijsink M, Hendriks D, Rimke V, Brus F. Iron deciency occurs frequently in children with
cystic brosis. Pediatr Pulmonol. 2013;136:458462.
137. Von Drygalski A, Biller J. Anemia in CF: incidence, mechanisms, and association with pulmonary function and
vitamin deciency. Nutr Clin Pract. 2008;23:55763.
138. Keevil B, Rowlands D, Burton I, Webb AK. Assessment of iron status in cystic brosis patients. Ann Clin
Biochem. 2000;37(Pt 5):6625.
139. Fischer R, Simmerlein R, Huber RM, Schif H, Lang SM. Lung disease severity, chronic inammation, iron
deciency and erythropoietin response in adults with CF. Pediatr Pulmonol. 2007;42:11937.
140. Hoo ZH, Wildman MJ. Regarding the article entitled Iron supplementation does not worsen respiratory health or
alter the sputum microbiome in cystic brosis. J Cyst Fibros. 2014. doi:10.1016/j.jcf2014.06.002.
85
141. Gifford AH, Alexandru DM, Zhigang L, Dorman DB, Moulton LA, Price KE, Hampton TH, Sogin ML,
Zuckerman JB, Parker HW, Stanton BA, OToole GA. Iron supplementation does not worsen respiratory health or
alter the sputum microbiome in cystic brosis. J Cyst Fibros. 2014;13(30):3118.
142. Hoo ZH, Wildman MJ. Intravenous iron among cystic brosis patients. J Cyst Fibros. 2012;11:5602.
143. Uijterschout L, Swinkels DW, Akkermans MD, Zandstra T, Nuijsink M, Hendriks D, Hudig C, Tjalsma H, Vos R,
van Goudoever JB, Brus F. The value of soluble transferrin receptor and hepcidin in the assessment of iron status
in children with cystic brosis. J Cyst Fibros. 2014. doi:10.1016/j.jcf.2014.03.007.
144. Skikne BS, Punnonen K, Caldron PH, Bennett MT, Rehu M, Gasior GH, et al. Improved differential diagnosis of
anemia of chronic disease and iron deciency anemia: a prospective multicenter evaluation of soluble transferrin
receptor and the sTfR/log ferritin index. Am J Hematol. 2011;86(11):9237.
145. Smith DJ, Anderson GJ, Lamont IL, Mael P, Bell SC, Reid DW. Accurate assessment of systemic iron status in
cystic brosis will avoid the hazards of inappropriate iron supplementation. J Cyst Fibros. 2013;12:3034.
146. Khalid S, McGrowder D, Kemp M, Johnson P. The use of soluble transferrin receptor to assess iron deciency in
adults with cystic brosis. Clin Chim Acta. 2007;378:194200.
Selenium
147. Rayman MP. The importance of selenium to human health. Lancet. 2000;356:23341.
148. Hubbard VS, Barbero G, Chase HP. Selenium and cystic brosis. J Pediatr. 1980;96:4212.
149. Snodgrass W, Rumack BH, Sullivan Jr JB, Peterson RG, Chase HP, Cotton EK, Sokol R. Selenium: childhood
poisoning and cystic brosis. Clin Toxicol. 1981;18:21120.
150. MacFarquhar JK, Broussard DL, Melstrom P, Hutchinson R, Wolkin A, Martin C, Burk RF, Dunn JR, Green AL,
Hammond R, Schaffner W, Jones TF. Acute selenium toxicity associate a dietary supplement. Arch Intern Med.
2010;170:25661.
151. Winklhofer-Roob BM, Tiran B, Tuchschmid PE, vant Hof MA, Shmerling DH. Effects of pancreatic enzyme
preparations on erythrocyte glutathione peroxidase activities and plasma selenium concentrations in CF. Free
Radical Biol Med. 1998;25:2429.
152. Michalke B. Selenium speciation in human serum of cystic brosis patients compared to serum from healthy
persons. J Chromatogr A. 2004;1058:2038.
153. Portal B, Richard MJ, Coudray C, Arnaud J, Favier A. Effect of double-blind cross-over selenium supplementation on lipid peroxidation markers in cystic brosis patients. Clin Chim Acta. 1995;234:13746.
154. Wood LG, Fitzgerald DA, Lee AK, Garg ML. Improved antioxidant and fatty acid status of patients with cystic
brosis after antioxidant supplementation is linked to improved lung function. Am J Clin Nutr. 2003;77:1509.
Copper
155. Best K, McCoy K, Gemma S, DiSilvestro RA. Copper enzyme activities in cystic brosis before and after copper
supplementation plus or minus zinc. Metabolism. 2004;53:3741.
156. Percival SS, Bowser E, Wagner M. Reduced copper enzyme activities in blood cells of children with cystic brosis. Am J Clin Nutr. 1995;62:6338.
157. Percival SS, Kauwell GPA, Bower E, Wagner M. Altered copper status in adult men with cystic brosis. J Am Coll
Nutr. 1999;18:6149.
Fluoride
158. Clark MB, Slayton RL, Section on Oral Health. Fluoride use in caries prevention in the primary care setting.
Pediatrics. 2014;134:62633.
Chapter 6
Nutrition in Infancy
Evans Machogu and Tami Miller
Key Points
Nutritional deciencies are usually the earliest manifestations in the infant with cystic brosis with
over 85% of infants being pancreatic insufcient.
Left untreated or undertreated pancreatic insufciency will lead to chronic malnutrition.
A comprehensive, yet individualized nutrition plan for the infant newly diagnosed with CF requires
a team approach and includes initiation of pancreatic enzymes (PERT), fat-soluble vitamins, salt
supplementation as well as breast milk and/or infant formula and complementary foods
Most pancreatic insufcient infants require up to 150% of the dietary reference values for age to
maintain appropriate growth
Gastrostomy tube placement should be considered early for children not gaining adequate weight
in spite of adequate or suboptimal intake due to a suppressed appetite.
The goals of management are to attain and maintain normal growth and development comparable
to healthy infants and frequent assessments through the rst 2 years of life are required to assure
optimal growth.
Nutritional status in cystic brosis has been associated with progression of pulmonary disease as
well as survival.
Keywords Cystic brosis Nutrition Malnutrition Failure to thrive Pancreatic enzyme replacement
therapy
E. Machogu, M.B.Ch.B., M.S.

Section of Pediatric Pulmonology, Allergy, and Sleep Medicine, Indiana University Health,
705 Riley Hospital Drive/ROC 4270, Indianapolis, IN 46202, USA
T. Miller, R.D., C.S.P., C.D. (*)
Cystic Fibrosis Program, Childrens Hospital of Wisconsin, 9000 W. Wisconsin Ave.,
Milwaukee, WI 53201, USA
87
88
E. Machogu and T. Miller
Abbreviations
BMI
CDC
CF
CFA
CFF
CFTR
FEV1
g
kcal
kg
MI
mmol
PERT
PI
PS
WFA
WFL
Body mass index

Center for Disease Control and Prevention
Cystic brosis
Coefcient of fat absorption
Cystic brosis foundation
Cystic brosis transmembrane regulator
Forced expiratory volume in 1 second
Gram
Kilocalorie
Kilogram
Meconium ileus
Millimoles
Pancreatic insufciency
Pancreatic sufcient
Weight for age
Weight for length
Introduction
Nourishing the infant with cystic brosis (CF) through the rst years of life is of utmost importance
and requires a team approach to optimize the growth and overall health of the infant. A comprehensive,
yet individualized nutrition plan for the infant newly diagnosed with CF often includes initiation of
pancreatic enzymes (PERT), fat-soluble vitamins, salt supplementation as well as breast milk, infant
formula, and complementary foods. The Cystic Fibrosis Foundation (CFF) evidenced-based guidelines
for management of infants with CF provide a framework of recommendations to address the nutritional
challenges in the early years of life. In addition to the medical and nutritional therapies, an
understanding of the correlation of early nutritional status and long-term CF outcomes is essential for
caregivers of the infant. This chapter will review many of these recommendations and expound on
some practical strategies to enhance the nutritional care of the infant with CF.
Choice of Feeding Method

The CF Foundation recommends that human milk be used as the initial type of feeding for infants
with CF. If infants are fed formula, standard infant formulas (as opposed to hydrolyzed protein
formulas) should be used and calorie-dense feedings should be used if weight loss or inadequate
weight gain is identied [1].
The benets of human milk feeding for healthy infants are well recognized. Reduction in respiratory
and diarrheal infections [2, 3], reduction in risk for sudden infant death syndrome [4], better
neurodevelopment, prevention or delay of the occurrence of atopic dermatitis, cow milk allergy, and
wheezing in early childhood [5, 6], enhanced maternal infant bonding, among others are well
documented.
6 Nutrition in Infancy
89
Despite the known benets of breastfeeding, infants with CF are more likely to receive formula
compared to breast milk [7, 8]. A 2004 survey of US accredited CF centers showed that, among
respondents, only 49% ever received breast milk [9]. In a cohort of infants born and diagnosed through
newborn screening in Wisconsin between 1994 and 2006, only 51% of them ever received breast milk
[10], while the most recent study of infants in ve US CF Centers reveals 72% received breast milk at
birth; however, breast milk intake was reduced to 25% by 2 months of age and 13% by 5 months of
age [11]. In comparison of infants born in the USA in 2011, 49% were breastfeeding at 6 months and
27% at 12 months [12].
Although breastfeeding should be encouraged for all infants with CF, parental choice should be
considered, and all mothers should be supported in their decision to breastfeed or not. The diagnosis
of CF often occurs during the rst couple of weeks of life when breast feeding is becoming established.
The stress of diagnosis and additional infant care requirements could contribute to a rapid decline in
breast feeding in the infant with CF. Strategies to promote breast feeding include lactation support
services, emotional support during the time of diagnosis, and encouragement to seek help for the
caregivers of newly diagnosed infants with CF from extended family and friends.
Clinicians may be concerned with meeting the energy requirements of infants with CF who
breastfeed. Few studies have compared growth between breast-fed and formula-fed infants. In the
Wisconsin retrospective study, exclusive breastfeeding for <2 months did not compromise growth and
was associated with fewer infections with Pseudomonas aeruginosa [10]. In another single-center
study patients with a history of prolonged breastfeeding showed higher values of Forced Expiratory
Volume in 1 second (FEV1) and fewer infections in the rst 3 years of life [7].
When formula feeding is used for infants with CF, cow milk-based formulas are recommended. In
one study, with enzyme replacement in pancreatic insufcient patients, fat absorption was equivalent
for both semi-elemental and non-elemental formulas [13]. In another prospective randomized study,
growth velocity was similar in infants fed either a hydrolysate formula or a standard cow milk-based
formula [14].
The use of fortied breast milk and high-calorie infant formulas is indicated when growth rates are
not optimal. Fortied breast milk and formulas ranging from 22 to 30 cal/oz (73100 cal/100 mL) can
be used to promote catch-up weight gain, meet increased energy expenditure related to illness, and
provide concentrated calories if the infant is only able to consume a limited volume of breast milk or
formula. Calorie concentration can be achieved with the addition of powdered infant formula to
standard formula or breast milk. Occasionally, modular products (Microlipid, medium chain
triglyceride oil) can be used to increase the calorie content of infant formula or breast milk, but the cost
of these products and the lack of additional nutrients besides fat and calories usually limit their use.
Beginning at about 6 months, complementary foods should be introduced to the infant with
CF. Higher calorie food choices should be emphasized particularly for infants with poor weight gain.
Mixing infant cereal with breast milk or formula, the addition of fat to infant foods, and selecting food
sources that contain higher amounts of calories are all strategies to maximize the calorie intake of
solid foods and promote normal growth rates in the infant with CF. Dietitians can counsel caregivers
on strategies to advance the texture and nutrient content of complementary foods as the infant
progresses to table foods later in the rst year of life (Table 6.1).
Assessment of Pancreatic Status and Initiation of PERT

As soon as a diagnosis of CF is suspected or proven, the need for supplemental pancreatic
enzymes should also be determined. This is covered in Chapter 7 in more detail. Pancreatic
insufciency (PI) is diagnosed in up to 60% of infants with CF diagnosed through newborn screening
90
Table 6.1 Feeding guide for the infant/toddler with CF. Feeding guide for the infant/toddler with CF
Age of baby
Birth to 6 months
Foods to offer
Breast milk or ironfortied formula
1/8 teaspoon salt per day
68 months
810 months

Single-grain infant cereal
High-calorie strained fruits
and vegetables
Strained meats
teaspoon salt per day
Multigrain infant cereals
Mashed avocado
Combination foods
Whole milk yogurt, vanilla
pudding, and ice cream
Mashed table foods
Hummus
Finger foods
Dry cereal soaked in milk
or formula
Buttered toast bites
Buttery snack crackers
Mufn bites
Soft fruits or vegetables
Cheese
Pancakes or wafes with
butter and syrup
teaspoon salt per day
Special instructions
Provide lactation support to optimize the success of breast
feeding (as indicated)
Fortied breast milk and/or calorie-dense formula to
maximize growth rates (as indicated)
Cow milk-based formula is recommended for infants with
CF. Modify type of formula to meet individual needs of the
infant
The American Academy of Pediatrics recommends
delaying solid foods until 6 months of age
Spoon feed cereal mixed with breast milk or formula
Strained foods can be given in any order
Select foods with the most calories (sweet potatoes and
bananas) most often
Add teaspoon melted butter, margarine, or oil to 2 oz.
(60 gm) strained foods when extra calories are needed
Offer foods 13 times a day; increase as the baby gets older
Feed the baby in an infant seat or high chair
Offer a variety of food 3 times a day; gradually add new
foods and increase the amount and texture of the food
Add extra strained meat to combination foods or baby food
dinners
Continue to add extra fats to food to increase calories; add
23 teaspoons whipping cream to yogurt or pudding
Puffs are very low in calories and nutrients and should be
given infrequently
Feed the baby in a high chair
Start to offer breast milk or formula in a cup
Avoid juice or sweetened drinks
[15]. However, even in children with mutations associated with pancreatic insufciency, PI may
not be present at the time of diagnosis [16, 17] but gradually develops in infancy with over 90%
of children diagnosed within the rst year.
The CF Foundation recommends that pancreatic enzyme replacement should be initiated in all
infants with two CFTR mutations associated with PI and in infants with objective evidence of PI
including a low fecal elastase <200 g/g or Coefcient of Fat Absorption (CFA) <85% and in infants
with unequivocal signs or symptoms of malabsorption, while awaiting conrmatory test results [1].
Furthermore, PERT should be started in patients with PI even in absence of signs and symptoms of fat
malabsorption. Pancreatic enzymes should not be started in infants with one or two CFTR mutations
associated with pancreatic sufciency unless there are unequivocal signs or symptoms of malabsorption
while awaiting conrmatory results unless there is an objective test of pancreatic function indicating
fat malabsorption [1].
91
Enzyme Administration and Dosing

Current consensus guidelines recommend that PERT should be initiated at a dose of 20005000 lipase
units at each feeding, adjusted up to a dose of no greater than 2500 lipase units per kg per feeding with
a maximum daily dose of 10,000 lipase units per kg per day due to the risk of brosing colonopathy
[1820]. In 2013, Borowitz et al. reported that the upper limit of enzyme dosing for infants with CF
is not evidence based, but rather extrapolated from an older child or adults usual intake of 3 meals
and 12 snacks. Infants, particularly neonates, may eat as frequently as every 23 h and may easily
exceed the previously recommended daily dose of PERT. Young infants have not shown evidence of
brosing colonopathy; therefore, exceeding the upper limit of PERT to greater than 10,000 units
lipase/kg per day may be tolerated during early infancy [21].
Recent analysis of CF Registry data reveals a strong association of improved growth rates when
infants with CF received initial PERT doses of 17502000 lipase units/kg per largest meal. A statistically
signicant linear relationship between PERT dose and weight-for-length percentile occurred for doses
02000 units lipase/kg per largest meal, but did not continue for doses beyond that [22].
Enzyme capsules should be opened and the contents mixed with small amounts of applesauce and
administered orally at the beginning of the feeding. Once administered, pancreatic enzymes are
effective for about 45 minutes and should be repeated when the next feeding falls after this time frame.
Parents should watch for stray enzyme microspheres in the infants mouth and/or on mothers breast,
as irritation could occur. With the initiation of PERT, parents should be advised to protect the perianal
skin from potential irritation from frequent stooling as active enzymes may be contained in the stool.
As the infant with CF begins to eat complementary foods with moderate amounts of fat and protein,
PERT will be necessary to aid in the absorption of these nutrients. Initially, the infants diet is limited
to single-grain cereals, fruits, and vegetables all of which are low in fat and protein. However, when
the cereal is mixed with breast milk or formula, as well as the addition of fat in the form of oil or butter
to enhance the calorie content of these foods, then PERT should be administered. When these foods
and breast milk or formula are given within the 45-minute window of PERT dosing, additional
enzymes may not be necessary. However, if offered separately from breast or bottle feedings, small
amounts of PERT may be needed when fortied foods are given. As the infant grows and his/her diet
expands to include more food sources that contain fats and proteins, additional PERT is often required
to digest these nutrients. Clinicians may need to specify PERT doses for breast/bottle feedings alone
versus feedings which combine breast milk/formula as well as fat and protein containing foods. As the
infant grows and the volume of intake increases, PERT dose should be adjusted.
Rapid Growth Change

Infants with CF should experience rapid growth when they are able to consume sufcient calories and
do not have signicant malabsorption. However, this is also a period of high metabolic demand, and
regular assessments are required to ensure adequate growth is occurring [1]. To closely assess growth
and the health of the newly diagnosed infant with CF, the CFF recommends monthly follow-up in an
accredited CF center until the age of 6 months and every 2 months from 6 months until the rst
birthday. Thereafter, patients should be seen every 23 months for routine care and more frequently if
warranted due to ongoing or acute issues.
The CF Registered Dietitian should conduct a thorough nutrition assessment and provide
anticipatory guidance to the infant and caregivers. An evaluation should include calculation of intake,
calorie needs, average daily weight gain, PERT dose, and vitamin and mineral supplementation. The
CFF consensus report provides guidelines for expected daily weight gain, calorie requirements, and
an algorithm to address suboptimal growth and intake. Of utmost importance is close follow-up to
92
Fig. 6.1 Evaluation of infants with weight loss or inadequate weight gain (based on consensus opinion)
monitor the impact of the interventions made and to make early interventions to maximize the growth
and nutritional status of the infant with CF. A guide for anticipated rates of growth and calorie needs
is presented in Fig. 6.1.
Micronutrient Needs
Infants with CF are at risk for deciency of fat-soluble vitamins including vitamins A, D, E, and K
[2327]. Despite widespread newborn screening, at diagnosis, many infants with CF show deciency
in one or more fat-soluble vitamins [23, 28] with development of symptoms reported in some children
93
Table 6.2 Tips for CF vitamin administration

Tips for CF vitamin administration
Divide the vitamin dose into two-half volumes to help the newborn tolerate the CF vitamin if emesis
occurs. Transition to one-full dose as tolerated.
Mix the CF vitamin into 1 ounce of breast milk or formula in a bottle and feed as the rst part of the
feeding. Complete the feeding with additional breast milk or formula.
CF vitamins are known to stain clothing. Let parents know that this can happen. Castile soap can be
helpful in removing stains. Do not use water. Pour the soap directly on the stain and scrub. When the
stain is faded, the item can be washed.
[29, 30]. Therefore, supplementation of CF-specic vitamin drops should be started in pancreatic
insufcient infants at the time of diagnosis (see Table 6.2).
The CFF recommends measurement of vitamin levels A, D, and E within the rst 2-3 months of
diagnosis and thereafter yearly [1]. Supplemental vitamins should be adjusted to achieve optimum
levels and further testing for vitamin levels should be performed sooner if levels are found to be low.
Most often, additional vitamin D supplementation may be required to achieve normal levels.
At the age of one year, guidelines for vitamin supplementation often imply that the dose should be
doubled; however, when vitamin levels are normal or slightly elevated, the additional supplementation
may not be necessary. Doses of fat soluble vitamins, like many CF therapies, should be tailored to the
individual needs of the patient.
For infants who consume breast milk, iron supplementation is recommended beginning at 4 months
of age. Multiple studies have shown the association of iron deciency anemia and later cognitive
decits [31, 32]. The American Academy of Pediatrics (AAP) recommends that exclusively breast-fed
term infants receive an iron supplementation of 1 mg/kg/day starting at 4 months of age which should
be continued until appropriate iron-containing complementary foods have been introduced [33].
The CFF Consensus Report on Nutrition for Pediatric Patients recommends that zinc levels not be
measured. Empiric zinc supplementation as a treatment trial for a period of 6 months can be considered
for CF patients who are failing to thrive or have short stature despite adequate calorie intake and PERT
[34]. Fluoride is both safe and effective in preventing and controlling dental caries. Patients aged 6
months to 2 years whose community water supply contains less than 0.3 parts per million of uoride
should be supplemented with 0.25 mg/day regardless of mode of feeding. A comprehensive review of
micronutrient requirements in CF is covered in Chapter 4 and this chapter.
Salt Supplementation
CF is characterized by increased electrolyte loss in sweat and other epithelial surfaces, especially in
infants who have a larger relative body surface area compared to adults. Furthermore, infants with CF
have much higher rates of unstimulated sweating than normal infants and are at risk of losing
substantial amounts of sodium and chloride even in the absence of extraneous high temperatures [35].
Up to 80 mEq of sodium and chloride may be lost per day with profuse sweating [36]. Risk factors for
the development of metabolic acidosis and hypoelectrolytemia include early infant age, breast feeding,
delayed CF diagnosis, heat exhaustion, and more severe CFTR mutations. Evidence of salt loss in
extreme weather is limited to case reports and case series and metabolic alkalosis can be the initial
presentation in newly diagnosed children [3740]. Acute salt depletion, especially in high ambient
temperature, may often lead to lethargy, irritation, vomiting, loss of appetite, and dehydration, while
infants with chronic salt depletion may exhibit anorexia and failure to thrive (FTT) [39].
The total daily sodium requirements in normal healthy infants are 5 and 16 mEq for 06 and 712
month olds, respectively [41]. Due to the relatively low salt content of human breast milk and infant
94
formula, and no added salt in commercial baby foods, infants with CF are at risk of receiving
inadequate amounts of salt through their diet [42]. Current CF Consensus guidelines recommend that
infants with CF should be supplemented with 1/8 teaspoon of table salt daily (equivalent to about
12.5 mEq sodium) until 6 months of age and increased to teaspoon daily until one year of age but
not exceeding 4 mEq/kg/day [34, 43]. Additional amounts should be considered in children living in
hot climates, during periods of illness and high environmental temperatures. This is especially
important prior to introduction of complementary feeds. Measuring spoons should be used to dispense
accurate amounts. Sodium chloride solution preparations are available from pharmacies and provide
more accurate measurements.
The salt should be distributed in feeds in small amounts throughout the day to avoid aversion due
to taste. For bottle-fed infants, small amounts of salt should be added to 34 bottles per day until the
total daily amount is distributed. Options to provide the salt to a breast-fed infant include adding it to
the fruit puree used for pancreatic enzyme dosing or adding it to expressed breast milk which is fed in
a bottle. The increased dosing at age 6 months usually corresponds to the initiation of solid food
which is a good vehicle for the additional salt supplementation. Measured salt supplementation can be
discontinued at the end of the rst year of life and when the child is consuming mostly table foods. At
that time, caregivers should be instructed to sprinkle salt on foods several times each day; they should
also be educated on the need for additional salt supplementation during extreme conditions likely to
produce perspiration such as during warm weather conditions, illness, or exercise.
Laboratory Assessment of Micronutrients

Vitamin levels including vitamin A, D, and E should be assessed approximately 2-3 months after
starting vitamin supplementation. Repeat testing is then done yearly and more frequently if adequate
vitamin levels are not achieved with the standard recommended doses. Alongside vitamin levels, a
complete blood count, serum electrolytes, BUN and creatinine, liver enzymes, GGT and albumin,
bilirubin as well as alkaline phosphatase are measured at the initial visit and yearly. More frequent
monitoring is dictated by vitamin levels, the patients clinical status, nutritional status, and assessment
of risk for deciencies [43].
Early Intervention and Long-Term Pulmonary Outcomes
Malnutrition is usually the earliest manifestation in infants with CF [44]. However, widespread
newborn screening for CF has reduced the time until both the diagnosis and nutritional therapies are
implemented. As a result, improvements in nutritional status have been demonstrated over the past
decade. Early treatment with pancreatic enzyme replacement therapy (PERT), fat-soluble vitamin
supplementation, as well as medical nutrition therapy frequently results in improved growth rates in
infants with CF.
Several studies have demonstrated the correlation between improved nutritional status and
pulmonary function as measured by FEV1, progression of lung disease, and survival in CF [4447].
For infants diagnosed early, recovery of birth weight z-score within 2 years of diagnosis of CF [48]
and a higher weight for length (WFL) have been shown to be positively associated with better lung
function status at 6 years [46, 4951]. After the age of 2 years, a higher baseline body mass index
(BMI), weight for age (WFA) maintenance above the 10th percentile and/or a slower rate of decline
in BMI are associated with a slower rate of decline in lung function [50, 52]. Konstan et al. demonstrated
95
in a cohort of 931 patients that nutritional status at 3 years correlated with pulmonary outcomes at
5.57.5 years [50]. A recent study also demonstrated that patients who achieved a WFA percentile
>50% at age 4 years attained a much higher height-for-age (HFA) percentile early in life which was
also associated with fewer pulmonary exacerbations and higher FEV1 [53]. Thus, lung functions at
later ages are variably dependent on nutritional status and growth beyond two years [52, 54, 55].
In 2008, the CFF issued a clinical practice guideline recommending early detection and aggressive
treatment of under-nutrition [56]. The Foundation currently recommends monitoring growth in
children with CF using the WFL measurements on the traditional 2000 Centers for Disease Control
and Prevention (CDC) growth charts for children under the age of two, and thereafter using BMI
percentile for age. The AAP recommends the use of World Health Organization (WHO) growth charts
for measuring infant growth until the age of 24 months. Most electronic medical record (EMR)
systems utilize the WHO growth charts making the use of CDC charts outdated. The 2013 CFF Center
Specic Registry Reports rst used WHO data to report infant outcomes as an initial step towards a
transition away from CDC growth charts.
Based on registry data, better FEV1 status at about 80% predicted or above was associated with
BMI percentiles at the 50th percentile and higher. For children diagnosed before age 2 years, the
Foundation recommends that children reach a weight-for-length status of 50th percentile by age 2
years [57]. For children and adolescents aged 220 years, the CF Foundation recommends that weightfor-stature assessment use the BMI percentile method, and that children and adolescents maintain a
BMI at or above the 50th percentile.
A recent analysis of the CF Registry data demonstrates that WFL at 5570 percentile on the WHO
charts at 2 years resulted in slightly higher FEV1 measurements age 6 than when WFL was less than
the 50th percentile on the WHO growth chart. Infants with WFL below the 50th percentile on the
CDC chart but greater than 50th percentile on the WHO chart had lower FEV1 compared to those
measuring above the 50th percentile on both charts [58]. Regardless of growth chart used, the goal for
infant growth rates is to maximize the WFL ratio to optimize lung function later in life. Nutritional
interventions made earlier in life can result in overall higher growth rates and improved lung function.
Special Considerations
Meconium Ileus
Approximately 1020% of infants with CF present with simple or complex meconium ileus at birth.
These infants require a variety of invasive and noninvasive strategies to decompress the bowel and
relieve the obstruction [5962]. Some infants with simple meconium ileus will respond to hyperosmolar
enemas; however, a recent review suggests decreased effectiveness of the use of contrast enemas
resulting in more surgical interventions [6]. Strategies reported to improve success of non-surgical
interventions include repeated attempts with enemas, radiologist experience, and use of Gastrogran
as the contrast agent. Infants with complex meconium ileus or those who fail to respond to contrast
enemas require a laparotomy with resection and primary anastomosis, enterotomy, and/or stoma
formation [61, 63].
While the operative management for meconium ileus is beyond the scope of this chapter, nutritional
management of newborns with meconium ileus is relevant to all providers. Infants with both simple
and complex meconium ileus may require parenteral nutrition from the time of admission to the
Neonatal Intensive Care Unit until full volume enteral feeds have been reached, bowel function has
normalized, and the infant demonstrates appropriate weight gain.
96
Once the patient shows readiness for enteral feedings, trophic feedings of expressed breast milk or
infant formula can gradually be transitioned to bolus feedings, while monitoring for signs of abdominal
distention, emesis, and/or constipation which may signal intolerance. While no specic guidelines are
available, common practice is to initiate PERT when feeding volumes reach 30 mL per bolus feeding.
Doses of 15003000 units of lipase per feeding are typically used and are increased as enteral feedings
reach the volumes necessary to promote age-appropriate weight gain. Enzymes are usually
administered orally with small amounts of applesauce at the beginning of the feeding. CF-specic
vitamin drops and salt supplementation should be introduced at the time parenteral nutrition is
discontinued.
For infants requiring ostomies, the aim is for closure as soon as possible. Closure times are variable
and range from 3 to 6 weeks with variable times to full enteral nutrition [61, 63].
In spite of the early complications of meconium ileus including the need for surgery, frequent
hospitalizations and earlier acquisition of Pseudomonas aeruginosa infection, long-term outcomes of
lung function have been reported to be similar to infants without meconium ileus [59, 62].
Long-term (1017 years) case-controlled follow-up revealed similar nutritional and pulmonary
outcomes of CF patients presenting with meconium ileus with early-diagnosed symptomatic CF
without meconium ileus [7]. A comparison of infants diagnosed through newborn screening in 2000,
however, showed children born with meconium ileus and who required surgical intervention were
more likely to be shorter and thinner than those who did not require surgery. Abnormal fatty acid
proles were also more prevalent in infants with meconium ileus before the age of 3 years. Daily
intake of calories was generally higher in infants with meconium ileus than babies with CF but without
meconium ileus [8].
Nutritional Requirements and Failure to Thrive

Nutritional and growth monitoring are vital in CF and are part of each clinic visit assessment. Although
most infants with CF have a normal birth weight, it is usually signicantly lower compared to healthy
infants at the initial evaluation [64]. As previously mentioned, the goal of treatment is to achieve
normal growth comparable to healthy infants. For children diagnosed before age 2 years, the CF
Foundation recommends that infants reach a weight-for-length status of 50th percentile by age 2
years. Figure 6.1 shows the expected weight gain and growth velocity for infants of different age
groups based on expected rate of weight gain at the 50th percentile for age [65]. Chapters 2 and 8
discuss in detail nutritional requirements as well as interventions for different age groups.
In certain circumstances, infants may fail to achieve adequate growth and would, therefore, be
deemed to have FTT. Several factors may individually or collectively contribute to impaired nutritional
status including pancreatic insufciency with inadequate PERT, chronic malabsorption, recurrent
sinopulmonary infections, chronic inammation, increased metabolic needs, and energy expenditure
as well as suboptimal intake. Poor appetite from chronic or recurrent infections may suppress adequate
intake and contribute to malnutrition. Nutritional assessment should be performed at diagnosis and at
each clinic visit and growth carefully monitored with early aggressive intervention. Infants not
meeting the expected growth should be evaluated for causes for poor weight gain as documented in
the algorithm in Table 6.1 in no particular order. Energy needs should be tailored to individual patient
needs with most pancreatic insufcient infants requiring up to 150% of the dietary reference values
for age [66]. Estimating energy needs based on ideal WFL rather than actual weight will establish
energy goals to result in catch-up weight gain. For children unable to increase their calorie intake
through volume, increased caloric density up to 30 cal/oz (100 cal/100 mL) should be considered.
Infant formulas can be fortied to increase the caloric density by revising the ratio of formula and
water and/or the addition of glucose polymers and/or medium chain triglyceride oil. Multiple studies
97
have demonstrated that higher energy intake resulted in improved weight gain. Many infants
demonstrate catch-up growth with initiation of appropriate nutritional intervention [67].
Additional considerations to address FTT in infancy include introducing the concept of enteral
tube feelings as a component of CF care. Gastrostomy tube placement should be considered early for
children not gaining adequate weight in spite of adequate or suboptimal intake due to a suppressed
appetite. Gastrostomy tube feeding will provide extra calories to compensate for the high energy
expenditure [68]. It has been established that supplemental gastrostomy tube feedings result in
improvement in nutritional status and stabilization of the pulmonary function [6971]. Despite the
nutritional advantages, parents are often reluctant and fearful about feeding tube placement. Thorough
education, emotional support, and involvement of sub-specialists such as pediatric gastroenterologists
may help parents cope with these difcult decisions.
For families unable to provide adequate nutrition due to nancial constraints, referral to communitybased programs such as Supplemental Nutrition Assistance Program (SNAP) and Women, Infants and
Children (WIC) should be made early. The CF team social worker can be a valuable resource for
families dealing with an infant with FTT and should be involved with the family early. Collaborative
follow-up care with the pediatrician, public health nurse, or home health care nurse can also allow the
CF team to closely monitor the infant when travel to the CF center is cost or time prohibited for
frequent weight checks and assessments that are necessary for an infant with FTT. Children with poor
weight gain and FTT should be seen in follow-up at 26 week intervals and often shorter intervals for
younger infants.
Appetite supplements are not usually prescribed for infants, but older toddlers and preschoolers
with a suppressed intake may benet from appetite supplements. Some appetite stimulants have been
used and shown to be effective in children and adults in improving enteral intake and ultimately
weight gain [7274].
Several nutrition strategies can be put into place to maximize the calorie content of foods and
liquids consumed in the rst 2 years of life. First and foremost, parents should be taught early on that
their childs need for high calorie diets begins in infancy and will likely continue throughout his/her
lifetime. Education regarding label reading, consistent practices of adding fats to foods, and high
calorie beverages will allow the family to maximize the caloric intake of the infants diet and maximize
weight gain.
Due to the simple nature of complementary foods in the infants early diet, the addition of vegetable
oils or softened butter or margarine is common practice to optimize calories in these foods. As the
childs diet progresses to more nger foods and a wider variety of foods, including more calorie-dense
foods becomes easier to incorporate, but still requires intent on the part of the parents to include them
in the childs diet. As the child weans from breast milk or formula around the rst birthday, whole
milk, whole milk with added whipping cream, or commercially available pediatric nutrition beverages
can continue provide a high energy source from beverages to the toddler with CF. Table 6.1 offers
suggestions and strategies for increasing the calorie content of the diet in the rst 2 years of life.
Conclusion
Nourishing the infant newly diagnosed with CF through the rst 2 years of life requires a team
approach with frequent assessments to assure optimal growth and provision of medical nutrition
therapy, PERT, vitamin, and mineral supplementation. The CF Foundation Consensus Guidelines
provide recommendations to enhance the care of these high-risk infants. Care teams should carefully
implement these guidelines while at the same time provide support and education to the caregivers.
Newborn screening for CF allows care teams to provide early and aggressive nutrition support to the
infant which is essential to the long-term health of the individual with CF.
98
References
1. Cystic Fibrosis F, Borowitz D, Robinson KA, Rosenfeld M, Davis SD, Sabadosa KA, et al. Cystic Fibrosis
Foundation evidence-based guidelines for management of infants with cystic brosis. J Pediatr. 2009;155(6 Suppl):
S7393.
2. Duijts L, Jaddoe VW, Hofman A, Moll HA. Prolonged and exclusive breastfeeding reduces the risk of infectious
diseases in infancy. Pediatrics. 2010;126(1):e1825. Epub 2010/06/23.
3. Quigley MA, Kelly YJ, Sacker A. Breastfeeding and hospitalization for diarrheal and respiratory infection in the
United Kingdom Millennium Cohort Study. Pediatrics. 2007;119(4):e83742. Epub 2007/04/04.
4. Hauck FR, Thompson JM, Tanabe KO, Moon RY, Vennemann MM. Breastfeeding and reduced risk of sudden
infant death syndrome: a meta-analysis. Pediatrics. 2011;128(1):10310. Epub 2011/06/15.
5. Greer FR, Sicherer SH, Burks AW. Effects of early nutritional interventions on the development of atopic disease
in infants and children: the role of maternal dietary restriction, breastfeeding, timing of introduction of
complementary foods, and hydrolyzed formulas. Pediatrics. 2008;121(1):18391. Epub 2008/01/02.
6. Thygarajan A, Burks AW. American Academy of Pediatrics recommendations on the effects of early nutritional
interventions on the development of atopic disease. Curr Opin Pediatr. 2008;20(6):698702. Epub 2008/11/14.
7. Colombo C, Costantini D, Zazzeron L, Faelli N, Russo MC, Ghisleni D, et al. Benets of breastfeeding in cystic
brosis: a single-centre follow-up survey. Acta Paediatr. 2007;96(8):122832. Epub 2007/06/26.
8. Tluczek A, Clark R, McKechnie AC, Orland KM, Brown RL. Task-oriented and bottle feeding adversely affect the
quality of mother-infant interactions after abnormal newborn screens. J Dev Behav Pediatr. 2010;31(5):41426.
Epub 2010/05/25.
9. Parker EM, OSullivan BP, Shea JC, Regan MM, Freedman SD. Survey of breast-feeding practices and outcomes
in the cystic brosis population. Pediatr Pulmonol. 2004;37(4):3627. Epub 2004/03/17.
10. Jadin SA, Wu GS, Zhang Z, Shoff SM, Tippets BM, Farrell PM, et al. Growth and pulmonary outcomes during the
rst 2 y of life of breastfed and formula-fed infants diagnosed with cystic brosis through the Wisconsin Routine
Newborn Screening Program. Am J Clin Nutr. 2011;93(5):103847. Epub 2011/03/25.
11. Huebner J, Oldroyd HBL, Andrade O, Horn B, Laxova A, Greer F, Lai HJ. Breastfeeding characteristics during the
rst six months of life in infants with CF diagnosed through newborn Screening in 201213. Pediatr Pulmonol.
2014;49(Supp 38):406.
12. Prevention CfDCa. Breastfeeding Report Card 2014. 2014.
13. Erskine JM, Lingard CD, Sontag MK, Accurso FJ. Enteral nutrition for patients with cystic brosis: comparison of
a semi-elemental and nonelemental formula. J Pediatr. 1998;132(2):2659. Epub 1998/03/20.
14. Ellis L, Kalnins D, Corey M, Brennan J, Pencharz P, Durie P. Do infants with cystic brosis need a protein
hydrolysate formula? A prospective, randomized, comparative study. J Pediatr. 1998;132(2):2706. Epub
1998/03/20.
15. Borowitz D. Update on the evaluation of pancreatic exocrine status in cystic brosis. Curr Opin Pulm Med.
2005;11(6):5247. Epub 2005/10/12.
growth, and nutrition in infants identied by newborn screening as having cystic brosis. J Pediatr. 1992;120(4 Pt
1):53340. Epub 1992/04/01.
17. Walkowiak J, Sands D, Nowakowska A, Piotrowski R, Zybert K, Herzig KH, et al. Early decline of pancreatic
function in cystic brosis patients with class 1 or 2 CFTR mutations. J Pediatr Gastroenterol Nutr. 2005;40(2):199
201. Epub 2005/02/09.
18. Borowitz DS, Grand RJ, Durie PR. Use of pancreatic enzyme supplements for patients with cystic brosis in the
context of brosing colonopathy. Consensus Committee. J Pediatr. 1995;127(5):6814. Epub 1995/11/01.
19. Schwarzenberg SJ, Wielinski CL, Shamieh I, Carpenter BL, Jessurun J, Weisdorf SA, et al. Cystic brosisassociated colitis and brosing colonopathy. J Pediatr. 1995;127(4):56570. Epub 1995/10/01.
20. FitzSimmons SC, Burkhart GA, Borowitz D, Grand RJ, Hammerstrom T, Durie PR, et al. High-dose pancreaticenzyme supplements and brosing colonopathy in children with cystic brosis. N Engl J Med. 1997;336(18):1283
9. Epub 1997/05/01.
21. Borowitz D, Gelfond D, Maguiness K, Heubi JE, Ramsey B. Maximal daily dose of pancreatic enzyme replacement
therapy in infants with cystic brosis: a reconsideration. J Cyst Fibros. 2013;12(6):7845. Epub 2013/07/03.
22. Schechter M, Michel SH, Haupt M, Seo B, Khurmi R, Liu S, Kapoor M. Relationship of initial pancreatic enzyme
replacement therapy dose and growth in young children with cystic brosis. Pediatr Pulmonol. 2014;49(Supp
38):420.
23. Feranchak AP, Sontag MK, Wagener JS, Hammond KB, Accurso FJ, Sokol RJ. Prospective, long-term study of
fat-soluble vitamin status in children with cystic brosis identied by newborn screen. J Pediatr. 1999;135(5):601
10. Epub 1999/11/05.
24. Rovner AJ, Stallings VA, Schall JI, Leonard MB, Zemel BS. Vitamin D insufciency in children, adolescents, and
young adults with cystic brosis despite routine oral supplementation. Am J Clin Nutr. 2007;86(6):16949.
99
25. Drury D, Grey VL, Ferland G, Gundberg C, Lands LC. Efcacy of high dose phylloquinone in correcting vitamin
K deciency in cystic brosis. J Cyst Fibros. 2008;7(5):4579.
26. Neville LA, Ranganathan SC. Vitamin D in infants with cystic brosis diagnosed by newborn screening. J Paediatr
Child Health. 2009;45(12):3641.
27. Bines JE, Truby HD, Armstrong DS, Carzino R, Grimwood K. Vitamin A and E deciency and lung disease in
infants with cystic brosis. J Paediatr Child Health. 2005;41(12):6638.
cystic brosis associated with early diagnosis and intervention. Am J Clin Nutr. 1991;54(3):57885. Epub
1991/09/01.
29. Rayner RJ, Tyrrell JC, Hiller EJ, Marenah C, Neugebauer MA, Vernon SA, et al. Night blindness and conjunctival
xerosis caused by vitamin A deciency in patients with cystic brosis. Arch Dis Child. 1989;64(8):11516.
30. Sitrin MD, Lieberman F, Jensen WE, Noronha A, Milburn C, Addington W. Vitamin E deciency and neurologic
disease in adults with cystic brosis. Ann Intern Med. 1987;107(1):514.
31. Lozoff B, De Andraca I, Castillo M, Smith JB, Walter T, Pino P. Behavioral and developmental effects of preventing
iron-deciency anemia in healthy full-term infants. Pediatrics. 2003;112(4):84654.
32. Logan S, Martins S, Gilbert R. Iron therapy for improving psychomotor development and cognitive function in
children under the age of three with iron deciency anaemia. Cochrane Database Syst Rev. 2001;2, CD001444.
33. Baker RD, Greer FR. Committee on Nutrition American Academy of P. Diagnosis and prevention of iron deciency
and iron-deciency anemia in infants and young children (03 years of age). Pediatrics. 2010;126(5):104050.
35. Sibinga MS, Barbero GJ. Studies in the physiology of sweating in cystic brosis. II. Elevated night sweating rates.
Arch Dis Child. 1961;36:5379. Epub 1961/10/01.
36. Gottlieb RP. Metabolic alkalosis in cystic brosis. J Pediatr. 1971;79(6):9306. Epub 1971/12/01.
37. Ballestero Y, Hernandez MI, Rojo P, Manzanares J, Nebreda V, Carbajosa H, et al. Hyponatremic dehydration as a
presentation of cystic brosis. Pediatr Emerg Care. 2006;22(11):7257. Epub 2006/11/18.
38. Laughlin JJ, Brady MS, Eigen H. Changing feeding trends as a cause of electrolyte depletion in infants with cystic
brosis. Pediatrics. 1981;68(2):2037. Epub 1981/08/01.
39. Fustik S, Pop-Jordanova N, Slaveska N, Koceva S, Efremov G. Metabolic alkalosis with hypoelectrolytemia in
infants with cystic brosis. Pediatr Int. 2002;44(3):28992. Epub 2002/05/02.
40. Beckerman RC, Taussig LM. Hypoelectrolytemia and metabolic alkalosis in infants with cystic brosis. Pediatrics.
1979;63(4):5803. Epub 1979/04/01.
41. National Research Council. Dietary Reference Intakes for Water, Potassium, Sodium, Chloride, and Sulfate.
Washington, DC: The National Academies Press, 2005.
42. Coates AJ, Crofton PM, Marshall T. Evaluation of salt supplementation in CF infants. J Cyst Fibros. 2009;8(6):
3825. Epub 2009/10/06.
43. Cystic Fibrosis F, Borowitz D, Parad RB, Sharp JK, Sabadosa KA, Robinson KA, et al. Cystic Fibrosis Foundation
practice guidelines for the management of infants with cystic brosis transmembrane conductance regulator-related
metabolic syndrome during the rst two years of life and beyond. J Pediatr. 2009;155(6 Suppl):S10616.
44. Matel JL, Milla CE. Nutrition in cystic brosis. Semin Respir Crit Care Med. 2009;30(5):57986.
45. Kraemer R, Rudeberg A, Hadorn B, Rossi E. Relative underweight in cystic brosis and its prognostic value. Acta
Paediatr Scand. 1978;67(1):337.
46. Hankard R, Munck A, Navarro J. Nutrition and growth in cystic brosis. Horm Res. 2002;58 Suppl 1:1620.
47. Rosenfeld M, Davis R, FitzSimmons S, Pepe M, Ramsey B. Gender gap in cystic brosis mortality. Am J Epidemiol.
1997;145(9):794803.
48. Lai HJ, Shoff SM, Farrell PM. Recovery of birth weight z score within 2 years of diagnosis is positively associated
with pulmonary status at 6 years of age in children with cystic brosis. Pediatrics. 2009;123(2):71422.
49. Rosenfeld M, Casey S, Pepe M, Ramsey BW. Nutritional effects of long-term gastrostomy feedings in children with
cystic brosis. J Am Diet Assoc. 1999;99(2):1914.
51. Steinkamp G, Wiedemann B. Relationship between nutritional status and lung function in cystic brosis: cross
sectional and longitudinal analyses from the German CF quality assurance (CFQA) project. Thorax. 2002;57(7):
596601.
52. McPhail GL, Acton JD, Fenchel MC, Amin RS, Seid M. Improvements in lung function outcomes in children with
cystic brosis are associated with better nutrition, fewer chronic pseudomonas aeruginosa infections, and dornase
alfa use. J Pediatr. 2008;153(6):7527.
outcomes and survival in patients with cystic brosis. J Pediatr. 2013;162(3):5305.
100
55. Walkowiak J, Przyslawski J. Five-year prospective analysis of dietary intake and clinical status in malnourished
cystic brosis patients. J Hum Nutr Diet. 2003;16(4):22531.
systematic review. J Am Diet Assoc. 2008;108(5):8329.
58. Machogu E, Cao Y, Miller T, Simpson P, Levy H, Quintero D, Goday PS. Comparison of the WHO and CDC
growth charts in predicting pulmonary outcomes in cystic brosis. JPGN. doi:10.1097/MPG.0000000000000610.
59. Kappler M, Feilcke M, Schroter C, Kraxner A, Griese M. Long-term pulmonary outcome after meconium ileus in
cystic brosis. Pediatr Pulmonol. 2009;44(12):12016. Epub 2009/11/17.
60. Gorter RR, Karimi A, Sleeboom C, Kneepkens CM, Heij HA. Clinical and genetic characteristics of meconium
ileus in newborns with and without cystic brosis. J Pediatr Gastroenterol Nutr. 2010;50(5):56972. Epub
2010/04/14.
61. Farrelly PJ, Charlesworth C, Lee S, Southern KW, Baillie CT. Gastrointestinal surgery in cystic brosis: a 20-year
review. J Pediatr Surg. 2014;49(2):2803. Epub 2014/02/18.
62. Carlyle BE, Borowitz DS, Glick PL. A review of pathophysiology and management of fetuses and neonates with
meconium ileus for the pediatric surgeon. J Pediatr Surg. 2012;47(4):77281. Epub 2012/04/14.
63. Escobar MA, Grosfeld JL, Burdick JJ, Powell RL, Jay CL, Wait AD, et al. Surgical considerations in cystic brosis:
a 32-year evaluation of outcomes. Surgery. 2005;138(4):56071. discussion 712. Epub 2005/11/05.
64. Farrell PM, Kosorok MR, Laxova A, Shen G, Koscik RE, Bruns WT, et al. Nutritional benets of neonatal screening
for cystic brosis. Wisconsin Cystic Fibrosis Neonatal Screening Study Group. N Engl J Med.
1997;337(14):9639.
65. Guo SM, Roche AF, Fomon SJ, Nelson SE, Chumlea WC, Rogers RR, et al. Reference data on gains in weight and
length during the rst two years of life. J Pediatr. 1991;119(3):35562. Epub 1991/09/01.
66. Davies PS. Energy requirements for growth and development in infancy. Am J Clin Nutr. 1998;68(4):939S43.
Epub 1998/10/15.
67. Pederzini F, DOrazio C, Tamiazzo G, Faraguna D, Giglio L, Mastella G. Growth evaluation at one year of life in
infants with cystic brosis diagnosed by neonatal screening. Pediatr Pulmonol Suppl. 1991;7:648.
68. Marin VB, Velandia S, Hunter B, Gattas V, Fielbaum O, Herrera O, et al. Energy expenditure, nutrition status, and
body composition in children with cystic brosis. Nutrition. 2004;20(2):1816.
69. Williams SG, Ashworth F, McAlweenie A, Poole S, Hodson ME, Westaby D. Percutaneous endoscopic gastrostomy
feeding in patients with cystic brosis. Gut. 1999;44(1):8790.
70. Bradley GM, Carson KA, Leonard AR, Mogayzel Jr PJ, Oliva-Hemker M. Nutritional outcomes following
gastrostomy in children with cystic brosis. Pediatr Pulmonol. 2012;47(8):7438.
71. Best C, Brearley A, Gaillard P, Regelmann W, Billings J, Dunitz J, et al. A pre-post retrospective study of patients
with cystic brosis and gastrostomy tubes. J Pediatr Gastroenterol Nutr. 2011;53(4):4538.
72. Homnick DN, Marks JH, Hare KL, Bonnema SK. Long-term trial of cyproheptadine as an appetite stimulant in
cystic brosis. Pediatr Pulmonol. 2005;40(3):2516.
73. Homnick DN, Homnick BD, Reeves AJ, Marks JH, Pimentel RS, Bonnema SK. Cyproheptadine is an effective
appetite stimulant in cystic brosis. Pediatr Pulmonol. 2004;38(2):12934.
74. Epifanio M, Marostica PC, Mattiello R, Feix L, Nejedlo R, Fischer GB, et al. A randomized, double-blind, placebocontrolled trial of cyproheptadine for appetite stimulation in cystic brosis. J Pediatr (Rio J). 2012;88(2):15560.
Chapter 7
Nutritional Assessment: Age 220 Years

KarenMaguiness andMollyBozic
Key Points
An accurate nutritional assessment for the 2 to 20-year-old child with cystic fibrosis is essential.
Anthropometric measures, biochemical data, clinical evaluation, and diet history comprise the
nutritional assessment for the 2- to 20-year-old child with cystic fibrosis.
Related diseases (such as CF liver disease, CF-related diabetes), stool and gastrointestinal history,
vitamin/mineral history, and pancreatic enzyme replacement history should also be obtained in the
nutritional assessment of the 2- to 20-year-old child with cystic fibrosis.
Short- and long-term weight goals should be established for the 2- to 20-year-old child with cystic
fibrosis. Standard yearly labs should be obtained for the 2- to 20-year-old child with cystic fibrosis
with additional labs obtained as indicated by the patients individual medical condition.
Keywords Nutritional assessment Anthropometric data Biochemical Clinical assessment Diet
history Vitamin history Stool history
Introduction
A thorough and comprehensive nutritional assessment performed by the combined efforts of a dietitian
and physician is essential for the management of the child with cystic fibrosis (CF). The primary
purpose of a nutritional assessment in CF is to evaluate diet, clinical status, growth velocity, and body
measurements while concomitantly monitoring the additional therapy required as a result of having
CF (e.g. pancreatic enzyme replacement and fat-soluble vitamin therapy). Based on these evaluations,
K. Maguiness, M.S., R.D., C.S.P.

Pediatric Pulmonology, Riley Hospital for Children,
ROC Room 4270, 705 Riley Hospital Drive, Indianapolis, IN 46202, USA
M. Bozic, M.D. (*)
Pediatric Gastroenterology, Riley Hospital for Children,
ROC Room 4210, 705 Riley Hospital Drive, Indianapolis, IN 46202, USA
DOI10.1007/978-3-319-16387-1_7, Springer International Publishing Switzerland 2015
101
102
K. Maguiness andM.Bozic
one can assess if the current nutrition regimen is adequate, or if intervention or modification is
required. Properly assessing and interpreting the nutritional status of patients with CF requires skill,
experience, and knowledge of the latest standards of care, clinical guidelines, and evidence-based
research. This chapter will detail what should be performed as part of a clinic nutrition evaluation for
individuals with CF who are 220 years of age.
The primary nutritional goal for a child with cystic fibrosis is the same as a child who does not
have CF; to be well-nourished! Without a doubt, children with CF present distinct challenges
regarding attaining and maintaining optimal nutrition. Food jags, maldigestion with resultant
malabsorption secondary to pancreatic insufficiency; intestinal resection due to meconium ileus,
poorly controlled CF-related diabetes, and impaired bile flow in cases of severe CF-related liver
disease all present potential unique nutritional challenges [1]. Recurrent pulmonary infections and
increased oxidative stress, fevers, and increased metabolic rates also further complicate nutritional
optimization [2].
Setting accurate and attainable nutritional goals is important in cystic fibrosis. The Cystic
Fibrosis Foundation (CFF) recommends a BMI of 50th percentile for 2- to 20-year-olds [3], as
this is associated with better pulmonary status as measured by FEV1. Additionally, a weight for
age of >10th percentile by age 4 years is associated with improved short- and long-term
pulmonary outcomes [4]. Families and patients with CF typically want to know where they
are and where they should be at in terms of their nutritional status. Nutrition goals may be
short term and simple: such as daily calorie goals or monthly weight gain goals, or long term:
such as an eventual weight goal based on either a previous weight for age percentile or on a
weight that corresponds with a BMI of 50th percentile.
Once nutrition goals are established, frequent and routine monitoring are necessary. The most
effective way to use growth charts diagnostically is through serial measurements [2]. The CFF
mandates that patients be seen in clinic every 3 months [1]; more often if indicated. The availability
of these frequent body measurements provides a certain luxury for dietitians and physicians; it allows
for close monitoring of nutritional status in a timely manner and permits early detection and
intervention when decline in nutritional status is noted. When performing a thorough and comprehensive
nutritional assessment in a child with CF, the following sentence with abbreviations may be of help:
Remember ABC&D and dont forget to RSVP (Tables7.1 and 7.2).
Anthropometric Data
A reliable nutritional assessment requires that the health professionals who obtain the body
measurements have been properly trained and that the measuring equipment being used is appropriate
and correctly calibrated [2]. A clinic serving those with CF can have the latest, state-of-the-art
devices to measure weights and heights; however, if the individual obtaining these measures does so
incorrectly (for example, does not ask patients to take off their shoes, or carelessly obtains these
measures), not only will the weight and height measurements be incorrect, but there will also be a
ripple effect leading to incorrect body mass index (BMI) calculation as well as incorrect estimation
of rates of growth between clinic visits. In addition to relying on accurate measurements, members
of the CF team who evaluate the weights and heights need to use the appropriate resources and
possess the skill set to accurately interpret the data to make recommendations in the context of CF.If
any of these components are lacking, the quality of the nutritional assessment is diminished.
Comparison of an individual to an established norm provides the basis for objective recommendations
and evaluation of nutritional care [5].
7 Nutritional Assessment: Age 220 Years
103
Table 7.1 Nutritional assessment of the patient with CF A, B, C, D Nutrition Evaluation

ABC&D evaluation
AAnthropometric
BBiochemical
CClinical evaluation
DDiet history
Weight (kg and NCHS percentile)

Height (cm and NCHS percentile)
Body mass index (percentile and kg/m2)
Goal weight (kg) Goal Weight (weight at which BMI would be equivalent to the
50th %tile)
Previous weight (kg)
Rate of weight gain in grams/day (or % weight loss)
Mid-arm circumference, skinfold measurements
Fat-soluble vitamin levels:
Aserum plasma retinol
D25-OH vitamin D
Ealpha tocopherol
KPIVKA-II (preferred) or PT/INR
Othersee biochemical section
Evaluation of clinical status: skin, nails, face, neck, mouth, tongue, eyes, hair,
teeth, and abdomen
Diet recall, food records, food frequency
Specific interventions to increase calories
Oral nutrition supplement history
Enteral feeding history
Any nutritional issues such as skipping meals, slow eating, food refusal, texture
aversion, binge eating, fad diets
A Anthropometric Data
B Biochemical Data
C Clinical Assessment
D Diet History
Weight, Height, andBody Mass Index

Gathering anthropometric data including weight, height, and BMI and plotting each on appropriate
growth curves should be performed at every clinic visit. The American Academy of Pediatrics (AAP)
[6] and the CFF [1] both recommend use of the Center for Disease Control (CDC) 2000 National
Center for Health Statistics growth charts for plotting weight, height, and BMI of the 2 to 20-year-old.
These may be found online at http://www.cdc.gov/growthcharts/.
Accurate Measurement ofWeight

Scales should be regularly calibrated and checked for accuracy. The clinic scale(s) should be kept in
an area that is protected, thus, decreasing the potential for it to be treated in a rough manner which
could lead to poor calibration and thus inaccurate weights. Children should be weighed in light
clothing or an exam gown, with shoes removed [2]. For toddlers or preschoolers not yet potty trained,
a clean and dry diaper may be worn. The best weight and height measurements are done when a child
is calm and willing to cooperate. The scale should be zeroed prior to the child standing on it. Once
zeroed, the patient should be instructed to stand in the middle of the scale platform until an accurate
reading has been obtained. Weight measurements should be made to the nearest 0.1kg [7]. Prior to
obtaining a patients weight, it is helpful to review previous measurements to ensure that the new
weight aligns with previous weights.
104
Table 7.2 Nutritional assessment of the patient with CF (RSVP)
RSVP Nutrition evaluation
RRelated Disease/Illness/Genetics/Previous
Medical history
SStool/GI history
VVitamin history
PPancreatic enzymes
Possible impact on nutrition from:

CF related diabetes
CF liver disease
Degree of pulmonary involvement
Presence of infection
Genetic mutations
Intestinal resection
Other
Number of stools/day
Color of stools
Consistency of stools
Caliber of stools
Visible oil or mucous in stools
Significant foul (ripe) smell to stools
Floating stools
Gassiness
Stomach pain
Stomach distention
Constipation
Use of H2 blocker or PPI
Use of polyethylene glycol/fiber/stool softener
Name/form/dose of multivitamin(s)
(liquid/gummy/chewable/gel cap)
Name/form/dose fat-soluble vitamins(A, D, E, K)
Use of non-prescribed vitamins or supplements
Any financial difficulties affording vitamin(s)?
Frequency of administration
Name and strength of enzyme
Number of enzymes/meal and snack
Number of enzymes with glass of milk or supplement
Number of enzymes with before/after tube feedings
Total number or enzymes taken in 24Hours
Lipase units/kg/meal and Lipase units/kg/day
Any nutrition issues with eating or taking enzymes at school,
daycare, and so forth.
Related illnesses history

Stool history
Vitamin and mineral history
Pancreatic enzyme replacement history
Accurate Measurement ofHeight

The words height or stature imply a linear measurement obtained when a child is standing, as
opposed to length, which indicates a measurement when a child is in a recumbent or lying down.
All children 2 years and older should be measured in a standing position [2].
The use of the sliding measuring devices commonly attached to standing scales is not recommended
for measurement of height as they do not consistently yield an accurate measurement. A wall mounted
stadiometer is the most precise instrument to measure height. A stadiometer has a moveable headboard
positioned at a 90 angle to a wall mounted fixed incremental linear measurement readout [7]. The
child should be in bare feet or thin socks and with removal of any hair adornment that would affect
height. The best height measurements are done when the child is calm and willing to cooperate. The
patient should be instructed to stand with his or her back, bottom, and shoulders against the wall, hands
105
at their side, feet flat on the floor with heels close together, head and chin level and with eyes looking
forward, and standing as tall as possible (with heels still flat on the ground) [2]. Asking the patient to
take a deep breath and hold it prior to the measurement assists them in standing tall. The sliding
headboard is then gently positioned atop of the childs head, with the height measurement made to the
nearest 0.1cm [7]. It is good practice to review previous height measurements prior to obtaining a new
one to ensure that the updated measurement corresponds with previous measurements.
Weight forAge andHeight forAge Percentiles

Weight and height for age percentiles may be plotted by hand on a growth chart, or by using a reliable
computerized program or smart device app. If plotting by hand, it is essential that the patients age be
accurately calculated (in years, months, and days) such that both the weight and the height percentiles
may be precisely plotted. If plotting by hand, the use of a page-size clear sturdy plastic template, with
perfectly centered edge-to-edge horizontal and vertical lines, and a small hole at their intersection in
the center can be a useful tool for accurate plotting.
Growth charts provide a useful visual depiction of weights and heights over time and allow one to
easily monitor trends. It may be beneficial for the clinician to place noteworthy landmarks on
growth charts, for example, when a gastrostomy tube was placed or removed. Where one is versus
where one should be on a growth chart requires discernment for the patient with CF.Of primary
importance is that children attain and maintain their highest potential for weight and height for age
and that any downward trending to a lower percentile be identified in a timely manner with appropriate
intervention.
A weight for age of >10th percentile by 4 years of age is associated with improved short- and
long-term pulmonary outcomes in CF [4]; thus, it should be of paramount importance to strive for
this in the preschool years. Consideration of mid-parental height may be used when evaluating the
height percentile of the child [1] and [8]. Mid-parental height may be calculated using the following
equation [9]:

Boys : Parental height + ( maternal height + 5 in. or 13 cm ) / 2
Girls : Maternal height + ( paternal height + 5 in. or13cm ) / 2
When calculating mid-parental height, an actual measurement of each parent, using a stadiometer,
will yield much more reliable results than a verbal report or estimate of the parents height.
Weight age equivalent is a term that can also provide descriptive information for patients who are
underweight. This may be defined as the age at which the patients present weight plots at the 50th
percentile on a growth chart. For example, if an 18-year-old male weighs just 43kg, he is the weight
age equivalent of a 12.5-year-old male. A height age equivalent may be similarly calculated.
Calculation ofBMI
Calculating BMI is straightforward; the accuracy of the BMI depends upon the precision of the weight
and height measurements inputted into the BMI equation. BMI may be reported as kg/m2 as well as
in percentiles for those aged 2-20 years, and should be plotted on the 2000 CDC BMI growth charts
(Table7.3) [7].
106
Table 7.3 Calculating BMI (kg/m2)
Weight ( kg )
Height ( m )
( Centimeters divided by100 = meters )
OR
Weight ( pounds )
703
2
Height ( in )
An inaccurate height measurement is more likely to occur than an inaccurate weight measurement
due to the nature of how these two measurements are obtained. An accurate weight essentially requires
only a properly calibrated scale and the patient standing still on the scale platform. A precise height,
however, necessitates a cooperative patient who is properly positioned and aligned (feet, legs, back,
shoulders, and head), as well as the health care professional who is obtaining this measure to carefully
position the headboard and to view the measurement readout at eye level. Because weight goals,
nutritional classification, and registry data are often based on BMI percentiles, accurate heights are
especially important in CF.If in doubt, re-measure the patients height.
Calculating Short- andLong-Term Goal Weights

For patients who are underweight, it is often helpful to mutually establish feasible, and achievable,
weight goals so that interim progress may be acknowledged and celebrated. For patients in need of a
substantial amount of catch-up weight gain, it may be useful to set in between or incremental
weight goals equivalent to a BMI at, for example, the 10th and 25th percentiles. Setting an immediate
weight goal for a BMI at the 50th percentile that is too discrepant from the present weight can seem
unattainable and be disheartening to the patient and their family.
Calculating Percent ofGoal Weight

Percent of goal weight may simply be calculated by dividing actual weight by goal weight and
multiplying by 100.
Calculating Rate ofWeight Gain or Growth Velocity

Rate of weight gain may be easily calculated by dividing the number of grams of weight the patient
gained by the number of days between visits (Tables7.4 and 7.5).
Mid-Upper Arm Circumference

Mid-upper arm circumference is another measure that may be used to evaluate nutritional status by
measuring soft tissue. Using a marker and a non-stretchable tape measurer (metallic tape or insert
tape), the midpoint on the right upper arm is marked half way between the acromion process (bony
protrusion on the upper shoulder) and the olecranon process (tip of the elbow) [7]. The marking of the
arm should occur with the elbow bent at a 90 angle. The measurement of the mid-arm circumference
107
Table 7.4 Example of calculating rate of weight gain between visits

Age: 11 years 6 months
Sex: Male
Todays date: July 13th
Todays weight: 38.2kg
Date of last clinic visit: April 20th
Weight on April 20th: 37.0kg
Number of days between April 20th and July 13th:
10 days (remaining in April)+31 days (May)+30 days (June)+13 days
(July 13)=84 days
Amount of weight gain:
38.237.0kg=1.2kg1000g/kg=1200g in 84 days
Divide 1200g by 84 days=13.7g/day
Table 7.5 Expected rate of rate gain (g/day) for Age
(50th to 97th percentile rate of gain)
Age range (years)
Male
Female
23
4.76.7
5.28.2
34
5.28.1
5.39.0
45
5.99.5
5.910.0
56
6.310.4
6.310.9
67
6.511.7
6.912.2
78
7.113.4
7.914.2
89
8.015.5
9.416.6
910
9.317.4
10.718.8
1011
10.918.8
11.920.0
1112
12.619.3
12.219.7
1213
14.119.1
11.417.7
1314
14.818.3
9.514.6
1415
14.417.2
7.210.8
1516
12.615.7
5.07.4
1617
9.913.2
3.44.9
1718
7.19.5
2.93.5
1819
5.25.3
2.73.1
1920
3.84.4
1.72.4
Reference: Please note that higher rates of weight gain
than those listed in this reference chart may be indicated
for those children requiring catch up weight gain. NCHS
2000 growth charts
should be done with the arm hanging relaxed at the side with fingertips facing the ground. The tape
measure should be snug, but not so tight as to compress the skin around the arm to the extent that an
indentation is made. Standards for values based on age are well documented [7].
Skinfold Measurements
Tricep and subscapular skinfold measurements may also be used to evaluate nutritional status in cystic
fibrosis. To be done accurately, proper equipment and training is required (e.g. correct measuring tape
and accurate calipers). Specific knowledge of appropriate body landmarks, precise application of
calipers, and knowledge of normative values is essential [7]. Serial measures of skinfold measurements
are needed to document depletion or repletion of fat stores.
108
Biochemical Data
Anthropometric data is only one aspect of the nutritional evaluation. Laboratory data is an essential
aspect of determining nutritional status in the cystic fibrosis patient. The following provides guidelines
for measurement of laboratory data.
Standard Yearly Labs

Standard yearly labs are recommended in all patients with cystic fibrosis (see Table 7.6). Current
guidelines recommend yearly evaluation of fat-soluble vitamins including Vitamin D (25-OH Vitamin
D), Vitamin A (retinol), Vitamin E (alpha-tocopherol), and Vitamin K (prothrombin time (PT)/
International Normalized Ratio (INR) [3]. For those patients with severe CF-related liver disease,
PIVKA-II (protein induced by vitamin K absence-II) may be helpful to determine Vitamin K stores.
It is not uncommon for patients with cystic fibrosis, and especially those with CF-related liver disease,
to require large amounts of fat-soluble vitamin supplementation [10]. Yearly measurements of
complete blood counts (CBC) allow for monitoring of anemia which may be secondary to iron
deficiency, low hemoglobin, low hematocrit, low MCV (mean corpuscular volume) or overt blood
loss; e.g. from bleeding esophageal/rectal varices in the cirrhotic CF patient or mucosal blood loss,
e.g., in the CF patient with Crohns disease. High MCV in the context of anemia may be indicative of
a Vitamin B12 deficiency. Yearly comprehensive metabolic profiles allow for evaluation of protein
stores (albumin) and screening for potential CF-related liver disease (abnormal alanine aminotransferase
test (ALT), aspartate aminotransferase test (AST), and bilirubin), which may place them at further risk
for nutritional deficiencies.
There are unique circumstances for some patients with cystic fibrosis which require additional
laboratory evaluation.
Table 7.6 Standard Yearly lab evaluation recommended in all patients with cystic fibrosis
Measurement
Comprehensive
metabolic profile
What to order
CMP
Complete blood count

with differential
CBC with differential
Gamma glutamyl
transferase
Vitamin A
Vitamin D
GGT
Vitamin E
Vitamin K
Alpha tocopherol
PT/INR
Retinol
25 (OH) Vitamin D
If abnormal
Elevated AST, ALT, bilirubin may indicate CF liver disease
(though poor predictor). Consider GI referral
Low albumin may be secondary to impaired liver synthetic
function (consider GI referral) or may indicate poor nutritional
status.
Elevated fasting glucose may be concerning for CF related
diabetes. (Consider HgbA1c and/or glucose tolerance test)
Low bicarbonate (in context of failure to thriveconsider renal
tubular acidosis)
Microcytic anemiaconsider checking iron studies for iron
deficiency; obtain Hemoccult to evaluate for possible GI
sources of blood loss.
Elevation may be indicative of CF related liver disease (though
poor predictor). Consider GI referral.
Deficiencymonitor for vision problems (e.g. night blindness)
Severe deficiency consider evaluation for osteoporosis/
osteopenia
Deficiencymonitor for peripheral neuropathy
Elevation may be secondary to nutritional deficiency or
impaired liver synthetic function
109
Stool Labs
In addition to serum laboratory evaluation, stool evaluation can also assess a patients nutritional
status. All patients diagnosed with cystic fibrosis should have a fecal elastase performed to assess
pancreatic sufficiency/insufficiency. A spot fecal elastase is an easy, quick, and reliable assessment of
pancreatic sufficiency. Formed stool may be placed in a specimen cup and frozen until taken to the
labs. Stool should be placed on ice and brought to the lab within 24h of collection.
The 72h fecal fat study is another method, albeit quite burdensome to do accurately, to diagnose
steatorrhea. A coefficient of fat absorption study may be done using stool markers taken 72h apart.
The diet history should start and finish at the same time the stool markers are ingested (72h timeframe).
The stools should be collected from the initial stool marker stain through the second stool marker
stain. The stool collection may take longer than 72h due to variability in intestinal transit time. The
result is calculated by using the following equation:
[Grams fat consumed - Grams fat excreted ]

[Grams fat consumed]

This result should then be multiplied by 100 to obtain percent fat absorption during the 72h time frame.
The validity of the results of 72h fecal fat collection rests upon meticulous measurement of food
intake, exact knowledge of fat content of foods and beverages consumed, and precise collection of
stool output for the entire duration of the study.
While a 72h fecal fat test can evaluate for fat malabsorption, a fecal hydrolysis stool study can
evaluate for carbohydrate malabsorption by evaluating the stool for reducing substances. This test is
ordered when there is a suspicion that a disaccharidase deficiency may be the cause of diarrhea. This
stool usually should be water to loose and placed in a specimen cup. A fresh specimen may be
submitted to the lab but needs to be submitted within 2h of collection. Fecal hydrolysis stool specimen
may also be a frozen specimen that is submitted to the lab within 24h of collection.
If there is a concern for possible protein malabsorption, a fecal alpha-1 antitrypsin stool study can
be useful in diagnosing protein-losing enteropathies especially when used in conjunction with serum
alpha-1-antitrypsin (A1A) levels as part of A1A clearance studies. This stool specimen should also be
a frozen specimen which is submitted within 24h of collection.
ersistent Failure toThrive Despite Optimal Caloric Intake/Other

P
Gastrointestinal Disorders Which May Contribute toPoor Nutrition
For those patients with cystic fibrosis that have persistent failure to thrive despite adequate caloric
intake, attention should be made to other conditions outside of cystic fibrosis that could contribute to
persistent failure to thrive. Good clinical exam skills and history taking can provide clues to other
reasons for poor growth. For instance, in a child with poor linear growth, providers may consider
obtaining a free thyroxine (T4) and thyroid-stimulating hormone (TSH) to evaluate for possible
thyroid disease. In the child with poor growth, abdominal pain, persistent loose stools with blood,
inflammatory bowel disease should be considered; sending an erythrocyte sedimentation rate (ESR),
C-reactive protein (CRP) albumin, CBC, and a stool calprotectin may be appropriate. The patient with
persistent failure to thrive, abdominal distension and bloating, loose stools and abdominal pain should
be evaluated for possible celiac disease with a Tissue Transglutaminase Immunoglobulin A (TTg IgA)
and Total serum immunoglobulin A (total IgA). Table 7.7 provides a summary of potential
gastrointestinal diseases that may be considered in the patient with cystic fibrosis and persistent
malnutrition/failure to thrive.
110
Table 7.7 Other conditions that may result in malnutrition/failure to thrive
Condition
Inflammatory
bowel disease
Celiac disease
Thyroid disease
Liver disease
Clinical symptoms
Abdominal pain, diarrhea,
blood in stool, nocturnal
stooling, perianal
disease
Abdominal pain, abdominal
bloating/distension,
diarrhea, rash
Poor linear growth,
temperature intolerance,
rapid heart rate,
sweating
Jaundice,
hepatosplenomegaly,
ascites, hematemesis,
hematochezia
Renal tubular
acidosis
Failure to thrive with

persistent acidosis
Disaccharidase
deficiency
Failure to thrive with

chronic diarrhea
Protein losing
enteropathy
Failure to thrive, diarrhea,

marked
hypoalbuminemia
Failure to thrive, hypoxia,
heart murmur
Failure to thrive, HSM,
acidosis, developmental
delay, abnormal muscle
tone
Cardiac disease
Metabolic disease
Laboratory evaluation
CBC with d/p, CMP, ESR,
CRP, Iron Studies, Fecal
calprotectin
TTg IgA, Total IgA, Celiac
Genetic Screen
T3, T4, TSH
Signs of disease
Anemia, low albumin,
elevated inflammatory
makers, marked elevation of
calprotectin, consider IBD
Elevated TTg with normal
levels of total IgAconsider
celiac disease
Low T3/T4 with elevated
TSH consider
hypothyroidism
AST, ALT, GGT, albumin,

PT/INR, CBC with d/p
Thrombocytopenia,
leukopenia may indicate
portal hypertension. Low
albumin or elevated INR may
indicate impaired liver
synthetic function
Serum, bicarbonate, urine pH, Unexplained normal anion
urine electrolytes,
gap metabolic acidosis may
be suggestive of RTA
Elevated post fecal
Fecal hydrolysis or
hydrolysis possible
disaccharidase analysis at
disaccharidase deficiency
endoscopy
Fecal alpha-1-antitrypsin level High fecal alpha-1
antitrypsin may be suggestive
of protein losing enteropathy.
Cardiac ECHO
Consider cardiology referral
for congenital heart disease
High lactate/pyruvate ratio,
Lactate, pyruvate, carnitine/
abnormal carnitine/
acylcarnitine profile,
acylcarnitine, UGS may
serum amino acids, urine
suggest mitochondrial/
genetic screen
metabolic disorder.
Clinical Assessment
The clinical exam can provide many clues to the nutritional status and evidence of nutritional
deficiencies. A complete and thorough physical exam is essential at each clinical visit. Attention
should be made not only to the pulmonary and gastrointestinal exam but to a full physical exam to
monitor for specific nutritional deficiencies. Table7.8 provides a comprehensive overview of physical
exam findings and potential nutritional deficiencies.
Diet History
To assess eating patterns as well as nutrient and caloric intake, a thorough diet history is required. The
type of diet history and the amount of desired detail can vary from for each patient. For example, for
a well-nourished individual who is gaining weight appropriately and who enjoys most foods, obtaining
a usual daily intake or a 24-hour recall may be sufficient. In the case of patients who struggle to
gain weight despite their best efforts, a comprehensive review of intake using a food record is
warranted to more accurately capture an understanding of feeding patterns and nutritional intake [2].
111
Table 7.8 Physical exam findings suggestive of possible nutritional deficiencya

Finding
Suggestive nutritional deficiency
Pallor
Iron deficiency
Dermatitis
Zinc deficiency
Neck
Enlarged thyroid
Iodine deficiency
Mouth
Dry, cracked, red lips
Riboflavin, niacin, or vitamin B6 deficiency
Bleeding gums
Vitamin C deficiency
Poor taste
Zinc deficiency
Eyes
Night blindness
Vitamin A deficiency
Hair
Thin or sparse hair
Zinc deficiency
Teeth
Excessive dental carries
Excessive simple carbohydrate intake
Enamel hypoplasia
May be suggestive of celiac disease
a
This table adapted from ASPEN Pediatric Nutrition Support Core Curriculum. 6th editioneditor in chief Mark
Corkins, MD, CNSP, SPR, FAAP.ASPEN 8630 Fenton Street, Suite 412, Silver Spring, MD 20910-3805 [2]
Skin
This should include type and measured amounts of food eaten and beverages consumed; location,
time, and duration of meal or snack; brand name or label of the food if available; preparation methods;
amount served and amount actually eaten; and the number of enzymes taken at each time. Supplements
and tube feedings should also be included in this history. The duration of the food record should be
for at least 3 consecutive days, with one of those days being a weekend for an accurate reflection of
average intake. There are also apps for smart phones which can assist patients and their famililes in
recording food intake food intake, or patients may record intake using computer programs. Food
records submitted electronically increase the potential for real-time communication between the
patient and the dietitian.
Asking patients and families about any adverse eating behaviors such as pain or difficulty
swallowing, coughing, or choking with eating, abdominal pain or vomiting after eating, early satiety,
and constipation may provide additional insight of factors that may contribute to poor caloric intake.
Related Diseases
A thorough medical history and knowledge of past medical history is important as related diseases can
have a large impact on a childs nutritional status. For instance, surgical resection from meconium
ileus in infancy can have a marked impact on nutritional status throughout a childs lifetime. A child
with poorly controlled diabetes will have additional challenges in establishing good weight gain.
CF-Related Liver Disease

The vast majority of patients with cystic fibrosis will have elevation of transaminases at some point in
their lifetime. Only a small percentage, 510% of patients with CF, will develop severe CF-related
liver disease characterized by cirrhosis, portal hypertension, and decreased liver synthetic function
[11]. The patient with severe CF-related liver disease is at increased risk for malnutrition given
impaired bile flow. Fat-soluble vitamin levels should be monitored at least yearly in all patients with
CF liver disease [10, 12]. If a patient requires additional vitamin supplementation, monitoring levels
12 months after starting supplementation ensures adequate levels have been obtained. Patients
should have CBC with differential and platelets. Thrombocytopenia and leukopenia may be an
indication of hypersplenism and/or portal hypertension. Iron deficiency anemia may be a result of
112
Table 7.9 Laboratory evaluation in the patient with severe CF related liver disease
Evaluation
CBC with differential
and platelets (d/p)
Comment
Anemiaconsider blood loss from bleeding
esophageal, gastric, rectal varices.
Thrombocytopeniamay be sign of portal
hypertension/splenic sequestration
Leukopeniamay be sign of portal
hypertension/splenic sequestration
CMP
PT/INR
GGT
Fat-soluble vitamins
Zinc
Further work up/evaluation

Hemoccult stool
Obtain iron studies
Consider endoscopy
Evaluate liver/spleen size on
physical exam
Consider abdominal
ultrasound with Dopplers
GI referral
GI referral
Hypoalbuminemiamay be sign of
malnutrition and/or impaired synthetic function Routine laboratory evaluation
every 412 months
Elevated AST, ALT, bilirubinmay be sign of
worsening liver disease (although poor
predictor)
Elevation indicative of impaired liver synthetic Replacement with Vitamin K
function or vitamin K deficiency
1mg/kg/year of age to max of
10mg p.o. once daily.
Elevation may be sign of obstructive liver
GI referral
disease (although poor predictor in CF)
Routine laboratory evaluation
every 412 months
Supplement as necessary with
Often low and require higher doses of
follow up evaluation to ensure
supplementation compared to the CF patient
normal/improving levels.
without liver disease
Often low in liver disease
Supplement as necessary with
follow up evaluation to ensure
normal/improving levels.
bleeding esophageal/rectal varices or bleeding portal hypertensive gastropathy. GGT is often elevated
in the patient with CF and may be an indication of further impaired bile flow. Albumin and PT/INR
evaluation allows for monitoring of impaired liver synthetic function which often does not occur until
late in the disease process (Table7.9).
CF-Related Diabetes
Cystic fibrosis-related diabetes is a common comorbidity in patients with cystic fibrosis affecting
almost 20% of adolescent children [13]. Poorly controlled CF-related diabetes can further impact the
nutritional status of the patient with cystic fibrosis. The CFF and American Diabetes Association have
published clinical care guidelines for cystic fibrosis-related diabetes [14]. Screening for CF-related
diabetes should begin at 10 years of age in all patients who do not have CF-related diabetes already
diagnosed. HgbA1c is not considered sufficiently sensitive and should not be used as a screening
modality for CF related diabetes. Screening for CFRD should be performed using a 2 hour, 75g oral
glucose tolerance test [14]. Refer to Chapter 10 for more detailed information on CF-related diabetes.
Bone Disease
Clinical evaluation of bone health and monitoring for evidence of bone disease is important in the
patient with cystic fibrosis. Pancreatic insufficient patients with CF are at further risk for poor bone
health secondary to malabsorption of fat-soluble vitamins. Risk factors for poor bone health include
113
Table 7.10 Risk factors for poor bone health

Risk factors for poor bone health
Patients with CF who are candidates for organ
transplantation
Post organ transplantation
End-stage lung disease
End-stage liver disease
Bone fracture secondary to low-impact
activity
Chronic use of corticosteroids
Delayed pubertal development
Nutritional failure
patients that are candidates for organ transplantation, post-organ transplantation, end-stage lung
disease, bone fracture with a low-impact activity, chronic corticosteroid use, delayed pubertal
development, and nutritional failure (Table7.10) [15]. Children 8 years and older who are at risk for
poor bone health should have an assessment of bone mass by lumbar spine DEXA.In addition to the
DEXA, children at risk for poor bone health should have annual serum calcium, phosphorous, intact
parathyroid hormone, and 25-hydroxy vitamin D measured [15]. Dietary intake of calcium and
vitamin D should be determined by dietary history at clinic visits [15]. See Chapter 4 for more detailed
information on CF and Bone Health.
Stool History
A thorough stool history is as important as a good diet history (see Table 7.11). Providers should
inquire as to how many stools a patient has in 24hours. Consistency and caliber the stool should be
ascertained (e.g. hard, soft, loose, watery, mushy, wide, difficult to pass). Presence of grease, oil, or
mucous may represent suboptimal pancreatic enzyme replacement. Stooling patterns such as nocturnal
stooling may be a clue to an underlying gastrointestinal disorder such as inflammatory bowel disease.
Presence of blood in stool may also be indicative of an inflammatory process or could indicate
presence of bleeding esophageal or rectal varices. It is important, especially in the pediatric population,
to inquire about dietary history when taking a stool history. For instance, a child consuming 40ounces
of fruit juice a day could clearly lead to problems with diarrhea.
Vitamin andMineral History

Since the first CF specific vitamin was introduced in 1991, there has been continued development of
new vitamin products and periodic reformulation of existing ones. Creation and modification of CF
specific vitamins reflects current research and knowledge of the specialized nutritional needs of
individuals with CF.Vitamins specific for CF not only undergo periodic modification in their actual
vitamin amounts, but also in the form in which specific vitamins are delivered. For example, vitamin
A is provided in several of the products as a combination of beta-carotene and retinol, whereas earlier
formulations and some of the current formulations are entirely from retinol (as a result, retinol activity
equivalents may be a more prudent way to compare vitamin A content between products). Because CF
specific vitamin products frequently change, specific product names and content have been purposely
omitted from this section.
114
Table 7.11 Stool history and associated conditions with suggestive interventions
Stool quality
Grease/oil in stool
Blood in stool
Acholic stools
Loose stools
Infrequent stools
Hard stools
Potential condition
Pancreatic
Insufficiency
Rectal Prolapse
Perianal fissure
from constipation
Inflammatory
bowel disease
Hemorrhoids
Biliary obstruction,
liver disease
Pancreatic
Insufficiency
Infectious
Malabsorption e.g.
celiac)
Inflammatory (e.g.
IBD)
Constipation
DIOS
Constipation
DIOS
Suggestive intervention
Review pancreatic enzyme supplementation and adherence
Obtain repeat fecal elastase if pancreatic sufficient patient with CF
Review pancreatic enzyme dosing
Soften stools with stool softener if hard stools/straining with
toileting
Obtain laboratory evaluation (CBC with d/p, CMP, ESR, CRP) if
concern for IBD
Soften stools if external hemorrhoids seen on exam
Obtain AST, ALT, bilirubin, GGT, PT/INR
Consider abdominal ultrasound with Dopplers
If acute and associated with prodromal symptoms consider
infectious stool workup
If chronic and failure to thrive, consider evaluation for celiac,
IBD, disaccharidase deficiency, adherence with pancreatic enzyme
supplementation
Consider TTg IgA, IgA if associated failure to thrive.

Consider T4/TSH if poor linear growth
Consider stool softener and/or colonic motility agent
Consider stool softener and/or colonic motility agent
To obtain a reliable vitamin history, it is often useful to encourage patients to photograph the vitamin
products they take (including all label information) or to ask them to bring their vitamin bottles with
them to their clinic appointments. This helps eliminate the guesswork as many vitamin products
have similar names which patients (as well as providers) can understandably have difficulty recalling
the exact name or formulation of the product.
Adherence with vitamins in CF has been demonstrated to be variable [16]. It is helpful to ask open-
ended questions such as, How many times a week do your take your vitamin? rather than Do you
take your vitamin every day? It is important to know specifically what products your patient takes,
as well as the dose and degree of frequency, in order to provide appropriate recommendations when
updated serum lab values are known.
Pancreatic Enzyme Replacement Therapy History

A good pancreatic enzyme replacement history involves thorough knowledge of all enzyme products
currently available on the market. The brand, strength, and dose of pancreatic enzyme replacement the
patient is taking with all meals, snacks, and with supplements or tube feedings should be recorded at
each clinic appointment. There should also be discussion regarding any difficulty taking or
remembering enzymes. The time spent obtaining this history not only provides useful information
to the clinician, but also affords the opportunity to assess patient knowledge and provide a refresher
on the rationale and function of pancreatic enzyme replacement therapy. Inquiring about specific
practices such as how many or even if enzymes are taken with a glass of milk, when and how enzymes
are given with tube feedings, and the number of total enzymes taken in a day provides valuable
information in assessing the adequacy of the present enzyme dosing regimen. Total comprehension of
individual enzyme practice is essential in the context of weight, BMI, calorie, and stool/GI history.
115
For some families, showing the different enzyme products available by using a laminated picture
or a pill case that contains all of the different pancreatic enzyme replacement capsules helps confirm
the product being taken as well as provide visual depiction of capsule size. Calculation of dosing
enzymes may be found in the chapter on pancreatic enzymes, but typically is estimated by lipase
units/kg/meal; lipase units/kg/day; or lipase units/gram of fat.
Conclusion
There are multiple considerations in executing a thorough nutritional assessment for the patient with
cystic fibrosis in the 2 to 20-year-old age group. Weight, height, and BMI are certainly key factors, but
only when taken into consideration along with biochemical and clinical data; diet and gastrointestinal
history; pancreatic enzyme replacement and vitamin supplementation practices; in addition to
consideration of past and present medical conditions. As we continue to learn more about the
association between nutrition and health outcomes, it is prudent to attain and maximize nutritional
status early in childhood and maintain through adulthood.
References
1. Borowitz D, Baker RD, Stallings V. Consensus report on nutrition for pediatric patients with cystic fibrosis.
2. Corkins MR, Balint J.American Society for P, Enteral N.A.S.P.E.N. pediatric nutrition support core curriculum.
Silver Spring: American Society for Parenteral and Enteral Nutrition; 2010.
3. Stallings VA, Stark LJ, Robinson KA, Feranchak AP, Quinton H.Evidence-based practice recommendations for
nutrition-related management of children and adults with cystic fibrosis and pancreatic insufficiency: results of a
4. Yen EH, Quinton H, Borowitz D.Better nutritional status in early childhood is associated with improved clinical
outcomes and survival in patients with cystic fibrosis. J Pediatr. 2013;162(3):5305.e1.
5. Hendricks KM.Manual of pediatric nutrition. In: Walker WA, editor. 2nd ed. Ontario: B.C.Decker; 1990.
6. Pediatric nutrition: policy of the American Academy of Pediatrics. In: Kleinman RE, Greer FR, editors. 7th ed.
7. Frisancho AR.Anthropometric standards for the assessment of growth and nutritional status. Ann Arbor: University
of Michigan Press; 1990.
8. Zhang Z, Shoff SM, Lai HJ.Incorporating genetic potential when evaluating stature in children with cystic fibrosis.
J Cyst Fibros. 2010;9(2):13542.
9. Himes JH, Roche AF, Thissen D, Moore WM.Parent-specific adjustments for evaluation of recumbent length and
stature of children. Pediatrics. 1985;75(2):30413.
10. Debray D, Kelly D, Houwen R, Strandvik B, Colombo C.Best practice guidance for the diagnosis and management
of cystic fibrosis-associated liver disease. J Cyst Fibros. 2011;10 Suppl 2:S2936.
11. Colombo C.Liver disease in cystic fibrosis. Curr Opin Pulm Med. 2007;13(6):52936.
12. Sokol RJ, Durie PR.Recommendations for management of liver and biliary tract disease in cystic fibrosis. Cystic
Fibrosis Foundation Hepatobiliary Disease Consensus Group. J Pediatr Gastroenterol Nutr. 1999;28 Suppl
1:S113.
13. Moran A, Dunitz J, Nathan B, Saeed A, Holme B, Thomas W.Cystic fibrosis-related diabetes: current trends in
prevalence, incidence, and mortality. Diabetes Care. 2009;32(9):162631.
14. Moran A, Brunzell C, Cohen RC, Katz M, Marshall BC, Onady G, etal. Clinical care guidelines for cystic fibrosis-
related diabetes: a position statement of the American Diabetes Association and a clinical practice guideline of the
Cystic Fibrosis Foundation, endorsed by the Pediatric Endocrine Society. Diabetes Care. 2010;33(12):2697708.
15. Aris RM, Merkel PA, Bachrach LK, Borowitz DS, Boyle MP, Elkin SL, etal. Guide to bone health and disease in
cystic fibrosis. J Clin Endocrinol Metab. 2005;90(3):188896.
16. Modi AC, Lim CS, Yu N, Geller D, Wagner MH, Quittner AL.A multi-method assessment of treatment adherence
for children with cystic fibrosis. J Cyst Fibros. 2006;5(3):17785.
Chapter 8
Nutrition Assessment: Adults and Obesity

Judith A. Fulton and Alexandra W.M. Wilson
Key Points
As patients with cystic brosis (CF) are living well into adulthood, nutrition-related comorbidities
are becoming more common. As with children with CF, maintaining optimal nutrition status is
associated with preserved lung function in adults with CF. Registered dietitians play a vital role in
maintaining optimal nutrition status in adults with CF.
An annual nutrition assessment is recommended and should include the following: assessment of
dietary intake, pancreatic enzyme therapy replacement (PERT) usage, review of vitamin and
mineral supplementation, and an evaluation of annual laboratory values.
CF Foundation recommends a goal body mass index of 22 kg/m2 or higher in adult females and
23 kg/m2 or higher in adult males.
A high calorie, unrestricted fat diet continues to be recommended in adults with CF with pancreatic
insufciency. Estimated protein needs are 1.52.0 times the recommended daily allowance.
Supplemental tube feeding is recommended to adult patients with CF when other weight gain
strategies have failed.
Due to increased fat malabsorption, adults with CF are at higher risk of fat-soluble vitamin
deciency. For this reason, they are encouraged to use regular CF-specic multivitamin daily to
prevent fat-soluble vitamin deciency.
Bone disease is common in adults with CF. Patients are encouraged to attain adequate intake of fat-soluble
vitamins and calcium, participate in regular physical activity, and maintain a healthy body weight.
CF-related diabetes is the most common co-morbidity in CF. It should be treated by a multidisciplinary team familiar with CF and in consultation with the CF team.
Gastroesophageal reux is common in adults with CF. Appropriate medical, diet, and lifestyle
management of reux are encouraged.
Overweight and obesity does occur in CF. Healthy weight, physical activity, and healthy diet are
encouraged in overweight or obese patients with CF.
J.A. Fulton, M.P.H., R.D., L.D.N.

Clinical Nutrition, Childrens Hospital Colorado, University of Colorado, Cystic Fibrosis Center,
13123 East 16th Avenue, B395, Aurora, CO 80045, USA
A.W.M. Wilson, M.S., R.D.N., C.D.E. (*)
Food Service and Clinical Nutrition, National Jewish Health, Adult Cystic Fibrosis Program,
Colorado Cystic Fibrosis Center, 1400 Jackson Street, Room A02C, Denver, CO 80206, USA
117
J.A. Fulton and A.W.M. Wilson
118
Keywords Assessment Dietitian Nutrition Body mass index Pancreatic enzyme replacement
therapy Vitamin supplementation Bone health Cystic brosis related diabetes Obesity
Overweight
Abbreviations
BMI
CDC
CF
CFRD
DEXA
FEV1
GER
PERT
Body mass index

Center of disease control and prevention
Cystic brosis
Cystic brosis related diabetes
Dual X-ray absorptiometry
Forced expiratory volume in 1 second
Gastroesophageal reux
Introduction
No achievement highlights the striking developments of the past few decades in cystic brosis (CF)
care more clearly than the tremendous growth of the adult CF population [1]. With the average life
expectancy of an individual with CF increasing dramatically over the last three decades, we are seeing
CF patients living well into adulthood and experiencing new non-respiratory illness such as diabetes,
osteoporosis, and reproductive concerns. The importance of nutrition in the long-term survival of patients
with CF has been well documented [25]. This section provides an overview of adult CF nutrition
assessment and the importance of nutritional status in the long-term survival of patients with CF.
In the 1950s, CF was a childhood disease. At that time, a child diagnosed with CF would not live
long enough to attend elementary school. With continual medical advancements as well as optimizing
nutrition the median predicted survival age in 2013 was 40.7 (95% condence interval: 37.744.1
years) [6]. In 2013 the CF Foundation Patient Registry followed 28,103 CF patients, and the number
of patients greater than 18 years of age was 13,975 or 49.7% [6]. As new drug therapies and treatments
continue to be developed, the number of adults living with this disease will only continue to increase.
The CF Foundation Patient Registry has also reported adults with CF are living fullling lives [6, 7].
Throughout the phases of adult life, maintaining optimal nutrition status can be challenging.
In general, as the disease advances, adults with CF have more severe pulmonary disease than they
do as children. This puts them at an increased risk for serious complications such as pneumothorax
and massive hemoptysis. The majority of adult CF patients die of respiratory failure [6]. Slowing or
preventing the decline in lung function is the most important challenge for a majority of patients.
Although pulmonary physiotherapy and antibiotics are important to maintain lung health, good
nutrition is a critical piece of this puzzle. By not accepting nutritional failure in pediatric CF patients,
we can preserve their lung function as adults.
CF Nutrition Assessment: Adults

The CF Foundation recommends that a registered dietitian complete a structured nutrition assessment
annually, in addition to nutrition follow-up and reinforcement visits. The CF annual visit should
include the following: assessment of dietary intake, pancreatic enzyme therapy replacement (PERT)
usage, and review of vitamin and mineral supplementation, and an evaluation of annual laboratory
119
values. The assessment should also include assessment of nutrition and metabolic complications, and
the appropriate screening tests [8, 9] as discussed in greater detail in this chapter. The annual nutrition
assessment provides the framework for future nutrition care planning and anticipatory guidance.
Refer to Table 8.1 for an adult CF nutrition assessment ow sheet.
Adult Weight/Height Assessment

Growth of a child with CF is monitored by tracking weight and height at intervals on a standard growth
curve. After 20 years of age the growth chart is no longer used, but this doesnt mean the importance of
weight and height diminishes when assessing nutrition. The CF Foundation Clinical Practice Guidelines
Growth and Nutrition Subcommittee published data looking at the relationship between body mass
index (BMI) and lung function in the CF population in 2008 [8]. As a result of this data CF Foundation
recommends a goal BMI of 22 kg/m2 or higher in females and 23 kg/m2 or higher in males [8]. These
values correlated with a forced expiratory volume in 1 second (FEV1) > 60% predicted [8]. In this adult
CF group, there was no evidence of decreased FEV1 up to a BMI of 29 and the sample of adults with a
BMI over 29.9 (obesity) was too small for analyses [8]. As described in the obesity section this
population is growing which may allow us to observe this trend change. It is not known whether a BMI
greater than the CF Foundation goal would be associated with further increased lung function.
Pancreatic Status
Pancreatic insufciency usually develops during infancy, and approximately 90% of adult patients
with CF are pancreatic insufcient resulting in chronic nutrient malabsorption [9]. There is a
correlation between genotype and phenotype in regard to the exocrine function of the pancreas [10].
Being pancreatic insufcient suggests not enough pancreatic function is available to achieve normal
digestion. That is, absorption of fat and protein is compromised, resulting in symptoms of
malabsorption. These symptoms include poor weight gain despite adequate calories, frequent bowel
movements, abdominal pain, bulky, large and/or light colored stools, oil or grease in stool, and
excessive gas. PERT adequacy is determined clinically by monitoring nutritional status, signs and
symptoms of malabsorption, and excessive appetite with poor weight gain. Inadequate doses of PERT
may result in malabsorption, abdominal pain, and constipation. Please refer to Chapter 7 for more
detailed information on pancreatic enzyme dosing and management.
In adult patients with CF, who are pancreatic sufcient, the pancreatic function can decline with
age. The result is pancreatic insufciency [1]. Pancreatic sufcient patients should be routinely asked
about their stools so that malabsorption can be addressed early. These patients are at higher risk for
acute or recurrent episodes of pancreatitis as compared to the general population [11]. Treatment of
pancreatitis with CF is similar to the general population and requires adequate pain management and
gut rest. Recurrent episodes of pancreatitis may lead to pancreatic insufciency requiring PERT. Please
refer to Chapter 12 for more information regarding pancreatitis.
Assessing Intake
Calorie and protein requirements can sometimes be higher in adults than children with CF, despite not
having to account for growth [12]. Higher calories may be needed for the increased work of breathing
and frequent infections along with the progressive pancreatic insufciency [9, 13]. A broad
120
Table 8.1 Adult CF nutrition assessment
(continued)
121
122
recommendation for energy requirements for patients with CF is 120150% of requirements for the
general population [14, 15]. Actual caloric requirements vary from person to person, but often increase
as the lung disease progresses. For example, an adult male could require between 3500 and 4500 cal
which is approximately 150% more than an individual without CF. To meet these higher caloric needs
the adult patient with CF needs to consume at least 3 meals and 23 snacks a day. Skipping a meal or
snack or not taking pancreatic enzymes as prescribed will cause caloric intake or nutrient absorption
to be inadequate. Monitoring weight at each CF clinic visit is important along with assessing caloric
intake. Please refer to Chapter 2, Table 2.1 for a review of the 2005 Estimated Energy Requirement
equations.
A high calorie, liberal fat diet is standard practice for the CF population throughout the life cycle.
The tendency to restrict fat consumption in these patients should be discouraged because dietary fat is
calorically dense, improves the palatability of the foods and is needed to prevent essential fatty acid
deciency. Research suggests lipid proles of adult CF patients who have been on a high calorie, high
fat diet their entire life were not elevated; therefore a high calorie, unrestricted fat diet continues to be
recommended in adults with CF with pancreatic insufciency [16].
Of note, reports of adult patients who were pancreatic sufcient did have high-normal cholesterol
levels [17]. Higher serum triglyceride levels in patients with CF compared to the standard population
with several incidences of hypertriglyceridemia have been observed [18, 19]. The etiology is not fully
understood, but chronic inammation, excessive carbohydrate intake, or absorption of a high fat diet
has been proposed [18, 19]. There are reports of premature atrial damage compared to controls [20]
and a few reports of myocardial infarction in the aging CF population [21, 22]. Due to the potential for
cardiovascular disease in the adult CF population, encouraging increased intake of mono-unsaturated
and poly-unsaturated fatty acids rather than saturated fatty acids may be prudent. Please refer to
Chapter 2, Table 2.2 to review common food sources of unsaturated and saturated fatty acids.
Protein is an important nutrient to prevent catabolism. The recommended intake for adults with CF
is 1.52 times the recommended daily allowance [23, 24]. A protein intake of 1520% of total calories
[23, 24] has been suggested. When recommending a protein amount to an adult patient with CF, it
may be best to provide the goal in total grams of protein per day. Please refer to Chapter 2, Table 2.4
for recommended daily allowance for protein.
Some adult patients with CF are not able to consume enough calories in their diet to maintain a
healthy weight and adequate BMI. For these patients, supplemental tube feedings can counter the
challenge of consuming enough calories every day. This option of nutrition therapy should be
discussed with each patient who continues to struggle with his or her weight and when other
recommendations have failed. There is concern placing and using feeding tubes in adults with
advanced lung disease and this is related to a decreased ability to achieve a productive cough and do
chest physiotherapy. With this decreased mucous clearance, there is more risk of lung infections.
Most feeding tube research in CF has been done in children, who usually have less lung disease. It is
important to place a gastrostomy tube prior to signicant decline in lung function to result in better
outcome results. The option of supplemental tube feeding should be initiated as a means to maintain
lung health and nutrition rather than a rescue option or a threat when all else has failed. Please refer
to Chapter 8 for more detail regarding supplemental tube feedings.
Adult Nutrition Intervention

Nutrition intervention and counseling are important parts of the CF clinic visit. The medical team
needs to work with the CF patient to help reach their BMI goal by using diet intervention and nutrition
counseling strategies. Table 8.2 offers examples of nutrition strategies to counsel adult CF patients.
123
Table 8.2 Nutrition strategies to counsel adult CF patients
Have snack foods available away from home, in ofce, backpack, or car.
Use a diet phone app to track calories to help reach caloric goal.
Avoid soda, empty calories, and try and drink milk with meals.
Keep peanut butter readily available to eat a spoonful 12x/day (1 tablespoon = 95 cal)
Investigate insurance coverage of oral supplementsuse a prior authorization form or letter.
Utilize the enzyme company programs for free CF vitamins and oral supplements.
Take the time to eat 3 meals and 23 snacks a dayuse a phone alarm to remind you.
Target 1 meal or snack a day to add extra calories. 100 extra calories can add up.
Easy ways to add caloriesorder extra cheese on pizza, butter the bread of your sandwich.
Have a container of heavy cream available to add when cooking.
Use a weekly pillbox, so you dont have to open bottles all the time and can help compliance.
Remember to take PERT with all meals and snacks to absorb all those calories.
If you forget to take enzymes at certain times, set a phone alarm to help remember.
Make meals on weekends for the week, or use a crockpot for a meal when you return home.
Put meal doses of enzymes in Baggies and put them next to your cell phone and car keys.
Take enzymes at the start of the meal or if eating >45 min spread over meal.
When eating fatty fast food take extra enzymes for those extra calories.
Keep enzymes in several places, backpack, ofce, friends and relatives, etc.
Remember to take enzymes with all beverages including lattes, milk, oral supplements.
Remember some foods dont require PERT (fruit, popsicles, juice, plain pretzels).
If doing night tube feedings, take PERT as prescribed to maximize absorption.
Remember enzymes are heat sensitive and cannot be stored in a hot place like a car.
Similar to guidelines in the United States, the European CF Society Standards of Care published
guidelines in 2014 recommending adults to maintain a BMI > 20 with an ideal BMI of 22 for females
and of 23 for males [25]. They also recommend nutrition intervention to be tried stepwise for a limited
period of time or until nutritional status is optimized, depending on the severity of malnutrition and
the age of the patient. They recommend the rst step to be anticipatory guidance and include the
following: reinforcement of adherence to the CF diet, enzyme recommendations, vitamin and mineral
supplementation, and using behavioral modication or motivational interviewing. The second step of
nutrition intervention for moderate malnutrition includes the use of oral supplements for additional
calories in a time-limited trial or temporarily as meal replacement for ill patients. In addition,
temporary tube feeds may be used to maintain calories during a pulmonary exacerbation to prevent
weight loss. In severe malnutrition, and when these two steps fail, the third step of nutrition intervention
would be enteral feeding to improve and then maintain nutrition [25].
Vitamin and Mineral Supplementation

Optimal vitamin and minerals are essential for the overall health of an individual with CF. Although
a balanced diet contributes to the overall nutrient intake, there is a need for oral vitamin and mineral
supplements. CF patients, especially those with pancreatic insufciency, are at risk of fat-soluble
vitamin deciency and the importance of supplementing vitamins A, D, E, and K has been well
documented [1, 9, 26, 27]. Through all stages of life, patients with CF are prescribed fat-soluble
vitamins as part of their medical therapy. The doses are higher than recommended for people without
124
CF to prevent deciency and keep their vitamin levels in an optimal range. Low vitamin levels occur
for several reasons including inadequate adherence to recommended therapy, inadequate dietary
intake, malabsorption, drug-nutrient interactions, liver disease, or bowel resection [2830].
The introduction of CF-specic multivitamin supplements coupled with improved pancreatic
enzyme replacement therapy has contributed to the reduction in the incidence and prevalence of vitamin
deciency. It is standard practice for all adult patients with CF who are followed at a CF Foundationaccredited Center to have their fat-soluble vitamin levels monitored annually. If levels are low and
require repletion, they should be re-evaluated, ideally in 3 months until optimal levels are reached.
Adult patients with CF are at risk of iron-deciency and iron-deciency anemia from chronic disease.
Finally, due to malabsorption of vitamins D and K, adult CF patients are at risk of low bone mineral
density, making assessment of calcium intake also important. Please review Chapter 6 on vitamins and
minerals for more specic information on the research and the current recommendations.
Bone Health
The prevalence of bone disease among adult patients with CF is growing as this population ages, and is
exacerbated by malnutrition and advanced lung disease [31]. As of 2012, the CF Foundation Patient
Registry reports 36% of adults ages 35 and older had CF-related bone disease (including fractures,
osteopenia, and osteoporosis) [32]. Multiple factors contribute to the development of bone disease
including: inadequate nutrition, suboptimal vitamin D levels, glucocorticoid therapy, physical inactivity,
delayed puberty, and early hypogonadism [31, 33]. Chronic pulmonary inammation can also increase
serum cytokine levels, which may increase bone resorption and decrease bone formation [31, 33].
Although prevention therapy of bone disease is encouraged in the pediatric population, adults
currently treat osteopenia to prevent progression to osteoporosis. According to the CF Foundation
guidelines, starting at 18 years of age, all individuals with CF should have a baseline dual X-ray
absorptiometry (DEXA) scan to determine bone mineral density. If the DEXA scan is normal, then
repeat scans should be conducted every ve years to monitor for disease [31]. Individuals with CF can
maintain their bone health by ensuring adequate intake of fat-soluble vitamins and calcium,
participating in regular physical activity, and maintaining a healthy body weight. The European CF
Society Standards of Care recommend all CF Centers be familiar with the risk factors contributing to
the development of reduced bone mass density. The most common risk factors include: pulmonary
infections, poor nutritional status, lack of weight bearing exercise, delayed puberty, glucocorticoid
treatment, hypogonadism, and vitamins D and K, as well as calcium deciencies [32]. Please refer to
Chapter 4 for specic guidelines for screening and treating bone disease in the CF population.
Cystic Fibrosis Related Diabetes

The number of patients diagnosed with CFRD is rapidly increasing, possibly reecting better screening
and improved CF survival. The annual incidence of CFRD is reported to increase with age at 5% a
year in patients 10 years of age and 9.3% a year in patients 20 years of age and older [33, 34]. Data
from the University of Minnesota, where they preformed annual screening oral glucose tolerance test
(OGTT) starting at age 6 years, reported CFRD in 2% of children, 19% of adolescents, and 4050%
adults [34]. Patients with CFRD require medical care from a multi-disciplinary management team
with experience in CFRD and in consultation with the CF team. CFRD is caused by progressive
insulin deciency secondary to progressive destruction of the pancreas in CF, specically to the
insulin-producing Beta cells [35]. CFRD shares characteristics of both type 1 and type 2 diabetes,
125
but is clinically distinct and requires a unique management approach [34]. Treatment with systemic
glucocorticoids can exacerbate hyperglycemia in CF. Declining lung function, weight loss, protein
catabolism and increased mortality are all associated with the CFRD diagnosis [34, 35]. In 2010 the
CF Foundation along with the American Diabetes Association and the Pediatric Endocrine Society
published clinical care guidelines for the screening, diagnosis, and medical management of CFRD
[35]. Refer to Chapter 10 on additional guidance for the screening, treatment, and nutritional
management of CFRD.
Gastroesophageal Reflux
Approximately 80% of adults with CF have heartburn or gastroesophageal reux (GER) [36]. Delayed
gastric emptying, increased stomach acid, the altered shape of the chest, and changes in the diaphragm
found in adults with CF may contribute to GER. The CF team should be aware of the signs and
symptoms of GER and be able to provide appropriate diagnostic testing (impedance and pH probe,
upper endoscopy) and treatment [25]. In most instances, typical GER symptoms are heartburn,
regurgitation of stomach contents into the mouth, and upper abdominal pain [36, 37]. The dietitian
should review the diet history and offer recommendations for avoiding foods that could be aggravating
symptoms and encourage smaller more frequent meals, eating slower and avoiding lying at after
eating. The usual medication treatment for GER is acid suppression and the use of motility agents.
Please refer to Chapter 12 for more details on GER in CF.
Obesity in Cystic Fibrosis

Cystic brosis (CF) is often associated with malnutrition primarily from pancreatic insufciency,
inadequate intake, and increased energy expenditure. Malnutrition has been associated with the rapid
progression of lung disease and shortened lifespan [38]. Countering malnutrition by promoting
normal growth velocity and maintaining adequate nutrition is standard CF therapy. With earlier CF
diagnosis through newborn screening, aggressive nutrition therapy and regular medical follow-up, the
prevalence of malnutrition has signicantly decreased in patients with CF [26]. In contrast, the 2013
CF Foundation Patient Registry reports that the percentage of both overweight and obesity in this
population is on the rise. The Centers for Disease Control and Prevention (CDC) has classied
overweight and obesity in pediatrics and adults using BMI [39, 40]. Tables 8.3 and 8.4 summarize the
metrics referenced by the CDC for overweight and obesity in the general population [39, 40].
Table 8.3 Pediatric CDC classication of overweight and obesity [3]

BMI percentile
>85th and <95th
Weight status
Overweight
>95th
Obesity
Table 8.4 Adult CDC classication of overweight and obesity [4]

BMI
2529.9
Weight status
Overweight
30 and above
Obesity
126
Pediatrics
The 2013 CF Foundation Patient Registry followed 28,103 patients with CF in the United States;
15,707 were children less than 20 years of age. Approximately 3.5% (or 543 of 15,707) of children
ages 219 years had a BMI > 95th percentile were considered obese. Approximately 8% (or 1279 of
15,707) of the CF pediatric population had a BMI % > 85% and <95th percentile were considered
overweight [6]. Some CF Centers have reported an obesity and overweight rate as high as 23% in
children and have noted 28% of their obese patients were pre-hypertensive and 6% were hypertensive
[41]. The overweight and obese patients were mostly pancreatic insufcient and were not associated
with better lung function [41]. The increase in the obesity rate in the CF population may be related to
the increased prevalence in the general population. In addition, the earlier diagnosis through neonatal
screening, combined with earlier intensive interventions could be contributing to this trend [42].
Adults
The 2013 CF Foundation Patient Registry followed 12,396 adults (non-transplant) with CF over the
age of 20. Approximately 5% (or 623 of 12,396) of adults had a BMI > 30 were considered obese [6].
Approximately 18% (or 2209 of 12,396) of the CF adult population reported a BMI between 25 and
29.9 were considered overweight [6]. This higher percentage of overweight and obese adult CF
patients is projected to increase as the life expectancy increases for this population.
The CF Foundation Clinical Practice Guidelines Growth and Nutrition Subcommittee published
the importance of BMI status as a function of optimal lung function in the CF population in 2008 [8].
They published recommended BMI percentile in children and recommended BMI in adults that were
sensitive to changes on percent predicted forced expiratory volume in 1 second (FEV1) [8]. The FEV1
is a spirometry measurement used to evaluate lung function. In children, they reported better FEV1
status at 80% predicted or above to be associated with a BMI at or above the 50th percentile [8]. In
adults they reported an FEV1 of 60% predicted or above to be associated with a BMI of 22 or higher
in females and a BMI of 23 or higher in males. For adults, there was no evidence of decreased FEV1
up to a BMI of 29 and the sample of adults with a BMI > 29 (obesity) was too small for analyses [8].
From the 2013 CF Patient Registry Report, we can see a subgroup of patients have achieved BMIs
higher than what is considered healthy for the general population. It is not known whether a BMI
higher than the CF Foundation goal would be associated with further increased lung function.
Since the CF Foundation nutrition guideline publication in 2008, the many CF Centers have
initiated quality improvement programs aimed at improving BMI in their CF populations. To date the
majority of nutrition guidelines for individuals with CF focus on increasing BMI. There is a lack of
recommendations to manage obese or overweight patients in this population. Since there are no
specic guidelines for CF, recommendations similar to those for the general population, including a
lower calorie, healthy diet along with increased exercise, may be some of the rst step in counseling
these patients. Further studies are needed to better determine optimal management of overweight and
obese pediatric and adult patients with CF.
Conclusion
Although CF has long been viewed as a pediatric disease, it has now evolved into an adult disease
bringing new medical advances, research breakthroughs, and interdisciplinary healthcare teams that
have led to a dramatic improvement in the life expectancy and the quality of life for these individuals.
127
Advanced age with CF can lead to complications, but it also means individuals can develop careers,
marry, and start families. Careful monitoring of nutritional status is important for early detection and
correction of unfavorable trends. Patients of all ages should be aware of their weight goals for optimal
nutrition. Dietitians should be a key member of the CF medical team and assist when a patient presents
with malnutrition or weight loss. The primary nutrition goal of the CF medical team should be the
prevention of malnutrition at all ages, including adults, and adequate management of nutrition-related
comorbidities.
References
1. Yankaskas JR, Marshall BC, Suan B, Simon RH, Rodman D. Cystic brosis adult care- consensus conference
report. Chest. 2004;125:1S39.
2. Kraemer R, Rudeberg A, Hadorn B. Relative underweight in cystic brosis and its prognostic value. Acta Paediatr
Scand. 1978;67:337.
3. Huang NN, Schidlow DV, Szatrowski TH. Clinical features, survival rate and prognostic factors in young adults
with cystic brosis. Am J Med. 1987;82:8719.
patients with cystic brosis in Boston and Toronto. J Clin Epidemiol. 1988;41 suppl 6:58391.
5. Liou TG, Adler FR, FitzSimmons SC. Predictive 5-year survivorship model of cystic brosis. Am J Epidemiol.
2001;153:34552.
6. Cystic brosis patient registry. Bethesda, MD: Cystic Fibrosis Foundation; 2013.
7. Orenstein DM, Spahr JE, Weiner DJ. Cystic brosis: a guide for patient and family. 4th ed. Philadelphia, PA.
Lippincott Williams & Wilkins; 2012.
8. Stallings VA, Stark LJ, Robison KA, Feranchak AP, Quinton H, The Clinical Practice Guidelines on Growth and
Nutrition Subcommittee. Evidence-based practice recommendations for nutrition-related management of children
and adults with cystic brosis and pancreatic insufciency: results of a systemic review. J Am Diet Assoc. 2008;108
suppl 5:8329.
9. Ramsey BW, Farrell PM, Pencharz P, Consensus Committee. Nutritional assessment and management in cystic
10. Schibli S, Durie PR, Tullis ED. Proper usage of pancreatic enzymes. Curr Opin Pulm Med. 2002;8(6):5426.
11. Cohn JA, Friedman KJ, Noone PG. Relation between mutations of the cystic brosis gene and idiopathic pancreatitis.
N Engl J Med. 1998;339:6538.
12. Bell SC, Saunders MJ, Elborn JS, Shale DJ. Resting energy expenditure and oxygen cost of breathing in patients
with cystic brosis. Thorax. 1996;51:12631.
13. Murphy JL, Wootton SA, Bond SA, Jackson AA. Energy content of stools in normal healthy controls and patients
with cystic brosis. Arch Dis Child. 1991;61:495500.
14. Dodge JA. Nutritional requirements in cystic brosis: a review. J Pediatr Gastroenterol Nutr. 1988;7 suppl 1:S811.
15. Dodge JA, Turck D. Cystic brosis: nutritional consequences and management. Best Pract Res Clin Gastroenterol.
2006;20 suppl 3:53146.
16. Slesinenski MJ, Gloninger MF, Costantino JP, Orenstein DM. Lipid levels in adults with cystic brosis. J Am Diet
Assoc. 1994;94:4028.
17. Rhodes B, Nash EF, Tullis E, Pencharz PB, Brotherwood M, Dupuis A, Stephenson A. Prevention of dyslipidemia
in adults with cystic brosis. J Cyst Fibros. 2010;9:248.
18. Figueroa V, Milla C, Parks EJ, Schwarzenberg SJ, Moran A. Abnormal lipid concentrations in cystic brosis. Am J
Clin Nutr. 2002;75:100511.
19. Georgiopoulou VV, Denker A, Bishop KL, Brown JM, Hirsh B, Wolfenden L, Sperling L. Metabolic abnormalities
in adults with cystic brosis. Respirology. 2010;15:8239.
20. Hull JH, Garrod R, Ho TB, Knight RK, Cockcroft JR, Shale DJ, Bolton CE. Increased augmentation index in
patients with cystic brosis. Eur Respir J. 2009;34 suppl 6:13228.
21. ONady GM, Farinet CL. An adult cystic brosis patient presenting with persistent dyspnea: case report. BMC
Pulm Med. 2006;6:912.
22. Aratari MT, Venuta F, DeGiacoma T, Rendina EA, Anile M, Diso D, Francioni F, Quattrucci S, Rolla M, Pugliese
F, Liparulo V, DiStasio M, Ricella C, Tsagkaropoulos S, Ferretti G, Coloni CF. Lung transplantation for cystic
brosis: ten years of experience. Transplant Proc. 2008;40:20012.
23. Macdonald A, Holden C, Harris G. Nutritional strategies in cystic brosis: current issues. J R Soc Med. 1991;
84 suppl 18:2835.
128
24. MacDonald A. Nutritional management of cystic brosis. Arch Dis Child. 1996;74:817.
25. Smyth AR, Bell SC, Bojein S, Bryon M, Duff A, Flume P, Kashirskaya N, Munck A, Ratjen F, Schwarzebberg SJ,
Sermet-Gaudelus I, Southern KW, Taccetti G, Ullrich G, Wolfe S. European Cystic Fibrosis Society standards of
care: best practice guidelines. J Cyst Fibros. 2014;13:2342.
26. Sinaasappel M, Stern M, Littlewood J, Wolfe S, Steinkamp G, Harry GM, Heijerman HGN, Robberecht E, Doring
G. Nutrition in patients with cystic brosis: a European consensus. J Cyst Fibros. 2002;1:5175.
27. Borowitz D, Durie PR, Clarke L. Gastrointestinal outcomes and confounders in cystic brosis. J Pediatr Gastroenterol
Nutr. 2005;41(3):27385.
28. Hollander FM, DeRoos NM, Dopheide J, Hoekstra T, Van Berkhout FT. Self-reported use of vitamin and other
nutritional supplements in adult patients with cystic brosis. Is daily practice in concordance with recommendations?
Int J Vitam Nutr Res. 2010;80(6):40815.
29. Palmery M, Saraceno A, Vaiarelli A, Carlomagno G. Oral contraceptives and changes in nutritional requirements.
Eur Rev Med Pharmacol Sci. 2013;17:180413.
30. Siwamogsatham O, Dong W, Binongo JN, Chowdhury R, Alvarez JA, Feinman SJ, Enders J, Tangpricha
V. Relationship between fat-soluble vitamin supplementation and blood concentrations in adolescents and adult
patients with cystic brosis. Nutr Clin Pract. 2014;29:4917.
31. Aris RM, Merkel PA, Bachrach LK. Guide to bone health and disease in cystic brosis. J Clin Endocrinol Metab.
2005;90(3):188896.
32. Lrgroux-Gerot I, Leroy S, Prudhomme C. Bone loss in adults with cystic brosis: prevalence, associated factors,
and usefulness of biological markers. Joint Bone Spine. 2012;79(1):737.
33. Moran A, Becker D, Casella SJ. Epidemiology, pathophysiology, and prognostic implications of cystic brosis
related diabetes: a technical review. Diabetes Care. 2010;33(12):267783.
34. Moran A, Dunitz J, Nathan B, Saeed A, Holme B, Thomas W. Cystic brosis related diabetes: current trends in
prevalence, incidence and mortality. Diabetes Care. 2009;32(9):162631.
35. Moran A, Brunzell C, Cohen RC, Katz M, Marshal BS, Onady G. Clinical care guidelines for cystic brosis related
diabetes: a position statement of the American Diabetes Association and a clinical practice guideline of the Cystic
Fibrosis Foundation, endorsed by the Pediatric Endocrine Society. Diabetes Care. 2010;33:2697708.
36. Ledson M, Tran J, Walshaw M. Prevalence and mechanisms of gastro-esophageal reux in adult cystic brosis
patients. J R Soc Med. 1998;91:79.
37. Orenstein S, Khan S. Gastroesophageal reux. In: Walker W, Goulet OJ, Kleinman R, Sherman P, Shneider B,
Sanderson I, editors. Pediatric gastrointestinal disease: pathophysiology, diagnosis, management. 4th ed. Ontario:
BC Decker; 2003.
38. Yen EH, Quinton H, et al. Better nutritional status in early childhood is associated with improved clinical outcomes
and survival in patients with cystic brosis. J Pediatr. 2013; 162:530535. e 531.
39. About BMI for Childrens and Teens. Centers for Disease Control and Prevention. 2015. http://www.cdc.gov/
healthyweight/assessing/bmi/childrens_bmi/about_childrens_bmi.html.
40. About BMI for Adults. Centers for Disease Control and Prevention. 2015. http://www.cdc.gov/healthyweight/
assessing/bmi/adult_bmi/.
41. Reem HM, Weiner DJ. Overweight and obesity in patients with cystic brosis: a center-based analysis. Pediatr
Pulmonol. 2014. doi:10.1002/ppul.23033.
42. Farrell PM, Kosorok MR, et al. Early diagnosis of cystic brosis through neonatal screening prevents severe
malnutrition and improves long-term growth. Wisconsin Cystic Fibrosis Neonatal Screening Study Group.
Pediatrics. 2001;107:113.
Chapter 9
Nutrition Intervention
Ala K. Shaikhkhalil, Suzanne H. Michel, Maria R. Mascarenhas, and Virginia A. Stallings
Key Points
Optimizing nutrition and obtaining goal body mass index is correlated with improved survival in
children and adults with cystic brosis (CF).
Maintaining an adequate intake of nutrients is often challenging in this patient population and
nutrition interventions become necessary.
Education, behavioral counseling, oral formulas, and calorie boosting are commonly used to
increase energy intake.
When interventions using the oral route are not sufcient to maintain weight and or growth, enteral
tube feeding is used.
Management of enteral tube feeding requires knowledge of caloric requirements, methods of
administration including use of enzymes and choice of formula, effect of tube feeding on quality
of life, and long-term health and pulmonary outcomes related to its use.
Appetite stimulants can serve as an adjuvant to other interventions and have been proven to provide
nutrition-related advantages with a reasonably safe side effect prole.
There is a role for using parenteral nutrition in severely ill patients, those who have short bowel, or
cant tolerate enteral nutrition
Well-designed, large-scale clinical trials are required to provide additional evidence on what
interventions are appropriate given the complexity of modern CF care.
Keywords Cystic brosis Nutrition interventions Oral supplements Calorie boosting Enteral
tube feeding Appetite stimulants Parenteral nutrition
A.K. Shaikhkhalil, M.D. (*)

Division of Gastroenterology, Hepatology and Nutrition, The Ohio State University College of Medicine,
Nationwide Childrens Hospital, 700 Childrens Drive, Columbus, OH 43205, USA
S.H. Michel, M.P.H., R.D., L.D.N.
Pulmonary Medicine, Medical University of South Carolina, PO Box 1674, Folly Beach, SC 29439-1674, USA
M.R. Mascarenhas, M.B.B.S. V.A. Stallings, M.D.
Division of Gastroenterology, Hepatology and Nutrition, Childrens Hospital of Philadelphia,
Philadelphia, PA, USA
129
A.K. Shaikhkhalil et al.
130
Abbreviations
BMI
BMR
CF
CFF
COA
FFM
GERD
PEG
PERT
PI
PN
ppFEV1
PS
RD
STF
WHO
Body mass index

Basal metabolic rate
Cystic brosis
Cystic brosis foundation
Fat-free mass
Gastroesophageal reux disease
Percutaneous endoscopic gastrostomy
Pancreatic insufcient
Parenteral nutrition
Percentage of predicted forced expiratory volume in 1 second
Pancreatic sufcient
Registered dietitian
Supplemental tube feeding
World Health Organization
Introduction
Optimal energy intake is paramount for persons who have CF. There is conicting evidence describing
energy intake by persons who have CF. Some research describes inadequate intake therefore
compromising weight and linear growth, [15] other studies reveal adequate energy intake, with
varied fat intake [6, 7]. Use of diet records may not provide data reective of actual intake and
therefore be unreliable [7, 8]. Determining appropriate energy intake for persons who have CF is
challenging and impacted by a constellation of factors including: sex [9, 10], age [11], pulmonary
status [12, 13], gastrointestinal status with resultant maldigestion and malabsorption [9], pubertal
stage [14], pulmonary exacerbation [15], fat-free mass [10], genotype [16, 17], physical activity [18],
and medical complications such as CF-related liver disease and diabetes [19].
Mathematical formulas are available to estimate patients energy needs [1921]. Trabulsi et al.
evaluated formulas and concluded the estimated energy requirement of the Dietary Reference Intake
at the active level is best for the CF population, see Table 9.1 [19, 21]. Formulas are best used as a
starting point for calculating energy needs. Increases in weight and stature (length or height), velocity
of increase in weight and length/height, and fat stores are best used to assess adequacy of energy
intake. In clinical care, adjustment in energy estimated intake may be needed to achieve optimal
weight and linear growth.
In general, energy intake of 110% or greater (up to 200%) of that for persons without CF is
recommended, this needs to be individualized to reect each patients energy needs [22]. Little is
known about energy needs specic to pancreatic sufcient patients. A diet high in fat, with 3540%
of calorie intake as fat, is necessary to meet high energy needs in patients with PI [22, 23]. Although
there are no specic recommendations regarding the type of fat to be consumed, to prevent essential
fatty acid deciency a diet containing adequate energy, a balanced intake of polyunsaturated fatty
acids n-6 and n-3, and antioxidants is best [23, 24]. Vegetable oils such as ax, canola, and soy, and
cold-water marine sh are good sources of linolenic acid and energy [23]. Breast milk is a good
source of DHA and is recommended for infants [23].
131
Table 9.1 Determination of energy requirements per US Cystic Fibrosis Foundation using active level
1. Calculate basal metabolic rate (BMR) using WHO equations.
Age range in years
Females
03
61.0 wt 51
1018
12.2 wt + 746
1830
14.7 wt + 496
Males
60.9 wt 54
17.5 wt + 651
15.3 wt + 679
2. Calculate the daily energy expenditure (DEE) by multiplying the BMR by activity plus disease coefcients.
Activity coefcients (AC)
Disease coefcients
Conned to bed: BMR 1.3
FEV1 > 80% predicted: BMR (AC + 0)
Sedentary: BMR 1.5
FEV1 4079% predicted: BMR (AC + 0.2)
Active: BMR 1.7
FEV1 < 40% predicted: BMR (AC + 0.3a)
3. Calculate total daily energy requirements (DERs) from DEE and degree of steatorrhea. If a stool collection is not
available to determine the fraction of fat intake, an approximate value of 0.85 may be used in the calculation. For
pancreatic sufcient patients and pancreatic insufcient patients with a coefcient of fat absorption (COA) > 93%
of intake, DER = DEE. For example: a patient with a COA of 0.78 the factor is 0.93/0.78 or 1.2. If the COA is not
known the factor is 1.
Example:
Ten year old boy. Weight = 32 kg; AC = active; FEV1% predicted = 85%. COA not available.
12.2 32 + 746 = 1136
1136 (1.7 + 0) = 1931
1931 1.1 = 2124 cal/day
a
May range up to 0.5 with very severe lung disease
It is logical to expect that diet counseling and provision of oral energy supplements will result in
increased total caloric intake and improved anthropometric measures. Yet the data from research
studies are inconsistent. Early work documenting the change to high-fat diets with patients previously
maintained on low-fat diets showed improved energy intake and BMI, as shown by Corey et al. in the
1988 report of better survival in patients consuming a high fat diet [1]. Recent work does not provide
a clear answer regarding the success of interventions to increase energy intake through diet counseling
and/or oral supplements and improvement in health parameters such as BMI. In a study by White
et al. adults did not achieve recommended energy and fat intake. The sickest patients used gastrostomy
tubes and although they achieved increased energy intake, BMI did not change [25]. Home visits,
improved adherence to supplemental enzymes, and energy supplements promoted increased energy
intake in patients less than 5 years of age [26]. Steinkamp et al. [27] randomized thirty-six CF patients
to standard nutrition counseling or nutrition counseling plus an energy supplement rich in fat and
linoleic acid. Those who received the energy supplement had greater energy intake, weight gain, and
fat mass than those who did not. No improvement was found in a group of malnourished patients with
CF provided either an oral energy supplement or diet counseling [28]. Use of an oral protein energy
supplement with mildly malnourished patients did not result in improvement in BMI [29]. A Cochrane
review of efcacy of oral supplements in CF care concluded that no benet was seen for moderately
malnourished patients [30]. Use of diet counseling, oral supplements, and/or tube feeding did not
result in improved BMI for patients waiting for lung transplant. Weight gain was achieved after lung
transplant. Groleau et al. [31] reported improved energy intake, growth status, and muscle stores in
school age children with mild lung disease given a structured, easily absorbable lipid supplement, or
a placebo supplement with the same energy level [32]. Supplemental energy intake was approximately
100 cal daily for both groups. This is the rst randomized placebo controlled trial that showed
sustained increase in energy intake and a growth response.
132
Studies have shown that behavioral intervention is feasible in toddlers [33], can be incorporated
into clinical practice [34], and resulted in increased knowledge and self-management skills in relation
to nutrition and PERT in adult subjects [35]. In a study by Stark et al. in 2009 [36], behavior
modication with nutrition intervention resulted in short-term increase in energy intake and BMI
when compared to nutrition intervention alone, but long-term evaluation revealed that both groups
had similar outcomes.
The energy demands of the diet for CF and the resultant diet recommendations can impact parent/
child relations starting in infancy and continuing throughout life. Parents of infants newly diagnosed
with CF exhibit adaptive feeding behavior [37]. Stark and Powers described parenting behaviors
surrounding meals that interfered with normal feeding development in young children [38, 39].
Adolescents and young adults with CF reported poorer quality of life when prescribed oral formulas
or tube-feeding [40].
To achieve an energy intake that promotes normal weight and growth yet avoids negative feeding/
eating behavior; diet education should be addressed in a step-wise fashion based in patient-centered
care with behavior modication and motivational interviewing. Using benchmarking and quality
improvement the Cystic Fibrosis Foundation (CFF) recommends techniques described in Table 9.2
[41]. Additionally, using quality improvement strategies may improve overall nutrition status at CF
Centers [41]. Chapter 18 provides a full review of nutrition-related quality improvement experience.
Incorporating methods of motivational interviewing into the design of the patients nutrition plan and
education may improve energy intake.
Maneuvers specic to increasing oral energy intake (increasing caloric density) include boosting
usual food intake and use of proprietary energy supplements in the form of drinks and/or energy bars.
Table 9.2 Nutrition smart changes ideas and benchmarking recommendations
Nutrition smart change ideas
1. Re-educate and set goals with patient and family surrounding increasing calories and vitamins/minerals and
proactive nutrition
2. Prevent malabsorption: Routine enzyme use in pancreatic insufcient patients. Review and evaluate use
3. Increase RD patient contact time and frequency
4. Provide standard screening and/or assessment of nutrition at every visit
5. Assess and address feeding behaviors
6. Form relationships with and increase referrals to gastroenterology, endocrinology, and psychology. Treat adverse
pulmonary, endocrine, and/or gastrointestinal symptoms
7. Formulate individual nutrition action plan with mutual goals set by patient, family and CF care team at every visit
8. Introduce the idea of a g-tube early in CF care
9. Standardize nutrition interventions
10. Provide more frequent monitoring of at risk patients: clinic visits, phone calls, emails, Skype
11. Have nutrition protocols in place
12. Perform in-depth reviews of patient nutritional status at a time other than clinic visits and activate nutrition care
plans
Benchmarking
1. Dene nutrition status at every visit as goal is prevention not rescue
2. Involve the whole team and meet regularly with focus on patient nutrition
3. Increase RD time and frequency
4. Develop patient take-home materials
4. Develop patient take-home materials
5. Increase g-tube use earlier rather than later
6. Assure that every team member and family know the nutrition assessment
7. Develop consensus that a patient without acceptable nutrition status needs an intervention
8. Deliver message to families by all team members regarding the importance of nutrition
9. Use the services of gastroenterology
133

10. Increase RD time for:
a. One on one nutrition education
b. Information on increasing calories
c. Obtaining diet history
11. Take-home material examples
a. Information from PortCF
b. Growth curve
c. Written nutrition information
d. Notebook for families to keep nutrition plan and materials
e. Menus
f. Information about appropriate websites
g. Nutrition information in quarterly newsletters
12. Team to support g-tube as part of CF care
13. All team members should feel empowered to bring up the idea of a g-tube
The goal of boosting a meal or snack is to increase the energy content without increasing the volume
of food and beverages, see Table 9.3 for an example. Concentrating formula or adding powdered
formula to expressed breast milk to increase to 24 or 27 calories per ounce (cal/oz) may be used with
infants. Increasing energy content to 30 cal/oz may be achieved with the addition of a high calorie
additive such as: Solcarb, Duocal, or MCTProcal. Energy content of infant solid foods can be
increased by using homemade baby foods thinned with infant formula or breast milk and adding fat
calories via butter, margarine, or vegetable oil. Parents may need direction from the CF Center RD as
to how to prepare homemade high calorie infant and toddler foods. Use of soft, energy-dense foods,
such as ripe avocado, contributes to overall energy intake. Directing parents toward high calorie
commercially prepared baby foods, including meats, will avoid the pitfalls of an infant/toddler diet
with excess amounts of lower calorie fruits and vegetables. Baby food companies provide lists of high
calorie baby foods, which are helpful to parents in choosing higher calorie products (Table 9.3).
Teaching parents and patients how to increase calories without increasing food/beverage volume is
central to optimizing energy intake in children. Boosting usual food intake introduces techniques
for high calorie additives to the usual diet and selecting high calorie foods rather than those lower
in calories. Table 9.3 provides an example of boosting a breakfast meal. High calorie additives and
spreadable include, but are not limited to: heavy cream, cheese, mayonnaise, butter, vegetable oil,
cream cheese, avocado, and thick salad dressings. Other more unusual ideas include: olives, ice cream
sprinkles, chocolate chips, and chopped nuts. The childs development level must be considered when
selecting the additive. Examples of higher calorie snack foods for a young child are: mini mufn vs
dry cereal; cereal bar vs. puff cereal, whole milk with added cream vs. plain milk; full-fat yogurt vs.
low fat yogurt. Many other ways to increase energy intake without increasing food volume can be
found at the CFF website, PORTCF website, and others such as Chef4CF.com.
Some persons with CF require even more calories than easily achieved with boosting usual food
intake. Canned or powdered supplemental nutritional products may be used. Taste fatigue and cost
often determines which product and how long a patient will use this approach. Some health insurance
plans pay for nutritional supplements, although in most cases they do not. Patient assistance programs
available through companies that make pancreatic enzyme medications provide a small amount of
supplemental nutritional products monthly. See Table 9.4 for a list of products provided through
company programs. There is limited evidence documenting the benet of the use of oral supplemental
nutrition products in increasing total caloric intake and weight gain. With appropriate use of pancreatic
enzyme replacement therapy (PERT), patients will digest and absorb these products as well as usual
foods [42]. Patient taste preference is a factor and inuences the product selection. Higher calorie
134
Table 9.3 Example of Boosting a meal
Food
cup oatmeal
Made with water
cup whole milk on oatmeal
Calories
83
cup orange juice

Toast 1 slice
1 tsp jelly
61
69
18
65
Food
cup oatmeal
Made with cup super milka
cup Super milk on oatmeal
1 tsp soft margarine on oatmeal
1 tbsp walnuts in oatmeal
cup orange juice
Toast 1 slice
1 tsp jelly
1 tsp soft margarine
Total calories:
296
Super milk: 4 oz whole milk with two tablespoons of cream
Calories
83
165
165
33
48
61
69
18
33
675
Table 9.4 Nutrition Supplements Available Through

Supplemental Enzyme Company Patient Assistance Programs:
October 2014
AbbVie (Creon)
Similac
Pediasure
Pediasure Peptide 1.5
Pediasure 1.5
Ensure Complete
Ensure Plus
Ensure Clear
Zone PerfectBars
Myoplex 30Bars
Myoplex Ready to Drink Shake
Forest (Ultresa, Zenpep)
Scandishake
Scandical
BoostVHC
Boost Kid Essential 1.5
Boost Plus
Cliff Bar
Cliff Kid Bar
Chiesi (Pertzye)
Patient will receive $75, up to $225 for each 3-month supply of
enzyme, to use for vitamins and nutritional supplements
products may have a thicker texture. Some patients use milk-based powdered supplements mixed with
whole milk and heavy cream to make a high calorie, lower cost supplement from typically available
foods. Another strategy to add calories without volume is the use of high calorie commercial additives
such as: Scandical, Solcarb, Polycose, Duocal, MCTProcal, and Microlipid. These products
are slowly added to the diet with adjustment of enzymes as needed based on the fat content of the
product.
Children and adults with CF need to consistently consume sufcient calories to optimize weight
status and ensure childhood growth at the individuals genetic potential. Achieving calorie goals is
challenging and requires the expertise and support of the CF Center dietitian and other experts who
will help support improving feeding and eating behavior.
135
Enteral Tube Feeding

Supplemental enteral tube feeding generally involves overnight delivery of a commercially available
enteral formula by the nasogastric, gastrostomy, or jejunostomy route. Below is a discussion of
indications, methods of administration, in addition to advantages and complications of supplemental
tube feeding (STF).
Indications of Supplemental Tube Feeding in Patients with CF

The decision to start STF should be individualized taking into consideration many factors including
patients nutrition status, success of previous nutrition interventions, comorbid conditions, in addition
to psychosocial factors and, nancial and time resources that will affect adherence. While evidence
regarding the optimal time to initiate STF is scarce; what is available seems to point to better outcomes
when STF is introduced before the patient has advanced lung disease [43, 44]. On the other hand,
individuals with advanced lung disease and who are candidates for transplantation may benet from
pre-operative STF.
STF is considered when behavioral and dietary interventions to improve nutritional status have
failed in patients with clinically signicant weight or growth decits. These approaches are discussed
elsewhere in this chapter and in Chapter 13. Diagnosis and treatment of CF and non-CF-related comorbidities (such as CF-related diabetes, liver disease, constipation, or bacterial overgrowth) are
important to understand the etiology and treatment of suboptimal nutritional and growth status in
patients of all ages.
In 2008 the CFF updated the denition and approach to nutritional status monitoring using weight
for stature [22] to employ age appropriate BMI criteria that are based on CDC growth charts [45]. Use
of the percentage of ideal body weight method is no longer recommended [23]. The monitoring
approach, guidelines, and denitions are summarized in Table 9.5.
The STF literature in CF includes patients with different degrees of malnutrition. Many studies
[44, 4649] were conducted before the 2008 changes in approach to weight for stature assessment
[22] (see Table 9.5). Some studies evaluated STF in patients with a weight z score of < 1.0 [46,
5052], while others intervened in participants with more signicant malnutrition and weight z
score < 2.0 [44, 48, 49].
Bradley et al. [50] is one of the few studies that used an outcome benchmark of BMI >50th
percentile [22] for their intervention in 20 children with an average age of 9 years and included a one
year follow-up. The authors found that children who received STF were ten times more likely to
attain the BMI goal than control subjects with similar baseline characteristics. Control subjects
received standard nutrition management including dietitian evaluation, counseling, and in some oral
nutritional supplements and/or appetite stimulants. The observed BMI gain in STF-treated children
was sustained up to 12 months. White et al. [53], in the UK, retrospectively studied a cohort of adults
with CF. Patients were eligible for STF with a BMI <19, or with a history of a minimum 5% weight
loss over 2 months and failure of oral nutrition supplements. This study design was generally based
on European consensus recommendations [24] for care of patients with CF. The study included 23
adults, 17 of whom agreed to STF and the remainder declined and served as a comparison group. The
authors found that those who were treated with STF had a signicant increase in weight (average
19.5%), the BMI moved into the recommended range, and lung function was stable over the threeyear follow-up. Patients who did not accept STF had a decline in lung function and no weight gain
over the three years.
136
Table 9.5 CFF recommendations on the appropriate method of
weight for stature assessment by age group (and gender in adults)
modied from [22]
Age group
<2 years
220 years
20 years- women
20 years- men
Recommended method for weight for stature

assessment, goal
Weight for length percentile, 50th percentile
BMI percentile, BMI 50th percentile
BMI 22
BMI 23
The variation in the timing of introduction of STF in research studies highlights the need of
large-scale prospective studies in children and adults to provide the evidence needed to establish
the ideal time to introduce STF across the range of ages and clinical status encountered in the care
of patients with CF.
Using its modied and more clinically applicable denitions [22]; the Consensus Committee
recommends the use of nutritional supplements (oral or enteral) in addition to dietary counseling to
help restore an ideal weight; a measure that has long been linked to improved pulmonary outcomes.
The CFF recommends starting with intensive behavioral intervention and counseling for children
aged 112 years but reported having insufcient evidence to support similar interventions in children
older than 13 years or adults.
Effects of Supplemental Tube Feeding on Pulmonary Function, Nutritional

Status, and Quality of Life
STF is used to achieve an increase in energy intake with the purpose to improve weight, BMI, and
linear growth (in children). Improved nutritional status is associated with better lung function
expressed as percentage of predicted FEV1 (ppFEV1), and most importantly longer survival. The
literature evaluating STF in CF contains no randomized controlled trials directly evaluating these
goals [54]. The ethical implications of randomizing malnourished subjects to a placebo/usual care
treatment arm represent an important barrier to conducting such trials.
Many studies assessed the effect of STF on lung function and frequency of pulmonary exacerbations.
There is no strong evidence that STF resulted in a reduction in pulmonary exacerbations or hospital
days [44, 49, 50, 53]. The effect of STF on ppFEV1, however, varied among studies. Some showed
stable ppFEV1 over study duration [49, 50], others showed improvement or decrease in the rate of
decline of ppFEV1 [47, 52, 53]. One study [44] reported a small initial reduction in ppFEV1 in the rst
year of STF and was followed by stabilization during the second year. Oliver et al. [43] found that
individuals who had ppFEV1 less than 50% at time of gastrostomy tube placement had higher mortality
over one year follow-up than those who had a greater than 50% at baseline. This may highlight the
importance of early intervention with STF and not waiting to offer it as a last resort [23].
There is variability in nutrition outcomes reported in studies of STF in CF. Only two studies
reported absolute changes in weight in addition to changes in BMI percentile [50, 53]. Studies usually
reported changes in BMI z score [44, 48, 49], BMI percentile [44, 46], or weight z score [43, 47]. Only
a few studies evaluated the impact on height [44, 46, 48]. Several studies found signicant improvement
in weight variables with STF that were sustained from one year [49, 50], two years [43, 44, 47, 48],
three years [46, 53], and up to four years [52]. One group [50] found that the degree of improvement
in BMI z score was greater at 6- than at 12-months and speculated that changes in adherence may play
137
a role in this observation. Other STF studies also showed faster or greater gains of weight in the rst
612 months [53, 55]. In a subgroup analysis of 46 subjects, Best et al. [52] found that women had a
negative BMI response following STF and speculated that body image issues may increase reluctance
to use STF in women with CF; this likely will apply to teenage girls.
As for the STF effect on height, Rosenfeld et al. [46] showed that, as expected, height improvement
temporally lagged behind weight improvements and increased from an average of 5th percentile to
10th percentile after 1820 months of STF. Efrati et al. [44] reported that height Z score showed a
trend toward improvement in the second year of STF. Those who started STF in infancy had the
greatest benet. Finally, Van Biervliet et al. [48] showed signicant improvements in catch-up linear
growth after 12 months of STF. Improvements were, however, incomplete especially in peri-pubertal
children.
Most of these studies were retrospective and all but one [50] did not include a control or comparison
group. Generally, the patients were used as their own control when comparing outcomes before and
after STF. The cohorts included in these studies also had variable degrees of baseline malnutrition,
lung disease, energy intake, and enzyme administration; all of which might impact nutrition outcomes.
A systematic Cochrane Review reported that there were no well-designed multicenter randomized
controlled trials of STF in subjects with CF [54]. As mentioned above, the ethical implications
represent a barrier to designing and conducting randomized trials in malnourished participants. There
is, however, great need for prospective multicenter evaluations of feasibility and tolerance of STF,
optimal timing to start STF, choice of formula and method of administration, dose and administration
of PERT, and nally the effect of STF on short- and long-term outcomes that include nutrition status,
lung function, quality of life, and survival.
There is little published on quality of life in patients with CF who receive STF. Gunnel et al.
evaluated the attitudes toward percutaneous endoscopic gastrostomy (PEG) placement by survey with
patients and their families with and without a PEG. Most with PEG, who responded (n = 29), thought
that it helped them gain weight, grow taller, be healthier, and have more energy. They did not perceive
the PEG as painful, embarrassing, or limiting to their abilities to play sports. Those without a PEG
were more likely to perceive it to be painful, to look bad or embarrassing, and were less likely to think
that a PEG would result in improved weight gain or pulmonary function. Van Biervliet et al. [48]
found that parents had more difculty accepting tube feeding than children themselves. Parents also
felt that although they had seen the tube on a doll, they were surprised by the degree of disturbance of
the body image of their child. They also reported that they forgot some of the information provided in
the initial teaching sessions. In a different study of only adults [53], the median time from rst
discussion of STF to initiation of treatment was ve months (range 0.236). A study in adults to
evaluate prevalence of disordered eating, self-image, and quality of life among patients with CF with
variable nutrition interventions (oral supplement, enteral feeds) and CF and healthy controls [40]
reported that those who receive STF were more likely to have a negative body image and a poorer
quality of life compared to the other groups. It is important to note, however, that the subjects on STF
(in this cohort) had the lowest ppFEV1 and it is possible that their worse disease course (and not the
tube feeds alone) played a role in their perception of self and quality of life.
This literature suggests that while patients with CF on STF may have favorable views of their
quality of life and health outcomes; patients and families can experience signicant difculties when
considering and accepting STF. It is important that healthcare professionals introduce the discussion
of STF early, provide guidance and repeated education, and quite possibly the opportunity to meet
with patients and families who have gone through the experience. The Consensus Committee [23]
recommended that STF be discussed as supplemental therapy with positive outcomes as opposed to a
threat, sign of failure, or poor outcome. More research should focus on prospectively assessing
attitudes, quality of life, and barriers experienced by individuals who receive STF and their families.
138
Supplemental Tube Feeding Methods

There is no evidence that one type of enteral access is superior to others for patients with CF. The
Consensus Committee recommended that the choice of tube and technique of placement should be
based on expertise at the CF Center [23]. Options include nasogastric, orogastric, gastrostomy, or
jejunostomy tubes. Gastrostomy feeding was the STF access of choice in patients with CF in the
published literature [43, 44, 46, 47, 49, 50, 52, 53, 56, 57] and likely reects their common use and
low risk of complications. All of the cited studies used continuous nocturnal feeding; this is consistent
with the Consensus Committee recommendations [23] and promotes a more normal eating pattern
during the day.
Nasogastric tubes can be considered for administration of STF when the expected duration of
treatment is short, prior to insertion of gastrostomy tube, or in teenagers who fear signicant changes
to their body image. Jejunostomy feeding was less commonly used and can be delivered through a
surgically created jejunostomy or by extending a gastrostomy catheter to the jejunum. Jejunostomy
feeding may be used in patients with severe gastroesophageal reux (as an alternative or adjuvant to
a surgical anti-reux procedure), those with short bowel syndrome, or more severe feeding intolerance.
Gastroesophageal reux disease (GERD) is common in patients with CF (see Chapter 12).
Gastrostomy (and nasogastric) tube feeding can worsen underlying GERD, but is not a contraindication
to STF. The Consensus Committee [23] stated that many clinicians advocate for assessing the presence
and severity of GERD before initiation of STF so that an anti-reux procedure (fundoplication) can
be considered at the time of gastrostomy tube placement in patients with severe GERD. There is little
information on the outcomes of fundoplication in patients with CF. One study [58] retrospectively
evaluated nutrition and pulmonary outcomes in children with CF who underwent fundoplication (with
or without gastrostomy tube placement). A higher incidence of recurrence of symptoms following
fundoplication was reported compared to children with neurological impairment and severe GERD
treated with fundoplication. Over the course of the follow-up period (average 33 months), the authors
reported that there was no increase in BMI, BMI percentile, or change in the slope of ppFEV1. In a
subgroup analysis, however, children with ppFEV1 greater than 60% at fundoplication showed an
improvement in the slope of ppFEV1. Another study that included adult and pediatric patients [59]
retrospectively evaluated 48 patients with CF who underwent fundoplication, 60% of whom also had
gastrostomy tube placement. This cohort showed signicant reductions in pulmonary exacerbations,
slower rate of decline of ppFEV1, and increased weight gain over the two-year follow-up. Patients
who had milder lung disease and those who received gastrostomy tube feeding exhibited the greatest
benets from fundoplication.
Formula Choice and Calorie Goals

Many studies used intact polymeric formulas for tube feeds in patients with CF [4648, 53] and
reported good tolerance. One author gave all patients with PI semi-elemental formula [49], while
others used elemental or semi-elemental formula in children who developed nausea or diarrhea (not
responsive to change in PERT dose) [43, 49]. Some authors used a mix of intact and elemental or
semi-elemental formula but did not explain why different formula choices were made [44, 50]. Many
studies provided about 50% of estimated energy requirements through STF [43, 46, 4850], while
some delivered a range of 4060% or 2060% [53].The caloric density of the study formulas also
varied. Two groups used 1.0 kcal/mL [43, 44], while the remainder used more calorically dense
formulas with a range of 1.52.0 kcal/mL [4649, 53].
139
The Consensus Committee report [23] stated that intact polymeric formula with high caloric
density (1.52.0 kcal/mL) appeared to be tolerated and delivered adequate calories while minimizing
the volume. The Committee also recommended providing 3050% of estimated energy requirements
with a continuous nocturnal infusion. Calories delivered are titrated based on feeding tolerance and
the patients weight gain and growth response. Clinical experience of some practitioners, in accordance
with the experience of Williams et al. [49], supports using a semi-elemental or elemental formula in
patients who develop nausea, bloating, morning anorexia, or diarrhea with standard formula.
Pancreatic Enzymes and Supplemental Tube Feeding

Data on appropriate dosing and timing of pancreatic enzymes with overnight tube feeds are lacking.
STF studies in children and adults with CF reported variable practices of enzyme administration.
The majority reported giving enzymes orally before overnight feeds and again at the end of the
infusion [43, 44, 48, 50], with one group recommending an additional dose mid-way through the
infusion [48]. Some authors provided enzymes only before the start of feeds [47]. Those who reported
the dose of PERT chose doses similar to a mealtime dose [50], calculated the dose based on the
formulas fat content [43], or gave 2500 lipase units per kg of body weight [47].
The CF Consensus Committee [23] recommended that pancreatic enzymes be given orally in a
mealtime dose just before overnight tube feeding was started and suggested that additional doses may
be needed mid-way or at the end of the feeding. In patients who receive elemental or low fat formula,
pancreatic enzymes administration may not be necessary. More research is needed to determine ideal
methods to administer pancreatic enzymes with STF.
There is no consensus among CF healthcare professionals on method of administration of pancreatic
enzymes to patients who are unable to take them by mouth. Variable practices have been reported
including suspending the capsule contents in a thicker uid and giving as a bolus through the feeding
tube, crushing the capsule contents, and adding them to the feeding bag, or mixing the contents with
sodium bicarbonate then adding them to the feeding bag or giving them directly through the feeding
tube [60]. These practices can increase the risk of clogging the feeding tube. Nicolo et al. [61] reported
success in eliminating clogging of feeding tubes by diluting the contents of the capsule with sodium
bicarbonate before directly administering pancreatic enzymes through the feeding tube.
Complications of Supplemental Tube Feeding

Nasogastric tubes can cause discomfort (especially in patients with nasal polyps) and when dislodged
can increase the risk of aspiration. Studies of gastrostomy tube feeding in CF reported no major
complications such as gastric perforation or wall separation. Granulation tissue [46, 50], redness and
tenderness at the site [48, 56], leakage [43, 46, 48], tube malfunction or displacement [50, 56] were
seen. One study also documented bedwetting and night sweats in some patients [48]. Nausea and
vomiting were also reported and in some cases and responded to treatment with prokinetic agents [46,
56]. STF associated diarrhea improved with elemental or semi-elemental formula [43, 46]. Enzyme
dosing adjustments and obtaining stool for infectious studies (including Clostridium Difficile) are
appropriate in patients who develop diarrhea while on STF.
CF-related diabetes can occur following the initiation of STF [43, 44]. It is possible that the
increase in calories can unmask already existing carbohydrate intolerance. The Consensus Committee
[23] recommended screening for glucose intolerance with measurement two to three hours after
140
initiation and at the end of the feeding cycle on two separate nights after caloric goal is reached.
Blood glucose should also be monitored when patients are ill, receiving steroids, or if they are unable
to gain weight with additional calories.
Other potential complications related to enteral feeding include worsening of existing GERD,
micro-aspiration, or bronchospasm. Assessment for and treatment of GERD is an important component
of considering STF (discussed in the previous section).
Summary
While there are many gaps in the current literature, it appears that delivery of STF can improve
nutritional status and possibly pulmonary health in patients with CF who have weight or growth
decits. The process requires a great deal of education and support from healthcare providers and
commitment on the part of patients and families. STF must be monitored closely and tailored to the
individual needs of the patient with adjustments made in response to changes in nutrition status.
Appetite Stimulants
The use of appetite stimulants is common practice in treating anorexia and promoting weight gain in
children and adults with CF. These agents are not licensed for this indication and controversy regarding
their efcacy and side effect prole continues. As we have outlined so far in this chapter, effective
treatment of weight loss, inadequate weight gain, or growth faltering in CF can be challenging.
Anorexia can be an important contributor to reduced energy intake in CF. The exact mechanism of
anorexia remains uncertain and objective tools for assessment of appetite are lacking. There are
multiple factors contributing to poor appetite and reduced energy intake in CF [62]. Many of these are
unique to CF and some are not. CF-related factors include pulmonary exacerbations, anorective effect
of increased cytokines, GERD, poor gastric emptying, distal intestinal obstruction syndrome, and
constipation. Nasal polyps and sinus disease alter the patients ability to smell and taste food and to
eat while breathing comfortably. Factors that are not unique to CF, but carry great importance, include
depression, anxiety, stress, eating disorder, medication use (i.e., ADHD medications and possibly
antibiotics), economic issues, impact of medical therapies on time and energy to prepare and eat food,
endocrine issues, and nally abnormalities in appetite neuro-transmitters (ghrelin, peptide Y, leptin,
and insulin) [62, 63].The above-mentioned factors are considered when evaluating reduced energy
intake in patients with CF, as successfully treating underlying issues can provide an effective and safe
treatment of malnutrition. If problems with appetite or food intake persist despite treating underlying
issues, then appetite stimulants can be considered based on the individuals needs.
Appetite Stimulants and Mechanisms

There is a variety of medications that have been used for appetite stimulation in CF, these agents have
a range of pharmacological characteristics and include hormones, antihistamines, steroids,
cannabinoids, antidepressants, and antipsychotics. Some of the most studied agents include megestrol
acetate, cyproheptadine hydrochloride, dronabinol, and mirtazapine.
Megestrol Acetate (MA) or Megace is a synthetic, orally active form of progesterone. It is used in
treatment of advanced breast cancer and also in uterine and prostate cancers. It has been used as
141
appetite stimulant in patients with AIDS and cancer where it was found to increase appetite, weight
gain, and promote a sense of well-being [62, 64]. The mechanism of how MA affects appetite has not
been well established. Some of the postulated mechanisms include inhibition of action of tumor
necrosis factor, altering serum cytokine prole, inducing adipocyte differentiation, and stimulating
synthesis and release of neuropeptide Y, a potent appetite stimulant [62, 65, 66]. Given its glucocorticoid
base, it is possible that a portion of the weight gain observed with MA treatment is due to water
retention.
Cyproheptadine Hydrochloride (CH) or Periactin is a rst generation anti-histamine which is both
a histamine and serotonin antagonist with the secondary effect of appetite stimulation [67, 68]. It has
been used as an appetite stimulant in anorexia nervosa [69], tuberculosis [70], and in underweight
adults [71]. The mechanism of action of CH is not fully understood and does not appear to be related
to hypoglycemic-induced hyperphagia or changes in growth hormone secretion [62, 68, 72].
Dronabinol or Marinol is an orally active synthetic cannabinoid with central sympathomimetic
activity. It has reversible effects on appetite, mood, cognition, memory, and perception. It has been
studied in patients with cancer and HIV with noted improvements in appetite and weight gain. In a
comparison trial with MA, it was not as effective but the study was criticized because a low dose of
dronabinol was used [73, 74]. Studies in patients with CF are limited [62, 75].
Mirtazapine or Remeron is a non-adrenergic and specic serotonergic antidepressant and is used
primarily in the treatment of depression. Other uses include appetite stimulation, control of emesis,
anxiolysis, and hypnosis. Sudden cessation will cause withdrawal symptoms. Data regarding use in
patients with CF are limited [62, 76, 77].
Efficacy of Appetite Stimulants in CF

The literature examining appetite stimulants in CF includes case reports and case series [78, 79]. The
number of randomized controlled studies [65, 72, 80] is limited and the ones that exist have relatively
small sample size and heterogeneous study design.
In 2007 Chinuck et al. [66] published a systematic review that evaluated the results of fteen
studies of appetite stimulation in CF (6 peer reviewed papers, 8 abstracts, and 1 letter to the editor).
Out of these fteen reports, ten used MA, one used dronabinol, two used mirtazapine, and one used
CH, and included a total of 139 subjects. Only three studies were randomized and placebo-controlled,
two were double-blinded. Studies evaluating use of MA demonstrated signicant gains in weight in
subjects who received the drug. Two randomized controlled trials used MA as the appetite stimulant
in CF [65, 80]. Both studies found signicant improvements in weight and lung function. The two
studies that evaluated the use of CH showed benecial effects on weight gain and variable results on
lung function [72, 81].
Homnick et al. in 2004 [72] randomized 16 children and adults to receive placebo or CH (4 mg four
times daily) in a double-blinded fashion for 12 weeks. The CH group had more signicant weight
gain, (3.45 kg vs. 1.1 kg), increased weight-for-age Z score, and ideal body weight. Side effects
included transient drowsiness in a few subjects. To evaluate the long-term outcomes of the use of CH
in a more real-life treatment program, the authors asked the subjects to continue the trial in an openlabel design for an additional nine months and started all placebo subjects on CH [81]. Twelve of the
original sixteen completed the subsequent nine months of the study. Subjects who changed from
placebo to CH gained weight signicantly over 36 months and those who continued on CH generally
maintained previously gained weight over the duration of the study. There was no difference in
pulmonary outcomes. Important observations in this study include a fairly signicant variability in the
degree of weight gain among subjects who were switched from placebo to CH (ranged from +1.8 to
+6.3 kg). In the group who continued CH, two subjects lost weight while the remainder maintained
142
their weight. The authors speculated that this variability was caused by changes in adherence after
long-term therapy especially with four-times per day dosing. Decreasing drug effect or intrinsic
individual variations may be factors too.
The authors concluded that after one year of therapy, CH appeared to be safe and well tolerated,
with a small weight gain in most subjects and most of weight gain occurring in the rst few months
of therapy. They, therefore, recommended the use of appetite stimulants as an intermediate step in a
program of CF nutritional interventions.
Marchand et al. [65] published a randomized double-blinded, placebo-controlled study with a
cross-over design. Twelve children with CF were randomized to receive placebo or MA (10 mg/kg/
dose) for 12 weeks, followed by a 12-week wash-out period, and 12 weeks of alternate treatment. The
study outcomes included weight, appetite, caloric intake, and ppFEV1. Importantly half of the study
sample (6 of 12) did not complete the study (three unrelated to the study, two children developed
diabetes while on MA and one developed glucose intolerance while on placebo). Treatment group had
signicant increases in weight gain and weight-for-age- Z score. There was a slight increase in height
in the treatment group. The authors also demonstrated gains in fat mass, fat-free mass (FFM), and
ppFEV1. Many subjects lost weight after the medication was stopped or when the dose was reduced.
In another randomized, double-blinded, placebo-controlled study of MA, Eubanks et al. [80]
included 17 participants who all had PI and met criteria for growth failure for preceding six months.
Subjects were randomized to receiving placebo or MA at 10 mg/kg/day (with adjustment at subsequent
visits as discussed below in the dosing section). The treatment group had signicant increases in
weight, weight-for-age Z score, and ppFEV1 compared with the placebo group. The authors speculated
that the anti-inammatory properties of MA could be playing a role in the improvement of pulmonary
outcomes. When they evaluated the quality of weight gain, Eubanks et al. showed, by use of DXA,
that both fat mass and FFM increased among MA users at 3- and 6-month intervals. In a subgroup
analysis, peri-pubertal children had the most increase in FFM which constituted up to 50% of their
weight gain.
Homnick et al. [81] showed that, in the short term, CH appears to induce more fat mass gain than
FFM. It can be argued, however, that restoration of fat mass and energy stores is of value in
malnourished patients with CF [66] and it is possible that long-term use can result in improvements
in FFM, an outcome linked to ppFEV1. Some studies reported trends toward improvement in quality
of life [65, 80]. Only one study reported an increase in dietary energy and protein intake [80].
A recently published Cochrane Review [82] on the use of appetite stimulants in CF concluded that
both MA and CH, despite many limitations to the studies included, have demonstrated efcacy in
short-term (up to six months) treatment of anorexia in CF patients. It could not be concluded that one
therapy was more effective than the other. The available evidence did not provide enough data to
recommend optimal dosing, duration, or timing of treatment. The authors added that given the
limitations in the available evidence, clinicians should be aware of and monitor for potential side
effects (discussed below) and continuously weigh those against clinical benets in an individualized
fashion. Further, the authors of the Cochrane Review called for future prospective, multi-centered,
adequately powered, randomized trials of appetite stimulation in CF to address some of the many gaps
in our current knowledge.
An important consideration in evaluating the literature pertaining to appetite stimulation in CF is
that the mechanisms of anorexia are not fully understood and there is no validated measure to assess
appetite; it is difcult to study the relationship among appetite, dietary intake, and subsequent weight
gain. The quality and sustainability of weight gain has not been well studied in the literature. Finally,
although many individuals gained weight, it is unclear how many achieved weight gain goals or
reached optimal weight and BMI. Other clinical questions include the optimal dose and duration of
use of appetite stimulants among different age groups, and whether patients awaiting lung transplants
should receive a different therapeutic approach, for example, including timing of the intervention and
possibly avoiding MA due to the speculative risk of osteoporosis.
143
Dosing and Duration of Appetite Stimulants

In a systematic literature review, Chinuck et al. [66] reported variable daily doses of MA ranging from
1.27 to 10 mg/kg or 15 to 800 mg. The doses were often divided in four daily doses. The duration of
use was also highly variable and ranged from 2 to 28 months. Eubanks et al. [80] used MA with a
starting dose of 10 mg/kg/day and increased by 2.5 mg/kg/day for weight gain <2% above baseline at
30 days and decreased the dose for weight gain > 5% at 30 days or >10% at day 60 or 90. The mean
dose of MA was 7.5 mg/kg/day. Marchand et al. [65] commented that when doses of MA were
dropped to 5 mg/kg/day (for irritability and insomnia), weight loss was observed. In their randomized
controlled trial of CH, Homnick et al. [72] used a dose of 4 mg four times daily for three months.
Side Effects of Appetite Stimulants in CF

Use of MA was associated with abnormalities in glucose tolerance [65, 80], development of diabetes
[65], and reversible adrenal suppression [65, 80]. Testicular failure and impotence have been reported
with the use of MA in a patient with CF [79]. Of note, diabetes and impaired glycemic control was
reported with the use of higher MA doses (10 mg/kg/day). Hyperglycemia was reversible in only one
study [80]. Glycaemia should be monitored closely after initiation of MA therapy. Although this has
not been reported in CF population, MA has been speculated to be a risk factor for osteoporosis [66,
83]. Osteoporosis can be a contraindication for CF-related lung transplant. CH side effects were
relatively minor and included sedation, mood changes, and perceived excessive weight gain.
Adherence to appetite stimulants can be a problem given the need for two to four times daily doses.
In summary, appetite stimulants appear to be effective in the short-term to induce weight gain in
patients with CF and anorexia. It is important to evaluate and manage any treatable conditions that
contribute to anorexia. While there are more studies on the use of MA, its side effect prole makes it
a less attractive option and leads to more use of CH in the CF clinical setting. It is important to
individualize therapeutic decisions and discuss the risk-benet ratio with the patient and family.
Our knowledge of appetite regulation has expanded with the understanding of the roles of peptides
and CFTR in appetite regulation which may expand future therapeutic options. Adequately powered,
randomized-controlled trials of various appetite stimulants are needed in CF. Future studies should
incorporate objective methods of assessment of appetite and energy intake, changes in weight
including fat and FFM, sustainability of weight gain in the long-term, side effects, in addition to
potential changes in lung function and quality of life.
Parenteral Nutrition
Studies on the use of parenteral nutrition (PN) in patients with CF are limited. In general PN is used
as a supportive measure when enteral plus oral nutrition cannot be used or fail to maintain or improve
patients nutritional status. In 1980, Shepherd et al. [84] studied 12 subjects with CF for 6 months
before and after 21 days of hyper-caloric PN while hospitalized. They noted catch-up weight and
height gain by 1 month and 3 months, respectively and this continued for 6 months. They also noted
decreased rate of lung infections, improvements in pulmonary function, well-being, and oral intake.
The PN regimen (protein 20%, carbohydrate 20% and fat 40% of calories) used, provided 90100%
RDA for calories and consisted of crystalline amino acids, dextrose, and Intralipid administered via
a peripheral IV. Eight of twelve participants also received IV antibiotics for pulmonary infections.
144
Goal for caloric intake from oral and PN routes was 130% RDA. Some improvement may have been
due to successful treatment of pulmonary infections and treatment of essential fatty acid deciency.
PN tends to be used primarily in the inpatient setting when a patient is critically ill, during a
pulmonary exacerbation, or with severe feeding intolerance. When a patient is NPO, PN is used to
provide full nutrition support. It can also be used to treat essential fatty acid deciency in patients, in
whom enteral supplementation failed (personal experience). Typically, PN is administered via a central
venous line since these patients often have central access for administration of antibiotics. This allows
the provision of a more concentrated PN solution which has a high osmolality. Some patients may
exhibit hyperglycemia, especially when PN is cycled and/or if a patient is on concomitant corticosteroids.
There is experience with Home PN in CF. Allen et al. [85] treated 25 subjects with CF with
declining nutritional and pulmonary status at home over a four-year period. Participants ranged in age
from 4 to 27 years with an average age of 16 and had previously failed a focused enteral approach to
improve nutritional status or linear growth. They had moderate to severe lung disease (mean ppFEV1
40.9%). PN regimens were started in the hospital and advanced to provide 50100% of total daily
needs over several days. Patients were discharged home on stable regimens and some needed insulin.
Weight loss returned within six months after PN was stopped. No change in lung function was noted.
Increased complications were noted while on PN: increased days needed for IV antibiotics, sepsis,
major vessel thrombosis, and mechanical problems. A subset of four subjects accounted for the
majority of the sepsis episodes. More than 50% of patients reported increased energy, better
appearance, weight gain, and less pressure to eat. Negative outcomes included nausea, activity
limitations with infusions, and more nighttime urinary frequency. Skeie et al. [86] followed two
people with severe lung disease and malnutrition on home PN and showed weight gain, improved
exercise tolerance, and increased participation in daily activities. Currently in the USA, the use of
omega-3 fatty acid is popular in patients with chronic inammation. At this time, intravenous sh oil
products are not FDA approved, however their use in CF has been explored. Katz et al. [87] compared
intravenous sh oil (Omegaven10%) to traditional IV fat emulsion containing soybean and safower
oils (Liposyn III 10%) for 1 month (dose of 150 mg/day) in 18 adult patients with CF at home.
During the study period patients were given standard PN (glucose, Novamine amino acid solution
11.4%, Liposyn 20%, mineral, vitamins, electrolytes, and trace elements). Caloric intake from PN
was set at 115% of measured REE with 14% calories derived from protein. No changes were noted in
pulmonary function or with fatty acid panels other than an increase in levels of omega-3 fatty acids.
The authors concluded that the short-term use of IV sh oil products was safe in patients with CF.
Conclusion
The information presented here describes the many approaches to be considered to provide an effective
nutrition intervention for an individual patient within his/her clinical and social environment. Clearly,
more well-designed clinical research is needed to provide additional evidence of what strategies are
best suited to the different degrees of malnutrition, ages, and other clinical and psychosocial variables
in the modern CF care setting.
References
2. Powers SW, Patton SR, Byars KC, Mitchell MJ, Jelalian E, Mulvihill MM, et al. Caloric intake and eating behavior
in infants and toddlers with cystic brosis. Pediatrics. 2002;109(5):E755.
145
children with cystic brosis. J Pediatr Gastroenterol Nutr. 2006;43(5):6519.
4. Kawchak DA, Zhao H, Scanlin TF, Tomezsko JL, Cnaan A, Stallings VA. Longitudinal, prospective analysis of
dietary intake in children with cystic brosis. J Pediatr. 1996;129(1):11929.
5. Moen IE, Nilsson K, Andersson A, Fagerland MW, Fluge G, Hollsing A, et al. Dietary intake and nutritional status
in a Scandinavian adult cystic brosis-population compared with recommendations. Food Nutr Res. 2011;55.
6. Maqbool A, Dougherty KA, Rovner AJ, Michel SH, Stallings VA. Nutrition. In: Alan J, Panitch H, Rubenstein R,
editors. Cystic Fibrosis, vol 242. New York, New York: Informa Healthcare; 2010. p. 30827.
7. Woestenenk JW, Castelijns SJ, van der Ent CK, Houwen RH. Dietary intake in children and adolescents with cystic
brosis. Clin Nutr. 2014;33(3):52832.
8. Trabulsi J, Schall JI, Ittenbach RF, Olsen IE, Yudkoff M, Daikhin Y, et al. Energy balance and the accuracy of
reported energy intake in preadolescent children with cystic brosis. Am J Clin Nutr. 2006;84(3):52330.
9. Allen JR, McCauley JC, Selby AM, Waters DL, Gruca MA, Baur LA, et al. Differences in resting energy expenditure
between male and female children with cystic brosis. J Pediatr. 2003;142(1):159.
10. Stallings VA, Tomezsko JL, Schall JI, Mascarenhas MR, Stettler N, Scanlin TF, et al. Adolescent development and
energy expenditure in females with cystic brosis. Clin Nutr. 2005;24(5):73745.
11. Bines JE, Truby HD, Armstrong DS, Phelan PD, Grimwood K. Energy metabolism in infants with cystic brosis.
J Pediatr. 2002;140(5):52733.
12. Fried MD, Durie PR, Tsui LC, Corey M, Levison H, Pencharz PB. The cystic brosis gene and resting energy
expenditure. J Pediatr. 1991;119(6):9136.
13. Kalnins D, Pencharz PB, Grasemann H, Solomon M. Energy expenditure and nutritional status in pediatric patients
before and after lung transplantation. J Pediatr. 2013;163(5):15002.
14. Barclay A, Allen JR, Blyler E, Yap J, Gruca MA, Asperen PV, et al. Resting energy expenditure in females with
cystic brosis: is it affected by puberty? Eur J Clin Nutr. 2007;61(10):120712.
15. Reilly JJ, Ralston JM, Paton JY, Edwards CA, Weaver LT, Wilkinson J, et al. Energy balance during acute respiratory
exacerbations in children with cystic brosis. Eur Respir J. 1999;13(4):8049.
16. Magofn A, Allen JR, McCauley J, Gruca MA, Peat J, Van Asperen P, et al. Longitudinal analysis of resting energy
expenditure in patients with cystic brosis. J Pediatr. 2008;152(5):7038.
17. Bradley GM, Blackman SM, Watson CP, Doshi VK, Cutting GR. Genetic modiers of nutritional status in cystic
brosis. Am J Clin Nutr. 2012;96(6):1299308.
18. Johnson MR, Ferkol TW, Shepherd RW. Energy cost of activity and exercise in children and adolescents with cystic
brosis. J Cyst Fibros. 2006;5(1):538.
brosis. Pediatr Clin North Am. 2009;56(5):112341.
21. Trabulsi J, Ittenbach RF, Schall JI, Olsen IE, Yudkoff M, Daikhin Y, et al. Evaluation of formulas for calculating
total energy requirements of preadolescent children with cystic brosis. Am J Clin Nutr. 2007;85(1):14451.
22. Stallings VA, Stark LJ, Robinson KA, Feranchak AP, Quinton H, Clinical Practice Guidelines on Growth, et al.
Evidence-based practice recommendations for nutrition-related management of children and adults with cystic
brosis and pancreatic insufciency: results of a systematic review. J Am Diet Assoc. 2008;108(5):8329.
24. Sinaasappel M, Stern M, Littlewood J, Wolfe S, Steinkamp G, Heijerman HG, et al. Nutrition in patients with cystic
brosis: a European Consensus. J Cyst Fibros. 2002;1(2):5175.
25. White H, Morton AM, Peckham DG, Conway SP. Dietary intakes in adult patients with cystic brosisdo they
achieve guidelines? J Cyst Fibros. 2004;3(1):17.
26. Adde FV, Rodrigues JC, Cardoso AL. Nutritional follow-up of cystic brosis patients: the role of nutrition education.
J Pediatr (Rio J). 2004;80(6):47582.
2000;31(4):41823.
28. Kalnins D, Corey M, Ellis L, Pencharz PB, Tullis E, Durie PR. Failure of conventional strategies to improve
nutritional status in malnourished adolescents and adults with cystic brosis. J Pediatr. 2005;147(3):399401.
29. Poustie VJ, Russell JE, Watling RM, Ashby D, Smyth RL, Group CTC. Oral protein energy supplements for
children with cystic brosis: CALICO multicentre randomised controlled trial. BMJ. 2006;332(7542):6326.
30. Smyth RL, Walters S. Oral calorie supplements for cystic brosis. Cochrane Database Syst Rev. 2012;
10, CD000406.
31. Hollander FM, van Pierre DD, de Roos NM, van de Graaf EA, Iestra JA. Effects of nutritional status and dietetic
interventions on survival in Cystic Fibrosis patients before and after lung transplantation. J Cyst Fibros.
2014;13(2):2128.
146
32. Groleau V, Schall JI, Dougherty KA, Latham NE, Maqbool A, Mascarenhas MR, et al. Effect of a dietary intervention
on growth and energy expenditure in children with cystic brosis. Journal of Cyst Fibros. 2014;13(5):5728.
33. Powers SW, Byars KC, Mitchell MJ, Patton SR, Schindler T, Zeller MH. A randomized pilot study of behavioral
treatment to increase calorie intake in toddlers with cystic brosis. Child Health Care. 2003;32:297311.
34. Stark LJ, Opipari-Arrigan L, Quittner AL, Bean J, Powers SW. The effects of an intensive behavior and nutrition
intervention compared to standard of care on weight outcomes in CF. Pediatr Pulmonol. 2011;46(1):315.
35. Watson H, Bilton D, Truby H. A randomized controlled trial of a new behavioral home-based nutrition education
program, Eat Well with CF, in adults with cystic brosis. J Am Diet Assoc. 2008;108(5):84752.
36. Stark LJ, Quittner AL, Powers SW, Opipari-Arrigan L, Bean JA, Duggan C, et al. Randomized clinical trial of
behavioral intervention and nutrition education to improve caloric intake and weight in children with cystic brosis.
Arch Pediatr Adolesc Med. 2009;163(10):91521.
37. Tluczek A, Clark R, McKechnie AC, Orland KM, Brown RL. Task-oriented and bottle feeding adversely affect the
quality of mother-infant interactions after abnormal newborn screens. J Dev Behav Pediatr. 2010;31(5):41426.
38. Janicke DM, Mitchell MJ, Stark LJ. Family functioning in school-age children with cystic brosis: an observational
assessment of family interactions in the mealtime environment. J Pediatr Psychol. 2005;30(2):17986.
39. Powers SW, Paton SR, Henry R, Heidemann M, Stark LJ. A tool to individualize nutritional care for children with
cystic brosis: Reliability, validity and utility of the CF Indiviualized NuTritional Assessment of Kids Eating (CF
INTAKE). Child Health Care. 2005;34:11331.
40. Abbott J, Morton AM, Musson H, Conway SP, Etherington C, Gee L, et al. Nutritional status, perceived body image
and eating behaviours in adults with cystic brosis. Clin Nutr. 2007;26(1):919.
41. Savant AP, Britton LJ, Petren K, McColley SA, Gutierrez HH. Sustained improvement in nutritional outcomes at
two paediatric cystic brosis centres after quality improvement collaboratives. BMJ Qual Saf. 2014;23 Suppl
1:i819.
a semi-elemental and nonelemental formula. J Pediatr. 1998;132(2):2659.
43. Oliver MR, Heine RG, Ng CH, Volders E, Olinsky A. Factors affecting clinical outcome in gastrostomy-fed children
with cystic brosis. Pediatr Pulmonol. 2004;37(4):3249.
44. Efrati O, Mei-Zahav M, Rivlin J, Kerem E, Blau H, Barak A, et al. Long term nutritional rehabilitation by
gastrostomy in Israeli patients with cystic brosis: clinical outcome in advanced pulmonary disease. J Pediatr
45. Kuczmarski RJ, Ogden CL, Guo SS, Grummer-Strawn LM, Flegal KM, Mei Z, et al. 2000 CDC growth charts for
the United States: methods and development. Vital and health statistics Series 11, Data from the national health
survey. Vital Health Stat 11. 2002;246:1190.
46. Rosenfeld M, Casey S, Pepe M, Ramsey BW. Nutritional effects of long-term gastrostomy feedings in children with
cystic brosis. J Am Diet Assoc. 1999;99(2):1914.
patients with gastrostomy tube feedings. J Pediatr Gastroenterol Nutr. 1998;27(1):536.
48. Van Biervliet S, De Waele K, Van Winckel M, Robberecht E. Percutaneous endoscopic gastrostomy in cystic
brosis: patient acceptance and effect of overnight tube feeding on nutritional status. Acta gastro-enterologica
Belgica. 2004;67(3):2414.
49. Williams SG, Ashworth F, McAlweenie A, Poole S, Hodson ME, Westaby D. Percutaneous endoscopic gastrostomy
feeding in patients with cystic brosis. Gut. 1999;44(1):8790.
50. Bradley GM, Carson KA, Leonard AR, Mogayzel Jr PJ, Oliva-Hemker M. Nutritional outcomes following
gastrostomy in children with cystic brosis. Pediatr Pulmonol. 2012;47(8):7438.
51. Truby H, Cowlishaw P, ONeil C, Wainwright C. The long term efcacy of gastrostomy feeding in children with
cystic brosis on anthropometric markers of nutritional status and pulmonary function. Open Respir Med
J. 2009;3:1125.
52. Best C, Brearley A, Gaillard P, Regelmann W, Billings J, Dunitz J, et al. A pre-post retrospective study of patients
with cystic brosis and gastrostomy tubes. J Pediatr Gastroenterol Nutr. 2011;53(4):4538.
53. White H, Morton AM, Conway SP, Peckham DG. Enteral tube feeding in adults with cystic brosis; patient choice
and impact on long term outcomes. J Cyst Fibros. 2013;12(6):61622.
54. Conway S, Morton A, Wolfe S. Enteral tube feeding for cystic brosis. Cochrane Database Syst Rev. 2012;12,
CD001198:114.
55. Steinkamp G, Rodeck B, Seidenberg J, Ruhl I, von der Hardt H. Stabilization of lung function in cystic brosis
during long-term tube feeding via a percutaneous endoscopic gastrostomy. Pneumologie. 1990;44(10):11513.
56. Steinkamp G, von der Hardt H. Improvement of nutritional status and lung function after long-term nocturnal
gastrostomy feedings in cystic brosis. J Pediatr. 1994;124(2):2449.
57. Gunnell S, Christensen NK, McDonald C, Jackson D. Attitudes toward percutaneous endoscopic gastrostomy
placement in cystic brosis patients. J Pediatr Gastroenterol Nutr. 2005;40(3):3348.
147
58. Boesch RP, Acton JD. Outcomes of fundoplication in children with cystic brosis. J Pediatr Surg. 2007;42(8):
13414.
59. Sheikh SI, Ryan-Wenger NA, McCoy KS. Outcomes of surgical management of severe GERD in patients with
60. O'Brien CE, Harden H, Com G. A survey of nutrition practices for patients with cystic brosis. Nutr Clin Pract.
2013;28(2):23741.
61. Nicolo M, Stratton KW, Rooney W, Boullata J. Pancreatic enzyme replacement therapy for enterally fed patients
with cystic brosis. Nutr Clin Pract. 2013;28(4):4859.
62. Nasr SZ, Drury D. Appetite stimulants use in cystic brosis. Pediatr Pulmonol. 2008;43(3):20919.
63. Strang P. The effect of megestrol acetate on anorexia, weight loss and cachexia in cancer and AIDS patients
(review). Anticancer Res. 1997;17(1B):65762.
64. Alexieva-Figusch J, van Gilse HA, Hop WC, Phoa CH, Blonk-van der Wijst J, Treurniet RE. Progestin therapy in
advanced breast cancer: megestrol acetate--an evaluation of 160 treated cases. Cancer. 1980;46(11):236972.
65. Marchand V, Baker SS, Stark TJ, Baker RD. Randomized, double-blind, placebo-controlled pilot trial of megestrol
acetate in malnourished children with cystic brosis. J Pediatr Gastroenterol Nutr. 2000;31(3):2649.
66. Chinuck RS, Fortnum H, Baldwin DR. Appetite stimulants in cystic brosis: a systematic review. J Hum Nutr Diet.
2007;20(6):52637.
67. Bergen Jr SS. Appetite Stimulating Properties of Cyproheptadine. Am J Dis Child. 1964;108:2703.
68. Stiel JN, Liddle GW, Lacy WW. Studies on mechanism of cyproheptadine-induced weight gain in human subjects.
Metabolism. 1970;19(3):192200.
69. Goldberg SC, Halmi KA, Eckert ED, Casper RC, Davis JM. Cyproheptadine in Anorexia-Nervosa. Br J Psychiatry.
1979;134(Jan):6770.
70. Rahman KM. Appetite stimulation and weight gain with cyproheptadine (periactin) in tuberculosis patients (doubleblind clinical study). Med J Malaysia. 1975;29(4):2704.
71. Noble RE. Effect of cyproheptadine on appetite and weight gain in adults. J Am Med Assoc. 1969;209(13):
20545.
72. Homnick DN, Homnick BD, Reeves AJ, Marks JH, Pimentel RS, Bonnema SK. Cyproheptadine is an effective
appetite stimulant in cystic brosis. Pediatr Pulmonol. 2004;38(2):12934.
73. Amar MB. Cannabinoids in medicine: a review of their therapeutic potential. J Ethno-Pharmacol. 2006;105:125.
74. Beal JE, Olson R, Laubenstein L, Morales JO, Bellman P, Yangco B, et al. Dronabinol as a treatment for anorexia
associated with weight loss in patients with AIDS. J Pain Symptom Manage. 1995;10(2):8997.
75. Anstead MI, Kuhn RJ, Martyn D, Craigmyle L, Kanga JF. Dronabinol, an effective and safe appetite stimulant in
cystic brosis. Pediatr Pulmonol Suppl. 2003;25:343.
76. Young J, Danduran MJ, McColley SA, Boas SR. The role of mirtazapine as an appetite stimulant in malnourished
individuals with cystic brosis. Pediatr Pulmonol Suppl. 2000;20S:325.
77. Sykes R, Kittel F, Marcus M, Tarter E, Schroth M. Mirtazapine for appetite stimulation in children with cystic
brosis. Pediatr Pulmonol Suppl. 2006;506:389.
78. Nasr SZ, Hurwitz ME, Brown RW, Elghoroury M, Rosen D. Treatment of anorexia and weight loss with megestrol
acetate in patients with cystic brosis. Pediatr Pulmonol. 1999;28(5):3802.
79. McKone EF, Tonelli MR, Aitken ML. Adrenal insufciency and testicular failure secondary to megestrol acetate
therapy in a patient with cystic brosis. Pediatr Pulmonol. 2002;34(5):3813.
80. Eubanks V, Koppersmith N, Wooldridge N, Clancy JP, Lyrene R, Arani RB, et al. Effects of megestrol acetate on
weight gain, body composition, and pulmonary function in patients with cystic brosis. J Pediatr. 2002;
140(4):43944.
81. Homnick DN, Marks JH, Hare KL, Bonnema SK. Long-term trial of cyproheptadine as an appetite stimulant in
82. Chinuck R, Dewar J, Baldwin DR, Hendron E. Appetite stimulants for people with cystic brosis. Cochrane
Database Syst Rev. 2014;7, CD008190:148.
83. Wermers RA, Hurley DL, Kearns AE. Osteoporosis associated with megestrol acetate. Mayo Clin Proc.
2004;79(12):155761.
84. Shepherd R, Cooksley WG, Cooke WD. Improved growth and clinical, nutritional, and respiratory changes in
response to nutritional therapy in cystic brosis. J Pediatr. 1980;97(3):3517.
85. Allen ED, Mick AB, Nicol J, McCoy KS. Prolonged parenteral nutrition for cystic brosis patients. Nutr Clin Pract.
1995;10(2):739.
86. Skeie B, Askanazi J, Rothkopf MM, Rosenbaum SH, Kvetan V, Ross E. Improved exercise tolerance with longterm parenteral nutrition in cystic brosis. Crit Care Med. 1987;15(10):9602.
87. Katz DP, Manner T, Furst P, Askanazi J. The use of an intravenous sh oil emulsion enriched with omega-3 fatty
acids in patients with cystic brosis. Nutrition. 1996;12(5):3349.
Chapter 10
Pancreatic Insufficiency
Elissa Downs and Sarah Jane Schwarzenberg
Key Points
Pancreatic sufciency (PS) occurs in approximately 1115% of patients diagnosed with cystic
brosis.
Most infants diagnosed with CF PS will progress to pancreatic insufciency in the rst 2 years of
life, although a more gradual decline in pancreatic function is possible.
Testing for pancreatic exocrine status may be conducted annually using the fecal elastase-1 (FE-1)
immunoabsorbent assay to monitor for progression to pancreatic insufciency status.
Although PS generally is associated with milder CFTR phenotypes and better nutritional status,
patients with CF and PS may experience clinically signicant nutritional and gastrointestinal
problems.
Nutritional standards determined by the Cystic Fibrosis Foundation for growth during infancy,
childhood and adolescence, maintenance of appropriate BMI during adult life, and nutrient
adequacy apply to all CF patients regardless of pancreatic status. However, caloric and nutrient
requirements may differ for the CF PS patient and should be evaluated on an individual basis.
Acute pancreatitis may occur in CF PS patients. Testing for pancreatitis is indicated for the CF PS
patient if clinical symptoms are present.
Keywords Pancreatic insufciency Pancreatic sufciency Pancreatic enzyme therapy Coefcient
of fat absorption Immunoreactive trypsinogen Fecal elastase Malabsorption Cholecystokinin
Abbreviations
CCK
CF
CFA
CFF
Cholecystokinin
Cystic brosis
Cystic Fibrosis Foundation
E. Downs, M.D., M.P.H. S.J. Schwarzenberg, M.D. (*)

Department of Pediatrics, Division of Pediatric Gastroenterology, Hepatology, and Nutrition, University of
Minnesota, East Building, 6th Floor, 2450 Riverside Avenue, Minneapolis, MN 55454, USA
149
E. Downs and S.J. Schwarzenberg
150
CFRD
CFTR
FDA
FE-1
IRT
PERT
PI
PS
Cystic brosis-related diabetes

Cystic brosis transmembrane receptor
Food and Drug Administration
Fecal elastase
Immunoreactive trypsinogen
Pancreatic insufciency
Pancreatic sufciency
The Clinical Manifestations of Pancreatic Insufficiency in CF

Since the publication in 1938 by Andersen [1], cystic brosis (CF) has been a disease characterized
by pancreatic insufciency (PI). Careful measurement of pancreatic function and study of the multiple
mutations in the CFTR gene led to recognition of both PI and pancreatic sufcient (PS) CF. The
development of pancreatic enzyme replacement therapy (PERT) and its application to children with
CF dramatically altered the outcomes of this disease. Microencapsulated pancreatic enzyme products
made provision of adequate enzyme therapy achievable. Further improvements in the detection and
management of PI in CF include the development of the fecal elastase test (FE-1), newborn screening,
and FDA regulations requiring testing of pancreatic enzymes.
The pancreas has both exocrine and endocrine functions [2]. Exocrine pancreatic functions include
synthesis and secretion into the duodenum of bicarbonate and a group of digestive enzymes, including
amylase, lipase, and trypsin. Loss of exocrine function leads to maldigestion and subsequent
malabsorption of many macronutrients (starches, proteins, and long-chain fats) and many micronutrients
(including vitamins B12, A, E, D, and K). Nutrients not specically requiring pancreatic secretions for
digestion may be malabsorbed as a result of intestinal hurry, the rapid movement of the small bowel
as undigested fat reaches the colon and creates irritant diarrhea. Fatty stools increase absorption of
dietary oxalates from the fecal stream, creating a risk for oxalate kidney stones.
Today, most North American children with CF are diagnosed at birth and rarely manifest the full
clinical picture of exocrine PI prior to diagnosis and treatment. Clinicians should be aware of the
clinical presentation of exocrine PI (Table 10.1). Children with PI may manifest poor growth, and
adults may have weight loss. Patients with poorly controlled PI may experience severe abdominal
pain, bloating, excessive atus passage, and/or steatorrhea. Some patients are asymptomatic. Absence
or denial of symptoms should not be considered evidence of PS nor should diarrhea and abdominal
pain be assumed to represent inadequate pancreatic enzyme therapy.
The primary endocrine functions are the synthesis and secretion into the bloodstream of insulin
(-cell) and glucagon (-cell) to regulate blood glucose levels. Loss of endocrine function, which
occurs gradually in many CF patients, leads to glucose dysregulation, and, ultimately, cystic brosisrelated diabetes (CFRD; see Chapter 10). Aggressive screening programs now detect CFRD ahead of
serious clinical problems [3]. If not detected early, CFRD may present with weight loss, or be
Table 10.1 Symptoms of exocrine pancreatic insufciency in cystic brosis

Failure to thrive
Short stature
Poor weight gain; weight loss
Hypoproteinemia; edema
Steatorrhea
Derived from [104]
Meconium ileus
Rectal prolapse
Clinical deciency of vitamin A, E, D, K
10 Pancreatic Insufciency
151
asymptomatic until the individual experiences an infection. During illness or infection, individuals
who until then have been glucose tolerant may develop glucose intolerance or diabetes. This condition
may last several weeks after recovery from the illness that precipitated it.
The Pancreas in CF
CFTR protein is expressed in the ductal epithelium of the pancreas, where it allows water and anions
access to the ductal lumen. It is also important in pancreatic bicarbonate transport. In the absence of
functional CFTR, there is diminished ductal uid, increased concentration of proteins in the uid, and
consequent precipitation of solutes in the ducts. The resulting ductal obstruction leads to acinar
damage and brosis [4, 5]. The injury begins in utero, and at birth the pancreas is often severely
damaged. Although some exocrine pancreatic tissue may be present at birth, and endocrine function
appears unimpaired, most individuals homozygous for two severe CFTR mutations are functionally
PI early in the rst year of life [6].
Exocrine PI is the gastrointestinal complication of CF that is most predictable from genotype [7, 8].
Patients homozygous for severe CFTR mutations (class I, II, III, and VI) are generally PI, while
individuals homozygous for mild CFTR mutations (class IV or V), or heterozygous for a mild and a
severe mutation, are generally born PS. This is not to suggest that genotype alone should be used to
make a clinical diagnosis of PI or PS. Investigation of pancreatic function is discussed below.
CFRD occurs in approximately 19% of adolescents and 4050% of adults [9]. The development of
CFRD is complex, involving reduced insulin secretion, genetic factors, insulin resistance, and other
factors [3]. Damage to the - and -cells results from the gradual pancreatic destruction associated
with obstruction of the ductal system.
The pancreas in the patient who is PS is generally not completely normal [10]. Some PS patients
may have diminished bicarbonate secretion or reduced pancreatic enzyme secretion. Because the PI
state requires loss of >85% of pancreatic function [11], PS individuals may have signicant pancreatic
functional impairment and still be clinically PS. Individuals born PS may become PI as they age. In
one study, about 25% of PS patients became PI over a 5-year period. This change may occur very
rapidly in some patients slowly in others [12].
Measuring Pancreatic Insufficiency

Choice of Tests and When to Use Them
PI can be measured by several different methods. Direct measurement, long considered the gold
standard due to high levels of sensitivity and specicity, can be used for research purposes or when
the indirect testing methods are inconclusive. Indirect testing methods, assaying serum or fecal
enzymes or enzymatic activity, are usually low cost, noninvasive, straightforward to perform, and can
largely be done on an outpatient basis. A number of different indirect tests exist with varying
sensitivities and specicities. No test accurately identies mild pancreatic insufciency. In CF patients
with compromised lung function, intubation or procedures that require additional sedation may
aggravate respiratory insufciency [13], and therefore, an indirect test may be preferable. In pediatric
patients, indirect tests may also be preferable as they are less invasive and better tolerated [14].
Tests may also be categorized as useful for diagnosing PI status, for the purposes of initiating PERT,
or tests useful for monitoring adequacy of PERT. The use of indirect tests to monitor adequacy of
PERT has not been standardized and no test thus far has proven completely accurate for this purpose.
152
Direct Measurement Methods

Direct measurement methods are often referred to as invasive tube tests, as they use an enteric tube
to collect stimulated pancreatic secretions from administration of secretin, cholecystokinin (CCK),
combined secretin-CCK, or a meal (Lundh test meal) [15]. Secretin stimulation provokes bicarbonate
production from the ductal cells, while CCK stimulation provokes enzyme secretion from the acinar
cells. Although perhaps easier to perform, the Lundh test meal is no longer widely used as secretin
testing has slightly improved sensitivity to detect mild PI [16].
The secretin stimulation test was modied by Dreiling [17] in 1948 and became the primary
methodology to directly measure pancreatic secretion. As described by Lieb and Draganov [18], a
large bore enteric tube is placed with gastric and duodenal ports and baseline measurements of pH are
taken from both ports. A bolus dose or continuous infusion of secretin is then given; duodenal uid
over the next hour, at 15-min increments, is collected and analyzed for volume, pH, and bicarbonate
concentration. Peak bicarbonate less than the reference range (80130 mEq/L) [18] correlates with PI.
The stimulation test can also be performed with CCK or cerulein, a CCK analogue. In this test, two
double-lumen enteric tubes are placed and again, baseline measurements from gastric and duodenal
ports are obtained [19]. A constant infusion of mannitol and polyethylene glycol is administered
duodenally, while IV CCK or cerulein is administered as a bolus or continuous infusion. Duodenal uid
over the next 80 min is collected in 20-min increments and analyzed for enzymatic output as well as
bicarbonate concentration. Enzymatic activity or concentration should rapidly increase in response to
CCK administration; peak concentration is signicantly decreased in those with pancreatic disease [20].
More recently, variations on the direct stimulation test that are more feasible and better tolerated
by patients were published. One such test is the secretin-stimulated endoscopic test [21], comparable
in performance to the Dreiling test, measuring peak bicarbonate secretion, but at less cost, decreased
procedure time, less radiation exposure, and with greater overall availability [22]. A secretin-enhanced
MRI may allow even mild PI to be detected [23], but would require sedation in younger patients.
While these direct measurement methods are considered the gold standard for diagnosing
pancreatic dysfunction, they are expensive, time consuming, and only performed at specialized centers
[24]. Studies that have compared these direct methods with indirect methods [13] found that some
indirect tests give comparable results with less cost, time commitment, and discomfort to the patient.
Indirect Methods
Currently, the three most commonly used indirect methods of assessing pancreatic insufciency are
coefcient of fat absorption (CFA), FE-1, and serum trypsinogen assays. Other tests will be described,
but have limited use.
Coefficient of Fat Absorption

A quantitative fecal fat measurement can be obtained by the van de Kamer method [25]. This entails
a 72-h stool collection on a diet with a xed amount of fat (80100 g/day in older patients). Normal
fecal fat excretion on this xed-fat diet should be <7 g/day for those aged 10 years and older, or
<45 g/day for those aged 210 years [14].
CFA can then be calculated from this 72-h stool collection comparing exact intake versus excretion
([fat intake fat excretion]/intake 100). CFA values differ by age, with a CFA >85% normal for
infants less than 6 months old [26, 27], and a CFA >93% normal for older infants, children, and adults
[26, 28]. Steatorrhea would then be dened as >15% malabsorption in infants or >7% in adults.
153
CFA values have been found to vary widely in PI CF patients, reective of the multifactorial
etiology of malabsorption in CF [29]; despite the wide range, these values are still markedly abnormal
with CFA values in untreated patients around 40% [29].
Disadvantages of quantifying fecal fat and calculating a CFA include low specicity as steatorrhea
can be caused by conditions such as celiac disease, Crohns disease, or small intestinal bacterial
overgrowth [24]. Thus, the CFA can be abnormal even in pancreatic sufcient patients with
confounding factors. Other disadvantages are that it requires 72 h collection on a xed-fat diet and the
patient must be off pancreatic enzymes if they have already been started [24]. Many patients nd this
test unpleasant. A single stool sample measurement of fecal fat is not recommended as fat content will
vary signicantly based on dietary intake [30].
In a study of CF patients with PI, the percentage fat in multiple single stool samples over several
days had a strong correlation with the CFA and could be used instead of the 72-h stool collection for
total fat measurement or for CFA calculation [31].
Fecal Elastase
The level of FE-1 is the predominately used indirect test. Elastase is an enzyme produced by the
pancreas, is not degraded during intestinal transit, and becomes concentrated in stool [32]. Testing is
via ELISA assay [32, 33], with a normal value dened as >200 micrograms of elastase per gram stool
(g/g). Assays using a monoclonal antibody may have higher sensitivity than those using a polyclonal
antibody [34]. This test is specic for the human enzyme, and will not detect exogenous enzyme
replacement [35]. It has dened sensitivity that detects severe PI more accurately: the sensitivity is
approximately 100% in severe, 77100% in moderate, and 063% in mild PI [3638]. In a study of
infants with cystic brosis, FE-1 was abnormal even at an initial visit around 34 months of age; by 6
months of age, all infants in the study had values <100 g/g [6], leading the authors to conclude this
test should be used early for the monitoring of pancreatic insufciency development. The specicity
of the test is also high (approximately 90%), but this may be decreased in those with type 1 diabetes
or small bowel disease [38].
FE-1 is an attractive test as it is easy to perform, can be done with a single stool sample, and
patients can continue PERT [24]. In some algorithms of diagnosing PI, it is one of the rst steps in the
process [14, 15]. Disadvantages include results that are unreliable on loose stool [39] and in newborn
infants under 2 weeks of age [40]; it also has decreased sensitivity in mild pancreatic insufciency.
FE-1 does not distinguish between primary and secondary causes of PI [39]. False positives can be
due to mucosal villous atrophy from celiac disease, or infectious or allergic enteropathy [41].
Researchers have also identied both within stool and day-to-day mild variation in levels of FE-1.
Thus if results are uncertain (in the borderline area as dened by Hamwi et al. [42] of 25% of the
normal 200 g/g), this assay should be repeated on a different stool sample [38].
Studies comparing CFA, serum immunoreactive trypsinogen (IRT), and FE-1 have shown poor
correlation of these three assays in PS CF patients [43]. FE-1 also has a lower sensitivity and high false
positive rate compared to direct measurement of pancreatic function by secretin-stimulated endoscopic
method [44]. However, for most purposes, the convenience of the FE-1 will outweigh its limitations.
Immunoreactive Trypsinogen
Levels of plasma IRT are elevated in infants with CF [4547]; this test forms the basis of the newborn
screen for CF. However, IRT levels are signicantly elevated in CF infants under 1 year old regardless
of PS or PI status [48]; thus this test would not be appropriate to use in infants to diagnose pancreatic
status. When CF infants become PI, IRT levels fall rapidly and a large proportion of patients will have
154
subnormal values by 6 years old [45], with >95% subnormal by 7 years old [46]. No corresponding
age-related declines have been found in CF patients who remain PS [45, 46]. After 7 years of age, the
difference in IRT levels between the PS and PI patients became statistically signicant [45] and was
an accurate predictor of pancreatic function. Lower IRT levels in older age groups were also
signicantly associated with steatorrhea [47]. The trends in IRT levels could be used to monitor for
the development of PI [46], but only after 7 years of age.
Other Fecal Tests

A stool steatocrit is a rough estimation of stool fat concentration and thus, malabsorption. Values
decline over the rst 3 months of life [49]. It is proposed as a means to monitor fat absorption and
sufciency of PERT in infants [50]. It should not be used to diagnose PI. Acidication of the stool
improves sensitivity of the test [51]. In CF, some groups nd good correlation of acid steatocrit and
CFA [51] and others nd the correlation to be poor [52]. Its advantages are that it can be done on a
small volume of stool (0.5 g) [53]. This test is less accurate in older children as fat is not distributed
evenly throughout stool as it is in younger children [54].
Chymotrypsin, a pancreatic protease, is not degraded in the stool and can be used to assess
pancreatic enzyme secretion. Activity is calculated by units per gram of stool (U/g); values <3 U/g are
abnormal [38]; an abnormal value of <6 U/g may increase the sensitivity of the test [55]. An advantage
to this test is that is can be performed off a single stool sample. It had 100% sensitivity and specicity
in one study in identifying CF patients with total PI [56], but in patients with mild PI, the sensitivity
drops signicantly [55]. Chymotrypsin is altered by exogenous enzyme supplementation, thus the test
may be useful to monitor compliance to therapy [14, 57]. A disadvantage of this test is an increased
rate of false positives in diarrhea stool due to diluted activity [18]. To assay PI, patients need to be off
pancreatic enzymes for several days prior. In comparison to FE-1, chymotrypsin was less sensitive in
detecting mild, moderate, and severe PI [55].
Breath Tests
The breath test is unique in that rather than measuring enzyme levels or enzymatic activity, it measures
triglyceride digestion. Patients are given a meal with labeled triglyceride substrates; the substrates are
then hydrolyzed, absorbed, and waste products are released across the pulmonary epithelium as
labeled CO2 [24]. This can then be measured via breath test at 6 h postingestion of the meal. In healthy
subjects, recovered labeled CO2 has ranged between 20 and 40%, with lower values for younger
children [58, 59]. Studies have demonstrated a sensitivity of 8990% and specicity of 8191% [60,
61]. Examples of different substrates that have been used include 13C-triolein [62, 63], 13C-tripalmitin
[64], and 13C-mixed triglyceride [65, 66].
Other Tests
The serum lipase can be measured in response to a meal challenge (Lundh test meal). A baseline
lipase is measured prior to the meal, and then a peak around 30 min after the meal. Consistently low
levels in response to the Lundh test meal correlated with known severe PI in CF patients [67].
So-called tube-less tests of pancreatic function, including the NBT-PABA test and pancreolauryl
or uorescein dilaurate test are no long used. Studies of newer assays, such as a nonabsorbable lipid
marker (behenic acid) have not shown good enough correlation with CFA to justify use [68].
155
The malabsorption blood test (MBT) is a novel approach to quantifying digestion and absorption
of fat [69]. Simultaneous oral doses of pentadecanoic acid (a free fatty acid) and triheptadecanoic acid
(a triglyceride with three saturated fatty acids) are given. These are naturally occurring but uncommon
lipids. The triheptadecanoic acid must undergo hydrolysis by pancreatic lipase before absorption. On
initial testing, the differential between the absorption of these substrates reected pancreatic digestion.
Ultimately, this may prove to be a useful tool to assess lipase-decient fat malabsorption.
Pancreatic Enzyme Replacement Therapy

Description of Enzyme Therapy
PERT has long been available in the USA for patients with cystic brosis or other causes of pancreatic
insufciency. These formulations are of bovine or porcine origin. Most of them had been in place
prior to 1938 and the enactment of the Federal Food, Drug, and Cosmetic Act, which required new
drugs to obtain government approval. In 1991, the FDA required that pancreatic enzyme replacement
products be provided by prescription only and in 2004, current products required new drug application
approval to assure safety, effectiveness, and product quality [70] by a deadline extended to 2010.
Products have evolved over time with the advent of micro-drug development and enteric coating to
protect the enzymes against gastric acid inactivation. The majority of enzymes currently available in
the USA are formulated in this manner; only one product is not enteric coated.
A non-porcine-derived pancreatic enzyme preparation is desirable for several reasons, including
the batch-to-batch variability associated with an animal-derived product and some religious objections
to animal-derived or porcine products [71, 72]. A synthetic non-porcine enzyme product is in
development and has undergone a phase III trial with outcomes of improved fat and nitrogen
absorption. This formulation contains only biotechnology-derived amylase, lipase, and trypsin
engineered to be stable at acidic pH; it does not require enteric coating. Further clinical trials will be
needed to determine if this approach can replace porcine-derived enzymes.
Dosing Pancreatic Enzymes

PERT should be started in the following situations: (1) based on presence of two CFTR mutations
associated with PI [73], (2) evidence of PI by testing methods as described above, or (3) frank
malabsorption symptoms [74].
Most PERT is provided via enteric-coated formulations to avoid gastric acid inactivation of
unprotected lipase; this coating will dissolve at alkaline pH in the small intestine. The enteric-coated
formulations should not be crushed or chewed [75]. However, the capsules can be opened and mixed
with food such as applesauce or another non-alkaline food to avoid premature dissolution of the
coating and thus enzyme activation [75].
A single pancreatic enzyme preparation is available that is not micro-encapsulated (Viokase).
Some providers use it during enteral feedings, as it can be crushed and added to the formula. It should
be noted that there is no evidence to support this practice. Viokase is also used by some providers to
treat or prevent the pain of chronic pancreatitis by reducing CCK and pancreas secretion [76].
While it is more physiologic to dose enzymes based on the grams of fat per meal, it is more
practical and convenient to use a weight-based dose or standard dose per meal or snack [28, 75].
156
Meal Method
Meal method dosing varies by age. In infants and children, doses per kilogram of body weight are
targeted. In adults, a standard dose is chosen independent of body weight. However regardless of age,
doses should not exceed 10,000 lipase units per kilogram per day [74, 77]. Doses higher than 10,000
lipase units/kg/day may be associated with side effects (see below) [77, 78]. Some authors have
questioned this limit, particularly for young infants, but as yet the optimal dose of enzymes in this
group is unknown [79]. Care should be taken in exceeding the recommended doses without further
evidence.
For infants, enzymes should be given for all types of formula and breast milk feedings [26]. The
capsules should be opened and mixed with an acidic baby food (like applesauce) or cereal. If uncoated
enzyme preparations are used, the infants mouth and gums should be cleaned with sterile water after
administration to prevent mucosal injury [80]. If coated preparations are used, the infants mouth
should be examined for residual microspheres.
The Cystic Fibrosis Foundation (CFF) recommends starting at a standard dose of 20005000 lipase
units per feeding (dened as 120 mL of formula or each breast feeding occurrence) for infants and
those under 12 months of age [26, 74]. For children from 12 months to 4 years of age, an initial dose
of 1000 lipase units per kilogram per meal is recommended. A dose of 500 lipase units per kilogram
per meal is a recommended starting point for older children, adolescents and adults [28, 75]. For all
ages the maximum recommended meal dose is 2,500 lipase units/kg [75]. In a study of Pancrease MT,
a dose of 500 lipase units per kilogram per meal was also well tolerated in infants and toddlers; higher
doses did not increase CFA signicantly [81]. For those consuming snacks, one-half the meal dose
should be given as coverage. Frequent reassessment of dosing is necessary at each visit to ensure
proper growth and weight gain. Doses should be adjusted as needed based on weight and on presence
of symptoms indicative of malabsorption [75].
To avoid excessive dosing for overweight/obese adults another recommendation is to provide
25,00040,000 (up to 75,000) units of lipase per meal, and 500025,000 units of lipase per snack, as
long as doses do not exceed 10,000 units per kilogram per day [24, 77]. Total doses of more than
75,000 units per meal are not recommended [77]. Half of the dose should be taken at the start of the
meal, with the remainder half-way through the meal [57, 82].
Fat Gram Method

Dosing enzymes by amount of fat per meal is more physiologic, but less convenient overall; however
it does take into account that fat intake is relatively higher in infancy and decreases over time [75].
Daily dosing by this method ranges from 500 to 4000 lipase units per gram of fat ingested per day. In
a study of delayed release pancrelipase (Creon), target doses of 4000 lipase units per gram of dietary
fat were well tolerated compared to placebo in those aged 711 years [83] and in those aged >12 years
[84]. In one study, matching enzyme dose to grams of fat per meal led to improvement in symptoms
of abdominal pain and diarrhea [85]. Patients took over twice as many capsules per day on this routine
versus a xed meal dose routine (511.5). If patients or their families are motivated, this regimen is
recommended to optimize absorption.
Enteral Feeds
Individuals who receive nocturnal enteral feeds should divide their doses throughout the feeding, with
a dose at the beginning of the feeding, midway, and at the end administered via the enteral tube [77].
Non-enteric-coated enzymes (Viokase) tablets can also be crushed and mixed directly into the formula
itself to start predigesting the formula [86]. If enteric-coated formulations are used, these should be
157
mixed with applesauce and delivered through a larger bore feeding tube [77]. Alternatively, some
institutions will dissolve the capsule contents in sodium bicarbonate solution and then administer via
the enteral tube [87, 88]. There are no randomized controlled trials to assess the comparative efcacy
of these techniques.
Other Issues
PI may lead to malabsorption of fat-soluble vitamins, including vitamins A, E, D, and K [89]. As
pancreatic enzymes are necessary for the release of vitamin B12 from proteins binding it prior to
complexing with intrinsic factor, deciency of B12 is possible in PI, but with appropriate care it is not
a clinical problem [90]. The CFF recommends supplementation of PI individuals with vitamin
preparations containing both fat-soluble and water-soluble vitamins. Yearly monitoring of vitamins A,
E, and D is recommended [89]. Serum levels of vitamin K are not recommended, as it reects recent
intake.
Complications of Excessive Doses of PERT

In the early 1990s, case reports detailing the development of brosing colonopathy in young children
and adolescents appeared in the UK [91, 92]. During examination of the National Cystic Fibrosis
Patient Registry, a total of 31 cases were identied in the USA between 1990 and 1994 [78] with a
strong dose-dependent response. In their analysis models, a dose between 24,000 and 50,000 lipase
units per kilogram per day had a relative risk of brosing colonopathy of 10.9; higher than 50,000
lipase units per kilogram per day had a relative risk of brosing colonopathy of 199.5. In 1995, a CFF
Consensus statement was published with recommendations to not exceed 10,000 units per kilogram
per day based on this risk [75]. This equates to <2500 lipase units per kilogram per meal or <4000
lipase units per gram of fat per day [89].
Monitoring Effectiveness of Enzymes

Efcacy of therapy is usually monitored clinically on the basis of improvement in symptoms of
steatorrhea and weight gain [57, 89]. If it is unclear whether poor weight gain or diarrhea is the result
of inadequate enzyme administration, some of the methods discussed above, such as the CFA, would
be appropriate measures to assess this [89].
Detecting Failure and Its Causes

Failure of PERT occurs due to numerous factors and analysis should be undertaken on a patient-bypatient basis; a good history should detect a number of these factors and underscores the importance
of working with a registered dietitian well trained in the management of cystic brosis. A common
cause of failure is poor adherence to medication dosing and administration. Rates of adherence have
been problematic in children [93], adolescents, and teenagers [94]. In studies of adolescents and
adults [95, 96], those with more severe disease were found to be more adherent, suggesting the
converse is also true.
158
Dietary factorssuch as excessive juice intake causing toddlers diarrhea or a periodic extremely
high-fat meal that a standard dose of enzymes may not cover [75]all can lead to perceived failure,
and should be assessed with a good diet history before pursuing other interventions.
In addition, other lifestyle factors, such as a perception that enzymes do not need to be given with
all meals or snacks or difculty dosing enzymes for children and adults who graze or snack all day
long [75], should be assessed. Clinicians should query the timing of enzyme administration as well;
enzymes should be taken no more than 30 min before or after a meal [86].
Underdosing may occur based on overall fat intake or when a patient outgrows their body
weight-based dosing. In this sense, underdosing is likely more common with meal method versus the
fat gram method [85]. Dosing may also be sufcient to decrease symptoms of steatorrhea, but may not
be sufcient enough to correct nutritional deciencies [97].
Failure can also be caused by an inappropriate intestinal pH milieu. Uncoated enzymes can be
inactivated by prolonged exposure to gastric acid [98]. Cystic brosis leads to impairment of
bicarbonate secretion [99]; this leads to a relatively acidic duodenal environment that may decrease
dissolution of the coating on micro-encapsulated enzyme replacement therapy [75, 100]. Enzymes
may then be activated in the distal jejunum or ileum, bypassing important areas of nutrient absorption.
Some providers administer proton pump inhibitor therapy in an attempt to reduce gastric acid secretion
and improve intestinal pH.
For enzyme therapy to be maximally effective, the enzymes need to reach the proximal duodenum
in conjunction with food substrate. With delayed gastric emptying, enzymes may exit the stomach
prior to the food bolus; in these patients, PERT is not as successful [101]. If delayed gastric emptying
is suspected, the timing of enzyme administration could be adjusted to midway through or at the end
of a meal [101], which has been shown to optimize efcacy [102]. The addition of non-coated enzyme
could be considered if rapid gastric emptying [86, 101], as this will empty from the stomach earlier
with the liquid portion of the meal.
PERT is costly; some insurance providers do not pay for PERT or pay only part of the costs. This
may lead patients to use fewer enzymes than prescribed. They may also try over-the-counter
enzymes, often sold in health food stores. These do not contain functional pancreatic enzymes and
cannot be substituted for PERT.
Patients with CF may develop confounding gastrointestinal disorders that may cause poor weight
gain or growth failure; this may also lead to perceived failure of PERT. Examples of these conditions
include lactose intolerance, gastroenteritis, small intestinal bacterial overgrowth, celiac disease,
Crohns disease, or Clostridium difficile colitis [75]. Comorbid conditions of CF, including CFRD and
CF liver disease, or pulmonary infections, may lead to poor growth and perceived failure of PERT.
Diagnosis of Persistent Malabsorption

Persistent failure of weight gain or growth when using adequate pancreatic enzyme doses should be
investigated carefully. If adherence and appropriate dosing is known, causes of poor appetite and/or
malabsorption other than PI should be suspected. Increasing enzyme doses above 10,000 lipase units/
kg/day without performing CFA or other tests of malabsorption should not be done. In addition, even
when fat malabsorption is demonstrated at appropriate doses of PERT, other causes should be
considered (see Chapter 11).
Fieker et al. [57] outline a systematic approach to detect causes of failure, starting with assessment
of compliance. If noncompliance is suspected, a fecal chymotrypsin level can be obtained and if low,
then education can be provided on adherence [14, 57]. If the patient is compliant, the lipase dose can
be increased, the diet can be modied, and/or acid suppression can be added. If these interventions fail
159
to reveal an etiology of the failure, further evaluation can be undertaken to look for alternate etiologies
of steatorrhea such as bacterial overgrowth, giardiasis, and blind loop among others, such as celiac
disease [24].
Monitoring PS CF for Developing PI (10%)

Individuals with CF who are PS at birth do not have completely normal pancreas function [4]. They
may remain PS throughout their life, or may become PI at any time during their life [12]. Development
of pancreatitis, which occurs in about 25% of PS CF patients, and most commonly in those with the
best preserved pancreatic function [103], may increase the risk for development of PI as a result of
injury to the pancreas. The CFF recommends that individuals with CF who are PS be evaluated yearly
for possible development of PI [74]. This may be done clinically or by using established tests of
pancreatic function, including CFA, direct pancreatic function, or FE-1 testing. Clinical evaluation
may miss early development of PI.
Conclusion
In summary, PI is a critical complication of cystic brosis, affecting 8090% of patients over the lifespan. Left untreated or undertreated, it can lead to malnutrition, vitamin and mineral deciencies, and
abdominal pain. Fecal elastase provides a simple measure of PI allowing recognition of individuals
transitioning from PS to PI and appropriate use of PERT. Meticulous attention to providing appropriate
doses of PERT, managing malabsorption related to non-PI medical complications, and promoting
adherence to PERT will improve the lives of individuals with CF.
References
1. Andersen DH. Cystic brosis of the pancreas and its relation to celiac disease: a clinical and pathological study.
Am J Dis Child. 1938;56:34499.
2. Owyang C, Williams J. Pancreatic secretion. In: Yamada T, Alpers DH, Kalloo AN, Kaplowitz N, Owyang C,
Powell DW, editors. Textbook of gastroenterology. 5th ed. Oxford: Wiley-Blackwell; 2008. p. 368400.
3. Kelly A, Moran A. Update on cystic brosis-related diabetes. J Cyst Fibros. 2013;12(4):31831.
4. Wilschanski M. Novel therapeutic approaches for cystic brosis. Discov Med. 2013;15(81):12733.
5. Durie PR, Forstner GG. Pathophysiology of the exocrine pancreas in cystic brosis. J R Soc Med. 1989;82 Suppl
16:210.
6. Walkowiak J, Sands D, Nowakowska A, Piotrowski R, Zybert K, Herzig KH, et al. Early decline of pancreatic
function in cystic brosis patients with class 1 or 2 CFTR mutations. J Pediatr Gastroenterol Nutr. 2005;40(2):
199201.
7. Kristidis P, Bozon D, Corey M, Markiewicz D, Rommens J, Tsui LC, et al. Genetic determination of exocrine
pancreatic function in cystic brosis. Am J Hum Genet. 1992;50(6):117884.
8. Kerem E, Corey M, Kerem BS, Rommens J, Markiewicz D, Levison H, et al. The relation between genotype and
phenotype in cystic brosisanalysis of the most common mutation (delta F508). N Engl J Med. 1990;
323(22):151722.
9. Moran A, Dunitz J, Nathan B, Saeed A, Holme B, Thomas W. Cystic brosis-related diabetes: current trends in
prevalence, incidence, and mortality. Diabetes Care. 2009;32(9):162631.
10. Wilschanski M, Novak I. The cystic brosis of exocrine pancreas. Cold Spring Harb Perspect Med. 2013;3(5):
a009746.
11. DiMagno EP, Go VL, Summerskill WH. Relations between pancreatic enzyme outputs and malabsorption in
severe pancreatic insufciency. N Engl J Med. 1973;288(16):8135.
160
12. Walkowiak J, Nousia-Arvanitakis S, Agguridaki C, Fotoulaki M, Strzykala K, Balassopoulou A, et al. Longitudinal

follow-up of exocrine pancreatic function in pancreatic sufcient cystic brosis patients using the fecal elastase-1
test. J Pediatr Gastroenterol Nutr. 2003;36(4):4748.
13. Walkowiak J, Cichy WK, Herzig KH. Comparison of fecal elastase-1 determination with the secretincholecystokinin test in patients with cystic brosis. Scand J Gastroenterol. 1999;34(2):2027.
14. Walkowiak J, Nousia-Arvanitakis S, Henker J, Stern M, Sinaasappel M, Dodge JA. Indirect pancreatic function
tests in children. J Pediatr Gastroenterol Nutr. 2005;40(2):10714.
15. Lindkvist B. Diagnosis and treatment of pancreatic exocrine insufciency. World J Gastroenterol. 2013;19(42):
725866.
16. Gyr K, Agrawal NM, Felsenfeld O, Font RG. Comparative study of secretin and Lundh tests. Am J Dig Dis.
1975;20(6):50612.
17. Dreiling DA, Hollander F. Studies in pancreatic function; preliminary series of clinical studies with the secretin
test. Gastroenterology. 1948;11(5):71429.
18. Lieb 2nd JG, Draganov PV. Pancreatic function testing: here to stay for the 21st century. World J Gastroenterol.
2008;14(20):314958.
19. Go VL, Hofmann AF, Summerskill WH. Simultaneous measurements of total pancreatic, biliary, and gastric
outputs in man using a perfusion technique. Gastroenterology. 1970;58(3):3218.
20. Conwell DL, Zuccaro G, Morrow JB, Van Lente F, Obuchowski N, Vargo JJ, et al. Cholecystokinin-stimulated
peak lipase concentration in duodenal drainage uid: a new pancreatic function test. Am J Gastroenterol.
2002;97(6):13927.
21. Stevens T, Conwell DL, Zuccaro Jr G, Van Lente F, Purich E, Khandwala F, et al. A randomized crossover study
of secretin-stimulated endoscopic and dreiling tube pancreatic function test methods in healthy subjects. Am J
Gastroenterol. 2006;101(2):3515.
22. Conwell DL, Zuccaro Jr G, Vargo JJ, Morrow JB, Obuchowski N, Dumot JA, et al. An endoscopic pancreatic
function test with cholecystokinin-octapeptide for the diagnosis of chronic pancreatitis. Clin Gastroenterol
Hepatol. 2003;1(3):18994.
23. Czako L. Diagnosis of early-stage chronic pancreatitis by secretin-enhanced magnetic resonance
cholangiopancreatography. J Gastroenterol. 2007;42 Suppl 17:1137.
24. Sikkens EC, Cahen DL, Kuipers EJ, Bruno MJ. Pancreatic enzyme replacement therapy in chronic pancreatitis.
Best Pract Res Clin Gastroenterol. 2010;24(3):33747.
25. Van De Kamer JH, Ten Bokkel Huinink H, Weyers HA. Rapid method for the determination of fat in feces. J Biol
Chem. 1949;177(1):34755.
26. Ramsey BW, Farrell PM, Pencharz P. Nutritional assessment and management in cystic brosis: a consensus
report. The Consensus Committee. Am J Clin Nutr. 1992;55(1):10816.
27. Fomon SJ, Ziegler EE, Thomas LN, Jensen RL, Filer Jr LJ. Excretion of fat by normal full-term infants fed various
milks and formulas. Am J Clin Nutr. 1970;23(10):1299313.
28. Yankaskas JR, Marshall BC, Suan B, Simon RH, Rodman D. Cystic brosis adult care: consensus conference
report. Chest. 2004;125(1 Suppl):1S39.
29. Borowitz D, Konstan MW, ORourke A, Cohen M, Hendeles L, Murray FT. Coefcients of fat and nitrogen
absorption in healthy subjects and individuals with cystic brosis. J Pediatr Pharmacol Ther. 2007;12(1):4752.
30. Taylor JR, Gardner TB, Waljee AK, Dimagno MJ, Schoenfeld PS. Systematic review: efcacy and safety of
pancreatic enzyme supplements for exocrine pancreatic insufciency. Aliment Pharmacol Ther.
2010;31(1):5772.
31. Caras S, Boyd D, Zipfel L, Sander-Struckmeier S. Evaluation of stool collections to measure efcacy of PERT in
subjects with exocrine pancreatic insufciency. J Pediatr Gastroenterol Nutr. 2011;53(6):63440.
32. Sziegoleit A, Krause E, Klor HU, Kanacher L, Linder D. Elastase 1 and chymotrypsin B in pancreatic juice and
feces. Clin Biochem. 1989;22(2):859.
33. Sziegoleit A, Knapler H, Peters B. ELISA for human pancreatic elastase 1. Clin Biochem. 1989;22(2):7983.
34. Borowitz D, Lin R, Baker SS. Comparison of monoclonal and polyclonal ELISAs for fecal elastase in patients
with cystic brosis and pancreatic insufciency. J Pediatr Gastroenterol Nutr. 2007;44(2):21923.
35. Dominici R, Franzini C. Fecal elastase-1 as a test for pancreatic function: a review. Clin Chem Lab Med.
2002;40(4):32532.
36. Dominguez-Munoz JE. Pancreatic enzyme therapy for pancreatic exocrine insufciency. Curr Gastroenterol Rep.
2007;9(2):11622.
37. Beharry S, Ellis L, Corey M, Marcon M, Durie P. How useful is fecal pancreatic elastase 1 as a marker of exocrine
pancreatic disease? J Pediatr. 2002;141(1):8490.
38. Loser C, Mollgaard A, Folsch UR. Faecal elastase 1: a novel, highly sensitive, and specic tubeless pancreatic
function test. Gut. 1996;39(4):5806.
39. Daftary A, Acton J, Heubi J, Amin R. Fecal elastase-1: utility in pancreatic function in cystic brosis. J Cyst
Fibros. 2006;5(2):716.
161
40. Nissler K, Von Katte I, Huebner A, Henker J. Pancreatic elastase 1 in feces of preterm and term infants. J Pediatr
41. Walkowiak J, Herzig KH. Fecal elastase-1 is decreased in villous atrophy regardless of the underlying disease.
Eur J Clin Invest. 2001;31(5):42530.
42. Hamwi A, Veitl M, Maenner G, Vogelsang H, Szekeres T. Pancreatic elastase 1 in stool: variations within one stool
passage and individual changes from day to day. Wien Klin Wochenschr. 2000;112(1):325.
43. Weintraub A, Blau H, Mussaf H, Picard E, Bentur L, Kerem E, et al. Exocrine pancreatic function testing in
patients with cystic brosis and pancreatic sufciency: a correlation study. J Pediatr Gastroenterol Nutr.
2009;48(3):30610.
44. Wali PD, Loveridge-Lenza B, He Z, Horvath K. Comparison of fecal elastase-1 and pancreatic function testing in
children. J Pediatr Gastroenterol Nutr. 2012;54(2):27780.
45. Durie PR, Forstner GG, Gaskin KJ, Moore DJ, Cleghorn GJ, Wong SS, et al. Age-related alterations of
immunoreactive pancreatic cationic trypsinogen in sera from cystic brosis patients with and without pancreatic
insufciency. Pediatr Res. 1986;20(3):20913.
46. Couper RT, Corey M, Durie PR, Forstner GG, Moore DJ. Longitudinal evaluation of serum trypsinogen measurement
in pancreatic-insufcient and pancreatic-sufcient patients with cystic brosis. J Pediatr. 1995;127(3):40813.
47. Bollbach R, Becker M, Rotthauwe HW. Serum immunoreactive trypsin and pancreatic lipase in cystic brosis. Eur
J Pediatr. 1985;144(2):16770.
48. Cleghorn G, Benjamin L, Corey M, Forstner G, Dati F, Durie P. Age-related alterations in immunoreactive
pancreatic lipase and cationic trypsinogen in young children with cystic brosis. J Pediatr. 1985;107(3):37781.
49. de Mello ED, da Silveira TR. The Steatocrit Test: a semiquantitative method to evaluate the fecal fat excretion
method standardization. J Pediatr (Rio J). 1995;71(5):2738.
50. Colombo C, Maiavacca R, Ronchi M, Consalvo E, Amoretti M, Giunta A. The steatocrit: a simple method for
monitoring fat malabsorption in patients with cystic brosis. J Pediatr Gastroenterol Nutr. 1987;6(6):92630.
51. Tran M, Forget P, Van den Neucker A, Strik J, van Kreel B, Kuijten R. The acid steatocrit: a much improved
method. J Pediatr Gastroenterol Nutr. 1994;19(3):299303.
52. Wagner MH, Bowser EK, Sherman JM, Francisco MP, Theriaque D, Novak DA. Comparison of steatocrit and fat
absorption in persons with cystic brosis. J Pediatr Gastroenterol Nutr. 2002;35(2):2025.
53. Phuapradit P, Narang A, Mendonca P, Harris DA, Baum JD. The steatocrit: a simple method for estimating stool
fat content in newborn infants. Arch Dis Child. 1981;56(9):7257.
54. Tardelli AC, Camargos PA, Penna FJ, Sarkis PF, Guimaraes EV. Comparison of diagnostic methods for pancreatic
insufciency in infants with cystic brosis. J Pediatr Gastroenterol Nutr. 2013;56(2):17881.
55. Walkowiak J, Herzig KH, Strzykala K, Przyslawski J, Krawczynski M. Fecal elastase-1 is superior to fecal
chymotrypsin in the assessment of pancreatic involvement in cystic brosis. Pediatrics. 2002;110(1 Pt 1), e7.
56. Girella E, Faggionato P, Benetazzo D, Mastella G. The assay of chymotrypsin in stool as a simple and effective
test of exocrine pancreatic activity in cystic brosis. Pancreas. 1988;3(3):25462.
57. Fieker A, Philpott J, Armand M. Enzyme replacement therapy for pancreatic insufciency: present and future.
Clin Exp Gastroenterol. 2011;4:5573.
58. Weaver LT, Amarri S, Swart GR. 13C mixed triglyceride breath test. Gut. 1998;43 Suppl 3:S139.
59. van Dijk-van Aalst K, Van Den Driessche M, van Der Schoor S, Schiffelers S, van't Westeinde T, Ghoos Y, et al.
13C mixed triglyceride breath test: a noninvasive method to assess lipase activity in children. J Pediatr Gastroenterol
Nutr. 2001;32(5):57985.
60. Vantrappen GR, Rutgeerts PJ, Ghoos YF, Hiele MI. Mixed triglyceride breath test: a noninvasive test of pancreatic
lipase activity in the duodenum. Gastroenterology. 1989;96(4):112634.
61. Iglesias-Garcia J, Vilarino M, Iglesias-Rey M, Lourido V, Dominguez-Munoz E. Accuracy of the optimized
13c-mixed triglyceride breath test for the diagnosis of steatorrhea in clinical practice. Gastroenterology.
2003;124(Supp1):A631.
62. OKeefe SJ, Stevens S, Lee R, Zhou W, Zfass A. Physiological evaluation of the severity of pancreatic exocrine
dysfunction during endoscopy. Pancreas. 2007;35(1):306.
63. Ritz MA, Fraser RJ, Di Matteo AC, Greville H, Butler R, Cmielewski P, et al. Evaluation of the 13C-triolein breath
test for fat malabsorption in adult patients with cystic brosis. J Gastroenterol Hepatol. 2004;19(4):44853.
64. Laiho KM, Gavin J, Murphy JL, Connett GJ, Wootton SA. Maldigestion and malabsorption of 13C labelled
tripalmitin in gastrostomy-fed patients with cystic brosis. Clin Nutr. 2004;23(3):34753.
65. Dominguez-Munoz JE, Iglesias-Garcia J, Vilarino-Insua M, Iglesias-Rey M. 13C-mixed triglyceride breath test to
assess oral enzyme substitution therapy in patients with chronic pancreatitis. Clin Gastroenterol Hepatol.
2007;5(4):4848.
66. Herzog DC, Delvin EE, Albert C, Marcotte JE, Pelletier VA, Seidman EG. 13C-labeled mixed triglyceride breath
test (13C MTG-BT) in healthy children and children with cystic brosis (CF) under pancreatic enzyme replacement
therapy (PERT): a pilot study. Clin Biochem. 2008;41(18):148992.
67. Augarten A, Katznelson D, Dubenbaum L, Doolman R, Sela BA, Lusky A, et al. Serum lipase levels pre and post
Lundh meal: evaluation of exocrine pancreatic status in cystic brosis. Int J Clin Lab Res. 1998;28(4):2269.
162
68. Dorsey J, Buckley D, Summer S, Jandacek RJ, Rider T, Tso P, et al. Fat malabsorption in cystic brosis: comparison
of quantitative fat assay and a novel assay using fecal lauric/behenic acid. J Pediatr Gastroenterol Nutr.
2010;50(4):4416.
69. Stallings VA, Mondick JT, Schall JI, Barrett JS, Wilson M, Mascarenhas MR. Diagnosing malabsorption with
systemic lipid proling: pharmacokinetics of pentadecanoic acid and triheptadecanoic acid following oral
administration in healthy subjects and subjects with cystic brosis. Int J Clin Pharmacol Ther.
2013;51(4):26373.
70. U.S. Department of Health and Human Services FaDA. Guidance for industry. Exocrine pancreatic insufciency
drug productssubmitting NDAs.
71. Borowitz D, Stevens C, Brettman LR, Campion M, Chateld B, Cipolli M, et al. International phase III trial of
liprotamase efcacy and safety in pancreatic-insufcient cystic brosis patients. J Cyst Fibros. 2011;10(6):44352.
72. Borowitz D, Stevens C, Brettman LR, Campion M, Wilschanski M, Thompson H, et al. Liprotamase long-term
safety and support of nutritional status in pancreatic-insufcient cystic brosis. J Pediatr Gastroenterol Nutr.
2012;54(2):24857.
73. Castellani C, Cuppens H, Macek Jr M, Cassiman JJ, Kerem E, Durie P, et al. Consensus on the use and interpretation
of cystic brosis mutation analysis in clinical practice. J Cyst Fibros. 2008;7(3):17996.
74. Cystic Fibrosis F, Borowitz D, Robinson KA, Rosenfeld M, Davis SD, Sabadosa KA, et al. Cystic Fibrosis
Foundation evidence-based guidelines for management of infants with cystic brosis. J Pediatr. 2009;155
(6 Suppl):S7393.
context of brosing colonopathy. Consensus Committee. J Pediatr. 1995;127(5):6814.
76. Chauhan S, Forsmark CE. Pain management in chronic pancreatitis: a treatment algorithm. Best Pract Res Clin
Gastroenterol. 2010;24(3):32335.
77. Ferrone M, Raimondo M, Scolapio JS. Pancreatic enzyme pharmacotherapy. Pharmacotherapy. 2007;27(6):91020.
78. FitzSimmons SC, Burkhart GA, Borowitz D, Grand RJ, Hammerstrom T, Durie PR, et al. High-dose pancreaticenzyme supplements and brosing colonopathy in children with cystic brosis. N Engl J Med.
1997;336(18):12839.
79. Borowitz D, Gelfond D, Maguiness K, Heubi JE, Ramsey B. Maximal daily dose of pancreatic enzyme replacement
therapy in infants with cystic brosis: a reconsideration. J Cyst Fibros. 2013;12(6):7845.
80. Kalnins D, Wilschanski M. Maintenance of nutritional status in patients with cystic brosis: new and emerging
therapies. Drug Des Devel Ther. 2012;6:15161.
81. Van de Vijver E, Desager K, Mulberg AE, Staelens S, Verkade HJ, Bodewes FA, et al. Treatment of infants and
toddlers with cystic brosis-related pancreatic insufciency and fat malabsorption with pancrelipase MT. J Pediatr
82. Bruno MJ, Haverkort EB, Tytgat GN, van Leeuwen DJ. Maldigestion associated with exocrine pancreatic
insufciency: implications of gastrointestinal physiology and properties of enzyme preparations for a causerelated and patient-tailored treatment. Am J Gastroenterol. 1995;90(9):138393.
83. Graff GR, Maguiness K, McNamara J, Morton R, Boyd D, Beckmann K, et al. Efcacy and tolerability of a new
formulation of pancrelipase delayed-release capsules in children aged 7 to 11 years with exocrine pancreatic
insufciency and cystic brosis: a multicenter, randomized, double-blind, placebo-controlled, two-period
crossover, superiority study. Clin Ther. 2010;32(1):89103.
84. Trapnell BC, Maguiness K, Graff GR, Boyd D, Beckmann K, Caras S. Efcacy and safety of Creon 24,000 in
subjects with exocrine pancreatic insufciency due to cystic brosis. J Cyst Fibros. 2009;8(6):3707.
85. Ramo OJ, Puolakkainen PA, Seppala K, Schroder TM. Self-administration of enzyme substitution in the treatment
of exocrine pancreatic insufciency. Scand J Gastroenterol. 1989;24(6):68892.
86. Goodin B. Nutrition issues in cystic brosis. Pract Gastroenterol. 2005;27(5):7694.
87. Nicolo M, Stratton KW, Rooney W, Boullata J. Pancreatic enzyme replacement therapy for enterally fed patients
with cystic brosis. Nutr Clin Pract. 2013;28(4):4859.
88. Ferrie S, Graham C, Hoyle M. Pancreatic enzyme supplementation for patients receiving enteral feeds. Nutr Clin
Pract. 2011;26(3):34951.
90. Maqbool A, Schall JI, Mascarenhas MR, Dougherty KA, Stallings VA. Vitamin B(12) status in children with
cystic brosis and pancreatic insufciency. J Pediatr Gastroenterol Nutr. 2014;58(6):7338.
91. Smyth RL, Ashby D, OHea U, Burrows E, Lewis P, van Velzen D, et al. Fibrosing colonopathy in cystic brosis:
results of a case-control study. Lancet. 1995;346(8985):124751.
92. Smyth RL, van Velzen D, Smyth AR, Lloyd DA, Heaf DP. Strictures of ascending colon in cystic brosis and
high-strength pancreatic enzymes. Lancet. 1994;343(8889):856.
children with cystic brosis. J Pediatr Gastroenterol Nutr. 2006;43(5):6519.
163
94. Faulkner C, Taper LJ, Scott M. Adherence to pancreatic enzyme supplementation in adolescents with cystic
brosis. Can J Diet Pract Res. 2012;73(4):1969.
95. DeLambo KE, Ievers-Landis CE, Drotar D, Quittner AL. Association of observed family relationship quality and
problem-solving skills with treatment adherence in older children and adolescents with cystic brosis. J Pediatr
Psychol. 2004;29(5):34353.
96. Conway SP, Pond MN, Hamnett T, Watson A. Compliance with treatment in adult patients with cystic brosis.
Thorax. 1996;51(1):2933.
97. Dominguez-Munoz JE, Iglesias-Garcia J. Oral pancreatic enzyme substitution therapy in chronic pancreatitis: is
clinical response an appropriate marker for evaluation of therapeutic efcacy? JOP. 2010;11(2):15862.
98. Kalnins D, Ellis L, Corey M, Pencharz PB, Stewart C, Tullis E, et al. Enteric-coated pancreatic enzyme with
bicarbonate is equal to standard enteric-coated enzyme in treating malabsorption in cystic brosis. J Pediatr
99. Quinton PM. Cystic brosis: impaired bicarbonate secretion and mucoviscidosis. Lancet. 2008;372(9636):4157.
100. Gelfond D, Ma C, Semler J, Borowitz D. Intestinal pH and gastrointestinal transit proles in cystic brosis patients
measured by wireless motility capsule. Dig Dis Sci. 2013;58(8):227581.
101. Symonds EL, Omari TI, Webster JM, Davidson GP, Butler RN. Relation between pancreatic lipase activity and
gastric emptying rate in children with cystic brosis. J Pediatr. 2003;143(6):7725.
102. Dominguez-Munoz JE, Iglesias-Garcia J, Iglesias-Rey M, Figueiras A, Vilarino-Insua M. Effect of the
administration schedule on the therapeutic efcacy of oral pancreatic enzyme supplements in patients with
exocrine pancreatic insufciency: a randomized, three-way crossover study. Aliment Pharmacol Ther.
2005;21(8):9931000.
103. Ooi CY, Dorfman R, Cipolli M, Gonska T, Castellani C, Keenan K, et al. Type of CFTR mutation determines risk
of pancreatitis in patients with cystic brosis. Gastroenterology. 2011;140(1):15361.
104. Rosenstein BJ, Cutting GR. The diagnosis of cystic brosis: a consensus statement. Cystic Fibrosis Foundation
Consensus Panel. J Pediatr. 1998;132(4):58995.
Chapter 11
Nutrition and Cystic Fibrosis Related Liver Disease

Kristin J. Brown, Cathy Lingard, and Michael R. Narkewicz
Key Points
Liver involvement is common in CF, but only certain types of liver disease result in unique
nutritional needs.
Neonatal cholestasis is rare in CF, but results in increased needs for fat-soluble vitamins, energy,
and fat
Cirrhosis leads to increased basal metabolic rate and energy requirements.
Protein restriction is generally not indicated in cirrhosis in CF
Hepatic steatosis merits investigation for malnutrition and essential fatty acid deciency
Keywords Cirrhosis Hepatic steatosis Cholestasis
Abbreviations
BMI
CF
NAFLD
PIVKA
RBP
TPGS
Body mass index (weight kg)/(height in meters)2

Cystic brosis
Nonalcoholic fatty liver disease
Protein induced in vitamin K absence
Retinol binding protein
Alpha tocopherol polyethylene glycol succinate
K.J. Brown, M.S., R.D., C.N.S.C. C. Lingard, R.D.

Childrens Hospital Colorado, 13123 East 16th Avenue, B290, Aurora, CO 80045, USA
M.R. Narkewicz, M.D. (*)
Childrens Hospital Colorado, 13123 East 16th Avenue, B290, Aurora, CO 80045, USA
Section of Pediatric Gastroenterology, Hepatology and Nutrition, Department of Pediatrics, University of
Colorado School of Medicine, Aurora, CO, USA
165
166
K.J. Brown et al.
Introduction
The liver is commonly affected in CF. While most individuals will have some liver involvement,
signicant liver disease affects 510% of all CF patients [1]. Despite this, liver disease is the third
leading cause of death in CF and accounts for 2.5% of the overall annual mortality [2]. In this chapter,
we will provide an overview of liver involvement in CF, address the disorders that occur in the liver
as a result of nutritional deciencies, and address the nutritional evaluation and management of the
two liver diseases in CF that directly affect nutritional status: cholestasis and cirrhosis.
There are many forms of liver involvement in CF. A recently recommended classication of liver
disease in CF is shown in Table 11.1 [1].
The two liver diseases that have a signicant impact on the nutritional status of individuals with CF
are neonatal cholestasis and cirrhosis with or without portal hypertension. In addition, hepatic steatosis
(fatty liver) can occur as a result of malnutrition, over nutrition (obesity associated nonalcoholic fatty
liver disease NAFLD), and nutritional deciencies such as essential fatty acid (EFA) deciency. The
other disorders involving the liver do not have a signicant impact on nutritional status and will not
be discussed.
Neonatal Cholestasis
Neonatal cholestasis is dened as liver disease with an elevation of direct bilirubin to >2 mg/dl or
>20% of the total bilirubin [3]. This is the earliest manifestation of liver involvement in CF and may
mimic biliary atresia. Only 1% of infants with CF who do not have meconium ileus present with
neonatal cholestasis [4]. Meconium ileus is a known risk factor for the development of cholestasis and
up to 25% of infants with meconium ileus will develop cholestasis [47]. While cholestasis generally
resolves by 9 months of age with no long-term sequelae, some studies have suggested an increased
risk for cirrhosis in children with meconium ileus [810]. The major impact of cholestasis in infants
with CF is a dramatic increase in fat malabsorption. In cholestasis, the total bile acid content and
concentration of bile is reduced. As bile acids are required for efcient lipase function, whatever
endogenous lipase secretion remains in infants with CF is further impaired in the face of cholestasis.
A key role of bile acids is to form mixed micelles, which is the nal step in the absorption of long
chain fat. Thus fat malabsorption is much more severe in the infant with CF and cholestasis.
The infant with CF and cholestasis presents a unique nutritional management problem. Attention
to adequate weight gain alone can underestimate the nutritional status of the infant. Anthropometric
assessment should be determined at least a monthly while the child is cholestatic [11]. Breast milk
should be the initial nutritional management for cholestatic infants. If infants fall off their expected
Table 11.1 Simplied classication of liver involvement in cystic brosis

1. CF related liver disease with cirrhosis with or without portal hypertension (based on clinical exam/ imaging,
histology, laparoscopy)
2. Liver involvement without cirrhosis/portal hypertension consisting of at least one of the following:
(a) Persistent elevation of AST, ALT or GGT >2 times upper limit of normal
(b) Intermittent elevations of the above laboratory values
(c) Steatosis (histologic determination)
(d) Fibrosis (histologic determination)
(e) Cholangiopathy (based on ultrasound, MRI, CT, ERCP)
(f) Ultrasound abnormalities not consistent with cirrhosis
(g) Neonatal cholestasis
11
167
Table 11.2 Options for fortication of breast milk for cholestatic infants
Brand name
Manufacturer
Breast milk fortification
Similac human milk fortier Abbott
Enfamil human milk fortier Mead Johnson
Formula supplement
Similac special care
Abbott
Enfamil prematurea
Mead Johnson
Gerber good start premature Nestle
Pregestimil
Mead Johnson
Alimentum
Abbott
Modulars
Liquigen
Nutricia
MCT oil
Nestle
MCT procal
Vitao
a
Available for institutional use only
Percent of fat as MCT oil

100%
70%
50%
40%
40%
55%
33%
96.4%
100%
99%
Table 11.3 Nutrient adjustments to parenteral nutrition in neonatal cholestasis

Nutrient
Copper: excreted in the bile, reduced excretion in
cholestasis leads to elevated copper blood levels
Manganese: similar to copper, excreted in the bile, reduced
excretion in cholestasis leads to elevated manganese
blood levels
Zinc: enhanced zinc losses in cholestasis [62, 89]
Soy based lipids Intralipid: evidence for worsening
cholestasis with high dose lipids [90]
Adjustment in cholestasis
Reduce copper to 10 mcg/kg/day (50% of
recommended dose)
Remove manganese if possible (trace amounts of
manganese are found in other trace elements)
Double the amount of zinc to 200 mcg/kg/day
If possible, reduce lipids to 1 g/kg/day
optimum growth, fortication of breast milk with products higher in medium chain triglycerides is
recommended. Options for supplementation are shown in Table 11.2.
Medium chain triglycerides are preferred as they are absorbed directly in the portal venous system
without the need to form mixed micelles. In cholestatic infants who are not breast-fed or who fail to
achieve optimum growth on fortied breast milk, a formula with at least 4050% of fat as medium
chain triglycerides is preferred. Additional supplementation may be necessary.
In cholestatic infants who fail oral intake, nasogastric supplementation can improve growth [12].
In addition, these infants are at risk for hypoglycemia due to impairment of liver glycogen storage
capacity, decreased capacity for gluconeogenesis and smaller glycogen stores. In this case, it is
optimal to feed every 4 hours. Older children are better able to utilize fat and protein as energy sources
when fasting [13].
Rarely, parenteral nutrition is required [14]. This is more common in infants with complicated
meconium ileus repair with delayed intestinal function. In the setting of cholestasis and the need for
parenteral nutrition, there are several specic adjustments to the parenteral nutrition formulation that
should be considered (Table 11.3). In most cases, the need for parenteral nutrition lasts for less than
13 months and enteral nutrition can be reestablished quickly. For children who require long-term
TPN and who have cholestasis, refer to reviews from Guglielmi [15] and Feranchak [16].
Another important aspect of the evaluation and management of children with CF and cholestasis is
the assessment of their fat-soluble vitamin status. Deciencies of the fat-soluble vitamins A, D, E and
K are common in cholestasis and can be much more profound than deciencies seen in noncholestatic
individuals with CF. These vitamins were discussed in Chapter 6. The importance of fat-soluble
K.J. Brown et al.
168
Table 11.4 Fat-soluble vitamin assessment and supplementation in cholestasis
Vitamin
Suggested monitoring
Vitamin A Retinol
Retinol to RBP molar

ratio
Vitamin D 25-hydroxy-Vitamin D
Recommended ranges
<20 mcg/dl
(deciency)
>140 mcg/dl (toxicity)
Deciency <0.8 mol/
mol
<10 ng/ml: severe
deciency
1020 ng/ml:
insufciency
2030 ng/ml: At risk
3040 ng/ml: Goal
>150 ng/ml: Toxicity
Dosing recommendations
1. 5000 IU orally daily
2. 25,00050,000 IU orally daily for 14 weeks
Vitamin D3
1) 12004000 IU orally daily
2) 40008000 IU orally daily
3) Consider co-administering vitamin D3 with
510 ml of TPGS to enhance absorption in
cholestatic children.
1, 25 dihydroxy-Vitamin D3 (calcitriol)
1) 0.050.2 mcg/kg/day orally *consider
supplemental calcium with this transition
TPGS
Vitamin E Alpha-tocopherol to total Goal: >0.8 mg/g
Deciency:
1) 25 IU/kg/day orally
lipidsa mg/g ratio
<0.6 mg/g for infants 2) 50 IU/kg/day orally
<0.8 mg/g for children 3) 100 IU/kg/day (orally divided 23 times per day)
>1 year
Vitamin K INR
>1.21.4 (deciency) 1) INR > 1.4 and <1.8: 2 mg orally daily
PIVKA
>3 mcg/l (deciency) 2) INR > 1.8 give 2 mg IM then oral daily dosing
max 5 mg
a
Total lipids assay has limited availability
TPGS alpha tocopherol polyethylene glycol succinate, PIVKA protein induced in vitamin K absence
vitamin supplementation is well understood and accepted within the nutritional management plan for
both CF and cholestatic liver disease populations. When dealing with the combined malabsorption
related to insufcient native pancreatic enzyme and cholestasis, fat-soluble vitamin absorption suffers.
The progression of cholestasis often requires fat-soluble vitamin dosing at 24 times the baseline CF
recommended doses for age. Levels should be monitored within the rst month of cholestasis and
about every 2 months while infants remain cholestatic to assure adequate intake. When deciencies
are identied, supplementation should be increased as shown in Table 11.4 [13, 1719].
There is a unique aspect of monitoring vitamin E status in cholestasis. Vitamin E is contained in
the lipid fraction and much of the vitamin E in the lipid component is not available. In cholestasis,
hyperlipidemia is common due to the poor bile ow. As a result infants with cholestasis can have
normal vitamin E levels but are functionally decient. Thus in cholestasis, assessment of vitamin E
status is best determined by the ratio of vitamin E (mg) to total lipids (g) with an optimal lower limit
of 0.8 [20].
Cirrhosis With or Without Portal Hypertension

Multilobular Cirrhosis: Multilobular cirrhosis differs from the classical pathognomonic liver lesion in
CF of focal biliary cirrhosis in that there are multiple regenerative nodules and diffuse involvement of
the liver. Clinically, multilobular cirrhosis is detected by a hard nodular liver that may or may not be
enlarged. On imaging, there is an irregular nodular liver edge and coarse heterogeneous parenchyma.
Prior to the development of portal hypertension, there are often no other clinical features. Once portal
hypertension is present, splenomegaly, esophageal or gastric varices, or ascites may be the rst
11
169
suggestion of previously unsuspected cirrhosis. Liver biopsy can show features consistent with
cirrhosis but may not be sensitive due to the patchy nature of the nodular involvement and the large
regenerative nodules that can be mistaken for normal hepatic parenchyma. Multilobular cirrhosis in
CF is a pediatric disorder. The median age of discovery is 10 years with very few new cases identied
after 20 years of age, and no increased prevalence with increased life span [21]. There is an average
prevalence of multilobular cirrhosis of 5.6%, portal hypertension 4.2%, and varices 2.4% [810,
2230]. Diabetes also seems to be more common in individuals with cystic brosis related liver
disease [31, 32].
Nutritional consequences of Cirrhosis: Although most of the nutritional complications of cirrhosis
are commonly felt to be related to portal hypertension, the presence of cirrhosis without portal
hypertension does have signicant physiologic effects.
First, in cirrhosis, there is an increase in cardiac output by up to twofold, related to peripheral
vasodilation [33]. This increase in cardiac output leads to a signicant increase in metabolic demand
manifesting as increased resting energy expenditure. Second, cirrhosis is also associated with
peripheral insulin resistance via mechanisms that are not clear [31]. This leads to less efcient use of
carbohydrates as energy sources and can increase glucose intolerance and its associated complications.
However, the most vexing nutritional issues are faced in individuals with CF cirrhosis and obvious
portal hypertension.
Complications or Portal Hypertension: The primary complications of portal hypertension include
hypersplenism, esophageal or gastric variceal hemorrhage, ascites, and rarely synthetic liver failure
with coagulopathy [34]. While liver disease is the third leading cause of death among CF patients,
some studies report no increase in mortality among patients with CF cirrhosis [8, 26, 27]. Two recent
studies report a trend towards younger age of death in those with cirrhosis [30, 35]. In a large 18-year
retrospective review of 1108 patients with CF, 53 developed cirrhosis, 23 with portal hypertension, 14
with varices, 8 with coagulopathy, 6 with overt liver failure resulting in 3 liver transplants, but only
one reported liver related death [23]. The incidence rate of major complications of cirrhosis (bleeding,
ascites, and encephalopathy) among a cohort of 177 CF patients (17 who developed cirrhosis) followed
longitudinally was 0.4%, with an all-cause mortality rate of 1.6% among cirrhotic patients [8]. This is
in contrast to older reports that showed 1119% mortality from variceal bleeding or liver failure in CF
cirrhosis [36].
Once portal hypertension develops in CF, some studies report an increased risk of malnutrition,
osteoporosis/hepatic osteodystrophy, and decline in lung function. The decline in lung function
secondary to portal hypertension has been variously attributed to intrapulmonary vascular shunting,
diaphragmatic splinting due to organomegaly and ascites, and potentially increased infections [37
40]. However, a recent retrospective study of 59 CF patients with cirrhosis and portal hypertension
found no decline in lung function associated with portal hypertension as compared to age and gender
matched CF specic reference values for lung function [41].
Malnutrition associated with portal hypertension is likely multifactorial due in part to decreased
nutrient absorption, increased resting energy expenditure, anorexia and decreased caloric intake. A
single center retrospective casecontrol study showed an odds ratio of 4.8 (95% CI, 2.49, 9.17) for
CF-related diabetes in those with cirrhosis and portal hypertension, using a surrogate marker
(thrombocytopenia) for cirrhosis with portal hypertension [32]. A case-control study of CF patients with
and without advanced CF liver disease found lower weight, height, and mid-upper arm circumference z
score and lower FEV1 percent predicted in patients with advanced CF liver disease [42].
Osteoporosis is the most common form of bone disease associated with cirrhosis [43]. In one study
of adults with cirrhosis awaiting liver transplantation, the individuals with cystic brosis had the most
severe osteopenia compared to all other causes with average T and z scores at the lumbar spine of 4
and 3 [43]. The mechanism of this dramatic osteopenia is unclear, but again points to the nutritional
impact of the combination of chronic liver disease with cystic brosis.
170
K.J. Brown et al.
Portal hypertension can also have a direct effect on small bowel function via small bowel edema
and decreased absorptive function. Finally, portal hypertension can lead to intrapulmonary shunting
with resultant hypoxia or pulmonary hypertension and further increases in energy demand [44].
Liver Synthetic Failure: Only about 10% of individuals with CF and cirrhosis and portal hypertension
progress to liver synthetic failure characterized by a high bilirubin and vitamin K-resistant coagulopathy
[35]. This is in contrast to other causes of cirrhosis where the rate of progression is seemingly much
higher.
Management of nutrition in Cirrhosis with and without portal hypertension: Individuals with CF and
advanced liver disease require careful assessment of growth and nutritional status combining objective
measures and physical exam. In addition to traditional measures of height and weight tracked on
established growth curves, measurement of mid-arm circumference, triceps skinfold, subscapular
skinfold, and calculated mid-arm muscle area are useful tools. Methods for obtaining these
measurements and reference data have been previously reported [45, 46]. Weight is not a reliable
indicator of nutritional status and is often falsely elevated related to organomegaly and/or the presence
of ascitic uid in advanced liver disease. Additionally this alteration in body composition may be due
to a greater proportion of body mass contributed by a metabolically active body compartment with
reduced body fat and an expansion in extracellular water [47]. Decreasing height velocity is a late
indicator of chronic under-nutrition and may be difcult to assess in older children. Mid-arm
circumference, triceps skinfold, and subscapular skinfold measures are indicators of the fat stores.
These measures should be obtained by a skilled practitioner to assure accuracy. When tracked over
time these additional measures indicate when nutritional goals are being met or when additional
nutritional support strategies are required. Goals for these indicators of fat mass and fat-free mass
should be within the range of a z score of 0 to +1 [11, 13, 17].
Energy Needs: For children with CF greater than 2 years of age, the general recommendation for
energy is greater than that of the general healthy population [48]. Prospective and retrospective
studies have found improved weight gain with intakes ranging from 110 to 200% of the recommended
intakes for the general population. In addition, there are many healthy CF patients who can gain
weight with a standard energy intake. For infants and children during the rst 2 years of life, the
CFF evidenced-based guidelines for weight gain and intake are based on term well-nourished
infants and between 100 and 130 kcals/kg [49]. Data for energy expenditure in cystic brosis
patients with cirrhosis are not available. However, children with advanced liver disease without
cystic brosis can have an elevated energy expenditure of 27% higher REE/body weight than
controls [47, 50]. It is reasonable to assume that CF patients with liver disease are also in a
hypermetabolic state of the same degree or higher. An energy intake 120150% of standard is
suggested by a several sources [5153].
Macronutrient Needs in Patients with CF and Advanced Liver Disease

Protein: Individuals with liver disease have increased protein turnover. This population benets from
a protein intake of 3 g/kg/day [53]. Note that this guideline typically provides approximately 1015%
of calories from protein. Children undergoing nutritional rehabilitation with enteral feedings to reverse
malnutrition can tolerate a protein intake of 34 g/kg without precipitating hepatic encephalopathy
[54]. Protein restriction is not necessary unless the patient has encephalopathy, and in these cases
protein should not be restricted below 2 g/kg/day to prevent endogenous protein consumption [13]. It
is good practice to distribute food over the course of the day to avoid undue stress to the liver at any
one time [55].
11
171
Fat: Individuals with CF benet from a high fat diet to more easily meet their increased energy needs.
For children with CF without liver disease the CF Foundation recommends a fat intake of 3540% of
calories [56]. When patients have liver disease in addition to CF a higher fat intake of 4050% is
suggested [53]. The increased amount of dietary fat attempts to overcome the increased losses due
to less efcient fat digestion in the setting of decreased bile acid pool and pancreatic insufciency.
The topic of fat in CF is thoroughly covered in Chapter 5.
Carbohydrates: Carbohydrates are an energy source that is easily digested in patients with fat
malabsorption. After the provision of an adequate fat and protein intake for patients with CFLD, the
remaining 4550% of calories is provided through carbohydrate. In patients with cirrhosis,
carbohydrates may not be optimally utilized due to peripheral insulin resistance and associated
glucose intolerance. Since there is an increased incidence of CF related diabetes in patients with
cirrhosis, it is also important for these patients to receive diabetes screening [32]. Continuous glucose
monitoring may be helpful to detect uctuations in serum glucose and assist in formulating a
supplemental insulin regimen. In addition, a more favorable glucose control may be achieved with
several small meals and snacks throughout the day rather than two or three larger meals. Refer to
Chapter 10 for nutritional management of CF-related diabetes.
When malnutrition is present with cirrhosis and portal hypertension, the initial approach is oral
enteral supplementation. When that is not successful, nasogastric (NG) supplementation can be
successful [12]. While many centers avoid gastrostomy tube placement in the setting of portal
hypertension due to the risk of gastrostomy stomal varices, one study did nd that this was safe in
CF patients with cirrhosis and led to improvement in pulmonary and nutritional status [57]. Specic
nutritional support recommendations from a European CF group were published in 2012 [53]. Their
recommendations included:
1.
2.
3.
4.
Providing 150% of estimated RDA for energy requirements

Provide 4050% of calories as fat
Provide a minimum of 3 g/kg/day of protein unless liver failure is present
Provide fat-soluble vitamin supplementation and monitor for deciency
Fat-soluble vitamins: Most individuals with CF and cirrhosis are not cholestatic. As such standard CF
vitamin supplementation is appropriate. There are two exceptions: Vitamin K: While vitamin K
deciency is very common in CF, vitamin K deciency as determined by PIVKA was more signicant
in those with liver disease compared to those without liver disease [58]. Thus individuals with CF and
cirrhosis should receive an additional 5 mg orally daily of vitamin K.
Vitamin A deciency may be difcult to assess in the setting of cirrhosis. Vitamin A in the
circulation is bound to retinol binding protein (RBP). In the setting of cirrhosis, RBP is low even in
the absence of hypoalbuminemia, resulting in low measured retinol (Vitamin A) levels. Individuals
with retinol <20 mcg/dl should receive Vitamin A supplementation [59]. The best indicator of vitamin
A status may be the molar ratio of Vitamin A to RBP [59], However, this may not be accurate in
cirrhosis. Since the main toxicity of vitamin A is hepatic toxicity, care must be exercised with
supplementation in the setting of cirrhosis. Close monitoring (monthly or every other month) of
vitamin A status during high dose supplementation is recommended. If despite high dose
supplementation vitamin A levels, or the molar ratio of vitamin A to RBP, do not improve, periodic
assessment of eye complications (xerophthalmia or night blindness) should be performed to guide the
need for higher dose supplementation.
Zinc: Zinc deciency has been described in CF [60]. Zinc deciency has also been reported in patients
with cirrhosis [61]. The mechanism of zinc deciency in cirrhosis is uncertain, but likely includes
inadequate intake, increased urinary zinc losses [62], impaired intestinal transport, and hepatic
sequestration. No study has investigated the zinc status of individuals with CF and cirrhosis. Zinc
172
K.J. Brown et al.
deciency may contribute to dermatitis, impaired immune function, and exacerbate the effects of
vitamin A deciency [60, 61] There are no controlled trials of zinc supplementation, but 50 mg of
elemental zinc given orally every day is often used in adults, while one study in infants and children
with CF (but not with liver disease) used 5 mg/kg/day orally of elemental zinc [63].
Sodium Chloride: The diet of individuals with CF is generally unrestricted for added salt. In times of
increased exercise or increased ambient temperatures supplemental sodium is encouraged to replace
excess losses [64]. This practice is encouraged until physical and biochemical assessments in light of
progressive liver disease determine that renal sodium retention has increased, leading to accumulation
of abdominal ascites. In the setting of cirrhosis with portal hypertension, the associated low systemic
blood volume triggers activation of the renin angiotensin system and sodium retention. This is
primarily related to the peripheral vasodilation and resultant arteriolar hypotension at the level of the
glomerulus. The resultant sodium retention can lead to ascites. In this setting, dietary/parenteral
sodium restriction should cautiously be limited to 2000 mg/day or 23 mEq/kg in conjunction with
diuretics to increase renal output [65]. The traditional measurement of urinary sodium and potassium
to assess activation of this system is complicated in CF. Typically, urinary sodium is low and potassium
high with renin angiotensin activation. However this pattern can also be seen in sodium depletion.
Since individuals with CF can have increased sodium losses, restriction of sodium should be reserved
for those individuals with cirrhosis, portal hypertension, and ascites.
Ursodeoxycholic acid is a hydrophilic bile acid that increases bile acid independent bile ow that
is frequently used in liver disease in CF. When present at high concentrations in bile critical micellar
concentrations cannot be reached. Thus patients on ursodeoxycholic acid may be at increased risk for
fat-soluble vitamin deciency and merit close monitoring [66].
Hepatic Steatosis
Steatosis (fat in the liver) is likely the most common hepatic nding in CF with a prevalence of
2375% of CF patients in all age categories [7]. Steatosis was present in 70% of children undergoing
liver biopsy for suspected liver disease [26, 67]. Hepatic steatosis has been associated with malnutrition,
and deciencies of EFA, carnitine, and choline. However, steatosis is also found in CF patients with
adequate nutritional status [5]. Hepatic steatosis can also be seen with obesity. In this setting it is
known as nonalcoholic fatty liver disease (NAFLD). This obesity related disorder is the leading cause
of liver disease in the general population and obesity has been recently recognized as increasing in CF
[68]. Independent of the cause, hepatic steatosis presents as smooth mild hepatomegaly without signs
of portal hypertension. There may be elevated AST and ALT and typically, the ALT is greater than the
AST. The appearance of the liver on ultrasound is usually one of uniform hyperechogenicity, but it
may also have a heterogeneous appearance on ultrasound or as one or several pseudomasses, which
are lobulated fatty structures 12 cm in size [6, 69]. In one study, 57% of cases of steatosis detected
on ultrasound were associated with elevations in aminotransferases [70]. A note of caution is warranted
in regard to this nding as the ultrasound ndings may not be specic for steatosis and can be seen in
periportal brosis [17]. Thus histology is still the gold standard for the diagnosis of hepatic steatosis.
The nding of steatosis in a patient with CF should trigger an evaluation for cause. The vast
majority of the causes of hepatic steatosis in CF are nutritional. In the past, the most common cause
of hepatic steatosis in CF was malnutrition. In malnutrition, hepatic steatosis is common. Protein
malnutrition leads to decreased apolipoprotein synthesis with subsequent decreased VLDL production
and transport, leading to lipid accumulation in the liver [71]. Children or adults with protein calorie
malnutrition should have their malnutrition addressed rst. Correction of nutritional status is associated
11
173
with an improvement in hepatic steatosis, but the improvement may lag several months after the
correction of the nutritional status.
Obesity (BMI 95th percentile) is strongly associated with hepatic steatosis and NAFLD. In the
USA, obesity is now the leading cause of liver disease [72, 73]. The prevalence of obesity varies
between 25 and 45% with differences in prevalence associated with age, gender, race, ethnicity, and
socioeconomic status. Obesity is less common in CF, with a reported prevalence of 7.5% [74]. The
approach to the CF patient with obesity induced hepatic steatosis or NAFLD should focus on diet and
lifestyle modication as it would for any other obese patient [75].
EFA deciency has been reported to cause hepatic steatosis [76]. Biochemical EFA deciency is
common in patients with CF without steatosis. The predominant deciency is linoleic acid. The
etiology is multifactorial and may include an inadequate calorie and fat intake and residual fat
malabsorption of 1020% despite treatment with pancreatic enzymes [77, 78]. Deciency has been
traditionally assessed by determination of a triene to tetraene ratio of plasma fatty acids. Serum
linoleic acid (LA) status has been positively associated with growth and pulmonary outcomes and
may be a more clinically relevant biomarker of EFA status in children with CF and pancreatic
insufciency than the triene:tetraene ratio [79].
CF patients who also have steatosis may have additional fat malabsorption due to functional bile
acid deciency that varies depending upon the severity of the disease. These patients may require a
higher amount of linoleic acid supplementation than CF patients without steatosis. They should be
treated with vegetable oils or margarine containing high amounts of linoleic acid.
Table 11.5 describes the linoleic acid content of some common vegetable oils that contain a
signicant amount of linoleic acid. These oils can be mixed into soft foods such as strained or pureed
foods, mashed potatoes, and pudding or added to pastas or toast. If the oil is not palatable for the child,
corn oil margarine can be used [80]; however, a greater quantity may be required. As with all fatcontaining meals, it is important to remind the families that the CF patient needs to take the prescribed
pancreatic enzyme dose with the EFA supplement.
The exact amount of linoleic acid needed in CF patients is not known. The DRI for acceptable
macronutrient distribution for linoleic acid intake ranges between 5 and 10% of calories for healthy
children [81]. The guidelines for pre-transplant pediatric liver patients are >10% of total calories [82].
In contrast, linoleic acid repletion trials in CF patients have reported that a much higher intake of calories
from linoleic acid fat is required to reverse a deciency state, ranging from 7 to 22% [8386]. It is
possible that malnourished patients require a higher percent of calories from EFA to reverse the
deciency. Since an exact recommendation is lacking, it is reasonable to aim for an EFA intake greater
than 10% of calories. Additionally, an adequate total caloric intake needs to be provided when
supplementing with EFA so that the fat supplement is not metabolized for caloric utilization rather
than the repletion of fatty acid stores.
While EFA deciency should be evaluated in children with CF and hepatic steatosis, other
nutritional deciencies can cause hepatic steatosis, and these are shown in Table 11.6.
Table 11.5 Options for oral supplementation of essential fatty acids

Selected vegetable oils
Corn
Peanut
Soybean
Safower
Adapted from Foman [91]
Linoleic acid of oil content

by weight (%)
50.9
53.8
53.8
76.8
ml/day of oil to provide 6% of kcals

in a 1000 kcal diet
13
12.5
12.5
9.0
K.J. Brown et al.
174
Table 11.6 Causes of hepatic steatosis
Disorders of lipid metabolism
Abetalipoproteinemia
Hypobetalipoproteinemia
Familial combined hyperlipidemia Lipodystrophy
Acid lipase deciency
Wolman disease
Glycogen storage disease
Disorders of fatty acid oxidation
Mitochondrial disorders
Micronutrient deficiency
Carnitine (primary or secondary)
Essential fatty acids
Choline
Medications
Corticosteroids
Parenteral nutrition
Tamoxifen
Amiodarone
HAART
Methotrexate
Others
Surgical weight loss
Celiac disease
Obesity
Malnutrition
Wilson disease
WeberChristian disease
Adapted in part from Kneeman et al. [92]
Children with CF who have malnutrition and/or a low carnitine intake can develop a secondary
carnitine deciency that may play a role in the development of hepatic steatosis. Carnitine deciency
causes a defect in fatty acid oxidation that can contribute at least in part to hepatic steatosis seen in
cystic brosis patients [87]. The primary role of carnitine is to transport long chain fatty acids across
the mitochondrial membrane where they undergo -oxidation to produce energy from stored fat
reserves. Carnitine is available in the food supply through meats, dairy, most enteral formulas, and
human milk (although the human milk concentration is dependent on the mothers carnitine status).
Carnitine is not present in parenteral nutrition unless it is added. Most infant formulas including soy
formulas are now supplemented with carnitine to be comparable to or higher than that found in human
milk [88]. The majority of people are able to synthesize carnitine endogenously from methionine and
lysine in the liver and kidney. Infants, however, have decreased biosynthetic capacity and are at risk
for developing carnitine deciency when receiving a low carnitine diet. Children with CF and hepatic
steatosis without evidence of EFA deciency should have carnitine status assessed by plasma carnitine
levels. If they are found to be decient, it is reasonable to provide a month of supplementation of
levocarnitine (50100 mg/kg/day orally divided three to four times a day with meals) in addition to a
carnitine-rich diet to reverse the deciency.
Conclusion
Liver involvement is common in CF, but nutritional consequences related to disease are primarily seen
in cholestasis and cirrhosis. Cholestasis is generally transient, but leads to increased energy, fat, and
fat-soluble vitamin requirements. Cirrhosis is rare, but when present results in increased energy
requirements and malnutrition in this setting can be challenging to manage. Nutritional assessment
and management of cirrhosis should focus on macro- and micro-nutrient needs and aggressive
intervention when standard therapies fail.
11
175
References
1. Flass T, Narkewicz MR. Cirrhosis and other liver disease in cystic brosis. J Cyst Fibros. 2013;12:11624.
2. Foundation CF. 2011 Annual Data Report to the Center Directors. Bethesda, MD; 2012.
3. Moyer V, Freese DK, Whitington PF, Olson AD, Brewer F, Colletti RB, et al. Guideline for the evaluation of
cholestatic jaundice in infants: recommendations of the North American Society for Pediatric Gastroenterology,
Hepatology and Nutrition. J Pediatr Gastroenterol Nutr. 2004;39(2):11528.
4. Leeuwen L, Magofn AK, Fitzgerald DA, Cipolli M, Gaskin KJ. Cholestasis and meconium ileus in infants with
cystic brosis and their clinical outcomes. Arch Dis Child. 2014;99(5):4437.
5. Colombo C. Liver disease in cystic brosis. Curr Opin Pulm Med. 2007;13(6):52936.
6. Diwakar V, Pearson L, Beath S. Liver disease in children with cystic brosis. Paediatr Respir Rev.
2001;2(4):3409.
7. Herrmann U, Dockter G, Lammert F. Cystic brosis-associated liver disease. Best Pract Res Clin Gastroenterol.
2010;24(5):58592.
8. Colombo C, Battezzati PM, Crosignani A, Morabito A, Costantini D, Padoan R, et al. Liver disease in cystic
brosis: a prospective study on incidence, risk factors, and outcome. Hepatology. 2002;36(6):137482.
9. Efrati O, Barak A, Modan-Moses D, Augarten A, Vilozni D, Katznelson D, et al. Liver cirrhosis and portal
hypertension in cystic brosis. Eur J Gastroenterol Hepatol. 2003;15(10):10738.
10. Lamireau T, Monnereau S, Martin S, Marcotte JE, Winnock M, Alvarez F. Epidemiology of liver disease in cystic
brosis: a longitudinal study. J Hepatol. 2004;41(6):9205.
11. Sokol RJ, Stall C. Anthropometric evaluation of children with chronic liver disease. Am J Clin Nutr.
1990;52(2):2038.
12. Chin SE, Shepherd RW, Cleghorn GJ, Patrick M, Ong TH, Wilcox J, et al. Pre-operative nutritional support in
children with end-stage liver disease accepted for liver transplantation: an approach to management. J Gastroenterol
Hepatol. 1990;5(5):56672.
13. Young S, Kwarta E, Azzam R, Sentongo T. Nutrition assessment and support in children with end-stage liver
disease. Nutr Clin Pract. 2013;28(3):31729.
14. Sullivan JS, Sundaram SS, Pan Z, Sokol RJ. Parenteral nutrition supplementation in biliary atresia patients listed for
liver transplantation. Liver Transpl. 2012;18(1):1208.
15. Guglielmi FW, Regano N, Mazzuoli S, Fregnan S, Leogrande G, Guglielmi A, et al. Cholestasis induced by total
parenteral nutrition. Clin Liver Dis. 2008;12(1):97110.
16. Feranchak AP, Suchy FJ, Sokol RJ. Medical and nutritional management of cholestasis in infants and children. In:
Suchy FJ, Sokol RJ, Balistreri WF, editors. Liver disease in children. Cambridge: Cambridge University Press;
2014. p. 11139.
17. Sokol RJ, Durie PR. Recommendations for management of liver and biliary tract disease in cystic brosis. Cystic
Fibrosis Foundation Hepatobiliary Disease Consensus Group. J Pediatr Gastroenterol Nutr. 1999;28(1 Suppl):S113.
18. Matel JL. Nutritional management of cystic brosis. J Parenter Enteral Nutr. 2012;36(1 Suppl):60S7.
19. Tangpricha V, Kelly A, Stephenson A, Maguiness K, Enders J, Robinson KA, et al. An update on the screening,
diagnosis, management, and treatment of vitamin D deciency in individuals with cystic brosis: evidence-based
recommendations from the Cystic Fibrosis Foundation. J Clin Endocrinol Metab. 2012;97(4):108293.
20. Sokol RJ, Heubi JE, Iannaccone ST, Bove KE, Balistreri WF. Vitamin E deciency with normal serum vitamin E
concentrations in children with chronic cholestasis. N Engl J Med. 1984;310(19):120912.
21. Bartlett JR, Friedman KJ, Ling SC, Pace RG, Bell SC, Bourke B, et al. Genetic modiers of liver disease in cystic
brosis. JAMA. 2009;302(10):107683.
22. Scott-Jupp R, Lama M, Tanner MS. Prevalence of liver disease in cystic brosis. Arch Dis Child. 1991;66(6):
698701.
23. Bhattacharjee R, Schibli S, Rose J, Tullis E, Durie P, Ellis L, et al. The natural history of liver disease in cystic
brosis. J Cyst Fibros. 2006;5:S61.
24. Williams SM, Goodman R, Thomson A, McHugh K, Lindsell DR. Ultrasound evaluation of liver disease in cystic
brosis as part of an annual assessment clinic: a 9-year review. Clin Radiol. 2002;57(5):36570.
25. Lenaerts C, Lapierre C, Patriquin H, Bureau N, Lepage G, Harel F, et al. Surveillance for cystic brosis-associated
hepatobiliary disease: early ultrasound changes and predisposing factors. J Pediatr. 2003;143(3):34350.
26. Lindblad A, Glaumann H, Strandvik B. Natural history of liver disease in cystic brosis. Hepatology. 1999;30(5):
11518.
27. Desmond CP, Wilson J, Bailey M, Clark D, Roberts SK. The benign course of liver disease in adults with cystic
brosis and the effect of ursodeoxycholic acid. Liver Int. 2007;27(10):14028.
28. Lewindon PJ, Ramm GA. Cystic brosis-cirrhosis, portal hypertension, and liver biopsy: reply. Hepatology.
2011;53(3):10656.
176
K.J. Brown et al.
29. Feigelson J, Anagnostopoulos C, Poquet M, Pecau Y, Munck A, Navarro J. Liver cirrhosis in cystic brosis
therapeutic implications and long term follow up. Arch Dis Child. 1993;68(5):6537.
30. Chryssostalis A, Hubert D, Coste J, Kanaan R, Burgel PR, Desmazes-Dufeu N, et al. Liver disease in adult patients
with cystic brosis: a frequent and independent prognostic factor associated with death or lung transplantation.
J Hepatol. 2011;55:137782.
31. Minicucci L, Lorini R, Giannattasio A, Colombo C, Iapichino L, Reali MF, et al. Liver disease as risk factor for
cystic brosis-related diabetes development. Acta Paediatr. 2007;96(5):7369.
32. Sullivan KM, Moran A, Schwarzenberg S. Cystic brosis related diabetes in CF patients with cirrhosis. Pediatr
Pulmonol. 2009;44:414.
33. Hsu EK, Murray KF. Cirrhosis and chronic liver failure. In: Suchy FJ, Sokol RJ, Balistreri WF, editors. Liver
disease in children. 4th ed. Cambridge: Cambridge University Press; 2014. p. 5167.
34. Shneider BL. Portal hypertension. In: Suchy FJ, Sokol RJ, Balistreri WF, editors. Liver disease in children. 4th ed.
Cambridge: Cambridge University Press; 2014. p. 6887.
35. Rowland M, Gallagher CG, OLaoide R, Canny G, Broderick A, Hayes R, et al. Outcome in cystic brosis liver
disease. Am J Gastroenterol. 2011;106(1):1049.
36. Debray D, Lykavieris P, Gauthier F, Dousset B, Sardet A, Munck A, et al. Outcome of cystic brosis-associated
liver cirrhosis: management of portal hypertension. J Hepatol. 1999;31(1):7783.
37. Milkiewicz P, Skiba G, Kelly D, Weller P, Bonser R, Gur U, et al. Transplantation for cystic brosis: outcome
following early liver transplantation. J Gastroenterol Hepatol. 2002;17(2):20813.
38. Colombo C, Russo MC, Zazzeron L, Romano G. Liver disease in cystic brosis. J Pediatr Gastroenterol Nutr.
2006;43 Suppl 1:S4955.
39. Westaby D. Cystic brosis: liver disease. Prog Respir Res. 2006;34:25161.
40. Linnane B, Oliver MR, Robinson PJ. Does splenectomy in cystic brosis related liver disease improve lung function
and nutritional status? A case series. Arch Dis Child. 2006;91(9):7713.
41. Polineni D, et al. Pulmonary function (FEV1) in cystic brosis patients with and without severe liver disease with
portal hypertension (CFLD). Am J Respir Crit Care Med. 2009;179.
42. Corbett K, Kelleher S, Rowland M, Daly L, Drumm B, Canny G, et al. Cystic brosis-associated liver disease: a
population-based study. J Pediatr. 2004;145(3):32732.
43. Bonkovsky HL, Hawkins M, Steinberg K, Hersh T, Galambos JT, Henderson JM, et al. Prevalence and prediction
of osteopenia in chronic liver disease. Hepatology. 1990;12(2):27380.
44. Rodriguez-Roisin R, Krowka MJ, Herve P, Fallon MB, Committee ERSTFP-HVDS. Pulmonary-hepatic vascular
disorders (PHD). Eur Respir J. 2004;24(5):86180.
45. Frisancho AR. New norms of upper limb fat and muscle areas for assessment of nutritional status. Am J Clin Nutr.
1981;34(11):25405.
46. Ryan AS, Martinez GA. Physical growth of infants 7 to 13 months of age: results from a national survey. Am J Phys
Anthropol. 1987;73(4):44957.
47. Greer R, Lehnert M, Lewindon P, Cleghorn GJ, Shepherd RW. Body composition and components of energy
expenditure in children with end-stage liver disease. J Pediatr Gastroenterol Nutr. 2003;36(3):35863.
Nutrition Subcommittee; Ad Hoc Working Group. Evidence-based practice recommendations for nutrition-related
management of children and adults with cystic brosis and pancreatic insufciency: results of a systematic review.
J Am Diet Assoc. 2008;108(5):8329.
49. Borowitz D, Robinson KA, Rosenfeld M, Davis SD, Sabadosa KA, Spear SL, et al. Cystic Fibrosis Foundation
evidence-based guidelines for management of infants with cystic brosis. J Pediatr. 2009;155(6 Suppl):S7393.
50. Pierro A, Koletzko B, Carnielli V, Superina RA, Roberts EA, Filler RM, et al. Resting energy expenditure is
increased in infants and children with extrahepatic biliary atresia. J Pediatr Surg. 1989;24(6):5348.
51. Cleghorn G. The role of basic nutritional research in pediatric liver disease: an historical perspective. J Gastroenterol
Hepatol. 2009;24 Suppl 3:S936.
52. Kocoshis SA, Wleman RE. Hepatic disease. In: Corkins MR, Ballant J, Bobo E, Plogsted S, Yaworski JA, Seebeck
ND, editors. A.S.P.E.N pediatric nutrition support core curriculum. Silver Spring: American Society of Parenteral
and Enteral Nutrition; 2010. p. 30210.
53. Debray D, Kelly D, Houwen R, Strandvik B, Colombo C. Best practice guidance for the diagnosis and management
of cystic brosis-associated liver disease. J Cyst Fibros. 2011;10 Suppl 2:S2936.
54. Charlton CP, Buchanan E, Holden CE, Preece MA, Green A, Booth IW, et al. Intensive enteral feeding in advanced
cirrhosis: reversal of malnutrition without precipitation of hepatic encephalopathy. Arch Dis Child.
1992;67(5):6037.
55. Pandit C, Graham C, Selvadurai H, Gaskin K, Cooper P, van Asperen P. Festival food coma in cystic brosis. Pediatr
Pulmonol. 2013;48(7):7257.
11
177
57. Vandeleur M, Massie J, Oliver M. Gastrostomy in children with cystic brosis and portal hypertension. J Pediatr
58. Rashid M, Durie P, Andrew M, Kalnins D, Shin J, Corey M, et al. Prevalence of vitamin K deciency in cystic
brosis. Am J Clin Nutr. 1999;70(3):37882.
59. Feranchak AP, Gralla J, King R, Ramirez RO, Corkill M, Narkewicz MR, et al. Comparison of indices of vitamin
A status in children with chronic liver disease. Hepatology. 2005;42(4):78292.
60. Krebs NF. Update on zinc deciency and excess in clinical pediatric practice. Ann Nutr Metab. 2013;62 Suppl
1:1929.
61. Mohammad MK, Zhou Z, Cave M, Barve A, McClain CJ. Zinc and liver disease. Nutr Clin Pract. 2012;27(1):
820.
62. Narkewicz MR, Krebs N, Karrer F, Orban-Eller K, Sokol RJ. Correction of hypozincemia following liver
transplantation in children is associated with reduced urinary zinc loss. Hepatology. 1999;29(3):8303.
63. Van Biervliet S, Vande Velde S, Van Biervliet JP, Robberecht E. The effect of zinc supplements in cystic brosis
patients. Ann Nutr Metab. 2008;52(2):1526.
64. Guimaraes EV, Schettino GC, Camargos PA, Penna FJ. Prevalence of hyponatremia at diagnosis and factors
associated with the longitudinal variation in serum sodium levels in infants with cystic brosis. J Pediatr. 2012;
161(2):2859.
65. Wong F. Management of ascites in cirrhosis. J Gastroenterol Hepatol. 2012;27(1):1120.
66. Narkewicz MR, Smith D, Gregory C, Lear JL, Osberg I, Sokol RJ. Effect of ursodeoxycholic acid therapy on
hepatic function in children with intrahepatic cholestatic liver disease. J Pediatr Gastroenterol Nutr.
1998;26(1):4955.
67. Lewindon PJ, Shepherd RW, Walsh MJ, Greer RM, Williamson R, Pereira TN, et al. Importance of hepatic brosis
in cystic brosis and the predictive value of liver biopsy. Hepatology. 2011;53(1):193201.
68. Hanna RM, Weiner DJ. Overweight and obesity in patients with cystic brosis: a center-based analysis. Pediatr
Pulmonol. 2014;50(1):3541.
69. Akata D, Akhan O. Liver manifestations of cystic brosis. Eur J Radiol. 2007;61(1):117.
70. Patriquin H, Lenaerts C, Smith L, Perreault G, Grignon A, Filiatrault D, et al. Liver disease in children with cystic
brosis: US-biochemical comparison in 195 patients. Radiology. 1999;211(1):22932.
71. Badaloo A, Reid M, Soares D, Forrester T, Jahoor F. Relation between liver fat content and the rate of VLDL
apolipoprotein B-100 synthesis in children with protein-energy malnutrition. Am J Clin Nutr.
2005;81(5):112632.
72. Koppe SW. Obesity and the liver: nonalcoholic fatty liver disease. Transl Res. 2014;164(4):31222.
73. Mencin AA, Lavine JE. Nonalcoholic fatty liver disease in children. Curr Opin Clin Nutr Metab Care. 2011;14(2):
1517.
74. Panagopoulou P, Fotoulaki M, Nikolaou A, Nousia-Arvanitakis S. Prevalence of malnutrition and obesity among
cystic brosis patients. Pediatr Int. 2014;56(1):8994.
75. Feldstein AE, Patton-Ku D, Boutelle KN. Obesity, nutrition, and liver disease in children. Clin Liver Dis.
2014;18(1):21931.
76. Werner A, Havinga R, Bos T, Bloks VW, Kuipers F, Verkade HJ. Essential fatty acid deciency in mice is associated
with hepatic steatosis and secretion of large VLDL particles. Am J Physiol Gastrointest Liver Physiol.
2005;288(6):G11508.
77. Lloyd-Still JD, Smith AE, Wessel HU. Fat intake is low in cystic brosis despite unrestricted dietary practices.
J Parenter Enteral Nutr. 1989;13(3):2968.
78. Kalivianakis M, Minich DM, Bijleveld CM, van Aalderen WM, Stellaard F, Laseur M, et al. Fat malabsorption in
cystic brosis patients receiving enzyme replacement therapy is due to impaired intestinal uptake of long-chain
fatty acids. Am J Clin Nutr. 1999;69(1):12734.
2008;47(5):63544.
cystic brosis associated with early diagnosis and intervention. Am J Clin Nutr. 1991;54(3):57885.
81. Macronutrients, healthful diets, and physical activity. In: Otten JL, Hellwig JP, Meyers LD, editors. DRI Dietary
Reference Intakes, The guide to nutrient requirements. Washington DC: The National Academies Press; 2006.
p. 71102.
82. Baker A, Stevenson R, Dhawan A, Goncalves I, Socha P, Sokal E. Guidelines for nutritional care for infants with
cholestatic liver disease before liver transplantation. Pediatr Transplant. 2007;11(8):82534.
83. Mischler EH, Parrell SW, Farrell PM, Raynor WJ, Lemen RJ. Correction of linoleic acid deciency in cystic
brosis. Pediatr Res. 1986;20(1):3641.
84. Landon C, Kerner JA, Castillo R, Adams L, Whalen R, Lewiston NJ. Oral correction of essential fatty acid deciency
in cystic brosis. J Parenter Enteral Nutr. 1981;5(6):5014.
178
K.J. Brown et al.
2000;31(4):41823.
86. van Egmond AW, Kosorok MR, Koscik R, Laxova A, Farrell PM. Effect of linoleic acid intake on growth of infants
with cystic brosis. Am J Clin Nutr. 1996;63(5):74652.
87. Treem WR, Stanley CA. Massive hepatomegaly, steatosis, and secondary plasma carnitine deciency in an infant
with cystic brosis. Pediatrics. 1989;83(6):9937.
88. Crill CM, Helms RA. The use of carnitine in pediatric nutrition. Nutr Clin Pract. 2007;22(2):20413.
89. Krebs NF, Westcott JE, Arnold TD, Kluger BM, Accurso FJ, Miller LV, et al. Abnormalities in zinc homeostasis in
young infants with cystic brosis. Pediatr Res. 2000;48(2):25661.
90. Colomb V, Jobert-Giraud A, Lacaille F, Goulet O, Fournet JC, Ricour C. Role of lipid emulsions in cholestasis
associated with long-term parenteral nutrition in children. J Parenter Enteral Nutr. 2000;24(6):34550.
91. Foman SJ. Fat. In: Fomon SJ, editor. Nutrition of normal infants. St Louis: Mosby; 1993. p. 14775.
92. Kneeman JM, Misdraji J, Corey KE. Secondary causes of nonalcoholic fatty liver disease. Therap Adv Gastroenterol.
2012;5(3):199207.
Chapter 12
Gastrointestinal Complications of Cystic Fibrosis

and Their Impact on Nutrition
Daniel Gelfond
Key Points
Nutrition status in cystic brosis (CF) patients is closely associated with pulmonary outcomes and
depends heavily on the activity of Cystic Fibrosis Transmembrane Conduction Regulator (CFTR)
in the gastrointestinal tract.
CF-related gastrointestinal complications often precede pulmonary complications and can be
observed in utero or early infancy often requiring radiological or surgical interventions.
Extent and degree of GI-related complications in CF patients varies with CFTR mutations and
often most prominent with class 1 and 2 mutations.
Nutritional deciencies in CF patients can stream from pancreatic enzyme and bile acid
insufciency, bicarbonate deciency to counteract gastric acidity, viscosity of the epithelial mucus,
or small bowel bacterial overgrowth.
CFTR regulates ow of bicarbonate in the gastrointestinal track that is important for pH regulation,
mucin unfolding, hydration, and luminal viscosity that can impact motility and bacterial stasis
Assessment of the gastrointestinal pH proles and bicarbonate-dependent pH change using wireless
motility capsule in patients with CF has promoted this technique as a gut specic CFTR biomarker.
Targeted therapy to correct CFTR gating defect in patients with G551D mutation has validated
the role of this technology to establish gut specic CFTR biomarker
Altered luminal physiology with dehydrated mucus, altered pH, immune deciency, dysmotility,
and nutrient malabsorption in CF patients predisposes to dysbiosis and small bowel bacterial
overgrowth causing signicant impact on overall health and quality of life in affected patients.
Diseases of the esophagus, stomach, small intestine, and colon are not uncommon in patients with
CF and often are addressed with similar therapeutic modalities as in non-CF patients.
Keywords CFTR Gastroesophageal reflux Gastric emptying Small intestinal bacterial
overgrowth Distal intestinal obstruction syndrome Constipation Gastrointestinal cancers
Gastrointestinal motility
D. Gelfond, M.D. (*)

WNY Pediatric Gastroenterology, 166 Washington Avenue, Batavia, NY 14020, USA
University of Rochester Medical Center, Rochester, NY USA
179
180
D. Gelfond
Introduction
Nutritional status is strongly associated with pulmonary outcomes and general health in CF patients.
Maintaining an optimal weight is a signicant goal of CF care [1]. The recognition and management
of pancreatic involvement in patients with cystic brosis (CF) has played a central role in improving
the nutritional status of these patients. However, recognition and management of other gastrointestinal
complications of CF is also important to help improve weight gain and quality of life. Breakthrough
developments in identifying the role of the cystic brosis transmembrane conductance regulator
(CFTR) in the gastrointestinal tract have led to a better understanding of CF associated gastrointestinal
diseases [2]. Recent pharmacological correctors of specic CFTR defects have provided a platform to
further understand and study the role of CFTR in the gastrointestinal tract [3]. Gastrointestinal
manifestations can be present in utero as well as in early neonatal life and often precede pulmonary
manifestations. Recognition of early gastrointestinal symptoms often leads to further testing for
diagnosing CF in infants. Inspissated secretions within the lumen of the gastrointestinal tract can lead
to the intestinal obstruction of meconium ileus. In complex cases, perforation of the bowel may lead
to meconium peritonitis, intestinal resection, and can further compromise nutrition and growth in
children with CF. More common gastrointestinal diseases such as gastroesophageal reux disease
(GERD) have been frequently seen in both children and adults with CF and often leads to clinical
discomfort and poor appetite. It is important to note that not all of the nutritional deciencies in CF
patients are secondary to insufcient caloric intake. Pancreatic diseases, in particular pancreatic
insufciency (PI) that is present at birth, will prevent adequate enzymatic breakdown of nutrients
required for mucosal absorption and assimilation. Use of pancreatic enzyme replacement therapy
(PERT) has been a life sustaining intervention in patients with PI. Pancreatic sufcient (PS) patients
might not manifest nutritional malabsorption as seen in PI patients, but can have GI discomfort.
Pancreatic diseases are covered in more detail in other chapters in this book.
Even with adequate enzymatic activity, whether endogenous or supplemental, nutritional absorption
can be compromised in CF patients as a result of viscous secretions that might prevent nutrient
interaction with absorptive surface of the mucosal brush border. Viscous secretions that concentrate
nutrients away from the epithelial layer, can interfere with the release and efcacy of defensins, part
of the innate immune system that are secreted from the crypts of the mucosal layer [4]. A compromised
immune system, evidence of delayed small bowel transit [5] and small intestinal bacterial overgrowth
(SIBO) may be a signicant factors in poor nutritional outcomes in patients with CF. Increased
viscosity of the intestinal mucus and delayed small bowel transit may also contribute to the development
of constipation or distal intestinal obstruction syndrome (DIOS), which in its subacute chronic form
can cause poor appetite and inadequate weight gain.
Biliary secretions are critical for fat emulsication and absorption. Liver disease seen in patients
with cystic brosis can lead to fat malabsorption through insufcient bile secretion. More thorough
discussion of liver diseases in CF is covered Chapter 11 in this book.
Other gastrointestinal diseases, such as Celiac disease, inammatory bowel disease, and
gastrointestinal cancers tend to have a higher incidence among CF patients with disease-associated
impact on nutrition and growth in pediatric and adult populations.
Role of CFTR in Gastrointestinal Tact

CFTR was identied and directly linked to CF in 1989 [6]. This complex protein is a cyclic-AMP
regulated chloride channel that also regulates the ow of bicarbonate (HCO3) along with other ions
across the apical surface of epithelial cells. Absence of CFTR or decreased functional capacity leads
to electrolyte imbalance external to the surface of the epithelial membranes, leading to desiccation
12
Gastrointestinal Complications of Cystic Fibrosis and Their Impact on Nutrition
181
Fig. 12.1 Classication of CFTR mutations
and reduced clearance of secretions. CFTR protein is expressed on epithelial surfaces lining the
gastrointestinal, integumentary, and pulmonary systems. CFTR distribution has higher abundance in
the upper GI track, with highest density in the duodenum, gradually decreasing caudally [7]. CFTR is
also present within pancreatic [8] and hepatobiliary systems [9]. Brunners glands are densely present
in the proximal small bowel and secrete bicarbonate-rich uid into the crypts of the epithelial lining
where it interacts with the mucin produced by epithelial goblet cells. Defective interaction between
mucin and bicarbonate in CF patients can lead to thick mucus clogging the crypts and interfering with
intestinal function [10]. The role of CFTR in the regulation of bicarbonate has been mostly described
in CF disease, but has also been described in pancreatic diseases not associated with CF [11].
New developments in targeted therapy for specic CFTR defects have presented great therapeutic
potential for a subgroup of CF patients with class III (gating) mutations (Fig. 12.1) [3, 12]. CFTR
potentiator therapy with ivacaftor, a drug that targets class III mutations, provides a better insight and
understanding of the pulmonary and gastrointestinal physiology in CF [13]. In particular, treatment
with ivacaftor is associated with steady and signicant weight gain, highlighting the central role of
CFTR dysfunction in the nutritional manifestations of CF. With more therapeutic interventions
developed specically to address and correct defective cellular pathways or proteins, clinical focus in
targeting CF will be aimed at early disease identication and prevention giving us the opportunity to
minimize the gastrointestinal and nutritional morbidity of the disease.
Gastroesophageal Reflux and Gastric Emptying

GERD is one of the most prevalent gastrointestinal problems in CF. The principal mechanism causing
GERD is an increase in the frequency and duration of transient lower esophageal sphincter relaxation
(TLSR) episodes, permitting gastric contents to reux into the esophagus. Symptoms include chest
pain, heartburn, acid brash, halitosis, and dysphagia. In the USA, GERD has been reported in 30% of
adult CF patients [14, 15]. There is a well-recognized relationship between GERD and chronic
obstructive pulmonary disease [16]. In a 2010 survey, GERD symptoms of heartburn, acid brash,
dysphagia, and dyspepsia were reported daily and occasionally in 24% and 39% of adult CF patients,
respectively [17]. It has been suggested that pathologic reux is associated with worse pulmonary
outcome in patients with CF [1820]. Despite these observations; there is poor correlation between
severity of GERD symptoms and FEV1 or FVC in adults with CF [17].
Clinical symptoms of GERD often impact nutrition by means of decreased appetite and poor
caloric intake. In infants and younger children with CF, feeding refusal due to discomfort and pain
associated with reux might not be well communicated. Standard therapy with acid suppression,
either histamine-2 receptor antagonist (H2RA) or proton pump inhibitor (PPI), has been used for
GERD treatment. In CF patients, rst-line therapy has been predominantly with PPI [21, 22]. Data
from the 2013 CF Foundation Patient Registry show that more than 50% of the US CF patients are
treated with PPI. This may not reect treatment of GERD; however, since pancreatic insufcient
182
D. Gelfond
patients are frequently prescribed acid-suppressing drugs to improve availability and efcacy of
enzyme supplementation. In practice, this may preemptively address possible GER symptoms.
Although pharmacological intervention is rst-line therapy, surgical intervention with
fundoplication is an alternative to acid suppression in severe cases. In one study of adults with CF and
reux conrmed by 24-hour pH monitoring, laparoscopic fundoplication resulted in a small
improvement in lung function, and a marked decrease in cough scores and number of pulmonary
exacerbation events [23]. A separate study looking at the benets of gastrostomy tube feedings in CF
patients who failed medical therapy and required fundoplication showed statistical improvement in
weight gain when gastrostomy tube feedings were used for more than 6 months [24]. This intervention
may be especially important for patients who are in need of lung transplantation, as anti-reux surgery
has been shown to have a benecial effect for patients without CF with end-stage lung disease and
may improve allograft survival after transplantation [25].
Frequent emphasis on high calorie foods in CF patients can further aggravate reux. CF dietary
and nutritional supplement recommendations advise high fat diets, which can lead to prolonged
gastric stasis, delayed gastric emptying, and an increased incidence of GER. However, this concern
about delayed gastric emptying has not been borne out, as studies have shown similar gastric emptying
time between CF patients and healthy matched controls [5, 26]. Furthermore, studies have shown no
association between gastric emptying and GERD in CF patients [27].
Pancreatic Disease
Defects in the exocrine function of the pancreas in patients with CF have been subdivided into pancreatic
insufciency (PI) and pancreatic sufciency (PS) based on the capacity to secrete pancreatic enzymes
required for digestion and nutrition. More thorough discussions of PS and PI can be found in Chapter
10 and this chapter. An objective determination of pancreatic status function and routine re-evaluation
is important in patients with CF, since those who are PI will need life-long PERT. A noninvasive stool
assay for fecal elastase using enzyme-linked immunosorbent assay (ELISA) has been shown to be an
excellent indicator of PI, with a sensitivity of 98100% and a specicity of 93100% [28, 29]. Serum
immunoreactive trypsinogen is used in newborn screening programs to identify infants with CF, based
on elevated trypsinogen from in utero pancreatic damage. Of note, even infants with PS-CF will have
elevated trypsinogen. Infants born with CF-PI will have a rapid decline in the levels of serum trypsinogen
in the rst few years of life. Consequently, PI can be diagnosed using a blood test if serum trypsinogen
is below the lower limits of normal in patients over 8 years of age [30]. Across all age groups, about
90% of patients with CF are PI. PI is usually seen in more severe CFTR mutations (class I, II, or III)
and is present at birth in 60% of infants with CF [31].
The nutritional impact of pancreatic insufciency is that it causes signicant malabsorption of
protein and fat, including fat-soluble vitamins A, D, E, and K. Deciencies in these vitamins can range
from xerophthalmia in vitamin A deciency, osteopenia in vitamin D deciencies, or coagulation
defect with vitamin K deciency along with other symptoms described in Chapters 4 and 5. In patients
with underlying liver disease, fat malabsorption is further exacerbated by deciency in bile salts.
Malnutrition resulting from PI can have long-term sequelae with permanent stunting of stature [32, 33],
cognitive dysfunction [34, 35], and a more rapid decline in pulmonary function [1, 3640]. Over 85%
of CF patients in the USA take exogenous PERT on a routine basis [21] with every meal and snack.
The nutritional efcacy of PERT relies on the physiological environment of the proximal
gastrointestinal tract once present in the small bowel. To prevent denaturation and inactivation of the
porcine enzyme, manufacturers encapsulated enzymes into small beads that are resistant to acid
degradation. The goal is to prevent breakdown of the enzymes when in the acidic environment in the
stomach and only enable their activity once in the small bowel. Microspheres are designed to dissolve
12
183
at the pH of 5.56.0 [41, 42], which is usually achieved within the very proximal small bowel. Once
gastric contents empty into the duodenum, the acidic pH is neutralized by bicarbonate-rich secretions
within 10 cm of the gastro-duodenal junction. The epithelium of the small bowel, pancreatic, and
biliary ducts secretes bicarbonate via a CFTR-assisted Cl/ HCO3 exchange process and electrogenic
secretion of HCO3 via a CFTR conductance pathway [43]. In patients with CF, reduced duodenal
bicarbonate secretion may fail to neutralize gastric acid and thereby prevent or delay dissolution of
the enteric coating until the microspheres reach more distal portions of the small bowel, thus allowing
undigested food to bypass some of the absorptive surface of the intestine. This can have a profound
effect on nutrition and lead to malabsorptive diarrhea. Delayed small bowel neutralization of the
gastric acid with defective bicarbonate secretion has been noted in CF-PI in comparison to healthy
controls in vivo [5]. Use of acid suppression in CF-PI patients on PERT might reduce gastric acidity
requiring less robust bicarbonate response in the small bowel and potentially improved digestion and
absorption by releasing encapsulated enzymes more proximal in the small bowel [44]. In CF patients,
gastric acid suppression by PPI has been associated with a decrease in malabsorption symptoms
[4547].
Contrary to CF-PI disease, CF-PS patient have milder rather than severe CFTR genotypes and
have adequate pancreatic enzyme secretion. CF-PS patients tend to have improved nutritional
parameters with lower sweat chloride levels and better lung function compared to CF-PI patients.
Acinar tissue in patients with PS is preserved, but there is a decreased ductal ow [48] that can lead
to relatively acidic and dehydrated intestinal contents. This may account for some of the gastrointestinal
symptoms seen in CF-PS patients. Decreased ductal bicarbonate and uid secretion can also lead to
intraductal enzyme activation presenting as pancreatitis in 10% of pancreatic sufcient patients.
Recurrent bouts of pancreatitis in CF-PS patients can lead to chronic scarring of the ductal system and
breakdown of the acinar cells causing patients to become PI. Early identication of pancreatic
insufciency in previously pancreatic sufcient patients is critical in preventing nutritional problems.
In a study of 630 PS patients, 3% were found to develop PI after 5.6 years [30]. There is a rationale in
advocating routine screening of the PS patients with fecal elastase and serum tripsinogen to identify
early onset of pancreatic failure. Although there is no current evidence to support that the development
of PI can be halted or reversed, further studies might identify triggers of developing PI.
Small Intestinal Bacterial Overgrowth

The symbiotic relationship between gastrointestinal microora and the intestinal mucosa plays a
signicant role in nutrition and immune regulation. The distribution, composition, and density of the
microbiome vary over a wide range across different regions of the gastrointestinal tract. The density
of the microorganisms is measured as number of organisms/gram and ranges from 0 to 102 in the
stomach, 102103 in the proximal small bowel up to 107108 in the terminal ileum, and 1012 in the
colon [49]. The ability to maintain a relatively low density of the microbiota in the proximal and midsmall bowel is coordinated by multiple physiological, immunological, and chemical functions within
the small bowel. Strong antegrade peristalsis, often termed the migrating motor complex, routinely
sweeps all of the contents of the small bowel into the colon, thus clearing all of the residual
microorganisms along with luminal contents. To assist clearance of the bacteria, intestinal mucus
layer traps bacteria and is cleared during the sweeping complex. This complex is inhibited during
meals to enable digestion and absorption of nutrients in the small bowel. In health, the low pH of the
gastric acid will destroy a large portion of ingested microorganisms in the stomach before they enter
the small bowel. Enzymatic digestion along with bile acids will further destroy bacteria in the proximal
small bowel. Bactericidal properties of the immunological secretion with mucosal immunoglobulin
A, along with defensins secreted from Paneth cells localized in the crypts of the small bowel, provide
additional bacterial killing [4].
184
D. Gelfond
In CF patients, disruption of the abovementioned mechanisms with thick mucus secretions,

intestinal dysmotility, chronic use of acid-suppressing agents, and antibiotics can predispose patients
to intestinal stasis facilitating development of SIBO, which is seen in 3055% of patients [50, 51].
More recent studies using wireless motility capsules along with other radioisotope studies concluded
delayed small bowel transit in patients with CF to be almost twice as long as in healthy matched
controls, which can further support SIBO [5, 26]. Bacterial overgrowth within the lumen of the small
intestine can produce gas, toxic byproducts, and metabolites often leading to malnutrition,
malabsorption, and adjacent enterocyte damage. SIBO will compete with the host for critical nutrients,
alter metabolism, and inict mucosal damage that can lead to further derangements in nutrient
digestion or absorption. Bacterial overgrowth can deconjugate bile acids impairing bile acid-dependent
fat absorption leading to steatorrhea and malabsorption of fats and fat-soluble vitamins. Deconjugated
bile acids may exert toxic effects on enterocytes, further exacerbating damage that can lead to protein
and carbohydrate malabsorption. Impaired disaccharidase activity from mucosal inammation or
from thick viscous secretions trapping access to brush border enzymes will interfere with
monosaccharide availability required for intestinal absorption; the unabsorbed disaccharides are then
available for bacterial degradation and fermentation. The impact on nutrition by SIBO is only in part
through direct effects on enterocytes, competition for nutrients, and production of toxins. Abdominal
distention from excessive fermentation and production of toxic metabolites can lead to signicant
clinical symptoms of abdominal pain, nausea, vomiting, diarrhea, and decreased appetite further
compromising nutritional status of a host.
Diagnostic modalities such as imaging, culture of duodenal aspirates during endoscopy, and breath
hydrogen testing are used to diagnose SIBO. All of these modalities have limitations in accurately
diagnosing SIBO. Breath testing has been the least invasive and most practical modality to diagnose
SIBO in older children and adults. Improved sensitivity to breath hydrogen testing was achieved
through adding methane to a routine breath testing [52]. D-Lactic acidosis has been associated with
SIBO through extrapolation that only bacteria can produce D-lactic acid in large enough volume to be
detected in serum. Measurement of only the D enantiomer is only done at academic institutions and
this modality has never been well-accepted as a clinical tool. Novel diagnostic developments in
imaging techniques and intraluminal diagnostic devices might add to our armamentarium of tools to
diagnose SIBO [53, 54].
Medical management of SIBO with broad-spectrum enteric antibiotics is the treatment of choice
and may be used as empiric therapy based on symptoms and clinical suspicion. The goal of the
therapy is to suppress and potentially eradicate pathogenic bacterial overgrowth that will not repopulate
the small intestine once therapy is discontinued. This approach is frequently augmented with adequate
bowel hydration with osmotic agents such as polyethylene glycol. Unlike antibiotics, probiotics have
limited bactericidal properties, but likely will compete with the pathogenic species for colonization
and nutrient availability. Discontinuation of the pharmacological agents that might be associated with
development of SIBO, such as chronic antibiotics or acid suppression therapy in CF patients, can
often lead to worsening clinical outcomes and has to be carefully assessed by a treating provider.
Diseases of the Small Intestine

The nutritional capacity of the small bowel is constrained not just by the surface area available for
digestion and absorption of nutrients but also by specic regions of the small bowel. The small bowel
is classically subdivided into duodenum, jejunum, and ileum and each region has specialized functions
in terms of nutrient absorption. The duodenum plays a major role in iron absorption and the ileum is
predominantly responsible for vitamin B12 and bile acid absorption. There is a signicant overlap in
nutritional and functional capabilities between different regions of the small bowel. Distal regions of
the small bowel have a greater versatility to compensate for the lack of proximal small bowel capacity.
12
185
The proximal small bowel, however, has a limited capacity to perform the functions of the distal
regions. This discrepancy in the regional capabilities of the small bowel and its impact on nutrition
becomes relevant in surgical resections of the small bowel and diseases involving segments or specic
regions of the small intestine. Postoperative strictures or distended bowel loops can facilitate
SIBO. Surgical resections in CF infants with inspissated meconium ileus (MI), intestinal atresias, or in
utero perforations can lead to a loss of bowel region and consequent malabsorption and nutritional
compromise. A retrospective study of infants over a 20-year duration identied MI in 20% of CF
conrmed cases, most requiring surgical interventions (92%) [55]. A higher incidence of MI has been
observed in infants with more severe CRTR mutations with proposed pathophysiology of small bowel
obstruction caused by loss of CFTR-mediated Cl and/or HCO3 transport in the intestinal epithelium
along with pancreatic dysfunction [56]. However, not all patients with a given genotype will develop
MI. In contrast, animal models of CF must be managed specically to avoid bowel obstruction. Animal
experiments of CFTR knock out models with transgenic intestinal expression of CFTR protein showed
that expressing 20% of the wild type CFTR in the gastrointestinal tract and improving Cl current to at
least 60% of wild type was sufcient to rescue animals from a phenotype with 100% MI [57].
Other comorbid conditions involving the small bowel such as celiac disease and inammatory
bowel disease are found to have a higher prevalence in the CF population and can further compromise
small bowel function and nutrition [58, 59].
Distal Intestinal Obstructions Syndrome

DIOS, previously termed meconium ileus equivalent, is a complete or partial obstruction of the distal
ileum with fecal material extending into cecum that can present in CF patients at any age [60].
Accumulation of this viscid fecal material adheres strongly to mucosal villi and crypts. DIOS can
present as an acute event or with chronic, intermittent symptoms of abdominal pain and distention
likely attributed to a partial breakdown and re-accumulation of new material over a strongly adherent
mucoid mass. Symptoms include cramps, abdominal pain localized to the right lower quadrant leading
to anorexia and subsequent weight loss. DIOS is seen more frequently in PI patients as well as those
with a prior history of MI or prior episodes of DIOS [61]. Although DIOS is rare in PS patients, it has
been reported [60]. Increased viscosity of the luminal mucus, intestinal dysmotility, and mucosal
inammation, along with defective chloride, bicarbonate, and water secretion into the gut lumen
collectively contribute to DIOS. Fat malabsorption and insufcient PERT supplementation has been
suggested as a pathophysiology causing DIOS, but has not been validated in a recent clinical study
[62]. Even though this study did observe a signicant increase in fat intake and pancreatic enzyme
intake, when the ratio of enzyme supplementation was corrected for fat intake, there was no difference
in the same cohort a year prior to DIOS. The impact of nutrition on pathophysiology of DIOS remains
to be answered. The role of DIOS on nutrition, however, is undeniably important. Unabsorbed
nutrients and distention in the distal portion of the small intestine contributes to the ileal brake, a
physiological mechanism inhibiting gastric emptying, intestinal peristalsis, and reduction of intestinal
secretions. All of these mechanisms along with clinical symptoms will interfere with appetite and
normal enteral nutrition.
Management and urgency of clinical intervention depends on the degree of obstruction and
suspicion of peritoneal irritation and symptoms. Treatment is aimed at safely disimpacting the
proximal fecal mass with hyperosmolar contrast enemas (Gastrogran) [63, 64] or anterograde
hyperosmotic agents (polyethylene glycol or lactulose) for milder forms of obstruction. Although
surgical intervention is rarely required, timely consultation in the event of failure of medical
management and acute decompensation is warranted. Persistent symptoms and signs of intestinal
obstruction unresponsive to the pharmacological therapy should raise concern for abscess, brosing
colonopathy, or neoplastic lesions within the gastrointestinal track, among others.
186
D. Gelfond
Emphasis is also placed on prevention of recurrent episodes of DIOS by re-educating patients on

the importance of adherence to PERT with meals and snacks, routine luminal hydration along with
occasional anterograde clean outs.
Constipation
Constipation is a frequent problem in patients with CF and likely shares some of the underlying
mechanism with DIOS such as dysmotility and decreased luminal hydration secondary to CFTR
defect. Poor appetite, excessive bloating, or abdominal pain may be the only symptoms. Patients and
clinicians should be aware that most chronically constipated patients with CF have bowel movements
every day [65]. DIOS starts in the ileum and extends distally into the colon while constipation starts
in the recto-sigmoid and extends proximally into the colon. Both DIOS and constipation are
independent of each other but can coexist. Similar to DIOS, fat malabsorption and prior history of MI
were noted to be independent risk factors in pediatric CF patients with constipation [66]. Prevalence
of constipation in CF patients (32%) is no different from general adult population (3437%). CF
patients with PI are on average 50% more likely to have a diagnosis of constipation in comparison to
PS patients [65].
In contrast to the general population where the likely contributors to functional constipation are
deciency in dietary ber, inadequate uid intake, and psychosomatic causes, these factors were not
associated with constipation in children with CF [66]. It is likely that CFTR dysfunction leading to
relatively dehydrated intestinal contents plays an important role in facilitating constipation among CF
patients. Therapeutic options in the CF patient with constipation are not different from the medical
management of constipation in the general population. Treatment options include oral hyperosmotic
agents such as polyethylene glycol, lactulose, or sorbitol that retain water in the intestines and facilitate
softer stools. Initiation of therapy often warrants an initial clean out with a large dose of osmotic
agents often in combination with stimulant agents such as senna or bisacodyl to induce colonic spasms
and fecal evacuation. Magnesium-containing agents (magnesium citrate, magnesium hydroxide, or
magnesium sulfate) that have both an osmotic and laxative effect and can induce colonic motility may
also be used. Disturbance to electrolyte balance can be seen in chronic and large dose of magnesium
preparation, so these should be used sparingly. Long-term use of dietary ber supplementation has
been advocated to maintain softer stools and establish normal defecation patterns. In general, the high
calorie diet consumed by CF patients tends to have a lower dietary ber intake; this has been suggested
to have an impact on development of constipation and DIOS [67]. A closer look at the relationship
between ber intake in pediatric patients with CF and gastrointestinal complaints including DIOS did
not show any relationship in 40 children [68]. Imaging modalities with abdominal X-rays may be
useful in assessing fecal loading distribution of stool or response to treatment, despite carrying an
inherent risk of minimal radiation exposure [66]. Clinical symptoms with a thorough history and a
physical examination are usually sufcient to guide therapeutic recommendations prior to committing
to additional investigations.
Gastrointestinal Cancers
Patients with CF are at increased risk for esophageal, gastric, hepatobiliary, gallbladder, small
intestinal, and colon cancers relative to the US population [69]. Increased prevalence of gastrointestinal
cancers has been suggested to correlate with organ specic CFTR expression, suggesting that defective
expression in tissues that normally have high CFTR expression will contribute to increased
inammation and lead to increased cell turnover [69, 70]. Other factors that can contribute to an
12
187
Table 12.1 Liver disorders in patients with cystic brosis

Micro gallbladder
Cholelithiasis
Biliary tract ductal stones
Focal biliary cirrhosis
Sclerosing cholangitis
Hepatic steatosis
Nodular regenerative hyperplasia
Portal hypertension
increased likelihood of gastrointestinal neoplasms in CF patients are defective mucus function along
with increased MUC 1, 2, and 3 expression, oxidative stress, activation of NF-B, excessive acid
exposure in the upper gastrointestinal tract, elevation of CA 199 and CEA and deciencies in
antioxidants (omega-3 fatty acids, vitamin E) [71]. This risk increases in post-transplant patients on
immunosuppression therapy. The nutritional impact on CF patients with gastrointestinal cancers is not
different from gastrointestinal cancers in the general population and management GI cancers in
patients with CF does not differ from management of patients without CF. In both cases, surveillance
and accurate diagnosis are crucial. Special attention to management of pulmonary issues is required
in patients with CF requiring anesthesia for endoscopic or surgical interventions. The distribution and
degree of neoplastic tissue, surgical interventions, and side effects of the therapeutic agents will
dictate whether cancer patients are able to tolerate enteral nutrition. Alternative to enteral nutrition is
parenteral nutrition, which can lead to multiple complications including sepsis.
CF-Related Liver Disease

Liver has many critical roles in the gastrointestinal, immunological, and hematological physiology
and homeostasis of the body. Its most direct impact on nutrition is through bile secretion to aid in
digestion and absorption of nutrients within the gastrointestinal tract. In patients with CF, the viscosity
of bile is increased because of the role that CFTR has in water and bicarbonate secretion in the biliary
tract. The most common mechanism of liver injury in CF patients is through cholestasis, as conjugated
bile acids are backed up within the bile ducts causing portal tract and hepatocyte inammation and
tissue brosis. This can further compromise nutrition in patients with CF. A wide spectrum of
hepatobiliary diseases can be seen in patients with CF (Table 12.1). Chapter 11 focuses in depth on
CF-related liver disease and its impact on nutrition.
Conclusion
CF affects the gastrointestinal as well as the respiratory tracts. If unrecognized and untreated, the
gastrointestinal manifestations can lead to poor appetite, maldigestion, and malabsorption of nutrients,
and other factors that contribute to inadequate weight gain or possibly weight loss. Nutritional status,
gastrointestinal factors, and pulmonary manifestations of CF are intertwined and addressing all of
them can lead to improved outcomes and quality of life or our patients.
References
systematic review. J Am Diet Assoc. 2008;108(5):8329. Epub 2008/04/30. eng.
2. Rowe SM, Miller S, Sorscher EJ. Cystic brosis. N Engl J Med. 2005;352(19):19922001. Epub 2005/05/13. eng.
188
D. Gelfond
3. Ramsey BW, Davies J, McElvaney NG, Tullis E, Bell SC, Drevinek P, et al. A CFTR potentiator in patients with
cystic brosis and the G551D mutation. N Engl J Med. 2011;365(18):166372. Epub 2005/05/13. eng.
4. Wehkamp J, Fellermann K, Herrlinger KR, Bevins CL, Stange EF. Mechanisms of disease: defensins in
gastrointestinal diseases. Nat Clin Pract Gastroenterol Hepatol. 2005;2(9):40615.
5. Gelfond D, Ma C, Semler J, Borowitz D. Intestinal pH and gastrointestinal transit proles in cystic brosis patients
measured by wireless motility capsule. Dig Dis Sci. 2012;58(8):227581. Epub 2012/05/18. Eng.
6. Riordan JR, Rommens JM, Kerem B, Alon N, Rozmahel R, Grzelczak Z, et al. Identication of the cystic brosis gene:
cloning and characterization of complementary DNA. Science. 1989;245(4922):106673. Epub 1989/09/08. eng.
7. Jakab R, Collaco A, Ameen N. Physiological relevance of cell-specic distribution patterns of CFTR, NKCC1,
NBCe1, and NHE3 along the crypt-villus axis in the intestine. Am J Physiol Gastrointest Liver Physiol.
2011;300(1):G8298. PubMed1152/ajpgi.00245.2010.
8. Marino CR, Matovcik LM, Gorelick FS, Cohn JA. Localization of the cystic brosis transmembrane conductance
regulator in pancreas. J Clin Invest. 1991;88(2):7126. PMCID: 295422. Epub 1991/08/01. eng.
9. Cohn JA, Strong TV, Picciotto MR, Nairn AC, Collins FS, Fitz JG. Localization of the cystic brosis transmembrane
conductance regulator in human bile duct epithelial cells. Gastroenterology. 1993;105(6):185764. Epub
1993/12/01. eng.
10. Chen EY, Yang N, Quinton PM, Chin WC. A new role for bicarbonate in mucus formation. Am J Physiol Lung Cell
Mol Physiol. 2010;299(4):L5429. PMCID: 2957415. Epub 2010/08/10. eng.
11. LaRusch J, Jung J, General IJ, Lewis MD, Park HW, Brand RE, et al. Mechanisms of CFTR functional variants that
impair regulated bicarbonate permeation and increase risk for pancreatitis but not for cystic brosis. PLoS Genet.
2014;10(7):e1004376. PMCID: 4102440.
12. Full Prescribing InformationKALYDECO (ivacaftor) Tablets. http://www.accessdata.fda.gov: Vertex
Pharmaceuticals Incorporated. 2014.
13. Rowe SM, Heltshe SL, Gonska T, Donaldson SH, Borowitz D, Gelfond D, et al. Clinical mechanism of the cystic
brosis transmembrane conductance regulator potentiator ivacaftor in G551D-mediated cystic brosis. Am J Respir
Crit Care Med. 2014;190(2):17584.
14. Cystic Fibrosis Foundation. Patient Registry, 2010 Annual Data Report to the Center Directors. Bethesda, MD; 2010.
16. Rabinovich RA, MacNee W. Chronic obstructive pulmonary disease and its comorbidities. Br J Hosp Med (Lond).
2011;72(3):13745. Epub 2011/04/09. eng.
17. Sabati AA, Kempainen RR, Milla CE, Ireland M, Schwarzenberg SJ, Dunitz JM, et al. Characteristics of
gastroesophageal reux in adults with cystic brosis. J Cyst Fibros. 2010;9(5):36570. Epub 2010/08/03. eng.
18. Navarro J, Rainisio M, Harms HK, Hodson ME, Koch C, Mastella G, et al. Factors associated with poor pulmonary
function: cross-sectional analysis of data from the ERCF. European Epidemiologic Registry of Cystic Fibrosis. Eur
Respir J. 2001;18(2):298305. Epub 2001/09/01. eng.
19. Stringer DA, Sprigg A, Juodis E, Corey M, Daneman A, Levison HJ, et al. The association of cystic brosis,
gastroesophageal reux, and reduced pulmonary function. Can Assoc Radiol J. 1988;39(2):1002. Epub 1988/06/01.
eng.
20. Palm K, Sawicki G, Rosen R. The impact of reux burden on pseudomonas positivity in children with cystic brosis.
Pediatr Pulmonol. 2012;47(6):5827. Epub 2011/12/14. eng.
context of brosing colonopathy. J Pediatr. 1995;127(5):6814. Epub 1995/11/01. eng.
23. Fathi H, Moon T, Donaldson J, Jackson W, Sedman P, Morice AH. Cough in adult cystic brosis: diagnosis and
response to fundoplication. Cough. 2009;5:1. PMCID: 2634760. Epub 2009/01/20. eng.
24. Sheikh S, Quach J, McCoy K. Nissen fundoplication in patients with cystic brosis. Chest. 2011;140
(4_MeetingAbstracts) Suppl 4:385A. PMID: 00002953-201110004-00385.
25. Hoppo T, Jarido V, Pennathur A, Morrell M, Crespo M, Shigemura N, et al. Antireux surgery preserves lung
function in patients with gastroesophageal reux disease and end-stage lung disease before and after lung
transplantation. Arch Surg. 2011;146(9):10417. Epub 2011/09/21. eng.
26. Rovner AJ, Schall JI, Mondick JT, Zhuang H, Mascarenhas MR. Delayed small bowel transit in children with cystic
brosis and pancreatic insufciency. J Pediatr Gastroenterol Nutr. 2013;57(1):814.
27. Pauwels A, Blondeau K, Mertens V, Farre R, Verbeke K, Dupont LJ, et al. Gastric emptying and different types of
reux in adult patients with cystic brosis. Aliment Pharmacol Ther. 2011;34(7):799807. Epub 2011/07/29. eng.
28. Walkowiak J. Faecal elastase-1: clinical value in the assessment of exocrine pancreatic function in children. Eur J
Pediatr. 2000;159(11):86970. Epub 2000/11/18. eng.
29. Beharry S, Ellis L, Corey M, Marcon M, Durie P. How useful is fecal pancreatic elastase 1 as a marker of exocrine
pancreatic disease? J Pediatr. 2002;141(1):8490. Epub 2002/07/02. eng.
30. Couper RT, Corey M, Moore DJ, Fisher LJ, Forstner GG, Durie PR. Decline of exocrine pancreatic function in
cystic brosis patients with pancreatic sufciency. Pediatr Res. 1992;32(2):17982. Epub 1992/08/01. eng.
12
189
growth, and nutrition in infants identied by newborn screening as having cystic brosis. J Pediatr. 1992;120(4 Pt
1):53340.
32. Farrell PM, Kosorok MR, Laxova A, Shen G, Koscik RE, Bruns WT, et al. Nutritional benets of neonatal screening
for cystic brosis. Wisconsin Cystic Fibrosis Neonatal Screening Study Group. N Engl J Med. 1997;337(14):9639.
Epub 1998/02/12. eng.
33. Farrell PM, Kosorok MR, Rock MJ, Laxova A, Zeng L, Lai HC, et al. Early diagnosis of cystic brosis through
neonatal screening prevents severe malnutrition and improves long-term growth. Wisconsin Cystic Fibrosis
Neonatal Screening Study Group. Pediatrics. 2001;107(1):113. Epub 2001/01/03. eng.
34. Koscik RL, Farrell PM, Kosorok MR, Zaremba KM, Laxova A, Lai HC, et al. Cognitive function of children with
cystic brosis: deleterious effect of early malnutrition. Pediatrics. 2004;113(6):154958. Epub 2004/06/03. eng.
35. Koscik RL, Lai HJ, Laxova A, Zaremba KM, Kosorok MR, Douglas JA, et al. Preventing early, prolonged vitamin
E deciency: an opportunity for better cognitive outcomes via early diagnosis through neonatal screening. J Pediatr.
2005;147(3 Suppl):S516. Epub 2005/10/06. Eng.
in early life predict pulmonary function in cystic brosis. J Pediatr. 2003;142(6):62430. Epub 2003/07/03. eng.
pulmonary function in children with cystic brosis. Pediatrics. 2003;112(3 Pt 1):58892. Epub 2003/09/02. eng.
sectional and longitudinal analyses from the German CF quality assurance (CFQA) project. Thorax. 2002;57(7):
596601. PMCID: 1746376. Epub 2002/07/04. Eng.
39. Lai HJ, Shoff SM, Farrell PM. Recovery of birth weight z score within 2 years of diagnosis is positively associated
with pulmonary status at 6 years of age in children with cystic brosis. Pediatrics. 2009;123(2):71422. PMCID:
2775492. Epub 2009/01/28. eng.
Patient Registry. J Pediatr. 2000;137(3):37480. Epub 2000/09/02. Eng.
41. Ferrone M, Raimondo M, Scolapio JS. Pancreatic enzyme pharmacotherapy. Pharmacotherapy. 2007;27(6):910
20. Epub 2007/06/05. eng.
42. Kraisinger M, Hochhaus G, Stecenko A, Bowser E, Hendeles L. Clinical pharmacology of pancreatic enzymes in
patients with cystic brosis and in vitro performance of microencapsulated formulations. J Clin Pharmacol.
1994;34(2):15866. Epub 1994/02/01. eng.
43. Clarke LL, Harline MC. Dual role of CFTR in cAMP-stimulated HCO3- secretion across murine duodenum. Am J
Physiol. 1998;274(4 Pt 1):G71826. Epub 1998/05/12. eng.
44. DiMagno EP. Gastric acid suppression and treatment of severe exocrine pancreatic insufciency. Best Pract Res
Clin Gastroenterol. 2001;15(3):47786. Epub 2001/06/14. eng.
45. Proesmans M, De Boeck K. Omeprazole, a proton pump inhibitor, improves residual steatorrhoea in cystic brosis
patients treated with high dose pancreatic enzymes. Eur J Pediatr. 2003;162(11):7603. Epub 2003/09/19. eng.
46. Tran TM, Van den Neucker A, Hendriks JJ, Forget P, Forget PP. Effects of a proton-pump inhibitor in cystic brosis.
Acta Paediatr. 1998;87(5):5538. Epub 1998/06/26. eng.
47. Ng SM, Franchini AJ. Drug therapies for reducing gastric acidity in people with cystic brosis. Cochrane Database
Syst Rev. 2014;7:CD003424.
48. Kopelman H, Forstner G, Durie P, Corey M. Origins of chloride and bicarbonate secretory defects in the cystic
brosis pancreas, as suggested by pancreatic function studies on control and CF subjects with preserved pancreatic
function. Clin Invest Med. 1989;12(3):20711. Epub 1989/06/01. eng.
49. Sartor RB. Microbial inuences in inammatory bowel diseases. Gastroenterology. 2008;134(2):57794.
50. Lewindon PJ, Robb TA, Moore DJ, Davidson GP, Martin AJ. Bowel dysfunction in cystic brosis: importance of
breath testing. J Paediatr Child Health. 1998;34(1):7982. Epub 1998/05/06. eng.
51. Fridge JL, Conrad C, Gerson L, Castillo RO, Cox K. Risk factors for small bowel bacterial overgrowth in cystic
brosis. J Pediatr Gastroenterol Nutr. 2007;44(2):2128. Epub 2007/01/27. eng.
52. Lisowska A, Wojtowicz J, Walkowiak J. Small intestine bacterial overgrowth is frequent in cystic brosis: combined
hydrogen and methane measurements are required for its detection. Acta Biochim Pol. 2009;56(4):6314. Epub
2009/12/10. eng.
53. Grace E, Shaw C, Whelan K, Andreyev HJ. Review article: small intestinal bacterial overgrowthprevalence,
clinical features, current and developing diagnostic tests, and treatment. Aliment Pharmacol Ther. 2013;38(7):
67488.
54. Roland BC, Ciarleglio MM, Clarke JO, Semler JR, Tomakin E, Mullin GE, et al. Small intestinal transit time is
delayed in small intestinal bacterial overgrowth. J Clin Gastroenterol. 2014.
55. Farrelly PJ, Charlesworth C, Lee S, Southern KW, Baillie CT. Gastrointestinal surgery in cystic brosis: a 20-year
review. J Pediatr Surg. 2014;49(2):2803.
190
D. Gelfond
56. Carlyle BE, Borowitz DS, Glick PL. A review of pathophysiology and management of fetuses and neonates with
meconium ileus for the pediatric surgeon. J Pediatr Surg. 2012;47(4):77281. Epub 2012/04/14. eng.
57. Stoltz DA, Rokhlina T, Ernst SE, Pezzulo AA, Ostedgaard LS, Karp PH, et al. Intestinal CFTR expression alleviates
meconium ileus in cystic brosis pigs. J Clin Invest. 2013;123(6):268593. PMCID: 3668832.
58. Lloyd-Still JD. Crohns disease and cystic brosis. Dig Dis Sci. 1994;39(4):8805.
59. Mihailidi E, Katakis E, Evangeliou A. Celiac disease: a pediatric perspective. Int Pediatr. 2003;18(3):1418.
60. Houwen RH, van der Doef HP, Sermet I, Munck A, Hauser B, Walkowiak J, et al. Dening DIOS and constipation
in cystic brosis with a multicentre study on the incidence, characteristics, and treatment of DIOS. J Pediatr
61. Colombo C, Ellemunter H, Houwen R, Munck A, Taylor C, Wilschanski M. Guidelines for the diagnosis and
management of distal intestinal obstruction syndrome in cystic brosis patients. J Cyst Fibros. 2011;10 Suppl 2:
S248.
62. Declercq D, Van Biervliet S, Robberecht E. Nutrition and pancreatic enzyme intake in patients with cystic brosis
with distal intestinal obstruction syndrome. Nutr Clin Pract. 2014;30(1):1347.
63. O'Halloran SM, Gilbert J, McKendrick OM, Carty HM, Heaf DP. Gastrogran in acute meconium ileus equivalent.
Arch Dis Child. 1986;61(11):112830. PMCID: 1778105. Epub 1986/11/01. eng.
64. Mahmoud Zahra CF, Thomas R, Iqbal V, Borowitz D. Gastrogran enemas for treatment of distal intestinal
obstruction syndrome in children and adults with cystic brosis. J Pharm Nutr Sci. 2014;4(2):7680.
65. Baker SS, Borowitz D, Duffy L, Fitzpatrick L, Gyam J, Baker RD. Pancreatic enzyme therapy and clinical
outcomes in patients with cystic brosis. J Pediatr. 2005;146(2):18993.
66. van der Doef HPJ, Kokke FTM, Beek FJA, Woestenenk JW, Froeling SP, Houwen RHJ. Constipation in pediatric
cystic brosis patients: an underestimated medical condition. J Cyst Fibros. 2010;9(1):5963.
67. Gavin J, Ellis J, Dewar AL, Rolles CJ, Connett GJ. Dietary bre and the occurrence of gut symptoms in cystic
brosis. Arch Dis Child. 1997;76(1):357. PMCID: 1717032.
68. Proesmans M, De Boeck K. Evaluation of dietary ber intake in Belgian children with cystic brosis: is there a link
with gastrointestinal complaints? J Pediatr Gastroenterol Nutr. 2002;35(5):6104.
69. Neglia JP, FitzSimmons SC, Maisonneuve P, Schoni MH, Schoni-Affolter F, Corey M, et al. The risk of cancer
among patients with cystic brosis. Cystic Fibrosis and Cancer Study Group. N Engl J Med. 1995;332(8):4949.
Epub 1995/02/23. eng.
70. Maisonneuve P, Marshall BC, Knapp EA, Lowenfels AB. Cancer risk in cystic brosis: a 20-year nationwide study
from the United States. J Natl Cancer Inst. 2013;105(2):1229.
71. Alexander CL, Urbanski SJ, Hilsden R, Rabin H, MacNaughton WK, Beck PL. The risk of gastrointestinal
malignancies in cystic brosis: case report of a patient with a near obstructing villous adenoma found on colon
cancer screening and Barrett's esophagus. J Cyst Fibros. 2008;7(1):16. Epub 2007/09/04. eng.
Chapter 13
Nutritional Management of Cystic Fibrosis Related

Diabetes Mellitus
Katie Larson Ode and Carol Brunzell
Key Points
Cystic Fibrosis Related Diabetes Mellitus (CFRD) is a serious and common complication of cystic
brosis. CFRD is a unique form of diabetes, which has a different cause and different natural
history then the more well-known type 1 and type 2 diabetes mellitus. Therefore, CFRD requires a
unique approach to nutritional therapy very different from the approach to other types of diabetes
mellitus.
CFRD is a silent disease and one of the very rst manifestations may be nutritional failure.
Importantly, CFRD leads to lung function decline before signs and symptoms of diabetes develop
and therefore screening for this disorder is required.
As with all forms of diabetes, nutrition therapy is essential to the care of the CF patient with
CFRD. However, CF has very specic nutritional and nutrition education needs and CFRD is
unique compared to other types of diabetes, which means that typical diabetic nutrition education
is not sufcient and may be inappropriate for the patient with CF and diabetes.
The underlying nutritional needs of the CF patient (high calorie, high fat, high sodium) do not
change with the diagnosis of diabetes. CF patients often have variable appetite due to illness and
often require oral or enteral supplementation to achieve adequate caloric intake. Therefore
traditional diabetic meal plans are not practical and may be inappropriate.
Other concerns specic to this population that affect nutrition care are alterations in sensitivity
with illness, the interaction between supplemental feeding and diabetic control, pregnancy, use of
steroid therapy and its complications for nutrition and diabetic control and the increased potential
for disordered eating in this population coupled with the overarching need for high caloric intake.
The only recommended treatment for CFRD is insulin, which means that carbohydrate counting
and management are essential parts of the nutritional management of this disease, and assume new
importance in patients who must consume a high-calorie and carbohydrate-rich diet due to the
underlying nature of their disease.
Treatment of CFRD normally results in reversal of nutritional failure and improvement in overall
health in the patient with CF.
K.L. Ode, M.D., M.S. (*)

University of Iowa Childrens Hospital, 200 Hawkins Dr., 2861 JPP, Iowa City, IA 52242-1083, USA
C. Brunzell, R.D., L.D., C.D.E.
Diabetes Care Centers, University of Minnesota Health, Fairview,
516 Delaware Street SE, MMC 88, Minneapolis, MN 55455, USA
191
192
K.L. Ode and C. Brunzell
Keywords Cystic brosis related diabetes Type 1 diabetes Type 2 diabetes Insulin Impaired
glucose tolerance Hypoglycemia Gestational diabetes Insulin resistance Basal insulin Bolus
insulin Long-acting insulin Rapid-acting insulin Intermediate-acting insulin Glucocorticoids
Hemoglobin A1c Oral glucose tolerance test Microvascular disease Macrovascular disease
Ketoacidosis American Diabetes Association
Abbreviations
ADA
AGT
BG
BMI
CF
CFF
CFRD
CGM
GDM
HbA1c
IGT
INDET
OGTT
PERT
T1D
T2D
American Diabetes Association

Abnormal glucose tolerance
Blood glucose
Body mass index
Cystic brosis
Continuous glucose monitoring
Gestational diabetes
Hemoglobin A1c
Impaired glucose tolerance
Indeterminate glycemia
Oral glucose tolerance test
Type 1 diabetes
Type 2 diabetes
Introduction
Improved treatment of cystic brosis (CF) has dramatically increased survival rates for those affected
by CF. As people with CF are living longer, CFRD has become one of the most common complications
of CF. Studies have shown that CFRD occurs in about 20% of adolescents and 4050% of adults, but
can occur at any age and is associated with worse survival. Impaired glucose tolerance (IGT) occurs
in up to 75% of adults with CF [13]. Ideally, given the high likelihood of the development of diabetes
in everyone with CF, the risk of development of diabetes should affect all nutrition education in CF.
Nutrition therapy for CFRD differs drastically from type 1 diabetes (T1D) and type 2 diabetes
(T2D) in many key areas. Attaining and maintaining good nutritional status is the cornerstone of
treatment in CF and has been shown to improve survival. For adults with CF, body mass index
(BMI) goals are 23 kg/m2 for males and 22 kg/m2 for females [4]. The usual nutrition therapy
guidelines for CF (high calorie, high fat, high sodium) do not change once the diagnosis of CFRD
has been made. Nutrition goals for CFRD include normal growth and nutrition for children, teens,
and adults with CF, and maintenance of near normal blood glucose. The recommended treatment
for CFRD is insulin. Differences in nutrition therapy for CFRD, pregnancy with CFRD, gestational
diabetes (GDM) in CF, IGT in CF, and treatment of hypoglycemia is essential for health care
providers to understand in order to ensure best patient care [5, 6]. Because appetite can be highly
variable from day to day, people with CF frequently require oral high-calorie supplements and/or
enteral tube feedings to meet caloric needs [7, 8]. For these reasons, traditional diabetic meal plans
13 Nutritional Management of Cystic Fibrosis Related Diabetes Mellitus
193
are not practical. Using carbohydrate counting and insulin-to-carbohydrate ratios in conjunction
with the CF eating pattern to guide insulin therapy can help to optimize glycemic control [6].
Nutritional Implications of Diabetes in CF

In CF patients who subsequently developed CFRD, compared to CF patients who were known to
maintain normal glucose tolerance, the patients who subsequently developed CFRD had lower weight
and BMI 4 years prior to diagnosis of CFRD, and signicantly higher decline lung function 13 years
prior to diagnosis of diabetes [9]. In follow-up, once the CFRD population was on insulin for 2 years,
BMI values were similar to the non-diabetic group and lung functions improved [10]. Hyperglycemia
has a negative effect on nutritional status and causes derangements in protein metabolism [11].
Diabetes Complications
People with CFRD are not at risk for macrovascular (cardiovascular) disease despite eating diets high
in total and saturated fat. There has never been a CF patient reported to have died from atherosclerotic
cardiovascular disease. As patients are living longer with CFRD, these recommendations may
eventually change [12, 13]. Recent studies have observed an increase in obesity in the CF population,
but underweight and malnutrition remain the primary nutrition focus for the majority of patients with
CF [14]. However, they are at risk for the development of microvascular disease: retinopathy,
neuropathy, and nephropathy, which are related to the duration and metabolic control of diabetes
[1517]. Ketoacidosis is rare, even with consistently elevated blood glucose levels as there is residual
endogenous insulin secretion [18].
Etiology
The etiology of CFRD is not fully understood and the lack of understanding of the full pathophysiology
of CFRD hampers development of dietary guidelines in CFRD [19]. However, it is known that CFRD
is not related to either T1D or T2D, and it cannot be prevented with current therapy. CFRD is not
autoimmune (as type 1 is), neither is insulin resistance a major part of the pathophysiology of CFRD
at baseline (as in type 2). Rather, CFRD is primarily caused by insulin insufciency due to progressive
scarring and brosis of the beta cells, reduced beta cell mass, chronic and acute inammation
secondary to recurrent sinopulmonary infections, and possibly as a direct result of the causative gene
mutation [18, 2022]. Even though CFRD is not Type 2, T2D risk genes typically increase risk of
CFRD [23].
Insulin is an anabolic hormone, therefore insulin deciency leads to unintentional loss of lean body
mass, adipose tissue, and malnutrition. Body weight and lean body mass are directly correlated with
pulmonary function in CF. Decline in nutritional status has been shown to occur 4 years prior to
diagnosis of CFRD and has been correlated with the degree of insulin deciency at baseline, with a
corresponding decline in pulmonary function and increased morbidity and mortality [24]. The
majority of patients with CF die from inammatory lung disease and CFRD accelerates this process
[24, 25].
Although insulin resistance is not a primary cause of CFRD, periods of marked insulin resistance
also occur in CF resulting from stress, pregnancy, illness, and glucocorticoid (steroid) therapy for
pulmonary exacerbations [1].
194
Treatment of CFRD with insulin has been shown to be superior to oral agents in reversing
protein catabolism and chronic weight loss, improving BMI, and reversing decline in pulmonary
function [26].
Diagnosis
Because clinical decline begins long before clinical symptoms of diabetes appear [24], it is
recommended to regularly screen CF patients for CFRD. Studies show that early diagnosis and
treatment of CFRD through aggressive screening improves overall health, nutritional status, lung
function, and survival [3].
Routine Screening
The most recent guidelines recommend yearly screening with Oral Glucose Tolerance testing (OGTT)
(done with the patient at baseline health) starting at 10 years of age. The recommended protocol is to
obtain fasting blood glucose followed by the administration of 1.75 g/kg of oral dextrose solution and
then obtaining serum glucose level 120 min after administration of the solution [6]. However, some
centers use alternative or modied protocols. As previously discussed, clinical decline occurs prior to
the onset of full-blown diabetes. Pre-diabetic range blood sugar levels have been associated with
declines in lung function [27, 28] and more rapid progression to full-blown diabetes [29]. It has been
shown that abnormal glucose tolerance (AGT) can be found in children younger than 10 and the
presence of AGT predicts more rapid progression to CFRD [29]. Others have found, in small studies,
that treatment of pre-diabetes can improve clinical decline [30, 31]. Therefore, some centers start
screening at younger ages (i.e. 6 years of age). Other centers include additional time points (such as a
1 h or 3 h glucose value), due to relationships with lung function decline [27, 32]. Some centers may
use alternative techniques, such as continuous glucose monitoring (CGM) [33, 34]. Some centers will
sometimes use 1 h testing and then refer for further screening [32, 35], but this is not recommended
by guidelines.
Tests That Are Not Recommended for Screening

Hemoglobin A1c (HbA1c) is not sensitive in CF population as patients with CF may have spuriously
low A1C values and so may not reach cut-offs for screening even when they have elevated blood
glucose values [36, 37]. Fasting blood sugar is also not reliable for screening as fasting hyperglycemia
is a late nding in CFRD. Therefore, neither is recommended by guidelines [6].
Diagnostic Cut-Offs for Routine OGTT Screening

CFRD is diagnosed when fasting blood sugar is 126 mg/dl or higher or the 120 min blood sugar is
200 mg/dl or higher. IGT is diagnosed when 120 min glucose is less than 200 mg/dl but is more than
140 mg/dl, and the fasting blood sugar is <126 mg/dl. If intermediate time points are used, any
intermediate time point with a value of 200 mg/dl or higher, with a 120 min time point <140 mg/dl,
and a fasting glucose <126 mg/dl is termed Indeterminate Glycemia (INDET) (Table 13.1).
195
Table 13.1 Criteria for glucose tolerance category based on OGTT results
Glucose tolerance category
Fasting glucose
Midpoint glucose
120 min glucose
CFRD
< or >126 mg/dla
N/A
200 mg/dl
IGT
<126 mg/dl
N/A
140 mg/dl and <200 mg/dl
INDET
<126 mg/dl
>200 mg/dl
<140 mg/dl
Normal
<100 mg/dl
<200 mg/dl
<140 mg/dl
a
Fasting blood sugar 126 meets criteria for diagnosis of diabetes as a single criteria and 120 min glucose 200 mg/dl
meets criteria for diagnosis of diabetes as a single criteria
Screening at the Time of Pulmonary Exacerbation

In patients with CF, frequent pulmonary exacerbations requiring hospitalization for intravenous (IV)
antibiotics are unfortunately a relatively common occurrence. Exacerbations are a time of signicant
illness and inammation. Inammation and illness can cause marked resistance to the actions of
insulin. Due to this, it is not at all uncommon for patients with CF who otherwise have normal blood
sugars at baseline health to develop abnormal blood sugars during hospitalization. Therefore, the
guidelines recommend standardized screening at time of hospitalization for pulmonary exacerbation
in addition to routine yearly screening for CFRD. Screening at the time of pulmonary exacerbation is
recommended to be done by rst a.m., pre-prandial, and 2 h post-prandial bedside glucose monitoring
with all meals for the rst 48 h of any admission for pulmonary exacerbation. Therefore, bedside
glucose monitoring would be performed 6 times daily (before breakfast, 2 h after breakfast, before
lunch, 2 h after lunch, before supper, and bedtime) for the rst 48 h of admission. If the blood sugar
values are normal, monitoring is discontinued at 48 h. If any of the blood glucose values reach 200 mg/
dl or higher, further evaluation and continued monitoring are recommended [6].
Treatment
Nutrition Therapy for CFRD
CF patients diagnosed with CFRD should continue to follow their usual high calorie, high fat, and
high sodium well-balanced diet. There are no diet restrictions for people with CF as the majority of
patients are at risk for nutritional decline due to elevated resting energy expenditure, malabsorption
due to pancreatic enzyme insufciency, and insulin insufciency. Sugar containing beverages are
requested to be taken with meals and snacks and avoided in between meals. Usual diet advice for
people with T1D and T2D does not apply in CFRD. Attainment and preservation of good nutrition
status is paramount for survival in CF. Monitoring carbohydrates, whether by counting grams or
exchanges/choices, is the key strategy for optimal metabolic control used in conjunction with insulin
therapy. Insulin therapy should be exible to easily t in with the patients usual lifestyle and eating
patterns [6]. Oral high calorie supplements and/or enteral tube feedings are often necessary to meet
caloric requirements. There is no need to use diabetes specic oral or enteral formulas as insulin can
be titrated to cover the most appropriate formula for the patient per CF team. An extremely important
part of nutrition therapy is education on carbohydrate counting as it is essential that the patient and the
family knows how to determine the carbohydrate content of meals and snacks so that insulin therapy
can be matched to carbohydrate intake.
196
Insulin Therapy
CFRD is typically treated using standard basal-bolus insulin regimens, using a combination of basal
and rapid-acting insulin by multiple daily subcutaneous injections, or rapid-acting insulin via an
insulin pump. Insulin pump therapy has been shown to be effective in CFRD [38]. Rapid-acting
insulin doses can be based on carbohydrates consumed using an insulin-to-carbohydrate ratio. Use of
additional rapid-acting insulin for correction of high blood sugars added to the mealtime insulin dose
is also necessary as in intensive insulin therapy for T1D and T2D. Since patients with CFRD still have
some endogenous insulin secretion, treatment with insulin is similar to patients with T1D in the
honeymoon period [6]. Insulin requirements for both adult and pediatric patients have been shown to
be modest throughout the lifespan of patients with CF, suggesting continued residual insulin secretion
[39]. Further studies have shown that total insulin requirements for the amount of carbohydrate intake
in CFRD are lower when compared to patients with TID [40]. Patients with CFRD without fasting
hyperglycemia (on a standard OGTT), using premeal rapid-acting insulin only without basal insulin,
reversed chronic weight loss and improved nutritional status [26].
Example Regimens
15-year-old female with fasting hyperglycemia and normal BMI, weight 62 kg.
managed with insulin pump utilizing insulin aspart with settings of :
basal rate 0.5 units/hour.
Insulin to carbohydrate ratios: 1 unit for every 10 g of carbohydrate with breakfast, 1 unit for
every 25 g with all snacks, and 1 unit for every 20 g with lunch and supper.
Sensitivity set at 1 unit to drop her blood sugar by 60 mg/dl.
25-year-old male without fasting hyperglycemia and normal BMI, weight 75 kg
insulin lispro 1 unit for every 30 g with all meals and snacks,
correction dose of 0.5 units for every 50 mg/dl his blood sugar is over 150 mg/dl,
no long-acting insulin
40-year-old female with fasting hyperglycemia, long history of CFRD, weight 50 kg
insulin glargine 20 units daily
insulin lispro 1 unit for every 15 g of carbohydrate with all meals and all snacks
insulin lispro correction dose of 1 unit for every 50 mg/dl her blood sugar is over 150
All insulin should be administered prior to meals and snacks. All patients on insulin should check
blood sugars before every meal, 2 h after each meal and at bedtime. Overnight checks should be done
when long-acting insulin is added or adjusted. Post-prandial blood glucose monitoring (done 2 h after
meals) is very important as those can be the only abnormal values in some patients.
These regimens above illustrate different sorts of insulin regimens that may be used. All of them
require accurate carbohydrate counting on the part of the patient and the family. All regimens will
need to be adjusted based on patient activity and disease status as illness and growth spurts will
increase insulin requirements and exercise will decrease them. The expectation is that these regimens
will be exible and that ongoing adjustment will be required.
Insulin Therapy for Enteral Feeds

Patients with CFRD typically have nutritional decline prior to the diagnosis of diabetes [9, 41]. In the
Leeds Adult CF Unit, however, this was not the case, but in their population, the proportion of patients
197
receiving enteral tube feeding increased steadily and by 1 year prior to diagnosis of CFRD, and
signicantly more subjects who would develop diabetes in the future were on tube feeds compared to
those who did not develop diabetes (44% of those who would develop CFRD, compared to 19% of
controls). In their cohort, the diagnosis of CFRD was 4 times as likely in patients who were prescribed
overnight enteral feeding. Those who subsequently developed diabetes also had increased rate of
decline in the forced expiratory volume in 1 second (FEV1) which stabilized when they were started
on insulin. In children, those with CFRD had decreased weight gain compared to those without,
beginning 2 years prior to diagnosis, which then normalized when they were started on insulin [8].
This study has raised concern that enteral feeds may increase the risk for CFRD. However, this study
could also be interpreted to show that the usual decline in nutritional status from the pre-diabetic state
can be offset with aggressive enteral nutrition support, but this does not avoid the decline in FEV1
associated with the pre-diabetic state.
In either case, enteral support should not be held due to concerns regarding diabetes or avoided in
patients with CFRD. Rather, enteral support should be started when clinically indicated and an
appropriate insulin regimen to cover the enteral feed should be designed. Also, special diabetic
formulas or supplements should not be used, rather formulas and supplements should be chosen based
on those most appropriate for patients with CF and the particular clinical situation.
Insulin regimens for overnight enteral feeds are relatively simple and very effective in reversing
weight loss. In some patients, insulin with overnight enteral feeds only (and not daytime carbohydrate
intake) may be adequate to reverse weight loss. In our practice, for an overnight continuous feed of
8 h, we recommend determining the total carbohydrate administered by the complete feed. This is
then covered by a combination of neutral protamine hagadorn (NPH) insulin and regular insulin given
in a mixed dose at the beginning of the feed. Typically this can be dosed based on the patients known
carbohydrate ratio and given as 70% NPH and 30% regular insulin. This is given in addition to
whatever insulin (including basal) the patient is already on. Blood sugar is monitored just prior to
initiation of feed, and the mid-point of feed and when the feed is discontinued. Blood sugar goals on
continuous feeds are non-fasting so should be in the 140180 mg/dl range. Daytime bolus feeds are
covered as if they were a meal. The carbohydrate content is ascertained, and the patients insulin to
carbohydrate ratio is used the same way as a typical meal would be covered.
For different durations of enteral feeds, insulin formulations with different durations of action can
be used. Please see Table 13.2.
Table 13.2 Insulin action

Insulin
Onset of actiona
Duration of actiona
Peak
Rapid acting
Aspart
1020 min
35 h
12 h
Lispro
1020 min
35 h
12 h
Glulisine
1020 min
35 h
12 h
Short acting
Regular
30 min
46 (up to 8) h
24 h
Intermediate acting
NPHb
13 h
812 h
46 h
Long acting
Glarginec
12 h
1826 h
None
Detemirc
13 h
1220 h
None (8 h)
a
All times vary depending on dose given, location of dose, physical activity
of the individual in question and insulin resistance. Insulin kinetics above
are in subjects with type 1 diabetes, not subjects with CF
b
NPH neutral protamine hagadorn
c
Glargine and Detemir insulins cannot be mixed with other insulins
198
Example Regimens
Overnight enteral feeds are initiated on an 18-year-old female with CFRD without fasting
hyperglycemia. She is well controlled on meal boluses of insulin lispro of 1 unit for every 15 g
of carbohydrate. Her 8- hour overnight continuous feed contains a total of 150 g of carbohydrate.
Therefore her insulin dose for the feed is 10 units of insulin, given as a dose of 7 units of NPH
mixed with 3 units of regular.
Three daytime bolus feeds are added to the nutrition regimen of a 25-year-old male with CFRD
without fasting hyperglycemia who is already on overnight feeds. The patients carbohydrate ratio
is 1 unit insulin aspart for every 10 g of carbohydrate. Each bolus feed contains 50 g of carbohydrate.
Prior to each bolus, the patient is administered 5 units of insulin aspart. This is in addition to the
patients coverage of all meals and snacks with 1 unit of insulin aspart for every 10 g of carbohydrate
and 10.5 units of NPH and 4.5 units of regular insulin mixed and administered prior to the 150 g
8 h continuous overnight feed.
Insulin Therapy in Illness

Patients with CFRD have many more hospitalizations for pulmonary exacerbations than CF patients
without CFRD, and at much younger ages [42].
During acute illness and/or treatment with glucocorticoids, insulin requirements increase
dramatically, typically two- to fourfold. Once the illness resolves, it takes about 46 weeks for insulin
requirements to return to baseline. Close monitoring for hypoglycemia is imperative during this
period and regular communication with the health care team is necessary [6].
In our practice, for patients who are eating normally, we recommend monitoring the typical 6 times
daily and increasing insulin doses until normoglycemia is achieved. This may require very large
doses. If the patients are ill enough that they cannot tolerate a normal diet, we recommend to monitor
blood glucose every 4 h, 24 h a day. High uid intake is encouraged. If they cannot take solid foods,
the patient should take both carbohydrate-containing and carbohydrate-free uids.
Insulin Therapy and Steroid Use

Glucocorticoid therapy causes marked insulin resistance and has been known to cause diabetes in
non-CF populations. In the CF population, it can cause diabetic-range blood sugars in patients without
previous diagnosis of CFRD, or markedly increased insulin needs in patients with established
CFRD. It also may increase hunger and therefore increase carbohydrate intake as well.
Short-term administration of methylprednisolone causes postprandial hyperglycemia that lasts
612 h. Therefore, some authors have recommended the administration of NPH insulin at the time of
methylprednisolone dose [42]. Rasouli et al. advocate for a dose of 0.25 units of NPH per 1 mg of
methylprednisolone. If the patient has steroid-induced diabetes without pre-existing CFRD, they
recommend 0.10.15 units of NPH per 1 mg of methylprednisolone.
For prednisone therapy, there is usually overall increase in insulin resistance, requiring increased
insulin doses. The effect usually lags by about 24 h, with increased blood sugars present for 2448 h
after prednisone is discontinued. Patients on prednisone therapy usually require marked increases in
insulin dosing (24 times base doses). Some CF patients without pre-existing CFRD may require
initiation of insulin with prednisone burst therapy. Meal coverage is usually the most important, which
requires teaching of carbohydrate counting.
199
Insulin Therapy and TPN

If TPN is needed, insulin can be given in multiple ways. First, Regular (human) insulin can be added
to the bag. This is typically dosed to cover the carbohydrate content of the TPN. This is ideal as if the
TPN is held or the rate is decreased, the insulin is automatically held or decreased in proportion to the
amount of carbohydrate the patient receives. However, in some institutions, this is not allowed.
Therefore, a subcutaneous insulin of appropriate duration can be given, dosed to cover the amount of
carbohydrates in the TPN. However, if this is done, great care must be taken to replace the carbohydrates
if TPN must be held or discontinued.
Example Regimen
TPN containing 95 g of carbohydrate is run as a continuous infusion over 24 h. The patients
carbohydrate ratio is 1:20. 4.5 units of regular insulin could be added to the bag, or conversely,
4.5 units of insulin glargine could be given subcutaneously when the TPN is hung. However, if the
latter option is taken, if the TPN has to be discontinued, the patient must be provided with an
alternate carbohydrate source until the glargine has worn off at 24 h after administration.
For types of insulin with different durations of action, please refer to Table 13.2.
Nutrition Recommendations for Pregnancy with CFRD and GDM

in Women with CF
Pregnancy in CF is challenging and diabetes increases the complexity of care. Good outcomes depend
on adequate pre-pregnancy nutritional status, and adequate nutrition during pregnancy. As in T1D and
T2D, preconception counseling and normalization of blood glucose are necessary in women with preexisting CFRD. In non-CF diabetic pregnancy, very small glycemic excursions can have negative
impact on both the mother and the infant and therefore guidelines for management of diabetes in
pregnancy are much more aggressive and request blood sugars much closer to the normal non-diabetic
range than management of non-pregnant diabetics [43]. In CF, pre-existing CFRD is associated with
worsened outcomes for the mother and the baby. However, there is very little published literature to
support specic recommendations for the management of CFRD during pregnancy [44]. Women with
CF are at higher risk for GDM because of underlying insulin deciency, and should be screened more
aggressively when planning a pregnancy. Screening is recommended as follows: women not having
an OGTT within 6 months of pregnancy are to be screened as soon as possible and then re-screened
during weeks 1216 and 2428, and if they develop GDM to be re-screened 612 weeks after delivery,
and insulin treatment recommended [6]. All pregnant women with CF and diabetes require increased
energy intake and require close monitoring of weight gain and nutritional status [44]. Standard
prenatal weight gain charts can be used to determine weight gain goals. Additional calorie needs will
vary based on pre-pregnancy weight, degree of pancreatic malabsorption, pulmonary status, and
presence of infections. Oral supplements may be necessary to promote adequate weight gain.
Suboptimal weight gain during pregnancy is a concern; therefore, current practice does not encourage
the restriction of calories or carbohydrate during pregnancy. However, empty calories should be
replaced with nutrient-dense foods. Aggressive initiation of insulin should be implemented rather
than diet restriction. In pregnant women with CFRD or CF with GDM requiring insulin therapy,
insulin should be matched to carbohydrate intake to optimize blood glucose control without restricting
carbohydrate intake [6]. Insulin pump therapy is often optimal if it can be obtained, given the level of
complexity of management of diabetes in pregnancy in a woman with CF. Management should be
coordinated with high-risk obstetrics.
200
Hypoglycemia
Management of Hypoglycemia
The risk of hypoglycemia in CFRD is the same as in people with T1D and T2D requiring insulin.
Since people with CFRD require pancreatic enzyme replacement therapy (PERT) with mixed nutrient
foods, low blood glucose should be treated with fat-free and protein free carbohydrate sources that do
not require pancreatic enzyme replacement. Absorption of fat-free carbohydrates is not compromised
as patients with CF are able to secrete amylase in their saliva.
Treatment Example
Fifteen grams of rapid-acting carbohydrate should be administered and then blood sugar rechecked in
15 min. This cycle should be repeated until blood sugar is over 100 mg/dl. Examples of appropriate
rapid-acting carbohydrate include: 4 oz apple juice, glucose tablets, glucose gel. If necessary, hard
candies and regular soft drinks can be used, but the amount should be limited to 15 g of carbohydrate.
Reactive Hypoglycemia
Patients with CF sometimes have reactive hypoglycemia, low blood sugars happening after a meal,
typically 23 h post-prandial. This has been clinically documented and can also be seen on 3 h
OGTT [45]. This is usually considered to be secondary to the abnormal insulin secretion that is
found in patients with CF, prior to progression to diabetes, although the literature has not shown a
direct connection between documented hypoglycemia and progression of glucose abnormalities [46,
47]. Unfortunately, there are no guidelines or published literature to recommend treatment or
screening for this condition. In our practice, we typically recommend avoidance of large carbohydrate
loads with high glycemic index, especially regular soft drinks or juice, especially if taken in the
absence of protein or fat.
IGT/Pre-diabetes
Nutrition Recommendations for Impaired Glucose Tolerance
Unlike the general population, IGT in CF is not due to excessive weight gain and insulin resistance,
but rather underlying beta cell failure and insulin deciency and therefore is not preventable. Due to
this, nutrition guidelines for IGT in the general population are not applicable for people with
CF. Weight loss is rarely recommended for people with CF. Exercise in people with CF is benecial
for overall health, and people with CF in their baseline state of health are insulin-sensitive, but exercise
will not help to slow the progression towards CFRD due to progressive insulin deciency. Most
people with CF, including those with severe pulmonary disease, are capable of engaging in strength
and aerobic exercise and are advised to do moderate aerobic exercise for at least 150 min per week.
Spreading carbohydrates throughout the day and replacing empty calorie-carbohydrates with nutrientdense carbohydrates are recommended. Maintenance of a healthy weight and nutritional status must
be monitored closely [6].
201
Insulin Therapy for Impaired Glucose Tolerance/Pre-diabetes

Some authors use low-dose insulin therapy in CF patients with IGT [30] or other forms of abnormal
glycemic tolerance [31, 48]. However, this is not generally recommended at this time, although it may
be in the future.
Disordered Eating
Many different chronic illnesses can be associated with disordered eating, due to focus on body image
caused by the illness. Chronic illnesses that require dietary management are at increased risk of
causing the development of abnormal relationships with food and weight and disordered eating habits
[49]. Diabetes is documented to lead to eating disorder in adolescents [50]. There are few studies of
eating disorders in cystic brosis, but disordered eating has been documented, and some studies argue
there is a higher rate than in the general population [49]. There is no literature specic to disordered
eating in the context of CFRD, but it seems not irrational to speculate that the combination of both
diabetes and CF may increase this risk, and it behooves the care team to be aware of and monitoring
for this possibility as undetected eating disorders can derail appropriate nutrition.
Summary of Nutrition Recommendations for CFRD

See Table 13.3.
Table 13.3 Nutrition recommendations for cystic brosis related diabetes

Nutrient
Calories
Carbohydrate
Fat
Protein
Sodium
Vitamins, minerals
Alcohol
Impaired glucose tolerance
CFRD in pregnancy and gestational

diabetes mellitus
Adapted from Moran et al. [6]

1.21.5 times Dietary Reference Intake (DRI) for age; individualized based
on weight gain and growth. High calorie oral supplements and enteral tube
feedings often necessary. Not necessary to use diabetes specic formulas
Individualized. Carbohydrates should be monitored to achieve glycemic
control. Use of articial sweeteners should be used sparingly due to lower
calorie content
No restriction on type of fat. High fat necessary for weight maintenance; aim
for 3540% total calories
Approximately 1.52.0 times the DRI for age, no reduction for nephropathy
Liberal, high salt diet, especially in warm conditions and/or when exercising
Routine supplementation with CF-specic multivitamins or a multivitamin
and additional fat-soluble vitamins A, D, E, and K
Consult with physician due to the higher prevalence of liver disease in CF and
possible use of hepatotoxic drugs
Weight loss not recommended, spread carbohydrates throughout day. Restrict
sugar sweetened and other empty calorie beverages. Exercise per usual CF
recommendations. Monitor nutritional status
No calorie or carbohydrate restriction except sugar sweetened and other
empty calorie beverages. A high calorie diet must be maintained for
adequate weight gain. Aggressive use of insulin rather than diet restriction
202
Medical and Nutrition Therapy Goals (Adapted from Moran et al. [6])
Medical Goals
Patients with CFRD should ideally be seen quarterly by a specialized multidisciplinary team with
expertise in diabetes and CF
Patients with CFRD should receive ongoing diabetes self-management education from diabetes
education programs that meet national standards for Diabetes Self-Management Education
Patients with CFRD should be treated with insulin
Oral diabetes agents are not as effective as insulin in improving nutritional and metabolic outcomes
in CFRD and are not recommended outside the context of clinical research trials
Patients with CFRD who are on insulin should monitor blood glucose at least 3 times a day
Blood glucose goals for patients with CFRD are consistent with glucose goals per the American
Diabetes Association (ADA) recommendations for all people with diabetes. Higher or lower goals
may be indicated for some patients and that individualization is important
A1C measurement is recommended quarterly for patients with CFRD
A1C treatment goal is <7%. Higher or lower goals may be indicated for some patients and that
individualization is important
Diabetes education about the symptoms, prevention, and treatment of hypoglycemia, including the
use of glucagon, is recommended for patients with CFRD and their care partners
Blood pressure should be measured at every routine diabetes visit per ADA guidelines. Systolic
blood pressure 130 mmHg or diastolic blood pressure 80 mmHg or >90th percentile for age and
sex for pediatric patients should have repeat measurement on a separate day to conrm a diagnosis
of hypertension
Annual monitoring for microvascular complications of diabetes is recommended using ADA
guidelines, beginning 5 years after the diagnosis of CFRD or, if the exact time of diagnosis is not
known, at the time that fasting hyperglycemia is rst diagnosed
Patients with CFRD who have hypertension or microvascular complications should receive
treatment as recommended by ADA for all people with diabetes, except that there is no restriction
of sodium and, in general, no protein restriction
An annual lipid prole is recommended for patients with CFRD and pancreatic exocrine sufciency
or if any of the following risk factors are present: obesity, family history of coronary artery disease,
or immunosuppressive therapy following transplantation
Patients are advised to do moderate aerobic exercise for at least 150 min per week.
Conclusion
Medical nutrition therapy is a critical aspect of the management of all forms of diabetes. It is especially
critical in CFRD as nutritional status is key to the health and survival of every patient with CF. Also,
CFRD is extremely common in the CF population and there is a very real chance that any given
patient with CF may have diabetes at some point in his or her lifetime. Moreover, the development of
CFRD leads to decreased nutritional status, decreased lung function, and increased mortality.
Therefore, the nutritional management of CFRD is relevant to nearly every CF patient.
Once diabetes is diagnosed, it must be treated, and insulin therapy has been shown to reverse
nutritional decline and lung function decline. Therefore, insulin is the only appropriate medication for
CFRD. Other anti-diabetic medications are not indicated. Nutritional education, however, is key.
Nutritional therapy of CFRD has several important differences from T1D and from T2D, primarily
203
due to the signicant nutrition needs for treatment of CF, but also due to the unique pathophysiology
of CFRD. Importantly, there is no indication for restriction of carbohydrate or caloric intake and,
rather, CF-specic guidelines for macronutrient composition should be followed. Appropriate enteral
feeds and supplements should not be held due to CFRD, and diabetic formulas are not indicated.
Rather, appropriate supplements and formulas indicated for CF care should be appropriately utilized.
CF patients are insulin sensitive at baseline, but may develop signicant insulin resistance with illness
or steroid use, such that these events may cause need for insulin therapy in a patient who has not
previously needed insulin. Insulin regimens should be exible and can be designed to successfully
treat patients in a variety of situations including supplemental/enteral feeds, TPN use, steroid therapy,
and pregnancy.
Pre-diabetic states are very common in CF, but they cannot be prevented through carbohydrate
restriction, rather, nutritional failure is often an indication that the pre-diabetic state is present and
increased nutrition may be required in the peri-diabetic time period. There is no role for caloric or
carbohydrate restriction in these states as; unlike in pre-diabetes related to T2D, it does not prevent
progression to CFRD. Low-dose insulin therapy may be useful in these situations, but more data is
needed at this point.
Despite the complexities of management of CF patients with CFRD, appropriate nutritional and
insulin therapy can reverse the nutritional and clinical decline associated with CFRD and improve
long-term outcomes for affected patients.
References
1. Moran A, Doherty L, Wang X, Thomas W. Abnormal glucose metabolism in cystic brosis. J Pediatr. 1998;133:
107.
2. Frohnert BI, Ode KL, Moran A, Nathan BM, Laguna T, Holme B, Thomas W. Impaired fasting glucose in cystic
brosis. Diabetes Care. 2010;33:26604.
3. Moran A, Dunitz J, Nathan B, Saeed A, Holme B, Thomas W. Cystic brosis-related diabetes: current trends in
prevalence, incidence, and mortality. Diabetes Care. 2009;32:162631.
5. Cystic Fibrosis Foundation (CFF). Patient Registry. 2012 Annual Data Report. Bethesda, MD; 2012.
6. Moran A, Brunzell C, Cohen RC, Katz M, Marshall BC, Onady G, Robinson KA, Sabadosa KA, Stecenko A, Slovis
B. Clinical care guidelines for cystic brosis-related diabetes: a position statement of the American Diabetes
Association and a clinical practice guideline of the Cystic Fibrosis Foundation, endorsed by the Pediatric Endocrine
Society. Diabetes Care. 2010;33:2697708.
7. Borowitz D, Baker RD, Stallings V, et al. Consensus report on nutrition for pediatric patients with cystic brosis.
8. White H, Pollard K, Etherington C, Clifton I, Morton AM, Owen D, Conway SP, Peckham DG. Nutritional decline
in cystic brosis related diabetes: the effect of intensive nutritional intervention. J Cyst Fibros. 2009;8:17985.
9. Lanng S, Thorsteinsson B, Nerup J, Koch C. Inuence of the development of diabetes mellitus on clinical status in
patients with cystic brosis. Eur J Pediatr. 1992;151:6847.
10. Lanng S, Thorsteinsson B, Nerup J, Koch C. Diabetes mellitus in cystic brosis: effect of insulin therapy on lung
function and infections. Acta Paediatr. 1994;83:84953.
11. Gougeon R, Pencharz PB, Marliss EB. Effect of NIDDM on the kinetics of whole-body protein metabolism.
Diabetes. 1994;43:31828.
12. Figueroa V, Milla C, Parks EJ, Schwarzenberg SJ, Moran A. Abnormal lipid concentrations in cystic brosis. Am J
Clin Nutr. 2002;75:100511.
13. Rhodes B, Nash EF, Tullis E, Pencharz PB, Brotherwood M, Dupuis A, Stephenson A. Prevalence of dyslipidemia
in adults with cystic brosis. J Cyst Fibros. 2010;9:248.
14. Stephenson AL, Mannik LA, Walsh S, Brotherwood M, Robert R, Darling PB, Nisenbaum R, Moerman J, Stanojevic
S. Longitudinal trends in nutritional status and the relation between lung function and BMI in cystic brosis: a
population-based cohort study. Am J Clin Nutr. 2013;97:8727.
204
15. Schwarzenberg SJ, Thomas W, Olsen TW, Grover T, Walk D, Milla C, Moran A. Microvascular complications in
cystic brosis-related diabetes. Diabetes Care. 2007;30:105661.
16. Andersen HU, Lanng S, Pressler T, Laugesen CS, Mathiesen ER. Cystic brosis-related diabetes: the presence of
microvascular diabetes complications. Diabetes Care. 2006;29:26603.
17. Van den Berg JMW, Morton AM, Kok SW, Pijl H, Conway SP, Heijerman HGM. Microvascular complications in
patients with cystic brosis-related diabetes (CFRD). J Cyst Fibros. 2008;7:5159.
18. Moran A, Diem P, Klein DJ, Levitt MD, Robertson RP. Pancreatic endocrine function in cystic brosis. J Pediatr.
1991;118:71523.
19. Wilson DC, Kalnins D, Stewart C, Hamilton N, Hanna AK, Durie PR, Tullis E, Pencharz PB. Challenges in the
dietary treatment of cystic brosis related diabetes mellitus. Clin Nutr. 2000;19:8793.
20. Orenstein D. Cystic brosis. In: Rudolph A, Hostetter M, Lister G, Siegel N, editors. Rudolphs pediatrics.
New York: McGraw Hill; 2002. p. 196980.
21. Gaskin K. Exocrine pancreatic function. In: Walker W, Goulet O, Kleinman R, Sherman P, Schneider B, Sanderson
I, editors. Pediatric gastrointestinal disease. Hamilton: B.C. Decker; 2004. p. 160723.
22. Tof S, Moreno JC, Miz L, Alonso M, Escobar H, Barrio R. Insulin-secretion abnormalities and clinical
deterioration related to impaired glucose tolerance in cystic brosis. Eur J Endocrinol. 2005;152:2417.
23. Blackman SM, Hsu S, Vanscoy LL, Collaco JM, Ritter SE, Naughton K, Cutting GR. Genetic modiers play a
substantial role in diabetes complicating cystic brosis. J Clin Endocrinol Metab. 2009;94:13029.
24. Milla CE, Warwick WJ, Moran A. Trends in pulmonary function in patients with cystic brosis correlate with the
degree of glucose intolerance at baseline. Am J Respir Crit Care Med. 2000;162:8915.
25. Rosenecker J, Her R, Steinkamp G, Eichler I, Smaczny C, Ballmann M, Posselt HG, Bargon J, von der Hardt
H. Diabetes mellitus in patients with cystic brosis: the impact of diabetes mellitus on pulmonary function and
clinical outcome. Eur J Med Res. 2001;6:34550.
26. Moran A, Pekow P, Grover P, Zorn M, Slovis B, Pilewski J, Tullis E, Liou TG, Allen H. Insulin therapy to improve
BMI in cystic brosis-related diabetes without fasting hyperglycemia: results of the cystic brosis related diabetes
therapy trial. Diabetes Care. 2009;32:17838.
27. Brodsky J, Dougherty S, Makani R, Rubenstein RC, Kelly A. Elevation of 1-hour plasma glucose during oral
glucose tolerance testing is associated with worse pulmonary function in cystic brosis. Diabetes Care.
2011;34:2925.
28. Hameed S, Morton JR, Jaff A, Field PI, Belessis Y, Yoong T, Katz T, Verge CF. Early glucose abnormalities in
cystic brosis are preceded by poor weight gain. Diabetes Care. 2010;33:2216.
29. Ode KL, Frohnert B, Laguna T, Phillips J, Holme B, Regelmann W, Thomas W, Moran A. Oral glucose tolerance
testing in children with cystic brosis. Pediatr Diabetes. 2010;11:48792.
30. Bizzarri C, Lucidi V, Ciampalini P, Bella S, Russo B, Cappa M. Clinical effects of early treatment with insulin
glargine in patients with cystic brosis and impaired glucose tolerance. J Endocrinol Invest. 2006;29:RC14.
31. Dobson L, Hattersley AT, Tiley S, Elworthy S, Oades PJ, Sheldon CD. Clinical improvement in cystic brosis with
early insulin treatment. Arch Dis Child. 2002;87:4301.
32. Waugh N, Royle P, Craigie I, Ho V, Pandit L, Ewings P, Adler A, Helms P, Sheldon C. Screening for cystic brosisrelated diabetes: a systematic review. Health Technol Assess. 2012;16. iiiiv, 1179.
33. Jefferies C, Solomon M, Perlman K, Sweezey N, Daneman D. Continuous glucose monitoring in adolescents with
cystic brosis. J Pediatr. 2005;147:3968.
34. Khammar A, Stremler N, Dubus J-C, Gross G, Sarles J, Reynaud R. Value of continuous glucose monitoring in
screening for diabetes in cystic brosis. Arch Pediatr. 2009;16:15406.
35. Franco WB, Brown RF, Bremer AA. Use of glucola alternatives for cystic brosis-related diabetes screening.
J Cyst Fibros. 2011;10:3845.
36. Holl RW, Buck C, Babka C, Wolf A, Thon A. HbA1c is not recommended as a screening test for diabetes in cystic
brosis. Diabetes Care. 2000;23:126.
37. Godbout A, Hammana I, Potvin S, Mainville D, Rakel A, Berthiaume Y, Chiasson J-L, Coderre L, Rabasa-Lhoret
R. No relationship between mean plasma glucose and glycated haemoglobin in patients with cystic brosis-related
diabetes. Diabetes Metab. 2008;34:56873.
38. Hardin DS, Rice J, Rice M, Rosenblatt R. Use of the insulin pump in treat cystic brosis related diabetes. J Cyst
Fibros. 2009;8:1748.
39. Sunni M, Bellin MD, Moran A. Exogenous insulin requirements do not differ between youth and adults with cystic
brosis related diabetes. Pediatr Diabetes. 2013;14:2958.
40. Scheuing N, Thon A, Konrad K, et al. Carbohydrate intake and insulin requirement in children, adolescents and
young adults with cystic brosis-related diabetes: a multicenter comparison to type 1 diabetes. Clin Nutr.
2015;34:7328.
41. Marshall BC, Butler SM, Stoddard M, Moran AM, Liou TG, Morgan WJ. Epidemiology of cystic brosis-related
diabetes. J Pediatr. 2005;146:6817.
205
42. Rasouli N, Seggelke S, Gibbs J, et al. Cystic brosis-related diabetes in adults: inpatient management of 121
patients during 410 admissions. J Diabetes Sci Technol. 2012;6:103844.
43. Metzger BE, Lowe LP, Dyer AR, et al. Hyperglycemia and adverse pregnancy outcomes. N Engl J Med.
2008;358:19912002.
44. Michel SH, Mueller DH. Nutrition for pregnant women who have cystic brosis. J Acad Nutr Diet.
2012;112:19438.
45. Hirsch IB, Janci MM, Goss CH, Aitken ML. Hypoglycemia in adults with cystic brosis during oral glucose
tolerance testing. Diabetes Care. 2013;36:e1212.
46. Radike K, Molz K, Holl RW, Poeter B, Hebestreit H, Ballmann M. Prognostic relevance of hypoglycemia following
an oral glucose challenge for cystic brosis-related diabetes. Diabetes Care. 2011;34, e43.
47. Battezzati A, Battezzati PM, Costantini D, Seia M, Zazzeron L, Russo MC, Dacc V, Bertoli S, Crosignani A,
Colombo C. Spontaneous hypoglycemia in patients with cystic brosis. Eur J Endocrinol. 2007;156:36976.
48. Hameed S, Morton JR, Field PI, et al. Once daily insulin detemir in cystic brosis with insulin deciency. Arch Dis
Child. 2012;97:4647.
49. Quick VM, Byrd-Bredbenner C, Neumark-Sztainer D. Chronic illness and disordered eating: a discussion of the
literature. Adv Nutr. 2013;4:27786.
50. Powers MA, Richter S, Ackard D, Gerken S, Meier M, Criego A. Characteristics of persons with an eating disorder
and type 1 diabetes and psychological comparisons with persons with an eating disorder and no diabetes. Int J Eat
Disord. 2012;45:2526.
Chapter 14
Nutrition Pre and Post Lung Transplant

Teresa Schindler
Key Points
Malnutrition is common in CF patients prior to transplant
Patients with a BMI <18.5, depletion of fat free mass, or hypoalbuminemia, may have worse
outcomes post-transplant
While nutritional status generally improves after transplant, CF patients face many complications
which have nutritional implications
Keywords Cystic brosis Lung transplantation Nutrition
Introduction
While the life expectancy for individuals with cystic brosis (CF) continues to improve, respiratory
failure continues to be the main cause of mortality for those aficted with the disease. Lung transplantation
offers those with end-stage lung disease a survival advantage and improved quality of life compared to
those who do not receive a transplant. Optimizing nutritional status prior to transplantation can improve
post-transplant outcomes, however this can be quite challenging to accomplish.
Despite noted improvements in nutritional status for CF patients after lung transplantation, they
face multiple unique nutritional considerations.
Overview of Lung Transplantation in CF

According to the CF Foundation Registry, over 200 lung transplants were performed in individuals
with CF in 2011, and about 2800 people with CF have received a lung transplant since 1990 [1].
Cystic brosis is the third major indication for lung transplantation, after emphysema and pulmonary
brosis [2].
T. Schindler, M.S., R.D.N. (*)

Pediatric Pulmonology, Rainbow Babies and Childrens Hospital Case Medical Center,
11100 Euclid Ave, Cleveland, OH 44106, USA
207
T. Schindler
208
Table 14.1 lists the indications for lung transplantation for cystic brosis. Absolute contraindications
to lung transplantation are listed in Table 14.2. The vast majority of those transplanted receive a bilateral
double lung transplant; a small minority (<5%) require liver and lung transplantation [3].
Survival rates for lung transplant recipients regardless of indication are lower compared to most
other solid organ transplants. Compared to other solid organ transplants, lung transplant recipients
experience higher rates of re-hospitalizations as well: 43.7% in the rst year and 36% in the second
year [3]. Compared to individuals receiving lung transplants for other indications, median accrual
survival is slightly better in individuals with CF: 7.5 years for all recipients, and 10.4 years for those
who survive the rst year [2].
In 2005, the Lung Allocation Score (LAS) was implemented to improve the outcomes of those who
are listed for transplant as well as those who receive a transplant. The LAS calculation (see Table 14.3)
is a score that reects risk of wait-list mortality while avoiding transplants in those who have a very
poor likelihood of survival [3].
Expected wait time in the US varies according to age, blood type, height, geography, and LAS
(for those age 12 years and older) [2, 3]. Approximately 65% of candidates are transplanted within a
year of listing. However, the wait can vary greatly depending on the area of the country in which the
person is listed [3].
Although wait-list mortality has decreased signicantly since implementation of the LAS, it is
important to optimize and stabilize nutritional status prior to transplant. The median body mass index
(BMI) prior to transplant is 19.2 kg/m2, with 39% of those who had a BMI below 18.5 kg/m2 [4].
Table 14.1 Indications for lung transplant referral [4, 5]

1.
FEV1 < 30% predicted and/or rapid decline in FEV1
2.
Recurrent, massive hemoptysis
3.
Relapsing or complicated pneumothorax
4.
Respiratory infections necessitating an ICU admission
5.
Malnutrition, diabetes, female gender, oxygen requirement, and poor quality of life/functional incapacity and/
or an increasing need for intravenous antibiotic therapy may also be important indications for early referral
Table 14.2 Absolute contraindications to lung transplantation (some factors may vary depending on location) [4, 6]
Malignant disease in the past 2 years
Lack of medical insurance
Untreatable severe dysfunction of another important organ system (heart, liver, kidney) not amenable to
surgical correction/combined transplant
Chronic, incurable extrapulmonary infection
Severe deformations of chest and spine
Severe or symptomatic osteoporosis
Lack of adherence to therapies
Untreated mental disorders combined with lack of cooperation
Addictive disorder currently or during the past 6 months (including tobacco, alcohol, substance abuse)
Lack of social support system
14
209
Table 14.3 Factors used in Lung Allocation Score (LAS)
Age
BMI
Presence/absence of diabetes
Functional status
FVC
O2 requirement
6 min walk distance
Mechanical ventilation
PCO2
Diagnosis
Impact of Nutritional Status on Transplant Outcomes

Malnutrition is a common condition for individuals with CF with end-stage lung disease. The cause of
malnutrition is multi-factorial. Factors leading to malnutrition in end-stage lung disease include elevated
resting energy expenditure (REE), poor appetite, and frequent pulmonary exacerbations. For example,
mean REE was 132% predicted in pediatric patients awaiting lung transplantation (majority with CF) [7].
In addition, frequent episodes of increased respiratory symptoms can cause poor appetite and intake, and
delayed gastric emptying is a common complication of end-stage disease in CF [8].
Extremes of body weight have been shown to negatively affect lung transplant outcomes. Specically,
adult CF patients with a BMI <18.5 kg/m2 have a signicantly higher risk of post-transplant mortality
than adult CF patients with a normal or higher BMI [9, 10]. Other markers of nutritional status have been
used to determine post-transplant outcomes, including Fat Free Mass (FFM) and serum albumin.
Depletion of FFM was strongly associated with increased mortality while awaiting lung transplant and
longer post-transplant intensive care unit stays [11]. A retrospective study in 2014 by Hollander et al.
conrmed previous studies in which a low BMI (18.5 kg/m2) and low FFM index appear to impair
survival in lung transplant candidates with CF [4]. Hypoalbuminemia (serum albumin <3 mg/dl) was
associated with an increased risk of early mortality in post-transplant patients [12].
Despite evidence that supports optimal nutritional status prior to transplant, malnutrition may not
be an absolute contraindication to transplantation, depending on the transplant center. Reversing
malnutrition can be a difcult endeavor, and aggressive nutrition support is not without risks. In fact,
Belkin et al. found that use of a nutritional intervention was associated with increased risk of death in
patients with CF awaiting lung transplantation [13]. See Table 14.4 for enteral nutrition support
considerations in pre-transplant patients.
There have been mixed reports regarding the effectiveness of dietary interventions in the pre-transplant
period. Despite dietetic interventions including oral supplements, tube feedings or both, Hollander and
colleagues did not see an improvement in BMI and FFM in the pre-transplant time period [4].
Nutrition Support in the Pre-Transplant Period

Ambulatory patients should continue a high calorie, high fat diet and be encouraged to consume
regular meals and snacks to meet high energy demands. Small, frequent meals may be better tolerated,
especially during a pulmonary exacerbation and if delayed gastric emptying is present. Reviewing
methods to boost calories in foods and beverages can be helpful, as well as providing lists of high
210
T. Schindler
Table 14.4 Post-gastrostomy tube placement and nutrition support considerations and recommendations in pre and
post-transplant patients
1. Adequate pain control, particularly to ensure proper airway clearance
2. Monitor stool elimination pattern; consider laxative prophylaxis, particularly if narcotics are used for pain control
3. Provide alternative methods for airway clearance (vest therapy and chest physiotherapy are often not tolerated
in the immediate post-placement period)
4. Monitor for hyperglycemia (glucose checks half way through feedings and at end of feedings once up to full rate)
5. Intact formula trial [25, 26]
6. Reux precautions unless patient has fundoplication
7. Soft diet if patient is post fundoplication
8. Monitor for re-feeding syndrome in severely malnourished patients
9. Avoid over-feeding patients with CO2 retention/mechanically ventilated patients [27]
10. Penn State Equation (PSU 2003) can be used to calculate energy needs for intubated patients (Academy of
Nutrition and Dietetics Evidence Analysis Library (Critical Illness Guidelines) April 2012; include additional
calories (approximately 15% of total calories) to compensate for malabsorption for patients with pancreatic
insufciency [28]
11. Non-enteric coated Viokace can be crushed and added to formula, or enzyme beads may be suspended in
nectar-thick uids and administered with tube feedings for patients with pancreatic insufciency [29, 30]
calorie snacks for between-meal consumption. An appetite stimulant may be helpful for patients with
anorexia [14], and encouraging the use of supplemental oxygen when needed may help lower energy
expenditure in patients with severe lung disease.
For patients with cystic brosis related diabetes (CFRD), optimizing blood sugar control can help
improve nutritional status. Patients who do not have known CFRD should be screened preoperatively
by oral glucose tolerance test if they have not had CFRD screening in the last 6 months [15]. It is
important to provide patients with anticipatory guidance about the increased likelihood of developing
temporary hyperglycemia necessitating insulin therapy during the immediate post-transplant period,
and the recommendation to continue routine monitoring for CFRD on an annual basis or earlier if
symptoms such as unexplained weight loss develop after transplantation.
The use of oral nutritional supplements in CF is common, however there is limited evidence to
support their use. A 2014 Cochrane systematic review on this topic indicated that oral supplements do
not confer additional benet in the nutritional management of moderately malnourished children with
CF, and that further controlled trials are needed to establish a role in the management of patients with
advanced lung disease [16]. Possible factors relating to variable success with oral supplements may
include avor fatigue and decreased food intake when supplements are taken with meals. Alternating
types and avors of supplements and consuming them after meals and/or at the end of the day may
improve the efcacy of oral nutritional supplements.
Gastrostomy tube (GT) placement for enteral feedings is another option for improving nutritional
support. Data regarding the effectiveness of gastrostomy tube feedings are conicting. A study from
2004 indicated that mortality was signicantly increased when FEV1 predicted was less that 50% at
the time of gastrostomy insertion [17]. However a more recent study found that FEV1 at the time of
GT placement did not correlate with FEV1 slope change after GT placement [18]. There is also
conicting data regarding effectiveness of gastrostomy tube feedings in patients with severe lung
disease with regard to improving both FEV1 and BMI [1821]. Since most studies were relatively
small and did not include prospective randomization, they were not included in a 2012 Cochrane
review of enteral tube feedings in cystic brosis [22].
Gastroesophageal reux disease (GERD) is reported in 30% of CF patients according to the CFF
registry, and is associated with worse pulmonary outcomes [23, 24]. Considering the potential, signicant
impact of GERD on pulmonary outcomes, screening prior to GT placement and tube feeding often
includes upper GI, pH probe, and gastric emptying study. Careful post-gastrostomy tube placement
monitoring should also be considered (Table 14.4 and Fig. 14.1).
Pre-transplant CF Nutrition Assessment (18 and older)

Social:
FEV1
Exercise/activity level:
Nutrition Concerns / Questions:
Financial/psychosocial considerations:
Pt goal for wt (pre-tx): Comment:
Transplant center:
LAS if listed:
Additional Diagnoses : CFRD +/- IGT +/- CFLD +/- Osteoporosis/penia +/Kidney stones +/- DIOS +/- Pancreatitis +/- Fracture +/ - Sinus dz* +/-Food allergy
+/-Colonoscopy+/-Other/describe: *interfering w/smell/taste
Current Date:
Prior Date:
Ht (cm)
Wt (kg)
BMI
Oral Intake
Pattern
Appetite => Baseline
Increased
Decreased
Tube Feeds (kcal)

Oral
Supplements
Calcium Intake
Medications / Vitamins
Pancreatic Enzymes
Enzyme Dose: units lipase/kg/ largest meal;
Total: units lipase /kg/day
EnzymeProgram:
CF Specific Vitamins
Dose: Soft / chew / liquid
Other vitamins/minerals :
Acid Blocker:
Other Pert Medications / Appetite Stimulants/ Insulin / ADHD /CAM/Herbal:
Subjective report of adherence to enzymes/vitamins/supplements/tube feeds
GI / Absorption
Sx: Abdominal Pain
GERD Constipation
# stools/d/description =>
Reflux screen
Gastric emptying
CFRD / Endocrine
IF CFRD: Endo MD and year diagnosed:
Last Seen:
Blood sugar Range:
? Lows/ Reactive hypoglycemia:
Labs / Date
GFR or CrCl
LFTs
Vitamin A
Vitamin E
Vitamin D
PT / INR or PIVKA
DEXA
OGTT
Fasting Glu / Hgb A1C
Other
Results
Nausea Vomiting
None
Interventions
Fig. 14.1 Pre-transplant nutrition assessment. Used with permission from University Hospitals Case Medical Center
212
T. Schindler
Evaluation:
Nutrition Risk
Assessment
Low Risk
Moderate Risk
BMI>20
BMI 19.9-18.6
High Risk
BMI 18.5
Alb <3
BMI>30
Estimated energy and protein needs:

Estimated energy and protein intake:
Nutritional Diagnosis:
Nutrition Prescription:
Goals / Plan:
Nutrition Intervention:
Education/Materials Provided:
Monitoring and Evaluation:
Signature:
Fig. 14.1 (continued)
Post-Transplant Considerations
Immediate Post-Transplant Period
In the immediate post-operative period, patients are managed in the intensive care unit until stable enough
to be transferred to a transplant unit or step-down unit. They may or may not need nutrition support
during this time, depending on how quickly they are extubated and complications they may encounter.
If enteral tube feedings are required, it is important to include additional calories for malabsorption when
estimating energy needs, and plan for enzyme replacement therapy (see # 11 Table 14.4).
Oropharyngeal dysphagia is a common complication after thoracic surgical procedures, including
lung transplantation, and can increase the risk of aspiration pneumonia [31]. Assessment for this
complication is recommended prior to allowing the patient to resume oral intake after transplant.
This complication may delay introduction of food and/or uids and necessitate enteral tube feedings
or the use of commercial thickeners until the dysphagia resolves.
Other gastrointestinal complications that can interfere with intake include distal intestinal obstruction
syndrome (DIOS), gastric bezoars, delayed gastric emptying, and side effects from post-transplant
medications. DIOS has been reported to occur in 1020% of patients after transplant; in one study, the
complication was particularly common in the early post-transplant time period [32, 33]. Monitoring
stool patterns, using laxatives as needed, and ensuring patients are restarted on appropriate enzyme
therapy can help reduce the risk of developing DIOS. Gastric bezoars, concretions of ingested matter
in the GI tract manifesting as foreign bodies, are a complication after transplant, particularly for patients
with cystic brosis. Dellon et al. in a retrospective study found that 11% of cystic brosis patients
developed bezoars with a mean incidence of 34 days from transplant [34]. Delayed gastric emptying
may develop or worsen post-transplant. Raviv et al. documented delayed gastric emptying in 50% of
all lung transplant candidates prior to transplantation; this increased to 74% at 3 months post-transplant
and decreased slightly to 63% at 12 months post-transplant [35]. Diets that are higher in fat and ber
may not be well tolerated during this time period due to delayed gastric emptying, and optimizing
blood sugar control should help minimize the adverse effects of hyperglycemia on gastric emptying.
Anti-rejection medications, particularly mycophenolate mofetil, as well as anti-microbial antibiotics
may cause considerable gastrointestinal upset and diarrhea, further leading to decreased intake. Certain
14
213
anti-rejection medications such as tacrolimus and cyclosporine are lipid-based and should be taken
consistently either with or without enzyme replacement therapy to maintain stable levels.
Stress from major surgery, infection, and medications such as prednisone all signicantly increase
the risk of either new onset diabetes or worsened blood sugar control for those with existing CFRD.
It is very common for patients to need insulin for the rst time or much higher doses than what was
required in the past in the immediate post-operative time period [15]. Patients who are discharged
from the hospital without the diagnosis of diabetes should continue to be screened annually for CFRD
[15] (Fig. 14.2).
Nutritional considerations 6 or more months out from transplant are unique. GERD is a particular
concern as it may be more common in patients with cystic brosis and is associated with increased
risk of chronic rejection [36]. Bronchiolitis obliterans syndrome (BO/BOS/OB), commonly referred
to as chronic rejection, is the major cause of mortality in patients after lung transplantation [2].
Which vitamin and mineral supplements, as well as doses, are recommended in post-transplant
patients is unknown. Routine, annual monitoring of fat soluble vitamin levels should continue posttransplant. Increased vitamin A and E levels have been reported in CF patients after lung transplantation;
hypervitaminosis A is particularly concerning as toxicity can cause increased intracranial pressure,
osteoporosis, and liver damage [37]. Standard CF vitamins may need to be discontinued since these
Post-transplant CF Nutrition Assessment (18 and older)

Social:
Nutrition Concerns / Questions:
Pt goal for wt (short and long term): Comment:
Transplant or CF center (circle):
Date of transplant:
Additional Diagnoses : CFRD +/ - IGT +/ - CFLD +/- Osteoporosis/penia +/Kidney stones +/- DIOS +/- Pancreatitis +/ - Fracture +/ - Sinus dz* +/Food allergy +/ - Colonoscopy +/ - Other/describe:* interfering w/smell/taste
?Fundoplication (date):
? BOS (date):
Current Date:
Prior Date:
Ht (cm)
Wt (kg)
BMI
Oral Intake
Pattern
Appetite => Baseline
Increased
Decreased
Tube Feeds (kcal)

Oral Supplements
Calcium Intake
Dietary restrictions
Medications / Vitamins
Pancreatic Enzymes
Enzyme Dose: units lipase/kg/ largest meal;
Total: units lipase /kg/day
EnzymeProgram: CF Specific Vitamins:
Other:
Dose: Soft / chew / liquid
Other vitamins /minerals :
Acid Blocker:
Other Pert Medications / Appetite Stimulants/ Insulin / ADHD /CAM/Herbal/anti rejection:
Fig. 14.2 Post-transplant nutrition assessment (after discharge). Used with permission from University Hospitals Case
Medical Center
T. Schindler
214
Following food safety guidelines? Y N

GI / Absorption
Sx: Abdominal Pain GERD
Constipation
# stools/d =>
Description:
Reflux screen
Gastric emptying
Nausea Vomiting
None
? in stool pattern ?blood
CFRD / Endocrine
OGTT screening completed N/A
IF CFRD: Endo MD and year diagnosed:
Last Seen:
Blood sugar Range:
? Lows / Reactive hypoglycemia
Labs / Date
GFR or CrCl
LFTs
Vitamin A
Vitamin E
Vitamin D
PT / INR or PIVKA
DEXA
OGTT
Fasting Glu / Hgb A1C
Other
Evaluation:
Nutrition Risk
Assessment
Results
Interventions
Low Risk
Moderate Risk
BMI>20
BMI 19.9-18.6
High Risk
BMI 18.5
Alb <3
BMI > 30
Estimated energy and protein needs:

Estimated energy and protein intake:
Nutritional Diagnosis:
Nutrition Prescription:
Goals / Plan:
Nutrition Intervention:
Education/Materials Provided:
Monitoring and Evaluation:
Signature:
Fig. 14.2 (continued)
products contain signicant doses of vitamins A and E compared to most general over-the-counter
multivitamin products. Optimizing vitamin D levels may be important as low serum vitamin D levels
are associated with increased rates of rejection and infection after lung transplantation [38].
Additionally, vitamin K2 supplementation showed a favorable effect on lumbar spine bone mineral
density in post lung transplant patients [39]. Adequate calcium, vitamin D, and vitamin K intake as
well as weight-bearing exercise should be encouraged to help negate the effects of corticosteroids on
bone health in the post-transplant period.
Renal dysfunction is another common complication that can occur in adults with CF after lung
transplantation and may require new dietary restrictions. A cohort study reviewing CFF patient
registry data from 20002008 showed a 2-year risk of 35% for developing renal dysfunction; risk
factors included pre-transplant renal function impairment, increased age, female gender, and CF
14
215
related diabetes [40]. Restrictions in potassium and phosphorus may be necessary, and patients who
develop renal insufciency may be particularly high risk for developing hypervitaminosis A.
Gastrointestinal malignancies are a particular concern for CF patients post-transplant.
Immunosuppressive agents, in addition to the inherent increased risk of GI malignancy associated
with cystic brosis, are believed to be the major causes of the increased incidence of GI malignancies
in this post lung transplant population [41]. Colorectal cancer appears to be the most common
malignancy, with one study showing a sevenfold increased risk of advanced adenomas [42]. More
aggressive screening for colorectal cancer is likely warranted for this population. In particular, it is
important to consider investigating malignancy as the cause of unexplained symptoms such as changes
in bowel habits, progressive weight loss, and/or anemia.
Food safety is important to review with all solid-organ transplant recipients. Immunosuppression
leads to increased risk of food-borne infections such as Salmonella and listeriosis [43, 44]. The Academy
of Nutrition and Dietetics offers general food safety tips, and the Food and Drug Administration
(FDA) offers a food safety handout designed specically for patients who have received solid organ
and bone marrow transplants http://www.fda.gov/downloads/Food/ResourcesForYou/Consumers/
SelectedHealthTopics/UCM312793.pdf.
Finally, for most patients with CF, signicant improvements in weight gain and BMI are noted
between 3 and 24 months after transplant, with most increase noted in underweight patients [4, 45].
There is no evidence to specify an optimal BMI for cystic brosis patients who are post lung transplant;
the 2008 published guidelines with BMI goals of 23 for males and 22 for females are based on
correlation to FEV1 in pre-transplant patients [46]. However, knowing that complications are quite
common after transplant, it would seem prudent to recommend achieving and maintaining a normal
BMI for age. Some patients may become overweight if they continue to follow the typical high fat,
high calorie CF diet; monitoring BMI trend is important.
Conclusion
Lung transplantation offers survival and quality of life advantage to patients with cystic brosis;
however they face many nutrition-related challenges before and after the transplant process. It is
important for nutrition professionals to be aware of the unique gastrointestinal and nutritional issues
that individuals with cystic brosis face, and continue to offer nutrition guidance throughout the
transplant process.
References
1. Cystic Fibrosis Foundation Patient Registry 2012 annual data report. Bethesda. Cystic Fibrosis Foundation; 2013.
2. Hirche TO, Knoop C, Hebestreit H, et al. ECORN-CF Study Group. Practical guidelines: lung transplantation in
patients with cystic brosis. Pulm Med. 2014;62:1342.
3. Scientic Registry of Transplant Recipients 2012 National data report. The SRTR is administered by the Chronic
Disease Research Group of the Minneapolis Medical Research Foundation, with oversight and funding from the
Health Resources and Services Administration; 2013.
4. Hollander FM, van Pierre DD, de Roos NM, van de Graaf EA, Iestra JA. Effects of nutritional status and dietetic
interventions on survival in cystic brosis patients before and after lung transplantation. J Cyst Fibros.
2014;13:2128.
5. Liou TG, Adler RD, Huang D. Use of lung transplantation survival models to rene patient selection in cystic
brosis. Am J Respir Crit Care Med. 2005;171:10539.
6. Yankaskas JR, Mallory GB, Consensus Committee. Lung transplantation in cystic brosis: consensus conference
statement. Chest. 1998;113:21726.
216
T. Schindler
7. Kalnins D, Pencharz PB, Grasemann H, Solomon M. Energy expenditure and nutritional status in pediatric patients
before and after lung transplantation. J Pediatr. 2013;163:15002.
8. Bodet-Milin C, Querellou S, Oudoux A, et al. Delayed gastric emptying scintigraphy in cystic brosis patients
before and after lung transplantation. J Heart Lung Transplant. 2006;25:107783.
9. Lederer DJ, Wilt JS, DOvidio F, et al. Obesity and underweight are associated with an increased risk of death after
lung transplantation. Am J Respir Crit Care Med. 2009;180:88795.
10. Singer JP, Peterson ER, Snyder ME, et al. Body composition and mortality after adult lung transplantation in the
United States. Am J Respir Crit Care Med. 2014;190:101221.
11. Schwebel C, Pin I, Barnoud D, et al. Prevalence and consequences of nutritional depletion in lung transplant
candidates. Eur Respir J. 2000;16:10505.
12. Baldwin MR, Arcasoy SM, Shah A, et al. Hypoalbuminemia and early mortality after lung transplantation: a cohort
study. Am J Transplant. 2012;12:125667.
13. Belkin RA, Henig NR, Singer LG, et al. Risk factors for death of patients with cystic brosis awaiting lung
transplantation. Am J Respir Crit Care Med. 2006;173:65966.
14. Nasr SZ, Drury D. Appetite stimulants use in cystic brosis. Pediatr Pulmonol. 2008;43:20919.
15. Moran A, Brunzell C, Cohen R, et al. Clinical care guidelines for cystic brosis-related diabetes. Diabetes Care.
2010;12:2697716.
16. Smyth RL, Rayner O. Oral calorie supplements for cystic brosis. Cochrane Database Syst Rev. 2014;11:CD000406.
17. Oliver MR, Heine RG, Ng CH, Volders E, Olinsky A. Factors affecting clinical outcome in gastrostomy-fed children
with cystic brosis. Pediatr Pulmonol. 2004;37:3249.
18. Best C, Brearly A, Gaillard P, et al. A pre-post retrospective study of patients with cystic brosis and gastrostomy
tubes. J Pediatr Gastroenterol Nutr. 2011;53:4538.
19. Efrati O, Mei-Zahav M, Rivlin J, et al. Long term nutritional rehabilitation by gastrostomy in Israeli patients with
cystic brosis: clinical outcome in advanced pulmonary disease. J Pediatr Gastroenterol Nutr. 2006;42:2228.
patients with gastrostomy tube feedings. J Pediatr Gastroenterol Nutr. 1998;27:536.
21. White H, Morton AM, Conway SP, Peckham DG. Enteral tube feeding in adults with cystic brosis; patient choice
and impact on long term outcomes. J Cyst Fibros. 2013;12:61622.
22. Conway S, Morton A, Wolfe S. Enteral tube feeding for cystic brosis. Cochrane Database Syst Rev.
2012;12:CD001198.
23. Navarro J, Rainisio M, Harms HK, et al. Factors associated with poor pulmonary function: cross-sectional analysis
of data from the ERCF. European Epidemiologic Registry of Cystic Fibrosis. Eur Respir J. 2001;18:298305.
24. Stringer DA, Sprigg A, Juodis E, et al. The association of cystic brosis, gastroesophageal reux, and reduced
pulmonary function. Can Assoc Radiol J. 1988;39:1002.
a semi-elemental and nonelemental formula. J Pediatr. 1998;132:2659.
26. Pelekanos JT, Holt TL, Ward LC, Cleghorn GJ, Shepherd RW. Protein turnover in malnourished patients with cystic
brosis: effects of elemental and nonelemental nutritional supplements. J Pediatr Gastroenterol Nutr.
1990;10:33943.
27. Talpers SS, Romberger DJ, Bunce SB, Pingleton SK. Nutritionally associated increased carbon dioxide production.
Excess total calories vs high proportion of carbohydrate calories. Chest. 1992;102:5515.
28. Concepts in CF Care Consensus Conferences: pediatric nutrition for patients with cystic brosis. Cystic Fibrosis
Foundation; 2008.
29. Written communication from Actavis Pharmaceuticals regarding in vitro Viokace validation studies.
30. Ferrie S, Graham C, Hoyle M. Pancreatic enzyme supplementation for patients receiving enteral feeds. Nutr Clin
Pract. 2011;26:34951.
31. Atkins BZ, Peterson RP, Daneshmand MA, et al. Impact of oropharyngeal dysphagia on long-term outcomes of
lung transplantation. Ann Thorac Surg. 2010;90:16229.
32. Morton JR, Ansari N, Glanville AR, Meagher AP, Lord RV. Distal intestinal obstruction syndrome (DIOS) in
patients with cystic brosis after lung transplantation. J Gastrointest Surg. 2009;13:144853.
33. Gillijam M, Chaparro C, Tullis E, et al. GI complications after lung transplantation in patients with cystic brosis.
Chest. 2003;123:3741.
34. Dellon ES, Morgan DR, Mohanty SP, Davis SP, Aris RM. High incidence of gastric bezoars in cystic brosis
patients after lung transplantation. Transplantation. 2006;81:11416.
35. Raviv Y, DOvidio F, Pierre A, et al. Prevalence of gastroparesis before and after lung transplantation and its
association with lung allograft outcomes. Clin Transplant. 2012;26:13342.
36. Mendez BM, Davis CS, Weber C, Joehl RJ, Fisichella PM. Gastroesophageal reux disease in lung transplant
patients with cystic brosis. Am J Surg. 2012;204:e216.
37. Stephenson A, Brotherwood M, Robert R, et al. Increased vitamin A and E levels in adult cystic brosis patients
after lung transplantation. Transplantation. 2005;79:6135.
14
217
38. Lowery EM, Bemiss B, Cascino T, et al. Low vitamin D levels are associated with increased rejection and infections
after lung transplantation. J Heart Lung Transplant. 2012;31:7007.
39. Forli L, Bollerslev J, Simonsen S, et al. Dietary vitamin K2 supplement improves bone status after lung and heart
transplantation. Transplantation. 2010;89:45864.
40. Quon BS, Mayer-Hamblett N, Aitken ML, Goss CH. Risk of post lung transplant renal dysfunction in adults with
cystic brosis. Chest. 2012;142:18591.
41. Meyer KC, Francois ML, Thomas HK, et al. Colon cancer in lung transplant recipients with CF: increased risk and
results of screening. J Cyst Fibros. 2011;10:3669.
42. Gory I, Brown G, Wilson J, et al. Increased risk of colorectal neoplasia in adult patients with cystic brosis: a
matched casecontrol study. Scand J Gastroenterol. 2014;49:12306.
43. Centers for Disease Control and Prevention. Outbreak of Salmonella serotype Javinia infections, Orlando, FL, June
2002. MMWR Morb Mortal Wkly Rep 2002;51:6834.
44. Goulet V, Hebert M, Hedberg C, et al. Incidence of listeriosis and related mortality among groups at risk of acquiring
listeriosis. Clin Infect Dis. 2012;54:65260.
45. Dirk H, Ralf E, Roland H, Stefan DA. Reversability of cachexia after bilateral lung transplantation. Int J Cardiol.
2008;133:4650.
Chapter 15
Pregnancy, Nutrition, and Cystic Fibrosis

Michelle Brotherwood
Key Points
As life expectancy increases in cystic brosis so does the incidence of women with CF becoming
pregnant. To date there are no consensus guidelines about managing these patients. It is important
to have a multidisciplinary approach including a registered dietitian to optimize the patients
health.
Weight gain can be a challenge in pregnancy for women with CF who have high calorie needs and
malabsorption. This can be exacerbated by GI symptoms common in pregnancy that can affect
intake.
All medications need to be reviewed for their safety in pregnancy. Vitamin levels need to be
monitored each trimester as Vitamin A can be of particular concern in pregnancy.
Women with CF who become pregnancy are at a higher risk of gestation diabetes and screening
this early (starting at 810 weeks) is recommended. Those women who have diabetes prior to
conception should be closely monitored to optimize their blood sugar control
Breastfeeding may be an option but should be discussed with the healthcare team
Keywords Pregnancy Weight gain Gestational diabetes Vitamins Enzymes Breastfeeding
Introduction
With increased life expectancy and improved health outcomes the number of pregnancies occurring in
women with cystic brosis (CF) is on the rise and is now considered a viable option for many women.
The rst successful pregnancy in cystic brosis was reported in 1960 [1] and the numbers reported have
been increasing each year. Published data shows that the outcomes for both women with CF and their
babies have improved considerably over time [25]. Several studies suggest that pregnancy itself does
not affect womens survival or disease related outcomes [2, 57]. However, there are very few research
studies looking at prenatal care for women with CF and as a result, there are no current consensus
guidelines for nutritional management of population [7]. In practice, as outlined in this chapter, care
M. Brotherwood, R.D., C.D.E. (*)

Pulmonary, Childrens Hospital Los Angeles, 4650 Sunset Blvd, Mailstop #8, Los Angeles, CA 90026, USA
219
220
M. Brotherwood
is provided based on current CF nutrition recommendations and nutrition recommendations for

the general population during pregnancy. This chapter will review nutrition guidelines for pre, during,
and post pregnancy as well as breastfeeding for the woman with CF.
Pre-pregnancy Nutrition & Evaluation

There may be a misconception among some women with CF, their families and even among some
healthcare providers that women with CF are not able to get pregnant or successfully sustain a
pregnancy. There is some conicting data in the literature. Some studies show decreased fertility
compared to the general population [8] and other studies show that there is no difference [9]. However,
pregnancy has been seen in women with CF who have very low lung function and even post-transplant
[2]. Ideally, the pregnancy is planned, which helps to optimize the woman medically, nutritionally,
and mentally for this challenging time [7, 10].
The counseling and support that the medical team, including a CF dietitian, provides to the woman
considering pregnancy is extremely important [7, 10]. It is imperative that the clinician has the most
up-to-date and accurate information that is shared in a hopeful, non-judgmental but realistic way [11].
A womans decisions about her own pregnancy should be supported, regardless of personal feelings,
so that a great team and patient relationship can continue [7]. Nutrition topics to address should
include nutrition intake, expected weight gain, safety of medications in pregnancy, social support,
nancial considerations, breastfeeding, and caring for a child while ensuring the womans health is
also being managed [7]. There may be value in connecting a woman considering pregnancy to other
women with CF (via email, social media, or phone) who have had successful pregnancies to offer
support and answer questions.
As with any pregnancy, rate of weight gain and total weight gained during a pregnancy are clinically
very important measures to follow for both the health of the mother and baby [12, 13]. A British study
did show that weight below the 10th percentile placed women at risk for infertility, preterm birth, and
increased complications during delivery [13]. There is some evidence to suggest that severe malnutrition,
as measured by a body mass index (BMI) <18 kg/m2, is considered a relative contraindication to
pregnancy given the resulting fetal outcomes [14]. In cystic brosis, the pre-pregnancy nutrition goal,
as with all women with CF, should focus on improving BMI to the current CFF recommendation of
22 mg/kg2.[15]. This can be achieved by optimizing oral intake of calories and with the use of oral
supplements and/or gastrostomy tube (GT) feeds [7, 16]. Other suggestions for nutrition interventions
to optimize nutrition are discussed in greater detail in this book. Infant outcomes are improved with
better nutritional status of the mother [2, 7, 17]. Maternal health post-partum is directly related to
nutritional status during pregnancy [2, 17]. A survey of mothers with CF in the UK has shown that
those who received nutritional advice before conceiving had a signicantly greater weight gain during
pregnancy and gave birth to signicantly heavier babies [10]. It is also important at this time to establish
baseline vitamin levels as vitamin A can be of concern in pregnancy [18]. This will be discussed in
more detail later in this chapter. Folic acid supplementation is also very important at this time as
discussed later in this chapter. Finally, establishing baseline glycemic status in a woman considering
pregnancy is very important as there may be undiagnosed hyperglycemia [19].
Pregnancy Tracking and Clinic Visits

It is important that each individual CF care center (both adult and pediatric) develop a protocol and
guidelines for pregnancy, or at the very least have a discussion together about this issue, with the hope
of standardizing treatment and optimizing patient care. It is recommended that the dietitian assess and
15 Pregnancy, Nutrition, and Cystic Fibrosis
221
counsel women at regular clinic visits throughout pregnancy. Nutrition assessments should occur at
least once a trimester, more often with complicated cases [7, 10]. During these visits, anthropometric
information such as height, weight history, and weight gain during pregnancy should be monitored
[7]. Furthermore, it is essential to record a dietary history, patients use of nutritional supplements and
vitamin/mineral preparations as well as associated symptoms such as nausea/vomiting. A pregnancy
owchart is a useful tool to track nutrition throughout the pregnancy. See example in Fig. 15.1.
Other Medication and Tests

In the planning stages of pregnancy, it is very important to review medications with a physician and
pharmacist, to ensure they are safe in pregnancy [7]. Not all medications used in CF have been tested
for safety during pregnancy. Each drug is classied into one of four categories in pregnancy [18, 20]:
A. Drugs that have been used widely during pregnancy and are assumed safe for the fetus
B. Drugs not known to cause harm to the human fetus but with insufcient experience to consider
them safe.
C. Drugs that could theoretically cause harm to the fetus by their pharmacological actions
D. Drugs known or believed to cause harm to the fetus. Pregnancy category C medications include
pancrelipase (use caution but not considered to cause a risk to the pregnancy), albuterol (but
unknown whether harm can be caused), vitamin K (use caution).
Enzymes in Pregnancy
Women who are pancreatic insufcient must continue to use pancreatic replacement therapy (PERT)
as directed during their pregnancy. The dose may not need to be adjusted with pregnancy but should
be assessed at each visit or with symptoms of malabsorption. When examining PERT and pregnancy,
there has been a concern addressed over the use of phthalates as an ingredient in the digestive enzymes
themselves. Phthalates are used as a plasticizer in enteric-coatings of solid oral drug products to
maintain exibility, but can be used for different functions in other drugs [21, 22]. Phthalates are used
in pancreatic enzymes as an enteric coating to protect the enzyme from the acid environment of the
stomach. Animal research is available describing the impact of phthalates. Some phthalates
demonstrate no toxicity, while others demonstrate problems related to developmental and reproductive
toxins in laboratory animals [21]. In December 2012 the Food and Drug Administration (FDA)
distributed Guidance for Industry: Limiting the use of certain phthalates as excipients in Center for
Drug Evaluation and Research (CDER) regulated products. The recommendation stated that although
there is limited human data the FDA has determined that there is evidence that the exposure to dibutyl
phthalate (DBP) and di (2-ethylhexyl) phthalate (DEHP) from pharmaceuticals presents a potential
risk of developmental and reproductive toxicity. The FDA recommended that the pharmaceutical
industry avoid the use of DBP and DEHP as excipients in CDER-regulated drug and biologic products.
Prior to the guidance many pancreatic enzymes used DBP or DEHP as the enteric coating; they are no
longer in pancreatic enzymes [22].
The FDA concluded that hypromellose phthalate (HPMCP) could be included in their unofcial
listing of items Generally Recognized as Safe (GRAS). The FDA is aware of the use of HPMCP in
pancreatic enzymes [22].
Phthalates have been found in the urine of patients taking pancreatic enzymes as rst discovered
by Keller et al. in 2009 [23]. As a result of the Keller et al.s paper, there was a great concern in the
222
M. Brotherwood
Fig. 15.1 Adult Cystic Fibrosis Program Nutrition Evaluation. Used with permission from Adult CF clinic at St.
Michaels Hospital in Toronto, Canada
223
CF community and the FDA was approached to provide guidance on the use of phthalates in enzymes.
As a result DBP and DEHP were removed from enzymes and replaced with HPMCP. The risk of
malnutrition for someone who has CF resulting from avoiding enzymes is real; therefore, the CFF
recommends that patients who require enzymes as part of their CF care should continue taking the
medication [24].
A body of data indicates toxicity of DBP and DEHP, especially for the developing fetus; therefore,
healthcare providers question the use of pancreatic enzymes containing phthalates by pregnant
women. Based on the available data there is no indication that the phthalate in currently available
enzyme products produces adverse effects. To date there are no papers describing fetal anomalies in
infants born to women taking pancreatic enzymes. Women who have CF and take enzymes should
continue taking their enzymes, including during pregnancy [25].
In considering the issue of phthalates in digestive enzymes, there are enteric coated enzymes on the
market which do not contain any phthalates [24]. It seems reasonable that if a woman with CF is able
to switch enzymes, without any issues related to malabsorption, a non-phthalate containing enzyme is
a good option given the ongoing need for research in this area.
Weight Gain
Regular monitoring of weight gain is extremely important during pregnancy [7]. Currently, there are
no CF specic guidelines of expected weight gain in pregnancy and therefore the standard pregnancy
weight gain recommendations apply in this patient population based on pre-pregnancy baseline
BMI. See Table 15.1 [26].
The challenge for many women with CF is that they are starting out with a low pre-pregnancy BMI,
therefore any work to optimize weight gain prior to conception is benecial in this often very motivated
group. In the general population, pregnancy increases calorie needs in the second trimester by
350 kcal/day and increases to 450 kcal/day in the third trimester (there is no increased need in the rst
trimester from pregnancy itself) [27]. Nutrition counseling should include creative ways to meet high
calorie needs with a patient centered approach without guilt or judgment. The use of high calorie oral
nutrition supplements can be extremely helpful at this time to meet the high calorie needs and should
be used liberally as tolerated [7, 28]. If the woman has a skin level gastrostomy tube prior to pregnancy,
it is suggested that it is changed to a variable length tube to allow for the abdomen to swell. During
pregnancy increased volume of feeds or the addition of daytime bolus feeds may be benecial to meet
increased calorie needs [7, 28].
More aggressive nutrition intervention may be needed if weight gain is poor and/or if there are
concerns over the growth of the baby [28]. Nasogastric (NG) feeds are an option to supplement oral
intake although for some women this may affect their ability to clear their sputum and exacerbate
reux. This method, in general, to be a well-tolerated and less invasive way to increase calories and
Table 15.1 Recommended weight gain during pregnancy

Pre-pregnancy BMI
<18.5 (underweight)
18.524.9 (normal weight)
2529.9 (overweight)
30 (obese)
Adapted from Institute of Medicine (US) Weight Gain During
DC. National Academies Press; 2009
Recommended range of total weight gain (pounds)

2840
2535
1525
1120
Pregnancy: reexamining the guidelines. Washington,
224
M. Brotherwood
most women are very motivated for a healthy pregnancy and are agreeable to NG feeds. Another
option can be parenteral nutrition (PN), if the woman is admitted to hospital (and already has PN
access). PN does not displace calories from food or supplements and does not have GI side effects,
however it is not without risks. If the woman is eating mixed meals, PN can be given as IV lipids to
provide a concentrated source of calories. This approach has been used at by some CF centers with
success (unpublished data).
GI Issues
The usual gastrointestinal problems of pregnancy, such as reux and constipation, may be particularity
troublesome for women with CF and should be managed aggressively to ensure that there is not an
impact weight gain [7, 16]. It is important to ask women often if they are experiencing these side
effects and offer advice on any nutrition interventions that may help.
Constipation and distal ileal obstruction syndrome (DIOS) are already common in people with CF
and can be made worse by pregnancy and iron supplementation (which is often prescribed in pregnancy)
[28]. Measures should be taken to manage these symptoms as per CF standard of care with PEG 3350
(ex.Miralax) and golytely bowel clear outs as needed [16, 28]. Probiotics from natural food sources are
safe in pregnancy and can help with these symptoms. If probiotics are being considered as a medication,
this should be discussed with the medical team, including the obstetrician, before initiation. Reux, a
common GI symptom in CF, can be exacerbated in pregnancy and affect intake [25, 29].
Medications used to treat reux are generally considered safe in pregnancy [20] and should be
considered. Hyperemesis is a serious medication condition that requires close attention and
management by the medical team [27].
Vitamin and Mineral Supplementation

The combination of CF and pregnancy presents unique challenges and considerations for vitamin and
mineral supplementation. Controversy exists around the recommendation for women to stay on their
CF specic multivitamin during pregnancy. It is very important in pregnancy to have fat soluble
vitamin levels tested, ideally prior to conception to ensure optimal serum levels. Serum fat soluble
vitamin levels should be tested each trimester [7, 16].
Folic Acid
Folic acid is important in the prevention of neural tube birth defects, which affect the brain and spinal
cord of the fetus. Neural tube defects develop in the rst 28 days after conception, before many
women know they are pregnant. It is recommended that any woman who could get pregnant take 400
micrograms (mcg) of folic acid daily, starting before conception and continuing for the rst 12
weeks of pregnancy. These guidelines are the same in the CF population [7, 12, 30]. Commercially
available CF specic multivitamins, developed specically for this population, contain folic acid
ranging between 200 and 400 mcg (2 soft gels). The amount of folic acid in CF specic multivitamins
alone may not meet needs, additional supplementation may be necessary. Folic acid is available as a
single supplement and does not need to come as part of a prenatal multivitamin. Many foods are rich
225
in folic acid including green leafy vegetables, nuts, beans, citrus fruits, and many fortied foods.
However folic acid intake from food may not be adequate, given the risk to the fetus, it is advisable
to take a supplement with the 400 mcg of folic acid to help prevent neural tube defects [12, 30].
Vitamin E
The role and importance of vitamin E in pregnancy is not well described in the literature. Serum levels
should be monitored and additional supplementation prescribed to reach therapeutic levels [7, 28].
Vitamin K
Vitamin K deciency can lead to increased risk of bleeding which may negatively impact a pregnancy.
If possible, a serum level measuring prothrombin induced by vitamin K absence-II (PIVKA II) should
be measured to assess vitamin K status [28]. If this is not possible, measure of blood coagulation using
prothrombin time (PT) or international normalized ration (INR) can be used. Vitamin K should be
supplemented as per CF care guidelines during pregnancy [7, 28].
Vitamin D
Vitamin D is extremely important both in CF and pregnancy and CF. Serum vitamin D levels should
be monitored closely to reach a level of >30 ng/mL (> 75nmol/L) prior to and during pregnancy [7,
12, 31]. A vitamin D deciency during pregnancy can cause growth retardation and skeletal
deformities and may also have an impact on birth weight [12]. A deciency of vitamin D has also
been linked to a greater risk of pregnancy complications, including preeclampsia, and a higher
likelihood of a delivery via cesarean section [12, 39]. For most women with CF, additional Vitamin
D3 supplementation is needed in addition to what is found in their CF specic multivitamins [28,
31]. While there are no consensus guidelines on the upper limit of safety of Vitamin D supplementation
in pregnancy, 10,000 IU/day of cholecalciferol (Vitamin D3), the upper limit used in non-pregnant
CF patients, is believed to be appropriate. Serum vitamin D levels should be closely monitored each
trimester [28, 31, 39].
Vitamin A
Vitamin A supplementation presents the greatest concern and area for debate when it comes to
pregnancy in CF. Most patients with CF who are pancreatic insufcient require additional
supplementation of vitamin A, from CF specic multivitamins, in order to achieve therapeutic levels
[16, 28]. In pregnancy, Vitamin A is essential for embryogenesis; however, high dietary supplementation
of retinol in the non-CF population has been associated with birth defect [7, 12, 32, 33]. These studies
evaluated the association between the amount of ingested vitamin A and birth defects. Serum vitamin
A levels were not monitored in these studies but the assumption is that high vitamin A intake would
result in high serum levels [32, 33]. The World Health Organization guidelines indicate an increased
risk with >10,000 IU retinol per day [18]. As a result, this level of vitamin A intake has become the
226
M. Brotherwood
consensus guideline recommendation for upper limit of safety in pregnancy [32, 33]. It is also important
to remember that low vitamin A levels can also be harmful to a babys growth and development [12].
The recommended adult dose of currently available CF specic multivitamins (2 soft gels) contain
between 28,000 and 36,344 IU of Vitamin A (retinal and beta carotene) [34], although most have
8892% of Vitamin A as beta carotene [20]. Unlike preformed vitamin A, beta carotene is not known
to be teratogenic or lead to reproductive toxicity. Even large supplemental doses (2030 mg/day) of
beta carotene or diets with high levels of carotenoid-rich food for long periods are not associated with
toxicity and therefore is felt to be safer in pregnancy [32]. A study by Stephenson et al. showed that
pregnant women on CF specic multivitamins maintained serum levels of vitamin A within normal
limits and no birth defects were noted.
If CF specic multivitamins are discontinued because of concerns of high vitamin A intake, it is
extremely important to monitor serum levels pre-pregnancy and during each trimester to avoid fat
soluble vitamin deciency. It is suggested that this decision should be made together with the obstetrics
and CF care center and blood work results shared and communicated to the patient.
Calcium
Calcium is also an important micronutrient for a pregnant woman [12, 27]. It can help prevent loss of
bone density, which can already be low with CF, as the baby uses calcium for its own bone growth. A
brief diet history on calcium intake during pregnancy is recommended to ensure that intake is adequate
[16]. At this time, the recommendation remains >1500 mg/day of calcium intake/day and should be
supplemented if dietary intake is inadequate [12, 27, 28].
Iron
Iron requirements go up signicantly during pregnancy, primarily because of the increased blood
volume [12]. A full iron panel including ferritin should be drawn prior to and during pregnancy and
microcytic anemia corrected with supplementation. Be aware of the gastrointestinal side effects of
iron supplementation which can affect intake and contribute to constipation [12].
CFRD and Gestational Diabetes

Both pre-existing CFRD and gestational diabetes are important considerations in pregnancy. Women
with CF who become pregnant are at increased risk of gestational diabetes which can affect the health
of the baby [2, 7, 19]. Women with CFRD who become pregnant need to optimize their blood glucose
control. Blood glucose levels can be affected by hormones, gastrointestinal issues, and stress [19].
Hyperglycemia can affect the developing fetus throughout the pregnancy. In early pregnancy, a
mothers diabetes can result in birth defects and an increased rate of miscarriage. Many of the birth
defects that occur affect major organs such as the brain and heart. During the second and third
trimester, ongoing hyperglycemia can lead to over-nutrition and excess growth of the baby and may
affect the infants risk of developing type 2 diabetes later in life [19, 33, 35]. Also, hypoglycemia can
exacerbate the difculties many women with CF have in achieving a positive protein balance and
sufcient weight gain during pregnancy. In addition, when high blood sugar from the mother causes
high insulin levels (hyperinsulinemia) in the baby, the babys blood sugar can drop very low after
birth, because it is no longer receiving large amounts of glucose from the mother [35].
227
Gestational Diabetes
In pregnancy, insulin secretion is enhanced with normal to decreased insulin sensitivity in the non-CF
population. Any insulin resistance that develops in late pregnancy is compensated for by the increased
secretion. Women with CF have been studied in pregnancy and shown to be unable to match this
increased insulin and hence are at higher risk of gestational diabetes and enhanced protein catabolism
with impaired weight gain [36]. Gestational diabetes occurs in 1433% of pregnancies in CF for those
who have previously had normal glucose tolerance (incidence in non-CF: 37%depending on
ethnicity). The main difference between CF and non-CF women is when gestation diabetes is rst
discovered. With CF, it can be identied as early as 8 weeks gestation and requires insulin (normally
seen by ~2428 weeks in non-CF population [19].
The Cystic Fibrosis Foundation guidelines recommend an oral glucose tolerance test (OGTT) if
considering pregnancy to determine baseline glucose status. Once pregnant, it is recommended to
repeat OGTT (if not previously done in the past 6 months). During the pregnancy, it is recommended
to repeat OGTT at the end of both the rst (1216 weeks) and second trimester (2428 weeks) (suggest
1 h & 2 h post prandial values) given how early gestation diabetes is shown to occur in women with
CF [7].
CFRD Prior to Pregnancy

For women who have known CFRD, detailed education about target blood sugars and risk during
pregnancy is important at this time [7, 19, 33, 35]. Target HbA1C prior to conception of <7% is
recommended, although ideally the target in pregnancy is <6.1% [19]. Given that most women are
highly motivated with compliance at this time, you can suggest a 3-month trial of optimizing HbA1C
prior to considering pregnancy may be helpful to see if this goal can be achieved. It is important to
have a referral to an endocrinologist with knowledge in gestational diabetes, even if the patient is
followed at a pediatric hospital [19].
Whether from gestational diabetes or CFRD, optimizing blood sugars during pregnancy is
extremely important and needs to be balanced with the high calorie requirements for weight gain [7,
19, 36]. Maintaining high calorie intake and using rapid/short acting insulin is treatment of choice.
This can be achieved with injections or with the use of an insulin pump. Carbohydrate counting is the
most effective way to control hyperglycemia and maintain a high calorie intake. Foods high in simple
sugars and oral nutrition supplements can still be consumed but should be taken with a meal so that
the total carbohydrate can be added into the insulin to carbohydrate ratio [19]. High calorie but lower
carbohydrate snacks can be recommended between meals to avoid hyperglycemia but maintain
calories such as cheese, nuts, seeds, or meat. It is very important that CF appropriate nutrition
counseling be given, and that the women are counseled not to limit portions and as is common in
gestational diabetes without CF [19].
Blood glucose guidelines are different in pregnancy with blood glucose targets of 60120 mg/dl
(3.36.7 mmol/l) [19, 37]. It is normal to see a rise in insulin requirements as pregnancy proceeds up
to 36 weeks gestation but those needs can decrease rapidly at the end of pregnancy and blood glucose
levels should be monitored. It is recommended that women check their blood sugars before and 2 h
after every meal [19, 37]. Insulin requirements may be disturbed by hyperemesis, delayed gastric
motility, and/or use of steroid therapy. In extreme cases of uncontrolled hyperglycemia [19, 37], inpatient care may be needed.
228
M. Brotherwood
Other Nutrition Considerations

As with any pregnancy, the same nutrition advice applies in CF regarding abstaining from alcohol,
limiting caffeine and sh consumption, food borne illness, and food safety [12]. This advice should
be given in the pre-conception time period if possible and re-enforced with education handouts.
Ideally, none of these changes to a womans dietary intake will signicantly affect her total calorie/fat
intake [7]. If a woman is a vegetarian or vegan, particular attention may need to be made to protein
intake as well as certain vitamins/minerals [12].
Breastfeeding
Breastfeeding remains the optimal choice for infant nutrition but for a variety of reasons this can be a
challenge in CF [12]. Limited literature is available on the composition of breast milk in women with
CF, however, Shiffman et al. concluded that milk secreted by women with CF appears to be
physiologically normal and safe for the infant [38]. It should be noted that during a pulmonary
exacerbation, the concentrations of milk macronutrients were shown to be reduced [12].
For many women with CF, keeping up with their own high calorie needs is very difcult. The extra
calorie requirements (300800 kcal/day) needed to sustain breastfeeding may require additional
nutrition interventions [12]. A number of CF related medications can be passed through breast milk.
Medications used during breastfeeding should be reviewed for safety [7]. It is also important to
consider social supports & nutritional status before/during pregnancy as breastfeeding can be
challenging for a woman who already herself has a complicated burden of treatment [7]. Above all,
patient choice/preference must be considered the most important part of a decision to breastfeed. The
moms decision should be fully supported by the entire team.
Conclusion
The nutrition management of pregnancy in CF presents a number of challenges. Despite a lack of
evidence and guidelines to optimize nutrition management there are many successful outcomes
reported. Careful nutrition assessment and interventions can allow for successful pregnancies.
References
1. Siegel D, Siegel S. Pregnancy and delivery in a patient with cystic brosis of the pancreas. Obstet Gynecol.
1960;16:43940.
2. Gillijam M, Antoniou M, Shin J, et al. Pregnancy in cystic brosis: fetal and maternal outcome. Chest. 2000;118:
8591.
3. Edenborough FP, Stableforth DE, Webb AK, et al. Outcome of pregnancy in women with cystic brosis. Thorax.
1995;50:1704.
4. Burden C, Ion R, Chung Y, et al. Current pregnancy outcomes in women with cystic brosis. Eur J Obstet Gynecol
Reprod Biol. 2012;164(2):1425.
5. degaard I, Stray-Pedersen B, Hallberg K. Maternal and fetal morbidity in pregnancies of Norwegian and Swedish
women with cystic brosis. Acta Obstet Gynecol Scand. 2002;81(8):698705.
6. Schechter, MS, Quittner, AL, Konstan, MW, et al. Long-term Effects of Pregnancy and Motherhood on Disease
Outcomes of Women with Cystic Fibrosis. Ann Am Thorac Soc. 2013;10(3):2139.
229
7. Edenborough FP, Borgo G, Knoop C, et al. Guidelines for the management of pregnancy in cystic brosis. J Cyst
Fibros. 2008;7(1):S232.
8. Schram CA, Stephenson AL, Hannam TG, et al. Cystic Fibrosis (cf) and ovarian reserve: a cross-sectional study
examining serum anti-mullerian hormone (AMH) in young women. J Cyst Fibros. 2014; pii: S1569-1993(14)00219-7
[Epub ahead of print].
9. Ahmad A, Ahmed A, Patrizio P, et al. Cystic brosis and fertility. Curr Opin Obstet Gynecol. 2013;25(3):16772.
10. Morton A, Wolfe S, Conway SP. Dietetic intervention in pregnancy in women with CFthe importance of
pre-conceptional counselling. Israel J Med Sci. 1996;32:S271.
11. McArdle JR. Pregnancy in cystic brosis. Clin Chest Med. 2011;32(1):11120.
12. Berzy D, Mehta A, Carlson S, et al. Pregnancy. Manual of clinical dietetics. Chicago: American Dietetic Association;
2000.
13. Boyd JM, Mehta A, Murphy DJ. Fertility and pregnancy outcomes in men and women with cystic brosis in the
United Kingdom. Hum Reprod. 2004;19:223843.
14. Lau EM, Moriarty C, Ogle R, et al. Pregnancy and cystic brosis. Pediatr Respir Rev. 2010;11:904.
15. Stallings VA, Stark LF, Robinson KA, Feranchak AP, Quinton H. Evidence-based practice recommendations for
16. Cystic Fibrosis Trust Nutrition Working Group. Nutritional management of cystic brosis. London: Cystic Fibrosis
Trust; 2002.
17. Kent NE, Farquharson DF. Cystic brosis in pregnancy. CMAJ. 1993;149:80913.
18. World Health Organization. Vitamin A dosage during pregnancy and lactation. Recommendations and report of a
consultation; 1998. Document NUT/98.4.
19. Moran A, Brunzell C, Cohen RC, et al. Clinical care guidelines for cystic brosis-related diabetes: a position
statement of the American Diabetes Association and a clinical practice guideline of the Cystic Fibrosis Foundation,
endorsed by the Pediatric Endocrine Society. Diabetes Care. 2010;33(12):2697708.
20. Lexicomp Online, Pediatric & Neonatal Lexi-Drugs, Hudson, OH: Lexi-Comp, Inc.; 29 January 2015. http://
webstore.lexi.com/s.nl/ctype.KB/it.I/id.342/KB.3234/.f.
21. Enright BP, McIntyre BS, Thackaberry EA, et al. Assessment of hydroxypropyl methylcellulose, propylene glycol,
polysorbate 80, and hydroxypropyl--cyclodextrin for use in developmental and reproductive toxicology studies.
Birth Defects Res B Dev Reprod Toxicol. 2010;89(6):50416.
22. Food and Drug Administration. Guidelines for industry; limiting the use of certain phthalates as excipients in
CDER-regulated products. December 2010.
23. Keller BO, Davidson AG, Innis SM. Phthalate metabolites in urine of CF patients are associated with use of entericcoated pancreatic enzymes. Environ Toxicol Pharmacol. 2009;27(3):4247. doi:10.1016/j.etap.2008.12.005. Epub
2009 Jan 14.
24. Cystic Fibrosis Foundation. Phthalates and pancreatic enzymes (position statement). March 2012 (website
publication).
25. Suzanne H. Michel, MPH, RD, LDN. Excerpt on phthalates and pregnancy for women with cystic brosis.
(unpublished work, used with permission) 2014.
26. Weight gain during pregnancy. Committee Opinion No. 548. American College of Obstetricians and Gynecologists.
Obstet Gynecol. 2013;121:2102.
27. Hark L, Catalano PM. Nutritional management during pregnancy. Obstetrics: normal and problem pregnancies. 6th
ed. Philadelphia, PA: Saunders Elsevier; 2012 (Chapter 7).
28. Pencharz PB, Durie PR. Nutritional management of cystic brosis. Annu Rev Nutr. 1993;13:11136.
29. Borowitz D, Gelfond D. Intestinal complications of cystic brosis. Curr Opin Pulm Med. 2013;19(6):67680.
doi:10.1097/MCP.0b013e3283659ef2.
30. Lassi ZS, Salam RA, Haider BA, et al. Folic acid supplementation during pregnancy for maternal health and
pregnancy outcomes. Cochrane Database Syst Rev. 2013;3:CD006896.
31. Tangpricha V, Kelly A, Stephenson A, et al. An update on the screening, diagnosis, management, and treatment of
vitamin D deciency in individuals with cystic brosis: evidence-based recommendations from the Cystic Fibrosis
Foundation. J Clin Endocrinol Metab. 2012;97(4):108293.
32. Johnson EJ, Russell RM. Beta-carotene. In: Coates PM, Betz JM, Blackman MR, et al., editors. Encyclopedia of
dietary supplements. 2nd ed. London and New York: Informa Healthcare; 2010. p. 11520.
33. Werler MM, Lammer EJ, Mitchell AA. Teratogenicity of high Vitamin A intake. N Engl J Med. 1996;334:11957.
author reply 1197.
34. http://www.yasoo.com/products/aquadeks/
35. Suhonen L, Hiilesmaa V, Teramo K. Glycaemic control during early pregnancy and foetal malformations in women
with type I diabetes mellitus. Diabetologia. 2000;43:7982.
230
M. Brotherwood
36. Hardin DS, Rice J, Cohen RC, et al. The metabolic effects of pregnancy in cystic brosis. Obstet Gynaecol.
2005;106:36775.
37. Clinical Practice Guidelines Expert Committee, Canadian Diabetes Association. Clinical Practice Guidelines, 2003.
38. Shiffman ML, Seale TW, Flux M, et al. Breast-milk composition in women with cystic brosis: report of two cases
and a review of the literature. Am J Clin Nutr. 1989;49(4):612.
39. Mahomed K, Gulmezoglu AM. Vitamin D supplementation in pregnancy. Cochrane Database Syst Rev 1999, Issue
1. Art No.: CD000228.
Chapter 16
Nutrition for Pancreatic Sufficient Individuals

with Cystic Fibrosis
John F. Pohl and Catherine M. McDonald
Key Points
Cystic brosis (CF) is typically associated with exocrine pancreatic insufciency (PI)
Although patients with CF and PS typically have milder CF transmembrane conductance regulator
(CFTR) gene mutations, they are still at risk of malnutrition without careful monitoring.
Tests for pancreatic exocrine status, including the fecal elastase-1 (FE-1) immunosorbent assay,
should be used to determine exocrine status as well as to monitor for progression to a PI status.
CF patients with PS are at risk of pancreatitis and testing for this scenario should be considered if
clinically warranted.
Keywords Pancreas Sufciency Elastase Celiac Pancreatitis
Introduction
Cystic brosis (CF) is typically associated with exocrine pancreatic insufciency (PI) and nutritional
care of the CF patient with exocrine pancreatic sufciency (PS) is less well described. Although
patients with CF and PS typically have milder CF transmembrane conductance regulator (CFTR)
gene mutations, they are still at risk of malnutrition without careful monitoring. Tests for pancreatic
exocrine status should be used to determine exocrine status as well as to monitor for progression to a
PI status. Such tests include the fecal elastase-1 (FE-1) immunosorbent assay which is associated with
excellent sensitivity and specicity. Clinicians also should be aware that CF patients with PS are at
risk of pancreatitis and testing for this scenario should be considered if clinically warranted.
According to the 2012 Cystic Fibrosis Foundations Patient Registry Annual Data Report, 87.3% of
people with CF use pancreatic enzyme supplements for pancreatic exocrine insufciency, suggesting
approximately 12.7% of CF patients are pancreatic sufcient (PS) [1]. Other estimates of PS with
cystic brosis range between 11 to 15% [2, 3]. Generally, PS is associated with milder CFTR
J.F. Pohl, M.D. (*) C.M. McDonald, Ph.D., R.D.N.

Division of Pediatric Gastroenterology, Department of Pediatrics, Primary Childrens Hospital,
University of Utah, Salt Lake City, UT 84112, USA
231
232
J.F. Pohl and C.M. McDonald
phenotypes and better nutritional status [47]. However, persons with CF PS are not exempt from
gastrointestinal and/or nutritional problems. Pancreatic status is not a predictor of mortality after
adjusting for CFTR genotype, lung function, and BMI [47]
Nutrition Goals
Regardless of pancreatic status, the primary goal for any infant, children, or adolescent with CF is to
attain and maintain normal growth for age [68]. Infants should achieve weight-for-age and lengthfor-age percentiles similar to the non-CF population by 2 years [8]. A body mass index (BMI) of at
least 50 percentile is recommended for children and adolescents with CF [8, 9]. Among CF children
aged 510 years, a positive correlation is noted between BMI and PS [4].
All adults with CF should maintain an absolute BMI greater than 20 kg/m2 (preferably 22 kg/m2
for females and 23 kg/m2 for males [9, 10]).
Assessment of Nutritional Status

A thorough nutritional assessment, regardless of exocrine pancreas status, is recommended for all CF
patients, and a registered dietitian/nutritionist with expertise in CF nutrition care is imperative in the
care of these patients [812]. The Cystic Fibrosis Foundation recommends that a nutritional assessment
occurs at least annually in the outpatient setting [8, 9]. In children, length/height, weight, and BMI
should be determined using Center for Disease Control growth charts [13]. Growth monitoring for PS
children and weight/BMI monitoring for PS adults should be conducted according to Cystic Fibrosis
Foundation recommendations for clinical care [11]. Other nutritional parameters, including fatsoluble vitamin and micronutrient status, should be monitored and maintained within normal limits
for age [10]. Whether PS or PI, the goal of nutritional treatment for infants, children, and adolescents
with CF is to maintain normal growth for age [8, 9]. Maintaining appropriate BMI in pediatric CF
patients is associated with better forced expiratory volume in 1 s (FEV1), so utilization of newborn CF
screening and serial determinations of BMI over time is necessary [14, 15].
The Cystic Fibrosis Foundation evidence-based guidelines for management of infants with CF do
not differentiate between PS and PI for treatment recommendations for feedings, vitamins, and other
micronutrients [8]. As with any infant, breastfeeding is recommended for infants with CF, regardless
of pancreatic status. If infants with CF are formula fed, standard infant formulas (as opposed to
hydrolyzed protein formulas) should be used [8]. Calorie-dense feedings should be used if weight loss
occurs or inadequate weight gain is observed [8]. The introduction of complementary foods should be
delayed until at least 46 months of age per guidelines of the American Academy of Pediatrics [16].
As children progress toward school-age years as well as adolescence, caloric requirements will
increase again as children become involved with physical activities [17].
Not all adult CF PS patients maintain adequate nutrition. Descriptions of underweight
(BMI < 18.5 kg/m2) range from 3.8 to 6.7% in CF PS adults [6, 7]. However, PS and milder CF
genotypes are associated with an increased propensity for overweight (BMI 2529) and obesity
(BMI 30) than CF PI [6]. Although a positive association exists between pulmonary function and
BMI, the potential benet of overweight or obesity for any person with CF may be offset by the
known risks, such as cardiovascular disease and metabolic syndrome [6, 11].
CF PS patients may be at the same risk of hyperlipidemia as the general population [12]. Although
overweight and obesity are more common in CF PS patients, hypertriglyceridemia is associated with
elevated BMI in CF regardless of pancreatic status [18]. The Cystic Fibrosis Foundation currently
does not have specic recommendations for lipid monitoring for CF PS patients other than those for
the general pediatric and adult populations [12, 19].
16
Nutrition for Pancreatic Sufcient Individuals with Cystic Fibrosis
233
Individualized medical nutrition therapy should address each patients specic needs. Persons with CF
PS may have lower energy requirements compared with those with more severe genotypes [6]. High-calorie,
high-fat diets may not be appropriate for CF PS children and adults [6]. Further studies are needed to
delineate more specic nutrition requirements for those patients with PS and milder expressions of CF.
Vitamin and Mineral Status

The CF patient with pancreatic sufciency (PS) should be able to maintain normal fat-soluble vitamin
levels (vitamins A, D, E, and K) due to preservation of exocrine pancreatic function, and it is less
common for fat-soluble vitamin deciencies to occur in this specic population [20]. Regardless,
fat-soluble vitamin levels should be obtained annually in all CF patients. Vitamin A is typically measured
as a serum retinol level, and low levels of this vitamin can lead to night blindness [21, 22]. Vitamin D
is measured in its hepatic-derived form known as 25-hydroxyvitamin D or calcifediol, and normal
levels of this vitamin are needed for osteoporosis prevention and reduction of CF respiratory
exacerbations [2325]. Vitamin D is synthesized by exposure to sunlight, is affected by northern
latitude climates where there is decreased ultraviolet B radiation, and is associated with lower levels
during the winter season of these geographic locations [26]. Vitamin E (alpha tocopherol) is measured
often through high-performance liquid chromatography and can be associated with neuropathy at low
levels although neuropathy is rarely observed in CF patients [27]. Prothrombin time and partial
thromboplastin time are used as indicators of vitamin K status although testing, including measuring
plasma proteins induced by vitamin K absence factor II and percentage of serum undercarboxylated
osteocalcin can be used to directly measure vitamin K in experimental settings [20, 28].
In a similar manner, CF patients with PS should not have any water-soluble vitamin or mineral
deciencies. Iron, zinc, and copper deciencies have been described in CF patients, but such studies
have not delineated associated exocrine pancreas status [29]. Iron deciency occurs in CF and can be
associated with worsening lung disease, including Pseudomonas aeruginosa infections although
healthy CF children also can have iron deciency [30]. In particular, P. aeruginosa can acquire iron
from its hosts hemoglobin [31]. Serum ferritin is an acute-phase reactant and can be elevated in CF
patients with associated inammation, such as in the setting of a pulmonary exacerbation [30]. Salt
supplementation also may be needed in both PS and PI CF infants to prevent failure to thrive [32].
Calcium supplementation should be given concurrently with vitamin D use in order to facilitate
calcium absorption. It is unknown if there is a maximum dosing of vitamin D that enhances calcium
absorption in CF patients although high dosing for Vitamin D dosing is recommended [33]. Magnesium
deciency has been reported in CF pediatric patients, and hypomagnesemia can be associated with
decreased respiratory muscle strength although specic deciency is not commonly reported in the
CF population [34]. Folic acid, copper, thiamine (vitamin B1), riboavin (vitamin B2), pyridoxine
(vitamin B6), and cobalamin (vitamin B12) can be associated with neuropathy; however, it is unclear
if neuropathy in the setting of CF is due to these specic deciencies [27].
In particular, CF patients with a history of ileum resection (as in a meconium ileus presentation)
can have impaired absorption of vitamin B12. Vitamin B12 from the diet is combined with R protein in
the saliva and intrinsic factor in the stomach. Pancreatic proteases break down R protein to facilitate
binding of Vitamin B12 linked intrinsic factor to its receptor in the terminal ileum. In the setting of CF,
pancreatic insufciency (PI) can affect vitamin B12 absorption which is further complicated in any CF
patient with ileal resection [35]. Of note, high vitamin B12 levels from excessive vitamin B12 intake
have been associated with a decline in forced expiratory volume at 1 s (FEV1) in pediatric CF patients,
but the cause of this nding is unknown and it is unclear if CF patients with PS have this same
outcome as those patients who have PI [36].
234
Table 16.1 Testing methods of exocrine pancreatic insufciency [38]

Stool smear
72-h fecal fat
collection
Steatocrit
Stool trypsin or
chymotrypsin
measurement
Breath testing
Test is not recommended. False positives can occur with petroleum lubricants
Fecal fat output greater than 7% is considered positive. Test is time consuming. Constipation
can cause false negatives. Stool must be collected in container and not in toilet
Crude technique for determining fat malabsorption in stool by centrifuging in hematocrit
tubing. Test is not recommended
Enzymes are degraded easily in stool, so false negatives are possible. Test is not recommended
This test is typically done by hydrogen breath testing. Test is difcult for young children to
do. False positives occur in bacterial overgrowth or intestinal dysmotility
Duodenal pancreatic This test is accurate but very invasive. Intravenous secretin or cholecystokinin can increase
enzyme
sample yield. Low pH can decrease pancreatic enzyme levels due to degradation
collection
Fecal pancreatic
This test has excellent sensitivity and specicity. Only a small amount of stool is needed. FE-1
elastase-1 testing
levels can be decreased in diarrhea or intestinal inammation. Other causes of pancreatic
exocrine insufciency can demonstrate a low FE-1 level (i.e., ShwachmanDiamond
Syndrome)
Assessing Pancreatic Status

Most CF children are tested for PI at the same time they are diagnosed with CF, and standard testing
for CF includes sweat testing, DNA screening, or newborn screening through immunoreactive
trypsinogen. PI is diagnosed in the majority of CF patients [37]. PS patients should be tested for
exocrine PI if there is evidence of pancreatic dysfunction such as diarrhea due to malabsorption,
steatorrhea, abdominal pain, or weight loss. Several tests of variable sensitivity and specicity exist to
diagnose PI including the stool smear utilizing the Sudan stain, the 72-h stool collection to determine
fractional excretion of fecal fat, steatocrit, measurement of trypsin and chymotrypsin, breath testing, and
duodenal intubation to obtain pancreatic enzymes after intravenous administration of secretin or
cholecystokinin (Table 16.1). Duodenal intubation to obtain pancreatic enzymes is considered the most
accurate test, although it is invasive and difcult to perform. On the other hand, fecal elastase-1 (FE-1)
is an easy test to perform with associated excellent sensitivity and specicity. FE-1 is excreted from the
pancreas and into the stool and has the advantage of not being affected by bacterial degradation or use
of pancreatic enzyme replacement therapy [38]. FE-1 is measured using a human monoclonal enzymelinked immunosorbent assay and has no special storage requirements. FE-1 measurements are
signicantly lower in PI patients compared to PS patients and can help delineate exocrine pancreatic
status [2]. Currently, measurement of FE-1 is considered standard of care to diagnose pancreatic
exocrine status and is recommended as annual testing in all CF PS patients [39].
It should be noted that other diseases associated with exocrine PI can be associated with a low FE-1
measurement, including ShwachmanDiamond Syndrome [40]. Low FE-1 levels are also associated
with intestinal resection as in short bowel syndrome, intestinal inammation, and many gastrointestinal
diseases associated with diarrhea. False-positive FE-1 testing in these clinical scenarios occur as a result
of diarrhea symptoms [41, 42]. Celiac disease also has been associated with a low FE-1. The cause of
low FE-1 in celiac disease is likely multi-factorial including diarrhea associated with celiac disease,
villous atrophy leading to decreased pancreatic enzyme production, and elevated peptide YY associated
with celiac disease leading to decreased pancreatic enzyme production. It is unknown if pancreatic
enzyme replacement therapy is helpful in such patients with celiac disease [43]. However, FE-1 typically
returns to normal levels after intestinal mucosa regeneration occurs on a gluten-free diet [44].
16
235
Table 16.2 Nutritional parameters to be followed in CF patients [54]

Growth parameters (length/height, weight, BMI)
Fecal elastase (to be checked annually in the PS patient)
Vitamin A (measure serum retinol)
Vitamin D (measure 25-hydroxy vitamin D or calcifediol)
Vitamin E
Vitamin K (measure prothrombin time and partial thromboplastin time)
Vitamin B12 (if history of surgery to terminal ileum, measure serum methylmalonic acid)
Serum electrolytes, especially serum sodium
Calcium
Zinc
Iron (consider serum iron, iron binding capacity, transferrin saturation, ferritin). Remember that ferritin is an acute-phase
reactant in the setting of acute inammation
Glucose (oral glucose tolerance test if concern for cystic brosis-related diabetes)
Essential fatty acid screen
Annual Assessment
CF patients with PS need to have exocrine pancreatic status and nutritional parameters followed
carefully (Table 16.2). Most CF patients with PS will progress to PI in the rst 2 years of life although
a decline in pancreatic exocrine function can occur more gradually [45, 46]. It is recommended that
CF patients with PS undergo annual FE-1 testing as part of their annual CF laboratory testing [47].
If a CF patient converts to PI, pancreatic enzyme replacement therapy with the addition of gastric acid
suppression therapy (H2 receptor antagonist or proton pump inhibitor) should be considered per
established guidelines as outlined by the Cystic Fibrosis Foundation [48]. Although uncommon in the
setting of CF, other causes of PI may need to be considered, if clinically warranted (Table 16.3) [38].
Another consideration in the setting of a CF PS who has symptoms of abdominal pain, diarrhea,
malabsorption, and weight loss is the possible diagnosis of celiac disease. Celiac disease can present
with symptoms similar to PI, and testing for celiac disease should occur with any CF PS patient or CF
PI patient who has continued symptoms despite being on pancreatic enzyme replacement therapy
[49]. Clinical studies have demonstrated that the percentage of patients with celiac disease in CF
patient populations ranges from 1.2 to 2.13% which is considered a higher prevalence compared to the
general population [4951]. The diagnosis of celiac disease requires screening blood work, including
the tissue transglutaminase IgA antibody titer followed by esophagogastroduodenoscopy with
duodenal biopsies if serum antibody titers are positive[49]. Typical duodenal biopsies in the setting of
celiac disease will reveal a spectrum of villous atrophy, crypt hyperplasia, and increased intraepithelial
lymphocytes based on the Marsh-Oberhuber classication system [52]. A gluten-free diet, with the
help of a dietitian with experience in both cystic brosis and celiac disease, is critical to provide
dietary education for these diseases. Guidelines for celiac disease diagnosis and management are
readily available from many gastroenterology societies [53, 54].
Pancreatitis in the Setting of Exocrine Pancreatic Sufficiency

CF PS patients are at risk of acute pancreatitis (AP). In particular, CF patients with PS or CF patients
with borderline sweat tests are predisposed to AP [55]. Mutations to the (CFTR) gene lead to
pancreatitis in CF PS patients as well as in some non-CF patients with heterozygous CFTR
mutations. The mechanism of AP development may be due to decreased bicarbonate secretion in the
236
Table 16.3 Causes of pancreatic insufciency in children [38]
Cystic brosis (most common cause of pancreatic insufciency)

ShwachmanDiamond syndrome (second most common cause of pancreatic insufciency)
Chronic pancreatitis (anatomical obstruction, hereditary pancreatitis, etc.)
JohansonBlizzard syndrome
Pearsons bone marrow syndrome
Congenital rubella syndrome
Pancreatic isolated enzyme defects
Pancreas agenesis/hypoplasia
Reproduced with permission from Practical Gastroenterology, Practical Gastroenterology Publishing, Inc.
pancreatic duct in which a subsequent decrease in pH leads to premature activation of trypsin and loss
of tight junction integrity leading to a process of pancreatic autodigestion. Interestingly, patients with
mild CF phenotypes (including CF PS patients) have a greater risk of AP, presumably due to their
retaining of some residual pancreatic duct ow [56]. AP can be seen in CF PS patients, although CF
PI patients can present with AP with similar elevations in serum amylase and lipase if residual
functioning pancreatic tissue is present. Rarely, AP also is an initial presenting symptom of CF [57].
Heterozygote CFTR mutations are a common cause of chronic pancreatitis (CP) and should be
considered in any patient, regardless of CF status, who presents with acute recurrent pancreatitis
(ARP) or CP. Additionally, CFTR mutations can potentially interact with other genetic causes of ARP
or CP, such as mutations of SPINK1, PRSS1, and CTRC, which can further exacerbate pancreatitis
symptoms [58].
In summary, CF PS patients should follow the same nutritional guidelines set out for CF PI patients.
Pancreatic exocrine function can decline over time and careful monitoring for this scenario is needed
to avoid nutritional complications arising from untreated evolving PI. Annual testing for exocrine
pancreatic function with a FE-1 stool assay is recommended. CF PS patients should also be monitored
for development of acute pancreatitis.
Conclusion
Although CF patients with PS are not common, it should be understood that such patients are at risk
of developing PI over time. Subsequently, these patients need careful monitoring of their nutritional
status as well as making sure they are not developing exocrine PI. Testing for PI, such as measuring
FE-1, should be considered for any CF PS patient who is losing weight or showing signs of
malabsorption. CF PS patients are at risk of acute pancreatitis (AP) and chronic pancreatitis (CP), and
any CF PS patient who presents with signicant abdominal pain should have a serum amylase, serum
lipase, and appropriate imaging (such as an abdominal ultrasound) obtained.
References
1. Cystic Fibrosis Foundation Patient Registry. 2012 annual data report. Bethesda, MD: Cystic Fibrosis Foundation;
2013.
2. Borowitz D, Baker SS, Duffy L, Baker RD, Fitzpatrick L, Gyam J, et al. Use of fecal elastase-1 to identify
misclassication of pancreatic functional status in patients with cystic brosis. J Pediatr. 2004;145:3226.
3. Couper RTL, Corey M, Moore DJ, Fisher LG, Forstner GG, Drurie PR. Decline of exocrine pancreatic function in
patients with pancreatic sufciency. Pediatr Res. 1992;32:17982.
16
237
4. Bradley GM, Blackburn SM, Watson CP, Doshi VK, Cutting GR. Genetic modiers of nutritional status in cystic
brosis. Am J Clin Nutr. 2012;96:1299308.
5. McKone EF, Goss CH, Aitken ML. CFTR genotype as a predictor of prognosis in cystic brosis. Chest.
2006;130:14417.
6. Stephenson AL, Mannik LA, Walsh S, Brotherwood M, Robert R, Darling PB, et al. Longitudinal trends in
nutritional status and the relation between lung function and BMI in cystic brosis: a population-based cohort study.
Am J Clin Nutr. 2013;97:8727.
7. Dray X, Kanaan R, Bienvenu T, Desmazes-Dufeu N, Dusser D, Marteau P, et al. Malnutrition in adults with cystic
brosis. Eur J Clin Nutr. 2005;59:1524.
8. Borowitz D, Robinson KA, Rosenfeld M, Davis SD, Sabadosa KA, Spear SL, et al. Cystic brosis foundation
evidence-based guidelines for management of infants with cystic brosis. J Pediatr. 2009;155:S7393.
9. Borowitz D, Baker RD, Stallings V. Consensus on nutrition for pediatric patients with cystic brosis. J Pediatr
Gastroenterol Nutr. 2002;35:24659.
10. Smyth AR, Bell SC, Bojcin S, Bryon M, Duff A, Flume P, et al. European cystic brosis society standards of care:
best practice guidelines. J Cyst Fibros. 2014;13:S2342.
Nutrition Subcommittee, Ad Hoc Working Group. Evidence-based practice recommendations for nutrition-related
management of children and adults with cystic brosis and pancreatic insufciency: results of a systematic review.
J Am Diet Assoc. 2008;108:8329.
12. Yankaskas JR, Marshall BC, Suan B, Simon R, Rodman D. Cystic brosis adult care consensus conference report.
Chest. 2004;125:1S39.
13. Centers for Disease Control Growth Charts. Available at http://www.cdc.gov/growthcharts/. Last Accessed 24 Nov
2014.
14. Martin B, Schechter M, Jaffe A, Cooper P, Bell S, Rangananthan S. Comparison of the US and Australian cystic
brosis registries: the impact of newborn screening. Pediatrics. 2012;129(2):e34855.
15. Peterson M, Jacobs D, Milla C. Longitudinal changes in growth parameters are correlated with changes in pulmonary
function in children with cystic brosis. Pediatrics. 2003;112(3 Pt 1):58892.
16. Grimshaw KEC, Maskell J, Oliver EM, Morris ECG, Foote KD, Mills C, et al. Introduction of complementary
foods and the relationship to food allergy. Pediatrics. 2013;132:e152938.
17. Karlberg J, Kjellmer I, Kristiansson B. Linear growth in children with cystic brosis. I. birth to 8 years of age. Acta
Paediatr Scand. 1991;80(5):50814.
18. Ishimo M-C, Belson L, Ziai S, Levy E, Berthiaume Y, Coderre L, Rabasa-Llhoret R. Hypertriglyceridemia is
associated with insulin levels in adult cystic brosis patients. J Cyst Fibros. 2013;12:2716.
19. US preventive services task force. Final recommendation statement lipid disorders in adults (cholesterol,
dyslipidemia): screening. Available at http://www.uspreventiveservicestaskforce.org/Page/Document/
RecommendationStatementFinal/lipid-disorders-in-adults-cholesterol-dyslipidemia-screening.Last Accessed
19 Nov 2014.
20. Rana M, Wong-See D, Katz T, Gaskin K, Whitehead B, Jaffe A, et al. Fat-soluble vitamin deciency in children and
adolescents with cystic brosis. J Clin Pathol. 2014;67:6058.
21. Brei C, Simon A, Krawinkel M, Naehrlich L. Individualized vitamin A supplementation for patients with cystic
brosis. Clin Nutr. 2013;32(5):80510.
22. Roddy M, Greally P, Clancy G, Leen G, Feehan S, Elnazir B. Night blindness in a teenager with cystic brosis. Nutr
Clin Pract. 2011;26(6):71821.
23. Sheikh S, Gemma S, Patel A. Factors associated with low bone mineral density in patients with cystic brosis. J Bone
Miner Metab. 2014;33(2):1805.
24. Javier R, Jacquot J. Bone disease in cystic brosis: whats new? Joint Bone Spine. 2011;78(5):44550.
25. Gilbert C, Arum S, Smith C. Vitamin D deciency and chronic lung disease. Can Respir J. 2009;16(3):7580.
26. Rosecrans R, Dohnal J. Seasonal vitamin D changes and the impact on health risk assessment. Clin Biochem.
2014;47(78):6702.
27. Chakrabarty B, Kabra S, Gulati S, Toteja G, Lodha R, Kabra M, et al. Peripheral neuropathy in cystic brosis:
a prevalence study. J Cyst Fibros. 2013;12(6):75460.
28. Bertolaso C, Groleau V, Schall J, Maqbool A, Mascarenhas M, Latham N, et al. Fat-soluble vitamins in cystic brosis
and pancreatic insufciency: efcacy of nutrition intervention. J Pediatr Gastroenterol Nutr. 2014;58(4):4438.
29. Yadav K, Singh M, Angurana S, Attri S, Sharma G, Tageja M, et al. Evaluation of micronutrient prole in North
Indian children with cystic brosis: a casecontrol study. Pediatr Res. 2014;75(6):7626.
30. Uijterschout L, Nuijsink M, Hendriks D, Vos R, Brus F. Iron deciency occurs frequently in children with cystic
brosis. Pediatr Pulmonol. 2014;49(5):45862.
31. Marviq R, Damkiaer S, Khademi S, Markussen T, Molin S, Jelsbak L. Within-host evolution of pseudomonas
aeruginosa reveals adaption toward iron acquisition from hemoglobin. MBio. 2014;5(3):e0096614.
238
32. Coates A, Crofton P, Marshall T. Evaluation of salt supplementation in CF infants. J Cyst Fibros. 2009;
8(6):3825.
33. Ferguson J, Chang A. Vitamin D supplementation for cystic brosis. Cochrane Database Syst Rev. 2014;5:CD007298.
34. Gontijo-Amaral C, Guimaraes E, Camargos P. Oral magnesium supplementation in children with cystic brosis
improves clinical and functional variables: a double-blind, randomized, placebo-controlled crossover trial. Am J
Clin Nutr. 2012;96(1):506.
35. Kotilea K, Quennery S, Decroes V, Hermans D. Successful sublingual cobalamin treatment in a child with short
bowel syndrome. J Pediatr Pharmacol Ther. 2014;19(1):603.
36. Maqbool A, Schall J, Mascarenhas M, Dougherty K, Stallings V. Vitamin B12 status in children with cystic brosis
and pancreatic insufciency. J Pediatr Gastroenterol Nutr. 2014;58(6):7338.
37. Weintraub A, Blau H, Mussaf H, Picard E, Bentur L, Kerem E, et al. Exocrine pancreatic function testing in patients
with cystic brosis and pancreatic sufciency: a correlation study. J Pediatr Gastroenterol Nutr. 2009;48(3):30610.
38. Pohl J, Easley D. Pancreatic insufciency in children. Pract Gastroenterol. 2003;27(10):3848.
39. Luth S, Teyssen S, Forssmann K, Kolbel C, Krummenauer F, Singer M. Fecal elastase-1 determination: gold standard
of indirect pancreatic function tests? Scand J Gastroenterol. 2001;36(10):10926.
40. Gokce M, Tuncer M, Cetin M, Gumruk F. Molecular diagnosis of SchwachmanDiamond syndrome presenting with
pancytopenia at an early age: the rst report from Turkey. Indian J Hematol Blood Transfus. 2013;29(3):1613.
41. Carroccio A, Verghi F, Santini B, Lucidi V, Iacono G, Cavataio F, et al. Diagnostic accuracy of fecal elastase 1 assay
in patients with pancreatic maldigestion or intestinal malabsorption: a collaborative study of the Italian Society of
Pediatric Gastroenterology and Hepatology. Dig Dis Sci. 2001;46(6):133542.
42. Salvatore S, Finazzi S, Barassi A, Verzelletti M, Tosi A, Melzi dEril G, et al. Low fecal elastase: potentially related
to transient small bowel damage resulting from enteric pathogens. J Pediatr Gastroenterol Nutr. 2003;36(3):3926.
43. Evans K, Leeds J, Morley S, Sanders D. Pancreatic insufciency in adult celiac disease: do patients require
long-term enzyme supplementation? Dig Dis Sci. 2010;55(10):29993004.
44. Walkowiak J, Herzig K. Fecal elastase-1 is decreased in villous atrophy regardless of the underlying disease. Eur J
Clin Invest. 2001;31(5):42530.
45. OSullivan BP, Baker D, Leung KG, Reed G, Baker SS, Borowitz D. Evolution of pancreatic function during the
rst year in infants with cystic brosis. J Pediatr. 2013;162:80812.
46. Walkowiak J, Nousia-Arvanitakis S, Agguridaki C, Fotoulaki M, Strzykala K, Balassopoulou A, et al. Longitudinal
follow-up of exocrine pancreatic function in pancreatic sufcient cystic brosis patients using fecal elastase-1 test.
47. Doull I. What and when to collect from infants with cystic brosis. Arch Dis Child. 2007;92(10):8312.
48. http://www.cff.org/UploadedFiles/treatments/CFCareGuidelines/Nutrition/Consensus-Statement-PancreaticEnzyme-Replacement-March-1995.pdf. Last Accessed 19 Nov 2014.
49. Pohl J, Judkins J, Meihls S, Lowichik A, Chateld B, McDonald C. Cystic brosis and celiac disease: both can
occur together. Clin Pediatr. 2011;50(12):11535.
50. Fluge G, Olesen H, Gilljam M, Meyer P, Pressler T, Storroston O, et al. Co-morbidity of cystic brosis and celiac
disease in Scandinavian cystic brosis patients. J Cyst Fibros. 2009;8(3):198202.
51. Walkowiak J, Blask-Osipa A, Lisowska A, Oralewska B, Pogorzelski A, Cichy W, et al. Cystic brosis is a risk
factor for celiac disease. Acta Biochim Pol. 2010;57(1):1158.
52. Dickson B, Streutker C, Chetty R. Coeliac disease: an update for pathologists. J Clin Pathol. 2006;59(10):100816.
53. Institute AGA. AGA Institute medical position statement on the diagnosis and management of celiac disease.
Gastroenterology. 2006;131(6):197780.
54. Hill I, Dirks M, Liptak G, Colletti R, Fasano A, Guadalini S, et al. Guideline for the diagnosis and treatment of
celiac disease in children: recommendations of the North American Society for Pediatric Gastroenterology,
Hepatology and Nutrition. J Pediatr Gastroenterol Nutr. 2005;40:119.
55. Terlizzi V, Tosco A, Tomaiuolo R, Sepe A, Amato N, Casale A, et al. Prediction of acute pancreatitis risk based on
PIP score in children with cystic brosis. J Cyst Fibros. 2014;13(5):57984.
56. Ooi C, Durie P. Cystic brosis transmembrane conductance regulator (CFTR) gene mutations in pancreatitis. J Cyst
Fibros. 2012;11(5):35562.
57. De Boeck K, Weren M, Proesmans M, Kerem E. Pancreatitis among patients with cystic brosis: correlation with
pancreatic status and genotype. Pediatrics. 2005;115(4):e4639.
58. Masson E, Chen J, Audrezet M, Cooper D, Ferec C. A conservative assessment of the major genetic causes of
idiopathic chronic pancreatitis: data from a comprehensive analysis of PRSS1, SPINK1, CTRC and CFTR genes in
253 young French patients. PLoS One. 2013;8(8):e73522.
Chapter 17
Behavioral Interventions and Anticipatory Guidance

Jamie L. Ryan, Stephanie S. Filigno, and Lori J. Stark
Key Points
For more than a decade, the nutritional guidelines set forth by the CF Foundation have
recommended a behavioral assessment of mealtime behaviors in youth with CF to identify
factors associated with nutritional management and to promote optimal growth through early
intervention.
Adherence to nutritional guidelines in CF is poor with fewer than 25% of children reaching the
minimum recommended 120% DRI for energy. Of the factors associated with dietary adherence,
disruptive child mealtime behavior coupled with ineffective parenting strategies are salient
predictors of lower calorie intake and lower weight status.
The Behavioral Pediatrics Feeding Assessment Scale is a psychometrically sound measure of
mealtime behavior that can be completed by parents during a standard nutritional assessment and
used to inform treatment recommendations.
A series of studies have demonstrated the many positive effects of a behavioral plus nutrition
intervention in children with CF, referred to as Be-In-CHARGE, including increased calorie
consumption and weight gain and improved parentchild interactions.
As part of Be-In-CHARGE, parents are taught several child behavioral management strategies
and how to apply them at meals. Examples include how to effectively use parent attention to
encourage increased energy intake and behavioral cooperation, setting specic action-oriented
goals for each meal as a way to gradually increase calories over time, and tracking calories to
monitor intake patterns and provide feedback toward progress with goals.
Providing anticipatory guidance about developmentally normative behavior and mealtime
challenges is important to help parents know what to expect as the child gets older and when more
intensive behavioral intervention may be necessary.
J.L. Ryan, Ph.D.

Division of Behavioral Medicine and Clinical Psychology, Cincinnati Childrens Hospital Medical Center,
Center for Adherence and Self-Management, 3333 Burnet Ave., MLC 7039, Cincinnati, OH 45229-3039, USA
S.S. Filigno, Ph.D. L.J. Stark, Ph.D., A.B.P.P. (*)
Division of Behavioral Medicine and Clinical Psychology, Cincinnati Childrens Hospital Medical Center,
3333 Burnet Ave., MLC 3015, Cincinnati, OH 45229-3039, USA
E.H. Yen, A.R. Leonard (eds.), Nutrition in Cystic Fibrosis, Nutrition and Health,
239
J.L. Ryan et al.
240
Keywords Dietary adherence Behavioral assessment Behavioral intervention Child development

Child behavior management
Abbreviations
BPFAS
CF
CFF
DRI
RCT
RDA
Behavioral Pediatric Feeding Assessment Scale

Cystic brosis
Dietary reference intake
Randomized clinical trial
Recommended dietary allowance
Introduction
The present chapter provides an overview of behavioral strategies and their use in managing the
nutritional needs of children with cystic brosis (CF) and is divided into six major sections. First, the
nutritional recommendations and consensus guidelines developed by the CF Foundation are reviewed.
Second, behavioral factors associated with dietary adherence are discussed. Knowledge of common
barriers to reaching nutrition goals can guide the clinical assessment and be used in conversations
between clinicians and families. Third, the use of behavioral assessment in identifying behavioral
targets for treatment is described. Including a brief face-valid measure of mealtime challenges can
help in determining the need for intervention.
Next, the outcomes of behavioral intervention studies targeting CF nutrition are reviewed. These
positive ndings are the basis for recommendations to integrate behavioral components with nutrition,
including monitoring of energy intake, goal setting, and using child behavioral management strategies
at meals. Fifth, a description of key behavioral strategies and recommendations for intervention to
increase dietary adherence are proposed. Each strategy is described such that clinicians could apply
these skills when working with families to improve nutrition. Finally, developmental issues to consider
when addressing the nutritional needs of children with CF are provided.
Nutritional Recommendations
Advancements in CF treatment have contributed to an increased life expectancy and early nutrition
intervention is one of the key clinical initiatives that has contributed to this outcome [1]. To help
children with CF reach the 50th percentile for growth (weight for length <2 years and body mass
index >2 years), nutritional recommendations include the consumption of 120150% of the
recommended dietary allowance (RDA) of energy for healthy peers [2, 3]. Maintaining a high-calorie,
high-fat diet is essential for normal growth, which in turn is associated with improved clinical
outcomes [46].
For more than 10 years, the CF Foundation has recommended a preventative approach to
nutritional care in CF, including consideration of behavioral, nutritional, and medical components
associated with nutritional management, in order to promote optimal health and quality of life for
children with CF. In addition to providing children with CF recommendations for energy intake,
17
241
Consensus Committees assembled by the CF Foundation have emphasized growth and nutritional
status monitoring and early intervention to optimize normal growth and prevent nutritional failure.
Early consensus-based guidelines focusing on children at risk for or diagnosed with nutritional
failure were informed, in part, by the ndings of observational studies documenting behaviors
incompatible with eating in children with CF from infancy through school-age. Specically,
behavioral assessment of mealtime feeding behaviors was recommended to identify factors
associated with nutritional management and appropriate targets for intervention [3].
Following a series of behavioral intervention studies and a systematic review of the evidence,
updated clinical care guidelines recommended that intensive behavioral intervention be combined
with nutrition education to promote weight gain in children aged 112 years, particularly when growth
decits were present [7]. For children younger than 1 year of age, nutritional guidelines recommended
that CF teams encourage positive eating behaviors early in development through the dissemination of
handouts on anticipatory guidance for managing behavior at meals (available to clinicians on PortCF)
at the 4- and 8-month visit, and at routine visits every 23 months after the age of 2 years [8]. Overall,
a behavioral approach to CF nutrition has been encouraged by the CF Foundation and reinforced in
consensus-based guidelines; this initiative will soon be extended to preschoolers as guidelines specic
to this age range are scheduled to be disseminated in the near future.
Adherence to Nutritional Recommendations

Given the robust association between weight status and lung function [46], adherence to nutritional
recommendations is critical to optimizing growth and survival for children with CF [9, 10]. In this
context, adherence is dened as the extent to which a persons behavior coincides with medical or
health advice [11]. Despite the establishment of consensus-based guidelines for nutritional care in
CF [3], adherence to calorie intake recommendations are poor ranging from 12 to 20% [1214], with
fewer than 25% of children with CF receiving the minimum recommended 120% DRI for energy
[12, 15, 16].
Factors associated with dietary adherence in CF have been examined to identify targets for
intervention. Perhaps the most salient predictor of a familys ability to adhere to nutritional
recommendations in CF is child mealtime behavior and parentchild mealtime interactions.
Specically, mealtime observations and parent-report of disruptive behavior among toddler, preschool,
and school-age children with CF have found behaviors incompatible with eating (e.g., whining,
crying, delaying meals by excessive talking, leaving the table, spitting out food) to be higher when
compared to children without CF [1719]. In an attempt to manage these behaviors and complete the
feeding task, there is an increased use of ineffective parenting practices (e.g., pleading, coaxing,
physically feeding the child, prolonging mealtime) [20]. While some of these approaches are typical
even among parents of children without CF, these strategies are counterproductive to meeting dietary
recommendations and can reinforce difcult child eating behaviors. In general, more disruptive
mealtime behaviors are predictive of lower calorie intake [17, 21] and lower weight status [18]. Even
when parents are successful in reaching nutritional goals during mealtime, opportunities for positive
family interactions may be compromised [22].
A related barrier to dietary adherence is decits in nutritional knowledge specic to CF, such as the
importance of offering snacks, taking enzyme medications before eating, and boosting caloric intake
[12, 23]. While nutrition education is an important rst step in addressing decits in CF-specic
knowledge, it is not sufcient to increase caloric intake [24]. Therefore, behavioral intervention
appears necessary to improve adherence to nutritional recommendations, global family functioning
during mealtimes, and growth outcomes in children with CF.
242
J.L. Ryan et al.
Behavioral Assessment of Feeding Concerns

In line with the Consensus Committees initiative focused on the prevention of nutritional failure in
children with CF [3, 7], early evaluation of adherence barriers including behaviors incompatible with
eating is critical to identifying children at risk for poor intake and growth and thus requiring intensive
intervention. The Behavioral Pediatrics Feeding Assessment Scale (BPFAS) [17] has been
recommended for use in CF clinical care to evaluate behavior at mealtimes [3]. The BPFAS is a
parent-report measure developed for use with children ages 7 months to 7 years [25] and consists of
35 items that assess the frequency of child and parent behaviors and if the behavior is a problem
during meals. Behaviors reported on the BPFAS have been associated with health outcomes, such as
energy intake [17] and weight gain [21] in children with CF. Behavioral concerns endorsed on the
BPFAS have also been linked to clinically important behaviors observed at mealtimes (i.e., meal
length, leaving table, talking, negotiating, coaxing, and feeding child) [26]. This measure does not
require any specic training and can easily be incorporated into standard nutritional assessment.
Direct observation of mealtime interactions (i.e., video-recorded or in-person) is another method for
evaluating child eating behavior and parentchild interactions. While this approach may not always
be feasible in a busy clinic setting, it has the benet of providing an opportunity for the therapist to
model behavioral strategies directly with the child and coaching parents how to use the skills in the
immediate moment.
Behavioral Intervention Outcomes

The CFF consensus recommendations were largely informed by a strong program of research started
after initial studies found that parents described mealtimes as a battle ground [27] and reported
typical parenting strategies to manage child behavior at mealtime were not effective [15, 19].
Subsequent studies applied behavioral theory to develop and test the effectiveness of behavioral
interventions targeting nutrition in CF. Table 17.1 provides an overview of study characteristics and
outcomes of behavioral interventions for children with CF.
In a series of programmatic studies, each with increasing methodological rigor, Stark and colleagues
have examined the effects of a behavioral plus nutrition education intervention (i.e., Be-In-CHARGE)
on dietary adherence among children with CF [2731]. First, in a small sample of ve mildly
malnourished children with CF (512 years old) and their parents [27], a multiple baseline design was
used to examine the effectiveness of the behavioral intervention on increasing caloric intake. The
intervention consisted of six 90-min group sessions. Parents were rst taught how to measure and
record their childs calorie intake to establish their baseline intake and to set and monitor the caloric
goals during intervention. Each intervention session targeted increasing daily calorie intake at one
meal, starting with snack, and proceeding across breakfast, lunch and dinner, thereby gradually
increasing the total daily caloric intake by a predetermined amount by the end of treatment.
In addition to providing nutritional education including examples of nutritious high-calorie foods
and ways to introduce new foods, each session focused on introducing a child behavior management
skill to promote increased calorie consumption. Key components included praise for eating, ignoring
child complaints or disruptive behaviors, using contingency management techniques (e.g., star chart),
implementing a token system for meeting weekly calorie goals, and setting rules for mealtime (e.g.,
limit meals to 20 minutes) [27]. The pretestposttest design indicated a 2543% increase in total daily
caloric intake and signicant improvements in weight and height; both were maintained at the 9-month
follow-up [27]. The multiple baseline design demonstrated that the average caloric intake of a meal
did not change until the meal was targeted, thereby demonstrating that the increase in caloric intake
was due to the intervention and not other factors. A replication study added relaxation training in the
N=3
38 years
N = 10
510 years
N=7
612 years
N = 79
412 years
N = 14
1848 months
N=4
2131 months
Stark et al. (1993)
Stark et al. (1996)
Stark et al. (2003)
Stark et al. (2009)
Powers et al. (2005)
Hourigan et al. (2013)
Adapted
BM+NE
BM+NE (n = 4);
SC (n = 6)
BM+NE
(n = 33);
NE (n = 34)
BM (n = 3);
NE (n = 4)
BM+NE (n = 5);
WLC (n = 4)
BM+NE
Self-monitoring, differential
attention, contingency
management, limit setting
management, limit setting
management, contracting,
goal setting, feedback, limit
setting
management, goal setting,
feedback
management, contracting,
goal setting, feedback, limit
setting
management, goal setting,
relaxation training
Increased caloric intake and weight

gain for two malnourished toddlers
BM+NE: Greater increased daily

caloric intake (842 vs. 131 kcal);
Maintained at 3- and 12-month
follow-up

caloric intake (M, 872 vs. 489) and
weight gain (M, 1.47 vs. 0.92 kg);
No differences at 24 months
BM: Greater increased daily caloric

intake (M, 1036 vs. 408);
Maintained for both conditions at
24-month follow-up (M, 964 vs.
313 calories/day)

caloric intake (M, 1.032 vs. 244)
and weight gain (M, 1.7 vs. 0.0 kg);
Maintained at 6-month follow-up
Increased daily caloric intake (M,

102% of RDA to 148%); Calorie
consumption maintained at
24-month follow-up
Preliminary support for decreased

disruptive behavior
Improved weight (M, 1.4 kg/6 months)

and height (M, 5.1 cm/6 months)
velocities pretreatment to 3-months and
post-treatment to 12-months (M,
2.5 kg/12 months and 8.3 cm/12 months)
BM+NE: Greater increased % of

estimated energy requirement (M, 148 vs.
127%) and BMI z-score (0.38 vs. 0.18);
EER maintained at 24 months
BM: Greater weight gain (M, 1.42 vs.

0.78 kg); No differences at 24-month
follow-up; No group differences in
parentchild interactions or coping
BM+NE: Improved weight z-scores

(1.180.74); Declined weight z-scores
for WLC; No changes in pulmonary
functioning resting energy expenditure,
or activity level pre- to post-treatment
Increased weight gain, height growth, and

body fat; Remained above baseline at 24
months
Secondary outcome
Increased weight gain (M, 2526 kg) and
height; No signicant changes in
pulmonary functioning from pre- to
post-treatment
Sample
N=5
512 years
Study
Stark et al. (1990)
Primary outcome
Increased daily caloric intake (M,
76% of RDA to 116% for three
children; M, 135186% for two
children); Posttreatment RDA
maintained at 9-month follow-up
for 3/5 children
Table 17.1 Overview of behavioral intervention studies in CF nutrition

Behavioral strategies
Self-monitoring,
contingency management,
goal setting, shaping
Intervention(s)
BM+NE
17
243
244
J.L. Ryan et al.
middle of the intervention to help with reported abdominal discomfort associated with eating and
found similar improvements for three young children with CF (38 years old). The 3260% increase
in total calorie consumption was achieved and maintained at the 2-year follow-up and greater than
expected weight gain was observed at follow-up periods for some children [28].
The scientic rigor of the aforementioned case series single subject design studies was enhanced
using a randomized group design in a sample of nine children with CF ranging between 5 and 10 years
of age [29] where the behavioral intervention was compared to a wait-list control. As hypothesized,
children in the behavioral intervention plus nutrition education group evidenced greater calorie intake
(increased daily calories: 1032 vs. 244) and weight gain (1.7 vs. 0 kg) pre- to post-treatment compared
to the wait-list control group [29].
While these studies demonstrate the utility of a combined behavioral and educational approach in
managing the nutritional needs of children with CF, there is evidence suggesting that behavioral
intervention alone may play a valuable role in increasing dietary adherence. For example, behavioral
intervention has been associated with an increase in positive parentchild mealtime interactions (e.g.,
parent attention to positive eating behavior) and a decrease in child disruptive behaviors and parental
attention to child behaviors incompatible with eating [32]. To examine the unique contributions of
behavioral intervention in a sample of seven school-age children with CF (612 years), a subsequent
pilot randomized clinical trial (RCT) was conducted in which families were randomly assigned to
either behavioral intervention or enhanced nutrition education. Both conditions were seen for the
same number of treatment sessions, received the same nutritional information related to calorie
content, calorie goals, and recommendations for goal attainment, but only the behavioral intervention
group was taught child behavior management strategies and given feedback on their childs progress
[30]. While both conditions were effective in increasing caloric intake, children in the behavioral
intervention group demonstrated greater improvements in calorie consumption (average of 1036 vs.
408 cal/day), gained twice as much weight, and were more likely to improve their weight percentile
for their age compared to the enhanced nutrition education group [30]. Average weekly caloric intake
decreased for both conditions at the 2-year follow-up, but remained above baseline and was less
variable for children in the behavioral intervention group.
Following the pilot RCT a multi-site RCT was conducted comparing behavioral intervention plus
nutrition education (n = 33) and nutrition education alone (n = 34) in school-age children with CF [31].
The behavior plus nutrition intervention was more effective than nutrition education alone at increasing
daily calorie intake (872 vs. 489 cal/day) and weight (1.47 vs. 0.92 kg). The two groups were comparable
at 24-month follow-up with children in both treatment groups maintaining the recommended 120%
estimated energy requirement, likely due to the fact that the nutrition education condition included
energy intake monitoring strategies, not typically included in standard care, which allowed for
maintenance of daily intake into follow-up [31]. This nding suggests that incorporating behavioral
components into standard nutrition counseling (e.g., setting caloric goals that gradually increase,
monitoring child caloric intake, and providing tailored dietary recommendations and feedback on
progress toward reaching calorie goals via graphs), even when the parentchild interaction is not a
focus of treatment, may be associated with increased adherence to nutritional recommendations.
The benets of behavioral intervention have also been seen in children with CF as young as 18
months [33]. In an RCT including 10 toddlers, ages 18 months to 4 years, parents of children in the
behavioral plus nutrition education group reported signicantly higher calorie intake pre- to posttreatment (increased daily calories: 842 vs. 131) and were more likely to meet the clinical goal of
120% RDA per day compared to children receiving usual care [33]. Furthermore, more children in the
intervention group reached or exceeded the benchmark for normal weight and height velocity
compared to the control group. Consistent with ndings in older children, treatment effects were
maintained at 12-month follow-up.
Overall, several behavioral strategies (e.g., praise, ignoring, contingency management, and token
systems) have been associated with increased dietary adherence, improved growth status, and
17
245
increases in positive mealtime interactions among children with CF and their parents. A description
of behavioral strategies highlighted in Be-In-CHARGE and how they can be used to manage child
behavior and promote calorie consumption is provided below and summarized in Table 17.2.
Additional information on Be-In-CHARGE can be found in the protocol available online at www.oup.
com/us/pediatricpsych.
Application of Behavioral Strategies to Improve Nutrition

Differential Attention
A basic building block of behavioral child management is differential attention in which desired
behaviors are attended to via praise and undesirable behaviors are ignored. By attending to and
reinforcing appropriate eating behaviors, the goal is to increase the frequency of these behaviors (e.g.,
the child takes more bites or sits cooperatively longer). By simultaneously ignoring or not attending
to inappropriate behaviors, the inappropriate behaviors decrease over time while appropriate behaviors
increase [34]. Differential attention can be particularly challenging for parents of children with CF, as
it is difcult for parents who feel such pressure for their child to gain weight and therefore eat, not to
coax or plead with their child to eat just part of the meal when the child is complaining about the food
or about not being hungry. However, parent attention is a form of reinforcement and when given
following problematic behavior will lead to an increase in these behaviors (e.g., complaints about
food or not being hungry) again in the future to get their parent's attention.
To increase desired eating behaviors, these behaviors must be attended to instead. Parent attention
is reinforcing to children. The most effective reinforcement is verbal praise that positively evaluates
and describes the specic behavior being targeted (e.g., Youre doing a great job eating your
crackers). Behaviors to praise include, but are not limited to, sitting at the table, loading the fork with
food, taking bites, eating quickly, chewing, and swallowing. Praise is most effective when it is genuine,
given immediately after the desired behavior, specic and varied. Some parents may be uncomfortable
praising their childs behavior, particularly for behaviors they are supposed to be doing, or not be
familiar with ways to reinforce the behavior. Providing handouts on different ways to phrase praise
and types of praise (e.g., thumbs up, pat on the back, hug) and practicing during clinic visits can help
families become more comfortable using this important skill at home.
Once parents understand how parent attention can function as reinforcement, ignoring child
behaviors incompatible with eating gets a little easier. For instance, a parent must acknowledge that
scolding their child or even telling their child to eat, while perceived by parents as negative, provides
powerful parent attention and rarely results in the desired outcome, the child eating their meal
cooperatively. Common behaviors to ignore include whining, complaints about the food or being full,
requests to eat less or requests for eat foods that were not prepared, excessive talking that delays
eating, and questions about being ignored [35]. Because ignoring problematic behavior can be
difcult, parents can be recommended to turn their head away from the child, talk to another family
member, or leave the room when the child begins to engage in the behavior. It is likely that strained
mealtime interactions have become a part of the familys daily routine, and the child is accustomed to
a predictable parent response and outcome. Thus it is important to emphasize the need for consistency
in using the behavioral skills and preparing parents that the child may test limits and engage in the
undesirable behavior at increased rates or try additional inappropriate behaviors (e.g., yelling they do
not like a food) when ignoring is rst implemented, can help parents stay focused on the end goal,
which is to out-wait the child until he or she engages in the desirable behavior.
Increase awareness of
consumption and eating behavior;
Identify barriers to calorie goals;
Feedback on treatment progress
Monitor progress; Promote
independence
Selfmonitoring
Limit setting
Decrease behaviors that cannot be

ignored; Increase parental control
Systematic approach to increase

motivation and engagement in
behavior change
Behavioral
contracts
Goal setting
Establish clear expectations for

desired behavior and the positive/
negative consequences
Ignoring: Decrease behavior

incompatible with eating
Purpose
Praising: Increase desired
behavior
Contingency
management
Behavioral
strategy
Differential
attention
Specific: Answers who, what, when, where, and how

Measurable: Can be seen and tracked; Answers how much/many
Attainable: Independent steps; Short-term versus long-term goals
Realistic: Considers capability and willingness
Timely: Set time frame to complete goal and motivate (typically
12 weeks)
Clear rules and consequences; Explain in advance; Keep rules
short and simple; Use of if/when-then statements to describe
positive and negative consequences; Rehearse new rules to check
the childs understanding; Consistently respond to behavior
Diet diary includes type of food, amount prepared and

consumed, method of preparation, enzymes and multivitamins;
Completed daily
Key elements
Praising: Specify desired behavior with positive evaluation;
Provide immediately after behavior; Be enthusiastic; Vary
responses; Behaviors include sitting at the table, loading utensil
with food, taking bites
Ignoring: Remove attention to problem behavior; Address
temporary extinction burst; Behaviors include whining,
complaints about food or being full, requests to eat less or other
foods, excessive talking or questions
Develop system to monitor target behavior; List of possible
rewards; Vouchers or tokens for older children and adolescents;
Provide tangible reward (reinforcer) immediately after desired
behavior; Withhold reward for problem behavior
Written agreement describing: key people and their roles; 12
target behaviors; goal; monitoring method; consequences
(positive/negative); date to re-evaluate terms
Table 17.2 Behavioral strategies and application in CF nutrition
Rule and rationale: You have 20 minutes to eat lunch so

you can get a lot of energy and go do other things.
Positive consequence: If you quickly (state calorie goal), we
will let you leave the table and go play video games.
Negative consequence: If you do not (state calorie goal) in
20 minutes, you cannot play video games and will not get
any food until our next meal.
I will eat 250 more calories at snack this week.

I will take my enzymes before each meal on 5 out of 7
days.
Key people: Patient, caregiver(s)

Target behavior: 1 snack/day
Goal: 2 snack/day for 5/7 days
Roles: Patient will eat snack and place sticker; Mom/dad will
provide 2 or more snacks/day and reward goal attainment
Monitor: Sticker chart
Consequence: 5 or more stickers for a movie night
Re-evaluate: 1 week
See Fig. 17.1
You ate your whole snack really fast. You can go color.
You stayed at the table for 20 minutes. Now you can put a
sticker on your chart.
Example
Praising: VerbalNice job eating so quickly. I like that
you came to the table for dinner right away. Im happy
with how many bites you have taken; Nonverbalhigh ve,
thumbs up, hug
Ignoring: Silence, turn or look away, get up from the table,
leave the room
17
247
Contingency Management
Similar to differential attention, contingency management is based on the principle that behavior
occurs in a predictable way, and increases or decreases in response to the consequence that follows it.
From this perspective, more desirable behavior (e.g., playing video games) is made contingent on
engaging in behavior that is less appealing (e.g., meeting dinner energy goal). In other words, the
child only receives a desired reward after completing the expected task. Typically contingencies are
used to encourage children to eat all the food on their plate or eat enough to meet their calorie goal.
Developing a contingency management plan allows parents and children to openly discuss expectations
for meals and what the child can earn by meeting the stated expectations. It also teaches children to
make informed choices and removes the parentchild struggle from the meal, because the parent can
allow the removal of a reward contingent upon not meeting a calorie goal to eventually motivate the
child to work harder to achieve the goal in order to get the desired reward. A monitoring plan (e.g.,
star chart) can help track the childs progress and provides a visual aid for children to see how close
they are to receiving the reward.
In order for contingency management to be effective, it is important to avoid giving the reward if
it is not earned (e.g., child consumes 75% of the energy goal instead of the complete goal), as
inconsistency increases the probability that the child will try to reduce the expectation next time.
Acknowledging that childrens interests frequently change and some rewards may not be available
immediately after the desired behavior, it is helpful to develop a list of possible rewards ahead of time.
Rewards or privileges do not need to cost much (e.g., one to one time with a parent, choice of desert,
movie night, going to the park), especially if they are to be delivered after each meal/snack in the
beginning, but they need to be in proportion to the expected behavior and something the child values
and will be motivated to earn. Children may be extremely resistant to changing their eating behavior;
therefore, rewarding desired behavior after each meal and snack helps maintain their motivation until
it becomes more comfortable and incorporated into the daily routine. Over time with consistently
experiencing the if-then pattern, the reward for desired eating behavior moves from daily to weekly
and is eventually faded out altogether.
Contracting
Behavioral contracting is a more formal and systematic approach to implementing contingency plans
and has been effective in increasing treatment adherence in children with CF [3638]. Contracts are
useful because they serve as a written reminder of the agreed upon terms and can be referred back to
if there are questions, thus reducing possible family conict at mealtime. By their very nature,
contracts displayed in a common area (e.g., refrigerator, kitchen table, counter) are a visual support
tool and can help remind parents and children of their responsibilities. For older children and
adolescents, being involved in the negotiation process promotes independence and can increase their
motivation to follow the terms of the contract [39].
Self-Monitoring
Self-monitoring (i.e., tracking behavior) is an effective tool for behavior change and serves many
purposes [40]. First, measuring ones behavior requires close attention to things that might otherwise
be overlooked, such as the type and amount of food consumed for a snack, and provides more accurate
248
J.L. Ryan et al.
estimates of caloric intake. Similarly, this increased attention may lead to increased calorie consumption.
Second, self-monitoring data provides rich information to be used in setting calorie goals, providing
tailored feedback on the types of foods to increase, identifying barriers to following nutritional
recommendations, and generating possible solutions to overcome these difculties. For example, a
detailed diet diary can help families and providers work more efciently to identify decits in
nutrition knowledge (i.e., calorie content) and environmental factors interfering with reaching the
calorie goal (i.e., mealtime duration) in order to choose the most appropriate intervention. Most
importantly, monitoring a childs energy intake and comparing it against energy goals gives parents a
clear stopping point for their childs food intake and thus when a child consumes sufcient calories to
meet the goal the parent can feel accomplished. When there are no energy goals or caloric monitoring
parents are often in the position of feeling they failed regardless of how much their child ate, because
they are never sure how much is enough.
In order for self-monitoring to be used effectively, accurate data collection is critical. Thus, it is
important for parents and possibly older children to learn the following: reading food labels and
understanding serving portions, measuring food and liquid in various forms, and recording hidden
foods (e.g., sugar added to oatmeal or butter on cooked vegetables) and meals/snacks eaten away from
home (i.e., school lunch). Dietary monitoring can be time-consuming at rst, particularly as families
learn how to get an accurate calorie amount and determine how to incorporate it into their daily
routine. Smartphone and web-based applications, such as MyFitnessPal and calorieking.com, can
save families a lot of time and effort because expansive databases are used to identify the specic food
in the correct measurement and automatic calculation of calories. These applications also have the
capability of reading UPC scans and thus saving more time for families because they do not have to
type in the food to search for it. For families who prefer to track calories on paper diaries, it is
important to help them identify an appropriate place to keep the diet diary so that it is seen regularly
and serves as a cue to record each meal and snack.
Tracking calories can be an important source of information for families who are concerned that
their child does not eat, as children with CF may be consuming as much as children without CF
[16]; however, the pressure for the child to eat [41] and grow leads to parent perceptions of poor
intake. Monitoring allows for the opportunity to identify specic times that warrant clinical attention,
such as snacks or dinner, or increasing calories following an illness. Moreover, tracking calories
provides the basis for goal setting, an essential component of behavioral interventions. See Fig. 17.1
for an example of how dietary data can be used to reinforce consistent use of behavioral strategies in
overcoming temporary declines in calorie intake in order to reach total daily calorie goals. The clinical
utility of self-monitoring relies on feedback and illustrating to parents the association between
monitoring observations and dietary changes. A graphical representation of the data can be used to
reinforce efforts to track daily calorie intake, monitor treatment progress, and identify ongoing barriers
preventing goal attainment. Graphic presentation with the average weekly caloric intake as well as the
daily calories also allows parents to see overall success and decrease the focus on any particular day
that may be low.
Goal Setting
Making dietary changes can seem daunting, but a collaborative goal setting process can help families
organize nutritional recommendations and skills into practical and manageable steps. Setting calorie
goals one meal at a time provides a means to monitoring the childs progress and reinforce increased
calorie intake. It also allows parents to feel comfortable stopping offers of food by giving them a clear
target for each meal/snack. To increase the chance of reaching the desired outcome, goals need to be
specic and action-oriented. Establishing how the goal will be measured provides a concrete indicator
17
249
Total Calories
(Goal = 2208 calories)
2900
Calories (Kcal)
2600
2300
2000
1700
1400
1100
800
3/30
3/16
3/13
3/10
2/28
2/25
2/22
2/19
2/16
2/13
2/10
2/7
2/4
2/1
1/29
12/20
12/17
12/14
12/8
12/11
12/5
12/2
11/29
500
Date
Fig. 17.1 Illustration of data obtained from a daily diet diary and use for monitoring progress toward calorie goals over
time. Red, calorie goal; Blue, total daily calories; Green, average calorie intake. aBaseline measurement of caloric intake
after starting self-monitoring and before setting calorie goals
of whether the goal is accomplished. While children with CF are advised to consume more than 120%
of the RDA, changing learned eating patterns quickly to reach calorie recommendations is nearly
impossible. Reinforcing success in reaching small attainable goals can increase the childs selfefcacy and encourage increased calorie consumption over time. Consistent with Be-In-CHARGE
[30, 31], snack is chosen as a starting point because there are several opportunities for snack during
the day and children may be more likely to accept snacks as each snack can be a small amount of food,
therefore making early treatment success more likely. Next, one meal is targeted per week with a goal
of increasing calories at the targeted meal by approximately 250 cal. The child and parents motivation
and ability to reach the calorie goal should be considered when determining whether the goal is
realistic or needs to be modied. Lastly, a calorie goal can be rened after a specied time period to
determine if the goal is appropriate. For example, if after 4 weeks of meeting a calorie goal a child
does not gain the expected amount of weight, the calorie goal could be increased.
Parental Limit Setting

As previously stated, often a childs rst response when parent attention is removed during planned
ignoring is to increase the frequency and/or intensity of behavior, or attempt to get their parents
attention another way. For example, the child may get up from the table before the meal is over. To
help parents maintain control over the mealtime, it is necessary to establish rules and consequences
for meals. Rules for meals are simple, made in advance, and explicitly state the relationship between
a specic behavior and its consequence, which may involve access or removal of privileges.
In order for children with CF to meet nutritional recommendations, it is important for them to be
seated at the table during a meal and consume enough food to meet calorie goals. Instructing children
to remain at the table until a parent or caregiver gives them permission to leave allows the adult to be
in control during meals. As recommended in the Be-In-CHARGE protocol, children who leave the
table prematurely should be escorted back to the table in a calm manner and without any discussion
250
J.L. Ryan et al.
or other attention, such as making eye contact. Parents are encouraged to praise the child throughout
the meal and make the association between staying at the table and positive consequences (i.e., I like
the way you are sitting at the table with the family.) to prevent the child from leaving.
Relatedly, setting a time to end the meal is necessary for several reasons. Previous observational
studies found that meals for children with CF lasted an average of 10 min longer than meals for
children without CF (27 vs. 17 min), and the second half of the meal included more behaviors
incompatible with eating [42]. Contrary to general weight-loss management strategies, children with
CF are encouraged to eat quickly because the brain and stomach register feeling full after roughly
20 min and longer mealtimes are less likely to be an effective long-term strategy for improving overall
consumption and growth [19, 43]. Thus, a 20-min time limit encourages children to eat quickly and
can be used to motivate them to reach calorie goals and earn their reward. If the child does not
consume enough calories within 20 min, parents are encouraged to remove the food and not allow
access to food until the next meal or snack. It is important that food not be given until the next
scheduled meal to increase the likelihood that the child will eat what is offered at the next meal.
In sum, child behavioral management strategies have been found to be effective in improving
behavior at meals and increasing dietary adherence in children with CF. Strategies can be tailored to
the needs of the child and family, applied to related aspects of nutritional care in CF (e.g., taking
enzymes as prescribed), and easily incorporated into standard nutritional counseling when
comprehensive behavioral intervention is not feasible.
Developmental Considerations
Preschool
Compared to infancy when eating behaviors are relatively predictable and parents are largely
responsible for the feeding schedule, the toddler and preschool period can pose unique challenges for
parents of children with and without CF. Parents may notice a decline in their childs appetite or
increased picky eating and be inclined to persist and push for high-calorie intake. They may be
comforted to learn that preferences for certain tastes are innate and others evolve over time, thereby
explaining why infants and toddlers readily accept sweet foods (e.g., fruits and juices) and reject new
foods with a bitter taste (e.g., vegetables) [44]. Being aware of this normal course of food acceptance
and fussy eating, parents of children with CF can gradually introduce new foods by combining them
with already preferred foods or making access to preferred foods contingent on tasting novel foods.
Repeated exposure in a nonthreatening setting is necessary, as preschoolers taste a new food up to 16
times before it is accepted [45]. Similar to other areas of a childs development, parental attitudes and
behaviors can inuence early childhood experiences that begin to shape long-term eating patterns and
behaviors. A childs food preferences and eating behaviors are largely reected by what is provided
and modeled early in life [46, 47]. Accordingly, parents play a critical role in making high-calorie,
high-fat foods available and easily accessible to encourage children to try a wide range of foods.
School-Age
For many parents, preparing children to start school can be exciting yet anxiety provoking as the
transition means less parental control. Notably, parents of school-age children with CF report an
inability to monitor their childs eating habits in school, with some children being offered portions
17
251
smaller than recommended and parents feeling pressured to compensate at home [41]. Educating the
school about the nutritional needs of children with CF and establishing a positive working relationship
can help relieve parental concerns and promote child nutritional management. For example, a Section
504 Plan can be developed allowing a child to carry or have access to extra snacks, have additional time
to eat lunch, and take enzymes and nutritional supplements as needed to increase daily calories [48].
During the school-age period, childrens cognitive abilities are rapidly expanding and they are
better able to form and express their thoughts and illness beliefs. This represents an ideal time to
address any misconceptions or fears that might interfere with the childs willingness to follow
nutritional recommendations [49]. Specically, peer inuences and the need for social acceptance are
developmentally appropriate topics worth discussing in order to problem-solve around perceived
barriers and meet nutrition goals [5052].
Adolescence
Adolescence is a transitional period marked by increasing autonomy and independence, and the desire
to establish an individual identity separate from the family unit. Developing a sense of self through
experimentation with different roles is typical among adolescents [53], but the risks and health
implications are much greater for adolescents with CF, as treatment burden increases in response to a
progressing illness and the regimen interferes with school-related or social activities [41, 54].
Consequently, up to 60% of adolescents with CF report being non-adherent to varying regimen
components [55, 56]. Among females with CF, perceived visible differences during puberty (e.g.,
short stature or low body mass) have been associated with body dissatisfaction and maladaptive eating
attitudes [57, 58] and may help explain the tendency to be less adherent to a high-fat diet. Parental
awareness and continued involvement are needed to ensure the competing demands in normal
adolescent development and pediatric disease management do not adversely impact health outcomes
in an already vulnerable population.
To prepare adolescents with CF and their parents for challenging developmental transitions, it is
important to educate families on what they can expect and to have these conversations early and often.
For example, encouraging families to consider the adolescents abilities and willingness (versus age)
to assume more treatment responsibility and recommending a gradual transition from the parent to the
child or adolescent can help prevent non-adherence and subsequent declines in physical functioning
[59]. Moreover, helping familys problem-solve around barriers to dietary adherence may decrease
resistance and parentchild conict associated with the process [60, 61]. In sum, all families must
manage the changes and milestones characteristic of child and adolescent development, but the
additional complexity of CF can complicate this process and requires considerable effort to promote
optimal health and maximize quality of life among youth with CF.
Conclusion
In order to support families in achieving what can feel like lofty CF nutrition benchmarks, it is
important for nutrition care to incorporate a behavioral approach that includes goal setting, caloric
intake tracking, timely feedback on energy intake, and child behavioral management strategies to
address child behaviors that limits intake and parentchild interactions that make mealtimes stressful.
Enhancing standard nutrition care to include these components gives families a goal to work towards
with the ability to know when it has been reached, engages them in problem-solving around barriers
to meeting nutritional recommendations, and equips them with the necessary skills to elicit improved
252
J.L. Ryan et al.
behavior from their child at meals. In addition, providing anticipatory guidance about developmentally
normative mealtime challenges can help families know when to ask for assistance in order to address
problem behaviors before they become more engrained and difcult to change. As childrens energy
needs increase with age, early programming for adaptive eating behavior will make it easier to reach
expectations for increased energy intake. Finally, increased life expectancy for individuals with CF
highlights the benet of behavioral intervention in assisting with the transition of treatment
responsibility to promote patient self-management and ease the move to adult care.
References
1. Cystic Fibrosis Foundation. Patients registry report. Bethesda, MD: Cystic Fibrosis Foundation; 2012 [November
14, 2014].
Patient Registry. J Pediatr. 2000;137(3):37480.
8. Borowitz D, Robinson KA, Rosenfeld M, Davis SD, Sabadosa KA, Spear SL, et al. Cystic Fibrosis Foundation
evidence-based guidelines for management of infants with cystic brosis. J Pediatr. 2009;155(6 Suppl):S7393.
9. Lai HJ, Shoff SM, Farrell PM, Wisconsin Cystic Fibrosis Neonatal Screening Group. Recovery of birth weight z
score within 2 years of diagnosis is positively associated with pulmonary status at 6 years of age in children with
cystic brosis. Pediatrics. 2009;123(2):71422.
outcomes and survival in patients with cystic brosis. J Pediatr. 2013;162(3):5305. 3.
11. Sackett DL, Snow JC. The magnitude of compliance and non compliance. In: Haynes NRB, Taylor DW, Sackett
DL, editors. Compliance in health care. Baltimore: John Hopkins University Press; 1980. p. 1122.
12. Anthony H, Paxton S, Bines J, Phelan P. Psychosocial predictors of adherence to nutritional recommendations and
growth outcomes in children with cystic brosis. J Psychosom Res. 1999;47(6):62334.
13. Mackner LM, McGrath AM, Stark LJ. Dietary recommendations to prevent and manage chronic pediatric health
conditions: adherence, intervention, and future directions. J Dev Behav Pediatr. 2001;22(2):13043.
14. Passero MA, Remor B, Salomon J. Patient-reported compliance with cystic brosis therapy. Clin Pediatr (Phila).
1981;20(4):2648.
15. Powers SW, Patton SR, Byars KC, Mitchell MJ, Jelalian E, Mulvihill MM, et al. Caloric intake and eating behavior
in infants and toddlers with cystic brosis. Pediatrics. 2002;109(5):E755.
16. Stark LJ, Jelalian E, Mulvihill MM, Powers SW, Bowen AM, Spieth LE, et al. Eating in preschool children with
cystic brosis and healthy peers: behavioral analysis. Pediatrics. 1995;95(2):2105.
17. Crist W, McDonnell P, Beck M, Gillespie CT. Behavior at mealtimes and the young child with cystic brosis. J Dev
Behav Pediatr. 1994;15(3):15761.
18. Hammons AJ, Fiese B. Mealtime interactions in families of a child with cystic brosis: a meta-analysis. J Cyst
Fibros. 2010;9(6):37784.
19. Stark LJ, Jelalian E, Powers SW, Mulvihill MM, Opipari LC, Bowen A, et al. Parent and child mealtime behavior
in families of children with cystic brosis. J Pediatr. 2000;136(2):195200.
20. Spieth LE, Stark LJ, Mitchell MJ, Schiller M, Cohen LL, Mulvihill M, et al. Observational assessment of family
functioning at mealtime in preschool children with cystic brosis. J Pediatr Psychol. 2001;26(4):21524.
21. Opipari-Arrigan L, Powers SW, Quittner AL, Stark LJ. Mealtime problems predict outcome in clinical trial to
improve nutrition in children with CF. Pediatr Pulmonol. 2010;45(1):7882.
17
253
22. Mitchell MJ, Powers SW, Byars KC, Dickstein S, Stark LJ. Family functioning in young children with cystic brosis:
observations of interactions at mealtime. J Dev Behav Pediatr. 2004;25(5):33546.
23. Modi AC, Lim CS, Yu N, Geller D, Wagner MH, Quittner AL. A multi-method assessment of treatment adherence
for children with cystic brosis. J Cyst Fibros. 2006;5(3):17785.
24. Bell L, Durie P, Forstner F. What do children with cystic brosis eat? J Pediatr Gastroenterol Nutr. 1984;3 Suppl
1:S13746.
25. Crist W, Napier-Phillips A. Mealtime behaviors of young children: a comparison of normative and clinical data.
J Dev Behav Pediatr. 2001;22(5):27986.
26. Piazza-Waggoner C, Modi AC, Powers SW, Williams LB, Dolan LM, Patton SR. Observational assessment of family
functioning in families with children who have type 1 diabetes mellitus. J Dev Behav Pediatr. 2008;29(2):1015.
27. Stark LJ, Bowen AM, Tyc VL, Evans S, Passero MA. A behavioral approach to increasing calorie consumption in
children with cystic brosis. J Pediatr Psychol. 1990;15(3):30926.
28. Stark LJ, Knapp LG, Bowen AM, Powers SW, Jelalian E, Evans S, et al. Increasing calorie consumption in children
with cystic brosis: replication with 2-year follow-up. J Appl Behav Anal. 1993;26(4):43550.
29. Stark LJ, Mulvihill MM, Powers SW, Jelalian E, Keating K, Creveling S, et al. Behavioral intervention to improve
calorie intake of children with cystic brosis: treatment versus wait list control. J Pediatr Gastroenterol Nutr.
1996;22(3):24053.
30. Stark LJ, Opipari LC, Spieth LE, Jelalian E, Quittner AL, Higgins L, et al. Contribution of behavior therapy to
dietary treatment in cystic brosis: a randomized controlled study with 2-year follow-up. Behav Ther. 2003;
34:23758.
31. Stark LJ, Quittner AL, Powers SW, Opipari-Arrigan L, Bean JA, Duggan C, et al. Randomized clinical trial of
behavioral intervention and nutrition education to improve caloric intake and weight in children with cystic brosis.
Arch Pediatr Adolesc Med. 2009;163(10):91521.
32. Stark LJ, Powers SW, Jelalian E, Rape RN, Miller DL. Modifying problematic mealtime interactions of children
with cystic brosis and their parents via behavioral parent training. J Pediatr Psychol. 1994;19(6):75168.
33. Powers SW, Jones JS, Ferguson KS, Piazza-Waggoner C, Daines C, Acton JD. Randomized clinical trial of
behavioral and nutrition treatment to improve energy intake and growth in toddlers and preschoolers with cystic
brosis. Pediatrics. 2005;116(6):144250.
34. Hanley GP, Tiger JH. Differential reinforcement procedures. In: Fisher WW, Piazza CC, Roane HS, editors.
Handbook of applied behavior analysis. New York, NY: Guilford Press; 2011. p. 22949.
35. Powers SW, Mitchell MJ, Patton SR, Byars KC, Jelalian E, Mulvihill MM, et al. Mealtime behaviors in families of
infants and toddlers with cystic brosis. J Cyst Fibros. 2005;4(3):17582.
36. Miller DL, Stark LJ. Contingency contracting for improving adherence in pediatric populations. JAMA. 1994;
271(1):813.
37. Stark LJ, Opipari LC, Jelalian E, Powers SW, Janicke DM, Mulvihill MM, et al. Child behavior and parent
management strategies at mealtimes in families with a school-age child with cystic brosis. Health Psychol.
2005;24(3):27480.
38. Stark LJ, Miller ST, Plienes AJ, Drabman RS. Behavioral contracting to increase chest physiotherapy. A study of a
young cystic brosis patient. Behav Modif. 1987;11(1):7586.
39. Wahl AK, Rustoen T, Hanestad BR, Gjengedal E, Moum T. Living with cystic brosis: impact on global quality of
life. Heart Lung. 2005;34(5):32431.
40. Butryn ML, Phelan S, Hill JO, Wing RR. Consistent self-monitoring of weight: a key component of successful
weight loss maintenance. Obesity (Silver Spring). 2007;15(12):30916.
41. Filigno SS, Brannon EE, Chamberlin LA, Sullivan SM, Barnett KA, Powers SW. Qualitative analysis of parent
experiences with achieving cystic brosis nutrition recommendations. J Cyst Fibros. 2012;11(2):12530.
42. Stark LJ, Mulvihill MM, Jelalian E, Bowen AM, Powers SW, Tao S, et al. Descriptive analysis of eating behavior
in school-age children with cystic brosis and healthy control children. Pediatrics. 1997;99(5):66571.
43. Wolff RP, Lierman CJ. Management of behavioral feeding problems in young children. Infants Young Child.
1994;7:1423.
44. Kern DL, McPhee L, Fisher J, Johnson S, Birch LL. The post ingestive consequences of fat condition preferences
for avors associated with high dietary fat. Physiol Behav. 1993;54(1):716.
45. Birch LL, Marlin DW. I dont like it; I never tried it: effects of exposure on two-year-old childrens food preferences.
Appetite. 1982;3(4):35360.
46. Cullen KW, Baranowski T, Owens E, Marsh T, Rittenberry L, de Moor C. Availability, accessibility, and preferences
for fruit, 100% fruit juice, and vegetables inuence childrens dietary behavior. Health Educ Behav. 2003;30(5):
61526.
47. Hearn M, Baranowski T, Baranowski J, Doyle C, Smith M, Lin LS, et al. Environmental inuences on dietary
behavior among children: availability and accessibility of fruits and vegetables enable consumption. J Health Educ.
1998;29(1):2632.
48. Cystic Fibrosis Foundation. A teachers guide to CF. Bethesda, MD: Cystic Fibrosis Foundation; 2014.
254
J.L. Ryan et al.
49. Ernst MM, Johnson MC, Stark LJ. Developmental and psychosocial issues in cystic brosis. Child Adolesc
Psychiatr Clin N Am. 2010;19(2):26383. 2.
50. Meyer TA, Gast J. The effects of peer inuence on disordered eating behavior. J Sch Nurs. 2008;24(1):3642.
51. Salvy SJ, de la Haye K, Bowker JC, Hermans RC. Inuence of peers and friends on childrens and adolescents
eating and activity behaviors. Physiol Behav. 2012;106(3):36978.
52. Cullen KW, Baranowski T, Rittenberry L, Cosart C, Hebert D, de Moor C. Child-reported family and peer inuences
on fruit, juice and vegetable consumption: reliability and validity of measures. Health Educ Res. 2001;16(2):
187200.
53. Segal TY. Adolescence: what the cystic brosis team needs to know. J R Soc Med. 2008;101 Suppl 1:S1527.
54. Hegarty M, Macdonald J, Watter P, Wilson C. Quality of life in young people with cystic brosis: effects of
hospitalization, age and gender, and differences in parent/child perceptions. Child Care Health Dev.
2009;35(4):4628.
55. Dziuban EJ, Saab-Abazeed L, Chaudhry SR, Streetman DS, Nasr SZ. Identifying barriers to treatment adherence
and related attitudinal patterns in adolescents with cystic brosis. Pediatr Pulmonol. 2010;45(5):4508.
56. Quittner AL, Drotar D, Ievers-Landis CE, Seidner D, Slocum N, Jacobsen J. Adherence to medical treatments in
adolescents with cystic brosis: the development and evaluation of family-based interventions. In: Drotar D, editor.
Hillsdale, NJ: Erlbaum Associates Inc; 2000.
57. Johannesson M, Carlson M, Brucefors AB, Hjelte L. Cystic brosis through a female perspective: psychosocial
issues and information concerning puberty and motherhood. Patient Educ Couns. 1998;34(2):11523.
58. Randlesome K, Bryon M, Evangeli M. Developing a measure of eating attitudes and behaviours in cystic brosis.
J Cyst Fibros. 2013;12(1):1521.
59. Modi A, Marciel K, Slater S, et al. The inuence of parental supervision on medical adherence in adolescents with
cystic brosis: developmental shifts from pre to late adolescence. Child Health Care. 2008;37(1):7892.
60. Wysocki T, Harris MA, Buckloh LM, Mertlich D, Lochrie AS, Taylor A, et al. Effects of behavioral family systems
therapy for diabetes on adolescents family relationships, treatment adherence, and metabolic control. J Pediatr
Psychol. 2006;31(9):92838.
61. DeLambo KE, Ievers-Landis CE, Drotar D, Quittner AL. Association of observed family relationship quality and
problem-solving skills with treatment adherence in older children and adolescents with cystic brosis. J Pediatr
Psychol. 2004;29(5):34353.
Chapter 18
Nutrition and Quality Improvement in Cystic Fibrosis

Key Points
Quality improvement is a multidisciplinary method of understanding and improving the efciency,
effectiveness, and reliability of health processes and outcomes of care
Patient registries are a useful tool in quality improvement work
Benchmarking allows for the determination of best practices
Patient and family involvement and education of care team in the techniques of quality improvement
are important for success
There are limited publications about quality improvement efforts in cystic brosis and nutrition
Utilizing a standardized approach to quality improvement projects improves success
Keywords Benchmarking Improvements Learning and Leadership Collaborative Nutrition
Outcomes Patient registries Quality improvement
Abbreviations
ACH
CCHMC
CF
CFF
LLC
OGTT
PDSA
QI
REACT
SDSA
UAB/COA
US
Arkansas Childrens Hospital

Cincinnati Childrens Hospital Medical Center
Cystic brosis
Learning and Leadership Collaborative
Oral Glucose Tolerance Test
Plan Do Study Act
Quality improvement
Re-Education of Airway Clearance Techniques
Standardize Do Study Act
University of Alabama at Birmingham CF Center/Childrens Hospital of Alabama
United States
A.R. Leonard, M.P.H., R.D., C.D.E. (*)

The Johns Hopkins Childrens Center, Department of Pediatrics,
Division of Gastroenterology and Nutrition, Baltimore, MD, USA
255
256
A.R. Leonard
Introduction
Quality improvement (QI) is a multidisciplinary, systems-focused, data driven method of
understanding and improving the efciency, effectiveness, and reliability of health processes and
outcomes of care [1]. QI is a powerful tool that has been used in a variety of care settings to improve
clinical outcomes [24]. With the provision of safe, patient centered, evidence-based, efcient,
timely and equitable healthcare delivery chronic disease outcomes improve [5]. In cystic brosis
(CF) QI has been utilized, along with new therapies to prolong the life expectancy of those affected
with the disease [6]. These improvement techniques can be used to focus on the nutritional care of
individuals with CF with the goal of improving their nutritional status and potentially their quality
of life [711].
Quality Improvement in Cystic Fibrosis

The life expectancy of individuals with CF has increased dramatically over the last 50 years [12].
Between 2002 and 2012, median life expectancy for CF patients in the United States (US) increased
from 32 to 41 years [13]. Improvements in medical outcomes for people with CF are a result of
advances in basic science and therapeutic development combined with quality improvement work
geared toward healthcare delivery [14]. With an increased focus on QI, the CF community has
encouraged improvements in delivery of care as well as developing evidenced based and consensus
based guidelines regarding standards of care [3, 15, 16]. Data transparency, as well as the renement
of patient registries to allow comparison of center processes and outcomes has also improved overall
care delivery [6]. Many countries have embarked on QI projects, including the United States, Europe,
Canada and Australia, but few have published their results [10, 13]. US Cystic Fibrosis Foundation
(CFF) has recently documented their program so their work will be discussed in greater detail [13].
Patient Registries
One of the key tools for QI in the CF community is the use of patient registries. Patient registries are
utilized in several countries including the United States, Canada, Australia, and several individual
European countries [1720]. A combined European registry, including multiple countries, was started
in 2004 to allow for the inclusion of a larger population [18]. Patient registries, which capture patient
data at point of care, allow for comparison both within the center and with other centers [17]. Registries
allow practitioners to identify variability in care and also track progress in patient outcomes [14]. This
variability can be associated with dramatic differences in outcomes [21]. Although the variability in
care, and outcomes, could be used to dene the best center, QI proponents believe that variation in
outcomes data provides an opportunity for learning, not judging [22]. The US CFF patient registry,
created in 1966, was initially used to track only survival [23]. Since that time it has been expanded to
include more than 300 unique variables including outcomes and care processes and can be used to
identify variability and measure outcomes [17]. While this variability may not always be immediately
improved, identication of differences can be helpful in determining the next steps. For instance,
Gutierrez and colleagues described the difference in life expectancy in Chile, in the teens, versus other
countries, which are as high as 40+ years [24]. With this information, obstacles to care in Chile were
identied which then increase the likelihood that inadequacies will be addressed.
18
257
Registries can be a useful tool in nutrition QI projects [79, 25]. Corey et al. published one of the
rst papers using registry data to describe nutrition related outcomes [26]. Using registry data the
group compared survival data between two similar sized CF centers, one in Boston, Massachusetts
and the other in Toronto, Ontario. Data showed that median survival in Toronto was better than
Boston by about 7 years. One main difference identied between the two centers was their approach
to nutrition. Boston prescribed a low fat diet to decrease symptoms of malabsorption, which was the
generally accepted approach at that time. Toronto advocated for a high fat diet and administered
more pancreatic replacement enzymes to decrease side effects from the high fat diet. Since the
publication of this study a high fat diet has become the generally accepted approach for individuals
with CF. In more recent years, registry data has been used to identify outcomes to improve and also
to track progress [810].
Benchmarking
Signicant variability in practice patterns and outcomes provides a great opportunity to identify
clinical practices associated with the best performing centers [27]. Benchmarking, the process of
using outcome data to identify high-performing centers and determine practices associated with their
outstanding performance, is another aspect of QI that promotes an improvement in CF care [27, 28].
Since 2006, US CFF patient registry data (case-mix adjusted) has been shared with the public [22].
This transparency encourages center accountability and promotes QI to improve outcomes [13, 17].
Benchmarking allows the discovery, and facilitates the spread, of effective approaches to care [28].
Benchmarking assessments can be done on a small (one center) or large (multiple centers) scale [7,
27, 28] Beginning in 2006, the CFF organized two teams, one with adult caregivers and one with
pediatric caregivers, to visit the top 10 performing centers in the US [27, 28]. The task of the teams
was to identify best practices. Table 18.1 describes the main themes identied [27].
Spreading the Quality Improvement Message

In addition to using the registry and benchmarking to help improve outcomes, CFF also started an
initiative to educate care centers on the specics of how to implement QI work. [30]. The Learning
and Leadership Collaboratives (LLC) were designed to accelerate the rate of improvement in CF care
by training care teams on methods of QI [14, 30]. In 2002, after a meeting with national quality
improvement leaders, CFF began to update its registry data so that it could support QI work [14, 17].
CFF also sponsored a training program on clinical improvement methods, which was launched in
2003 [21]. Standardized care, which has been shown to improve outcomes in a variety of disciplines,
is an important part of the LLC training [21, 30]. The standardized care model allows for an individual
approach to patient care within a standardized framework [21]. Through specic, targeted, evidenced
based QI projects CF care centers were able to improve outcomes [13, 30]. James, a thought leader in
healthcare QI, estimates that the medical profession could achieve as much benet for patients if it
could routinely apply and deliver current best medical knowledge, as will be achieved by the next 25
years of government funding for new biomedical research [21].
Patient and Family Involvement

Engaging patient and families in CF care has been part of many improvement efforts and is one of
the goals of the CFF [9, 10, 13, 14, 22, 28, 29]. Patients and families participate on Family Advisory
boards which help direct improvement work [9, 10, 22, 28, 29]. Many centers have patients and/or
A.R. Leonard
258
Table 18.1 Key characteristics of programs with top-quintile
cystic brosis clinical outcomes
Benchmarking themes
Systems
1. Strong leadership
2. Dedicated multidisciplinary team
3. Easy accessibility by patients and families
4. Close tracking of clinical details and outcomes
Attitudes
1. High expectations for pulmonary and nutritional status
2. Low threshold for vigorous treatment of health declines
3. Aggressive use of antibiotics for pulmonary symptoms
4. Team consensus on standard approach to care
Practices
1. Preclinic review of patients and treatment planning
2. More frequent clinic visits for identied health concerns
3. Regular patient visits with full multidisciplinary team
Patient/family engagement and empowerment
1. Patients provided with data on their clinical outcomes
2. Patients/families educated on high outcome expectations
and need for early, aggressive intervention for declines
3. Patients/families encouraged to provide feedback on their
clinical care experiences and concerns
Projects
1. Self-assess program outcomes and practice patterns
2. Develop projects to improve program performance of key
clinical practices
Reproduced from Boyle MP, et al. Key ndings of the US
Cystic Fibrosis Foundation's clinical practice benchmarking
project. BMJ Qual Saf. 2014;23 Suppl 1:i15-i22. with
permission from BMJ Publishing Group Ltd.
family members as part of the QI, participating in meetings and working with the care team on
projects [9, 10, 22]. The perspective of patients and families in QI work has motivated clinicians
and provided valuable insight [14, 28].
Implementing a Quality Improvement Project

Nutrition plays an integral role in the health of individuals with CF [11, 3133]. Nutrition assessment
and interventions are important for outpatient, as well as inpatient, care [16, 34, 35]. Although CF
nutrition QI projects have been reported at meetings, there are limited publications about projects
specic to CF nutrition [6]. The primary approach for most centers is to focus on implementing
guidelines for CF care. This section will provide an overview of the steps for implementing a nutrition
related QI project. The approach described is based on the Dartmouth Microsystem Improvement
Curriculum and is described in the Action Guide for Accelerating Improvement in Cystic Fibrosis
Care (Action Guide) [36]. This method was used by CFF for the LLC [30]. More detailed information
can be found in the Action Guide and other works devoted to QI [36].
18
259
Prior to embarking on a nutrition QI project, it is vital to assess clinic structure and function [36]. By
understanding the people involved, the current state of the program, and current outcomes it will be
easier to achieve desired results. The assessment should include the 5 Ps: purpose, patients, professionals,
processes, and patterns. Dening a purpose will guide decision making and focus improvements.
Identifying your patient population and the professionals involved in their care, as well as the processes
and patterns, will further describe your current system. Ideally, QI work will involve the entire care team
[36, 37]. Members of a comprehensive QI team will vary depending on a variety of factors, but might
include a dietitian/nutritionist, physician(s), nurse, social worker, respiratory therapist, physical therapist,
behavioral psychologist, pharmacist, and a patient/parent. From this broader team, a lead team can be
identied to pursue the project [36]. Once the lead team is selected a theme, global aim, and specic
aims should be determined for the work. The theme and aims will help decide where the improvement
efforts will focus. It is helpful to look at registry results to assist with identifying areas where improvement
is warranted. Review of center outcomes can help the team choose the theme, for example nutrition care.
From the broad reaching theme a global aim and smaller specic aims can be identied to dene the
work. For instance, with a theme of nutrition care, a global aim might be to improve the nutritional status
of patients at the center. The specic aim(s) would detail the change needed to achieve this goal such as
clinic dietitian will assess all patients with a body mass index less than the 50 percentile. The actual
change instituted to achieve the specic aim is referred to as a change idea. Many QI projects are not
necessarily new recommendations but new approaches to applying the current recommendations or
guidelines at the center [810]. The goal is to identify and correct inconsistencies, or to apply a new
method to allow patients and families to succeed [36]. For instance, assessing BMI at every clinic visit
for every patient or adopting a screening tool to assess nutrition risk. Barriers to achieving these goals
can be identied and addressed as the process progresses.
In order to assess change over time improvement projects should be measurable. Metrics can be
gathered from registry data or collected and organized by clinic staff. Once a measurable change idea
is chosen it is often helpful to have a smaller scale pilot using a subset of patients before applying to
a greater proportion of your center. This process will help identify, and correct, potential issues with
the planned changes. One way to approach implementation of a change idea is a Plan Do Study Act
(PDSA) Cycle (Fig. 18.1). With this approach the team plans the change, then implements the change,
assesses the impact of the change, and nally takes action. Each PDSA cycle should be about a
specic aspect of care. The action at the end of the cycle could be a small adjustment to the plan or
moving to the next step in the improvement process. Once a PDSA cycle is complete, and the outcomes
are acceptable, the process can become standardized. It may take many times through the cycle before
the plan is ready to become standardized. At this point the cycles are called Standardize, Do, Study,
Act (SDSA). The use of PDSA cycles allows QI work to begin on a small, manageable scale and then
grow to spread throughout the care center. PDSA cycles related to the overall theme will drive
improvements at your center.
Applications in CF Nutrition
Although many centers have participated in nutrition related quality improvement work, there are a
limited number of publications describing these efforts [6]. This section will review the currently
available published works.
The Cincinnati Childrens Hospital Medical Center (CCHMC) has been working on QI for over a
decade [10]. The CCHMC CF center reports a dramatic improvement in median clinic BMI (as
reported in CFF patient registry) as a result of their QI work. The median clinic BMI improved from
35% in 2000 to 55% in 2010. Siracusa and colleagues report that the center focused on specic
outcomes, empowering families and patients, using data effectively, standardizing the care processes,
260
A.R. Leonard
Fig. 18.1 PDSA Ramp used with permission from Action Guide For Accelerating Improvement In Cystic Fibrosis
Care, 2006
transformation of culture and care delivery. Benchmarking visits were conducted by the team to
identify best practices. Additional dietitian stafng was added to the team in 2007 to facilitate effective
and equitable care. Nutrition specic action plans, using PDSA cycles, were implemented to effect
change. Although specic change ideas are not detailed in the manuscript, lessons learned at CCHMC
during a decade of QI work can be found in Table 18.2.
Savant et al. describe sustained improvement in nutrition outcomes at two CF centers, the Ann and
Robert Lurie Childrens hospital of Chicago CF Center (Lurie Childrens) and the University of
Alabama at Birmingham CF Center/Childrens Hospital of Alabama (UAB/COA) [9]. Both Lurie
Childrens and UAB/COA improved and sustained nutrition outcomes through implementation of
CFF practice guidelines for CF nutrition management. Improvement was achieved through changes
in the care delivery processes, nutrition interventions, team engagement, and data display. Specic
nutrition interventions included a standardized clinic worksheet to assess patient data and a nutrition
algorithm. The nutrition algorithm included increased visit frequency for patients who were determined
to be at nutritional risk and individualized action plans for patients with inadequate nutritional status.
Action plans focused on the specic needs of the patient included enzyme adjustment, increased
caloric intake, and mealtime behaviors. Both centers also offered dietitian only visits to those
patients with suboptimal nutritional status. With these changes signicant improvements were made
in mean clinic BMI at both centers. Lurie Childrens mean BMI increased from 42.2% in 2002 to
54.4% in 2004. The mean clinic BMI has continued to be above the 50th percentile for 10 years.
Similar improvements were seen at UAB/COA. In 2002 the mean BMI at UAB/COA was 37.2% and
it increased to 44.2% by 2005. A mean BMI above 50th percentile has been maintained for 9 years at
UAB/COA.
Leonard and colleagues implemented a standardized nutrition risk assessment and treatment
protocol to improve nutrition outcomes [8]. A nutrition risk category, optimal, acceptable, concerning,
risk or failure, was assigned at each clinic visit based on BMI, weight change, and linear growth
(Fig. 18.2). The concerning category was developed to catch small changes in nutritional status before
they developed into nutrition risk or failure. Patients in this category had a BMI above the 50th
18
261
Table 18.2 Lessons learned during a decade of

quality improvement process
Lesson learned
1. Start with a project with an established baseline
that is easy to measure and trend over time
2. Choose a project that is meaningful to both care
team members and patients
3. Bring members to the team who are committed
to the success of the project, including patients
and families
4. Include formal training in QI, a QI coach and
team members with dedicated time for QI work
5. Have regular meetings to review results and
plan next steps
Reproduced Siracusa CM, et al. The impact of
transforming healthcare delivery on cystic brosis
outcomes: a decade of quality improvement at
Cincinnati Children's Hospital. BMJ Qual Saf.
2014;23 Suppl 1:i56-i63. with permission from BMJ
Publishing Group Ltd.
percentile but did not gain weight between clinic visits. The goal of this approach was to provide early
intervention and more frequent follow-up in the hope of preventing a decline in nutritional status.
Patients identied as concerning, nutrition risk, or nutrition failure were assessed using the
treatment protocol. The protocol included assessment of caloric intake, nutrient absorption, and risk
for cystic brosis related diabetes (CFRD). Based on the treatment protocol an individualized
treatment plan, including more frequent follow-up, was developed with the patient and family. During
the 15-month study period the median BMI percentile of the subjects improved from 37.8 (2006) to
42 (2007). Since the report the protocol has been adopted for the entire pediatric clinic (unpublished
data). Median clinic BMI percentile has improved from 43 in 2006 to 50.7 in 2012 [12].
Some groups report improvements in nutritional outcomes as a result of QI work targeting the
entire treatment plan [7, 38]. For example, Kraynack reports that as part of their QI initiative they
identied and treated patients with and at risk for nutrition failure but did not elaborate on techniques
or outcomes [7]. Arkansas Childrens Hospital (ACH), as part of an LLC project, aimed to increase
the percentage of patients with four or more outpatient visits, as recommended by CFF [38]. With this
initiative they also noted an increase in BMI. It is possible that the more frequent visits led to better
access to nutrition care. The group later developed a nutrition pathway to provide consistent nutrition
support. The nutrition pathway included screening weight, length, and BMI to determine nutrition
risk category and an individualized nutrition plan for at risk patients.
Although the majority of CF nutrition QI work is geared toward improving weight and BMI, some
centers focus on other aspects of care that impact nutrition, such as screening for CFRD [8, 39]. The
CHRISTUS Santa Rosa Childrens Hospital CF Center focused improvement efforts on screening for
CFRD [39]. They implemented a clinic based algorithm to improve compliance with oral glucose
tolerance test (OGTT). The goal of the algorithm was to provide consistent parameters for ordering
and interpreting OGTT results. During the 6-month study period there was a statistically signicant
improvement in screening with OGTT from 65 to 89%. However, in the year following the
implementation of the algorithm, the completed OGTT rate fell to 79%, despite a high (97%) rate of
physician ordering. The group suggests that barriers to compliance with OGTT need to be explored.
262
A.R. Leonard
Fig. 18.2 Nutrition classication algorithm used from Leonard A, et al. Description of a standardized nutrition
classication plan and its relation to nutritional outcomes in children with cystic brosis. J Pediatr Psychol. 2010;35:
613. by permission of Oxford University Press
Applying these concepts, as well as those from other QI projects has the potential to improve outcomes
in CF. Although screening for nutritional status is a common rst step in nutrition QI work, there is
little published data about screening [40]. McDonald validated a nutrition risk screening tool for
children and adolescents with CF ages 220 years. The tool assigns points based on weight gain,
height velocity, and BMI and straties the patient into low, moderate, or high risk. The purpose of the
quick screening is to standardize nutrition risk categorization and provide clinical direction for
determining those individuals at nutrition risk who would benet from more extensive medical
nutrition therapy. Modifying currently available tools to t your center population is also a useful
approach.
There are concepts from QI work in other aspects of CF that can be applied to the nutrition arena
as well. For example, the CF Center at Monmouth Medical Center had improvements in clinic
pulmonary function outcomes with the Re-Education of Airway Clearance Techniques (REACT)
program [41]. REACT focused on re-educating patients and families about the importance of, and
approach to, airway clearance. Knowledge about airway clearance and barriers to adherence were
also assessed. A similar education program could be used with nutrition topics including a knowledge
assessment, identication of barriers to success, and re-education.
18
263
Conclusion
CF is a complex disease and care requires the interdependent cooperative work of patients, parents,
families, and the health care professionals [22]. Quality improvement is a means to provide the best
possible care and improve outcomes. There are a variety of quality improvement factors that have
inuenced CF care including patient registries, benchmarking, patient and family involvement,
collaborative learning, effective data management, and a culture of improvement [3]. Although there
is little published data about nutrition QI projects, many centers have worked in this area [6]. As QI
work in this area continues, it will ideally lead to a culture of quality, with expectations of ongoing
improvements in CF care and life expectancy.
References
1. McPheeters ML, Kripalani S, Peterson NB, Idowu RT, Jerome RN, Potter SA, Andrews JC. Closing the quality gap:
revisiting the state of the science (vol. 3: quality improvement interventions to address health disparities). Evid Rep
Technol Assess. 2012;208(3):1475.
2. Berwick DM. The science of improvement. JAMA. 2008;12(299):11824.
3. Stevens DP, Marshall BC. A decade of healthcare improvement in cystic brosis: lessons for other chronic diseases.
BMJ Qual Saf. 2014;23 Suppl 1:i12.
4. Kaplan HC, Brady PW, Dritz MC, et al. The inuence of context on quality improvement success in healthcare: a
systematic review of the literature. Milbank Q. 2010;88:50059.
5. Crossing the quality chasm: a new health system for the 21st century: Institute of Medicine of the National
Academies. National Academy Press: Washington, DC; 2001.
6. Schechter MS, Gutierrez HH. Improving the quality of care for patients with cystic brosis. Curr Opin Pediatr.
2010;22:296301.
7. Kraynack NC, McBride JT. Improving care at cystic brosis centers through quality improvement. Semin Respir
Crit Care Med. 2009;30:54758.
8. Leonard A, Davis E, Rosenstein BJ, Zeitlin PL, et al. Description of a standardized nutrition classication plan and
its relation to nutritional outcomes in children with cystic brosis. J Pediatr Psychol. 2010;35:613.
9. Savant AP, Britton LJ, Petren K, et al. Sustained improvement in nutritional outcomes at two paediatric cystic
brosis centres after quality improvement collaboratives. BMJ Qual Saf. 2014;23 Suppl 1:i819.
10. Siracusa CM, Weiland JL, Acton JD, et al. The impact of transforming healthcare delivery on cystic brosis
outcomes: a decade of quality improvement at Cincinnati Childrens Hospital. BMJ Qual Saf. 2014;23 Suppl
1:i5663.
outcomes and survival in patients with cystic brosis. J Pediatr. 2013;162:5305.
12. Cystic Fibrosis Foundation Patient Registry. 2012 annual data report. Bethesda, MD: Cystic Fibrosis Foundation;
2012.
13. Marshall BC, Nelson EC. Accelerating implementation of biomedical research advances: critical elements of a
successful 10 year Cystic Fibrosis Foundation healthcare delivery improvement initiative. BMJ Qual Saf. 2014;23
Suppl 1:i95103.
14. Marshall BC, Penland CM, Hazle L, Ashlock M, Wetmore D, Campbell 3rd PW, Beall RJ. Cystic brosis foundation:
achieving the mission. Respir Care. 2009;54:78895. discussion 795.
16. Stallings VA, Stark LJ, Robinson KA, et al. Clinical practice guidelines on growth and nutrition subcommittee.
evidence-based practice recommendations for nutrition-related management of children and adults with cystic
brosis and pancreatic insufciency: results of a systematic review. J Am Diet Assoc. 2008;108:8329.
17. Schechter MS, Fink AK, Homa K, et al. The cystic brosis foundation patient registry as a tool for use in quality
improvement. BMJ Qual Saf. 2014;23 Suppl 1:i914.
18. Stern M, Bertrand DP, Bignamini E, et al. European cystic brosis society standards of care: quality management
in cystic brosis. J Cyst Fibros. 2014;13 Suppl 1:S4359.
19. Stern M. The use of a cystic brosis patient registry to assess outcomes and improve cystic brosis care in Germany.
Curr Opin Pulm Med. 2011;17:4737.
264
A.R. Leonard
20. Wiedemann B, Steinkamp G, Sens B, et al. German cystic brosis quality assurance group. The German cystic
brosis quality assurance project: clinical features in children and adults. Eur Respir J. 2001;17:118794.
21. James BC. The cystic brosis improvement story: we count our successes in lives. BMJ Qual Saf. 2014;23:
26871.
22. Sabadosa KA, Batalden PB. The interdependent roles of patients, families and professionals in cystic brosis: a
system for the coproduction of healthcare and its improvement. BMJ Qual Saf. 2014;23 Suppl 1:i904.
23. Warwick WJ, Pogue RE. Cystic brosis. An expanding challenge for internal medicine. JAMA. 1977;238:
215962.
24. Gutierrez HH, Sanchez I, Schidlow DV. Cystic brosis care in Chile. Curr Opin Pulm Med. 2009;15:6327.
25. Antos NJ, Quintero DR, Walsh-Kelly CM, et al. Improving inpatient cystic brosis pulmonary exacerbation care:
two success stories. BMJ Qual Saf. 2014;23 Suppl 1:i3341.
26. Corey M, McLaughlin FJ, Williams M, et al. A comparison of survival, growth, and pulmonary function in patients
with cystic brosis in Boston and Toronto. J Clin Epidemiol. 1998;41:58391.
27. Boyle MP, Sabadosa KA, Quinton HB, et al. Key ndings of the US cystic brosis foundation's clinical practice
benchmarking project. BMJ Qual Saf. 2014;23 Suppl 1:i1522.
28. Schechter MS. Benchmarking to improve the quality of cystic brosis care. Curr Opin Pulm Med. 2012;18:
596601.
29. Britton LJ, Thrasher S, Gutierrez H. Creating a culture of improvement: experience of a pediatric cystic brosis
center. J Nurs Care Qual. 2008;23:11520.
30. Godfrey MM, Oliver BJ. Accelerating the rate of improvement in cystic brosis care: contributions and insights of
the learning and leadership collaborative. BMJ Qual Saf. 2014;23 Suppl 1:i2332.
31. Konstan MW, Butler SM, Wohl ME, et al. Investigators and coordinators of the epidemiologic study of cystic brosis.
Growth and nutritional indexes in early life predict pulmonary function in cystic brosis. J Pediatr. 2003;142:
62430.
32. McPhail GL, Acton JD, Fenchel MC, et al. Improvements in lung function outcomes in children with cystic brosis
are associated with better nutrition, fewer chronic pseudomonas aeruginosa infections, and dornase alfa use.
J Pediatr. 2008;153:7527.
sectional and longitudinal analyses from the German CF quality assurance (CFQA) project. Thorax. 2002;57:
596601.
34. Ferkol T, Rosenfeld M, Milla CE. Cystic brosis pulmonary exacerbations. J Pediatr. 2006;148:25964.
35. Flume PA, Mogayzel Jr PJ, Robinson KA, et al. Clinical practice guidelines for pulmonary therapies committee.
Cystic brosis pulmonary guidelines: treatment of pulmonary exacerbations. Am J Respir Crit Care Med. 2009;180:
8028.
36. Action guide for accelerating improvement in cystic brosis. Cystic Fibrosis Foundation version 1. 2006.
37. Tiddens HA. Quality improvement in your CF centre: taking care of care. J Cyst Fibros. 2009;8 Suppl 1:S25.
38. Berlinski A, Chambers MJ, Willis L, et al. Redesigning care to meet national recommendation of four or more
yearly clinic visits in patients with cystic brosis. BMJ Qual Saf. 2014;23 Suppl 1:i429.
39. Rayas MS, Willey-Courand DB, Lynch JL, et al. Improved screening for cystic brosis-related diabetes by an
integrated care team using an algorithm. Pediatr Pulmonol. 2014;49:9717.
40. McDonald CM. Validation of a nutrition risk screening tool for children and adolescents with cystic brosis ages
220 years. J Pediatr Gastroenterol Nutr. 2008;46:43846.
41. Zanni RL, Sembrano EU, Du DT, et al. The impact of re-education of airway clearance techniques (REACT) on
adherence and pulmonary function in patients with cystic brosis. BMJ Qual Saf. 2014;23 Suppl 1:i505.
Index
A
Acute pancreatitis (AP), 235236
Acute pulmonary exacerbation, 13
Adolescence, 251
Age percentiles, 105
Alpha linolenic acid (ALA), 37
Alpha-1 antitrypsin (A1A), 109
Amino acids, 22
cysteine and glutathione, 24
leucine and arginine, 23
taurine, 23
Anorexia, 140
Antioxidant-rich foods, 21
Appetite stimulants, 140
and mechanisms, 140141
dosing and duration of, 143
efficacy of, 141142
side effects of, 143
Arginine, 2324
Autosomal recessive disorder, 1
B
Basal metabolic rate (BMR), 130
Basal-bolus insulin, 196
Behavioral intervention, 240, 245250, 252
adherence, 241
application
contingency management, 247
contracting, 247
differential attention, 245246
goal setting, 248249
parental limit setting, 249250
self-monitoring, 247248
developmental considerations
adolescence, 251
preschool, 250
school-age, 250251
feeding concerns, 242
nutritional recommendations, 241
outcomes, 242245
Behavioral Pediatrics Feeding Assessment

Scale (BPFAS), 242
Blood sugar, 197
Body mass index (BMI), 103, 105106
Bone disease
adults, nutrition assessments, 124
medical treatment, 59
nutritional assessment, 113
nutrition-related recommendations, 55
pathophysiology, 55
Bone health, 5759
assessment, 5557
nutrients, 5859
nutritional management, 57
calcium, 5758
physical activity and body composition, 59
vitamin K, 58
Bone mineral density (BMD), 57
BOS. See Bronchiolitis obliterans syndrome (BOS)
Breastfeeding, 89, 228
Breath tests, 154
Bronchiolitis obliterans syndrome (BOS), 213
C
Calcium, 5758, 76
pregnancy, 226
pancreatic sufficiency (PS), 233
Calories, 1213
actual intake, 15
energy expenditure, 1314
energy intake vs. growth status, 15
energy needs, 1415
recommendations, 16
Carbohydrate, 2526
concerns, 2627
dietary carbohydrate goal, 2728
fiber, 27
intake, recommendations, 2627
potential benefits, 26
Carbohydrates, 171172
DOI 10.1007/978-3-319-16387-1, Springer International Publishing Switzerland 2015
265
266
Carnitine deficiency, 174
Celiac disease, 2, 234, 235
Ceramide, 42
CF. See Cystic fibrosis (CF)
CFF. See Cystic Fibrosis Foundation (CFF)53
CFTR. See Cystic fibrosis transmembrane
regulator (CFTR)1
Cholecalciferol, 50
Cholecystokinin (CCK), 152
Cholestatic infants, 166
Choline, 41
Chronic rejection, 213
Chymotrypsin, 154
Cirrhosis
complications/portal hypertension, 169
energy needs, 170
liver synthetic failure, 170
multilobular, 168169
nutrition management, 170
nutritional consequences of, 169
Community-based programs, 97
Constipation, 186, 224
Copper, 78
Customary laboratory tests, 75
Cyproheptadine hydrochloride (CH), 141
Cysteine, 24
Cystic fibrosis (CF), 1, 35, 7, 180187
celiac disease, 2
clinical outcomes, 4, 7
diagnosis, 2
etiology, 1
gastrointestinal complications, 185
CFTR, 181
constipation, 186
DIOS, 185186
gastrointestinal cancers, 186187
GERD and gastric emptying, 181182
nutritional status, 180
pancreatic disease, 182183
SIBO, 183184
small intestine, diseases of, 184185
gene mutation, 1, 8
liver disease, 114, 187
malnutrition, 3
nutrition
%IBW and BMI, 45
children growth, 3
cluster randomization model, 8
early interventions, 4
neonatal screening, 1, 4
pulmonary outcomes, 4
pancreas, 151
pancreatic insufficiency, 3, 151
PERT, 34
Cystic Fibrosis Foundation (CFF), 53
Cystic Fibrosis Foundation Registry, 3
Cystic Fibrosis Foundation Subcommittee
on Growth and Nutrition, 5
Index
Cystic fibrosis related diabetes
(CFRD), 27, 112, 195, 200, 201
chronic illnesses, 201
complications, 193
diagnosis, 194
etiology, 193194
HbA1c, 194
hypoglycemia, 200
IGT/pre-diabetes, 200
medical goals, 202
nutritional
recommendations, 202
therapy, 192
implications, 193
pregnancy, 227
pulmonary exacerbation, screening, 195
routine OGTT screening, diagnostic
cut-offs, 194, 195
treatment, 195
insulin therapy, 196 (see Insulin therapy)
nutrition therapy, 195
Cystic fibrosis transmembrane regulator
(CFTR), 1, 180, 181
Cystic fibrosis-related bone disease, 5455, 5759
assessment, 5557
medical treatment, 59
nutritional management, bone health, 57
calcium, 5758
nutrients, 59
physical activity and body composition, 59
vitamin K, 58
pathophysiology, 55
D
Daily energy expenditure (DEE), 131
Di (2-ethylhexyl) phthalate (DEHP), 221
Diabetes, 193
Dibutyl phthalate (DBP), 221
Dietary fat, 3639, 41
ceramide, 42
choline, 41
fatty acid, 41
abnormalities, 3839
EFA and metabolism, 3738
modification, 4142
normalization, 4142
tissue compartments and reporting
modalities, 36
nutritional interventions, 3940
requirements, 36, 4243
Direct measurement methods, 152
Distal intestinal obstruction syndrome (DIOS), 180,
185186, 224
Docosahexaenoic acid (DHA), 37, 40
Dreiling test, 152
Dronabinol, 141
Dual energy X-ray absorptiometry (DEXA), 56
267
Index
E
Eating disorder, 201
Eicosanoids, 38
Endocrine functions, 150
Energy expenditure, 1314
Energy intake, 130
Enteral feeds, 196198
Enteral tube feeding, 135
Enzyme therapy, 155
Enzymes, in pregnancy, 221223
Epidemiology Study of Cystic Fibrosis (ESCF), 5
Ergocalciferol, 50
Essential fatty acid deficiency (EFAD), 19, 36, 173
Essential fatty acids (EFA)
and metabolism, 3738
options, oral supplementation, 173
Exocrine pancreatic functions, 150
Exocrine pancreatic insufficiency, 150151
Exocrine pancreatic sufficiency, 235236
F
Failure to thrive (FTT), 93, 97
Fat, 17
antioxidant-rich foods, high fat diet, 21
dietary fat goal, 21
high calorie foods, high fat diet, 21
high fat diet, defining, 18
high fat diet, shifting, 1718
MCT vs. LCT, 18
potential benefits, high fat diet, 19
Fat absorption, 152
Fat gram method, 156
Fat-soluble vitamin supplementation, 167
Fat-soluble vitamins, 171
Fatty acid
abnormalities, 3839
EFA and metabolism, 3738
tissue compartments and reporting modalities, 36
Fecal elastase (FE), 153
Fecal elastase-1 (FE-1), 231, 234
72 h fecal fat method, 109
Feeding method, 8889
Fiber, 27
Fluoride, 78, 93
Folic acid, 224225
Food safety, 215
Fortified breast milk formulas, 89
G
Gastric emptying, 181182
Gastroesophageal reflux (GER), 125
Gastroesophageal reflux disease (GERD)
and gastric emptying, 181182
CF, 180
pre-transplant period, 209210
STF method, 138
Gastrointestinal cancers, 186187, 215

Gastrointestinal tact, 180181
Gastrostomy tube (GT) placement, 210
Gestational diabetes, 227
Glucocorticoid therapy, 198
Glutathione, 24
H
HbA1c. See Hemoglobin A1c (HbA1c)
Hemoglobin A1c (HbA1c), 194
Hepatic steatosis, 172174
High fat diet
concerns, 1920
definition, 18
high calorie foods, 21
shifting, 1718
High fiber foods, 27
High protein foods, 24
High-calorie infant formulas, 89
High-performance liquid chromatography (HPLC), 51
HPLC. See High-performance liquid
chromatography (HPLC)
Hydrolyzed protein sources, 2223
Hypoglycemia, 200
Hypromellose phthalate (HPMCP), 223
I
Illness, 198
Immediate post-operative period, 212215
Immunoreactive trypsinogen, 153154
Impaired glucose tolerance (IGT), 201
Infants, 8897
FTT, 97
nutrition
early intervention and long-term
pulmonary outcomes, 9495
enzyme administration and dosing, 91
feeding method, 8889
meconium ileus, 9596
micronutrient, 9294
pancreatic status assessment and
PERT initiation, 8990
rapid growth change, 9192
requirements and FTT, 9697
salt supplementation, 9394
Insulin, 55, 193, 196198
Insulin therapy, 196198
and steroid use, 199
and TPN, 199
enteral feeds, 196198
IGT/pre-diabetes, 200
illness, 198
Intact protein sources, 2223
Invasive tube tests, 152
Iron, 7778, 226, 233
268
J
Jejunostomy feeding, 138
L
LC-MS/MS. See Liquid chromatography tandem mass
spectroscopy (LC-MS/MS)
Learning and Leadership Collaboratives (LLC), 257
Leucine, 2324
Linoleic acid (LA), 37, 39, 40, 173
Liquid chromatography tandem mass spectroscopy
(LC-MS/MS), 51
Liver disease, 165164, 166174
carbohydrates, 171
cirrhosis, 168170
classification, 166
fat-soluble vitamins, 171
hepatic steatosis, 172174
neonatal cholestasis, 166168
protein, 170
sodium chloride, 172
zinc deficiency, 171172
Liver synthetic failure, 170
Long chain triglycerides (LCT), 18
Long-chain polyunsaturated fatty acids (LCPUFA), 37
Lung Allocation Score (LAS), 208
Lung transplantation, 207, 209
absolute contraindications, 208
immediate post-operative period, 212215
indications for, 208
LAS calculation, 208
nutritional status, impact of, 209
pre-transplant period, nutrition support, 209212
M
Macronutrients, 1720, 2227
carbohydrate, 2526
concerns, 2627
dietary carbohydrate goal, 2728
fiber, 27
fat, 17
antioxidant-rich foods, high fat diet, 21
dietary fat goal, 21
high calorie foods, high fat diet, 21
high fat diet, defining, 18
high fat diet, shifting, 1718
MCT vs. LCT, 18
potential benefits, high fat diet, 19
protein, 22
amino acids, 2324
concerns, 24
dietary protein goal, 2425
intact vs. hydrolyzed protein sources, 2223
metabolism, 23
Index
Magnesium, 76, 186, 233
Malabsorption blood test (MBT), 155
Malnutrition, 94, 209
Marinol, 141
Meal method, 156
Meconium ileus, 96, 185
Medium chain triglycerides (MCT), 17, 18
Megace, 140
Megestrol acetate (MA), 140141
Methylprednisolone, 198
Microlipid, 89
Micronutrients
laboratory assessment of, 94
nutrition, 93
Microspheres, 183
Mid-upper arm circumference, 106107
Minerals
adults, nutrition supplements, 122123
calcium, 76
history, nutritional assessment, 113
magnesium, 76
post-transplant patients, 213
pregnancy, 223
PS and, 232
recommendations, 71
sodium chloride, 7576
Mirtazapine, 140
Moore method, 4
Multilobular cirrhosis, 168169
N
Nasogastric (NG) feeds, 224
Neonatal cholestasis, 168170
Nonalcoholic fatty liver disease (NAFLD), 172
Non-porcine-derived pancreatic enzyme, 155
Nutrition, 8897
infants, 88
early intervention and long-term pulmonary
outcomes, 9495
enzyme administration and dosing, 91
feeding method, 8890
meconium ileus, 9596
micronutrient needs, 9293
micronutrients, laboratory assessment, 94
pancreatic status assessment and PERT
initiation, 8990
rapid growth change, 9192
requirements and FTT, 9697
salt supplementation, 9394
pre-pregnancy, 220
pre-transplant period, 209212
vitamin administration, 93
Nutrition assessment, 119121, 124126
adults, 118
assessing intake, 119122
bone disease, 124
CFRD, 124125
GER, 125
269
Index
intervention, 122123
obesity, 125, 126
pancreatic status, 119
vitamin and mineral supplementation, 123124
weight/height, 119
post-transplants, 213
pre-transplant, 210
Nutrition intervention, 135143
appetite stimulants, 140
and mechanisms, 140141
dosing and duration of, 143
efficacy of, 141142
behavioral intervention, 132
boosting, meal, 133
energy intake, 130
formula choice and calorie goals, 138139
mathematical formulas, 130
nutrition supplements, 133
oral supplements, 131
PN, 143144
recommendations, 132
STF, 135
CFF recommendations, 135
complications, 139140
indications, 135136
methods, 138
pancreatic enzymes and, 139
pulmonary exacerbations, function, 136
quality of life, 137
Nutrition therapy, 202
CFRD, 195
for CFRD, 192
Nutritional assessment, 103109
2 to 20-year-olds, 103104
anthropometric data, 102, 105
age percentiles, 105
BMI calculation, 102, 105106
height, accurate measurement, 103, 104
goal weight calculation, 106
mid-upper arm circumference, 106
skinfold measurements, 107
weight accurate measurement, 103, 105
weight gain rate calculation, 106
biochemical data, 108
persistent FTT, 109
standard yearly labs, 108
stool labs, 109
bone disease, 112113
CF-related diabetes, 112
CF-related liver disease, 111112
clinical assessment, 110
diet history, 110111
PERT history, 114115
stool history, 113
vitamin and mineral history, 113114
Nutritional status, 180
assessment of, 232233
impact, transplant outcomes, 209
O
Obesity, 125
OGTT. See Oral glucose tolerance testing (OGTT)
Oral glucose tolerance test (OGTT), 194, 261
Oral hyperosmotic agents, 186
Oropharyngeal dysphagia, 212
Osteoporosis, 169
P
Pancreatic disease, 182183
Pancreatic enzyme replacement therapy (PERT), 34,
155, 157, 159
detecting failure and causes, 157158
dosing pancreatic enzymes, 155
enteral feeds, 156157
fat gram method, 156
meal method, 156
enzyme therapy, 155
excessive doses complications, 157
fat-soluble vitamins, malabsorption, 157
initiation of, 8990
monitoring effectiveness, 157
persistent malabsorption, diagnosis of, 158159
Pancreatic insufficiency (PI), 89, 153155, 180
clinical manifestations of, 150151
direct measurement methods, 152
indirect methods, 152
tube-less tests, 154
breath test, 154
fat absorption coefficient, 152153
FE, 153
immunoreactive trypsinogen, 153154
MBT, 155
stool steatocrit, 154
monitoring PS CF, 159
nutrition goal, 232
nutritional impact, 182
test choice, 151, 152
Pancreatic status
assessment of, 8990
nutrition assessment, 119120
Pancreatic sufficiency (PS)
annual assessment, 234
AP, 234235
assessing, 234235
causes of, 235
celiac disease, 235
nutritional parameters, 235
nutritional status, assessment of, 232
pancreatitis, 235236
testing methods, 234
vitamin and mineral status, 233
Parenteral nutrition (PN), 143144, 224
Patient registries, 256
Percent Ideal Body Weight (%IBW), 45
Percutaneous endoscopic gastrostomy (PEG), 137
Periactin, 141
270
Persistent malabsorption, 158
PERT. See Pancreatic Enzyme Replacement
Therapy (PERT)
Phthalates, 221, 223
Plan Do Study Act (PDSA) Cycle, 259
Polyunsaturated fatty acid (PUFA), 37
Portal hypertension, 168170
Pre-diabetes, 201
Prednisone therapy, 198
Pregnancy
breastfeeding, 231
calcium, 226
CF, 219
CFRD and gestational diabetes, 227
CFRD prior, 227
constipation, 224
diabetes, 199
enzymes, 221223
folic acid, 224
gestational diabetes, 227
GI issues, 224
iron, 226
medication and tests, 221
nutrition considerations, 228
tracking and clinic visits, 220
vitamin A, 225
vitamin and mineral supplementation, 224
vitamin D, 225
vitamin E, 225
vitamin K deficiency, 225
weight gain, 223224
Pre-pregnancy nutrition, 220
Pre-transplant period, 209212
Protein, 22, 170171
adult, nutrition, 122
amino acids, 2324
concerns, 24
dietary protein goal, 2425
metabolism, 23
Pulmonary exacerbation, 195
Q
Quality improvement (QI), 256
applications, 259262
benchmarking, 257
implementation, 258259
LLC, 257
patient and family involvement, 257258
patient registries, 256
R
Randomized clinical trial (RCT), 244
Rapid-acting insulin, 196
Recommendation, calories, 1617
Re-Education of Airway Clearance Techniques (REACT)
program, 262
Index
Remeron, 141
Renal dysfunction, 214
Resting energy expenditure (REE), 13
Retinol, 71, 73
Retinol activity equivalents (RAE), 73
S
Salt supplementation, 9394
Secretin stimulation test, 152
Selenium, 78
Serum ferritin, 233
Serum immunoreactive trypsinogen, 182
Skinfold measurements, 108
Small bowel, nutritional capacity, 184
Small intestinal bacterial overgrowth (SIBO), 180,
183184
Small intestine, diseases of, 184185
Sodium chloride, 76, 172
Standard yearly labs, 108
Standardize, Do, Study, Act (SDSA), 259
Steatosis, 172174
Steroid, 198
Stool labs, 109
Supplemental tube feeding (STF), 135
CFF recommendations, 135
indications, 135136
methods, 138
pancreatic enzymes and, 139
pulmonary exacerbations, function, 136
quality of life, 137
T
Taurine, 23
The Cincinnati Childrens Hospital Medical Center
(CCHMC), 259
Total energy expenditure (TEE), 13
Trace minerals
copper, 78
fluoride, 78
iron, 78
selenium, 78
zinc, 77
Tube-less tests, 154
U
Ursodeoxycholic acid, 172
V
Viokase, 155, 157
Vitamin
adults, nutrition supplements, 122
and mineral supplementation, 67
post-transplant patients, 213
271
Index
pregnancy, 224
PS and, 233
recommendations, 71
vitamin A, 7173
vitamin E, 7374
vitamin K, 7475
water-soluble vitamins, 75
Vitamin A, 7173
deficiency, 171
pregnancy, 226
Vitamin D, 5052, 225
CFF guidelines, 53
foods and CF supplements, 50
immune function, 52
management, 5354
pathophysiology, 52
physiological function, 52
PS and, 233
Vitamin E, 7374
cholestasis, 168
pregnancy, 225
PS and, 233
Vitamin K, 58, 7475, 171, 225
W
Water-soluble vitamins, 75
Weight age equivalent, 105
Weight gain
infants, evaluation of, 92
pregnancy, 223224
rate, calculation, 106
Z
Zinc, 77, 171172

CF Nutrition

Uploaded by

Copyright:

Available Formats

CF Nutrition

Uploaded by

Document Information

Original Title

Copyright

Available Formats

Share this document

Share or Embed Document

Sharing Options

Did you find this document useful?

Is this content inappropriate?

Copyright:

Available Formats

CF Nutrition

Uploaded by

Copyright:

Available Formats

What is cystic fibrosis and how does it affect nutrition?

What is cystic fibrosis and how does it affect nutrition?

What are some nutritional challenges faced by those with cystic fibrosis?

What are some nutritional challenges faced by those with cystic fibrosis?

Nutrition and Health

Series Editor: Adrianne Bendich

Nutrition and Health

More information about this series at http://www.springer.com/series/7659

Elizabeth H. Yen Amanda Radmer Leonard

Nutrition in Cystic Fibrosis

Amanda Radmer Leonard, M.P.H., R.D., L.D., C.D.E.

Benioff Childrens Hospital

Nutrition and Health

Library of Congress Control Number: 2015952012

Series Editor Page

Series Editor Page

advice concerning the implementation of nutritional interventions to CF patients from infancy to

Series Editor Page

Series Editor Page

reduced resulting in a concentration of proteins and eventual obstruction leading to pancreatic

Series Editor Page

Series Editor Page

Adrianne Bendich, Ph.D., F.A.C.N., F.A.S.N.

About Series Editor

About Series Editor

About Series Editor

About Volume Editors

About Volume Editors

What Is Cystic Fibrosis? The Relationship Between Nutrition

Macronutrient Requirements ............................................................................................

Dietary Fat and Fat Metabolism in CF .............................................................................

Vitamin D and Bone Health ...............................................................................................

Vitamins and Minerals .......................................................................................................

Nutrition in Infancy ............................................................................................................

Nutritional Assessment: Age 220 Years ..........................................................................

Nutrition Assessment: Adults and Obesity .......................................................................

Nutrition Intervention ........................................................................................................

Nutrition and Cystic Fibrosis Related Liver Disease .......................................................

Gastrointestinal Complications of Cystic Fibrosis and Their Impact

Nutritional Management of Cystic Fibrosis Related Diabetes Mellitus.........................

Nutrition Pre and Post Lung Transplant ..........................................................................

Pregnancy, Nutrition, and Cystic Fibrosis ........................................................................

Nutrition for Pancreatic Sufficient Individuals with Cystic Fibrosis .............................

Behavioral Interventions and Anticipatory Guidance ....................................................

Nutrition and Quality Improvement in Cystic Fibrosis ..................................................

Danielle Usatin, M.D. Department of Pediatrics, Division of Gastroenterology, Hepatology and

What Is Cystic Fibrosis? The Relationship Between

D. Usatin and E.H. Yen

History of Cystic Fibrosis

Affects of Cystic Fibrosis on Nutrition

Treatment with Pancreatic Enzymes

D. Usatin and E.H. Yen

Associations with Malnutrition in Cystic Fibrosis

anthropomorphic measures. Perhaps further consideration needs to be taken to individual inherited

D. Usatin and E.H. Yen

J. Brownlee, R.D., C.N.S.C. (*)

Keywords Calories Energy expenditure Estimated energy requirement Fat Antioxidants

Body mass index

be affected by gastrointestinal symptoms [810] as well as pulmonary symptoms [11] in addition to